Drug;Gene;Genotype;Alleles;Outcome;Variation
NIFEDIPINE;CYP3A4;CYP3A4*1, CYP3A4*17;*17;OTHER, LADME_PK;DECREASED_METABOLISM
SITAGLIPTIN;DPP4;rs2909451;TT;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE
SITAGLIPTIN;KCNJ11;rs2285676;GG;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C9;CYP2C9*11;*11/*11;DOSAGE;DECREASED_DOSE
SITAGLIPTIN;KCNQ1;rs163184;GG;EFFICACY;DECREASED_RESPONSE
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*18;*1/*18;LADME_PK;INCREASED_CONCENTRATIONS
SITAGLIPTIN;DPP4;rs4664443;GG;EFFICACY;DECREASED_RESPONSE
CODEINE;CYP2D6;CYP2D6*1xN;*1xN;LADME_PK;INCREASED_METABOLISM
SITAGLIPTIN;CYP2C9;rs1799853;TT;EFFICACY;DECREASED_RESPONSE
SITAGLIPTIN;GLP1R;rs3765467;AG;EFFICACY;INCREASED_RESPONSE
IVACAFTOR / LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE
FLUOXETINE;CYP2C19;CYP2C19;intermediate_metabolizer;EFFICACY;INCREASED_RESPONSE
PAROXETINE;CYP2C19;CYP2C19;ultrarapid_metabolizer;EFFICACY;DECREASED_RESPONSE
SITAGLIPTIN;GLP1R;rs6923761;AA;EFFICACY;DECREASED_RESPONSE
CODEINE;CYP2D6;CYP2D6*2, CYP2D6*2xN;*2/*2xN;LADME_PK;INCREASED_METABOLISM
EXENATIDE, LIRAGLUTIDE;GLP1R;rs3765467;GG;EFFICACY;INCREASED_CLINICAL BENEFIT
IVACAFTOR / LUMACAFTOR;CFTR;rs113993960;del;EFFICACY;RESPONSE
CITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;CYP2C19;CYP2C19;poor_metabolizer;EFFICACY;DECREASED_RESPONSE
ALBIGLUTIDE, DULAGLUTIDE, GLP-1 RECEPTOR AGONISTS;GLP1R;rs6923761;A;EFFICACY;DECREASED_CLINICAL BENEFIT
EXENATIDE;TCF7L2;rs7903146;CT + TT;EFFICACY;INCREASED_RESPONSE
RIFAPENTINE;NAT2;NAT2;slow_acetylator;LADME_PK;INCREASED_CONCENTRATIONS
EFAVIRENZ;CYP2B6;CYP2B6;poor_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;LADME_PK;DECREASED_EXPOSURE
ALBIGLUTIDE, DULAGLUTIDE, GLP-1 RECEPTOR AGONISTS;ARRB1;rs140226575;A;EFFICACY;INCREASED_CLINICAL BENEFIT
EFAVIRENZ;NAT2;NAT2;slow_acetylator;LADME_PK;INCREASED_CONCENTRATIONS
PROPAFENONE;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;LADME_PK;INCREASED_CONCENTRATIONS
PROPAFENONE;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;EFFICACY;INCREASED_RESPONSE
DEXTROMETHORPHAN;CYP2D6;CYP2D6*4, CYP2D6*6;*4/*6;LADME_PK;DECREASED_METABOLISM
NEVIRAPINE;NAT2;NAT2;slow_acetylator;LADME_PK;INCREASED_CONCENTRATIONS
ALBIGLUTIDE, DULAGLUTIDE, GLP-1 RECEPTOR AGONISTS;ARRB1;rs78979036;A;EFFICACY;INCREASED_CLINICAL BENEFIT
METHADONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*2xN;*1/*2xN + *2/*2xN;EFFICACY;INCREASED_RESPONSE
LURBINECTEDIN;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*1;LADME_PK;DECREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
ALBIGLUTIDE, DULAGLUTIDE, GLP-1 RECEPTOR AGONISTS;ARRB1;rs78052828;T;EFFICACY;INCREASED_CLINICAL BENEFIT
METHYLMERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;LADME_PK;DECREASED_CONCENTRATIONS
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;LADME_PK;INCREASED_CONCENTRATIONS
ALBIGLUTIDE, DULAGLUTIDE, GLP-1 RECEPTOR AGONISTS;ARRB1;rs58428187;C;EFFICACY;INCREASED_CLINICAL BENEFIT
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*36;*10/*36;DOSAGE;INCREASED_DOSE
RALOXIFENE 6-GLUCURONIDE, RALOXIFENE-4â€²-GLUCURONIDE;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;LADME_PK;INCREASED_CONCENTRATIONS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*17;*1/*4 + *1/*5 + *1/*9 + *1/*10 + *4/*10 + *5/*10 + *10/*10 + *10/*17;LADME_PK;DECREASED_CLEARANCE
CLOZAPINE, N-DESMETHYLCLOZAPINE;CYP1A2;CYP1A2*35;*35;LADME_PK;INCREASED_CONCENTRATIONS
VENLAFAXINE;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;INCREASED_EXPOSURE
LURBINECTEDIN;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;LADME_PK;INCREASED_CLEARANCE
LURBINECTEDIN;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;LADME_PK;DECREASED_CONCENTRATIONS
LEFLUNOMIDE;PON1;rs705379;GG;EFFICACY;INCREASED_CLINICAL BENEFIT
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;DOSAGE;DECREASED_DOSE
LETROZOLE;CYP2A6;rs56113850;T;;INCREASED_CONCENTRATIONS
TRAMADOL;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;INCREASED_EXPOSURE
(S)-METHADONE;CYP2B6;CYP2B6*1, CYP2B6*5, CYP2B6*6, CYP2B6*7;*6/*6;LADME_PK;INCREASED_CONCENTRATIONS
ANTIEPILEPTICS;SCN1A;rs2298771;C;EFFICACY;INCREASED_RESISTANCE
ANTIEPILEPTICS;SCN1A;rs10167228;T;EFFICACY;INCREASED_RESISTANCE
O-DESMETHYLTRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10;*3/*4 + *4/*4;LADME_PK;DECREASED_CONCENTRATIONS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;DOSAGE;DECREASED_DOSE
CODEINE;CYP2D6;CYP2D6*2, CYP2D6*2xN;*2/*2xN;LADME_PK;INCREASED_METABOLISM
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*5;*1/*5;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*11;*1/*11;DOSAGE;DECREASED_DOSE
METHADONE;;low activity;;LADME_PK;INCREASED_TROUGH CONCENTRATION
SN-38;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;LADME_PK;DECREASED_METABOLISM
BILIRUBIN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;OTHER;INCREASED_
SN-38;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;LADME_PK;DECREASED_METABOLISM
CARVEDILOL;UGT1A1;UGT1A1*1, UGT1A1*28;*28;LADME_PK;INCREASED_METABOLISM
LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE
ACENOCOUMAROL;VKORC1;rs9934438;A;DOSAGE;DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3/*3 + *1/*3;DOSAGE;DECREASED_DOSE
LIRAGLUTIDE;CNR1;rs1049353;CT + TT;EFFICACY;INCREASED_CLINICAL BENEFIT
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;DECREASED_CONCENTRATIONS
FLUVOXAMINE, PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs104894542;C;DOSAGE;INCREASED_DOSE
CLONIDINE;ADRA2C;rs11269124;GGGGAGCTTTCCCAGAGACCC/del + del/del;EFFICACY;INCREASED_RESPONSE
SIMVASTATIN ACID;SLCO1B1;rs4149056;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS
SIMVASTATIN ACID;SLCO1B1;rs2306283;AG + GG;LADME_PK;INCREASED_CONCENTRATIONS
DEXTROMETHORPHAN;CYP2D6;CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5;*4/*2xN;LADME_PK;INCREASED_METABOLISM
ASPIRIN;P2RY1;rs1371097;T;EFFICACY;DECREASED_CLINICAL BENEFIT
ASPIRIN;ABCB1;rs1045642;GG;EFFICACY;INCREASED_CLINICAL BENEFIT
SN-38;UGT1A1;UGT1A1*1, UGT1A1*28;*28;LADME_PK;INCREASED_CONCENTRATIONS
DEXTROMETHORPHAN;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;DECREASED_METABOLISM
SIROLIMUS;CYP3A4;CYP3A4*8, CYP3A4*20;*8/*20;LADME_PK;INCREASED_CONCENTRATIONS
DEXTROMETHORPHAN;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;DECREASED_METABOLISM
RIBAVIRIN, SOFOSBUVIR;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE
RIFAMPIN;SLCO1B1;rs4149032;TT;LADME_PK;INCREASED_CONCENTRATIONS
MODAFINIL;COMT;rs4680;GG;EFFICACY;INCREASED_RESPONSE
ISONIAZID;;rs1495741;AA;LADME_PK;INCREASED_CONCENTRATIONS
VALSARTAN;AGT;rs699;GG;EFFICACY;DECREASED_CLINICAL BENEFIT
NALTREXONE;OPRM1;rs1799971;G;EFFICACY;INCREASED_CLINICAL BENEFIT
IVACAFTOR;CFTR;rs113993960;del;EFFICACY;INCREASED_RESPONSE
IVACAFTOR;CFTR;rs113993960;del;EFFICACY;INCREASED_RESPONSE
IVACAFTOR;CFTR;rs113993960;del;EFFICACY;INCREASED_RESPONSE
IVACAFTOR;CFTR;rs113993960;del;EFFICACY;INCREASED_RESPONSE
ELEXACAFTOR;CFTR;CFTR deficiency;;LADME_PK;DECREASED_CONCENTRATIONS
REMIFENTANIL;ADRA2A;rs1800544;CG + GG;DOSAGE;INCREASED_DOSE
WARFARIN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;DOSAGE;INCREASED_DOSE
REMIFENTANIL;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE
ELIGLUSTAT;CYP2D6;CYP2D6;ultrarapid_metabolizer;DOSAGE;INCREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_CLEARANCE
POSACONAZOLE, TACROLIMUS;ABCB1;rs1045642;GG;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*6;*6;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
LACOSAMIDE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*3;*3;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*7;*7;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_DOSE
SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;DOSAGE;INCREASED_DOSE
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*1/*1 + *1/*3 + *1/*6 + *1/*7;DOSAGE;INCREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_CLEARANCE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;CONCENTRATIONS
COUMARIN;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*10;*4/*4 + *4/*10;LADME_PK;DECREASED_METABOLISM
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*2;*1/*2 + *2/*2;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_CLEARANCE
BELINOSTAT;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*60;*28/*28 + *1/*60 + *60/*60;DOSAGE;DECREASED_DOSE
MOXIFLOXACIN;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*36, UGT1A1*37;*1/*36;LADME_PK;DECREASED_CLEARANCE
DEXTROMETHORPHAN;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;DECREASED_METABOLISM
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*46;*46/*46;LADME_PK;INCREASED_CLEARANCE
BUPRENORPHINE;SLC39A10;rs149319538;C;EFFICACY;INCREASED_CLINICAL BENEFIT
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE, LADME_PK;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2/*2;DOSAGE, EFFICACY;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE
SIMVASTATIN, WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE, LADME_PK;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE, LADME_PK;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*4;*4;LADME_PK;DECREASED_METABOLISM
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE, LADME_PK;DOSE
LETROZOLE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*12;*1/*1;LADME_PK;DECREASED_CONCENTRATIONS
LETROZOLE;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9, CYP2A6*46;*1/*46 + *1/*46 + *46/*46;LADME_PK;INCREASED_CLEARANCE
WARFARIN;CYP4F2;CYP4F2*3;*3;DOSAGE;DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE
ARIPIPRAZOLE;DRD2;rs1799732;G/del;EFFICACY;DECREASED_RESPONSE
RIVAROXABAN;ABCB1;rs4148738;CC;LADME_PK;INCREASED_CONCENTRATIONS
RIVAROXABAN;ABCB1;rs1128503;AA;LADME_PK;INCREASED_CONCENTRATIONS
METHOTREXATE;TYMS;rs2853542;GG;EFFICACY;DECREASED_RESPONSE
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*2, TPMT*3A;*1/*2 + *1/*3A;DOSAGE;DECREASED_DOSE
MERCAPTOPURINE, THIOGUANINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*9, TPMT*21, TPMT*33, TPMT*34;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;DOSAGE;DECREASED_DOSE
METHOTREXATE;ATIC;rs4673993;TT;EFFICACY;DECREASED_CLINICAL BENEFIT
FLUOXETINE;HTR1A;rs6295;GG;EFFICACY;INCREASED_RESPONSE
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*41;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;EFFICACY;INCREASED_DISCONTINUATION
SN-38;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28, UGT1A1*60;*6/*60 + *6/*28;LADME_PK;DECREASED_METABOLISM
TAMOXIFEN;CYP2D6;rs16947;A;EFFICACY, TOXICITY;INCREASED_DISCONTINUATION
DIHYDROPYRIDINE DERIVATIVES;NUMA1;rs10898815;AA + AG;OTHER;INCREASED_DISCONTINUATION
TAMOXIFEN;ABCC2;rs3740065;G;EFFICACY, TOXICITY;INCREASED_DISCONTINUATION
WARFARIN;CYP4F2;rs2108622;CC;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;DOSAGE;DECREASED_DOSE
HYDRALAZINE;NAT2;NAT2;rapid_acetylator;DOSAGE, EFFICACY;INCREASED_DOSE
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_METABOLISM
LANSOPRAZOLE;CYP2C19;CYP2C19;poor_metabolizer;LADME_PK;DECREASED_CLEARANCE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*2/*2 + *2/*3 + *1/*2 + *1/*3 + *2/*17;LADME_PK;DECREASED_METABOLISM
SULFONAMIDES, UREA DERIVATIVES;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2  + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE
CORTICOSTEROIDS;NR3C1;rs10482634;GG;EFFICACY;INCREASED_RESISTANCE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*10, CYP2C9*11;*11 + *2 + *3 + *5 + *6;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_DOSE
VALPROIC ACID;UGT1A6;rs6759892;TT;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE
METHYLPHENIDATE;SYT1;rs2251214;AA + AG;EFFICACY;INCREASED_CLINICAL BENEFIT
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE
VORICONAZOLE;CYP2C19;CYP2C19*17;*17/*17;LADME_PK;DECREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_DOSE
HYDRALAZINE;NAT2;NAT2;slow_acetylator;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_TROUGH CONCENTRATION
CHOP, RITUXIMAB;CBR3;rs8133052;AA + AG;EFFICACY;DECREASED_RESPONSE
CHOP, RITUXIMAB;ABCC2;rs8187710;AA + AG;EFFICACY;DECREASED_RESPONSE
N-DESMETHYLTAMOXIFEN;SEPTIN3;rs11914200;AG;LADME_PK;DECREASED_METABOLISM
FENTANYL;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_CONCENTRATIONS
ANTIEMETICS AND ANTINAUSEANTS;SLC22A1;rs34130495;A;EFFICACY, LADME_PK;DECREASED_RESPONSE
N-DESMETHYLTAMOXIFEN;SREBF2;rs133290;AC;LADME_PK;DECREASED_METABOLISM
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DECREASED_DOSE
N-DESMETHYLTAMOXIFEN;TCF20;rs5751251;GG;LADME_PK;INCREASED_METABOLISM
N-DESMETHYLTAMOXIFEN;SREBF2;rs2267439;TT;LADME_PK;INCREASED_METABOLISM
N-DESMETHYLTAMOXIFEN;SREBF2;rs9607850;TT;LADME_PK;INCREASED_METABOLISM
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;DOSAGE, LADME_PK;DECREASED_DOSE
N-DESMETHYLTAMOXIFEN;CENPM, SMIM45;rs8140869;AG;LADME_PK;DECREASED_METABOLISM
RIBAVIRIN, SOFOSBUVIR;IFNL4;rs11322783;GG;EFFICACY;DECREASED_RESPONSE
VARENICLINE;CYP2A6;CYP2A6 high activity;;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*24;*2/*24;DOSAGE;DECREASED_CLEARANCE
ETOPOSIDE;;rs446112;AA;OTHER;INCREASED_RESISTANCE
ROSUVASTATIN;ABCG2;rs2231142;GT + TT;LADME_PK;INCREASED_EXPOSURE
FLUVOXAMINE, PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE
PAROXETINE;CYP2D6;CYP2D6*2;*2/*2;LADME_PK;INCREASED_CLEARANCE
OPIOIDS;CYP2D6;CYP2D6 poor and ultrarapid metabolizers;;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*24;*2/*24;DOSAGE;DECREASED_DOSE
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE
IVACAFTOR, LUMACAFTOR;CFTR;rs113993960;del;EFFICACY;RESPONSE
PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE
AFATINIB;EGFR;rs28929495;GG;EFFICACY;DECREASED_CLINICAL BENEFIT
HYDROMORPHONE;CYP2D6;CYP2D6*5, CYP2D6*17;*5/*17;LADME_PK;DECREASED_CONCENTRATIONS
IVACAFTOR, LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE
3-AMINOISOBUTYRATE;DPYD;rs3918290;TT;LADME_PK;DECREASED_CONCENTRATIONS
HYDRALAZINE;NAT2;NAT2;rapid_acetylator;DOSAGE, EFFICACY;INCREASED_DOSE
MEXILETINE;CYP2D6;CYP2D6*41;*41;EFFICACY;DECREASED_RESPONSE
HYDROCODONE, TRAMADOL;CYP2D6;CYP2D6*5, CYP2D6*17;*5/*17;EFFICACY;DECREASED_RESPONSE
3-AMINOISOBUTYRATE;UPB1;rs143493067;AA;LADME_PK;DECREASED_CONCENTRATIONS
3-AMINOISOBUTYRATE;AGXT2;rs114286107;TT;LADME_PK;INCREASED_CONCENTRATIONS
FENTANYL;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_CONCENTRATIONS
URACIL;DPYD;rs3918290;TT;LADME_PK;INCREASED_CONCENTRATIONS
2-AMINOHEPTANOATE, 2-AMINOOCTANOIC ACID, 2-HYDROXYLAURATE;ACAD11;rs41272317;AA;LADME_PK;INCREASED_CONCENTRATIONS
CYSTEINE-S-SULFATE, L-ORNITHINE;NPC2;rs140130028;TT;LADME_PK;INCREASED_CONCENTRATIONS
HYDRALAZINE;NAT2;NAT2;slow_acetylator;EFFICACY;INCREASED_RESPONSE
5,6-DIHYDROTHYMINE;UPB1;rs143493067;AA;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
HYDRALAZINE;NAT2;NAT2;slow_acetylator;LADME_PK;INCREASED_CONCENTRATIONS
10-MONOHYDROXY OXCARBAZEPINE;ABCC2;rs2273697;G;LADME_PK;INCREASED_CLEARANCE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DECREASED_DOSE
RIVAROXABAN;CYP3A5;rs776746;TT;TOXICITY;DECREASED_CONCENTRATIONS
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_DOSE
CYTARABINE;SLC29A1;rs2396243;T;EFFICACY;DECREASED_CLINICAL BENEFIT
CYTARABINE;NME4;rs5841;CT + TT;EFFICACY;INCREASED_CLINICAL BENEFIT
PRAZIQUANTEL;CYP1A2;CYP1A2*1, CYP1A2*30;*1/*30 + *30/*30;LADME_PK;INCREASED_METABOLISM
PRAZIQUANTEL;CYP2C9;CYP2C9*1, CYP2C9*9;*1/*9 + *9/*9;LADME_PK;INCREASED_METABOLISM
CYTARABINE;CDA;rs10916819;AG + GG;EFFICACY;DECREASED_CLINICAL BENEFIT
CYTARABINE;CMPK1;rs17103168;AG + GG;EFFICACY;INCREASED_CLINICAL BENEFIT
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME_PK;INCREASED_CONCENTRATIONS
CYTARABINE;CTPS1;rs12067645;A;EFFICACY;INCREASED_CLINICAL BENEFIT
CYTARABINE;RRM1;rs11030918;CC;EFFICACY;INCREASED_CLINICAL BENEFIT
CYTARABINE;DCK;rs4643786;C;EFFICACY;DECREASED_CLINICAL BENEFIT
CYTARABINE;RRM2;rs1138729;AG + GG;EFFICACY;DECREASED_CLINICAL BENEFIT
CYTARABINE;CMPK1;rs1044457;CT + TT;EFFICACY;INCREASED_CLINICAL BENEFIT
CYTARABINE;SLC28A3;rs17343066;AA;EFFICACY;INCREASED_CLINICAL BENEFIT
ARIPIPRAZOLE;CYP2D6;rs1065852;AA + AG;EFFICACY;INCREASED_CLINICAL BENEFIT
ARIPIPRAZOLE;CYP2D6;rs1080989;CT + TT;EFFICACY;INCREASED_CLINICAL BENEFIT
QUINAPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESPONSE
ARIPIPRAZOLE;CYP2D6;rs1080989;CT + TT;EFFICACY;DECREASED_CLEARANCE
CYCLOPHOSPHAMIDE;CYP3A4;rs2740574;CC + CT;EFFICACY;DECREASED_CLINICAL BENEFIT
CYCLOPHOSPHAMIDE;CYP3A5;CYP3A5*1, CYP3A5*3;*3;EFFICACY;DECREASED_CLINICAL BENEFIT
WARFARIN;CYP2C9;rs72558189;A;DOSAGE;DOSE
AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE
WARFARIN;CYP2C9;rs28371686;C;DOSAGE;DOSE
WARFARIN;CYP2C9;rs1057910;A;DOSAGE;DOSE
WARFARIN;CYP4F2;rs2108622;C;DOSAGE;DOSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TACROLIMUS;UGT1A4;rs2011425;TT;LADME_PK;DECREASED_CONCENTRATIONS
TACROLIMUS;CYP3A4;rs35599367;GG;LADME_PK;DECREASED_CONCENTRATIONS
ROSUVASTATIN;SLCO1B1;rs4149056;CC + CT;LADME_PK;INCREASED_EXPOSURE
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*22;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*2/*3;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;DOSAGE;INCREASED_DOSE
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*28;*28;LADME_PK;INCREASED_EXPOSURE
ALOGLIPTIN;PNPLA3;rs738409;CG + GG;EFFICACY;INCREASED_CLINICAL BENEFIT
AMLODIPINE;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
IVACAFTOR, LUMACAFTOR;CFTR;rs113993960;CTT/del;EFFICACY;RESPONSE
SERTRALINE;DRD3;rs167770;AG;EFFICACY;INCREASED_CLINICAL BENEFIT
SERTRALINE;DRD3;rs11721264;AG;EFFICACY;INCREASED_CLINICAL BENEFIT
ILOPERIDONE, ILOPERIDONE METABOLITE P88;CYP2D6;rs1065852;AA;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY;DECREASED_RESPONSE
IVACAFTOR, LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*4;*1/*4;LADME_PK;DECREASED_CONCENTRATIONS
IVACAFTOR, LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE
VALPROIC ACID;CACNA1H;rs3751664;T;EFFICACY;INCREASED_RESISTANCE
FLUVOXAMINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE
PENICILLIN G;IFNG;rs1861494;CC;EFFICACY;DECREASED_CLINICAL BENEFIT
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;DECREASED_RESPONSE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;DECREASED_RESPONSE
PENICILLIN G;IFNG;rs2430561;TT;EFFICACY;DECREASED_CLINICAL BENEFIT
IVACAFTOR, LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE
IMIPRAMINE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN;*1/*1xN + *1/*2xN;DOSAGE;INCREASED_DOSE
ISONIAZID;NAT2;NAT2*4, NAT2*5, NAT2*6, NAT2*7;*6/*6 + *6/*7 + *7/*7;LADME_PK;DECREASED_METABOLISM
SIMVASTATIN;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME_PK;INCREASED_CONCENTRATIONS
FLUVOXAMINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;DOSAGE, LADME_PK;DECREASED_METABOLISM
IVACAFTOR, LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;LADME_PK;DECREASED_METABOLISM
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5;*3 + *5 + *2 + *1;DOSAGE;DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_DOSE
VENETOCLAX;CYP3A5;rs776746;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
CLOZAPINE;NFIB;rs28379954;CT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A4;rs2740574;TT;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_CONCENTRATIONS
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME_PK;INCREASED_METABOLISM
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;LADME_PK;INCREASED_METABOLISM
METHYLPHENIDATE;SLC6A2;rs998424;GG;EFFICACY;INCREASED_CLINICAL BENEFIT
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;LADME_PK;DECREASED_METABOLISM
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_CONCENTRATIONS
LITHIUM;;rs7405404;T;EFFICACY;INCREASED_RESPONSE
NICOTINE;CYP2A6;rs28399454;CT + TT;LADME_PK;DECREASED_METABOLISM
3,4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*41;*4/*4 + *3/*5;EFFICACY;INCREASED_RESPONSE
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2 + *2/*2;DOSAGE;DECREASED_DOSE
EFAVIRENZ;CYP2B6;rs28399499;C;LADME_PK;DECREASED_METABOLISM
ANTIEMETICS AND ANTINAUSEANTS;SLC22A1;rs35167514;del;EFFICACY, LADME_PK;DECREASED_RESPONSE
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;DOSAGE;DECREASED_DOSE
FENTANYL;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;DOSAGE;INCREASED_DOSE
VARENICLINE;HYKK;rs7164594;CT + TT;EFFICACY;INCREASED_RESPONSE
SIROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
VORICONAZOLE;CYP2C19;CYP2C19*17;*17/*17;EFFICACY;DECREASED_RESPONSE
4-HYDROXYTAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;LADME_PK;DECREASED_CONCENTRATIONS
CAPTOPRIL;ACE;rs1799752;del/del;EFFICACY;DECREASED_RESPONSE
3,4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*41;*4/*4 + *3/*5;LADME_PK;DECREASED_METABOLISM
MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5;*1/*1;LADME_PK;INCREASED_METABOLISM
EFAVIRENZ;CYP2B6;rs3745274;T;LADME_PK;DECREASED_METABOLISM
VENLAFAXINE;CYP2D6;CYP2D6*4, CYP2D6*5;*4/*5;LADME_PK;DECREASED_METABOLISM
ENALAPRIL, LOSARTAN;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED_RESPONSE
VENLAFAXINE;CYP2C19;CYP2C19*2;*2/*2;LADME_PK;DECREASED_METABOLISM
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1;LADME_PK;INCREASED_CLEARANCE
BENAZEPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESPONSE
BUPROPION;CYP2B6;rs8109525;GG;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;INCREASED_METABOLISM
MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4, NUDT15*5;*1/*1;DOSAGE;INCREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_CLEARANCE
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*41;*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10;LADME_PK;DECREASED_CONCENTRATIONS
MESALAZINE, THIOGUANINE;NAT1;NAT1*3, NAT1*4, NAT1*10;*10;LADME_PK;DECREASED_CONCENTRATIONS
PIOGLITAZONE;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;LADME_PK;INCREASED_METABOLISM
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_TROUGH CONCENTRATION
EXEMESTANE;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;CYP4F2;CYP4F2*1, CYP4F2*3;*3;DOSAGE;INCREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_METABOLISM
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5;*4 + *5;LADME_PK;DECREASED_METABOLISM
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*14;*4 + *5 + *10 +*14;LADME_PK;DECREASED_METABOLISM
METOPROLOL;CYP2D6;CYP2D6*4;*4;DOSAGE;DECREASED_DOSE
CETUXIMAB;VEGFA;rs144854329;del/del;EFFICACY;INCREASED_RESPONSE
SN-38;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;LADME_PK;DECREASED_METABOLISM
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE
LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE
LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;INCREASED_TROUGH CONCENTRATION
SN-38;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;LADME_PK;DECREASED_CLEARANCE
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*6;*1/*6;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;DOSAGE;INCREASED_TROUGH CONCENTRATION
WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DOSE
VENLAFAXINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;*3/*4 + *4/*4 + *4/*5;LADME_PK;DECREASED_METABOLISM
LETROZOLE;;rs7937;C;;INCREASED_CONCENTRATIONS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE
PROPOFOL;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*1 + *1/*2;LADME_PK;DECREASED_CONCENTRATIONS
WARFARIN;VKORC1;rs104894540;G;DOSAGE;INCREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;LADME_PK;CLEARANCE
CODEINE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;EFFICACY;DECREASED_RESPONSE
LANSOPRAZOLE, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE
NOROXYCODONE, OXYCODONE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;LADME_PK;INCREASED_CONCENTRATIONS
CITALOPRAM, ESCITALOPRAM, FLUOXETINE, FLUVOXAMINE, PAROXETINE, SERTRALINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;DOSAGE, EFFICACY;DECREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_TROUGH CONCENTRATION
DISULFIRAM;SLC6A3;rs28363170;GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT/GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;DOSAGE;INCREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DECREASED_DOSE
BENAZEPRIL, PERINDOPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESPONSE
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;*4/*4;LADME_PK;DECREASED_CLEARANCE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;DOSAGE;DECREASED_DOSE
THIOGUANINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;INCREASED_CLEARANCE
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE
PROGUANIL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME_PK;DECREASED_METABOLISM
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C + *3A/*3A;DOSAGE;DECREASED_DOSE
CITALOPRAM;CYP2C19;CYP2C19*17;*17/*17;EFFICACY;DECREASED_RESPONSE
N-DESMETHYLCLOZAPINE;CYP2C19;CYP2C19*1, CYP2C19*17;*17;LADME_PK;INCREASED_CONCENTRATIONS
CLOZAPINE;CYP2C19;CYP2C19*17;*17/*17;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs104894541;C;DOSAGE;INCREASED_DOSE
EFAVIRENZ;CYP2B6;rs36118214;GG;LADME_PK;DECREASED_METABOLISM
WARFARIN;VKORC1;rs104894539;A;DOSAGE;INCREASED_DOSE
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME_PK;DECREASED_METABOLISM
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*1, CYP2B6*30;*1/*30;LADME_PK;DECREASED_METABOLISM
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*1, CYP2B6*29;*1/*29;LADME_PK;DECREASED_METABOLISM
LANSOPRAZOLE, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE
CYCLOPHOSPHAMIDE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;LADME_PK;DECREASED_METABOLISM
QUINAPRIL;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del;EFFICACY;INCREASED_RESPONSE
CYCLOPHOSPHAMIDE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;EFFICACY;DECREASED_RESPONSE
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE
TESTOSTERONE;UGT1A4;UGT1A4*1a, UGT1A4*3a;*3a;EFFICACY, LADME_PK;INCREASED_CLEARANCE
CYCLOPHOSPHAMIDE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE
HYDRALAZINE;NAT2;NAT2;slow_acetylator;LADME_PK;DECREASED_METABOLISM
ACENOCOUMAROL;CYP2C9;CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DOSE
LAMOTRIGINE;UGT1A4;UGT1A4*1a, UGT1A4*2, UGT1A4*3a;*2 + *3a;EFFICACY, LADME_PK;DECREASED_CLEARANCE
CURCUMIN, IVACAFTOR;CFTR;rs77010898;AA + AG;EFFICACY;RESPONSE
AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;LADME_PK;INCREASED_CONCENTRATIONS
3-HYDROXYCOTININE;CYP2A6;CYP2A6*1, CYP2A6*12;*1/*12;LADME_PK;DECREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;LADME_PK;DECREASED_METABOLISM
CAPTOPRIL;ACE;rs1799752;del/del;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1;EFFICACY;DECREASED_RESPONSE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;DOSAGE, LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE
METOPROLOL;CYP2D6;CYP2D6*1, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*45, CYP2D6*46;*9 + *29 + *45 + *46 + *17 + *10;TOXICITY, LADME_PK;DECREASED_METABOLISM
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED_RESISTANCE
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *17/*2 + *17/*3 + *2/*2 + *2/*3 + *3/*3;LADME_PK;DECREASED_CLEARANCE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17;DOSAGE, LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;INCREASED_CLEARANCE
METHOTREXATE;HLA-G;rs371194629;del/del;EFFICACY;INCREASED_RESPONSE
METOPROLOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*4 + *3 + *5  + *6;TOXICITY, LADME_PK;DECREASED_METABOLISM
SN-38;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;LADME_PK;DECREASED_METABOLISM
ESOMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*17;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;LADME_PK;INCREASED_CLEARANCE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;DOSAGE, LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*6/*6 + *28/*28 + *6/*28;DOSAGE;DECREASED_DOSE
CAPTOPRIL;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED_RESPONSE
PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE
IVACAFTOR, TEZACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN;LADME_PK;INCREASED_METABOLISM
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;DOSAGE;DECREASED_DOSE
LOSARTAN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3;EFFICACY;DECREASED_CLINICAL BENEFIT
CHIGLITAZAR;PPARA;rs1800234;CC + CT;EFFICACY;DECREASED_CLINICAL BENEFIT
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;LADME_PK;DECREASED_METABOLISM
LAMOTRIGINE;UGT1A4;UGT1A4*1a, UGT1A4*1b;*1b;LADME_PK;DECREASED_CONCENTRATIONS
HALOPERIDOL;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*5 + *10;LADME_PK;DECREASED_METABOLISM
HALOPERIDOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*3 + *4;LADME_PK;DECREASED_METABOLISM
ZUCLOPENTHIXOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*1/*4 + *3/*4;LADME_PK;DECREASED_METABOLISM
AZATHIOPRINE, MERCAPTOPURINE;TPMT;TPMT low activity;;LADME_PK;DECREASED_METABOLISM
O-DESMETHYLTRAMADOL;SLC22A1;SLC22A1 deficiency;;LADME_PK;INCREASED_CONCENTRATIONS
MERCAPTOPURINE;TPMT;TPMT intermediate activity;;EFFICACY;INCREASED_RESPONSE
FENTANYL;CYP3A4;rs2242480;T/T;DOSAGE;DECREASED_DOSE
SULFASALAZINE;NAT2;NAT2;slow_acetylator;OTHER;INCREASED_DISCONTINUATION
FENTANYL;CYP3A4;rs2242480;T/T;LADME_PK;INCREASED_CONCENTRATIONS
ETHANOL;OPRM1;rs1799971;G;DOSAGE;INCREASED_DOSE
SUFENTANIL;CYP3A4;rs2242480;T/T;EFFICACY;INCREASED_RESPONSE
SUFENTANIL;CYP3A4;rs2242480;T/T;DOSAGE;DECREASED_DOSE
SUFENTANIL;CYP3A4;rs2242480;T/T;LADME_PK;DECREASED_CONCENTRATIONS
TACROLIMUS;CYP3A4;rs2242480;C/C;OTHER, LADME_PK;DECREASED_METABOLISM
FENTANYL;CYP3A4;rs2242480;T/T;DOSAGE;DECREASED_DOSE
SUFENTANIL;CYP3A4;rs2242480;T/T;DOSAGE;DECREASED_DOSE
FENTANYL;CYP3A4;rs2242480;T/T;DOSAGE;DECREASED_DOSE
BETA BLOCKING AGENTS;GRK5;rs4752292;T;EFFICACY;DECREASED_RESPONSE
INTERFERON BETA-1A;HLA-B;HLA-B*15:01;*15:01;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DOSE
RUBELLA VACCINES;HLA-B;HLA-B*35:03;*35:03;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;HLA-B;HLA-B*38:01;*38:01;EFFICACY;DECREASED_RESPONSE
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART);OPRM1;rs671531;GG;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*18;*1/*18;LADME_PK;INCREASED_METABOLISM
CYCLOSPORINE;CYP3A4;CYP3A4*1, CYP3A4*18;*18/*18;LADME_PK;INCREASED_METABOLISM
USTEKINUMAB;HLA-C;HLA-C*06:02;*06:02;EFFICACY;INCREASED_RESPONSE
METHOTREXATE;HLA-C;HLA-C*06:02;*06:02;EFFICACY;INCREASED_RESPONSE
FENTANYL;CYP3A4;CYP3A4*1, CYP3A4*18;*18/*18;DOSAGE, EFFICACY;DECREASED_DOSE
RUBELLA VACCINES;HLA-C;HLA-C*15:02;*15:02;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;HLA-C;HLA-C*01:02, HLA-C*02:02, HLA-C*03:02, HLA-C*04:01, HLA-C*05:01, HLA-C*06:02, HLA-C*07:01, HLA-C*08:01, HLA-C*12:02, HLA-C*14:02, HLA-C*15:02, HLA-C*16:01, HLA-C*17:01;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;EFFICACY;DECREASED_RESPONSE
MEASLES VACCINES;HLA-DQA1;HLA-DQA1*01:04;*01:04;EFFICACY;INCREASED_RESPONSE
MEASLES VACCINES;HLA-DRB1;HLA-DRB1*01:01;*01:01;EFFICACY;RESPONSE
CYCLOSPORINE;CYP3A4;CYP3A4*1, CYP3A4*18;*1/*1;LADME_PK;INCREASED_CONCENTRATIONS
INTERFERON BETA-1A;HLA-DRB1;HLA-DRB1*04:01;*04:01;EFFICACY;INCREASED_RESPONSE
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;HLA-DRB1;HLA-DRB1*04:01;*04:01;EFFICACY;INCREASED_RESPONSE
HEPATITIS VACCINES;HLA-DRB1;HLA-DRB1*07:01;*07:01;EFFICACY;DECREASED_RESPONSE
INFLUENZA VACCINES;HLA-DRB1;HLA-DRB1*07:01;*07:01;EFFICACY;DECREASED_RESPONSE
MEASLES VACCINES;HLA-DRB1;HLA-DRB1*08:01;*08:01;EFFICACY;RESPONSE
INFLUENZA VACCINES;HLA-DRB1;HLA-DRB1*13:01;*13:01;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP2C8;CYP2C8*1, CYP2C8*3;*1/*3 + *3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
METHOTREXATE;GGH;rs11545078;AA + AG;TOXICITY;INCREASED_DISCONTINUATION
IBUPROFEN;CYP2C8;CYP2C8*1, CYP2C8*3;*1/*3;DOSAGE;DECREASED_DOSE
METHADONE;CYP2B6;CYP2B6*1, CYP2B6*5, CYP2B6*6, CYP2B6*7, CYP2B6*18;*1/*6 + *1/*18 + *6/*6 + *6/*18;LADME_PK;DECREASED_METABOLISM
DISULFIRAM;SLC6A4;SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T;HTTLPR short form (S allele) / HTTLPR short form (S allele) + HTTLPR short form (S allele) / L allele-rs25531C + L allele-rs25531C / L allele-rs25531C;EFFICACY;INCREASED_RESPONSE
SERTRALINE;CYP2B6;CYP2B6*1, CYP2B6*4;*1/*4 + *4/*4;LADME_PK;DECREASED_CONCENTRATIONS
SERTRALINE;CYP2B6;CYP2B6*1, CYP2B6*6, CYP2B6*9;*6 + *9;LADME_PK;INCREASED_CONCENTRATIONS
SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;LADME_PK;DECREASED_CONCENTRATIONS
SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4;*2 + *3 + *4;LADME_PK;INCREASED_CONCENTRATIONS
SERTRALINE;CYP2B6;CYP2B6*1, CYP2B6*9;*9/*9;LADME_PK;INCREASED_HALF_LIFE TIME
PRAVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*15;*1/*15;EFFICACY;DECREASED_RESPONSE
RIFAMPIN, WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*11;*2 + *3 + *11;EFFICACY;INCREASED_RESPONSE
ACYCLOVIR;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5;*2/*2 +*2/*3 +*3/*3 + *5/*5;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;ABCB1;rs1045642;GG;LADME_PK;INCREASED_METABOLISM
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE
FLUVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*14;*14;EFFICACY;INCREASED_RESPONSE
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_DOSE
METHADONE;CYP2B6;CYP2B6*6;*6/*6;TOXICITY;DECREASED_METABOLISM
METHOTREXATE;SLCO1B1;SLCO1B1*1, SLCO1B1*31, SLCO1B1*37;*31;LADME_PK;DECREASED_CLEARANCE
METHOTREXATE;SLCO1B1;SLCO1B1*1, SLCO1B1*20, SLCO1B1*37;*20;LADME_PK;INCREASED_CLEARANCE
CONJUGATED ESTROGENS;SLCO1B1;rs4149056;TT;LADME_PK;DECREASED_CONCENTRATIONS
METHOTREXATE;SLCO1B1;SLCO1B1*1, SLCO1B1*23, SLCO1B1*37;*23;LADME_PK;DECREASED_CLEARANCE
ACENOCOUMAROL;CYP2C18;rs1998591;GG;DOSAGE;INCREASED_DOSE
ACENOCOUMAROL;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3;EFFICACY;INCREASED_RESISTANCE
METHOTREXATE;SLCO1B1;SLCO1B1*1, SLCO1B1*15, SLCO1B1*37;*15;LADME_PK;DECREASED_CLEARANCE
ATORVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*15, SLCO1B1*37;*15;LADME_PK;INCREASED_CONCENTRATIONS
ATRASENTAN;SLCO1B1;SLCO1B1*1, SLCO1B1*14, SLCO1B1*15, SLCO1B1*37;*15/*15 + *1/*15 + *15/*37 + *14/*37;LADME_PK;INCREASED_CONCENTRATIONS
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;LADME_PK;DECREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_STEADY_STATE CONCENTRATION
3,4-DEHYDROCILOSTAZOL;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_CONCENTRATIONS
BETA BLOCKING AGENTS;ADRA2C;rs61767072;del;EFFICACY;INCREASED_RESPONSE
ARIPIPRAZOLE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41;*3 + *4 + *4xN + *5 + *6 + *10 + *41;LADME_PK;INCREASED_CONCENTRATIONS
ATOMOXETINE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;LADME_PK;INCREASED_CONCENTRATIONS
DOCETAXEL, THALIDOMIDE;SULT1C4;rs1402467;G;EFFICACY;INCREASED_RESPONSE
ATOMOXETINE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;DOSAGE;DECREASED_DOSE
ATOMOXETINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2;LADME_PK;INCREASED_CONCENTRATIONS
AMITRIPTYLINE, CLOMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17;OTHER;INCREASED_DISCONTINUATION
MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5, NUDT15*6;*1/*2 + *1/*3 + *1/*5 + *1/*6;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*1;DOSAGE;INCREASED_DOSE
BREXPIPRAZOLE;CYP2D6;CYP2D6*1, CYP2D6*2;*2;LADME_PK;DECREASED_METABOLISM
BREXPIPRAZOLE;CYP2D6;CYP2D6*1, CYP2D6*9, CYP2D6*10, CYP2D6*14, CYP2D6*17, CYP2D6*29, CYP2D6*41;*9 +*10 + *14 + *17 + *29 + *41;LADME_PK;DECREASED_METABOLISM
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE
N-DESMETHYLTRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;*1/*5 + *1/*10 + *2/*5 + *2/*10 + *5/*10 + *10/*10;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE
VENLAFAXINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE
VENLAFAXINE;SLC6A4;SLC6A4 L allele-rs25531T;L allele-rs25531T/L allele-rs25531T;EFFICACY;INCREASED_RESPONSE
VENLAFAXINE;SLC6A4;SLC6A4 L allele-rs25531T;L allele-rs25531T/L allele-rs25531T;EFFICACY;DECREASED_RESPONSE
METHOTREXATE;ABCC2;rs717620;CT + TT;TOXICITY;DECREASED_DISCONTINUATION
KETOROLAC;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;EFFICACY;INCREASED_RESPONSE
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*4;*4;EFFICACY;DECREASED_RESPONSE
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ERCC1;rs3212948;C;EFFICACY;INCREASED_RESPONSE
SERTRALINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE
ENDOXIFEN;CYP3A4;CYP3A4*1, CYP3A4*22;*22/*22;LADME_PK;DECREASED_CONCENTRATIONS
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*22;DOSAGE;DECREASED_DOSE
MIDAZOLAM;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_CLEARANCE
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*17, CYP2D6*29;*17/*29 + *17/*17;LADME_PK;DECREASED_CONCENTRATIONS
LIRAGLUTIDE;GLP1R;rs10305420;TT;EFFICACY;INCREASED_CLINICAL BENEFIT
TAMOXIFEN;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;LADME_PK;DECREASED_METABOLISM
N-DESMETHYLTAMOXIFEN;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME_PK;DECREASED_METABOLISM
TAMOXIFEN;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;LADME_PK;DECREASED_METABOLISM
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
OXYCODONE;CYP2C19;CYP2C19 poor metabolizers and intermediate metabolizers;;LADME_PK;DECREASED_METABOLISM
OXYCODONE;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;LADME_PK;DECREASED_METABOLISM
OXYCODONE;CYP3A4;CYP3A4*1, CYP3A4*22;*22;LADME_PK;DECREASED_METABOLISM
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_CLEARANCE
BEVACIZUMAB, CYCLOPHOSPHAMIDE;CXCL8;rs4073;AA + AT;EFFICACY;DECREASED_RESPONSE
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*4;*4/*4;LADME_PK;DECREASED_METABOLISM
DULOXETINE;CYP2D6;CYP2D6*4;*4/*4;LADME_PK;INCREASED_CONCENTRATIONS
N-DESMETHYLCLOZAPINE;CYP3A4;CYP3A4 low activity;;LADME_PK;DECREASED_CONCENTRATIONS
DIHYDROPYRIDINE DERIVATIVES;CYP3A5;rs776746;TT;OTHER;INCREASED_DISCONTINUATION
DESVENLAFAXINE;CYP2D6;CYP2D6*4;*4/*4;LADME_PK;DECREASED_CONCENTRATIONS
N-DESMETHYLCLOZAPINE;CYP1A2;CYP1A2 low activity;;LADME_PK;DECREASED_CONCENTRATIONS
DESVENLAFAXINE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;LADME_PK;DECREASED_CONCENTRATIONS
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*9, CYP2A6*17, CYP2A6*35;*1/*35 + *9/*35 + *17/*35;LADME_PK;DECREASED_METABOLISM
DISULFIRAM;ALDH2;ALDH2 deficiency;;EFFICACY;INCREASED_RESPONSE
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*46;*1/*46 + *46/*46;LADME_PK;INCREASED_METABOLISM
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*12, CYP2A6*17, CYP2A6*20, CYP2A6*23, CYP2A6*24, CYP2A6*25, CYP2A6*26, CYP2A6*27, CYP2A6*28, CYP2A6*35;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;LADME_PK;DECREASED_METABOLISM
EFAVIRENZ;CYP2B6;CYP2B6*6;*6;LADME_PK;INCREASED_CONCENTRATIONS
NICOTINE;CYP2A6;rs137904044;A;LADME_PK;DECREASED_METABOLISM
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*35;*35/*35;LADME_PK;DECREASED_METABOLISM
NICOTINE;CYP2A6;rs571335587;A;LADME_PK;DECREASED_METABOLISM
NICOTINE;CYP2A6;rs28399454;T;LADME_PK;DECREASED_METABOLISM
NICOTINE;CYP2A6;rs140471703;T;LADME_PK;DECREASED_METABOLISM
NICOTINE;CYP2A6;rs199515342;A;LADME_PK;DECREASED_METABOLISM
NICOTINE;CYP2A6;rs61605570;T;LADME_PK;DECREASED_METABOLISM
NICOTINE;CYP2A6;rs768416963;T;LADME_PK;DECREASED_METABOLISM
NICOTINE;CYP2A6;rs1302192284;C;LADME_PK;DECREASED_METABOLISM
NICOTINE;CYP2A6;rs111869995;A;LADME_PK;DECREASED_METABOLISM
NICOTINE;CYP2A6;rs200554095;A;LADME_PK;DECREASED_METABOLISM
NICOTINE;CYP2A6;rs772964366;G;LADME_PK;DECREASED_METABOLISM
NICOTINE;CYP2A6;rs145308399;T;LADME_PK;DECREASED_METABOLISM
NICOTINE;CYP2A6;rs758479488;T;LADME_PK;DECREASED_METABOLISM
NICOTINE;CYP2A6;rs145157460;T;LADME_PK;DECREASED_METABOLISM
NICOTINE;CYP2A6;rs148693084;G;LADME_PK;DECREASED_METABOLISM
NICOTINE;CYP2A6;rs1303839356;T;LADME_PK;DECREASED_METABOLISM
NICOTINE;CYP2A6;rs374515279;T;LADME_PK;DECREASED_METABOLISM
NICOTINE;CYP2A6;rs777098658;G;LADME_PK;DECREASED_METABOLISM
WARFARIN;VKORC1;rs11150606;C;DOSAGE;DECREASED_DOSE
NICOTINE;CYP2A6;rs5031016;G;LADME_PK;DECREASED_METABOLISM
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*14, CYP2A6*38, CYP2A6*46;*1 + *46 + *9 + *14 + *38;LADME_PK;INCREASED_METABOLISM
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*9, CYP2A6*12, CYP2A6*38, CYP2A6*46;*1 + *9 + *12 + *38;LADME_PK;DECREASED_METABOLISM
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE
OXALIPLATIN;MTHFR;rs1801131;GG + GT;EFFICACY;INCREASED_RESPONSE
ALPRAZOLAM;CYP3A4;CYP3A4 low activity;;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A4;rs2242480;C/C;LADME_PK;DECREASED_METABOLISM
TACROLIMUS;CYP3A4;rs2242480;C/C;LADME_PK;DECREASED_METABOLISM
TACROLIMUS;CYP3A4;rs2242480;C/T + T/T;LADME_PK;INCREASED_CLEARANCE
TACROLIMUS;CYP3A4;rs2242480;C/C;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
FENTANYL;CYP3A4;rs2242480;T/T;DOSAGE;DECREASED_DOSE
ENDOXIFEN;CYP2D6;CYP2D6;intermediate_metabolizer;LADME_PK;DECREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5 intermediate metabolizer and normal metabolizer;;DOSAGE;INCREASED_DOSE
CLOZAPINE;ABCG2;rs2231142;GT + TT;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
DOLUTEGRAVIR;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*28/*28 + *6/*6;LADME_PK;INCREASED_CONCENTRATIONS
ASPIRIN, CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED_RESPONSE
(S)-METHADONE;CYP2B6;CYP2B6*1, CYP2B6*6, CYP2B6*7, CYP2B6*9, CYP2B6*18;*6 + *7 + *9 + *18;LADME_PK;DECREASED_CLEARANCE
MERCAPTOPURINE, THIOGUANINE;TPMT;TPMT*1, TPMT*3C;*1/*3C;DOSAGE;DECREASED_DOSE
MERCAPTOPURINE, THIOGUANINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;DOSAGE;DECREASED_DOSE
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7;*4/*4 + *4/*7;OTHER, LADME_PK;DECREASED_METABOLISM
HYDRALAZINE;NAT2;NAT2;rapid_acetylator;DOSAGE, EFFICACY;INCREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*13;*1/*13;DOSAGE;DECREASED_DOSE
L-METHYLFOLATE;MTHFR;rs1801133;AG;EFFICACY;INCREASED_RESPONSE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
HYDRALAZINE;NAT2;NAT2;slow_acetylator;LADME_PK;INCREASED_CONCENTRATIONS
VENLAFAXINE;CYP2D6;CYP2D6;intermediate_metabolizer;LADME_PK;DECREASED_METABOLISM
ESCITALOPRAM;CYP2C19;CYP2C19;intermediate_metabolizer;LADME_PK;DECREASED_METABOLISM
SOMATROPIN RECOMBINANT;COL1A1;rs1800012;AA;DOSAGE;DECREASED_DOSE
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*7, CYP2A6*9, CYP2A6*10, CYP2A6*11, CYP2A6*13, CYP2A6*15, CYP2A6*17, CYP2A6*19, CYP2A6*20;*2 + *4 + *7 + *9 + *10 + *11 + *13 + *15 + *17 + *19 + *20;LADME_PK;DECREASED_METABOLISM
TEGAFUR;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*11;*11/*4;LADME_PK;DECREASED_METABOLISM
LETROZOLE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*12, CYP2A6*17, CYP2A6*20, CYP2A6*23, CYP2A6*35;*1/*17 + *20/*23 + *9/*9 + *1/*4 + *1/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1/*9 + *1/*12;LADME_PK;DECREASED_CLEARANCE
L-METHYLFOLATE;MTHFR;rs1801131;GT;EFFICACY;INCREASED_RESPONSE
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*46;*1/*46;LADME_PK;INCREASED_CLEARANCE
COUMARIN;CYP2A6;CYP2A6*5, CYP2A6*47;*5/*47;LADME_PK;DECREASED_METABOLISM
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*12, CYP2A6*17, CYP2A6*20, CYP2A6*23, CYP2A6*24, CYP2A6*25, CYP2A6*26, CYP2A6*27, CYP2A6*28, CYP2A6*35, CYP2A6*46;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;LADME_PK;DECREASED_METABOLISM
VITAMIN B-COMPLEX, INCL. COMBINATIONS;MTHFR;rs1801133;A;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs2359612;A;DOSAGE;DECREASED_DOSE
VITAMIN B-COMPLEX, INCL. COMBINATIONS;MTHFR;rs1801131;G;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;G;DOSAGE;DOSE
ATOMOXETINE;SLC6A2;rs12708954;A;EFFICACY;INCREASED_RESPONSE
CYCLOSPORINE, TACROLIMUS;CYP3A4;rs2740574;C;LADME_PK;DECREASED_CONCENTRATIONS
MERCAPTOPURINE;NUDT15;rs746071566;del;DOSAGE, TOXICITY;DECREASED_DOSE
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_DOSE
RIZATRIPTAN;DRD2;rs6275;AA + AG;EFFICACY;DECREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;DECREASED_CLEARANCE
WARFARIN;CYP2C9;rs1799853;C;DOSAGE;DOSE
WARFARIN;VKORC1;rs61162043;G;DOSAGE;INCREASED_DOSE
SULFONAMIDES, UREA DERIVATIVES;CYP2C9;rs1057910;CC;EFFICACY;INCREASED_RESPONSE
NICOTINE;OPRM1;rs1799971;AG + GG;EFFICACY;DECREASED_RESPONSE
RISPERIDONE;DRD3;rs6280;CC + CT;EFFICACY;INCREASED_RESPONSE
ACENOCOUMAROL;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE
SIROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;DECREASED_CONCENTRATIONS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2/*3;DOSAGE;DECREASED_DOSE
CYSTEAMINE;CFTR;rs113993960;CTT/del + del/del;EFFICACY;INCREASED_RESPONSE
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3/*3;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2/*2;DOSAGE;DECREASED_DOSE
HYDRALAZINE;NAT2;NAT2;slow_acetylator;LADME_PK;INCREASED_CONCENTRATIONS
FLUOROURACIL;DPYD;DPYD deficiency;;LADME_PK;DECREASED_METABOLISM
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C;DOSAGE;DECREASED_DOSE
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME_PK;INCREASED_CONCENTRATIONS
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;EFFICACY;DECREASED_RESPONSE
HYDRALAZINE;NAT2;NAT2;slow_acetylator;LADME_PK;DECREASED_METABOLISM
CODEINE;CYP2D6;CYP2D6*17;*17;LADME_PK;DECREASED_METABOLISM
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;DOSAGE;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*17 + *1/*2 + *17/*17;DOSAGE;DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1;LADME_PK;DECREASED_TROUGH CONCENTRATION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;DOSAGE, EFFICACY;DECREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_METABOLISM
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
ARIPIPRAZOLE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6;*4 + *5 + *6;LADME_PK;DECREASED_METABOLISM
RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*17 + *17/*17 + *1/*2;DOSAGE;DOSE
PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*1 + *1/*17;LADME_PK;INCREASED_METABOLISM
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*3;DOSAGE;DECREASED_DOSE
ANTHRACYCLINES AND RELATED SUBSTANCES, CAPECITABINE, CYCLOPHOSPHAMIDE, FLUOROURACIL, TAXANES;GSTM1;GSTM1 non-null, GSTM1 null;;EFFICACY;DECREASED_RESPONSE
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_TROUGH CONCENTRATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_METABOLISM
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_DOSE
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME_PK;INCREASED_METABOLISM
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_METABOLISM
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;DOSAGE;INCREASED_DOSE
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;LADME_PK;INCREASED_METABOLISM
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_METABOLISM
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;LADME_PK;DECREASED_CLEARANCE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;INCREASED_CLEARANCE
MIANSERIN;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*1/*10 + *5/*10;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME_PK;DECREASED_CLEARANCE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_CLEARANCE
SALVIANOLIC ACID B;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE
VALPROIC ACID;UGT1A6;UGT1A6*1a, UGT1A6*2a, UGT1A6*3a, UGT1A6*4a, UGT1A6*8;*1a;LADME_PK;METABOLISM
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
VALPROIC ACID;UGT1A6;UGT1A6*1a, UGT1A6*2a, UGT1A6*3a, UGT1A6*4a, UGT1A6*8;*1a;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*8;*8/*8;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;LADME_PK;INCREASED_CONCENTRATIONS
CYCLOSPORINE;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*1;LADME_PK;INCREASED_CLEARANCE
CAPECITABINE, FLUOROURACIL;DPYD;rs55886062;C;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
SIROLIMUS, TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*18;*18;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;DOSAGE, EFFICACY;INCREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;EFFICACY;DECREASED_RESPONSE
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *3/*3 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*41;LADME_PK;DECREASED_METABOLISM
VORICONAZOLE;CYP2C19;CYP2C19*17;*17/*17;EFFICACY;DECREASED_RESPONSE
ENDOXIFEN;CYP2D6;CYP2D6 normal metabolizer and ultrarapid metabolizer;;LADME_PK;INCREASED_CONCENTRATIONS
IMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2;LADME_PK;INCREASED_CONCENTRATIONS
O-DESMETHYLTRAMADOL;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE
ISONIAZID;NAT2;NAT2;slow_acetylator;LADME_PK;DECREASED_CONCENTRATIONS
ESCITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;DOSAGE;DECREASED_DOSE
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;DOSAGE;DECREASED_DOSE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE
OMEPRAZOLE, PANTOPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2;LADME_PK;DECREASED_METABOLISM
CORTICOSTEROIDS;NR1I2;rs3842689;del/del;EFFICACY;INCREASED_RESISTANCE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;GG;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;DOSAGE;DECREASED_DOSE
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28;DOSAGE;DECREASED_DOSE
VORICONAZOLE;CYP2C19;CYP2C19 poor metabolizers and intermediate metabolizers;;LADME_PK;INCREASED_TROUGH CONCENTRATION
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*26;*26;LADME_PK;DECREASED_METABOLISM
IRBESARTAN;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED_RESPONSE
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;LADME_PK;DECREASED_EXPOSURE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_CONCENTRATIONS
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4;*2 + *3 + *4;LADME_PK;INCREASED_EXPOSURE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_CLEARANCE
SIPOGLITAZAR;UGT2B15;UGT2B15*1, UGT2B15*2;*2/*2;EFFICACY, LADME_PK;INCREASED_RESPONSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE
SERTRALINE;CYP2B6;CYP2B6*1, CYP2B6*6, CYP2B6*9;*6/*9 + *1/*6 + *6/*6;LADME_PK;INCREASED_CONCENTRATIONS
CLOMIPRAMINE;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN;LADME_PK;DECREASED_CONCENTRATIONS
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10 + *1/*10;DOSAGE, LADME_PK;INCREASED_DOSE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED_RESISTANCE
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME_PK;INCREASED_CONCENTRATIONS
NORTRIPTYLINE;CYP2D6;CYP2D6*1xN, CYP2D6*2;*2/*1xN;LADME_PK;INCREASED_METABOLISM
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DECREASED_DOSE
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6, CYP2B6*26;*1/*26 + *6/*6 + *6/*26;DOSAGE;DECREASED_DOSE
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE
NORTRIPTYLINE;CYP2D6;CYP2D6*1xN, CYP2D6*2;*2/*1xN;DOSAGE, EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;CYP3A5*1;*1;LADME_PK;DECREASED_TROUGH CONCENTRATION
CLOPIDOGREL, PRASUGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1 + *1/*2 + *1/*3;EFFICACY;RESPONSE
CLOPIDOGREL;CYP2C19;CYP2C19*2, CYP2C19*3, CYP2C19*17;*2 + *3 + *17;DOSAGE;DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
CLOMIPRAMINE;CYP2D6;CYP2D6*1xN, CYP2D6*2;*2/*1xN;DOSAGE, EFFICACY;DECREASED_RESPONSE
SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;LADME_PK;DECREASED_METABOLISM
SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17;LADME_PK;INCREASED_METABOLISM
NICOTINE;CYP2A6;CYP2A6*4, CYP2A6*9, CYP2A6*17, CYP2A6*26;*4/*17 + *9/*26;LADME_PK;DECREASED_METABOLISM
SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME_PK;DECREASED_METABOLISM
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;EFFICACY;INCREASED_RESISTANCE
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*41;*3/*4 + *4/*4;LADME_PK;DECREASED_CONCENTRATIONS
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*4/*4 + *3/*4 + *4/*5 + *4/*6;LADME_PK;DECREASED_CONCENTRATIONS
MORPHINE;SLC22A1;rs72552763;GAT/del + del/del;LADME_PK;DECREASED_CLEARANCE
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*17, CYP2D6*41;*4/*41 + *4/*10 + *4/*17 + *5/*41;LADME_PK;DECREASED_CONCENTRATIONS
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*1/*4 + *2/*4 + *1/*5 + *1/*3 + *2/*5 + *1/*6 + *2/*3 + *2/*6;LADME_PK;DECREASED_CONCENTRATIONS
IMATINIB;GSTT1;GSTT1 non-null, GSTT1 null;null/null;EFFICACY;DECREASED_RESPONSE
GLUCOCORTICOIDS;HSD3B1;rs1047303;AA + AC;EFFICACY;INCREASED_RESISTANCE
DEXTROMETHORPHAN;CYP2D6;CYP2D6*4xN, CYP2D6*12, CYP2D6*29, CYP2D6*84;*12/*84 + *4xN/*29;LADME_PK;DECREASED_METABOLISM
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;LADME_PK;DECREASED_METABOLISM
ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, PANTOPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17;LADME_PK;INCREASED_METABOLISM
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;LADME_PK;DECREASED_METABOLISM
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*17/*17;LADME_PK;DECREASED_CONCENTRATIONS
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*1 + *1/*17;LADME_PK;INCREASED_METABOLISM
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DECREASED_DOSE
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*41;*3/*9 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*17 + *5/*41 + *41/*41;LADME_PK;DECREASED_CONCENTRATIONS
SIMVASTATIN;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME_PK;CONCENTRATIONS
MORPHINE;SLC22A1;rs72552763;del/del;LADME_PK;DECREASED_CLEARANCE
METHOTREXATE;SLCO1B1;SLCO1B1*1, SLCO1B1*5, SLCO1B1*37;*5;LADME_PK;DECREASED_CLEARANCE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;LADME_PK;DECREASED_METABOLISM
FLUVOXAMINE, PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;EFFICACY;DECREASED_RESPONSE
SILDENAFIL;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME_PK;INCREASED_CONCENTRATIONS
EFAVIRENZ;CYP2B6;CYP2B6*6;*6/*6;LADME_PK;DECREASED_CLEARANCE
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;DOSAGE;DECREASED_DOSE
SN-38;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28 + *1/*28;LADME_PK;DECREASED_METABOLISM
EFAVIRENZ;CYP2B6;CYP2B6*6;*6;LADME_PK;METABOLISM
ANTIEMETICS AND ANTINAUSEANTS;SLC22A1;rs55918055;C;EFFICACY, LADME_PK;DECREASED_RESPONSE
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3;EFFICACY;INCREASED_RESPONSE
BILIRUBIN;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6 + *6/*6;LADME_PK;INCREASED_CONCENTRATIONS
METHADONE;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3;LADME_PK;INCREASED_CONCENTRATIONS
BILIRUBIN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;LADME_PK;INCREASED_CONCENTRATIONS
METHADONE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_CONCENTRATIONS
METHADONE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME_PK;INCREASED_CONCENTRATIONS
METHOTREXATE;SLCO1B1;SLCO1B1*1, SLCO1B1*14, SLCO1B1*37;*14;LADME_PK;INCREASED_CLEARANCE
WARFARIN;CYP2C9;CYP2C9*1;*1/*1;DOSAGE, LADME_PK;INCREASED_DOSE
SN-38;UGT1A1;UGT1A1*1, UGT1A1*6;*6/*6 + *1/*6;LADME_PK;DECREASED_METABOLISM
PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1;LADME_PK;INCREASED_CLEARANCE
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*1;LADME_PK;INCREASED_METABOLISM
VENLAFAXINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*41;*3/*9 + *4/*17 +  *4/*41 + *4/*10;DOSAGE;DECREASED_DOSE
PACLITAXEL;CYP2C8;CYP2C8*3;*3;LADME_PK;DECREASED_EXPOSURE
PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;LADME_PK;DECREASED_CLEARANCE
CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;LADME_PK;METABOLISM
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_METABOLISM
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE
GLATIRAMER ACETATE;CCR5;rs333;del;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3, CYP2C9*13, CYP2C9*16, CYP2C9*60;*1/*13 + *1/*16 + *1/*60;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_TROUGH CONCENTRATION
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*1;LADME_PK;DOSE_ADJUSTED TROUGH CONCENTRATIONS
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*3A/*3C;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A;*3A/*3A;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DOSE
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*9;*2 + *3 + *8 + *9;LADME_PK;DECREASED_METABOLISM
GLIPIZIDE;TCF7L2;rs7903146;T;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_CLEARANCE
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;DECREASED_RESPONSE
CLOPIDOGREL;SLC14A2;rs12456693;T;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*1;LADME_PK;INCREASED_METABOLISM
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
CISPLATIN, FLUOROURACIL;TPMT;TPMT*3C;*3C;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;DOSAGE;INCREASED_DOSE
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE
CAVOSONSTAT;CFTR;rs113993960;del/del;EFFICACY;RESPONSE
BUPROPION;CYP2B6;CYP2B6*6;*6;LADME_PK;DECREASED_METABOLISM
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2 + *2/*2;LADME_PK;DECREASED_METABOLISM
RISPERIDONE;CYP2D6;CYP2D6*5, CYP2D6*10;*10 + *5;LADME_PK;INCREASED_CONCENTRATIONS
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*2 + *3;LADME_PK;INCREASED_TROUGH CONCENTRATION
ZUCLOPENTHIXOL;CYP2D6;CYP2D6*1, CYP2D6*4;*4;LADME_PK;DECREASED_METABOLISM
NEVIRAPINE;NR1I2;rs3842689;GAGAAG/del + del/del;DOSAGE, LADME_PK;INCREASED_CLEARANCE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
IVACAFTOR / LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;LADME_PK;DECREASED_TROUGH CONCENTRATION
MIDAZOLAM;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME_PK;DECREASED_CLEARANCE
SN-38;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*6 + *28;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;DOSAGE;DECREASED_DOSE
IVACAFTOR / LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE
HALOPERIDOL;CYP2D6;CYP2D6*1, CYP2D6*5;*5;LADME_PK;DECREASED_METABOLISM
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_METABOLISM
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED_RESPONSE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;LADME_PK;DECREASED_CONCENTRATIONS
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*17;*1/*2 + *1/*8 + *2/*2 + *2/*3;LADME_PK;DECREASED_METABOLISM
MEASLES VACCINES;HLA-B;HLA-B*51:01;*51:01;EFFICACY;DECREASED_RESPONSE
BUCINDOLOL;ADRA2C;rs61767072;GGGGCGGGGCCG/GGGGCGGGGCCG;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_METABOLISM
RISPERIDONE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;DOSAGE;DECREASED_DOSE
MEASLES VACCINES;HLA-B;HLA-B*07:02;*07:02;EFFICACY;INCREASED_RESPONSE
MEASLES VACCINES;HLA-B;HLA-B*13:01;*13:01;EFFICACY;DECREASED_RESPONSE
MEASLES VACCINES;HLA-B;HLA-B*08:01;*08:01;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*3;DOSAGE;DECREASED_DOSE
INFLUENZA VACCINES;HLA-DQB1;HLA-DQB1*03:03;*03:03;EFFICACY;DECREASED_RESPONSE
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1 + *1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE
OMEPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE
MEASLES VACCINES;HLA-DQA1;HLA-DQA1*02:01;*02:01;EFFICACY;DECREASED_RESPONSE
MEASLES VACCINES;HLA-DRB1;HLA-DRB1*03:01;*03:01;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_METABOLISM
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*20;*1/*20;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_METABOLISM
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE
FLUOROURACIL;DPYD;DPYD;poor_metabolizer;DOSAGE;DECREASED_DOSE
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME_PK;INCREASED_CONCENTRATIONS
ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;DOSAGE;DECREASED_DOSE
ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;DOSAGE;INCREASED_DOSE
CISPLATIN, FLUOROURACIL;TPMT;TPMT*3B;*3B;EFFICACY;DECREASED_RESPONSE
ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;EFFICACY;DECREASED_RESPONSE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_METABOLISM
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;DOSAGE;INCREASED_DOSE
AMITRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*10;*4/*5 + *4/*4;LADME_PK;DECREASED_METABOLISM
SIROLIMUS, TEMSIROLIMUS;ABCB1;rs1128503;GG;LADME_PK;DECREASED_EXPOSURE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_CLEARANCE
AMITRIPTYLINE;CYP2D6;CYP2D6*4;*4/*4;LADME_PK;INCREASED_CONCENTRATIONS
PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *2/*2 + *1/*3 + *3/*3;DOSAGE;DECREASED_DOSE
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1 + *1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*59;*1/*59;DOSAGE;DECREASED_DOSE
METHADONE;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;LADME_PK;INCREASED_CONCENTRATIONS
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *3/*3 + *2/*3;DOSAGE;DECREASED_DOSE
GRANISETRON;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_CLEARANCE
CODEINE;CYP2D6;CYP2D6*1, CYP2D6*40;*40;EFFICACY;DECREASED_RESPONSE
CODEINE;CYP2D6;CYP2D6*1, CYP2D6*17;*17;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;OTHER;INCREASED_DISCONTINUATION
CODEINE;CYP2D6;CYP2D6*1, CYP2D6*6;*6;EFFICACY;DECREASED_RESPONSE
CODEINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4;EFFICACY;DECREASED_RESPONSE
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;EFFICACY;DECREASED_RESPONSE
CODEINE;CYP2D6;CYP2D6*1, CYP2D6*5;*5;EFFICACY;DECREASED_RESPONSE
GRANISETRON;CYP1A1;CYP1A1*1, CYP1A1*2A;*2A;LADME_PK;INCREASED_CLEARANCE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
CLOMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;LADME_PK;DECREASED_METABOLISM
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
HMG COA REDUCTASE INHIBITORS;UGT1A1;UGT1A1*28;*28;TOXICITY;DECREASED_DISCONTINUATION
ROCURONIUM;SLCO1A2;rs7967354;CC;DOSAGE;DECREASED_DOSE
PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *2/*2 + *1/*3 + *2/*3;DOSAGE;DECREASED_DOSE
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*3 + *4 + *5 + *6;LADME_PK;INCREASED_CONCENTRATIONS
AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;LADME_PK;INCREASED_CONCENTRATIONS
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*11;*11;LADME_PK;INCREASED_TROUGH CONCENTRATION
ANTIEMETICS AND ANTINAUSEANTS;SLC22A1;rs12208357;T;EFFICACY, LADME_PK;DECREASED_RESPONSE
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME_PK;INCREASED_TROUGH CONCENTRATION
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*3 + *2;DOSAGE;DECREASED_DOSE
CAPECITABINE, FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/CCGCGC(CACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RESPONSE
AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2;LADME_PK;DECREASED_METABOLISM
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;LADME_PK;DECREASED_CLEARANCE
LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE
CARVEDILOL;CYP2D6;CYP2D6*3, CYP2D6*4, CYP2D6*10;*3/*10 + *4/*4;DOSAGE;INCREASED_DOSE
LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3/*3 + *1/*3;DOSAGE;DECREASED_DOSE
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *3/*3 + *2/*3;DOSAGE;DECREASED_DOSE
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE
LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*58;*58;DOSAGE;DECREASED_DOSE
VORICONAZOLE;CYP3A4;CYP3A4*1, CYP3A4*22;*22;LADME_PK;INCREASED_EXPOSURE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;DOSAGE;INCREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;EFFICACY;INCREASED_RESPONSE
AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2;LADME_PK;DECREASED_METABOLISM
IMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*3 + *3/*3;DOSAGE;DECREASED_DOSE
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*3 + *2/*2;DOSAGE;DECREASED_DOSE
VARENICLINE;CYP2A6;CYP2A6 normal metabolizer;;EFFICACY;INCREASED_RESPONSE
AZATHIOPRINE;GSTM1;GSTM1 non-null, GSTM1 null;;LADME_PK;INCREASED_DOSE
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *2/*2 + *1/*3 + *3/*3 + *2/*3;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*12;*1/*12;DOSAGE;DECREASED_DOSE
RALOXIFENE;UGT1A8;UGT1A8*1a, UGT1A8*2, UGT1A8*3;*1a/*3;LADME_PK;INCREASED_METABOLISM
PHENAZEPAM;CYP2C19;CYP2C19*1, CYP2C19*17;*17;EFFICACY;DECREASED_CLINICAL BENEFIT
DAUNORUBICIN;G6PD;G6PD Mediterranean, Dallas, Panama, Sassari, Cagliari, Birmingham;Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham;LADME_PK;DECREASED_METABOLISM
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*5, CYP2C9*6, CYP2C9*11;*5 + *6 + *11;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE
DOLUTEGRAVIR;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28, UGT1A1*36, UGT1A1*37;*28/*28 + *28/*37 + *1/*6 + *1/*28 + *1/*37 + *28/*36 + *36/*37;LADME_PK;DECREASED_CLEARANCE
NICOTINE;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME_PK;DECREASED_METABOLISM
MERCAPTOPURINE;TPMT;TPMT*3A, TPMT*3C;*3A/*3C;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE
DIMETHYL FUMARATE;GSTP1;rs1695;GG;EFFICACY;DECREASED_RESPONSE
MERCAPTOPURINE;TPMT;TPMT*3A;*3A/*3A;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE
VENLAFAXINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;*1/*3 + *1/*4 + *1/*5;LADME_PK;DECREASED_METABOLISM
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_METABOLISM
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE
ESCITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C + *3A/*3A;OTHER;INCREASED_DISCONTINUATION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*8, CYP2C9*11;*2 + *3 + *5 + *8 + *11;DOSAGE;DECREASED_DOSE
O-DESMETHYLTRAMADOL;CYP2D6;CYP2D6;ultrarapid_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS
TOREMIFENE;CYP2D6;CYP2D6*10;*10;EFFICACY;INCREASED_CLINICAL BENEFIT
PRIMAQUINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41;*4/*41 + *5/*6;EFFICACY;DECREASED_RESPONSE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;DECREASED_RESPONSE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;EFFICACY;DECREASED_RESPONSE
TAMOXIFEN;CYP2C19;CYP2C19*1, CYP2C19*2;*2;LADME_PK;DECREASED_METABOLISM
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_CLEARANCE
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;EFFICACY;INCREASED_RESPONSE
ANTIEMETICS AND ANTINAUSEANTS;SLC22A1;rs34059508;A;EFFICACY, LADME_PK;DECREASED_RESPONSE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;OTHER;INCREASED_RESISTANCE
CAPECITABINE, FLUOROURACIL;TYMP;rs11479;AA + AG;DOSAGE;DOSE
USTEKINUMAB;HLA-C;HLA-C*06:02;*06:02;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DOSE
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DOSE
DOXEPIN;CYP2D6;CYP2D6*3, CYP2D6*4;*3/*4;LADME_PK;DECREASED_METABOLISM
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE
PHENYTOIN;CYP2C19;CYP2C19*2, CYP2C19*3;*2 + *3;DOSAGE;DOSE
CLOZAPINE;SLC6A4;SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T;HTTLPR short form (S allele)/L allele-rs25531C;EFFICACY;DECREASED_RESPONSE
PHENYTOIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DOSE
ANTIPSYCHOTICS, HALOPERIDOL, OLANZAPINE, RISPERIDONE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2;EFFICACY;DECREASED_RESPONSE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;EFFICACY;DECREASED_RESPONSE
FOLIC ACID, HYDROXYCHLOROQUINE, METHOTREXATE, SULFASALAZINE;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RESPONSE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;LADME_PK;DECREASED_METABOLISM
FLUVASTATIN;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESPONSE
ONDANSETRON;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN;LADME_PK;INCREASED_METABOLISM
INTERFERON ALFA-2A, RECOMBINANT, RIBAVIRIN;HLA-B;HLA-B*44:02;*44:02;EFFICACY;INCREASED_RESPONSE
ONDANSETRON, TROPISETRON;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN;EFFICACY;DECREASED_RESPONSE
CYCLOSPORINE, TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1;LADME_PK;DECREASED_CONCENTRATIONS
PRAVASTATIN;ACE;rs1799752;del/del;EFFICACY;RESPONSE
MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4, NUDT15*6;*1/*2 + *1/*3 + *1/*4 + *1/*6;DOSAGE;DECREASED_DOSE
EFAVIRENZ;CYP2B6;CYP2B6*6;*6/*6;LADME_PK;DECREASED_METABOLISM
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*18;*1/*18;LADME_PK;DECREASED_METABOLISM
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*9;*1/*9;LADME_PK;DECREASED_METABOLISM
FLUOXETINE, SERTRALINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE
CAPECITABINE, FLUOROURACIL;DPYD;rs3918290;CT;DOSAGE;DOSE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*2/*2 + *2/*3 + *3/*3 + *1/*2 + *1/*3 + *2/*17;EFFICACY;DECREASED_RESPONSE
4-HYDROXYTAMOXIFEN, ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*10;LADME_PK;DECREASED_CONCENTRATIONS
(S)-METHADONE;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE
METOPROLOL;ADRA2C;rs61767072;del;EFFICACY;INCREASED_RESPONSE
ENDOXIFEN;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME_PK;INCREASED_CONCENTRATIONS
IMATINIB;ABCG2;rs2231142;GT + TT;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;DOSAGE;DECREASED_DOSE
CAPECITABINE, FLUOROURACIL;DPYD;rs67376798;AT;DOSAGE;DOSE
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME_PK;DECREASED_CLEARANCE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;LADME_PK;DECREASED_METABOLISM
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME_PK;DECREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*3/*3 + *6/*6 + *7/*7 + *3/*6 + *3/*7 + *6/*7;LADME_PK;DECREASED_METABOLISM
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
GEFITINIB;EGFR;rs121434568;GT;EFFICACY;INCREASED_RESPONSE
VINCRISTINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;INCREASED_METABOLISM
ENDOXIFEN;CYP2D6;CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*41;*9/*4;LADME_PK;INCREASED_CONCENTRATIONS
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6;*1/*4 + *1/*5 + *1/*6;LADME_PK;DECREASED_CONCENTRATIONS
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*9, CYP2D6*10, CYP2D6*41;*9/*41 + *10/*10 + *41/*41;LADME_PK;DECREASED_CONCENTRATIONS
PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*9, CYP2D6*10, CYP2D6*41;*1/*9 + *1/*10 + *1/*41;LADME_PK;DECREASED_CONCENTRATIONS
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;DOSAGE;DECREASED_DOSE
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*81;*1/*81;LADME_PK;INCREASED_CONCENTRATIONS
CAPECITABINE, FLUOROURACIL;DPYD;rs75017182;CG;DOSAGE;DOSE
SIROLIMUS, TEMSIROLIMUS;NR1I2;rs6785049;GG;LADME_PK;INCREASED_EXPOSURE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_CLEARANCE
TACROLIMUS;;rs4646458;G;DOSAGE;DOSE
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;DOSAGE;DECREASED_DOSE
ROCURONIUM;IAPP, SLCO1A2;rs11045995;CC;DOSAGE;DECREASED_DOSE
MEASLES VACCINES;HLA-B;HLA-B*44:02;*44:02;EFFICACY;RESPONSE
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*3 + *4 + *5 + *6;LADME_PK;DECREASED_CONCENTRATIONS
NORTRIPTYLINE;CYP2D6;CYP2D6*1xN, CYP2D6*2;*2/*1xN;LADME_PK;INCREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_CONCENTRATIONS
METOPROLOL;CYP2D6;rs5030655;del/del;EFFICACY;INCREASED_RESPONSE
AMOXICILLIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;RESPONSE
AMOXICILLIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE
MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3;*2/*3;TOXICITY;DECREASED_DOSE
MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5;*1/*2 + *1/*3 + *1/*5;TOXICITY;DECREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_DOSE
ESTRONE SULFATE;SLCO1B1;SLCO1B1*1, SLCO1B1*5;*5;LADME_PK;INCREASED_
HMG COA REDUCTASE INHIBITORS;CXCL5;rs352046;CC;EFFICACY;INCREASED_RESPONSE
AMOXICILLIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;DOSAGE, LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE
DEBRISOQUINE;CYP2D6;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*15;*4/*5 + *4/*15 + *4/*6 + *3/*4 + *4/*4 + *3/*5;LADME_PK;DECREASED_METABOLISM
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;DECREASED_CONCENTRATIONS
DEXTROMETHORPHAN;CYP2D6;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*15;*4/*5 + *4/*15 + *4/*6 + *3/*4 + *4/*4 + *3/*5;LADME_PK;DECREASED_METABOLISM
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3;DOSAGE;DECREASED_DOSE
ATAZANAVIR / RITONAVIR;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*36;*28/*28;TOXICITY;INCREASED_DISCONTINUATION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*5, CYP2C9*6, CYP2C9*11;*2 + *6 + *5 + *11;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*9, CYP2C9*11;*2 + *6 + *5 + *11;DOSAGE;DECREASED_DOSE
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;DECREASED_RESPONSE
CYCLOSPORINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;LADME_PK;DECREASED_CONCENTRATIONS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DOSE
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*6, CYP2D6*8;*4 + *6 + *8;LADME_PK;DECREASED_CONCENTRATIONS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;DOSAGE;DOSE
METFORMIN;CSMD1;rs2954625;CT + TT;EFFICACY;DECREASED_RESPONSE
ATAZANAVIR / RITONAVIR;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED_DISCONTINUATION
ESTRONE;SLCO1B1;SLCO1B1*1, SLCO1B1*5;*5/*5;EFFICACY;INCREASED_CONCENTRATIONS
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED_RESPONSE
VORICONAZOLE;ABCB1;rs1045642;AA;LADME_PK;DECREASED_TROUGH CONCENTRATION
MERCAPTOPURINE;NT5C2;rs72846714;AA + AG;LADME_PK;DECREASED_METABOLISM
HALOPERIDOL;CYP2D6;CYP2D6*1, CYP2D6*2;*2/*2;LADME_PK;INCREASED_CONCENTRATIONS
CYCLOSPORINE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_DOSE
IRINOTECAN, OXALIPLATIN, TEGAFUR / GIMERACIL / OTERACIL;UGT1A1;UGT1A1*60;*60;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*8;*1/*8 + *8/*8;LADME_PK;DECREASED_CLEARANCE
WARFARIN;VKORC1;rs7294;T;DOSAGE;INCREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DOSE
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;LADME_PK;DECREASED_CONCENTRATIONS
AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C;*2 + *3A + *3B + *3C;DOSAGE;DECREASED_DOSE
SERTRALINE;CYP2C18;rs11188059;GG;LADME_PK;DECREASED_CONCENTRATIONS
IRINOTECAN, OXALIPLATIN, TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;*4 + *7 + *9;EFFICACY;DECREASED_RESPONSE
DONEPEZIL;CYP2D6;CYP2D6*4, CYP2D6*5;*4/*4 + *4/*5;LADME_PK;DECREASED_CLEARANCE
DEBRISOQUINE;CYP2D6;CYP2D6*4, CYP2D6*17;*4/*17;LADME_PK;DECREASED_METABOLISM
NICOTINE;CYP2A6;CYP2A6 high activity;;EFFICACY;INCREASED_RESPONSE
AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;TPMT*1, TPMT*2, TPMT*3A;*1/*2 + *1/*3A;DOSAGE;DECREASED_DOSE
FENTANYL;CYP2D6;CYP2D6*1, CYP2D6*29;*29;LADME_PK;DECREASED_CLEARANCE
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*35, CYP2D6*41;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;LADME_PK;DECREASED_CONCENTRATIONS
DEXTROMETHORPHAN;CYP2D6;CYP2D6*4xN, CYP2D6*56;*4xN/*56;LADME_PK;DECREASED_METABOLISM
LEVONORGESTREL;CYP2B6;rs3745274;GT + TT;LADME_PK;DECREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
ADALIMUMAB;;rs9828223;T;EFFICACY;DECREASED_RESPONSE
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;EFFICACY;INCREASED_RESPONSE
ESCITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE
PROGESTERONE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2 + *2/*17;LADME_PK;INCREASED_EXPOSURE
TACROLIMUS;CYP3A5;CYP3A5*3, CYP3A5*6, CYP3A5*7;*3 + *6 + *7;LADME_PK;DECREASED_CLEARANCE
DONEPEZIL;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN + *1xN/*1xN;LADME_PK;INCREASED_CLEARANCE
CYCLOPHOSPHAMIDE, FLUDARABINE;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*6 + *6/*6;EFFICACY;DECREASED_RESPONSE
LEVONORGESTREL;CYP2B6;rs4803419;CT;LADME_PK;DECREASED_CONCENTRATIONS
MERCAPTOPURINE;TPMT;TPMT;poor_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS
ATORVASTATIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;DECREASED_CLEARANCE
SORAFENIB;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;LADME_PK;INCREASED_EXPOSURE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B;*1/*3A;DOSAGE, TOXICITY;DECREASED_DOSE
FLUOXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE
CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;LADME_PK;DECREASED_DOSE
CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME_PK;METABOLISM
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*2;LADME_PK;DECREASED_CLEARANCE
ATENOLOL, ENALAPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESISTANCE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;LADME_PK;INCREASED_CONCENTRATIONS
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;*1/*3C + *1/*2 + *1/*3A;DOSAGE;DECREASED_DOSE
CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME_PK;METABOLISM
BREXPIPRAZOLE;CYP2D6;CYP2D6;intermediate_metabolizer;LADME_PK;DECREASED_METABOLISM
CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;EFFICACY;DECREASED_RESISTANCE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS
LOPINAVIR;CYP3A4;CYP3A4*1, CYP3A4*22;*22/*22;LADME_PK;DECREASED_CLEARANCE
CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;LADME_PK;METABOLISM
CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE
CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;LADME_PK;METABOLISM
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*9;*4/*9 + *9/*9;LADME_PK;DECREASED_METABOLISM
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_DOSE
CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;LADME_PK;METABOLISM
EFAVIRENZ;ABCB1;rs3842;C;LADME_PK;METABOLISM
CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;LADME_PK;METABOLISM
CITALOPRAM, FLUOXETINE;SERPINE1;rs2227631;G;EFFICACY;DECREASED_RESPONSE
PHENYTOIN;CYP2C9;rs12782374;AG;OTHER, LADME_PK;INCREASED_METABOLISM
PHENYTOIN;CYP2C9;rs71486745;GT/del + del/del;DOSAGE, LADME_PK;DECREASED_DOSE
ATENOLOL, HYDROCHLOROTHIAZIDE, METOPROLOL;SLC25A31;rs201279313;TTA/del;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE, LADME_PK;DECREASED_DOSE
CAPTOPRIL;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED_RESPONSE
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28;DOSAGE;DECREASED_DOSE
TEGAFUR;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9, CYP2A6*10;*1/*1;LADME_PK;INCREASED_METABOLISM
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*1/*1 + *1/*3 + *1/*6 + *1/*7;DOSAGE;INCREASED_DOSE
TAMOXIFEN;CYP2C19;CYP2C19*1, CYP2C19*17;*17;EFFICACY, LADME_PK;DECREASED_RESPONSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*1;DOSAGE;INCREASED_DOSE
TAMOXIFEN;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY, LADME_PK;INCREASED_RESPONSE
CAPTOPRIL;ACE;rs1799752;del/del;EFFICACY;DECREASED_RESPONSE
MERCAPTOPURINE;CNNM2;rs58700372;CC + CT;LADME_PK;DECREASED_METABOLISM
OXYCODONE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;DOSAGE;INCREASED_DOSE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*1 + *1/*17;LADME_PK;DECREASED_TROUGH CONCENTRATION
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;LADME_PK;INCREASED_CONCENTRATIONS
FLUOROURACIL;TYMS;rs11280056;TTAAAGTTA/del;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_METABOLISM
PRIMAQUINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*41;*4/*41 + *1/*4 + *10/*10 + *10/*41 + *2/*4 + *41/*41;EFFICACY;DECREASED_RESPONSE
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*2 + *2/*3 + *3/*3;LADME_PK;INCREASED_CONCENTRATIONS
SERTRALINE;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESPONSE
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_DOSE
PRIMAQUINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41;*4/*41 + *5/*6;LADME_PK;DECREASED_CLEARANCE
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3C;*1/*3C;DOSAGE, TOXICITY;INCREASED_DOSE
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;DOSAGE, TOXICITY;DECREASED_DOSE
O-DESMETHYLTRAMADOL;CYP2D6;CYP2D6 deficiency;;LADME_PK;DECREASED_EXPOSURE
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*10/*10 + *5/*10;LADME_PK;DECREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_CONCENTRATIONS
ESOMEPRAZOLE, PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A7;CYP3A7*1A, CYP3A7*1C;*1A/*1A;LADME_PK;DECREASED_CONCENTRATIONS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE
KETAMINE;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME_PK;DECREASED_CLEARANCE
ESOMEPRAZOLE, PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;EFFICACY;INCREASED_RESPONSE
ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, PANTOPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE
ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, PANTOPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE
WARFARIN;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_DOSE
CLOMIPRAMINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;EFFICACY;DECREASED_RESPONSE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;LADME_PK;INCREASED_METABOLISM
CLOMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;EFFICACY;DECREASED_RESPONSE
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE
CAPECITABINE, FLUOROURACIL;DPYD;rs3918290;T;DOSAGE;DECREASED_DOSE
ETHANOL;DRD2;rs1800497;A;DOSAGE;INCREASED_DOSE
VARDENAFIL;CYP3A5;rs776746;TT;OTHER, LADME_PK;INCREASED_CLEARANCE
ETHANOL;OPRM1;rs1799971;G;DOSAGE;INCREASED_DOSE
IMATINIB;SLC22A1;rs683369;CC;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;INCREASED_RESISTANCE
CAPECITABINE, FLUOROURACIL;DPYD;rs56038477;T;DOSAGE;DECREASED_DOSE
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_RESISTANCE
ACETAMINOPHEN;UGT1A6;UGT1A6*1a, UGT1A6*2a;*2a;LADME_PK;INCREASED_CLEARANCE
CAPECITABINE, FLUOROURACIL;DPYD;rs67376798;A;DOSAGE;DECREASED_DOSE
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE
HALOPERIDOL;CYP2D6;CYP2D6*1, CYP2D6*10;*10;LADME_PK;DECREASED_METABOLISM
METHADONE;OPRK1;rs3802281;TT;DOSAGE;DECREASED_DOSE
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE
AZATHIOPRINE;TPMT;rs1142345;CT;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_METABOLISM
DEBRISOQUINE;CYP2D6;CYP2D6*17;*17/*17;LADME_PK;DECREASED_METABOLISM
TOLTERODINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*3 + *4;LADME_PK;DECREASED_METABOLISM
CITALOPRAM, MIANSERIN, MIRTAZAPINE, NORTRIPTYLINE, PAROXETINE, VENLAFAXINE;CYP2D6;CYP2D6*1xN, CYP2D6*2xN;*1xN + *2xN;EFFICACY;DECREASED_RESPONSE
SPARTEINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*10;*10/*10 + *4/*10;LADME_PK;DECREASED_METABOLISM
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_CONCENTRATIONS
HYDROXYUREA;SIN3A;rs7166737;GG;EFFICACY;DECREASED_RESPONSE
RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;LADME_PK;DECREASED_CLEARANCE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
FLUOXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE
HYDRALAZINE;NAT2;NAT2;slow_acetylator;LADME_PK;DECREASED_METABOLISM
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*6;LADME_PK;INCREASED_METABOLISM
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1799964;TT;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;EFFICACY;INCREASED_RESPONSE
VENLAFAXINE;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;DECREASED_METABOLISM
CAPECITABINE, RALTITREXED;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*1;DOSAGE;INCREASED_DOSE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY;DECREASED_RESPONSE
VENLAFAXINE;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;DECREASED_METABOLISM
WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DOSE
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL4;rs11322783;G/TT + TT/TT;EFFICACY;INCREASED_RESPONSE
VENLAFAXINE;CYP2D6;CYP2D6 normal metabolizer;;LADME_PK;DECREASED_METABOLISM
DEBRISOQUINE, SPARTEINE;CYP2D6;CYP2D6*3, CYP2D6*4;*4/*4 + *3/*4;LADME_PK;DECREASED_METABOLISM
ESCITALOPRAM;CYP2C19;CYP2C19 normal metabolizer;;LADME_PK;DECREASED_METABOLISM
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;TOXICITY;INCREASED_CONCENTRATIONS
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;LADME_PK;DECREASED_CONCENTRATIONS
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*3;LADME_PK;INCREASED_CONCENTRATIONS
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME_PK;DECREASED_CLEARANCE
SERTRALINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE
MIDAZOLAM;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_CLEARANCE
BUPROPION;HTR2A;rs2770296;CC;EFFICACY;INCREASED_RESPONSE
CAPECITABINE, FLUOROURACIL;HLA-G;rs371194629;ATTTGTTCATGCCT/ATTTGTTCATGCCT + ATTTGTTCATGCCT/del;EFFICACY;INCREASED_RESPONSE
VORICONAZOLE;CYP2C19;CYP2C19;ultrarapid_metabolizer;LADME_PK;DECREASED_CONCENTRATIONS
VORICONAZOLE;CYP2C19;CYP2C19;poor_metabolizer;LADME_PK;INCREASED_TROUGH CONCENTRATION
HYDRALAZINE;NAT2;NAT2;slow_acetylator;LADME_PK;DECREASED_METABOLISM
HYDRALAZINE;NAT2;NAT2;slow_acetylator;LADME_PK;DECREASED_METABOLISM
PRAVASTATIN;KIF6;rs20455;AG + GG;EFFICACY;INCREASED_RESPONSE
FLUVOXAMINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;DOSAGE;INCREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2/*3 + *3/*3;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE
DONEPEZIL;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;DECREASED_METABOLISM
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
FLUOXETINE;ABCB1;rs2032582;A;EFFICACY;INCREASED_RESPONSE
4-HYDROXYTAMOXIFEN, ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5;*4/*4 + *4/*5;LADME_PK;DECREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_EXPOSURE
BUPROPION;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*6 + *6/*6;EFFICACY;INCREASED_RESPONSE
COLCHICINE;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*1;EFFICACY;INCREASED_RESPONSE
FLUOXETINE, SERTRALINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE
TEGAFUR;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;*1/*4 + *4/*4 + *4/*7 + *4/*9;LADME_PK;DECREASED_METABOLISM
ESCITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE
AZATHIOPRINE;GSTM1;GSTM1 non-null, GSTM1 null;;EFFICACY;DECREASED_CLINICAL BENEFIT
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10;*4/*10 + *5/*10;LADME_PK;DECREASED_METABOLISM
OXYCODONE;CYP2D6;CYP2D6*4;*4;LADME_PK;INCREASED_CONCENTRATIONS
NILOTINIB;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*27, UGT1A1*28;*6/*6 + *6/*28;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5;*1/*2 + *1/*3 + *2/*3 + *2/*2 + *1/*5 + *2/*5;DOSAGE;DECREASED_DOSE
METHADONE;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME_PK;DECREASED_CLEARANCE
BUPROPION;DBH;rs2873804;CC;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;EFFICACY;INCREASED_RESPONSE
HYDRALAZINE;NAT2;NAT2;slow_acetylator;LADME_PK;DECREASED_METABOLISM
PACLITAXEL, PLATINUM COMPOUNDS;GSTM1;GSTM1 non-null, GSTM1 null;non-null;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3, CYP2C9*13;*3/*13;DOSAGE;DECREASED_DOSE
BLEOMYCIN, DACARBAZINE, DOXORUBICIN, VINBLASTINE;GSTM1;GSTM1 non-null, GSTM1 null;non-null/non-null;EFFICACY;INCREASED_RESPONSE
METHADONE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;DECREASED_CONCENTRATIONS
WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DOSE
S-EDDP;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;INCREASED_CONCENTRATIONS
CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2;*2;LADME_PK;DECREASED_METABOLISM
ENALAPRIL, LISINOPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_CLINICAL BENEFIT
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;DOSAGE;DECREASED_DOSE
BUPROPION;SLC18A2;rs363225;CC;EFFICACY;INCREASED_RESPONSE
RALTEGRAVIR;UGT1A9;UGT1A9*3a;*3a;LADME_PK;INCREASED_EXPOSURE
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*9;*1/*2 + *1/*9;LADME_PK;DECREASED_METABOLISM
SERTRALINE;CYP2C18;rs2860840;TT;LADME_PK;DECREASED_CONCENTRATIONS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DOSE
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE
ARIPIPRAZOLE;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;DECREASED_METABOLISM
4-HYDROXYTAMOXIFEN;CYP3A4;CYP3A4*1, CYP3A4*22;*22;LADME_PK;INCREASED_CONCENTRATIONS
TAMOXIFEN;CYP3A4;CYP3A4*1, CYP3A4*22;*22;LADME_PK;INCREASED_CONCENTRATIONS
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RESPONSE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*14;*1/*14;DOSAGE;DECREASED_DOSE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;LADME_PK;DECREASED_TROUGH CONCENTRATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1799724;CC;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_DOSE
ACETYLCYSTEINE;EPHX1;EPHX1;poor_metabolizer;EFFICACY;INCREASED_RESPONSE
BUPROPION;SLC18A2;rs363226;GG;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DECREASED_DOSE
METHOTREXATE;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;EFFICACY;INCREASED_RESPONSE
ISONIAZID;NAT2;NAT2*4;*4;LADME_PK;INCREASED_METABOLISM
LEVODOPA, METHYLPHENIDATE;SLC6A3;rs3836790;ACATACACACTCAGACACACATACCATGCA/ACATACACACTCAGACACACATACCATGCA;EFFICACY;INCREASED_RESPONSE
ATOMOXETINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*29, CYP2D6*41;*4/*4xN + *4/*4;LADME_PK;DECREASED_CLEARANCE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3/*3;DOSAGE, EFFICACY;DECREASED_DOSE
LEVODOPA;SLC6A3;rs3836790;ACATACACACTCAGACACACATACCATGCA/ACATACACACTCAGACACACATACCATGCA;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2/*3;DOSAGE, EFFICACY;DECREASED_DOSE
FLUOROURACIL;DPYD;DPYD deficiency;;LADME_PK;CLEARANCE
ATOMOXETINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*41;*4/*4xN + *4/*4;LADME_PK;INCREASED_CONCENTRATIONS
BUPROPION;FKBP5;rs17614642;TT;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE, EFFICACY;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;DOSAGE, EFFICACY;DECREASED_DOSE
INTERFERON BETA-1A;ACE;rs1799752;del/del;EFFICACY;DECREASED_RESPONSE
ETHANOL;OPRM1;rs1799971;AG;EFFICACY;INCREASED_RESPONSE
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE
WARFARIN;EPHX1;rs2260863;CG;DOSAGE;INCREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
CAPTOPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESPONSE
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE
LOSARTAN;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A4;rs35599367;GG;LADME_PK;INCREASED_METABOLISM
THALIDOMIDE;CYP2C19;CYP2C19*1, CYP2C19*2;*2;DOSAGE;INCREASED_DOSE
CARVEDILOL;CYP2D6;CYP2D6*10;*10;LADME_PK;DECREASED_METABOLISM
EFAVIRENZ;CYP2B6;CYP2B6*1;*1/*1;LADME_PK;INCREASED_CLEARANCE
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE, LADME_PK;DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*8;*8;DOSAGE, LADME_PK;DOSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_METABOLISM
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_CLEARANCE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;LADME_PK;INCREASED_METABOLISM
DIHYDROCODEINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;LADME_PK;DECREASED_METABOLISM
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6;*1/*1 + *1/*3 + *1/*6;LADME_PK;INCREASED_CONCENTRATIONS
NICOTINE;CYP2A6;CYP2A6 low activity;;DOSAGE;DECREASED_DOSE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;LADME_PK;DECREASED_METABOLISM
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*3;DOSAGE;DECREASED_DOSE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DECREASED_DOSE
IMATINIB;CYP3A5;rs776746;CC;LADME_PK;INCREASED_TROUGH CONCENTRATION
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE
PACLITAXEL;SLCO1B1;SLCO1B1*5, SLCO1B1*15;*5 + *15;LADME_PK;INCREASED_EXPOSURE
IMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*3 + *2/*2;LADME_PK;DECREASED_METABOLISM
RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME_PK;INCREASED_METABOLISM
LAMOTRIGINE;UGT2B7;rs7668258;CC;DOSAGE, LADME_PK;INCREASED_CLEARANCE
RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;LADME_PK;INCREASED_METABOLISM
BUPRENORPHINE;UGT2B7;UGT2B7;*2;EFFICACY;DECREASED_RESPONSE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;DOSAGE;INCREASED_DOSE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;LADME_PK;INCREASED_TROUGH CONCENTRATION
IMATINIB;ABCB1;rs1045642;AG;LADME_PK;DECREASED_TROUGH CONCENTRATION
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;LADME_PK;DECREASED_TROUGH CONCENTRATION
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;LADME_PK;CONCENTRATIONS
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;LADME_PK;INCREASED_CONCENTRATIONS
NELFINAVIR;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;LADME_PK;DECREASED_METABOLISM
HYDROXYBUPROPION;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;LADME_PK;DECREASED_CONCENTRATIONS
NELFINAVIR;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE
BUPROPION;CYP2B6;CYP2B6*1, CYP2B6*4, CYP2B6*5, CYP2B6*6, CYP2B6*18, CYP2B6*22;*1/*6 + *1/*18;LADME_PK;DECREASED_METABOLISM
IVACAFTOR, TEZACAFTOR;CFTR;rs113993960;del/del;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE
BUPROPION;CYP2B6;CYP2B6*1, CYP2B6*4, CYP2B6*5, CYP2B6*6, CYP2B6*18, CYP2B6*22;*6/*6 + *6/*18;LADME_PK;DECREASED_METABOLISM
IVACAFTOR, TEZACAFTOR;CFTR;rs113993960;CTT/del;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;DOSAGE;INCREASED_DOSE
WARFARIN;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;DOSAGE;INCREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6;*1/*1 + *1/*3 + *1/*6;DOSAGE;INCREASED_DOSE
ATOMOXETINE;CYP2D6;CYP2D6;poor_metabolizer;DOSAGE;DECREASED_DOSE
GEMCITABINE;CDA;rs60369023;A;OTHER, LADME_PK;DECREASED_METABOLISM
APIXABAN, DABIGATRAN, EDOXABAN, RIVAROXABAN;ABCB1;rs1045642;GG;LADME_PK;DECREASED_CONCENTRATIONS
ATAZANAVIR;NR1I2;rs2472677;TT;LADME_PK;DECREASED_CONCENTRATIONS
IMATINIB;ABCB1;rs2032582;A;EFFICACY;INCREASED_CLINICAL BENEFIT
ANTIDEPRESSANTS;FKBP5;rs1360780;CC;EFFICACY;DECREASED_RESPONSE
IMATINIB;ABCB1;rs1128503;A;EFFICACY;INCREASED_CLINICAL BENEFIT
TACROLIMUS;CYP3A5;rs776746;TT;LADME_PK;INCREASED_METABOLISM
ANTIDEPRESSANTS;GNB3;rs5443;CC + CT;EFFICACY;INCREASED_RESPONSE
IMATINIB;ABCB1;rs1045642;A;EFFICACY;INCREASED_CLINICAL BENEFIT
ANTIDEPRESSANTS;FKBP5;rs3800373;AC + CC;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DECREASED_DOSE
METHADONE;OPRK1;rs963549;CC;DOSAGE;DECREASED_DOSE
ANTIPSYCHOTICS;ABCB1;rs1128503;AA;DOSAGE, LADME_PK;INCREASED_DOSE
IMATINIB;ABCG2;rs2231142;T;EFFICACY;INCREASED_CLINICAL BENEFIT
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;EFFICACY;DECREASED_RESISTANCE
TACROLIMUS;PPARA;rs4823613;G;LADME_PK;DECREASED_METABOLISM
INFLIXIMAB;SLCO1C1;rs3794271;G;EFFICACY;DECREASED_RESPONSE
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE
TACROLIMUS;POR;rs1057868;T;LADME_PK;INCREASED_METABOLISM
DALCETRAPIB;ADCY9;rs1967309;AA;EFFICACY;INCREASED_RESPONSE
ANTIDEPRESSANTS;BDNF;rs6265;CT;EFFICACY;INCREASED_RESPONSE
BETA BLOCKING AGENTS, FLECAINIDE;ADRB1;rs1801253;G;EFFICACY;DECREASED_RESPONSE
METHOTREXATE;ABCC2;rs717620;T;LADME_PK;DECREASED_CLEARANCE
RITUXIMAB;FCGR3A;rs396991;AA;EFFICACY;INCREASED_CLINICAL BENEFIT
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*18;*18;LADME_PK;INCREASED_CONCENTRATIONS
DRUGS USED IN ALCOHOL DEPENDENCE;GATA4;rs13273672;CC;EFFICACY;DECREASED_CLINICAL BENEFIT
CHORIONIC GONADOTROPIN;FSHR;rs6166;CC;DOSAGE;INCREASED_DOSE
BEPRIDIL;CYP2D6;CYP2D6*10;*10;LADME_PK;INCREASED_CLEARANCE
TACROLIMUS;CYP3A4;rs35599367;GG;DOSAGE;INCREASED_DOSE
NICARDIPINE, NIMODIPINE;CACNA1B;rs2739260;AG + GG;EFFICACY;INCREASED_CLINICAL BENEFIT
CITALOPRAM, ESCITALOPRAM;GLDC;rs10975641;G;EFFICACY;INCREASED_RESPONSE
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;DOSAGE;DOSE
CORTISONE ACETATE;CYP3A7;CYP3A7*1A, CYP3A7*1C;*1C;DOSAGE;DECREASED_DOSE
DAUNORUBICIN;G6PD;G6PD A- 202A_376G;A-202A_376G;LADME_PK;DECREASED_METABOLISM
TEGAFUR;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7;*4/*4 + *4/*7 + *7/*7;LADME_PK;DECREASED_CLEARANCE
EFAVIRENZ;CYP2A6;CYP2A6*2;*2;OTHER, LADME_PK;DECREASED_METABOLISM
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;DOSAGE, EFFICACY;DECREASED_DOSE
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;DOSAGE;DOSE
METFORMIN;HNF1B;rs11868513;AA + AG;EFFICACY;INCREASED_RESPONSE
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_DOSE
ATORVASTATIN;CYP3A4;rs2242480;C/C;EFFICACY;DECREASED_RESPONSE
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE
GLATIRAMER ACETATE;HLA-DRB1;HLA-DRB1*15:01;*15:01;EFFICACY;DECREASED_RESPONSE
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE, LADME_PK;DECREASED_CLEARANCE
WARFARIN;CYP2C9;CYP2C9*1;*1/*1;DOSAGE, LADME_PK;INCREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*3;*3;LADME_PK;DECREASED_DOSE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*1 + *1/*17 + *2/*17 + *3/*17;EFFICACY;INCREASED_RESPONSE
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE
ATORVASTATIN;CYP3A4;rs2242480;C/C;EFFICACY;DECREASED_RESPONSE
DIAZEPAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;OTHER, LADME_PK;DECREASED_METABOLISM
INTERFERON ALFA-2A, RECOMBINANT, INTERFERON ALFA-2B, RECOMBINANT, INTERFERONS, PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IL18;rs1946518;T;EFFICACY;INCREASED_RESPONSE
FLUOXETINE, PAROXETINE;SLC6A4;rs57098334;(CCCACCCGA)12/(CCCACCCGA)12;EFFICACY;INCREASED_RESPONSE
VENLAFAXINE;CYP2D6;CYP2D6*4;*4/*4;LADME_PK;DECREASED_METABOLISM
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;EFFICACY;INCREASED_RESPONSE
THIOGUANOSINE DIPHOSPHATE, THIOGUANOSINE MONOPHOSPHATE, THIOGUANOSINE TRIPHOSPHATE;TPMT;TPMT;poor_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS
COUMARIN;CYP2A6;CYP2A6*1, CYP2A6*12;*12;OTHER, LADME_PK;DECREASED_METABOLISM
VALPROIC ACID;CYP2A6;CYP2A6*1, CYP2A6*4;*4;LADME_PK;DECREASED_METABOLISM
TEGAFUR;CYP2A6;CYP2A6*4;*4;LADME_PK;DECREASED_METABOLISM
TEGAFUR;CYP2A6;CYP2A6*1, CYP2A6*4;*4;LADME_PK;DECREASED_METABOLISM
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*7;*1/*7;LADME_PK;DECREASED_METABOLISM
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3/*3;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2/*2;DOSAGE;DECREASED_DOSE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP4F2;CYP4F2*1, CYP4F2*3;*3/*3;DOSAGE;INCREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2/*3;DOSAGE;DECREASED_DOSE
PACLITAXEL;CYP2C8;CYP2C8*1, CYP2C8*3;*1/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE
CAFFEINE;CYP2A6;CYP2A6*1, CYP2A6*7, CYP2A6*10, CYP2A6*11;*7 + *10 + *11;OTHER, LADME_PK;DECREASED_METABOLISM
CAFFEINE;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*9;*1/*4 + *1/*9 + *4/*4 + *4/*9;OTHER, LADME_PK;DECREASED_METABOLISM
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE, LADME_PK;DECREASED_DOSE
TOCILIZUMAB;IL6R;rs4845625;CT + TT;EFFICACY;INCREASED_RESPONSE
ATORVASTATIN;CYP3A4;rs2242480;T/T;EFFICACY;INCREASED_RESPONSE
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;OTHER, LADME_PK;DECREASED_CLEARANCE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;OTHER, LADME_PK;DECREASED_CLEARANCE
LETROZOLE;CYP2A6;CYP2A6*1, CYP2A6*26;*1/*26;LADME_PK;METABOLISM
LETROZOLE;CYP2A6;CYP2A6*1, CYP2A6*35;*1/*35;;METABOLISM
MIRTAZAPINE;CYP2B6;CYP2B6*6;*6/*6;EFFICACY;INCREASED_RESPONSE
METHOTREXATE;SLC19A1;rs1051266;CT;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE, LADME_PK;DECREASED_CLEARANCE
WARFARIN;CYP2C9;CYP2C9*2;*2;LADME_PK;DECREASED_DOSE
INTERFERON ALFA-2A, RECOMBINANT, INTERFERON ALFA-2B, RECOMBINANT, INTERFERONS, PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IL18;rs187238;C;EFFICACY;DECREASED_RESPONSE
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME_PK;DECREASED_METABOLISM
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*1/*1;DOSAGE;INCREASED_DOSE
ISONIAZID;NAT2;NAT2*4;*4/*4;LADME_PK;INCREASED_METABOLISM
ISONIAZID;NAT2;NAT2*4;*4/*4;LADME_PK;INCREASED_METABOLISM
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_DOSE
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_DOSE
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*1/*1;DOSAGE;INCREASED_DOSE
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_DOSE
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;LADME_PK;TROUGH CONCENTRATION
LOSARTAN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3;EFFICACY;DECREASED_RESPONSE
TROPISETRON;CYP2D6;CYP2D6*3;*3/*3;EFFICACY;DECREASED_METABOLISM
LOSARTAN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2;EFFICACY;DECREASED_RESPONSE
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;DOSAGE;DECREASED_DOSE
METOPROLOL;CYP2D6;CYP2D6*10;*10;LADME_PK;DECREASED_CLEARANCE
SIMVASTATIN;CYP3A4;CYP3A4*1, CYP3A4*4;*1/*4;EFFICACY;INCREASED_RESPONSE
PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;LADME_PK;DECREASED_METABOLISM
ONDANSETRON;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2xN;*1xN + *2xN;EFFICACY;DECREASED_RESPONSE
PHENPROCOUMON;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE
PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*10;*10;LADME_PK;DECREASED_METABOLISM
DEBRISOQUINE;CYP2D6;CYP2D6*2xN;*2xN;LADME_PK;INCREASED_METABOLISM
HALOPERIDOL;CYP2D6;CYP2D6*1, CYP2D6*10;*10;LADME_PK;DECREASED_METABOLISM
CARVEDILOL;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4;LADME_PK;DECREASED_CLEARANCE
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE
PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*1;EFFICACY;DECREASED_RESPONSE
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE
CARVEDILOL;CYP2D6;CYP2D6*4, CYP2D6*5, CYP2D6*6;*4/*5 + *4/*6;DOSAGE;INCREASED_DOSE
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;INCREASED_RESPONSE
OMEPRAZOLE, PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;EFFICACY;INCREASED_RESPONSE
CARVEDILOL;CYP2D6;CYP2D6*10;*10/*10;LADME_PK;DECREASED_CLEARANCE
CARVEDILOL;CYP2D6;CYP2D6*1, CYP2D6*5;*1/*5;LADME_PK;DECREASED_CLEARANCE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE
ZUCLOPENTHIXOL;CYP2D6;CYP2D6*1, CYP2D6*3;*3;LADME_PK;DECREASED_METABOLISM
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;EFFICACY;INCREASED_RESPONSE
FLUOXETINE;CYP2D6;rs3892097;CC;EFFICACY;INCREASED_RESPONSE
AMITRIPTYLINE, CLOMIPRAMINE, DOXEPIN, IMIPRAMINE, MAPROTILINE, NORTRIPTYLINE, OPIPRAMOL;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;DOSAGE, EFFICACY;DECREASED_DOSE
SUFENTANIL;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;DOSAGE;INCREASED_DOSE
METFORMIN;;rs6719578;CG;EFFICACY;INCREASED_RESPONSE
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*10;*10;EFFICACY, LADME_PK;DECREASED_METABOLISM
AMITRIPTYLINE;CYP2D6;CYP2D6*4;*4/*4;TOXICITY, LADME_PK;DECREASED_CLEARANCE
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;LADME_PK;INCREASED_CONCENTRATIONS
HALOPERIDOL;CYP2D6;CYP2D6*1, CYP2D6*10;*10;LADME_PK;DECREASED_METABOLISM
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*4;*4;LADME_PK;DECREASED_METABOLISM
METHOTREXATE;ATIC;rs4673993;CC;EFFICACY;INCREASED_RESPONSE
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE
CLOPIDOGREL;CYP2C19;CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;EFFICACY;DECREASED_RESPONSE
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;LADME_PK;DECREASED_METABOLISM
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *2/*2 + *2/*3;DOSAGE;DECREASED_DOSE
HYDROMORPHONE, KETOROLAC, MORPHINE, OPIOIDS, OXYCODONE;CYP2D6;CYP2D6*4;*4/*4;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*3 + *3/*3;DOSAGE;DECREASED_DOSE
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE
BUPROPION;CYP2B6;CYP2B6*1, CYP2B6*22;*1/*22;LADME_PK;INCREASED_METABOLISM
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;LADME_PK;DECREASED_METABOLISM
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE
FLUOXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C9;CYP2C9*1;*1/*1;DOSAGE, LADME_PK;INCREASED_DOSE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2;DOSAGE;DECREASED_DOSE
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DECREASED_DOSE
FLUOXETINE, PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE
HYDRALAZINE;NAT2;NAT2;slow_acetylator;LADME_PK;DECREASED_METABOLISM
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;EFFICACY;INCREASED_RESPONSE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3;EFFICACY, TOXICITY;DECREASED_RESPONSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;HLA-A;HLA-A*01:01;*01:01;EFFICACY;INCREASED_RESPONSE
CITALOPRAM, FLUOXETINE, PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE
ACENOCOUMAROL;VKORC1;rs104894542;AC + CC;DOSAGE;INCREASED_DOSE
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;EFFICACY;DECREASED_RESPONSE
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;DOSAGE;DECREASED_DOSE
MEPHENYTOIN;CYP2C19;rs28399504;G;LADME_PK;DECREASED_METABOLISM
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *3/*3;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;DOSAGE;DECREASED_DOSE
4-HYDROXYTAMOXIFEN, ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*10/*10 + *5/*5;LADME_PK;DECREASED_CONCENTRATIONS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*3 + *3/*3 + *2/*2;DOSAGE;DECREASED_DOSE
CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME_PK;DECREASED_CLEARANCE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2 + *2/*2;DOSAGE;DECREASED_DOSE
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *3/*3;DOSAGE;DECREASED_DOSE
LAMIVUDINE, NEVIRAPINE, STAVUDINE;HLA-B;HLA-B*40:01;*40:01;EFFICACY;RESPONSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *2/*2 + *1/*3 + *3/*3;DOSAGE;DECREASED_DOSE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;LADME_PK;INCREASED_CONCENTRATIONS
BELINOSTAT;UGT1A1;UGT1A1*1, UGT1A1*60;*1/*60 + *60/*60;LADME_PK;INCREASED_CONCENTRATIONS
BELINOSTAT;UGT1A1;UGT1A1*1, UGT1A1*60;*1/*60 + *60/*60;LADME_PK;DECREASED_METABOLISM
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;LADME_PK;INCREASED_CONCENTRATIONS
BOCEPREVIR, PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL4;rs11322783;TT;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*11;*2 + *3 + *5 + *6 + *11;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE
ACENOCOUMAROL, PHENPROCOUMON;CYP2C19;CYP2C19*2, CYP2C19*3;*2 + *3;DOSAGE;DOSE
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DOSE
WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DOSE
COUMARIN;CYP2A6;CYP2A6*1, CYP2A6*6;*6;LADME_PK;DECREASED_METABOLISM
ECULIZUMAB;C5;rs56040400;CT;EFFICACY;DECREASED_RESPONSE
DEFERASIROX;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;LADME_PK;DECREASED_CONCENTRATIONS
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DOSE
CLOPIDOGREL, PRASUGREL, TICAGRELOR;CYP2C19;rs4244285;A;EFFICACY;RESPONSE
WARFARIN;CYP2C9;rs9332131;A;DOSAGE;DOSE
WARFARIN;CYP2C9;rs28371685;C;DOSAGE;DOSE
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME_PK;INCREASED_CONCENTRATIONS
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;EFFICACY;INCREASED_RESISTANCE
VALPROIC ACID;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3;DOSAGE;DECREASED_DOSE
WARFARIN;POR;rs41301394;CT + TT;DOSAGE;INCREASED_DOSE
METHADONE;DRD2;rs6275;AA + AG;;INCREASED_DOSE
CARBOPLATIN, PACLITAXEL;GSTP1;rs1695;G;TOXICITY;DECREASED_RESPONSE
VORICONAZOLE;CYP2C19;CYP2C19;ultrarapid_metabolizer;LADME_PK;DECREASED_TROUGH CONCENTRATION
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*6 + *6/*6;LADME_PK;INCREASED_CONCENTRATIONS
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28;DOSAGE;DECREASED_DOSE
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*18;*1/*1;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
CISPLATIN;MIR335;rs3807348;AA + AG;EFFICACY;INCREASED_RESPONSE
HYDROCODONE;CYP2D6;CYP2D6*2, CYP2D6*41;*2/*41;LADME_PK;INCREASED_CONCENTRATIONS
CYCLOPHOSPHAMIDE, DOXORUBICIN;ALDH1A1;rs6151031;CTGGTGAGGAGAGAACC/del;EFFICACY;DECREASED_RESPONSE
BUPRENORPHINE, METHADONE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE
DESVENLAFAXINE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;VKORC1;VKORC1 low activity;;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2 + *2/*2 + *2/*17;EFFICACY;DECREASED_RESPONSE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17;LADME_PK;DECREASED_METABOLISM
CLOMIPRAMINE;CYP2D6;CYP2D6*4, CYP2D6*5;*4/*5;LADME_PK;DECREASED_METABOLISM
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_TROUGH CONCENTRATION
CLOZAPINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;DOSAGE;DECREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;DECREASED_TROUGH CONCENTRATION
SIROLIMUS, TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_CLEARANCE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_TROUGH CONCENTRATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_CLEARANCE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1;DOSAGE;INCREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_DOSE
CARBAMAZEPINE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_CLEARANCE
FENTANYL;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_CONCENTRATIONS
FENTANYL;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_CLEARANCE
MIDAZOLAM;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;INCREASED_METABOLISM
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_METABOLISM
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
CYCLOSPORINE;CYP3A5;CYP3A5*1, CYP3A5*3;*3;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1;DOSAGE;INCREASED_DOSE
FENTANYL;CYP2D6;CYP2D6*1, CYP2D6*9;*9;LADME_PK;DECREASED_CLEARANCE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE
SIMVASTATIN;F3;rs3917643;CT;EFFICACY;INCREASED_RESPONSE
IVACAFTOR / LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;INCREASED_RESPONSE
FLUVASTATIN;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESPONSE
IVACAFTOR;CFTR;rs113993960;CTT/del;EFFICACY;INCREASED_RESPONSE
ENALAPRIL;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del;EFFICACY;INCREASED_RESPONSE
BEVACIZUMAB, CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, OXALIPLATIN, TRASTUZUMAB;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED_RESPONSE
IMATINIB;CYP3A5;rs776746;C;EFFICACY;INCREASED_CLINICAL BENEFIT
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
FENTANYL, MEPERIDINE, MIDAZOLAM;CYP3A5;CYP3A5;poor_metabolizer;LADME_PK;DECREASED_DOSE
FENTANYL, MEPERIDINE, MIDAZOLAM;CYP2C19;CYP2C19 poor metabolizers and intermediate metabolizers;;LADME_PK;DECREASED_DOSE
FENTANYL, MEPERIDINE, MIDAZOLAM;UGT1A1;UGT1A1;poor_metabolizer;LADME_PK;DECREASED_DOSE
BELZUTIFAN;UGT2B17;UGT2B17;poor_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS
BELZUTIFAN;CYP2C19;CYP2C19;poor_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A4;rs35599367;AG;LADME_PK;DECREASED_METABOLISM
O-DESMETHYLTRAMADOL;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;DECREASED_CONCENTRATIONS
4-HYDROXYTAMOXIFEN;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;LADME_PK;INCREASED_CONCENTRATIONS
TAMSULOSIN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*41;*1/*4 + *4/*10;EFFICACY;INCREASED_CLINICAL BENEFIT
IMATINIB;CYP3A4;rs2242480;C;EFFICACY;INCREASED_CLINICAL BENEFIT
FULVESTRANT;CYP2C9;CYP2C9;poor_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS
ANASTROZOLE;CYP2C9;CYP2C9;intermediate_metabolizer;LADME_PK;DECREASED_CONCENTRATIONS
ANASTROZOLE;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME_PK;DECREASED_CONCENTRATIONS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_DOSE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
ABATACEPT;HLA-DRB1;HLA-DRB1*04:05;*04:05;EFFICACY;INCREASED_CLINICAL BENEFIT
ETANERCEPT;SLCO1C1;rs3794271;G;EFFICACY;DECREASED_RESPONSE
APATINIB;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_CLEARANCE
ESCITALOPRAM;CYP2C19;CYP2C19;rapid_metabolizer;LADME_PK;INCREASED_CLEARANCE
ESCITALOPRAM;CYP2C19;CYP2C19;poor_metabolizer;LADME_PK;DECREASED_CLEARANCE
SERTRALINE;CYP2C19;CYP2C19;poor_metabolizer;LADME_PK;DECREASED_CLEARANCE
DULOXETINE;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
AMOXICILLIN, CLARITHROMYCIN, OMEPRAZOLE;VDR;rs7975232;A;EFFICACY;INCREASED_RESPONSE
AMOXICILLIN, CLARITHROMYCIN, OMEPRAZOLE;VDR;rs2228570;A;EFFICACY;INCREASED_RESPONSE
BUPROPION, NALTREXONE;ANKK1, DRD2;rs1800497;AA + AG;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_CLEARANCE
RISPERIDONE;CYP2D6;CYP2D6;intermediate_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*1;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
DOCETAXEL, THALIDOMIDE;PPARD;rs6922548;G;EFFICACY;INCREASED_RESPONSE
SN-38;UGT1A1;UGT1A1*1, UGT1A1*6;*6;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1;*1;LADME_PK;INCREASED_TIME TO RESPONSE
O-DESMETHYLTRAMADOL;CYP2D6;CYP2D6;intermediate_metabolizer;LADME_PK;DECREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
NALDEMEDINE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_CONCENTRATIONS
METHADONE;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*41, CYP2D6*65;*10/*10 + *10/*65 + *10/*41;LADME_PK;INCREASED_CONCENTRATIONS
DOCETAXEL, THALIDOMIDE;PPARD;rs7769719;G;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;TT;LADME_PK;INCREASED_DOSE
WARFARIN;NEDD4;rs2288344;G;DOSAGE;INCREASED_DOSE
QUETIAPINE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_CLEARANCE
TACROLIMUS;CYP3A5;rs776746;TT;LADME_PK;INCREASED_DOSE
WARFARIN;DDHD1;rs17126068;G;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5;intermediate_metabolizer;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
CISPLATIN, IRINOTECAN;UGT1A1;rs4148323;AA;EFFICACY;DECREASED_RESPONSE
DESVENLAFAXINE, VENLAFAXINE;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;INCREASED_EXPOSURE
TACROLIMUS;CYP3A5;rs776746;CT;LADME_PK;INCREASED_DOSE
METHOTREXATE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_CLINICAL BENEFIT
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*22;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
SALBUTAMOL;;rs7903366;T;EFFICACY;DECREASED_RESPONSE
PRAZIQUANTEL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3;LADME_PK;INCREASED_EXPOSURE
LOSARTAN;CYP2C9;rs1057910;C;LADME_PK;DECREASED_METABOLISM
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;EFFICACY;DECREASED_RESPONSE
RISPERIDONE;CYP2D6;CYP2D6 poor metabolizer genotype;;LADME_PK;INCREASED_EXPOSURE
ISONIAZID;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;LADME_PK;DECREASED_METABOLISM
ISONIAZID;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16/*16 + *16/*6 + *6/*6 + *6/*7 + *7/*7;LADME_PK;DECREASED_METABOLISM
SALBUTAMOL;;rs7081864;A;EFFICACY;DECREASED_RESPONSE
SULFINPYRAZONE;UGT1A9;rs72551330;T;LADME_PK;INCREASED_METABOLISM
SULFAMETHOXAZOLE;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*4/*4;LADME_PK;INCREASED_METABOLISM
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MICA;rs1051792;AA;EFFICACY;DECREASED_CLINICAL BENEFIT
WARFARIN;VKORC1;rs9923231;GG;DOSAGE;INCREASED_DOSE
METHADONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*2xN;*1/*2xN + *2/*2xN;LADME_PK;INCREASED_CONCENTRATIONS
LITHIUM;GSK3B;rs6438552;GG;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;ABCB1;rs1045642;AA;DOSAGE;DECREASED_DOSE
LITHIUM;NR1D1, THRA;rs2071427;TT;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;CYP3A5 poor metabolizers;;LADME_PK;INCREASED_CONCENTRATIONS
MORPHINE;CYP2D6;CYP2D6 poor metabolizer phenotype;;LADME_PK;DECREASED_EXPOSURE
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;DECREASED_CONCENTRATIONS
ARIPIPRAZOLE;CYP2D6;CYP2D6 poor metabolizer genotype;;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
ATOMOXETINE;CYP2C19;CYP2C19 poor metabolizers;;LADME_PK;INCREASED_CONCENTRATIONS
CAFFEINE;NAT2;NAT2*1, NAT2*4, NAT2*5, NAT2*6, NAT2*7, NAT2*16;*4/*5 + *1/*16 + *4/*6 + *4/*7;LADME_PK;INCREASED_METABOLISM
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*1/*1 + *1/*3 + *1/*6 + *1/*7;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
ISONIAZID;NAT2;NAT2*1, NAT2*4, NAT2*5, NAT2*6, NAT2*6J, NAT2*7, NAT2*7G, NAT2*39;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;LADME_PK;DECREASED_CLEARANCE
TACROLIMUS;ABCB1;rs1045642;GG;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
INFLIXIMAB;HLA-DQA1;HLA-DQA1*05;*05;EFFICACY;INCREASED_DISCONTINUATION
TACROLIMUS;ABCB1;rs1045642;AA;LADME_PK;DECREASED_CLEARANCE
ENZYME INHIBITORS;CYP19A1;rs700518;CC;OTHER;RESPONSE
TACROLIMUS;ABCB1;rs1128503;AA;LADME_PK;DECREASED_CLEARANCE
CORTICOSTEROIDS;FCER2;rs28364072;G;DOSAGE;INCREASED_DOSE
TACROLIMUS;ABCB1;rs2032582;AA;LADME_PK;DECREASED_CLEARANCE
ISONIAZID;NAT2;NAT2*1, NAT2*4, NAT2*6, NAT2*7, NAT2*14, NAT2*16;*16 + *6 + *7 + *14;LADME_PK;DECREASED_CLEARANCE
TACROLIMUS;ABCB1;rs1045642;AG + GG;LADME_PK;INCREASED_CLEARANCE
HYDRALAZINE;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*4/*16 + *4/*6 + *4/*7;LADME_PK;INCREASED_METABOLISM
DEXTROMETHORPHAN;CYP2D6;CYP2D6*4, CYP2D6*59;*4/*59;LADME_PK;DECREASED_METABOLISM
HALOPERIDOL;CYP2D6;CYP2D6 poor metabolizer genotype;;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
ESCITALOPRAM;;rs12154537;G;EFFICACY;INCREASED_RESPONSE
MORPHINE;ABCB1;rs1128503;AG + GG;LADME_PK;DECREASED_CONCENTRATIONS
ISONIAZID;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*14, NAT2*16, NAT2*19;*4/*4;DOSAGE, LADME_PK;INCREASED_DOSE
DOCETAXEL;SLCO1B3;rs11045585;G;OTHER, LADME_PK;DECREASED_CLEARANCE
DOCETAXEL;SLCO1B3;rs7311358;A;OTHER, LADME_PK;DECREASED_CLEARANCE
DOCETAXEL;SLCO1B3;rs4149118;G;OTHER, LADME_PK;DECREASED_CLEARANCE
CAFFEINE;NAT2;NAT2*5, NAT2*6, NAT2*7, NAT2*16, NAT2*34;*16/*5 + *5/*5 + *5/*6 + *5/*34 + *5/*7 + *6/*6 + *6/*7;LADME_PK;DECREASED_METABOLISM
ISONIAZID;NAT2;NAT2*4, NAT2*5, NAT2*6, NAT2*6J, NAT2*7, NAT2*7G;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;LADME_PK;DECREASED_METABOLISM
WARFARIN;VKORC1;rs9934438;A;DOSAGE, LADME_PK;DECREASED_DOSE
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
MIDAZOLAM;VDR;rs1544410;C;LADME_PK;INCREASED_CLEARANCE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;KLRC4;rs1154831;GG;EFFICACY;INCREASED_CLINICAL BENEFIT
TACROLIMUS;CYP3A5;CYP3A5*1;*1;DOSAGE;INCREASED_DOSE
ESCITALOPRAM;CYP2C19;CYP2C19;intermediate_metabolizer;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
METHADONE;CYP2D6;CYP2D6 ultrarapid metabolizer genotype;;EFFICACY;DECREASED_RESPONSE
FLUOXETINE;CYP2D6;CYP2D6;ultrarapid_metabolizer;EFFICACY;DECREASED_CLINICAL BENEFIT
HYDRALAZINE;NAT2;NAT2*6, NAT2*7, NAT2*14, NAT2*16;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *7/*6;EFFICACY;INCREASED_RESPONSE
ISONIAZID;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*14, NAT2*16;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;LADME_PK;INCREASED_CONCENTRATIONS
ACETYLISONIAZID;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*14, NAT2*16;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;LADME_PK;DECREASED_CONCENTRATIONS
ACETAMINOPHEN;CYP2D6;CYP2D6*10;*10;EFFICACY;INCREASED_CLINICAL BENEFIT
BUPROPION;CYP2B6;CYP2B6*6;*6;LADME_PK;INCREASED_EXPOSURE
WARFARIN;VKORC1;rs7294;T;DOSAGE, LADME_PK;INCREASED_DOSE
PARAMETHOXYMETHAMPHETAMINE;CYP2D6;CYP2D6 normal metabolizer genotype;;LADME_PK;INCREASED_METABOLISM
VORICONAZOLE;CYP2C19;CYP2C19 intermediate metabolizers;*1/*2 + *1/*3 + *2/*17;LADME_PK;INCREASED_CONCENTRATIONS
MARAVIROC;CYP3A5;CYP3A5 intermediate metabolizers;;LADME_PK;INCREASED_CONCENTRATIONS
CLOPIDOGREL;CYP2C19;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;;EFFICACY;DECREASED_RESPONSE
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizer phenotype;;EFFICACY;DECREASED_RESPONSE
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizer phenotype;;LADME_PK;DECREASED_CONCENTRATIONS
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME_PK;DECREASED_TROUGH CONCENTRATION
CITALOPRAM, ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *3/*17;LADME_PK;INCREASED_EXPOSURE
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;DECREASED_METABOLISM
NORTRIPTYLINE;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;LADME_PK;INCREASED_METABOLISM
HALOPERIDOL, OLANZAPINE, PERPHENAZINE, QUETIAPINE, RISPERIDONE;DRD2;rs1799978;C;EFFICACY;INCREASED_RESISTANCE
MARAVIROC;CYP3A5;CYP3A5 poor metabolizers;;LADME_PK;INCREASED_CONCENTRATIONS
CITALOPRAM, ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17;LADME_PK;DECREASED_EXPOSURE
TACROLIMUS;CYP3A5;CYP3A5 intermediate metabolizer and normal metabolizer;;DOSAGE, LADME_PK;INCREASED_TIME TO RESPONSE
RISPERIDONE;CYP2D6;CYP2D6;ultrarapid_metabolizer;LADME_PK;INCREASED_METABOLISM
RISPERIDONE;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;DECREASED_METABOLISM
NORTRIPTYLINE;CYP2D6;CYP2D6 intermediate metabolizers;;LADME_PK;DECREASED_METABOLISM
IMIPRAMINE;CYP2D6;CYP2D6 poor metabolizers;;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME_PK;INCREASED_CONCENTRATIONS
HYDROCODONE;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;DECREASED_METABOLISM
ATOMOXETINE;CYP2C19;CYP2C19 poor metabolizers;;LADME_PK;DECREASED_CLEARANCE
IMIPRAMINE;CYP2C19;CYP2C19 poor metabolizers;;LADME_PK;INCREASED_CONCENTRATIONS
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;DECREASED_CONCENTRATIONS
RISPERIDONE;CYP2D6;CYP2D6 poor metabolizer genotype;;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*8, CYP2C19*17;*1/*2 + *1/*8 + *2/*2;EFFICACY, LADME_PK;DECREASED_METABOLISM
TAMOXIFEN;CYP2D6;CYP2D6 intermediate metabolizers;;LADME_PK;INCREASED_DOSE
PROPAFENONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*36;*1/*5 + *2/*36 + *5/*10 + *5/*5;LADME_PK;INCREASED_CONCENTRATIONS
IMIPRAMINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5;*4/*4 + *4/*5;DOSAGE;DECREASED_DOSE
CITALOPRAM, ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;LADME_PK;DECREASED_EXPOSURE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*8, CYP2C19*17;*1/*2 + *1/*8 + *2/*2;EFFICACY, LADME_PK;DECREASED_RESPONSE
METHAMPHETAMINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*14, CYP2D6*18, CYP2D6*36;*4/*10 + *5/*10 + *5/*14 + *10/*10 + *10/*18 + *10/*36;LADME_PK;INCREASED_CONCENTRATIONS
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;LADME_PK;DECREASED_CONCENTRATIONS
RISPERIDONE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;LADME_PK;INCREASED_EXPOSURE
NORTRIPTYLINE;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;DOSAGE, EFFICACY;DECREASED_RESPONSE
4-HYDROXYTAMOXIFEN, ENDOXIFEN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;LADME_PK;DECREASED_CONCENTRATIONS
DESVENLAFAXINE;CYP2D6;CYP2D6*99;*99;LADME_PK;DECREASED_CONCENTRATIONS
DEXTROMETHORPHAN;CYP2D6;CYP2D6*4, CYP2D6*4x2, CYP2D6*36;*4/*36 + *4x2/*36;LADME_PK;DECREASED_METABOLISM
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*5/*10 + *4/*10 + *10/*10 + *10/*41;LADME_PK;DECREASED_METABOLISM
VENLAFAXINE;CYP2D6;CYP2D6 poor metabolizer phenotype;;LADME_PK;DECREASED_METABOLISM
METHADONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*2xN;*1/*2xN + *2/*2xN;DOSAGE;INCREASED_DOSE
VENLAFAXINE;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;EFFICACY;INCREASED_RESPONSE
DESIPRAMINE, IMIPRAMINE;CYP2D6;CYP2D6*4, CYP2D6*5;*4/*4 + *4/*5;LADME_PK;INCREASED_CONCENTRATIONS
TRANS 4-HYDROXYPRAZIQUANTEL;CYP2J2;rs890293;AA + AC;LADME_PK;INCREASED_CONCENTRATIONS
VENLAFAXINE;CYP2D6;CYP2D6 poor metabolizer phenotype;;LADME_PK;DECREASED_METABOLISM
PERPHENAZINE;CYP2D6;CYP2D6 poor metabolizer genotype;;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 +*2/*3;DOSAGE, LADME_PK;DECREASED_DOSE
VORTIOXETINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;TOXICITY;INCREASED_DISCONTINUATION
DEBRISOQUINE;CYP2D6;CYP2D6*4, CYP2D6*38;*4/*38;LADME_PK;DECREASED_METABOLISM
NORTRIPTYLINE;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;INCREASED_CONCENTRATIONS
FENTANYL;;poor metabolizers;;LADME_PK;DECREASED_METABOLISM
ESCITALOPRAM;CYP2C19;CYP2C19 ultrarapid metabolizer phenotype;;LADME_PK;INCREASED_METABOLISM
NORTRIPTYLINE;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;DECREASED_METABOLISM
ESCITALOPRAM;CYP2C19;CYP2C19 poor metabolizers;;LADME_PK;DECREASED_METABOLISM
ETHANOL;OPRM1;rs2075572;G;EFFICACY;INCREASED_RESPONSE
PROTON PUMP INHIBITORS;CYP2C19;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;;EFFICACY;INCREASED_CLINICAL BENEFIT
DEXAMETHASONE;CHRM3;rs2165870;AA;EFFICACY;INCREASED_RESPONSE
METOPROLOL;CYP2D6;CYP2D6 poor metabolizers;;DOSAGE;DECREASED_DOSE
ETHANOL;OPRM1;rs548646;T;EFFICACY;INCREASED_RESPONSE
GLICLAZIDE;KCNQ1;rs2237892;T;EFFICACY;INCREASED_CLINICAL BENEFIT
DEXTROMETHORPHAN;CYP2D6;CYP2D6*4, CYP2D6*31;*4/*31;LADME_PK;DECREASED_METABOLISM
NORTRIPTYLINE;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;LADME_PK;INCREASED_METABOLISM
NICOTINE;DRD2;rs1799732;G/del + del/del;EFFICACY;INCREASED_RESPONSE
LINAGLIPTIN;TCF7L2;rs7903146;CC + CT;EFFICACY;INCREASED_CLINICAL BENEFIT
DEXTROMETHORPHAN;CYP2D6;CYP2D6*5, CYP2D6*13;*5/*13;LADME_PK;DECREASED_METABOLISM
CITALOPRAM, ESCITALOPRAM;CYP2C19;CYP2C19 poor metabolizer phenotype;;EFFICACY;INCREASED_RESPONSE
PAROXETINE;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;DECREASED_CLEARANCE
ETHANOL;OPRM1;rs681243;T;EFFICACY;INCREASED_RESPONSE
DEXTROMETHORPHAN;CYP2D6;CYP2D6 normal metabolizer genotype;;LADME_PK;INCREASED_METABOLISM
AMOXICILLIN, CLARITHROMYCIN, ESOMEPRAZOLE;CYP2C19;CYP2C19 normal metabolizer genotype;;EFFICACY;DECREASED_RESPONSE
ESCITALOPRAM;CYP2C19;CYP2C19 poor metabolizers;;LADME_PK;DECREASED_METABOLISM
VENLAFAXINE;CYP2D6;CYP2D6 poor metabolizers;;EFFICACY;DECREASED_RESPONSE
BUPROPION;COMT;rs4680;AG + GG;EFFICACY;INCREASED_RESPONSE
ARIPIPRAZOLE;CYP2D6;CYP2D6 intermediate metabolizer phenotype;;LADME_PK;DECREASED_METABOLISM
CODEINE, FENTANYL, HYDROCODONE, HYDROMORPHONE, METHADONE, MORPHINE, OXYCODONE, TRAMADOL;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;EFFICACY;DECREASED_RESPONSE
TRIMIPRAMINE;CYP2C19;CYP2C19 poor metabolizers;;LADME_PK;DECREASED_METABOLISM
VENLAFAXINE;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;DECREASED_METABOLISM
ETHANOL;OPRM1;rs1461773;A;EFFICACY;INCREASED_RESPONSE
3,4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*41;*4/*4 + *3/*5;EFFICACY;INCREASED_RESPONSE
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;DECREASED_CONCENTRATIONS
ETHANOL;OPRM1;rs3778148;T;EFFICACY;INCREASED_RESPONSE
AMOXICILLIN, CLARITHROMYCIN, LANSOPRAZOLE;CYP2C19;CYP2C19 normal metabolizer genotype;;EFFICACY;DECREASED_CLINICAL BENEFIT
AMOXICILLIN, CLARITHROMYCIN, OMEPRAZOLE;CYP2C19;CYP2C19 normal metabolizer genotype;;EFFICACY;DECREASED_CLINICAL BENEFIT
MIDAZOLAM;VDR;rs4516035;T;LADME_PK;INCREASED_CLEARANCE
DESIPRAMINE;CYP2D6;CYP2D6 poor metabolizers;;DOSAGE;DECREASED_DOSE
AMITRIPTYLINE;CYP2D6;CYP2D6 poor metabolizer phenotype;;EFFICACY;DECREASED_RESPONSE
TRAMADOL;CYP2D6;CYP2D6 poor metabolizer phenotype;;EFFICACY;INCREASED_RESPONSE
MORPHINE;COMT;rs4680;A;EFFICACY;INCREASED_RESPONSE
VORICONAZOLE;CYP2C19;CYP2C19 poor metabolizers;;EFFICACY;INCREASED_RESPONSE
ANTIDEPRESSANTS;FKBP5;rs3800373;AC + CC;EFFICACY;INCREASED_RESPONSE
VENLAFAXINE;CYP2D6;CYP2D6 poor metabolizer phenotype;;LADME_PK;DECREASED_CLEARANCE
DESIPRAMINE;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;INCREASED_CONCENTRATIONS
VORICONAZOLE;CYP2C19;CYP2C19 poor metabolizers and intermediate metabolizers;;LADME_PK;INCREASED_TROUGH CONCENTRATION
TRIMIPRAMINE;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;DECREASED_METABOLISM
OPIOIDS;COMT;rs4680;GG;DOSAGE;INCREASED_DOSE
ATENOLOL, METOPROLOL;ADRB2;rs1042714;CC;EFFICACY;INCREASED_RESPONSE
GLICLAZIDE;KCNQ1;rs2237895;C;EFFICACY;INCREASED_CLINICAL BENEFIT
WARFARIN;CYP2C9;CYP2C9 normal metabolizers;;DOSAGE;INCREASED_DOSE
SOLANIDINE;CYP2D6;CYP2D6 poor metabolizer genotype;;LADME_PK;DECREASED_METABOLISM
FLECAINIDE;CYP2D6;CYP2D6 normal metabolizer genotype;;LADME_PK;CONCENTRATIONS
NOROXYCODONE, OXYCODONE;CYP2D6;CYP2D6 poor metabolizer phenotype;;LADME_PK;INCREASED_CONCENTRATIONS
OXYCODONE;CYP2D6;CYP2D6 poor metabolizer phenotype;;EFFICACY;DECREASED_RESPONSE
VORICONAZOLE;CYP2C19;CYP2C19 poor metabolizers;*2/*2 + *2/*3 + *3/*3;LADME_PK;DECREASED_METABOLISM
VORICONAZOLE;CYP2C19;CYP2C19*2;*2/*2;LADME_PK;INCREASED_CONCENTRATIONS
PIMOZIDE;CYP2D6;CYP2D6 poor metabolizers;;DOSAGE;DECREASED_DOSE
PERPHENAZINE;CYP2D6;CYP2D6 normal metabolizer genotype;;LADME_PK;INCREASED_CLEARANCE
BUPROPION;CYP2C19;CYP2C19*2, CYP2C19*3, CYP2C19*17;*2 + *3;LADME_PK;DECREASED_METABOLISM
(R)-METHADONE, (S)-METHADONE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*1/*1xN;LADME_PK;DECREASED_CONCENTRATIONS
METHADONE;OPRM1;rs1799971;AA;EFFICACY;INCREASED_CLINICAL BENEFIT
ARSENIC COMPOUNDS;CBS;rs4920037;AA + AG;TOXICITY, LADME_PK;INCREASED_METABOLISM
(R)-METHADONE, (S)-METHADONE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*3/*4 + *4/*4 + *4/*6;LADME_PK;INCREASED_CONCENTRATIONS
VORICONAZOLE;CYP2C19;CYP2C19*2;*2/*2;LADME_PK;INCREASED_CONCENTRATIONS
MORPHINE;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;DOSAGE, EFFICACY;DECREASED_DOSE
CODEINE;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;DECREASED_METABOLISM
O-DESMETHYLTRAMADOL;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;LADME_PK;DECREASED_CONCENTRATIONS
(S)-METHADONE;CYP2D6;CYP2D6 ultrarapid metabolizer genotype;;LADME_PK;DECREASED_CONCENTRATIONS
WARFARIN;VKORC1;rs9934438;GG;DOSAGE;INCREASED_DOSE
VORICONAZOLE;CYP2C19;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;;EFFICACY;INCREASED_CLINICAL BENEFIT
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*9;*4/*4;LADME_PK;DECREASED_METABOLISM
METHOTREXATE;FOXP3;rs3761548;G;OTHER;DECREASED_RESPONSE
ATENOLOL, METOPROLOL;ADRB2;rs1042713;AA;EFFICACY;INCREASED_RESPONSE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;LADME_PK;INCREASED_TROUGH CONCENTRATION
N-DESMETHYLTRAMADOL;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;LADME_PK;INCREASED_CONCENTRATIONS
4-HYDROXYTAMOXIFEN, ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;DECREASED_CONCENTRATIONS
GEMCITABINE;NT5C2;rs11598702;TT;LADME_PK;DECREASED_CLEARANCE
GEMCITABINE;CDA;rs1048977;TT;LADME_PK;DECREASED_METABOLISM
VORICONAZOLE;CYP2C19;CYP2C19*17;*17/*17;LADME_PK;DECREASED_CONCENTRATIONS
METHADONE;ABCB1;rs1045642;AG;LADME_PK;DECREASED_CONCENTRATIONS
CLOMIPRAMINE;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;DECREASED_METABOLISM
OXYMORPHONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*17, CYP2D6*41;*1/*1 + *1/*9 + *2/*9 + *1/*2 + *2/*2;LADME_PK;INCREASED_EXPOSURE
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;CTRB1, CTRB2;rs7202877;GG + GT;EFFICACY;DECREASED_RESPONSE
LANSOPRAZOLE, OMEPRAZOLE;CYP2C19;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;;EFFICACY;INCREASED_CLINICAL BENEFIT
SERTRALINE;CYP2B6;CYP2B6*1, CYP2B6*6, CYP2B6*9;*6/*6 + *6/*9;LADME_PK;INCREASED_CONCENTRATIONS
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;*3 + *4 + *5 + *6 + *9 + *10 + *17 + *29 + *41;LADME_PK;DECREASED_CONCENTRATIONS
ARSENIC COMPOUNDS;CBS;rs234709;CT + TT;TOXICITY, LADME_PK;INCREASED_METABOLISM
3-HYDROXYCOTININE, 3-HYDROXYCOTININE GLUCURONIDE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*9, CYP2A6*10;*1 + *2;LADME_PK;INCREASED_CONCENTRATIONS
RISPERIDONE;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;LADME_PK;INCREASED_CLEARANCE
RISPERIDONE;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;DECREASED_METABOLISM
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;VDR;rs2239179;C;EFFICACY;DECREASED_RESPONSE
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*41;*1/*1 + *2/*2 + *1/*2;LADME_PK;INCREASED_CONCENTRATIONS
AMITRIPTYLINE;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;DECREASED_METABOLISM
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;VDR;rs1540339;C;EFFICACY;DECREASED_RESPONSE
ENDOXIFEN;CYP2C9;CYP2C9 poor metabolizers;;LADME_PK;DECREASED_CONCENTRATIONS
CLOPIDOGREL;CYP2C19;rs12248560;CT + TT;DOSAGE, EFFICACY;INCREASED_RESPONSE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3;LADME_PK;INCREASED_TROUGH CONCENTRATION
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;DECREASED_CONCENTRATIONS
IMIPRAMINE;CYP2C19;CYP2C19 poor metabolizers;;LADME_PK;DECREASED_METABOLISM
DEBRISOQUINE;CYP2D6;CYP2D6*21, CYP2D6*36xN;*21/*36xN;LADME_PK;DECREASED_METABOLISM
GEMIGLIPTIN, LINAGLIPTIN, SAXAGLIPTIN, SITAGLIPTIN, VILDAGLIPTIN;GLP1R;rs3765467;AA + AG;EFFICACY;INCREASED_CLINICAL BENEFIT
METHADONE;ABCB1;rs1045642;AA;LADME_PK;INCREASED_CONCENTRATIONS
FENTANYL;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6;*1/*3 + *1/*6 + *3/*3 + *3/*6 + *6/*6;LADME_PK;DECREASED_CLEARANCE
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE
NORQUETIAPINE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;LADME_PK;INCREASED_EXPOSURE
CODEINE;CYP2D6;CYP2D6 normal metabolizers;;EFFICACY;INCREASED_RESPONSE
VORICONAZOLE;CYP2C19;CYP2C19 intermediate metabolizers;*1/*2 + *1/*3;LADME_PK;DECREASED_METABOLISM
CITALOPRAM, ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *3/*3 + *2/*3;LADME_PK;INCREASED_EXPOSURE
INDOMETHACIN;CYP2C9;rs2153628;G;EFFICACY;INCREASED_RESPONSE
GEMCITABINE;CDA;rs2072671;AA;LADME_PK;DECREASED_METABOLISM
TACROLIMUS;CYP3A5;CYP3A5 poor metabolizer genotype;;LADME_PK;INCREASED_CONCENTRATIONS
VENLAFAXINE;SLC6A4;rs25531;TT;EFFICACY;INCREASED_CLINICAL BENEFIT
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;DECREASED_CONCENTRATIONS
ENDOXIFEN;CYP2D6;CYP2D6 intermediate metabolizers;;LADME_PK;DECREASED_CONCENTRATIONS
TRAMADOL;CYP2D6;CYP2D6 ultrarapid metabolizer genotype;;LADME_PK;INCREASED_METABOLISM
CODEINE;CYP2D6;CYP2D6 normal metabolizers;;EFFICACY;INCREASED_RESPONSE
MARAVIROC;CYP3A5;CYP3A5 poor metabolizers;;LADME_PK;DECREASED_CONCENTRATIONS
VENLAFAXINE;GABRQ;rs3810651;AA + AT;EFFICACY;INCREASED_RESPONSE
METOPROLOL;CYP2D6;CYP2D6 normal metabolizers;;LADME_PK;INCREASED_CLEARANCE
CYTARABINE, IDARUBICIN;DCK;rs80143932;G;EFFICACY;INCREASED_RESPONSE
CLOMIPRAMINE;CYP1A2;rs762551;AA;EFFICACY;INCREASED_DOSE
FENTANYL, HYDROMORPHONE, OPIOIDS, OXYCODONE, TRAMADOL;CYP2D6;CYP2D6;ultrarapid_metabolizer;DOSAGE;INCREASED_DOSE
CLOZAPINE, N-DESMETHYLCLOZAPINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);LADME_PK;DECREASED_CONCENTRATIONS
IBOGAINE;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;DECREASED_CLEARANCE
ATOMOXETINE;CYP2D6;CYP2D6*10;*10/*10;LADME_PK;INCREASED_EXPOSURE
ATOMOXETINE;CYP2D6;CYP2D6*10;*10/*10;EFFICACY;INCREASED_CLINICAL BENEFIT
AMPHETAMINE, LISDEXAMFETAMINE;CYP2D6;CYP2D6;poor_metabolizer;EFFICACY;INCREASED_CLINICAL BENEFIT
SELECTIVE SEROTONIN REUPTAKE INHIBITORS, VENLAFAXINE;GRIA3;rs502434;CC;EFFICACY;DECREASED_RESPONSE
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*41;*41;LADME_PK;DECREASED_METABOLISM
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*55;*55;LADME_PK;DECREASED_METABOLISM
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*39;*39;LADME_PK;DECREASED_METABOLISM
ISONIAZID;NAT2;NAT2;slow_acetylator;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_EXPOSURE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;HLA-DQA1;HLA-DQA1*05;*05;EFFICACY;DECREASED_CLINICAL BENEFIT
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;DOSAGE, EFFICACY;DOSE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;LADME_PK;DECREASED_CONCENTRATIONS
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED_RESPONSE
SELECTIVE SEROTONIN REUPTAKE INHIBITORS, VENLAFAXINE;GRIA3;rs3761554;TT;EFFICACY;DECREASED_RESPONSE
WARFARIN;CALU;rs339097;G;DOSAGE;INCREASED_DOSE
ISONIAZID;NAT2;NAT2;intermediate_acetylator;LADME_PK;INCREASED_CLEARANCE
OPIOIDS;OPRM1;rs1799971;GG;DOSAGE;INCREASED_DOSE
DIHYDROARTEMISININ;CYP2B6;CYP2B6*1, CYP2B6*6, CYP2B6*18;*6/*6 + *18/*18 + *1/*6;LADME_PK;DECREASED_CONCENTRATIONS
DESBUTYL LUMEFANTRINE;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6;*1/*3;LADME_PK;DECREASED_CONCENTRATIONS
SERTRALINE;CYP2D6;CYP2D6*1, CYP2D6*2;*2;LADME_PK;DECREASED_CLEARANCE
SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2 + *2/*2 + *2/*17;LADME_PK;DECREASED_CLEARANCE
TACROLIMUS;ABCC2;rs3740066;TT;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
LEVONORGESTREL;CYP2B6;CYP2B6;poor_metabolizer;LADME_PK;INCREASED_CLEARANCE
SELECTIVE SEROTONIN REUPTAKE INHIBITORS, VENLAFAXINE;GRIA3;rs3761555;TT;EFFICACY;DECREASED_RESPONSE
WARFARIN;NKX2-6;rs310279;AG + GG;DOSAGE;INCREASED_DOSE
CYTARABINE, IDARUBICIN;DCK;rs2306744;T;EFFICACY;INCREASED_RESPONSE
VENLAFAXINE;HTR2A;rs7997012;AG + GG;EFFICACY;INCREASED_CLINICAL BENEFIT
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME_PK;INCREASED_CONCENTRATIONS
ANTIEPILEPTICS;;rs16935279;CC + CT;LADME_PK;DECREASED_METABOLISM
FOLLITROPIN BETA, UROFOLLITROPIN;FSHR;rs6166;CC + CT;DOSAGE;INCREASED_DOSE
PAROXETINE;CYP2D6;CYP2D6;ultrarapid_metabolizer;LADME_PK;DECREASED_STEADY_STATE CONCENTRATION
PAROXETINE;CYP2D6;CYP2D6;ultrarapid_metabolizer;EFFICACY;DECREASED_CLINICAL BENEFIT
CLOMIPRAMINE;CYP2D6;CYP2D6*1xN, CYP2D6*2;*2/*1xN;LADME_PK;DECREASED_CONCENTRATIONS
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE
CLOMIPRAMINE;CYP2D6;CYP2D6*4, CYP2D6*6;*4/*6;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*17 + *17/*17;LADME_PK;INCREASED_CLEARANCE
ATORVASTATIN;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*4, CYP2C19*8, CYP2C19*11;*2 + *4 + *8;EFFICACY;DECREASED_CLINICAL BENEFIT
CISPLATIN, IRINOTECAN;UBE2I;rs9597;CG;EFFICACY;INCREASED_RESPONSE
WARFARIN;FRAS1;rs4386623;AA + AG;DOSAGE;INCREASED_DOSE
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE
WARFARIN;FAM201A;rs1890109;AG + GG;DOSAGE;INCREASED_DOSE
METHOTREXATE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED_RESPONSE
VALPROIC ACID;SCN1A;rs3812718;T;EFFICACY;INCREASED_CLINICAL BENEFIT
PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE
PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE
CAPECITABINE;DPYD;rs1801159;CC + CT;EFFICACY;INCREASED_RESPONSE
NICOTINE;DRD2;rs6277;A;EFFICACY;INCREASED_RESPONSE
CAPTOPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESISTANCE
APIXABAN, DABIGATRAN, EDOXABAN, RIVAROXABAN;CYP3A5;rs776746;CC;LADME_PK;INCREASED_CONCENTRATIONS
BUPROPION;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR short form (S allele) + HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE
ETHANOL;OPRM1;rs648007;A;EFFICACY;INCREASED_RESPONSE
MIDAZOLAM;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME_PK;DECREASED_CLEARANCE
CLOZAPINE;NFIB;rs28379954;CT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
ETHANOL;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;INCREASED_EXPOSURE
PRIMAQUINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41;*4/*41 + *5/*6;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_DOSE
NICOTINE;UGT2B10;rs61750900;T;OTHER, LADME_PK;DECREASED_METABOLISM
NICOTINE;CHRNA7;rs2337980;CC;EFFICACY;INCREASED_RESPONSE
BUPROPION;DRD2;rs1799732;GG;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs7294;CT + TT;DOSAGE;INCREASED_DOSE
CLOZAPINE;CYP1A1;rs2472297;CT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
SIMVASTATIN;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME_PK;CONCENTRATIONS
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*17;LADME_PK;DECREASED_CONCENTRATIONS
QUETIAPINE;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;EPHX1;rs1131873;A;DOSAGE;DECREASED_DOSE
CLOZAPINE;CYP1A1;rs2472297;CT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
METFORMIN;SLC2A2;rs8192675;C;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C9;rs28371686;G;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_METABOLISM
WARFARIN;CYP2C9;rs28371685;T;DOSAGE;DECREASED_DOSE
DULOXETINE;CYP2D6;rs3892097;CC;EFFICACY;INCREASED_CLINICAL BENEFIT
SN-38;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;CYP2C9;rs9332131;del;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_CONCENTRATIONS
CLOZAPINE;NFIB;rs28379954;CT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
HYDROXYUREA;BCL11A;rs4671393;A;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C9;rs7900194;A;DOSAGE;DECREASED_DOSE
ROSIGLITAZONE;CYP2C8;CYP2C8*1, CYP2C8*3;*3;EFFICACY;DECREASED_RESPONSE
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;LADME_PK;INCREASED_CONCENTRATIONS
BETA BLOCKING AGENTS;KL;rs36217263;A/del + del/del;EFFICACY;DECREASED_RESPONSE
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6 + *1/*6;LADME_PK;INCREASED_CONCENTRATIONS
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *1/*2 + *1/*3;LADME_PK;INCREASED_CONCENTRATIONS
GEMCITABINE;RRM1;rs12806698;AC;EFFICACY;INCREASED_RESPONSE
FLUOXETINE, SERTRALINE;SLC6A4;rs57098334;(CCCACCCGA)12/(CCCACCCGA)12;EFFICACY;INCREASED_RESPONSE
BUPROPION;ACE;rs8075924;TT;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;DECREASED_METABOLISM
SERTRALINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
SUNITINIB;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME_PK;DECREASED_CLEARANCE
HYDROXYCHLOROQUINE;CYP3A4;rs3735451;CC;LADME_PK;DECREASED_CONCENTRATIONS
FLUOROURACIL;XRCC1;rs25487;CC;EFFICACY;INCREASED_RESPONSE
MIRTAZAPINE;CYP2B6;CYP2B6*6;*6/*6;LADME_PK;INCREASED_METABOLISM
CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE
GEMCITABINE;RRM1;rs11030918;CT;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;ABCB1;rs1045642;AG + GG;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*3;LADME_PK;DECREASED_CLEARANCE
RISPERIDONE;CYP2D6;CYP2D6 intermediate metabolizer phenotype;;LADME_PK;DECREASED_METABOLISM
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;DOSAGE, EFFICACY;DECREASED_RESPONSE
PACLITAXEL;CYP2C8;rs11572080;T;OTHER, LADME_PK;DECREASED_METABOLISM
PACLITAXEL;CYP2C8;rs10509681;C;OTHER, LADME_PK;DECREASED_METABOLISM
CYCLOSPORINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;DECREASED_CONCENTRATIONS
CYCLOSPORINE;CYP3A4;rs35599367;A;LADME_PK;DECREASED_METABOLISM
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE
FLUOXETINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*10;*1/*1 + *10/*10 + *1/*4 + *1/*10;LADME_PK;DECREASED_CONCENTRATIONS
CODEINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;LADME_PK;DECREASED_METABOLISM
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;LADME_PK;INCREASED_METABOLISM
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
DOCETAXEL, THALIDOMIDE;PPARD;rs3734254;T;EFFICACY;INCREASED_RESPONSE
ATENOLOL, METOPROLOL;OR10P1;rs17117817;G;LADME_PD;DECREASED_RESPONSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3;DOSAGE;DECREASED_DOSE
CARBOPLATIN, GEMCITABINE;RRM1;rs12806698;AC;EFFICACY;INCREASED_RESPONSE
METFORMIN;C11orf65;rs11212617;C;EFFICACY;INCREASED_CLINICAL BENEFIT
ABATACEPT;HLA-DRB1;HLA-DRB1*04:01, HLA-DRB1*04:04, HLA-DRB1*04:05, HLA-DRB1*04:10, HLA-DRB1*10:01;*04:01 + *04:04 + *04:05 + *04:10 + *10:01;EFFICACY;INCREASED_CLINICAL BENEFIT
METHADONE;;rs17180299;AG + GG;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;CALU;rs339097;G;DOSAGE;INCREASED_DOSE
VINCRISTINE;;rs1247117;G;LADME_PD;INCREASED_RESISTANCE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_METABOLISM
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_CONCENTRATIONS
ATENOLOL, METOPROLOL;SNX9;rs2364349;A;LADME_PD;DECREASED_RESPONSE
TACROLIMUS;;rs11265572;GT + TT;LADME_PK;DECREASED_METABOLISM
WARFARIN;STX4;rs10871454;T;DOSAGE;DECREASED_DOSE
SIROLIMUS, TEMSIROLIMUS;CYP3A5;rs776746;CT;LADME_PK;DECREASED_CONCENTRATIONS
PERAMPANEL;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;LADME_PK;INCREASED_CONCENTRATIONS
VORICONAZOLE;CYP2C19;CYP2C19*17;*17;LADME_PK;DECREASED_CONCENTRATIONS
ENALAPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESPONSE
URACIL;DPYD;DPYD c.295_298delTCAT (*7), DPYD Reference;c.295_298delTCAT (*7);LADME_PK;INCREASED_CONCENTRATIONS
URACIL;DPYD;DPYD c.2846A>T, DPYD Reference;c.2846A>T;LADME_PK;INCREASED_CONCENTRATIONS
URACIL;DPYD;DPYD c.1679T>G (*13), DPYD Reference;c.1679T>G (*13);LADME_PK;INCREASED_CONCENTRATIONS
URACIL;DPYD;DPYD c.1905+1G>A (*2A), DPYD Reference;c.1905+1G>A (*2A);LADME_PK;INCREASED_CONCENTRATIONS
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*29, CYP2D6*35, CYP2D6*41;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;LADME_PK;DECREASED_METABOLISM
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;LADME_PK;DECREASED_METABOLISM
ATORVASTATIN;CYP3A5;CYP3A5*3;*3/*3;EFFICACY;DECREASED_RESPONSE
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10 + *1/*10;LADME_PK;INCREASED_CONCENTRATIONS
ESCITALOPRAM;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS
ESCITALOPRAM;CYP2D6;CYP2D6;intermediate_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS
AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2 + *1/*2;TOXICITY, LADME_PK;DECREASED_METABOLISM
EFAVIRENZ;CYP2B6;CYP2B6;poor_metabolizer;LADME_PK;INCREASED_EXPOSURE
BCR-ABL TYROSINE KINASE INHIBITORS;HLA-A;HLA-A*03:01;*03:01;EFFICACY;DECREASED_CLINICAL BENEFIT
BCR-ABL TYROSINE KINASE INHIBITORS;HLA-A;HLA-A*23:17;*23:17;EFFICACY;DECREASED_CLINICAL BENEFIT
BCR-ABL TYROSINE KINASE INHIBITORS;HLA-B;HLA-B*57:03;*57:03;EFFICACY;INCREASED_CLINICAL BENEFIT
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*7;*1/*1 + *1/*3;LADME_PK;INCREASED_CLEARANCE
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*9, CYP2D6*10, CYP2D6*35, CYP2D6*41;*2 + *9 + *10 + *35 + *41;LADME_PK;DECREASED_CLEARANCE
ANTIDEPRESSANTS;CYP2C19;CYP2C19;poor_metabolizer;EFFICACY;INCREASED_CLINICAL BENEFIT
SUMATRIPTAN;SLC22A1;rs1349294037;TAAGTTGT/TAAGTTGT;OTHER;INCREASED_CONCENTRATIONS
METHADONE;CYP2B6;CYP2B6*1, CYP2B6*6, CYP2B6*18;*6 + *18;LADME_PK;INCREASED_CONCENTRATIONS
LAMOTRIGINE;UGT1A4;UGT1A4*3b;*3b;EFFICACY;DECREASED_CLINICAL BENEFIT
DOCETAXEL, THALIDOMIDE;PPARD;rs2016520;C;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1;DOSAGE;INCREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
INFLIXIMAB;HLA-DQA1;HLA-DQA1*05;*05;EFFICACY;DECREASED_RESPONSE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*4, CYP2C19*17;*2 + *4;EFFICACY;DECREASED_RESPONSE
DOCETAXEL, THALIDOMIDE;CHST3;rs1871450;A;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;T;DOSAGE, LADME_PK;DECREASED_DOSE
PROPOFOL;CYP2B6;CYP2B6*1, CYP2B6*6;*6;TOXICITY;DECREASED_RESPONSE
TILDRAKIZUMAB;PDE4D;rs10556657;CT/CT;EFFICACY;DECREASED_CLINICAL BENEFIT
BUPRENORPHINE, DIHYDROCODEINE, FENTANYL, HYDROMORPHONE, METHADONE, MORPHINE, OXYCODONE, PIRITRAMIDE, TILIDINE, TRAMADOL;ABCB1;rs1045642;A;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;DOSAGE;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME_PK;DECREASED_CLEARANCE
SIROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_CONCENTRATIONS
DOCETAXEL, THALIDOMIDE;PPARD;rs1883322;C;EFFICACY;INCREASED_RESPONSE
PHENYTOIN;CYP2C19;CYP2C19;intermediate_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS
VALPROIC ACID;CYP2C19;CYP2C19;intermediate_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS
CARBAMAZEPINE;CYP3A5;CYP3A5;poor_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS
VALPROIC ACID;CYP2C9;CYP2C9;intermediate_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS
VALPROIC ACID;UGT1A6;UGT1A6*1a, UGT1A6*2a;*2a;LADME_PK;DECREASED_CONCENTRATIONS
PHENYTOIN;CYP2C9;CYP2C9;intermediate_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS
SN-38;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28;LADME_PK;INCREASED_CONCENTRATIONS
DOCETAXEL, THALIDOMIDE;CHST3;rs12418;A;EFFICACY;INCREASED_RESPONSE
FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*60;*28 + *60;DOSAGE;DECREASED_DOSE
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28 + *1/*28;DOSAGE;DECREASED_DOSE
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;LADME_PK;INCREASED_METABOLISM
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*8;*1/*8;LADME_PK;DECREASED_METABOLISM
ABROCITINIB;CYP2C19;CYP2C19;poor_metabolizer;LADME_PK;INCREASED_EXPOSURE
WARFARIN;CYP2C9;CYP2C9*1;*1/*1;DOSAGE;INCREASED_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*8;*2 + *3 + *8;DOSAGE;DECREASED_DOSE
OPIOIDS;OPRM1;rs1799971;GG;DOSAGE;INCREASED_DOSE
DULOXETINE;DRD3;rs963468;GG;EFFICACY;DECREASED_RESPONSE
SIMVASTATIN;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME_PK;INCREASED_EXPOSURE
METFORMIN;C11orf65;rs11212617;C;EFFICACY;INCREASED_CLINICAL BENEFIT
CYCLOSPORINE;CYP3A5;rs776746;CC;DOSAGE, LADME_PK;DECREASED_DOSE
EFAVIRENZ, NEVIRAPINE;NR1I3;rs2307424;AA + AG;EFFICACY;INCREASED_RESPONSE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*1 + *1/*2;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
ARIPIPRAZOLE;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME_PK;INCREASED_CONCENTRATIONS
ARIPIPRAZOLE, DEHYDROARIPIPRAZOLE;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS
PIMOZIDE;CYP3A4;CYP3A4*1, CYP3A4*22;*22;LADME_PK;DECREASED_CONCENTRATIONS
DOCETAXEL, THALIDOMIDE;CHST3;rs4148943;C;EFFICACY;INCREASED_RESPONSE
RISPERIDONE;CYP2D6;CYP2D6;ultrarapid_metabolizer;LADME_PK;DECREASED_CONCENTRATIONS
DOCETAXEL, THALIDOMIDE;CHST3;rs4148945;C;EFFICACY;INCREASED_RESPONSE
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs80034486;CG;EFFICACY;INCREASED_CLINICAL BENEFIT
GLYBURIDE;ABCB11;rs4148776;G;EFFICACY;INCREASED_RESPONSE
IMATINIB;SLCO1B3;rs7311358;AA + AG;EFFICACY;DECREASED_RESPONSE
IMATINIB;SLCO1B3;rs4149117;GG + GT;EFFICACY;DECREASED_RESPONSE
PRAZIQUANTEL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *2/*2 + *1/*3 + *3/*3;LADME_PK;INCREASED_CONCENTRATIONS
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
GLYBURIDE;CHST13;rs1054097;C;EFFICACY;INCREASED_RESPONSE
LACOSAMIDE;CYP2C19;CYP2C19 normal metabolizer;;LADME_PK;DECREASED_EXPOSURE
LACOSAMIDE;ABCC2;rs717620;T;LADME_PK;DECREASED_EXPOSURE
ZUCLOPENTHIXOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*1/*3 + *1/*4;LADME_PK;INCREASED_CONCENTRATIONS
ZUCLOPENTHIXOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*4/*4;LADME_PK;INCREASED_CONCENTRATIONS
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*1;LADME_PK;DECREASED_CONCENTRATIONS
CLOZAPINE;CYP2D6;CYP2D6 normal metabolizer;;DOSAGE;INCREASED_DOSE
EFAVIRENZ;CYP2B6;CYP2B6;intermediate_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS
MERCAPTOPURINE;TPMT;TPMT deficiency;;DOSAGE;DECREASED_DOSE
THIOGUANOSINE DIPHOSPHATE, THIOGUANOSINE MONOPHOSPHATE, THIOGUANOSINE TRIPHOSPHATE;TPMT;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;*3A + *3B + *3C;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_CONCENTRATIONS
TOLTERODINE;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS
METOPROLOL;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;DECREASED_METABOLISM
CLOZAPINE;ITIH3;rs2535629;AA;EFFICACY;INCREASED_RESPONSE
ATOMOXETINE;CYP2D6;CYP2D6;poor_metabolizer;EFFICACY;INCREASED_RESPONSE
EFAVIRENZ;CYP2B6;CYP2B6;poor_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS
EFAVIRENZ;NAT2;NAT2;slow_acetylator;LADME_PK;INCREASED_CONCENTRATIONS
COTININE;CYP2A6;CYP2A6 low activity;;LADME_PK;INCREASED_METABOLISM
COTININE;CYP2A6;CYP2A6 low activity;;LADME_PK;INCREASED_CONCENTRATIONS
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*12, CYP2A6*17, CYP2A6*20, CYP2A6*23, CYP2A6*24, CYP2A6*25, CYP2A6*26, CYP2A6*27, CYP2A6*28, CYP2A6*35;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;LADME_PK;DECREASED_METABOLISM
ESCITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE
DEOXY-THIOGUANOSINE TRIPHOSPHATE, THIOGUANOSINE TRIPHOSPHATE;TPMT;TPMT deficiency;;LADME_PK;INCREASED_CONCENTRATIONS
ENDOXIFEN;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;DECREASED_CONCENTRATIONS
CAFFEINE;ADORA1;rs10920573;CC;EFFICACY;DECREASED_CLINICAL BENEFIT
NORQUETIAPINE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_CONCENTRATIONS
QUETIAPINE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_CONCENTRATIONS
AMLODIPINE;CACNA1D;rs312481;GG;EFFICACY;INCREASED_CLINICAL BENEFIT
PEGINTERFERON ALFA-2A;ZHX2;rs17289471;C;EFFICACY;INCREASED_RESPONSE
BERBERINE;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;DECREASED_METABOLISM
CLOPIDOGREL;CYP2C19;rs12248560;T;EFFICACY, OTHER;RESPONSE
RANIBIZUMAB;VEGFA;rs833069;CC + CT;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs4646449;CC;LADME_PK;INCREASED_CONCENTRATIONS
ONDANSETRON;CYP2D6;CYP2D6;poor_metabolizer;DOSAGE;INCREASED_DOSE
IMATINIB;ABCA3;rs150929;GG + GT;EFFICACY;DECREASED_RESPONSE
METFORMIN;CBARP, STK11;rs2301759;TT;EFFICACY;DECREASED_CLINICAL BENEFIT
METFORMIN;SLC22A3;rs3127602;T;EFFICACY;INCREASED_RESPONSE
METFORMIN;PRKAA1;rs11749180;A;EFFICACY;DECREASED_RESPONSE
METFORMIN;SLC29A4;rs10234709;A;EFFICACY;DECREASED_RESPONSE
METFORMIN;PRKAG2;rs4725434;T;EFFICACY;INCREASED_RESPONSE
METFORMIN;SLC47A1;rs2120274;A;EFFICACY;INCREASED_RESPONSE
METFORMIN;STK11;rs2301759;C;EFFICACY;INCREASED_RESPONSE
METFORMIN;SLC47A2;rs4621031;C;EFFICACY;DECREASED_RESPONSE
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;CFTR 3849+10kbC->T;3849+10kbC->T;;INCREASED_CLINICAL BENEFIT
ALECTINIB;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME_PK;INCREASED_CONCENTRATIONS
METFORMIN;TCF7L2;rs7903146;T;EFFICACY;INCREASED_RESPONSE
METHADONE;OPRK1;rs3802279;CC;DOSAGE;DECREASED_DOSE
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs80034486;GG;EFFICACY;INCREASED_CLINICAL BENEFIT
LACOSAMIDE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;SLC22A1;rs41267797;AG;LADME_PK;INCREASED_CONCENTRATIONS
N,N-DIDESMETHYLTRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*41, CYP2D6*45;*4/*6 + *4/*5;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs75961395;AA;EFFICACY;INCREASED_CLINICAL BENEFIT
TOCILIZUMAB;IL6R;rs35717427;AG + GG;EFFICACY;DECREASED_CLINICAL BENEFIT
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;ABCC2;rs17216317;CT;LADME_PK;INCREASED_CONCENTRATIONS
TOCILIZUMAB;IL6R;rs6690230;CG + GG;EFFICACY;DECREASED_CLINICAL BENEFIT
TOCILIZUMAB;IL6R;rs11265621;AA + AG;EFFICACY;DECREASED_CLINICAL BENEFIT
TOCILIZUMAB;;rs10108210;AA;EFFICACY;DECREASED_CLINICAL BENEFIT
TOCILIZUMAB;CLEC2D;rs1560011;GG;EFFICACY;INCREASED_CLINICAL BENEFIT
TOCILIZUMAB;KCNMB1;rs703505;AA + AG;EFFICACY;DECREASED_CLINICAL BENEFIT
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
MORPHINE;CCL11;rs17809012;AA;EFFICACY;DECREASED_CLINICAL BENEFIT
MORPHINE;IL16;rs4778889;TT;EFFICACY;INCREASED_CLINICAL BENEFIT
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;SLC22A1;rs35235578;CT;LADME_PK;INCREASED_CONCENTRATIONS
VALPROIC ACID;SLC16A1;rs7169;GG;EFFICACY;INCREASED_CLINICAL BENEFIT
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;SLC22A1;rs9457841;C;LADME_PK;INCREASED_CONCENTRATIONS
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;SLC22A1;rs34134157;CC;LADME_PK;DECREASED_CONCENTRATIONS
TENOFOVIR;ABCC4;rs3742106;AC + CC;TOXICITY;INCREASED_CONCENTRATIONS
ANTIDEPRESSANTS;FKBP5;rs1360780;CT + TT;EFFICACY;INCREASED_RESPONSE
ACETAMINOPHEN SULFATE;CYP2E1;CYP2E1*1, CYP2E1*5B;*1/*5B;LADME_PK;INCREASED_CONCENTRATIONS
FENTANYL;ABCC1;rs58572178;(A)14;LADME_PK;INCREASED_CLEARANCE
VORICONAZOLE;CYP2C19;CYP2C19*2, CYP2C19*17;*2 + *17;DOSAGE;DOSE
ACETAMINOPHEN;CYP1A2;rs2069514;A;EFFICACY;INCREASED_CLINICAL BENEFIT
DOXORUBICIN;CBR1;rs20572;T;LADME_PK;INCREASED_CONCENTRATIONS
SUNITINIB;KDR;rs34231037;AG;EFFICACY;INCREASED_CLINICAL BENEFIT
ANTIDEPRESSANTS;FKBP5;rs3800373;CC;EFFICACY;INCREASED_RESPONSE
GLICLAZIDE, GLIMEPIRIDE, GLIPIZIDE, GLYBURIDE;KCNQ1;rs163184;GT + TT;EFFICACY;INCREASED_CLINICAL BENEFIT
ISONIAZID;NAT2;NAT2;slow_acetylator;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE
MORPHINE;CYP2D6;CYP2D6*10, CYP2D6*41;*41;LADME_PK;INCREASED_EXPOSURE
DULOXETINE;DRD3;rs324026;CC + CT;EFFICACY;DECREASED_RESPONSE
CYTARABINE, DAUNORUBICIN;RAD50;rs2299014;AA + AC;EFFICACY;INCREASED_RESISTANCE
TENOFOVIR;ABCC4;rs1751034;TT;TOXICITY;INCREASED_CONCENTRATIONS
DULOXETINE;DRD3;rs324023;CT;EFFICACY;DECREASED_RESPONSE
EFAVIRENZ, NEVIRAPINE;NR1I2;rs1523127;AA + AC;EFFICACY;DECREASED_RESPONSE
EZETIMIBE;ABCG8;ABCG8 deficiency;;EFFICACY;INCREASED_CLINICAL BENEFIT
EZETIMIBE;ABCG5;ABCG5 deficiency;;EFFICACY;INCREASED_CLINICAL BENEFIT
RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE
DULOXETINE;DRD3;rs167770;AG;EFFICACY;DECREASED_RESPONSE
RISPERIDONE;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS
TAMSULOSIN;CYP2D6;CYP2D6*10, CYP2D6*41;*10 + *41;EFFICACY;INCREASED_CLINICAL BENEFIT
HYDROXYUREA;HBG2;rs7482144;AG;EFFICACY;INCREASED_CLINICAL BENEFIT
HYDROXYUREA;HBG2;rs7482144;AA + AG;EFFICACY;INCREASED_CLINICAL BENEFIT
HYDROXYUREA;HBG2;rs7482144;AA;EFFICACY;INCREASED_CLINICAL BENEFIT
HYDROXYUREA;BCL11A;rs766432;C;EFFICACY;INCREASED_CLINICAL BENEFIT
IMATINIB;PDGFRB;rs201866603;CT;EFFICACY;DECREASED_RESPONSE
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MTHFR;rs1801133;A;EFFICACY;INCREASED_RESPONSE
VORTIOXETINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*10;*4/*4 + *4/*10;LADME_PK;INCREASED_CONCENTRATIONS
ANTIEPILEPTICS;SCN1A;rs121917953;AA + AT;EFFICACY;INCREASED_RESISTANCE
NICOTINE;CYP2A6;rs778019189;G;LADME_PK;DECREASED_METABOLISM
METHOTREXATE;ENG;rs1800956;G;LADME_PK;DECREASED_CLEARANCE
METHOTREXATE;PKD1L2;rs16954698;A;LADME_PK;DECREASED_CLEARANCE
MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4;*1/*2 + *1/*3 + *1/*4 + *2/*4 + *3/*3;DOSAGE;DECREASED_DOSE
ANTIDEPRESSANTS;FKBP5;rs1360780;TT;EFFICACY;INCREASED_RESPONSE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY, LADME_PK;INCREASED_CONCENTRATIONS
EFAVIRENZ, NEVIRAPINE;NR1I3;rs3003596;AG + GG;EFFICACY;DECREASED_RESPONSE
ANTIDEPRESSANTS;FKBP5;rs4713916;AA;EFFICACY;INCREASED_RESPONSE
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10;*10/*10 + *2/*10;LADME_PK;DECREASED_CONCENTRATIONS
ENDOXIFEN;CYP2D6;CYP2D6 normal metabolizer;;LADME_PK;INCREASED_CONCENTRATIONS
DEXTROMETHORPHAN;CYP2D6;CYP2D6*4;*4/*4;LADME_PK;DECREASED_METABOLISM
CLOZAPINE;CYP2D6;rs202102799;C;LADME_PK;DECREASED_CONCENTRATIONS
CLOZAPINE;CYP2D6;rs28371726;G;LADME_PK;DECREASED_CONCENTRATIONS
CLOZAPINE, N-DESMETHYLCLOZAPINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;LADME_PK;INCREASED_CONCENTRATIONS
CLOZAPINE;DRD4;rs762502;C;EFFICACY;INCREASED_CLINICAL BENEFIT
NIFEDIPINE;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_CLEARANCE
CLOZAPINE;DRD4;rs2133251840;del;EFFICACY;INCREASED_CLINICAL BENEFIT
CLOZAPINE, N-DESMETHYLCLOZAPINE;CYP1A2;CYP1A2;ultrarapid_metabolizer;LADME_PK;DECREASED_CONCENTRATIONS
EXENATIDE;SORCS1;rs1416406;GG;EFFICACY;INCREASED_RESPONSE
LINAGLIPTIN, SITAGLIPTIN, VILDAGLIPTIN;KCNJ11;rs2285676;GG;EFFICACY;INCREASED_CLINICAL BENEFIT
LINAGLIPTIN, SAXAGLIPTIN, SITAGLIPTIN, VILDAGLIPTIN;PRKD1;rs57803087;G;EFFICACY;INCREASED_RESPONSE
CLOZAPINE;CYP1A2;rs72547516;T;;DECREASED_METABOLISM
CLOZAPINE;CYP1A2;CYP1A2*8;*8;LADME_PK;DECREASED_METABOLISM
MIDAZOLAM;NR1I2;rs2461817;CC;LADME_PK;INCREASED_CONCENTRATIONS
METHADONE, R-EDDP, S-EDDP;CYP2D6;CYP2D6;intermediate_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MTHFR;rs1801131;G;EFFICACY;INCREASED_RESPONSE
AZATHIOPRINE;NUDT15;rs116855232;CT + TT;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;rs1057910;AA;DOSAGE;INCREASED_DOSE
WARFARIN;APOE;rs7412;CC;DOSAGE;INCREASED_DOSE
METHACHOLINE;ADRB2;rs1042713;AA;EFFICACY;DECREASED_RESPONSE
NALTREXONE;OPRM1;rs1799971;AG + GG;EFFICACY;DECREASED_RESPONSE
ACENOCOUMAROL;VKORC1;rs9923231;CT;DOSAGE;DECREASED_DOSE
TEMSIROLIMUS;NR1I2;rs3814055;TT;LADME_PK;DECREASED_METABOLISM
TEMSIROLIMUS;ABCB1;rs2032582;CC;LADME_PK;INCREASED_METABOLISM
TACROLIMUS;CYP3A5;rs776746;TT;DOSAGE;INCREASED_DOSE
TACROLIMUS;;rs4646457;C;DOSAGE;DOSE
TACROLIMUS;CYP3A5;rs15524;G;DOSAGE;DOSE
TACROLIMUS;CYP3A4;rs12333983;A;DOSAGE;DOSE
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE
FLECAINIDE;SCN4A;rs80338792;T;EFFICACY;INCREASED_RESPONSE
ATENOLOL, METOPROLOL;;rs294610;A;EFFICACY;INCREASED_RESPONSE
ATENOLOL, METOPROLOL;SLC4A1;rs45545233;CC + CT;EFFICACY;DECREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLCO1C1;rs3794271;G;EFFICACY;DECREASED_RESPONSE
CAPECITABINE, FLUOROURACIL;DPYD;rs56038477;CT;DOSAGE;DOSE
SUNITINIB;ABCB1;rs2032582;AA;EFFICACY;DECREASED_RESPONSE
FLUOROURACIL;DPYD;rs17376848;AG + GG;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE
HYDROCHLOROTHIAZIDE;;rs11065987;AA + AG;EFFICACY;INCREASED_RESPONSE
METHADONE;ABCB1;rs1128503;AA;DOSAGE;INCREASED_DOSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
ETHANOL;OPRM1;rs553202;T;EFFICACY;INCREASED_RESPONSE
ETHANOL;OPRM1;rs524731;A;EFFICACY;INCREASED_RESPONSE
S-EDDP;ABCB1;rs1128503;AG;LADME_PK;INCREASED_CONCENTRATIONS
NICOTINE;HINT1;rs3852209;CT + TT;EFFICACY;INCREASED_RESPONSE
S-EDDP;ABCB1;rs1045642;AG;LADME_PK;INCREASED_CONCENTRATIONS
OPIOIDS;OPRM1;rs1799971;AG;EFFICACY;DECREASED_RESPONSE
METHADONE;ABCB1;rs1128503;AG;LADME_PK;DECREASED_CONCENTRATIONS
PHENPROCOUMON;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE
FLUOXETINE;CYP2D6;rs3892097;CT;EFFICACY;INCREASED_CONCENTRATIONS
LEVODOPA;DBH;rs1611115;CT + TT;EFFICACY;INCREASED_RESPONSE
VENLAFAXINE;COMT;rs4680;GG;EFFICACY;INCREASED_RESPONSE
AXITINIB;OR2B11;rs35305980;A;LADME_PK;CONCENTRATIONS
SULFONAMIDES, UREA DERIVATIVES;KCNJ11;rs5219;CT;EFFICACY;INCREASED_RESPONSE
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED_RESPONSE
WARFARIN;VKORC1;rs7294;T;DOSAGE, LADME_PK;INCREASED_DOSE
SULFONAMIDES, UREA DERIVATIVES;ABCC8;rs757110;AA + CC;EFFICACY;INCREASED_RESPONSE
TIPIRACIL HYDROCHLORIDE, TRIFLURIDINE;SLC29A1;rs9394992;CT + TT;EFFICACY;INCREASED_RESPONSE
ANTIDEPRESSANTS, DESIPRAMINE, FLUOXETINE;BDNF;rs61888800;GG;EFFICACY;INCREASED_RESPONSE
AXITINIB;UGT1A10, UGT1A8, UGT1A9;rs3832043;del;LADME_PK;CONCENTRATIONS
AXITINIB;UGT1A7;rs17868323;G;LADME_PK;CONCENTRATIONS
RISPERIDONE;HTR2C;rs3813928;A;EFFICACY;DECREASED_RESPONSE
METHOTREXATE;MTRR;rs1532268;CT + TT;LADME_PK;INCREASED_EXPOSURE
RISPERIDONE;HTR2A;rs6311;CT + TT;EFFICACY;INCREASED_RESPONSE
AXITINIB;ABCB1;rs1045642;A;LADME_PK;CONCENTRATIONS
AXITINIB;ABCG2;rs2231142;T;LADME_PK;CONCENTRATIONS
AXITINIB;ABCB1;rs2032582;T;LADME_PK;CONCENTRATIONS
VORICONAZOLE;CYP2C19;rs4244285;AA + AG;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
ERLOTINIB;EGFR;rs121434568;GT + TT;EFFICACY;DECREASED_RESPONSE
METHOTREXATE;ABCB1;rs1045642;AA;EFFICACY;DECREASED_RESPONSE
CYTARABINE;SLC29A1;rs3734703;A;EFFICACY;INCREASED_RESPONSE
SUNITINIB;ABCB1;rs1045642;AA + AG;LADME_PK;INCREASED_CLEARANCE
METHOTREXATE;SLC19A1;rs1051266;CC + TT;EFFICACY;DECREASED_RESPONSE
SN-38;UGT1A9;rs3832043;TT;DOSAGE;INCREASED_METABOLISM
EFAVIRENZ;CYP2B6;rs2279345;CC + CT;LADME_PK;INCREASED_METABOLISM
RISPERIDONE;ABCB1;rs1128503;AA + AG;EFFICACY;INCREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs2279345;CT;LADME_PK;INCREASED_METABOLISM
GLUCOCORTICOIDS;CRHR1;rs1876828;T;EFFICACY;INCREASED_RESPONSE
ANTIDEPRESSANTS;ERICH3;rs11580409;C;EFFICACY;INCREASED_RESPONSE
SN-38;SLCO1B1;rs4149056;CC + CT;DOSAGE;INCREASED_DOSE
SALMETEROL;ADRB2;rs1042713;AA;EFFICACY;DECREASED_RESPONSE
(S)-METHADONE;CYP3A4;rs2740574;CT;LADME_PK;INCREASED_CONCENTRATIONS
VORICONAZOLE;CYP2C19;rs4986893;AA + AG;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
METHYLPHENIDATE;GRIN2B;rs2284411;CC;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs17708472;A;DOSAGE, LADME_PK;INCREASED_DOSE
FENTANYL;CYP3A4;rs2740574;C;LADME_PK;DECREASED_CLEARANCE
METHOTREXATE;SLC19A1;rs1051266;TT;LADME_PK;DECREASED_CONCENTRATIONS
SALBUTAMOL, SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;CRHR2;rs7793837;T;EFFICACY;DECREASED_RESPONSE
ATORVASTATIN, ROSUVASTATIN, SIMVASTATIN;ABCA1;rs2230806;T;EFFICACY;DECREASED_RESPONSE
SALBUTAMOL, SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;CRHR2;rs7793837;T;EFFICACY;DECREASED_RESPONSE
ATORVASTATIN, ROSUVASTATIN, SIMVASTATIN;CYP2D6;rs3892097;T;EFFICACY;DECREASED_RESPONSE
NICARDIPINE, NIMODIPINE;CACNA1B;rs2739258;AG + GG;EFFICACY;INCREASED_CLINICAL BENEFIT
METHOTREXATE;MTHFR;rs1801131;TT;EFFICACY;DECREASED_RESPONSE
IMATINIB;CYP3A5;rs776746;C;EFFICACY;INCREASED_RESPONSE
IMATINIB;SLC22A1;rs683369;CG + GG;EFFICACY;DECREASED_RESPONSE
SIMVASTATIN;APOA5;rs662799;AA;EFFICACY;INCREASED_RESPONSE
IRBESARTAN;APOB;rs1367117;AG;EFFICACY, LADME_PK;RESPONSE
IRBESARTAN;APOB;rs1367117;GG;EFFICACY;RESPONSE
ATORVASTATIN;APOA5;rs662799;AA;EFFICACY;INCREASED_RESPONSE
EFAVIRENZ;CYP2A6;rs28399433;C;LADME_PK;DECREASED_METABOLISM
METHOTREXATE;MTHFR;rs1801133;AA;EFFICACY;INCREASED_RESPONSE
BENAZEPRIL;PRCP;rs2229437;GG + GT;EFFICACY;DECREASED_RESPONSE
EFAVIRENZ;UGT2B7;rs28365062;GG;LADME_PK;DECREASED_METABOLISM
EFAVIRENZ;CYP2B6;rs28399499;C;LADME_PK;METABOLISM
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY, OTHER;RESPONSE
EFAVIRENZ, LAMIVUDINE, TENOFOVIR;CYP2B6;rs2279343;AG + GG;EFFICACY;INCREASED_CLINICAL BENEFIT
METHOTREXATE;MTHFR;rs1801131;GG;EFFICACY;INCREASED_RESPONSE
CLOPIDOGREL;ABCB1;rs1045642;G;EFFICACY, OTHER;RESPONSE
QUETIAPINE, ZIPRASIDONE;RGS4;rs951439;TT;EFFICACY;INCREASED_RESPONSE
MIDAZOLAM;VDR;rs11568820;CT + TT;LADME_PK;INCREASED_CLEARANCE
METHYLDOPA;ARG2;rs3742879;G;EFFICACY;INCREASED_RESPONSE
FLUOROURACIL;MTHFR;rs1801133;AA + AG;EFFICACY;INCREASED_RESPONSE
ARIPIPRAZOLE;ABCB1;rs1128503;AA;LADME_PK;INCREASED_CONCENTRATIONS
OMEPRAZOLE;CYP2C19;rs12248560;TT;DOSAGE, LADME_PK;INCREASED_METABOLISM
MEPHENYTOIN;CYP2C19;rs12248560;TT;DOSAGE, LADME_PK;INCREASED_METABOLISM
OMEPRAZOLE;CYP2C19;rs11188072;TT;DOSAGE, LADME_PK;INCREASED_METABOLISM
MEPHENYTOIN;CYP2C19;rs11188072;TT;DOSAGE, LADME_PK;INCREASED_METABOLISM
METHADONE;CYP2B6;rs3211371;TT;LADME_PK;INCREASED_CONCENTRATIONS
MERCAPTOPURINE, METHOTREXATE;SLCO1B1;rs4149056;CC + CT;DOSAGE;DECREASED_DOSE
GEMCITABINE;CMPK1;rs1044457;CC;EFFICACY;INCREASED_RESPONSE
DEXMEDETOMIDINE;ADRA2A;rs1800035;CG + GG;EFFICACY;DECREASED_RESPONSE
BUDESONIDE, FLUTICASONE / SALMETEROL, FORMOTEROL, OMALIZUMAB;IL10;rs3024498;CC + CT;EFFICACY;DECREASED_CLINICAL BENEFIT
DEXMEDETOMIDINE;ADRA2A;rs775887911;CT + TT;EFFICACY;DECREASED_RESPONSE
DEXMEDETOMIDINE;ADRA2A;rs201376588;CT + TT;EFFICACY;DECREASED_RESPONSE
GEMCITABINE;CMPK1;rs35687416;GG;EFFICACY;INCREASED_RESPONSE
GEMCITABINE;DCTD;rs12507552;CC;EFFICACY;INCREASED_RESPONSE
BETA BLOCKING AGENTS;;rs139945292;T;EFFICACY;DECREASED_RESPONSE
ROSUVASTATIN;APOA5;rs662799;AA;EFFICACY;INCREASED_RESPONSE
GEMCITABINE;TENT4A;rs274713;GG;EFFICACY;INCREASED_RESPONSE
METHOTREXATE;FPGS;rs1544105;CT + TT;EFFICACY;DECREASED_RESPONSE
GEMCITABINE;CDC5L;rs992160;CT + TT;EFFICACY;INCREASED_RESPONSE
METHOTREXATE;TYMS;rs2853539;AA;EFFICACY;DECREASED_RESPONSE
ATORVASTATIN, ROSUVASTATIN, SIMVASTATIN;APOA5;rs662799;AA;OTHER;RESPONSE
BUDESONIDE, FLUTICASONE / SALMETEROL, FORMOTEROL, OMALIZUMAB;IL17A;rs3819024;AG + GG;EFFICACY;DECREASED_CLINICAL BENEFIT
GEMCITABINE;SH2D5;rs10916852;GT + TT;EFFICACY;INCREASED_RESPONSE
ROSUVASTATIN;CETP;rs708272;A;EFFICACY;DECREASED_RESPONSE
ATORVASTATIN;ABCB1;rs1045642;AA;EFFICACY;INCREASED_CLINICAL BENEFIT
ATORVASTATIN;SLCO1B1;rs2306283;AA;EFFICACY;INCREASED_CLINICAL BENEFIT
PHENPROCOUMON;VKORC1;rs9923231;TT;DOSAGE, TOXICITY;DECREASED_DOSE
AZATHIOPRINE;TPMT;rs1142345;CT;LADME_PK;DECREASED_METABOLISM
AZATHIOPRINE;ITPA;rs1127354;AC;LADME_PK;INCREASED_METABOLISM
BUPRENORPHINE;CYP3A4;rs2740574;TT;EFFICACY;INCREASED_RESPONSE
PERINDOPRIL;AGTR1;rs5186;AA;EFFICACY;DECREASED_RESPONSE
NITRENDIPINE;AGTR1;rs5186;AA;EFFICACY;INCREASED_RESPONSE
LAMOTRIGINE;HNF4A;rs2071197;AA;LADME_PK;DECREASED_CONCENTRATIONS
LAMOTRIGINE;ABCG2;rs2231142;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS
LAMOTRIGINE;ABCG2;rs3114020;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS
CYCLOSPORINE;TSPYL1;rs3828743;AG + GG;LADME_PK;INCREASED_CLEARANCE
GEMCITABINE;CMPK1;rs7543016;CC;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE
GEMCITABINE;ESR2;rs944050;TT;EFFICACY;INCREASED_RESPONSE
RISPERIDONE;DRD2;rs1799978;TT;EFFICACY;INCREASED_RESPONSE
IRINOTECAN;ABCC2;rs2273697;AA + AG;LADME_PK;INCREASED_METABOLISM
RISPERIDONE;DRD2;rs1799978;T;OTHER;INCREASED_RESPONSE
LETROZOLE;CYP19A1;rs4646;A;EFFICACY;INCREASED_CLINICAL BENEFIT
ANTIEPILEPTICS;ABCC2;rs717620;CT + TT;EFFICACY;INCREASED_RESISTANCE
WARFARIN;;rs12777823;A;DOSAGE;DOSE
METHOTREXATE;SLCO1B1;rs2306283;AA + AG;LADME_PK;INCREASED_CLEARANCE
IVACAFTOR;CFTR;rs75527207;AA + AG;EFFICACY;INCREASED_RESPONSE
METHOTREXATE;SLCO1B1;rs4149056;CC + CT;LADME_PK;DECREASED_CLEARANCE
CONJUGATED ESTROGENS;SLCO1B1;rs4149056;CT;EFFICACY;INCREASED_RESPONSE
CISPLATIN;ERCC1;rs3212986;A;EFFICACY;DECREASED_RESPONSE
ANTIPSYCHOTICS;ABCB1;rs1045642;GG;DOSAGE, LADME_PK;INCREASED_DOSE
ANTIPSYCHOTICS;ABCB1;rs2032582;AA;DOSAGE, LADME_PK;INCREASED_DOSE
DIAZEPAM;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_CLINICAL BENEFIT
ALPRAZOLAM;CYP3A4;rs35599367;AG;LADME_PK;INCREASED_CONCENTRATIONS
DIAZEPAM;CYP2C19;rs12248560;CT + TT;EFFICACY;DECREASED_CLINICAL BENEFIT
CLOZAPINE;POR;rs1057868;CT + TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
SALBUTAMOL;IGF2R;rs8191725;AG;EFFICACY;INCREASED_RESPONSE
SALBUTAMOL;SLC24A4;rs77441273;AG;EFFICACY;INCREASED_RESPONSE
ALPRAZOLAM;CYP3A4;rs35599367;AG;EFFICACY;DECREASED_RESPONSE
LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;IL1B;rs16944;AG;EFFICACY;INCREASED_RESPONSE
LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;IL1B;rs16944;AA;EFFICACY;INCREASED_RESPONSE
METHOTREXATE;AHRR;rs2292596;G;EFFICACY;DECREASED_RESPONSE
WARFARIN;VKORC1;rs2359612;AA;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_METABOLISM
PLATINUM COMPOUNDS;ERCC1;rs11615;AG + GG;EFFICACY;INCREASED_CLINICAL BENEFIT
ULINASTATIN;MMP2;rs243865;T;EFFICACY;DECREASED_RESPONSE
ANTIPSYCHOTICS;ABCB1;rs1128503;G;EFFICACY;INCREASED_RESPONSE
ULINASTATIN;MMP9;rs3918242;T;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A4;rs35599367;AA + AG;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TACROLIMUS;NR1I2;rs2276707;CT + TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
ANTIPSYCHOTICS;ABCB1;rs1045642;G;EFFICACY;INCREASED_RESPONSE
IRINOTECAN;NR1I2;rs10934498;AA;TOXICITY, LADME_PK;DECREASED_EXPOSURE
TACROLIMUS;IL10;rs1800896;CC;DOSAGE;DECREASED_DOSE
OLANZAPINE, PERPHENAZINE;RGS4;rs2842030;TT;EFFICACY;INCREASED_RESPONSE
OLANZAPINE;DRD3;rs324026;C;EFFICACY;INCREASED_CLINICAL BENEFIT
CYTARABINE, FLUDARABINE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN;ADH1A;rs6811453;A;EFFICACY;INCREASED_RESISTANCE
RISPERIDONE;RGS4;rs2842030;GG;EFFICACY;INCREASED_RESPONSE
MEASLES VACCINES;TLR3;rs3775291;CT;EFFICACY;DECREASED_RESPONSE
CYTARABINE, FLUDARABINE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN;ADH1A;rs1826909;T;EFFICACY;INCREASED_RESISTANCE
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE
TAMOXIFEN;ABCC2;rs717620;CT;EFFICACY;INCREASED_RESPONSE
SALBUTAMOL;;rs77149876;CT;EFFICACY;INCREASED_RESPONSE
ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1800629;A;EFFICACY;DECREASED_RESPONSE
CARBAMAZEPINE;SCN1A;rs3812718;TT;DOSAGE;INCREASED_DOSE
SALBUTAMOL;PAPPA2;rs77977790;CT;EFFICACY;INCREASED_RESPONSE
NORBUPRENORPHINE;OPRD1;rs569356;GG;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TACROLIMUS;CYP3A4;rs2740574;CT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
SALMETEROL;ADRB2;rs1042713;G;EFFICACY;INCREASED_RESPONSE
SALBUTAMOL;;rs116551936;AG;EFFICACY;INCREASED_RESPONSE
SALBUTAMOL;NCOA3;rs115501901;CT;EFFICACY;INCREASED_RESPONSE
LITHIUM;CACNG2;rs2284017;C;EFFICACY;INCREASED_RESPONSE
SALBUTAMOL;;rs74973995;AG;EFFICACY;INCREASED_RESPONSE
SALBUTAMOL;CRHR2;rs73294475;CT;EFFICACY;INCREASED_RESPONSE
PHENPROCOUMON;CYP3A4;rs2740574;C;DOSAGE;DECREASED_DOSE
SALBUTAMOL;ADCY9;rs144315541;AG;EFFICACY;INCREASED_RESPONSE
PERPHENAZINE;MCPH1;rs17570753;A;EFFICACY;RESPONSE
PERPHENAZINE;CDH13;rs2116971;G;EFFICACY;RESPONSE
PERPHENAZINE;SKOR2;rs9952628;G;EFFICACY;RESPONSE
METFORMIN;SLC47A2;rs12943590;AA;EFFICACY, LADME_PK;DECREASED_RESPONSE
QUETIAPINE;KCNMA1;rs35793;G;EFFICACY;RESPONSE
PERPHENAZINE;MAML3;rs11100483;A;EFFICACY;RESPONSE
VALPROIC ACID;UGT2B7;rs7668258;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS
METHACHOLINE;RUNX1;rs11702779;AA;OTHER;INCREASED_RESPONSE
RISPERIDONE;LRP1B;rs874295;G;EFFICACY;RESPONSE
BEVACIZUMAB;HTRA1;rs11200638;AA;EFFICACY;DECREASED_RESPONSE
RISPERIDONE;PSMD14;rs9713;A;EFFICACY;RESPONSE
RISPERIDONE;AGAP1;rs1869295;C;EFFICACY;RESPONSE
BEVACIZUMAB;ARMS2;rs10490924;TT;EFFICACY;DECREASED_RESPONSE
VALPROIC ACID;APEH;rs3816877;CC;LADME_PK;INCREASED_CONCENTRATIONS
RISPERIDONE;NPAS3;rs1315115;G;EFFICACY;RESPONSE
RISPERIDONE;TMEFF2;rs3738883;G;EFFICACY;RESPONSE
METFORMIN;PCK1;rs4810083;CT + TT;EFFICACY;INCREASED_CLINICAL BENEFIT
ZIPRASIDONE;CDH4;rs4925300;A;EFFICACY;RESPONSE
ZIPRASIDONE;LYN;rs1546519;G;EFFICACY;RESPONSE
BEVACIZUMAB;CFH;rs800292;GG;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP2C9;rs1799853;CT;DOSAGE;DECREASED_DOSE
ZIPRASIDONE;NALCN;rs9585618;C;EFFICACY;RESPONSE
ZIPRASIDONE;CNTN4;rs17194378;A;EFFICACY;RESPONSE
OPIOIDS;COMT;rs4680;GG;DOSAGE;INCREASED_DOSE
IMATINIB;SLCO1A2;rs4148978;CT + TT;TOXICITY, LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
IMATINIB;SLCO1B3;rs4149117;GG;TOXICITY, LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
HYDROCHLOROTHIAZIDE;ADD1;rs4961;GT + TT;EFFICACY;INCREASED_RESPONSE
WARFARIN;CALU;rs2290228;AA;DOSAGE;DECREASED_DOSE
OLANZAPINE;;rs12610827;T;EFFICACY;INCREASED_CLINICAL BENEFIT
REMIFENTANIL;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE
FENOFIBRATE;APOB;rs676210;AA;EFFICACY;INCREASED_RESPONSE
METHACHOLINE;RUNX1;rs11702779;AG + GG;OTHER;INCREASED_RESPONSE
CITALOPRAM, FLUOXETINE;SERPINE1;rs1799889;G;EFFICACY;DECREASED_RESPONSE
METHOTREXATE;MTR;rs1805087;G;LADME_PK;INCREASED_CONCENTRATIONS
CITALOPRAM, FLUOXETINE, MIRTAZAPINE, PAROXETINE, SELECTIVE SEROTONIN REUPTAKE INHIBITORS, VENLAFAXINE;FKBP5;rs4713916;A;EFFICACY;INCREASED_RESPONSE
OLANZAPINE;CSMD1;rs17070785;A;EFFICACY;RESPONSE
OLANZAPINE;PLAGL1;rs2247408;C;EFFICACY;RESPONSE
SIROLIMUS;CYP3A5;rs15524;AA;LADME_PK;INCREASED_TROUGH CONCENTRATION
OLANZAPINE;PLAGL1;rs3819811;A;EFFICACY;RESPONSE
SIROLIMUS;CYP3A5;rs4646453;CC;LADME_PK;INCREASED_TROUGH CONCENTRATION
ACETAMINOPHEN;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE
OLANZAPINE;PTPRN2;rs221253;C;EFFICACY;RESPONSE
IMATINIB;SLC22A1;rs628031;AA + AG;EFFICACY;DECREASED_RESPONSE
WARFARIN;NQO1;rs1800566;AA + AG;DOSAGE;INCREASED_DOSE
PERPHENAZINE;PRKCE;rs2278773;C;EFFICACY;RESPONSE
PERPHENAZINE;;rs11774231;C;EFFICACY;RESPONSE
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED_RESPONSE
HYDROCHLOROTHIAZIDE;DOT1L;rs2269879;CT + TT;EFFICACY;INCREASED_RESPONSE
PAROXETINE;ADM;rs11042725;CC;EFFICACY;DECREASED_RESPONSE
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_DOSE
TILDRAKIZUMAB;ATG5;rs9373839;CT;EFFICACY;DECREASED_CLINICAL BENEFIT
TILDRAKIZUMAB;IL17RC;rs708567;CC;EFFICACY;INCREASED_CLINICAL BENEFIT
CITALOPRAM;BDNF;rs7124442;TT;EFFICACY;DECREASED_RESPONSE
ARIPIPRAZOLE;ABCB1;rs2032582;AA;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
CLOZAPINE;OXT;rs2740204;T;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE
DIAZEPAM;CYP3A4;rs35599367;GG;EFFICACY;INCREASED_CLINICAL BENEFIT
METHOTREXATE;MTHFR;rs1801133;G;EFFICACY;DECREASED_CLINICAL BENEFIT
METHOTREXATE;DHFR;rs408626;C;EFFICACY;DECREASED_CLINICAL BENEFIT
REPAGLINIDE;NOS1AP;rs10494366;T;DOSAGE, EFFICACY;INCREASED_RESPONSE
CITALOPRAM;BDNF;rs7103411;TT;EFFICACY;DECREASED_RESPONSE
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART);ABCB1;rs1045642;AA + AG;EFFICACY;INCREASED_RESISTANCE
CITALOPRAM;BDNF;rs6265;CC;EFFICACY;DECREASED_RESPONSE
LAMIVUDINE, LOPINAVIR, RITONAVIR, ZIDOVUDINE;ABCC1;rs212091;CC + CT;EFFICACY;INCREASED_RESISTANCE
FLUOXETINE;BDNF;rs6265;CT;EFFICACY;INCREASED_CLINICAL BENEFIT
TILDRAKIZUMAB;TNFAIP3;rs610604;GG;EFFICACY;DECREASED_CLINICAL BENEFIT
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;DECREASED_RESPONSE
ANTIDEPRESSANTS;ERICH3;rs11580409;CC;EFFICACY;INCREASED_CLINICAL BENEFIT
CLOPIDOGREL;CYP2C19;rs12248560;CT;EFFICACY;INCREASED_RESPONSE
ARIPIPRAZOLE;ABCB1;rs1045642;AA;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
IVACAFTOR;CFTR;rs77932196;A;EFFICACY;INCREASED_RESPONSE
PAROXETINE;DRD3;rs6280;CC + CT;EFFICACY;INCREASED_RESPONSE
ENTACAPONE;COMT;rs4680;GG;EFFICACY;INCREASED_RESPONSE
CLOZAPINE;CYP2D6;rs1065852;AA;LADME_PK;INCREASED_CONCENTRATIONS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
CLOZAPINE;CYP2D6;rs16947;GG;LADME_PK;INCREASED_CONCENTRATIONS
ATORVASTATIN, SIMVASTATIN;ABCG8;rs11887534;CC + CG;EFFICACY;DECREASED_CLINICAL BENEFIT
IVACAFTOR;CFTR;rs121909011;C;EFFICACY;INCREASED_RESPONSE
IMATINIB;ULK3;rs2290573;GG;EFFICACY;DECREASED_RESPONSE
CLOZAPINE;DRD1;rs265976;GT;EFFICACY;DECREASED_RESPONSE
IVACAFTOR;CFTR;rs75527207;AA + AG;EFFICACY;INCREASED_RESPONSE
INTERFERONS;STAT3;rs4796793;GG;EFFICACY;INCREASED_RESPONSE
TAMOXIFEN;SLCO2B1;rs12422149;AA + AG;LADME_PK;INCREASED_CONCENTRATIONS
ACENOCOUMAROL;VKORC1;rs7294;CT + TT;DOSAGE;INCREASED_DOSE
WARFARIN;VKORC1;rs2359612;AA + AG;DOSAGE;DECREASED_DOSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;DOSAGE, EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs8050894;CG + GG;DOSAGE;DECREASED_DOSE
RISPERIDONE;HRH3;rs3787430;TT;EFFICACY;INCREASED_RESPONSE
WARFARIN;;rs12777823;AA + AG;DOSAGE;DECREASED_DOSE
WARFARIN;VKORC1;rs2884737;AC + CC;DOSAGE;DECREASED_DOSE
WARFARIN;VKORC1;rs7294;CT + TT;DOSAGE;INCREASED_DOSE
RISPERIDONE;HRH3;rs3787429;TT;EFFICACY;INCREASED_RESPONSE
ACENOCOUMAROL;VKORC1;rs17708472;AA + AG;DOSAGE;INCREASED_DOSE
ARIPIPRAZOLE;TAAR6;rs4305746;AA + AG;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2A;IL6;rs1800795;G;EFFICACY;DECREASED_RESPONSE
PEGINTERFERON ALFA-2A;IL6;rs1800796;G;EFFICACY;DECREASED_RESPONSE
PEGINTERFERON ALFA-2A;IL6;rs1800797;G;EFFICACY;DECREASED_RESPONSE
WARFARIN;VKORC1;rs104894540;G;DOSAGE;INCREASED_DOSE
ROSUVASTATIN;ABCG2;rs2199936;AA + AG;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs104894542;C;DOSAGE;INCREASED_DOSE
ILOPERIDONE;CNTF, ZFP91-CNTF;rs1800169;GG;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_DOSE
DISULFIRAM;OPRD1;rs678849;CC;EFFICACY;INCREASED_RESPONSE
ERYTHROPOIETIN;STIM1;rs1561876;AG + GG;EFFICACY;INCREASED_RESISTANCE
LATANOPROST;PTGFR;rs3753380;CC;EFFICACY;INCREASED_RESPONSE
RANIBIZUMAB;VEGFA;rs699947;AC + CC;EFFICACY;INCREASED_RESPONSE
FUROSEMIDE;ABCC4;rs17268282;T;EFFICACY;INCREASED_RESPONSE
METFORMIN;SLC22A1;rs622342;CC;EFFICACY;RESPONSE
MORPHINE;COMT;rs737866;T;DOSAGE, EFFICACY;DECREASED_DOSE
MORPHINE;COMT;rs2075507;G;DOSAGE, EFFICACY;DECREASED_DOSE
ANTIEPILEPTICS;CYP1A1;rs2606345;AA;EFFICACY;DECREASED_RESPONSE
MORPHINE;COMT;rs5746849;A;DOSAGE, EFFICACY;DECREASED_DOSE
MORPHINE;COMT, TXNRD2;rs7287550;C;DOSAGE, EFFICACY;DECREASED_DOSE
MORPHINE;COMT;rs6269;A;DOSAGE, EFFICACY;DECREASED_DOSE
CARBAMAZEPINE;CYP3A4;rs2740574;TT;LADME_PK;INCREASED_CLEARANCE
MORPHINE;COMT;rs740603;A;DOSAGE, EFFICACY;DECREASED_DOSE
MORPHINE;ABCC3;rs4793665;T;LADME_PK;DECREASED_CLEARANCE
TACROLIMUS;POR;rs1057868;T;DOSAGE;INCREASED_DOSE
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;CYP2D6;rs35742686;DELT/T;LADME_PK;INCREASED_CONCENTRATIONS
N-DESMETHYLTRAMADOL, TRAMADOL;CYP3A4;rs35599367;AG;LADME_PK;INCREASED_CONCENTRATIONS
CLOPIDOGREL;CYP2C19;rs4244285;AA;EFFICACY;DECREASED_RESPONSE
CLOPIDOGREL;CYP2C19;rs4986893;AG;EFFICACY;DECREASED_RESPONSE
CLOPIDOGREL;ABCC2;rs717620;CC;EFFICACY;DECREASED_RESPONSE
ATAZANAVIR;SORCS2;rs73208473;A;LADME_PK;DECREASED_EXPOSURE
WARFARIN;VKORC1;rs104894539;A;DOSAGE;INCREASED_DOSE
WARFARIN;VKORC1;rs104894541;C;DOSAGE;INCREASED_DOSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;ZNF816;rs9304742;CC;EFFICACY;DECREASED_RESPONSE
CARBAMAZEPINE;UGT2B7;rs28365063;AA;LADME_PK;DECREASED_CLEARANCE
CARBAMAZEPINE;NR1I2;rs3814055;T;LADME_PK;DECREASED_CLEARANCE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;PGLYRP4;rs2916205;CC + CT;EFFICACY;DECREASED_RESPONSE
METHOTREXATE;MTHFR;rs1801133;AA + AG;LADME_PK;INCREASED_EXPOSURE
SULFONAMIDES, UREA DERIVATIVES;CYP2C9;rs1799853;TT;EFFICACY;INCREASED_RESPONSE
SUMATRIPTAN;GNB3;rs5443;CT;EFFICACY;INCREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL12B;rs2546890;AG + GG;EFFICACY;DECREASED_RESPONSE
DESETHYL HYDROXYCHLOROQUINE;CYP2D6;rs1135840;G;LADME_PK;DECREASED_CONCENTRATIONS
CANNABINOIDS;TRPV1;rs8065080;CC;EFFICACY;INCREASED_CLINICAL BENEFIT
RIVAROXABAN;ABCB1;rs4728709;AA + AG;LADME_PK;INCREASED_CLEARANCE
CANNABINOIDS;UGT2B7;rs7438135;AA;EFFICACY;INCREASED_CLINICAL BENEFIT
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CTNNA2;rs11126740;AA;EFFICACY;DECREASED_RESPONSE
IMATINIB;ABCG2;rs2231142;GT;OTHER, LADME_PK;DECREASED_METABOLISM
DESETHYL HYDROXYCHLOROQUINE;CYP2D6;rs1065852;AA;LADME_PK;DECREASED_CONCENTRATIONS
REPAGLINIDE;KCNJ11;rs5219;T;EFFICACY;INCREASED_RESPONSE
TRAMADOL;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_RESPONSE
REPAGLINIDE;TCF7L2;rs290487;TT;EFFICACY;INCREASED_RESPONSE
MORPHINE;COMT;rs4680;A;DOSAGE, EFFICACY;DECREASED_DOSE
CARBAMAZEPINE;EPHX1;rs1051740;TT;LADME_PK;DECREASED_METABOLISM
MORPHINE;COMT;rs4818;C;DOSAGE, EFFICACY;DECREASED_DOSE
ERYTHROPOIETIN;ORAI1;rs12320939;GG + GT;EFFICACY;INCREASED_RESISTANCE
CARBAMAZEPINE;ABCB1;rs1128503;AA + AG;LADME_PK;INCREASED_CLEARANCE
MORPHINE;COMT;rs2239393;A;DOSAGE, EFFICACY;DECREASED_DOSE
MERCAPTOPURINE;NUDT15;rs116855232;CT;DOSAGE;DECREASED_DOSE
MORPHINE;ARVCF, COMT;rs165728;T;DOSAGE, EFFICACY;DECREASED_DOSE
CARBAMAZEPINE;ABCB1;rs4148740;AG;LADME_PK;INCREASED_METABOLISM
CARBAMAZEPINE;ABCB1;rs4148739;TT;LADME_PK;DECREASED_METABOLISM
MORPHINE;ARVCF, COMT;rs174699;T;DOSAGE, EFFICACY;DECREASED_DOSE
ANTIPSYCHOTICS;DRD2;rs1799732;del;EFFICACY;DECREASED_RESPONSE
HMG COA REDUCTASE INHIBITORS;CETP;rs1532624;AA;EFFICACY;DECREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CDKAL1;rs6908425;CT + TT;EFFICACY;INCREASED_RESPONSE
CARBAMAZEPINE;ABCC2;rs2273697;AA + AG;LADME_PK;INCREASED_CLEARANCE
HMG COA REDUCTASE INHIBITORS;SIK3;rs533556;AA;EFFICACY;DECREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;HLA-C;rs12191877;CT + TT;EFFICACY;INCREASED_RESPONSE
RITODRINE;KCNMB2;rs7624046;TT;EFFICACY;DECREASED_RESPONSE
CARBAMAZEPINE;ABCC2;rs4148386;AA + AG;LADME_PK;INCREASED_CLEARANCE
WARFARIN;VKORC1;rs61742245;AA + AC;DOSAGE;INCREASED_DOSE
CARBAMAZEPINE;ABCC2;rs3740066;CT + TT;LADME_PK;DECREASED_METABOLISM
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MAP3K1;rs96844;AG + GG;EFFICACY;INCREASED_RESPONSE
RITODRINE;KCNMB2;rs9839376;CC;EFFICACY;DECREASED_RESPONSE
WARFARIN;GGCX;rs11676382;G;DOSAGE;DECREASED_DOSE
CARBAMAZEPINE;NR1I2;rs7643645;G;LADME_PK;INCREASED_METABOLISM
MORPHINE;METTL21A;rs2952768;CC;DOSAGE;INCREASED_DOSE
CARBAMAZEPINE;NR1I2;rs4688040;T;LADME_PK;INCREASED_METABOLISM
CANNABINOIDS;ABCB1;rs1045642;AG + GG;EFFICACY;INCREASED_CLINICAL BENEFIT
MORPHINE;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE
CARBAMAZEPINE;NR1I2;rs2461817;C;LADME_PK;INCREASED_METABOLISM
METOPROLOL;ADRB1;rs1801252;AA;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE
WARFARIN;VKORC1;rs2884737;CC;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
CITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;SRP19;rs495794;G;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE
CITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;REEP5;rs153560;G;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs8050894;GG;DOSAGE;DECREASED_DOSE
CITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;REEP5;rs153549;A;EFFICACY;INCREASED_RESPONSE
ATAZANAVIR;ABCB1;rs1045642;AA + AG;DOSAGE;DOSE
ATAZANAVIR;SLCO1B1;rs4149056;TT;DOSAGE;DOSE
FLUOROURACIL;DPYD;rs3918290;CT;OTHER, LADME_PK;DECREASED_METABOLISM
ATAZANAVIR;NR1I2;rs2472677;TT;DOSAGE;DOSE
WARFARIN;VKORC1;rs61742245;AC;DOSAGE;INCREASED_DOSE
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE
ACENOCOUMAROL;VKORC1;rs9923231;CT;DOSAGE;DECREASED_DOSE
DOCETAXEL, GEMCITABINE, PACLITAXEL, PLATINUM COMPOUNDS, VINORELBINE;CASP7;rs2227310;CG + GG;EFFICACY;INCREASED_RESPONSE
DOCETAXEL, GEMCITABINE, PACLITAXEL, PLATINUM COMPOUNDS, VINORELBINE;CASP7;rs4353229;CC + CT;EFFICACY;INCREASED_RESPONSE
DOCETAXEL, GEMCITABINE, PACLITAXEL, PLATINUM COMPOUNDS, VINORELBINE;CASP7;rs12415607;AA + AC;EFFICACY;INCREASED_RESPONSE
DOCETAXEL, GEMCITABINE, PACLITAXEL, PLATINUM COMPOUNDS, VINORELBINE;CASP7;rs7921977;CT;EFFICACY;DECREASED_RESPONSE
OLANZAPINE;SLC26A9;rs11240594;A;DOSAGE, EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE
SOLANIDINE;NFIB;rs28379954;CC + CT;LADME_PK;INCREASED_METABOLISM
ZIPRASIDONE;EHF;rs286913;A;DOSAGE, EFFICACY;INCREASED_RESPONSE
CLOZAPINE;SLC6A3;rs2975226;A;DOSAGE, EFFICACY;INCREASED_RESPONSE
OLANZAPINE;IL1A;rs11677416;C;DOSAGE, EFFICACY;INCREASED_RESPONSE
CYCLOSPORINE;POR;rs1057868;TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
CARBAMAZEPINE;EPHX1;rs1051740;C;DOSAGE, LADME_PK;INCREASED_METABOLISM
PIOGLITAZONE;PTPRD;rs17584499;CC;EFFICACY;INCREASED_RESPONSE
ACENOCOUMAROL, WARFARIN;VKORC1;rs9923231;CC + CT;EFFICACY;INCREASED_DOSE
ETHANOL;OPRM1;rs1799971;G;TOXICITY;INCREASED_RESPONSE
ACAMPROSATE;GRIN2B;rs2058878;A;EFFICACY;INCREASED_RESPONSE
OLANZAPINE;ATP1A2;rs6688363;T;EFFICACY;DECREASED_RESPONSE
RISPERIDONE;;rs8050896;T;EFFICACY;INCREASED_RESPONSE
RISPERIDONE;TNFRSF11A;rs2980976;A;EFFICACY;DECREASED_RESPONSE
RISPERIDONE;PPA2;rs2636697;G;EFFICACY;DECREASED_RESPONSE
METHOTREXATE;;rs1232027;A;EFFICACY;INCREASED_RESPONSE
FENTANYL, HYDROMORPHONE, OPIOIDS, OXYCODONE, TRAMADOL;OPRM1;rs1799971;AA;DOSAGE;INCREASED_DOSE
RISPERIDONE;PPA2;rs2636719;A;EFFICACY;DECREASED_RESPONSE
REPAGLINIDE;IGF2BP2;rs4402960;GT + TT;DOSAGE, EFFICACY;INCREASED_RESPONSE
REPAGLINIDE;IGF2BP2;rs1470579;AC + CC;DOSAGE, EFFICACY;DECREASED_RESPONSE
DISULFIRAM;MTHFR;rs1801133;AA + AG;EFFICACY;INCREASED_RESPONSE
IVACAFTOR;CFTR;rs78655421;A;EFFICACY;RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;rs1801274;AG + GG;EFFICACY;INCREASED_RESPONSE
ISONIAZID;NAT2;rs4646244;AT;TOXICITY, LADME_PK;DECREASED_CLEARANCE
PLATINUM COMPOUNDS;ERCC1;rs11615;AA;EFFICACY;DECREASED_RESPONSE
ISONIAZID;NAT2;rs1799930;AA;TOXICITY, LADME_PK;DECREASED_CLEARANCE
HYDROCHLOROTHIAZIDE;BEST3;rs61747221;AA + AG;EFFICACY;INCREASED_RESPONSE
DEFERIPRONE;UGT1A6;rs2070959;AA;EFFICACY;INCREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR3A;rs396991;C;EFFICACY;INCREASED_RESPONSE
NIFEDIPINE;ADRA1A;rs1048101;AA + AG;EFFICACY;INCREASED_RESPONSE
DEFERIPRONE;UGT1A6;rs2070959;AA;EFFICACY;INCREASED_RESPONSE
DEFERIPRONE;UGT1A6;rs6759892;GG;EFFICACY;INCREASED_RESPONSE
PIOGLITAZONE;PPARG;rs1801282;CG;EFFICACY;INCREASED_RESPONSE
PACLITAXEL, PLATINUM COMPOUNDS;CASP7;rs4353229;CC + CT;EFFICACY;INCREASED_RESPONSE
OPIOIDS;TNF;rs1800629;GG;DOSAGE;INCREASED_DOSE
CARBAMAZEPINE;SCN1A;rs3812718;CT;DOSAGE, LADME_PK;INCREASED_DOSE
PACLITAXEL, PLATINUM COMPOUNDS;CASP7;rs2227310;CG + GG;EFFICACY;INCREASED_RESPONSE
RISPERIDONE;TJP1;rs813676;T;EFFICACY;INCREASED_RESPONSE
OPIOIDS;IL6;rs1800797;A;DOSAGE;DECREASED_DOSE
WARFARIN;VKORC1;rs9934438;AA + AG;DOSAGE, EFFICACY;DECREASED_DOSE
METHYLPHENIDATE;ADGRL3;rs734644;CC + CT;EFFICACY;INCREASED_RESPONSE
PACLITAXEL, PLATINUM COMPOUNDS;CASP7;rs1127687;AA + AG;EFFICACY;DECREASED_RESPONSE
FLUTICASONE PROPIONATE, MONTELUKAST;CA10;rs967676;CC + CT;EFFICACY;INCREASED_RESPONSE
CARBAMAZEPINE;EPHX1;rs1051740;CT;DOSAGE, LADME_PK;INCREASED_DOSE
CARBAMAZEPINE;EPHX1;rs1051740;CC;DOSAGE, LADME_PK;INCREASED_DOSE
GEMCITABINE, PLATINUM COMPOUNDS;CASP7;rs1127687;AA + AG;EFFICACY;DECREASED_RESPONSE
FLUTICASONE PROPIONATE, MONTELUKAST;;rs1786929;AA + AG;EFFICACY;INCREASED_RESPONSE
CYTARABINE;CDA;rs2072671;CC;TOXICITY, LADME_PK;DECREASED_CLEARANCE
TACROLIMUS;ABCB1;rs2032582;AA;LADME_PK;DECREASED_CONCENTRATIONS
CARBAMAZEPINE;SCN1A;rs3812718;TT;DOSAGE, LADME_PK;INCREASED_DOSE
ROSUVASTATIN;ABCG2;rs2231142;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS
METHYLPHENIDATE;ADGRL3;rs1355368;AG + GG;EFFICACY;INCREASED_RESPONSE
METHYLPHENIDATE;ADGRL3;rs6813183;CC + CG;EFFICACY;INCREASED_RESPONSE
RISPERIDONE;;rs7395555;C;EFFICACY;INCREASED_RESPONSE
RANIBIZUMAB;CFH;rs1061170;TT;EFFICACY;INCREASED_RESPONSE
OLANZAPINE;SPOPL;rs10170310;C;EFFICACY;DECREASED_RESPONSE
QUETIAPINE;PDE4D;rs17382202;T;EFFICACY;INCREASED_RESPONSE
ACENOCOUMAROL;VKORC1;rs9923231;T;DOSAGE;DOSE
ACENOCOUMAROL;CYP4F2;rs2108622;T;DOSAGE;DOSE
QUETIAPINE;PDE4D;rs17742120;G;EFFICACY;INCREASED_RESPONSE
QUETIAPINE;PDE4D;rs2164660;A;EFFICACY;INCREASED_RESPONSE
ACENOCOUMAROL;VKORC1;rs9923231;CC;DOSAGE;INCREASED_DOSE
PERINDOPRIL;AGTR1;rs5182;CC + CT;EFFICACY;DECREASED_RESPONSE
RISPERIDONE;TJP1;rs711355;T;EFFICACY;INCREASED_RESPONSE
RISPERIDONE;TJP1;rs785423;A;EFFICACY;INCREASED_RESPONSE
TENOFOVIR ALAFENAMIDE;ABCB1;rs3842;CT;LADME_PK;INCREASED_CONCENTRATIONS
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_CONCENTRATIONS
CLOZAPINE;SLC6A4;rs25531;T;EFFICACY;RESPONSE
RALOXIFENE;UGT1A8;rs1042597;CC;EFFICACY;INCREASED_RESPONSE
ACENOCOUMAROL, PHENPROCOUMON;VKORC1;rs9923231;T;DOSAGE;DOSE
ESOMEPRAZOLE;STAT6;rs1059513;CC + CT;EFFICACY;INCREASED_RESPONSE
RISPERIDONE;WBP2NL;rs5758550;A;LADME_PK;DECREASED_CLEARANCE
PACLITAXEL, PLATINUM COMPOUNDS;CASP7;rs12415607;AA + AC;EFFICACY;INCREASED_RESPONSE
ADALIMUMAB;CD40LG;rs1126535;T;EFFICACY;INCREASED_RESPONSE
RALOXIFENE;ESR1;rs11543791;CC;EFFICACY;DECREASED_RESPONSE
PERINDOPRIL;AGTR1;rs275651;AA + AT;EFFICACY;DECREASED_RESPONSE
LITHIUM;MYO1H;rs7959663;C;EFFICACY;DECREASED_RESPONSE
INFLIXIMAB;FCGR2A;rs1801274;G;EFFICACY;DECREASED_RESPONSE
LITHIUM;EPHX2;rs59724122;T;EFFICACY;INCREASED_RESPONSE
LITHIUM;GRAMD1B;rs61123830;A;EFFICACY;DECREASED_RESPONSE
WARFARIN;VKORC1;rs7294;T;DOSAGE;DECREASED_DOSE
LITHIUM;;rs66486766;A;EFFICACY;DECREASED_RESPONSE
LITHIUM;;rs324899;A;EFFICACY;DECREASED_RESPONSE
LITHIUM;;rs1611259;T;EFFICACY;DECREASED_RESPONSE
LITHIUM;;rs6942227;A;EFFICACY;DECREASED_RESPONSE
NEVIRAPINE;CYP2D6;rs28371706;AA + AG;DOSAGE, LADME_PK;DECREASED_CLEARANCE
NEVIRAPINE;CYP2B6;rs3745274;GT + TT;DOSAGE, LADME_PK;DECREASED_CLEARANCE
CATECHOLAMINES;ADRB1;rs1801253;CC;DOSAGE;DECREASED_DOSE
ACENOCOUMAROL;APOE;rs429358;CC;DOSAGE;INCREASED_DOSE
PERINDOPRIL;BDKRB1;rs12050217;AA + AG;EFFICACY;DECREASED_RESPONSE
WARFARIN;VKORC1;rs17708472;A;DOSAGE;INCREASED_DOSE
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA5;rs680244;C;OTHER;INCREASED_RESPONSE
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;NFATC2;rs3787186;CC + CT;EFFICACY;DECREASED_RESPONSE
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA3, CHRNA5;rs16969968;G;OTHER;INCREASED_RESPONSE
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA5;rs680244;T;OTHER;INCREASED_RESPONSE
ALLOPURINOL;ABCG2;rs2231142;T;EFFICACY;DECREASED_RESPONSE
LITHIUM;FAM177A1;rs79403677;T;EFFICACY;DECREASED_RESPONSE
CLOPIDOGREL;;rs2487032;A;EFFICACY;DECREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;A;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CHUK;rs11591741;G;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_DOSE
LITHIUM;ADCY1;rs1521470;A;EFFICACY;DECREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;CC;DOSAGE;INCREASED_DOSE
REPAGLINIDE;KCNQ1;rs2237892;CT + TT;EFFICACY;INCREASED_RESPONSE
LITHIUM;;rs7588746;A;EFFICACY;DECREASED_RESPONSE
LITHIUM;FAM178B;rs6728642;A;EFFICACY;DECREASED_RESPONSE
BETA BLOCKING AGENTS;GRK5;rs2230345;AT + TT;EFFICACY;INCREASED_RESPONSE
ZILEUTON;PRORP;rs12436663;AA;EFFICACY;DECREASED_RESPONSE
LITHIUM;ZNF804A;rs62200793;T;EFFICACY;INCREASED_RESPONSE
LITHIUM;;rs1611255;A;EFFICACY;DECREASED_RESPONSE
LITHIUM;;rs209474;A;EFFICACY;DECREASED_RESPONSE
REPAGLINIDE;KCNQ1;rs2237895;AC + CC;EFFICACY;INCREASED_RESPONSE
LITHIUM;;rs3919583;A;EFFICACY;DECREASED_RESPONSE
PLATINUM COMPOUNDS;XRCC1;rs1799782;AA + AG;EFFICACY;INCREASED_RESPONSE
GLATIRAMER ACETATE;TGFB1;rs1800469;A;EFFICACY;DECREASED_RESPONSE
ANTIEPILEPTICS;ABCC2;rs3740066;CT + TT;EFFICACY;INCREASED_RESISTANCE
N-DESMETHYLTAMOXIFEN;ABCG2;rs2231142;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE
GLUCOCORTICOIDS;GLCCI1;rs37973;G;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_DOSE
ANTIEPILEPTICS;ABCC2;rs717620;CT + TT;EFFICACY;INCREASED_RESISTANCE
AMLODIPINE;CYP3A4;rs2246709;AG + GG;EFFICACY;INCREASED_RESPONSE
NICOTINE;CYP2B6;rs2279343;G;LADME_PK;INCREASED_METABOLISM
TENELIGLIPTIN;FMO3;rs2266780;AG + GG;LADME_PK;DECREASED_CLEARANCE
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA3, CHRNA5;rs16969968;A;OTHER;INCREASED_RESPONSE
QUETIAPINE;COMT;rs4818;C;EFFICACY;DECREASED_RESPONSE
HYDROCHLOROTHIAZIDE;GPR83;rs3758785;GG;EFFICACY;DECREASED_RESPONSE
QUETIAPINE;COMT;rs5993883;T;EFFICACY;DECREASED_RESPONSE
TENELIGLIPTIN;FMO3;rs909530;CT + TT;LADME_PK;DECREASED_CLEARANCE
MENOTROPINS;FSHR;rs6166;CT;;DECREASED_DOSE
QUETIAPINE;COMT;rs6269;A;EFFICACY;DECREASED_RESPONSE
CANDESARTAN;GPR83;rs3758785;GG;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;IL6;rs1800795;GG;DOSAGE;INCREASED_DOSE
TENELIGLIPTIN;FMO3;rs2266782;AG + GG;LADME_PK;DECREASED_CLEARANCE
PACLITAXEL;ABCB1;rs2032582;CT;LADME_PK;INCREASED_METABOLISM
HYDROCHLOROTHIAZIDE;HSD3B1;rs7553527;CC + CT;EFFICACY;INCREASED_RESPONSE
HYDROCHLOROTHIAZIDE;TTC6;rs177852;CC + CT;EFFICACY;INCREASED_RESPONSE
TENELIGLIPTIN;CYP3A4;rs2242480;CT + TT;LADME_PK;DECREASED_CONCENTRATIONS
GLATIRAMER ACETATE;IFNAR1;rs1012335;G;EFFICACY;DECREASED_RESPONSE
DARUNAVIR;SLCO3A1;rs8027174;GT + TT;LADME_PK;DECREASED_CLEARANCE
ACENOCOUMAROL;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_DOSE
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;DECREASED_CLEARANCE
ATORVASTATIN;CYP3A4;rs2740574;CC;EFFICACY;DECREASED_RESPONSE
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs121909047;A;EFFICACY;INCREASED_CLINICAL BENEFIT
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs75961395;AA + AG;EFFICACY;INCREASED_CLINICAL BENEFIT
6-HYDROXY S-WARFARIN;;rs368245720;A;LADME_PK;INCREASED_CONCENTRATIONS
ATORVASTATIN;CYP3A5;rs776746;CC;EFFICACY;INCREASED_RESPONSE
CITALOPRAM, ESCITALOPRAM, FLUOXETINE, SERTRALINE;BDNF;rs6265;CC;EFFICACY;INCREASED_CLINICAL BENEFIT
6-HYDROXY S-WARFARIN;PARP14;rs10433340;A;LADME_PK;INCREASED_CONCENTRATIONS
METOPROLOL;ADRB1;rs1801253;C;EFFICACY;INCREASED_RESPONSE
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs121909019;T;EFFICACY;INCREASED_CLINICAL BENEFIT
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs121909011;T;EFFICACY;INCREASED_CLINICAL BENEFIT
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs75549581;A;EFFICACY;INCREASED_CLINICAL BENEFIT
EFAVIRENZ;NR1I3;rs3003596;GG;LADME_PK;INCREASED_METABOLISM
IMATINIB;ABCG2;rs12505410;G;EFFICACY;INCREASED_RESPONSE
IMATINIB;ABCG2;rs12505410;GG + GT;EFFICACY;INCREASED_RESPONSE
TAMOXIFEN;CYP19A1;rs4646;AA + AC;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
6-HYDROXY R-WARFARIN, 6-HYDROXY S-WARFARIN;GRID2;rs558364281;G;LADME_PK;INCREASED_CONCENTRATIONS
IMATINIB;ABCG2;rs13120400;CC + CT;EFFICACY;INCREASED_RESPONSE
METHOTREXATE;SLCO1B1;rs10841753;CT + TT;LADME_PK;DECREASED_CONCENTRATIONS
IMATINIB;ABCG2;rs2725252;AC + CC;EFFICACY;INCREASED_RESPONSE
LACIDIPINE, NIFEDIPINE, NITRENDIPINE;CACNA1C;rs2238032;TT;EFFICACY;INCREASED_RESPONSE
LUMEFANTRINE;CYP3A4;rs2740574;C;LADME_PK;INCREASED_CONCENTRATIONS
QUETIAPINE;HTR1A;rs10042486;TT;LADME_PK;INCREASED_CONCENTRATIONS
AMITRIPTYLINE, CLOMIPRAMINE, DULOXETINE, IMIPRAMINE, MILNACIPRAN, VENLAFAXINE;BDNF;rs6265;CT + TT;EFFICACY;INCREASED_CLINICAL BENEFIT
CHLORPROMAZINE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE, TRIFLUOPERAZINE;EPM2A;rs1415744;C;EFFICACY;INCREASED_RESPONSE
AMLODIPINE, FELODIPINE;CACNA1C;rs2239050;GG;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C18;rs41291550;A;LADME_PK;DECREASED_METABOLISM
ATORVASTATIN;CYP3A4;rs2740574;TT;LADME_PK;INCREASED_CONCENTRATIONS
CITALOPRAM, FLUOXETINE;GSK3B;rs334558;GG;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C9;rs9332241;T;LADME_PK;DECREASED_METABOLISM
LUMEFANTRINE;CYP3A5;rs10264272;T;LADME_PK;INCREASED_CONCENTRATIONS
ATORVASTATIN;CYP3A5;rs776746;CC;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;FPGS;rs7856096;G;DOSAGE;DECREASED_DOSE
WARFARIN;FPGS;rs7856096;G;DOSAGE;DECREASED_DOSE
LUMEFANTRINE;CYP3A5;rs776746;C;LADME_PK;INCREASED_CONCENTRATIONS
INFLIXIMAB;FCGR3A;rs396991;A;EFFICACY;INCREASED_RESPONSE
CETUXIMAB;FCGR3A;rs396991;A;EFFICACY;INCREASED_RESPONSE
NALTREXONE;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_RESPONSE
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs80034486;CG + GG;EFFICACY;INCREASED_CLINICAL BENEFIT
AMLODIPINE, FELODIPINE;CACNA1C;rs2239128;C;EFFICACY;INCREASED_RESPONSE
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY, LADME_PK;DECREASED_CLEARANCE
SUNITINIB;CYP3A5;rs776746;T;DOSAGE;DECREASED_DOSE
N-DESMETHYLCLOZAPINE;UGT2B10;rs61750900;GT;LADME_PK;DECREASED_CONCENTRATIONS
LUMEFANTRINE;CYP3A4;rs2740574;T;EFFICACY;DECREASED_RESPONSE
CLOPIDOGREL;N6AMT1;rs2254638;G;EFFICACY;DECREASED_RESPONSE
VALPROIC ACID;UGT1A6;rs6759892;TT;LADME_PK;INCREASED_EXPOSURE
FENTANYL;ASTN2;rs7858836;CT + TT;DOSAGE;DECREASED_DOSE
BENAZEPRIL, IMIDAPRIL;CYP11B2;rs1799998;AA + AG;EFFICACY;INCREASED_RESPONSE
FENTANYL;ASTN2;rs958804;CC + CT;DOSAGE;DECREASED_DOSE
VALPROIC ACID;UGT1A6;rs1105879;AA;LADME_PK;INCREASED_EXPOSURE
VALPROIC ACID;UGT1A6;rs2070959;AA;LADME_PK;INCREASED_EXPOSURE
TACROLIMUS;CYP3A4;rs35599367;AA + AG;LADME_PK;INCREASED_CONCENTRATIONS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC + CT;EFFICACY;INCREASED_RESPONSE
ETIDRONIC ACID;COL1A1;rs1800012;AA + AC;EFFICACY;DECREASED_RESPONSE
VORICONAZOLE;ABCG2;rs13120400;CC;LADME_PK;INCREASED_TROUGH CONCENTRATION
MORPHINE, NORTRIPTYLINE;ABCB1;rs1045642;GG;EFFICACY;INCREASED_RESPONSE
RISPERIDONE;HTR1A;rs6295;CG + GG;LADME_PK;INCREASED_CONCENTRATIONS
DULOXETINE;;rs4858478;G;EFFICACY;INCREASED_RESPONSE
FLUOROURACIL;DPYD;rs67376798;AT;TOXICITY, LADME_PK;DECREASED_CLEARANCE
VALPROIC ACID;UGT1A6;rs6759892;GG;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
DULOXETINE;ZNF385D;rs13093500;T;EFFICACY;INCREASED_RESPONSE
ESCITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;BDNF;rs6265;CC;EFFICACY;INCREASED_CLINICAL BENEFIT
FOLIC ACID, HYDROXYCHLOROQUINE, METHOTREXATE, SULFASALAZINE;SLC19A1;rs1051266;T;EFFICACY;INCREASED_RESPONSE
DULOXETINE;ZNF385D;rs4334661;T;EFFICACY;INCREASED_RESPONSE
FOLIC ACID, HYDROXYCHLOROQUINE, METHOTREXATE, SULFASALAZINE;MTR;rs1805087;A;EFFICACY;INCREASED_RESPONSE
DULOXETINE;;rs7625956;G;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs4646453;CC;LADME_PK;INCREASED_CONCENTRATIONS
TAMOXIFEN;SULT1A1;rs1042028;TT;EFFICACY;DECREASED_RESPONSE
DULOXETINE;ZNF385D;rs7616119;G;EFFICACY;INCREASED_RESPONSE
DULOXETINE;;rs2933304;T;EFFICACY;DECREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;CT;DOSAGE;INCREASED_DOSE
METHOTREXATE;SLC19A1;rs1051266;T;EFFICACY;INCREASED_RESPONSE
DULOXETINE;NRXN1;rs4971678;T;EFFICACY;DECREASED_RESPONSE
TRAMADOL;RGL4;rs184199168;A;LADME_PK;DECREASED_METABOLISM
DULOXETINE;ZNF385D;rs12630569;G;EFFICACY;DECREASED_RESPONSE
TRAMADOL;;rs72732317;T;LADME_PK;DECREASED_METABOLISM
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE
BEVACIZUMAB, CAPECITABINE, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, OXALIPLATIN;VEGFA;rs699947;CC;EFFICACY;INCREASED_RESPONSE
TRAMADOL;HCN1;rs79983226;C;LADME_PK;DECREASED_METABOLISM
TRAMADOL;ICA1;rs62435418;A;LADME_PK;DECREASED_METABOLISM
ERYTHROPOIETIN;HFE;rs1800562;A;DOSAGE, LADME_PK;DECREASED_DOSE
DULOXETINE;;rs6700741;C;EFFICACY;DECREASED_RESPONSE
ENALAPRIL;ADRB2;rs1042714;CG + GG;EFFICACY;INCREASED_RESPONSE
ATENOLOL, ENALAPRIL;ADRB2;rs1042714;CG + GG;EFFICACY;INCREASED_RESPONSE
BEVACIZUMAB, CAPECITABINE, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, OXALIPLATIN;VEGFA;rs3025039;TT;EFFICACY;DECREASED_RESPONSE
ERYTHROPOIETIN;HFE;rs1799945;G;DOSAGE, LADME_PK;DECREASED_DOSE
TRAMADOL;RFPL4B;rs9384825;T;LADME_PK;DECREASED_METABOLISM
DULOXETINE;TEX10;rs6479008;C;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs15524;AA;LADME_PK;INCREASED_CONCENTRATIONS
DULOXETINE;TEX10;rs7035619;A;EFFICACY;INCREASED_RESPONSE
DULOXETINE;TEX10;rs10989064;T;EFFICACY;INCREASED_RESPONSE
DIGOXIN;ABCB1;rs1045642;GG;LADME_PK;INCREASED_METABOLISM
DULOXETINE;ATP10A;rs12595802;G;EFFICACY;DECREASED_RESPONSE
DULOXETINE;TEX10;rs7472;G;EFFICACY;INCREASED_RESPONSE
MYCOPHENOLIC ACID;IMPDH2;rs11706052;G;EFFICACY;DECREASED_RESPONSE
DULOXETINE;;rs56229625;G;EFFICACY;DECREASED_RESPONSE
DIGOXIN;ABCB1;rs2032582;CC;LADME_PK;INCREASED_METABOLISM
DULOXETINE;;rs61692318;G;EFFICACY;DECREASED_RESPONSE
DULOXETINE;;rs62319299;A;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_CONCENTRATIONS
DULOXETINE;TEX10;rs10124893;G;EFFICACY;INCREASED_RESPONSE
DULOXETINE;INVS;rs10123866;G;EFFICACY;INCREASED_RESPONSE
ABEMACICLIB, PALBOCICLIB, RIBOCICLIB;ABCB1;rs1045642;A;DOSAGE, TOXICITY;DECREASED_DOSE
DULOXETINE;;rs10007051;C;EFFICACY;DECREASED_RESPONSE
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;INCREASED_CLINICAL BENEFIT
DULOXETINE;ZNF385D;rs9879065;C;EFFICACY;INCREASED_RESPONSE
DULOXETINE;;rs55881666;C;EFFICACY;DECREASED_RESPONSE
INFLIXIMAB;;rs2097432;CC + CT;EFFICACY;DECREASED_RESPONSE
VALPROIC ACID;CYP2C9;rs4918758;CC + CT;LADME_PK;INCREASED_EXPOSURE
DULOXETINE;;rs11933890;A;EFFICACY;DECREASED_RESPONSE
VALPROIC ACID;CYP2C19;rs4244285;AA + AG;LADME_PK;INCREASED_EXPOSURE
DULOXETINE;ZNF385D;rs9310658;C;EFFICACY;INCREASED_RESPONSE
DULOXETINE;ZNF385D;rs7653345;A;EFFICACY;INCREASED_RESPONSE
VALPROIC ACID;ABAT;rs1731017;GG;LADME_PK;INCREASED_EXPOSURE
DULOXETINE;ZNF385D;rs9310657;T;EFFICACY;INCREASED_RESPONSE
DULOXETINE;ZNF385D;rs9824595;G;EFFICACY;INCREASED_RESPONSE
DULOXETINE;ZNF385D;rs9873889;C;EFFICACY;INCREASED_RESPONSE
DULOXETINE;ZNF385D;rs9819548;G;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_DOSE
CAPECITABINE;CDA;rs532545;CC;EFFICACY;DECREASED_RESPONSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE
HYDRALAZINE / ISOSORBIDE DINITRATE;NOS3;rs1799983;GG;EFFICACY;INCREASED_CLINICAL BENEFIT
WARFARIN;CYP2C9;rs56165452;C;DOSAGE;DECREASED_DOSE
TACROLIMUS;ABCB1;rs1045642;AA;LADME_PK;DECREASED_METABOLISM
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;GG + GT;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE
ADALIMUMAB;CRP;rs1130864;AG + GG;EFFICACY;INCREASED_RESPONSE
OLANZAPINE;CYP3A43;rs472660;AA;DOSAGE, EFFICACY, TOXICITY, LADME_PK;INCREASED_CLEARANCE
GLATIRAMER ACETATE;EOMES;rs2371108;T;EFFICACY;INCREASED_RESPONSE
CARVEDILOL;UGT1A1;rs4148323;A;LADME_PK;DECREASED_METABOLISM
ETOPOSIDE;ABCB1;rs1045642;GG;LADME_PK;INCREASED_METABOLISM
ADALIMUMAB;ATG5;rs9373839;CC + CT;EFFICACY;INCREASED_RESPONSE
DULOXETINE;MIEF2;rs56355515;G;EFFICACY;DECREASED_RESPONSE
DULOXETINE;MIEF2;rs12603700;G;EFFICACY;DECREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs28399499;C;LADME_PK;DECREASED_METABOLISM
ADALIMUMAB;ATG5;rs510432;CT + TT;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;ABCB1;rs1045642;GG;LADME_PK;INCREASED_DOSE
DULOXETINE;MIEF2;rs3889402;G;EFFICACY;DECREASED_RESPONSE
AZATHIOPRINE;AOX1;rs55754655;G;EFFICACY;DECREASED_RESPONSE
AZATHIOPRINE;AOX1;rs55754655;AG + GG;DOSAGE;INCREASED_DOSE
HYDRALAZINE / ISOSORBIDE DINITRATE;CYP11B2;rs1799998;AA;EFFICACY;INCREASED_CLINICAL BENEFIT
DULOXETINE;;rs58042962;G;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A4;rs2740574;C;DOSAGE;INCREASED_DOSE
DULOXETINE;;rs10771997;T;EFFICACY;DECREASED_RESPONSE
FENOFIBRATE;LPL;rs320;GG;EFFICACY;DECREASED_RESPONSE
DULOXETINE;FCN2;rs3124955;T;EFFICACY;DECREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE
FENOFIBRATE;APOA1;rs2727786;CG;EFFICACY;DECREASED_RESPONSE
DULOXETINE;FCN2;rs3128624;A;EFFICACY;DECREASED_RESPONSE
DULOXETINE;;rs7306991;A;EFFICACY;DECREASED_RESPONSE
GLATIRAMER ACETATE;CLEC16A;rs6498169;A;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A4;rs2740574;C;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
DIGOXIN;ABCB1;rs1045642;AA;LADME_PK;DECREASED_METABOLISM
DULOXETINE;;rs10771999;C;EFFICACY;DECREASED_RESPONSE
DULOXETINE;;rs10771998;A;EFFICACY;DECREASED_RESPONSE
DULOXETINE;SKIC3;rs12657120;G;EFFICACY;DECREASED_RESPONSE
ETHOSUXIMIDE;CACNA1H;rs61734410;T;EFFICACY;DECREASED_CLINICAL BENEFIT
DULOXETINE;SKIC3;rs4639250;G;EFFICACY;DECREASED_RESPONSE
DULOXETINE;;rs4437856;A;EFFICACY;DECREASED_RESPONSE
ETHOSUXIMIDE;CACNA1I;rs3747178;T;EFFICACY;DECREASED_CLINICAL BENEFIT
DULOXETINE;TREML4;rs9369266;A;EFFICACY;DECREASED_RESPONSE
AZATHIOPRINE;MOCOS;rs594445;AA + AC;DOSAGE;DECREASED_DOSE
DULOXETINE;TREML4;rs13204353;G;EFFICACY;DECREASED_RESPONSE
LAMOTRIGINE;ABCB1;rs2032582;A;EFFICACY;DECREASED_CLINICAL BENEFIT
CYCLOSPORINE;CALM1;rs12885713;T;EFFICACY;INCREASED_RESPONSE
IRBESARTAN;AGT;rs699;GG;EFFICACY;INCREASED_RESPONSE
DULOXETINE;;rs2419128;C;EFFICACY;DECREASED_RESPONSE
METHOTREXATE;SLC19A1;rs1051266;T;EFFICACY;INCREASED_RESPONSE
DULOXETINE;;rs12502866;G;EFFICACY;INCREASED_RESPONSE
METHOTREXATE;GGH;rs3758149;AA + AG;EFFICACY;DECREASED_RESPONSE
DULOXETINE;;rs12094644;T;EFFICACY;DECREASED_RESPONSE
CAPECITABINE;CDA;rs2072671;AA + AC;EFFICACY;DECREASED_RESPONSE
LAMOTRIGINE;CACNA1H;rs2753326;A;EFFICACY;INCREASED_CLINICAL BENEFIT
RIVAROXABAN;ABCB1;rs4728709;GG;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
ATENOLOL;ADRA2A;rs1800545;GG;EFFICACY;INCREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;DECREASED_METABOLISM
CYCLOSPORINE;;rs2874116;G;EFFICACY;INCREASED_RESPONSE
IRBESARTAN;APOB;rs1801701;CC;EFFICACY;INCREASED_RESPONSE
RIVAROXABAN;ABCB1;rs4148738;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
EFAVIRENZ;CYP2B6;rs28399499;C;LADME_PK;INCREASED_CONCENTRATIONS
MEPHENYTOIN;CYP2C19;rs183701923;T;LADME_PK;DECREASED_CLEARANCE
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE
MEPHENYTOIN;CYP2C19;rs140278421;A;LADME_PK;DECREASED_CLEARANCE
EFAVIRENZ;CYP2B6;rs4803419;T;LADME_PK;INCREASED_CONCENTRATIONS
CLOZAPINE, N-DESMETHYLCLOZAPINE;CYP1A2;rs34067076;A;LADME_PK;INCREASED_CONCENTRATIONS
CHLORPROMAZINE;DRD2;rs1799732;GG;EFFICACY;INCREASED_RESPONSE
CLOZAPINE, N-DESMETHYLCLOZAPINE;CYP1A2;rs59410695;A;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;CYP2C9;rs28371686;G;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;rs28371685;T;DOSAGE;DECREASED_DOSE
METHOTREXATE;AMPD1;rs17602729;AA + AG;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C9;rs28371686;G;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;rs56165452;C;DOSAGE;DECREASED_DOSE
BENAZEPRIL;AGT;rs7079;TT;EFFICACY;INCREASED_RESPONSE
PLATINUM COMPOUNDS;XRCC3;rs861539;A;EFFICACY;INCREASED_RESPONSE
CLOZAPINE, N-DESMETHYLCLOZAPINE;CYP1A2;rs200571120;C;LADME_PK;INCREASED_CONCENTRATIONS
EFAVIRENZ;CYP2B6;rs3745274;T;LADME_PK;INCREASED_CONCENTRATIONS
OMEPRAZOLE;ABCB1;rs1045642;AA + AG;LADME_PK;INCREASED_CONCENTRATIONS
OPIOIDS;OPRM1;rs1799971;AA;DOSAGE, EFFICACY;DECREASED_DOSE
NELFINAVIR;CYP2C19;rs4244285;AA;LADME_PK;DECREASED_METABOLISM
TOLBUTAMIDE;CYP2C9;rs771237265;C;LADME_PK;DECREASED_CLEARANCE
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE
METHOTREXATE;SLC19A1;rs1051266;TT;EFFICACY;INCREASED_RESPONSE
TOLBUTAMIDE;CYP2C9;rs762081829;T;LADME_PK;DECREASED_CLEARANCE
METFORMIN;SLC22A1;rs628031;A;EFFICACY;DECREASED_RESPONSE
MEPHENYTOIN;CYP2C19;rs145119820;A;LADME_PK;DECREASED_CLEARANCE
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_DOSE
TOLBUTAMIDE;CYP2C9;rs761895497;C;LADME_PK;DECREASED_CLEARANCE
WARFARIN;F7;rs510317;AA + AG;DOSAGE;INCREASED_DOSE
FLUOXETINE;HTR1A;rs6295;GG;EFFICACY;INCREASED_RESPONSE
MEPHENYTOIN;CYP2C19;rs61311738;T;LADME_PK;DECREASED_CLEARANCE
SULFONAMIDES, UREA DERIVATIVES;TCF7L2;rs7903146;TT;EFFICACY;DECREASED_RESPONSE
BENAZEPRIL;AGT;rs4762;G;EFFICACY;INCREASED_RESPONSE
BENAZEPRIL;AGT;rs699;A;EFFICACY;INCREASED_RESPONSE
FLUOROURACIL, OXALIPLATIN;GSTP1;rs1695;AG + GG;EFFICACY;INCREASED_RESPONSE
ACENOCOUMAROL;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE
BENAZEPRIL;AGT;rs7079;T;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_DOSE
FENOFIBRATE;APOA5;rs3135506;CG + GG;EFFICACY;INCREASED_RESPONSE
PRAVASTATIN, SIMVASTATIN;RHOA;rs11716445;A;EFFICACY;DECREASED_RESPONSE
SULFONAMIDES, UREA DERIVATIVES;KCNJ11;rs587783672;T;EFFICACY;RESPONSE
EFAVIRENZ;CYP2B6;rs35303484;AG;LADME_PK;INCREASED_CONCENTRATIONS
CLOZAPINE, N-DESMETHYLCLOZAPINE;CYP1A2;rs72547516;G;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE
CITALOPRAM;;rs585719;CT;EFFICACY;INCREASED_RESPONSE
WARFARIN;GGCX;rs11676382;CG + GG;DOSAGE;DECREASED_DOSE
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE
CLOZAPINE, N-DESMETHYLCLOZAPINE;CYP1A2;rs566851431;T;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;;rs12777823;A;LADME_PK;DECREASED_METABOLISM
WARFARIN;CYP2C9;rs7900194;A;LADME_PK;DECREASED_METABOLISM
ISONIAZID;CYP2E1;rs6413432;A;LADME_PK;INCREASED_CONCENTRATIONS
EFAVIRENZ;CYP2B6;rs4803419;TT;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_DOSE
WARFARIN;GATA4;rs2645400;TT;DOSAGE;INCREASED_DOSE
WARFARIN;CYP2C9;rs28371685;T;LADME_PK;DECREASED_METABOLISM
WARFARIN;GATA4;rs4841588;TT;DOSAGE;INCREASED_DOSE
MYCOPHENOLIC ACID ACYL GLUCURONIDE;UGT2B7;rs7662029;GG;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
BUPRENORPHINE;UGT2B7;rs7439366;CC;LADME_PK;DECREASED_CONCENTRATIONS
METHOTREXATE;SLCO1B1;rs4149056;CC;EFFICACY;DECREASED_RESPONSE
MYCOPHENOLIC ACID ACYL GLUCURONIDE;UGT2B7;rs7439366;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
METHOTREXATE;SLC19A1;rs2838958;AA;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP2C9;rs1057910;AC + CC;DOSAGE, LADME_PK;DECREASED_DOSE
SILDENAFIL;VEGFA;rs1570360;AA;EFFICACY;DECREASED_RESPONSE
SILDENAFIL;VEGFA;rs699947;AA + AC;EFFICACY;DECREASED_RESPONSE
CAPTOPRIL;ACE2;rs2106809;GG;EFFICACY;INCREASED_RESPONSE
CYCLOPHOSPHAMIDE, DOXORUBICIN, PACLITAXEL, TRASTUZUMAB;FCGR2A;rs1801274;AA;EFFICACY;INCREASED_RESPONSE
TRASTUZUMAB;FCGR3A;rs396991;CC;EFFICACY;INCREASED_RESPONSE
BUPRENORPHINE;UGT2B7;rs7662029;GG;LADME_PK;DECREASED_CONCENTRATIONS
ECULIZUMAB;CR1;rs2274567;AG + GG;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;NR1I2;rs3814055;TT;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A4;rs2740574;CT;LADME_PK;INCREASED_EXPOSURE
MYCOPHENOLIC ACID;UGT1A1;rs4148323;AG;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE
PHENPROCOUMON;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE
CLOZAPINE;DRD1;rs686;G;EFFICACY;INCREASED_RESPONSE
MYCOPHENOLIC ACID ACYL GLUCURONIDE;UGT2B7;rs7438135;AA;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
CLOZAPINE;DRD3;rs6280;TT;EFFICACY;INCREASED_RESPONSE
FOLLITROPIN BETA, MENOTROPINS, THYROTROPIN ALFA, UROFOLLITROPIN;FSHR;rs6166;CT;EFFICACY;DECREASED_RESPONSE
MERCAPTOPURINE;TPMT;rs12199316;G;DOSAGE;INCREASED_DOSE
TICAGRELOR;CYP3A4;rs56324128;CC;LADME_PK;DECREASED_CONCENTRATIONS
CANDESARTAN;AGTR1;rs5186;AA;EFFICACY;INCREASED_RESPONSE
IRBESARTAN;AGTR1;rs5186;AC;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C9;rs2256871;G;LADME_PK;DECREASED_METABOLISM
DOCETAXEL, PACLITAXEL;CYP3A5;rs776746;CC;EFFICACY;DECREASED_RESPONSE
CAPECITABINE, FLUOROURACIL, TEGAFUR / GIMERACIL / OTERACIL;DPYD;rs1801159;CC + CT;EFFICACY;DECREASED_RESPONSE
CANDESARTAN;AGTR1;rs5186;AC;EFFICACY;INCREASED_RESPONSE
TICAGRELOR;SLCO1B1;rs113681054;C;LADME_PK;INCREASED_CONCENTRATIONS
TICAGRELOR;SLCO1B1;rs4149056;T;LADME_PK;DECREASED_CONCENTRATIONS
GEMCITABINE, PACLITAXEL;SLC29A1;rs760370;A;EFFICACY;DECREASED_RESPONSE
CITALOPRAM, ESCITALOPRAM, FLUOXETINE, FLUVOXAMINE, PAROXETINE, SERTRALINE;BDNF;rs6265;CC;EFFICACY;INCREASED_CLINICAL BENEFIT
WARFARIN;CYP2C19;rs11188082;T;LADME_PK;DECREASED_METABOLISM
METHYLPHENIDATE;CES1;rs71647871;CT;DOSAGE, LADME_PK;DECREASED_DOSE
TICAGRELOR;UGT2B7;rs61361928;TT;LADME_PK;DECREASED_CONCENTRATIONS
QUETIAPINE;HTR1A;rs6295;GG;LADME_PK;INCREASED_CONCENTRATIONS
TICAGRELOR;CYP3A43;rs62471956;G;LADME_PK;DECREASED_CONCENTRATIONS
ACENOCOUMAROL, WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE
SIMVASTATIN;LEPR;rs1137101;GG;EFFICACY;DECREASED_RESPONSE
LAMOTRIGINE;ABCG2;rs2231142;T;LADME_PK;INCREASED_CONCENTRATIONS
OPIOIDS;IL2;rs2069762;AA;DOSAGE;INCREASED_DOSE
OPIOIDS;BDNF;rs6265;CC;DOSAGE;INCREASED_DOSE
ACENOCOUMAROL, WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE
VORICONAZOLE;CYP3A4;rs4646437;AG;LADME_PK;INCREASED_CONCENTRATIONS
OPIOIDS;IL6;rs1800795;CC;DOSAGE;INCREASED_DOSE
ATENOLOL, IRBESARTAN;AGT;rs4762;AG;EFFICACY;INCREASED_RESPONSE
TENOFOVIR;ABCC4;rs1059751;AA + AG;LADME_PK;DECREASED_CONCENTRATIONS
CAFFEINE;CYP1A1;rs2472297;T;LADME_PK;INCREASED_METABOLISM
DOCETAXEL;VEGFA;rs1570360;GG;EFFICACY;DECREASED_RESPONSE
OPIOIDS;IL1B;rs1143634;AA + AG;EFFICACY;DECREASED_CLINICAL BENEFIT
FENOFIBRATE;SCARB1;rs4238001;CT + TT;EFFICACY;INCREASED_RESPONSE
TENOFOVIR;SLC22A6;rs4149170;TT;LADME_PK;INCREASED_CONCENTRATIONS
NEVIRAPINE;CYP2B6;rs3745274;TT;LADME_PK;DECREASED_METABOLISM
OPIOIDS;OPRD1;rs678849;CC;EFFICACY;DECREASED_CLINICAL BENEFIT
ACENOCOUMAROL, WARFARIN;CYP2C9;rs1057910;AC + CC;DOSAGE;DECREASED_DOSE
IRBESARTAN;AGT;rs699;AG + GG;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;CXCL10;rs56061981;CT + TT;EFFICACY;INCREASED_RESPONSE
ATORVASTATIN;ABCB1;rs2032582;T;EFFICACY;INCREASED_RESPONSE
ATORVASTATIN;ABCB1;rs2032582;T;EFFICACY;INCREASED_RESPONSE
ATALUREN;CFTR;rs113993959;T;EFFICACY;RESPONSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
FOLIC ACID;MTHFR;rs1801131;G;LADME_PK;DECREASED_METABOLISM
ATALUREN;CFTR;rs75039782;T;EFFICACY;RESPONSE
FOLIC ACID;MTHFR;rs1801133;A;LADME_PK;DECREASED_METABOLISM
ATALUREN;CFTR;rs77010898;A;EFFICACY;RESPONSE
PLATINUM COMPOUNDS;ERCC2;rs1052555;AA + AG;EFFICACY;DECREASED_RESPONSE
FENOFIBRATE;APOA5;rs3135506;CC + CG;EFFICACY;INCREASED_RESPONSE
METHYLPHENIDATE;DRD1;rs5326;CT + TT;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
FENTANYL;ABCB1;rs1045642;GG;DOSAGE, EFFICACY;INCREASED_DOSE
FOLIC ACID, METHOTREXATE;ATIC;rs2372536;CC;EFFICACY;INCREASED_RESPONSE
CORTICOSTEROIDS, SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;ADAM33;rs2853209;AA;EFFICACY;DECREASED_CLINICAL BENEFIT
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE
LITHIUM;GADL1;rs17026688;T;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;POR;rs1057868;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
FOLIC ACID, METHOTREXATE;ITPA;rs1127354;CC;EFFICACY;INCREASED_RESPONSE
METHOTREXATE;ATIC;rs4673993;C;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;TT;DOSAGE, LADME_PK;DECREASED_DOSE
WARFARIN;GGCX;rs12714145;C;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE
METHOTREXATE;ADA;rs244076;C;EFFICACY;DECREASED_RESPONSE
METHOTREXATE;ADORA2A;rs5751876;T;EFFICACY;DECREASED_RESPONSE
FOLIC ACID, METHOTREXATE;AMPD1;rs17602729;A;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE
RITUXIMAB;FCGR3A;rs396991;CC;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_DOSE
FLUOROURACIL;EGFR;rs2293347;CC;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_DOSE
ANTIDEPRESSANTS;TGFBR3;rs12082710;TT;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs7294;C;DOSAGE;DECREASED_DOSE
METHOTREXATE;SLC19A1;rs1051266;TT;EFFICACY;INCREASED_CLINICAL BENEFIT
ALLOPURINOL;ABCG2;rs2231142;T;DOSAGE;INCREASED_DOSE
WARFARIN;VKORC1;rs2884737;C;DOSAGE;DECREASED_DOSE
WARFARIN;VKORC1;rs2359612;A;DOSAGE;DECREASED_DOSE
RIFAMPIN;AADAC;rs1803155;GG;LADME_PK;DECREASED_EXPOSURE
CETUXIMAB, PANITUMUMAB;AREG;rs9996584;AA;EFFICACY;INCREASED_RESPONSE
NEVIRAPINE;CYP2B6;rs28399499;CT;LADME_PK;DECREASED_CLEARANCE
CETUXIMAB, PANITUMUMAB;AREG;rs1353295;GG;EFFICACY;INCREASED_RESPONSE
NEVIRAPINE;CYP2B6;rs28399499;CT;TOXICITY, LADME_PK;DECREASED_CLEARANCE
METHOTREXATE;MTHFR;rs1801133;AA + AG;LADME_PK;INCREASED_CONCENTRATIONS
RIFAMPIN;ABCB1;rs3842;CC;LADME_PK;INCREASED_EXPOSURE
NEVIRAPINE;CYP2B6;rs3745274;GT + TT;TOXICITY, LADME_PK;DECREASED_CLEARANCE
METHOTREXATE;ABCB1;rs1045642;AA;LADME_PK;INCREASED_CONCENTRATIONS
CLOPIDOGREL;CYP2C19;rs4986893;AG;EFFICACY;INCREASED_CLINICAL BENEFIT
FENTANYL;P2RX7;rs1718125;CT + TT;DOSAGE;INCREASED_DOSE
METHYLPHENIDATE;DRD1;rs4867798;CC + CT;EFFICACY;INCREASED_RESPONSE
METHYLPHENIDATE;DRD3;rs6280;TT;EFFICACY;INCREASED_RESPONSE
METHYLPHENIDATE;DRD4;rs11246226;AA;EFFICACY;INCREASED_RESPONSE
PLATINUM COMPOUNDS;XRCC1;rs25487;CT + TT;EFFICACY;INCREASED_RESPONSE
METHYLPHENIDATE;ADRA2A;rs1800544;CC;EFFICACY;INCREASED_RESPONSE
METHYLPHENIDATE;COMT;rs4680;AA + AG;EFFICACY;INCREASED_RESPONSE
ESTRONE SULFATE;SLCO1B1;rs10841753;C;EFFICACY;DECREASED_CONCENTRATIONS
ESTRONE SULFATE;SLCO1B1;rs10841753;C;LADME_PK;DECREASED_
WARFARIN;GGCX;rs12714145;TT;DOSAGE;INCREASED_DOSE
NEVIRAPINE;CYP2B6;rs3745274;GT + TT;LADME_PK;DECREASED_CLEARANCE
CETUXIMAB, PANITUMUMAB;AREG;rs13104811;GG;EFFICACY;INCREASED_RESPONSE
CETUXIMAB, PANITUMUMAB;AREG;rs11942466;AA;EFFICACY;DECREASED_RESPONSE
ANTIDEPRESSANTS;CRHR1;rs28364032;AA + AG;EFFICACY;INCREASED_RESPONSE
TOPIRAMATE;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs4148324;GG + GT;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
CAPECITABINE, FLUOROURACIL;EXO1;rs1047840;A;EFFICACY;INCREASED_RESPONSE
CAPECITABINE, FLUOROURACIL;CYP19A1;rs2236722;G;EFFICACY;DECREASED_RESPONSE
CAPECITABINE, FLUOROURACIL;PTEN;rs17431184;C;EFFICACY;INCREASED_RESPONSE
CYCLOSPORINE;POR;rs1057868;T;LADME_PK;INCREASED_CONCENTRATIONS
CAPECITABINE, FLUOROURACIL;DLG5;rs2289310;T;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;SLC29A1;rs760370;GG;EFFICACY;INCREASED_RESPONSE
METHOTREXATE;MTHFR;rs1801133;AA + AG;LADME_PK;DECREASED_CLEARANCE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
TIPIRACIL HYDROCHLORIDE, TRIFLURIDINE;SLC29A1;rs760370;AG + GG;EFFICACY;INCREASED_RESPONSE
ETHANOL;ADH1B;rs2018417;A;TOXICITY, LADME_PK;METABOLISM
ETHANOL;ADH1B;rs17033;C;TOXICITY, LADME_PK;METABOLISM
ETHANOL;ADH1B;rs1229985;G;TOXICITY, LADME_PK;METABOLISM
PHENPROCOUMON;PPARA;rs4253728;A;DOSAGE;INCREASED_DOSE
ETHANOL;ADH1A;rs931635;A;TOXICITY, LADME_PK;METABOLISM
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
METHADONE;KCNJ6;rs2070995;TT;;INCREASED_DOSE
ETHANOL;ADH1C;rs283416;A;TOXICITY, LADME_PK;METABOLISM
CAPECITABINE, FLUOROURACIL;ABCB1;rs17160359;T;EFFICACY;INCREASED_RESPONSE
ROSIGLITAZONE;PPARG;rs1801282;CG;EFFICACY;INCREASED_RESPONSE
ETHANOL;ADH1C;rs283411;A;TOXICITY, LADME_PK;METABOLISM
ETHANOL;ADH1C;rs1662060;C;TOXICITY, LADME_PK;METABOLISM
TACROLIMUS;SUMO4;rs237025;AA;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
ACENOCOUMAROL;VKORC1;rs17878544;TT;DOSAGE;DECREASED_DOSE
HMG COA REDUCTASE INHIBITORS;LPA;rs10455872;G;EFFICACY;DECREASED_RESPONSE
ACENOCOUMAROL;VKORC1;rs7200749;AA + AG;DOSAGE;INCREASED_DOSE
HMG COA REDUCTASE INHIBITORS;ABCG2;rs2231142;G;EFFICACY;DECREASED_RESPONSE
ACENOCOUMAROL;VKORC1;rs61742245;AA + AC;DOSAGE;INCREASED_DOSE
WARFARIN;VKORC1;rs7200749;A;DOSAGE;INCREASED_DOSE
ACENOCOUMAROL;VKORC1;rs9923231;CC;DOSAGE;INCREASED_DOSE
WARFARIN;VKORC1;rs7294;T;DOSAGE;INCREASED_DOSE
CITALOPRAM;NEDD4L;rs520210;A;EFFICACY;INCREASED_RESPONSE
HMG COA REDUCTASE INHIBITORS;TOMM40;rs2075650;G;EFFICACY;DECREASED_RESPONSE
ACENOCOUMAROL;VKORC1;rs55894764;CT + TT;DOSAGE;INCREASED_DOSE
VALPROIC ACID;UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs28898617;G;LADME_PK;INCREASED_CONCENTRATIONS
IVACAFTOR;CFTR;rs78655421;AA + AG;EFFICACY;RESPONSE
METHYLPHENIDATE;PEBP4;rs17685420;T;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE
VERAPAMIL;ITGAL;rs2230433;C;EFFICACY;INCREASED_CLINICAL BENEFIT
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS
PAZOPANIB;KDR;rs34231037;AG;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
ETHANOL;ADH7;rs1154461;C;TOXICITY, LADME_PK;METABOLISM
HEPATITIS VACCINES;IL4R;rs1805015;C;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;DECREASED_METABOLISM
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
ETHANOL;ADH1A;rs1229967;C;TOXICITY, LADME_PK;METABOLISM
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE
ETHANOL;ADH1A;rs2276332;C;TOXICITY, LADME_PK;METABOLISM
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE
BENAZEPRIL, IMIDAPRIL;AGT;rs5051;CC;EFFICACY;INCREASED_RESPONSE
ETHANOL;ADH1A;rs1229976;C;TOXICITY, LADME_PK;METABOLISM
URSODEOXYCHOLIC ACID;MGAT5;rs661899;TT;EFFICACY;DECREASED_CLINICAL BENEFIT
CLOPIDOGREL THIOL METABOLITE H4;CYP2C19;rs4244285;A;LADME_PK;EXPOSURE
HEPATITIS VACCINES;IL13;rs1295686;T;EFFICACY;DECREASED_RESPONSE
PHENPROCOUMON;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_DOSE
PHENPROCOUMON;VKORC1;rs7294;CT + TT;DOSAGE;INCREASED_DOSE
TACROLIMUS;ABCB1;rs1045642;AA;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
PEGINTERFERON ALFA-2B, RIBAVIRIN;CYP27B1;rs10877012;GT + TT;EFFICACY;INCREASED_RESPONSE
DABIGATRAN;CES1;rs8192935;AA + AG;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
IRINOTECAN;VDR;rs11574077;TT;LADME_PK;INCREASED_METABOLISM
METHYLPHENIDATE;ADGRL3;rs1868790;AA;EFFICACY;DECREASED_RESPONSE
METHYLPHENIDATE;SNAP25;rs3746544;GG + GT;EFFICACY;INCREASED_RESPONSE
METHYLPHENIDATE;SLC6A3;rs2550948;CC + CT;EFFICACY;INCREASED_RESPONSE
PHENPROCOUMON;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE
ATORVASTATIN;SLCO1B1;rs4149056;C;LADME_PK;INCREASED_EXPOSURE
INTERFERONS, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
MORPHINE;SLC22A1;rs34059508;AA + AG;LADME_PK;DECREASED_CLEARANCE
METHYLPHENIDATE;ADRA2A;rs1800544;G;EFFICACY;INCREASED_RESPONSE
PLATINUM;XRCC1;rs25487;CT + TT;EFFICACY;DECREASED_RESPONSE
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;;rs10514475;A;EFFICACY;INCREASED_RESPONSE
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;PLCB1;rs6108160;A;EFFICACY;INCREASED_RESPONSE
WARFARIN;LRP1;rs1800139;TT;DOSAGE;INCREASED_DOSE
METHYLPHENIDATE;ADRA2A;rs1800544;GG;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP4F2;rs2108622;T;DOSAGE, EFFICACY;INCREASED_DOSE
WARFARIN;LRP1;rs1800154;CC;DOSAGE;INCREASED_DOSE
NICOTINE;CYP2A6;rs56113850;T;LADME_PK;DECREASED_CLEARANCE
WARFARIN;VKORC1;rs9923231;TT;EFFICACY;INCREASED_RESPONSE
INTERFERONS, RIBAVIRIN;IFNL3;rs8099917;GG;EFFICACY;INCREASED_RESPONSE
PHENPROCOUMON;VKORC1;rs2359612;AA + AG;EFFICACY;INCREASED_RESPONSE
METHYLPHENIDATE;COMT;rs4680;GG;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP4F2;rs2108622;T;DOSAGE, EFFICACY;INCREASED_DOSE
PLATINUM COMPOUNDS;XRCC1;rs1799782;G;EFFICACY;DECREASED_RESPONSE
MORPHINE;SLC22A1;rs12208357;TT;LADME_PK;DECREASED_CLEARANCE
PHENPROCOUMON;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE
METHYLPHENIDATE;ADRA2A;rs1800544;GG;EFFICACY;DECREASED_RESPONSE
FLUOROURACIL;LGR5;rs17109924;CC + CT;EFFICACY;INCREASED_RESPONSE
ROSUVASTATIN;ABCG2;rs2231142;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS
MORPHINE;SLC22A1;rs34059508;AA;LADME_PK;DECREASED_CLEARANCE
METHYLPHENIDATE;COMT;rs4680;AA + AG;EFFICACY;INCREASED_RESPONSE
MORPHINE;SLC22A1;rs34130495;AA;LADME_PK;DECREASED_CLEARANCE
ATORVASTATIN, PRAVASTATIN;KIF6;rs9462535;AA + AC;EFFICACY;INCREASED_RESPONSE
CAPECITABINE, FLUOROURACIL;MTHFR;rs1801133;AA + AG;DOSAGE;DECREASED_DOSE
ROSUVASTATIN;ABCG2;rs1481012;AG + GG;EFFICACY;INCREASED_RESPONSE
SOMATROPIN RECOMBINANT;CDK4;rs2069502;CC;EFFICACY;DECREASED_RESPONSE
ATORVASTATIN, PRAVASTATIN;KIF6;rs9471077;AG + GG;EFFICACY;INCREASED_RESPONSE
METFORMIN;FMO5;rs7541245;A;EFFICACY;DECREASED_RESPONSE
METHYLPHENIDATE;ADGRL3;rs6858066;A;EFFICACY;INCREASED_RESPONSE
METHYLPHENIDATE;ADGRL3;rs1947274;C;EFFICACY;INCREASED_RESPONSE
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;DECREASED_RESPONSE
ROSUVASTATIN;USP24;rs17111584;CC + CT;EFFICACY;DECREASED_RESPONSE
METHYLPHENIDATE;ADGRL3;rs6551665;G;EFFICACY;INCREASED_RESPONSE
METHYLPHENIDATE;ADGRL3;rs2345039;G;EFFICACY;DECREASED_RESPONSE
METHYLPHENIDATE;ADGRL3;rs6858066;G;EFFICACY;INCREASED_RESPONSE
METHYLPHENIDATE;ADGRL3;rs1947274;C;EFFICACY;DECREASED_RESPONSE
METHYLPHENIDATE;SLC6A2;rs5569;GG;EFFICACY;INCREASED_RESPONSE
INTERFERON BETA-1A;RORA;rs4774388;TT;EFFICACY;INCREASED_RESPONSE
METHYLPHENIDATE;SLC6A2;rs28386840;AT + TT;EFFICACY;INCREASED_RESPONSE
METHYLPHENIDATE;ADGRL3;rs6551665;G;EFFICACY;DECREASED_RESPONSE
REMIMAZOLAM;CES1;rs71647871;CT + TT;LADME_PK;DECREASED_METABOLISM
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE
NICOTINE;;rs113288603;T;LADME_PK;DECREASED_CLEARANCE
ROSUVASTATIN;APOE;rs71352238;CC + CT;EFFICACY;DECREASED_RESPONSE
METHYLPHENIDATE;ADRA2A;rs1800544;GG;EFFICACY;INCREASED_RESPONSE
NICOTINE;;rs12461964;A;LADME_PK;DECREASED_CLEARANCE
ROSUVASTATIN;APOE;rs7412;CT + TT;EFFICACY;INCREASED_RESPONSE
METHYLPHENIDATE;ADRA2A;rs1800544;CG + GG;EFFICACY;INCREASED_RESPONSE
IDARUBICIN;NCF4;rs1883112;AA;EFFICACY;INCREASED_RESPONSE
SIMVASTATIN;ABCC2;rs717620;CT + TT;EFFICACY;DECREASED_RESPONSE
IDARUBICIN;RAC2;rs13058338;AT;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
ROSUVASTATIN;LPA;rs10455872;AG + GG;EFFICACY;DECREASED_RESPONSE
ATORVASTATIN;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs887829;T;LADME_PK;INCREASED_METABOLISM
METHYLPHENIDATE;BDNF;rs6265;CC;EFFICACY;INCREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs3745274;GG + GT;LADME_PK;DECREASED_CONCENTRATIONS
IVACAFTOR;CFTR;rs78655421;AA + AG;EFFICACY;RESPONSE
ATORVASTATIN;CYP3A7;rs45446698;G;LADME_PK;INCREASED_METABOLISM
ATALUREN;CFTR;rs77010898;A;EFFICACY;RESPONSE
METHYLPHENIDATE;GRM7;rs3792452;CT;EFFICACY;INCREASED_RESPONSE
CLOZAPINE;CYP1A2;rs762551;AA;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
EFAVIRENZ;CYP2B6;rs2279343;G;LADME_PK;INCREASED_CONCENTRATIONS
EFAVIRENZ;CYP2B6;rs2279345;T;LADME_PK;DECREASED_CONCENTRATIONS
ATORVASTATIN, PRAVASTATIN;KIF6;rs20455;AG + GG;EFFICACY;INCREASED_RESPONSE
METHYLPHENIDATE;ADGRL3;rs6551665;AG + GG;EFFICACY;INCREASED_RESPONSE
ATALUREN;CFTR;rs113993959;T;EFFICACY;RESPONSE
METHYLPHENIDATE;COMT;rs4680;GG;EFFICACY;INCREASED_RESPONSE
EFAVIRENZ;ABCB1;rs1045642;AG;LADME_PK;INCREASED_CONCENTRATIONS
SOMATROPIN RECOMBINANT;CDK4;rs2270777;TT;EFFICACY;INCREASED_RESPONSE
IVACAFTOR;CFTR;rs78655421;AG;EFFICACY;RESPONSE
METHYLPHENIDATE;ADRA2A;rs1800544;G;EFFICACY;INCREASED_RESPONSE
ACENOCOUMAROL;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE
ATALUREN;CFTR;rs75039782;T;EFFICACY;RESPONSE
ACENOCOUMAROL;VKORC1;rs9923231;CT;DOSAGE;DECREASED_DOSE
METFORMIN;PRPF31;rs254271;C;EFFICACY;DECREASED_RESPONSE
GABAPENTIN;SLC7A5;rs4240803;AG;DOSAGE;INCREASED_DOSE
ATALUREN;CFTR;rs77010898;A;EFFICACY;RESPONSE
METFORMIN;NBEA;rs57081354;C;EFFICACY;DECREASED_RESPONSE
METFORMIN;SLC22A1;rs628031;AA + AG;EFFICACY;INCREASED_CLINICAL BENEFIT
CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;GT + TT;EFFICACY;INCREASED_RESPONSE
DRUGS USED IN DIABETES;IRS1;rs1801278;CT + TT;EFFICACY;DECREASED_RESPONSE
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;XRCC1;rs25487;CC;EFFICACY;INCREASED_RESPONSE
METHOTREXATE;MTRR;rs1801394;A;EFFICACY;DECREASED_RESPONSE
SALBUTAMOL;DUSP1;rs881152;G;EFFICACY;INCREASED_RESPONSE
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ERCC1;rs11615;GG;EFFICACY;INCREASED_RESPONSE
HYDROCHLOROTHIAZIDE;NEDD4L;rs4149601;A;EFFICACY;INCREASED_RESPONSE
METFORMIN;SLC22A1;rs622342;AC + CC;EFFICACY;INCREASED_CLINICAL BENEFIT
WARFARIN;CYP4F2;rs2108622;CT;DOSAGE;INCREASED_DOSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;IFNL3;rs12980275;AA;EFFICACY;INCREASED_RESPONSE
EMTRICITABINE;ABCC2;rs2273897;TT;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE, LADME_PK;DECREASED_CLEARANCE
ATALUREN;CFTR;rs113993959;T;EFFICACY;RESPONSE
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE
GABAPENTIN, PREGABALIN;SLC7A5;rs4240803;AG;EFFICACY;DECREASED_RESPONSE
METHOTREXATE;SLC19A1;rs1051266;CT + TT;TOXICITY;DECREASED_DISCONTINUATION
MORPHINE;COMT;rs4680;AA;DOSAGE, EFFICACY;DECREASED_DOSE
METFORMIN;CPA6;rs2162145;T;EFFICACY;INCREASED_RESPONSE
SALBUTAMOL;DUSP1;rs881152;G;EFFICACY;INCREASED_RESPONSE
IVACAFTOR;CFTR;rs75527207;AA + AG;EFFICACY;RESPONSE
MIGALASTAT;GLA;rs372966991;T;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A4;rs2242480;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
MIGALASTAT;GLA;rs869312146;T;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs61742245;AA + AC;DOSAGE;INCREASED_DOSE
TRAMADOL;SLC22A1;rs34059508;A;DOSAGE;DECREASED_DOSE
TACROLIMUS;SLCO1B3;rs4149117;GG + GT;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
MIGALASTAT;GLA;rs397515870;G;EFFICACY;INCREASED_RESPONSE
ESCITALOPRAM;IL11;rs1126757;CT + TT;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE
CLOPIDOGREL;CES1;rs2307240;CT + TT;EFFICACY;INCREASED_RESPONSE
MIGALASTAT;GLA;rs398123223;G;EFFICACY;INCREASED_RESPONSE
MIGALASTAT;GLA;rs190347120;A;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;SLC2A2;rs1499821;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE
MIGALASTAT;GLA;rs28935490;T;EFFICACY;INCREASED_RESPONSE
ABIRATERONE;YBX1;rs10493112;AC + CC;EFFICACY;INCREASED_CLINICAL BENEFIT
TACROLIMUS;NFATC4;rs1955915;CC + CT;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
GRAZOPREVIR;SLCO1B1;rs4149056;C;LADME_PD;INCREASED_EXPOSURE
BISOPROLOL;CYP2D6;rs1080985;CC;LADME_PK;DECREASED_CONCENTRATIONS
GRAZOPREVIR;SLCO1B1;rs11045819;A;LADME_PD;INCREASED_EXPOSURE
WARFARIN;CYP4F2;rs2108622;TT;DOSAGE;INCREASED_DOSE
WARFARIN;VKORC1;rs9923231;C;LADME_PK;INCREASED_STEADY_STATE CONCENTRATION
WARFARIN;VKORC1;rs9923231;C;LADME_PK;INCREASED_DOSE
MIGALASTAT;GLA;rs398123212;T;EFFICACY;INCREASED_RESPONSE
WARFARIN;;rs12777823;AA + AG;DOSAGE;DECREASED_DOSE
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE
MIGALASTAT;GLA;rs398123217;C;EFFICACY;INCREASED_RESPONSE
METHADONE;BDNF, BDNF-AS;rs7127507;C;EFFICACY;DECREASED_RESPONSE
O-DESMETHYLTRAMADOL;SLC22A1;rs12208357;T;LADME_PK;INCREASED_CONCENTRATIONS
MIGALASTAT;GLA;rs397515874;G;EFFICACY;INCREASED_RESPONSE
MIGALASTAT;GLA;rs727505292;G;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE
ENALAPRIL;NOS3;rs2070744;CC + CT;EFFICACY;INCREASED_RESPONSE
METHADONE;BDNF, BDNF-AS;rs11030118;G;EFFICACY;DECREASED_RESPONSE
MIGALASTAT;GLA;rs869312399;C;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs2359612;AG + GG;DOSAGE;INCREASED_DOSE
WARFARIN;CYP2C9;rs7089580;T;DOSAGE;DECREASED_DOSE
MIGALASTAT;GLA;rs104894828;T;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_DOSE
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE
METHADONE;BDNF, BDNF-AS;rs1967554;C;EFFICACY;DECREASED_RESPONSE
WARFARIN;VKORC1;rs8050894;CG + GG;DOSAGE;DECREASED_DOSE
BISOPROLOL;CYP2D6;rs1080985;G;LADME_PK;INCREASED_CONCENTRATIONS
MIGALASTAT;GLA;rs398123226;T;EFFICACY;INCREASED_RESPONSE
MIGALASTAT;GLA;rs398123226;C;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE
WARFARIN;VKORC1;rs7294;CT + TT;DOSAGE;INCREASED_DOSE
METHADONE;BDNF;rs2030324;G;EFFICACY;DECREASED_RESPONSE
MIGALASTAT;GLA;rs727504348;T;EFFICACY;INCREASED_RESPONSE
BISOPROLOL;CYP2D6;rs3892097;CT + TT;LADME_PK;INCREASED_CONCENTRATIONS
BUSULFAN;GSTA1;rs3957357;AA;LADME_PK;INCREASED_CLEARANCE
O-DESMETHYLTRAMADOL;SLC22A1;rs34130495;A;LADME_PK;INCREASED_CONCENTRATIONS
O-DESMETHYLTRAMADOL;SLC22A1;rs34059508;A;LADME_PK;INCREASED_CONCENTRATIONS
ENALAPRIL;BDKRB2;rs1799722;TT;EFFICACY;DECREASED_RESPONSE
METHADONE;BDNF;rs988748;C;EFFICACY;DECREASED_RESPONSE
O-DESMETHYLTRAMADOL;SLC22A1;rs55918055;C;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;VKORC1;rs61742245;A;DOSAGE;INCREASED_DOSE
MIGALASTAT;GLA;rs869312136;C;EFFICACY;INCREASED_RESPONSE
TRAMADOL;SLC22A1;rs55918055;C;DOSAGE;DECREASED_DOSE
MIGALASTAT;GLA;rs28935195;T;EFFICACY;INCREASED_RESPONSE
METHADONE;BDNF;rs11030119;G;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TRAMADOL;SLC22A1;rs12208357;T;DOSAGE;DECREASED_DOSE
MIGALASTAT;GLA;rs104894827;A;EFFICACY;INCREASED_RESPONSE
FENTANYL;CYP3A4;rs2242480;T;DOSAGE, EFFICACY;DECREASED_DOSE
MIGALASTAT;GLA;rs869312138;C;EFFICACY;INCREASED_RESPONSE
CELECOXIB;CYP2C9;rs1057910;CC;LADME_PK;DECREASED_METABOLISM
BISOPROLOL;CYP3A5;rs776746;TT;LADME_PK;DECREASED_CONCENTRATIONS
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE
TRAMADOL;SLC22A1;rs34130495;A;DOSAGE;DECREASED_DOSE
MIGALASTAT;GLA;rs1569304898;T;EFFICACY;INCREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1A;rs4149570;AA;EFFICACY;INCREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR4;rs5030728;AA + AG;EFFICACY;INCREASED_RESPONSE
METFORMIN;SLC47A1;rs8065082;CT + TT;EFFICACY;INCREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;rs4696480;TT;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_DOSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNG;rs2430561;AA + AT;EFFICACY;INCREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR9;rs352139;TT;EFFICACY;DECREASED_RESPONSE
WARFARIN;VKORC1L1;rs4072879;AA;DOSAGE;DECREASED_DOSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;rs3804099;CC + CT;EFFICACY;INCREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;rs1816702;CT + TT;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A4;rs35599367;A;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
SUFENTANIL;OPRM1;rs1799971;G;DOSAGE;DECREASED_DOSE
OPIOIDS;ENPP2;rs2249015;AA;DOSAGE;INCREASED_DOSE
DONEPEZIL, GALANTAMINE, RIVASTIGMINE;APOE;rs429358;CC + CT;EFFICACY;DECREASED_RESPONSE
ROSIGLITAZONE;PAX4;rs6467136;AA + AG;EFFICACY;INCREASED_RESPONSE
ROSIGLITAZONE;PAX4;rs6467136;AA + AG;EFFICACY;INCREASED_RESPONSE
ATORVASTATIN;APOE;rs429358;CT;EFFICACY;DECREASED_RESPONSE
OPIOIDS;ABCB1;rs1045642;AA;DOSAGE, EFFICACY;DECREASED_DOSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL6;rs10499563;CC + CT;EFFICACY;INCREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL17A;rs2275913;AA + AG;EFFICACY;DECREASED_RESPONSE
LATANOPROST;ABCC4;rs11568658;AC;EFFICACY;DECREASED_RESPONSE
ADALIMUMAB, ETANERCEPT, INFLIXIMAB, USTEKINUMAB;TNFRSF1B;rs1061622;GG + GT;EFFICACY;DECREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CNPY4;rs1554973;CC + CT;EFFICACY;DECREASED_RESPONSE
BOTULINUM TOXIN TYPE A;CALCA;rs3781719;G;EFFICACY;DECREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CD14;rs2569190;AA + AG;EFFICACY;DECREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;rs11938228;AA + AC;EFFICACY;DECREASED_RESPONSE
BOTULINUM TOXIN TYPE A;TRPV1;rs222749;A;EFFICACY;DECREASED_RESPONSE
OPIOIDS;ENPP2;rs7832704;AA;DOSAGE;INCREASED_DOSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL1B;rs4848306;AA + AG;EFFICACY;INCREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL1RN;rs4251961;CC + CT;EFFICACY;DECREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;rs6927172;CG + GG;EFFICACY;DECREASED_RESPONSE
HMG COA REDUCTASE INHIBITORS;APOE;rs429358;CC;EFFICACY;INCREASED_RESPONSE
LOSARTAN;ABCB1;rs1045642;AA + AG;EFFICACY;INCREASED_RESPONSE
PEMETREXED;FOLR3;rs61734430;CT + TT;EFFICACY;DECREASED_RESPONSE
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs4803217;AC + CC;EFFICACY;INCREASED_RESPONSE
METOPROLOL;GRK4;rs1801058;CT;EFFICACY;DECREASED_RESPONSE
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART);IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
FLUOXETINE;HTR2A;rs7997012;GG;EFFICACY;INCREASED_CLINICAL BENEFIT
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1800629;GG;EFFICACY;INCREASED_RESPONSE
DIRECT ACTING ANTIVIRALS, ELBASVIR / GRAZOPREVIR, LEDIPASVIR / SOFOSBUVIR;IFNL3, IFNL4;rs8099917;GG + GT;EFFICACY;DECREASED_CLINICAL BENEFIT
METOPROLOL;GRK4;rs2960306;GT + TT;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;ABCC2;rs3740066;CT + TT;LADME_PK;DECREASED_DOSE
TACROLIMUS;ABCC2;rs3740066;CT + TT;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
METHOTREXATE;ABCC2;rs717620;CT + TT;LADME_PK;INCREASED_CLEARANCE
TACROLIMUS;ABCC2;rs717620;CT + TT;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
METOPROLOL;GRK4;rs1024323;CC;EFFICACY;DECREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1799724;CC;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C19;rs3814637;T;OTHER, LADME_PK;DECREASED_CLEARANCE
METHADONE;GAD1;rs3762556;G;DOSAGE;INCREASED_DOSE
WARFARIN;CYP3A4;rs2242480;CT;OTHER, LADME_PK;INCREASED_CLEARANCE
INFLIXIMAB;IL1B;rs1143634;GG;EFFICACY;DECREASED_RESPONSE
METHADONE;GAD1;rs769404;TT;DOSAGE;DECREASED_DOSE
CLOZAPINE;CYP1A2;rs762551;AA + AC;LADME_PK;DECREASED_CONCENTRATIONS
ACENOCOUMAROL;VKORC1;rs9934438;GG;DOSAGE;INCREASED_DOSE
CAPECITABINE;DPYD;rs67376798;AT;DOSAGE;DECREASED_DOSE
CLOZAPINE;UGT1A4;rs2011404;C;LADME_PK;INCREASED_CONCENTRATIONS
CAPECITABINE;DPYD;rs3918290;CT;DOSAGE;DECREASED_DOSE
URIC ACID;VEGFC;rs1002976;C;LADME_PK;INCREASED_CONCENTRATIONS
LETERMOVIR;SLCO1B1;rs4149032;TT;LADME_PK;DECREASED_EXPOSURE
CLOZAPINE;UGT1A1;rs34946978;T;LADME_PK;DECREASED_CONCENTRATIONS
METFORMIN;CAPN10;rs3792269;G;EFFICACY;DECREASED_RESPONSE
LETERMOVIR;SLCO1B1;rs4149056;CC + CT;LADME_PK;INCREASED_EXPOSURE
LETERMOVIR;UGT1A1;rs4148323;AA + AG;LADME_PK;INCREASED_EXPOSURE
INTERFERON BETA-1A, INTERFERON BETA-1B;FHIT;rs760316;C;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE
GLYBURIDE;FMO2;rs7512785;T;EFFICACY;INCREASED_RESPONSE
METHOTREXATE;MTRR;rs1801394;AG + GG;EFFICACY;INCREASED_RESPONSE
PROPRANOLOL;ADRB2;rs1042713;GG;EFFICACY;INCREASED_RESPONSE
METHOTREXATE;ABCB1;rs1128503;AA;EFFICACY;INCREASED_RESPONSE
METHOTREXATE;ABCB1;rs1045642;AA;EFFICACY;INCREASED_RESPONSE
CLOZAPINE;ABCB1;rs10248420;G;EFFICACY;INCREASED_CLINICAL BENEFIT
METHOTREXATE;SLC16A7;rs3763980;A;EFFICACY;DECREASED_RESPONSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;IFNL3, IFNL4;rs12979860;C;EFFICACY;INCREASED_RESPONSE
METHOTREXATE;SLC16A7;rs12231740;T;EFFICACY;DECREASED_RESPONSE
METHOTREXATE;ARID5B;rs4948496;CC;LADME_PK;INCREASED_CONCENTRATIONS
CLOZAPINE;UGT1A1;rs4148323;A;LADME_PK;DECREASED_CONCENTRATIONS
FENOFIBRATE;APOE;rs7412;CT + TT;EFFICACY;INCREASED_RESPONSE
METHOTREXATE;SLCO1B1;rs4149056;TT;LADME_PK;DECREASED_CONCENTRATIONS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;IFNL3, IFNL4;rs8099917;T;EFFICACY;INCREASED_RESPONSE
METHADONE;GAD1;rs3762555;G;DOSAGE;INCREASED_DOSE
METHOTREXATE;MTHFR;rs1801133;AA;EFFICACY;DECREASED_RESPONSE
METHADONE;GAD1;rs3749034;G;DOSAGE;INCREASED_DOSE
CLOZAPINE;ABCB1;rs7787082;A;EFFICACY;INCREASED_CLINICAL BENEFIT
IGURATIMOD;NAT2;rs1495741;AG + GG;EFFICACY;DECREASED_CLINICAL BENEFIT
INTERFERON BETA-1A, INTERFERON BETA-1B;;rs4278350;T;EFFICACY;INCREASED_RESPONSE
SITAGLIPTIN, VILDAGLIPTIN;KCNQ1;rs163184;GG + GT;EFFICACY;DECREASED_CLINICAL BENEFIT
IGURATIMOD;ABCG2;rs2231142;GT + TT;EFFICACY;INCREASED_CLINICAL BENEFIT
INTERFERON BETA-1A, INTERFERON BETA-1B;GAPVD1;rs2291858;G;EFFICACY;INCREASED_RESPONSE
METHADONE;OPRD1;rs204047;GG;DOSAGE;INCREASED_DOSE
METHADONE;OPRD1;rs797397;AA;LADME_PK;INCREASED_CONCENTRATIONS
METHADONE;OPRD1;rs204047;GG;LADME_PK;INCREASED_CONCENTRATIONS
ANTIPSYCHOTICS;ZNF804A;rs1344706;AA;EFFICACY;DECREASED_RESPONSE
PLATINUM COMPOUNDS;XRCC1;rs25487;CC + CT;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE
INTERFERON BETA-1A, INTERFERON BETA-1B;GAPVD1;rs10819043;T;EFFICACY;INCREASED_RESPONSE
INTERFERON BETA-1A, INTERFERON BETA-1B;;rs3133084;A;EFFICACY;INCREASED_RESPONSE
CAPECITABINE, DOCETAXEL;CYP1A1;rs1048943;AG + GG;EFFICACY;INCREASED_RESPONSE
GLYBURIDE;CYP51A1;rs7793861;G;EFFICACY;INCREASED_RESPONSE
INTERFERON BETA-1A, INTERFERON BETA-1B;;rs1448673;G;EFFICACY;INCREASED_RESPONSE
GLYBURIDE;FMO2;rs7515157;T;EFFICACY;INCREASED_RESPONSE
ANASTROZOLE;ABCB1;rs2032582;AA;LADME_PK;INCREASED_CONCENTRATIONS
AMISULPRIDE, ANTIPSYCHOTICS, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR1A;rs10042486;TT;EFFICACY;INCREASED_RESPONSE
URIC ACID;BRINP3;rs950569;T;LADME_PK;INCREASED_CONCENTRATIONS
GLYBURIDE;UGT2B15;rs4148269;G;EFFICACY;INCREASED_RESPONSE
INTERFERON BETA-1A, INTERFERON BETA-1B;GAPVD1;rs10760397;C;EFFICACY;INCREASED_RESPONSE
URIC ACID;PADI4;rs2477134;G;LADME_PK;INCREASED_CONCENTRATIONS
INTERFERON BETA-1A, INTERFERON BETA-1B;ZNF697;rs10494227;A;EFFICACY;INCREASED_RESPONSE
DOXORUBICIN;ABCC5;rs1533682;TT;LADME_PK;INCREASED_CLEARANCE
PLATINUM COMPOUNDS;XRCC3;rs861539;AA + AG;EFFICACY;INCREASED_RESPONSE
GLYBURIDE;MAPK1;rs1803545;A;EFFICACY;INCREASED_RESPONSE
GLYBURIDE;ABCC5;rs3749442;A;EFFICACY;INCREASED_RESPONSE
GLYBURIDE;SPINK5;rs2303070;T;EFFICACY;INCREASED_RESPONSE
GLYBURIDE;BDKRB2;rs5224;A;EFFICACY;INCREASED_RESPONSE
GLYBURIDE;MAPK1;rs3729910;G;EFFICACY;INCREASED_RESPONSE
IGURATIMOD;ABCB1;rs2032582;CT + TT;EFFICACY;INCREASED_CLINICAL BENEFIT
WARFARIN;CYP4F2;rs2108622;TT;DOSAGE;INCREASED_DOSE
ETHANOL;KLB;rs11940694;A;TOXICITY;DECREASED_DOSE
PLATINUM COMPOUNDS;XRCC1;rs1799782;AA + AG;EFFICACY;INCREASED_RESPONSE
GLYBURIDE;ESR1;rs2077647;T;EFFICACY;INCREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1800629;G;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE
ANTIDEPRESSANTS;BDNF;rs6265;C;EFFICACY;INCREASED_RESISTANCE
FLUNISOLIDE;TBXT;rs2305089;TT;EFFICACY;INCREASED_RESPONSE
GRANISETRON, PALONOSETRON;ERCC1;rs3212986;AC + CC;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;IL6;rs1800795;GG;EFFICACY;DECREASED_CLINICAL BENEFIT
VALPROIC ACID;CYP2D6;rs3892097;CT + TT;EFFICACY;DECREASED_CLINICAL BENEFIT
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;rs1061622;T;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;IL6;rs1800795;GG;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1799724;C;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A4;rs4646437;GG;LADME_PK;INCREASED_EXPOSURE
RASAGILINE;DRD2;rs1076560;CC;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_EXPOSURE
TACROLIMUS;CYP3A4;rs2242480;CC;LADME_PK;INCREASED_EXPOSURE
RASAGILINE;DRD2;rs2283265;CC;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A4;rs4646437;GG;LADME_PK;INCREASED_EXPOSURE
TACROLIMUS;CTLA4;rs4553808;AG + GG;LADME_PK;INCREASED_EXPOSURE
ANTIDEPRESSANTS;BDNF-AS;rs10501087;T;EFFICACY;INCREASED_RESISTANCE
TACROLIMUS;IL3;rs181781;AA;LADME_PK;INCREASED_EXPOSURE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_CLEARANCE
LAMOTRIGINE;UGT1A4;rs6755571;CC;LADME_PK;DECREASED_CONCENTRATIONS
WARFARIN;CYP2C9;rs4917639;C;DOSAGE;DECREASED_DOSE
TELAPREVIR;CYP24A1;rs2585428;C;LADME_PK;DECREASED_TROUGH CONCENTRATION
TACROLIMUS;CTLA4;rs4553808;AA;LADME_PK;INCREASED_EXPOSURE
TACROLIMUS;CYP3A4;rs2242480;CC;LADME_PK;INCREASED_EXPOSURE
VARENICLINE;CHRNA4;rs1044396;GG;EFFICACY;DECREASED_RESPONSE
ESCITALOPRAM;CYP1A2;rs4646425;T;LADME_PK;INCREASED_METABOLISM
ESCITALOPRAM;CYP1A2;rs2069526;G;LADME_PK;INCREASED_METABOLISM
ESCITALOPRAM;CYP1A2;rs4646427;C;LADME_PK;INCREASED_METABOLISM
PLATINUM COMPOUNDS;HSPA5;rs430397;TT;EFFICACY;INCREASED_RESISTANCE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;rs1801274;A;EFFICACY;INCREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR3A;rs396991;C;EFFICACY;INCREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs2279343;GG;LADME_PK;DECREASED_CLEARANCE
MORPHINE;ABCB1;rs1045642;AA;LADME_PK;INCREASED_METABOLISM
CLOPIDOGREL;P2RY12;rs6785930;AA + AG;EFFICACY;INCREASED_RESISTANCE
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;DECREASED_CLEARANCE
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;DECREASED_CLEARANCE
EFAVIRENZ;CYP2B6;rs3745274;GT;LADME_PK;DECREASED_CLEARANCE
CLOPIDOGREL;P2RY12;rs6809699;AA + AC;EFFICACY;INCREASED_RESISTANCE
EFAVIRENZ;CYP2B6;rs2279343;AG;LADME_PK;DECREASED_CLEARANCE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs361525;G;EFFICACY;INCREASED_RESPONSE
FLUTICASONE PROPIONATE;ORMDL3;rs2872507;AA + AG;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_DOSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE
RITUXIMAB;FCGR3A;rs396991;AC + CC;EFFICACY;INCREASED_RESPONSE
ABATACEPT, RITUXIMAB, TOCILIZUMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;rs1801274;AG + GG;EFFICACY;INCREASED_RESPONSE
VALPROIC ACID;CYP2C9;rs1057910;AC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE, LADME_PK;DECREASED_DOSE
WARFARIN;CALU;rs339097;G;DOSAGE;INCREASED_DOSE
ATAZANAVIR / RITONAVIR;SLCO1B1;rs4149056;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS
DEFERASIROX;ABCG2;rs13120400;CT + TT;LADME_PK;INCREASED_EXPOSURE
ATAZANAVIR / RITONAVIR;CYP3A5;rs776746;CC;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;CYP2C9;rs10509680;T;DOSAGE;DECREASED_DOSE
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, GOLIMUMAB, INFLIXIMAB;VDR;rs7975232;AA + AC;EFFICACY;INCREASED_CLINICAL BENEFIT
ANTIEPILEPTICS;NR3C1;rs41423247;GG;EFFICACY;DECREASED_CLINICAL BENEFIT
TACROLIMUS;CYP3A5;rs776746;CT;EFFICACY, LADME_PK;INCREASED_DOSE
DEFERASIROX;ABCC2;rs2273697;AG;LADME_PK;INCREASED_EXPOSURE
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;DECREASED_METABOLISM
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE
FLUVASTATIN;APOE;rs7412;CT;EFFICACY;INCREASED_RESPONSE
METFORMIN;SLC47A1;rs2289669;A;EFFICACY;DECREASED_RESPONSE
LAMOTRIGINE;UGT2B7;rs7439366;TT;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A4;rs2740574;CC + CT;DOSAGE, LADME_PK;INCREASED_DOSE
RITODRINE;PDE4B;rs598961;AA;EFFICACY;DECREASED_CLINICAL BENEFIT
TACROLIMUS;CYP3A4;rs4986910;G;DOSAGE, LADME_PK;DECREASED_DOSE
ACENOCOUMAROL, WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE
LAMOTRIGINE;UGT2B15;rs1902023;AA;LADME_PK;DECREASED_CONCENTRATIONS
PLATINUM COMPOUNDS;XPA;rs1800975;CC;EFFICACY;INCREASED_RESPONSE
ARIPIPRAZOLE, DEHYDROARIPIPRAZOLE;ABCB1;rs2032582;CC;LADME_PK;INCREASED_CONCENTRATIONS
ARIPIPRAZOLE, DEHYDROARIPIPRAZOLE;ABCB1;rs1045642;GG;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE
ARIPIPRAZOLE, DEHYDROARIPIPRAZOLE;ABCB1;rs1128503;GG;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE
TACROLIMUS;IL10;rs1800871;AA;LADME_PK;DECREASED_METABOLISM
ANTIHYPERTENSIVES, HYDRALAZINE, METHYLDOPA, NIFEDIPINE;MMP9;rs3918242;CT;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP2C9;rs1799853;T;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DOSE
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;DOSE
WARFARIN;CYP2C9;rs1057910;C;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE
DACLATASVIR;VDR;rs11568820;TT;LADME_PK;DECREASED_CONCENTRATIONS
MORPHINE;COMT;rs4680;AG + GG;EFFICACY;INCREASED_DOSE
CLOMIPRAMINE;CYP2D6;rs1080985;CG;EFFICACY;DECREASED_RESPONSE
METHYLDOPA;MMP9;rs3918242;CT + TT;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DOSE
DACLATASVIR;CYP24A1;rs2248359;CT + TT;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;VKORC1;rs9923231;A;DOSAGE;DOSE
TACROLIMUS;ABCB1;rs1045642;AG + GG;LADME_PK;INCREASED_CLEARANCE
CARBAMAZEPINE, OXCARBAZEPINE;SCN1A;rs3812718;TT;EFFICACY;RESISTANCE
METOPROLOL;ADRB1;rs1801252;AA;EFFICACY;INCREASED_RESPONSE
METOPROLOL;ADRB1;rs1801253;CC;EFFICACY;INCREASED_RESPONSE
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs139304906;C;EFFICACY;INCREASED_CLINICAL BENEFIT
CALCIUM CHANNEL BLOCKERS;NUMA1;rs10898815;GG;EFFICACY;INCREASED_RESPONSE
CARBAMAZEPINE, OXCARBAZEPINE;SCN1A;rs3812718;TT;EFFICACY;RESISTANCE
CALCIUM CHANNEL BLOCKERS;TANC2;rs2429427;GG;EFFICACY;INCREASED_RESPONSE
SIBUTRAMINE;GNB3;rs5443;CC;EFFICACY;INCREASED_RESPONSE
CARBAMAZEPINE, OXCARBAZEPINE;ABCC2;rs2273697;AG;EFFICACY;RESISTANCE
METHOTREXATE;ABCC2;rs765027508;AG;LADME_PK;INCREASED_EXPOSURE
BUSULFAN;GSTA1;rs3957356;T;LADME_PK;DECREASED_CLEARANCE
S-EDDP;CYP2B6;rs8192709;CT;LADME_PK;INCREASED_CONCENTRATIONS
BUSULFAN;GSTA1;rs3957357;A;LADME_PK;DECREASED_CLEARANCE
SIMVASTATIN;UGT1A9;rs12052787;T;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;EFFICACY, LADME_PK;INCREASED_DOSE
SIMVASTATIN;UGT1A9;rs2003569;A;EFFICACY;INCREASED_RESPONSE
PLATINUM COMPOUNDS;ERCC4;rs1799801;TT;EFFICACY;DECREASED_RESPONSE
PLATINUM COMPOUNDS;ERCC1;rs11615;AA + AG;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;EFFICACY, LADME_PK;INCREASED_CLEARANCE
AMITRIPTYLINE, CLOMIPRAMINE, DOXEPIN, IMIPRAMINE, MAPROTILINE, NORTRIPTYLINE, OPIPRAMOL;CYP2D6;rs3892097;TT;DOSAGE, EFFICACY;DECREASED_DOSE
PLATINUM COMPOUNDS;ERCC3;rs3738948;AG + GG;EFFICACY;INCREASED_RESPONSE
TEGAFUR;CYP2A6;rs8192720;AA + AG;LADME_PK;INCREASED_METABOLISM
ANTIPSYCHOTICS, CHLORPROMAZINE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE;MTHFR;rs1801133;AG;EFFICACY;DECREASED_CLINICAL BENEFIT
OXYCODONE;UGT2B7;rs7439366;TT;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE
BUPROPION;CYP2B6;rs3745274;T;LADME_PK;INCREASED_EXPOSURE
RISPERIDONE;HRH4;rs4483927;TT;EFFICACY;DECREASED_RESPONSE
ATENOLOL;GRK4;rs2960306;T;EFFICACY;DECREASED_RESPONSE
ATENOLOL;GRK4;rs1024323;T;EFFICACY;DECREASED_RESPONSE
CALCIUM CHANNEL BLOCKERS;PICALM;rs588076;GG;EFFICACY;INCREASED_RESPONSE
DELEOBUVIR, FALDAPREVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C9;rs9332131;del;DOSAGE, EFFICACY;DECREASED_DOSE
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;rs28371686;G;DOSAGE, EFFICACY;DECREASED_DOSE
PROPOFOL;GABRA2;rs11503014;CC;OTHER;DECREASED_RESPONSE
WARFARIN;HNF4A;rs3212198;T;DOSAGE;INCREASED_DOSE
CODEINE, TRAMADOL;CYP1B1;rs1056836;C;EFFICACY;DECREASED_CLINICAL BENEFIT
ERLOTINIB, GEFITINIB;EGFR;rs121434568;G;EFFICACY;DECREASED_RESPONSE
WARFARIN;NR1I3;rs2501873;TT;DOSAGE;INCREASED_DOSE
VERAPAMIL;PCDHB8;rs3733694;G;EFFICACY;DECREASED_CLINICAL BENEFIT
RIVAROXABAN;POR;rs1057868;TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
VERAPAMIL;PCDHB6;rs17844444;A;EFFICACY;DECREASED_CLINICAL BENEFIT
WARFARIN;VKORC1;rs72547529;T;DOSAGE;INCREASED_DOSE
WARFARIN;VKORC1;rs72547529;T;DOSAGE;INCREASED_DOSE
WARFARIN;VKORC1;rs72547529;T;DOSAGE;INCREASED_DOSE
CAPECITABINE, CETUXIMAB, OXALIPLATIN;KRAS;rs61764370;AC;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE
SIMVASTATIN ACID;SLCO1B1;rs4149056;CT;LADME_PK;INCREASED_EXPOSURE
LOSARTAN;AGTR1;rs5186;AA;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME_PK;INCREASED_METABOLISM
HEROIN;OPRM1;rs9479757;AG;DOSAGE;INCREASED_DOSE
5-HYDROXYINDOLE-3-ACETIC ACID, SEROTONIN;MAOB;rs1799836;T;LADME_PK;INCREASED_CONCENTRATIONS
ANTIDEPRESSANTS;GRIK4;rs1954787;CC;EFFICACY;INCREASED_RESPONSE
RIVAROXABAN;ABCB1;rs4148738;CT;LADME_PK;INCREASED_CONCENTRATIONS
5-HYDROXYINDOLE-3-ACETIC ACID, SEROTONIN;MAOB;rs1799836;TT;LADME_PK;INCREASED_CONCENTRATIONS
APIXABAN;POR;rs1057868;T;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
OXCARBAZEPINE;UGT1A9;rs2741049;CC;EFFICACY;INCREASED_RESPONSE
CODEINE, TRAMADOL;CYP1B1;rs1056837;A;EFFICACY;DECREASED_CLINICAL BENEFIT
CANDESARTAN;CYP11B2;rs1799998;GG;EFFICACY;INCREASED_RESPONSE
3-HYDROXYCOTININE;;rs4105144;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS
HYDROCODONE, OXYCODONE;CYP2D6;rs35742686;DELT;EFFICACY;INCREASED_CLINICAL BENEFIT
3-HYDROXYCOTININE;EGLN2;rs3733829;AA + AG;LADME_PK;DECREASED_CONCENTRATIONS
HYDROCODONE, OXYCODONE;MACROD2;rs76026520;G;EFFICACY;INCREASED_CLINICAL BENEFIT
MERCAPTOPURINE;NUDT15;rs116855232;CT;DOSAGE;DECREASED_DOSE
BENAZEPRIL;MTHFR;rs1801133;AA;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_DOSE
DEFERASIROX;CYP1A1;rs2606345;AC + CC;LADME_PK;INCREASED_TROUGH CONCENTRATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_METABOLISM
PITRAKINRA;IL4R;rs1029489;GG;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_METABOLISM
CIPROFLOXACIN;CYP1A2;rs762551;AA + AC;;INCREASED_CLEARANCE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_DOSE
RADIOTHERAPY;CACNA2D3;rs11130424;AG + GG;EFFICACY;INCREASED_RESISTANCE
HYDROXYUREA;MAP3K5;rs9483947;CC;EFFICACY;INCREASED_CLINICAL BENEFIT
ANTIHYPERTENSIVES;CLNK;rs13144136;G;EFFICACY;INCREASED_RESPONSE
HYDROXYUREA;MAP3K5;rs9376230;CC;EFFICACY;INCREASED_CLINICAL BENEFIT
IMATINIB;ABCB1;rs1128503;GG;EFFICACY;DECREASED_RESPONSE
IMATINIB;ABCB1;rs1045642;AA;EFFICACY;INCREASED_RESPONSE
ATORVASTATIN;ABCC2;rs717620;CT + TT;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME_PK;INCREASED_METABOLISM
LENALIDOMIDE, THALIDOMIDE;FGF2;rs308395;CG + GG;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME_PK;INCREASED_DOSE
METHOTREXATE;ABCC2;rs717620;CT + TT;LADME_PK;DECREASED_CONCENTRATIONS
ANTIDEPRESSANTS;MAOA;rs979605;AA;LADME_PK;DECREASED_CLINICAL BENEFIT
METHOTREXATE;ABCB1;rs1045642;GG;EFFICACY;INCREASED_RESPONSE
ANTIDEPRESSANTS;GRIK4;rs1954787;C;EFFICACY;INCREASED_RESPONSE
ETHANOL;ALDH2;rs671;AG;OTHER;INCREASED_EXPOSURE
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE
HYDROCHLOROTHIAZIDE;NEDD4L;rs292449;CC + CG;EFFICACY;INCREASED_RESPONSE
PITRAKINRA;IL4R;rs8832;GG;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;T;DOSAGE;INCREASED_DOSE
PITRAKINRA;IL4R;rs3024530;AA;EFFICACY;INCREASED_RESPONSE
PITRAKINRA;IL4R;rs1110470;AA;EFFICACY;INCREASED_RESPONSE
PITRAKINRA;IL4R;rs2239347;AA;EFFICACY;INCREASED_RESPONSE
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE
BENAZEPRIL;MTR;rs1805087;AG + GG;EFFICACY;DECREASED_RESPONSE
PITRAKINRA;IL4R;rs1805010;AA;EFFICACY;INCREASED_RESPONSE
VORICONAZOLE;ABCC2;rs717620;CT + TT;LADME_PK;INCREASED_TROUGH CONCENTRATION
ACENOCOUMAROL, PHENPROCOUMON;VKORC1;rs9934438;GG;DOSAGE, TOXICITY;INCREASED_DOSE
MYCOPHENOLATE MOFETIL;SLCO1B3;rs7311358;A;LADME_PK;DECREASED_CLEARANCE
MORPHINE;ABCC3;rs4793665;CC;LADME_PK;INCREASED_METABOLISM
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs8105790;C;EFFICACY;INCREASED_RESPONSE
ATORVASTATIN;SLCO1B1;rs4149056;CT;LADME_PK;INCREASED_EXPOSURE
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs8103142;C;EFFICACY;INCREASED_RESPONSE
MEMANTINE;NR1I2;rs1523130;CT + TT;LADME_PK;DECREASED_CLEARANCE
BENAZEPRIL;ADRB2;rs1042713;AG + GG;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs11881222;G;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs7248668;A;EFFICACY;INCREASED_RESPONSE
AMISULPRIDE;ANKS1B;rs7968606;CC;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs28416813;C;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs4803219;C;EFFICACY;INCREASED_RESPONSE
MORPHINE;OPRM1;rs1799971;AG;DOSAGE;INCREASED_DOSE
ESCITALOPRAM;;rs2069521;A;LADME_PK;INCREASED_METABOLISM
IMATINIB;CYP3A5;rs776746;CC;LADME_PK;INCREASED_RESPONSE
ROSUVASTATIN;SCARB1;rs4238001;CC;EFFICACY;INCREASED_CLINICAL BENEFIT
IMATINIB;ABCB1;rs1045642;AA;LADME_PK;INCREASED_RESPONSE
IMATINIB;CYP3A5;rs776746;CC;LADME_PK;INCREASED_CONCENTRATIONS
LACOSAMIDE;ABCC2;rs2273697;GG;LADME_PK;INCREASED_CONCENTRATIONS
IMATINIB;ABCB1;rs1045642;AA;LADME_PK;INCREASED_CONCENTRATIONS
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE
OLANZAPINE;SV2C;rs11960832;TT;EFFICACY;DECREASED_RESPONSE
CORTICOSTEROIDS;TBX21;rs2240017;CG;EFFICACY;INCREASED_RESPONSE
METHOTREXATE;ABCC1;rs2238476;GG;EFFICACY;INCREASED_RESPONSE
ANTIDEPRESSANTS;HTR2A;rs6314;AG + GG;EFFICACY;INCREASED_RESPONSE
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN, PRIMIDONE, VALPROIC ACID;CYP2D6;rs1065852;A;EFFICACY;INCREASED_RESPONSE
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN, PRIMIDONE, VALPROIC ACID;CYP2C9;rs9332120;C;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;C;LADME_PK;DECREASED_METABOLISM
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN, PRIMIDONE, VALPROIC ACID;CYP2D6;rs3892097;C;EFFICACY;INCREASED_RESPONSE
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN, PRIMIDONE, VALPROIC ACID;CYP3A4;rs2740574;C;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_CLEARANCE
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN, PRIMIDONE, VALPROIC ACID;CYP3A4;rs2687116;C;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME_PK;INCREASED_DOSE
DULOXETINE;ANO2;rs61908411;C;EFFICACY;DECREASED_RESPONSE
DULOXETINE;ANO2;rs61908409;C;EFFICACY;DECREASED_RESPONSE
DULOXETINE;ANO2;rs61908410;T;EFFICACY;DECREASED_RESPONSE
DULOXETINE;ANO2;rs78615940;A;EFFICACY;DECREASED_RESPONSE
DULOXETINE;ANO2;rs78482393;G;EFFICACY;DECREASED_RESPONSE
DULOXETINE;ANO2;rs61908405;C;EFFICACY;DECREASED_RESPONSE
DULOXETINE;ANO2;rs61908406;G;EFFICACY;DECREASED_RESPONSE
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;ARG1;rs2781659;A;EFFICACY;INCREASED_RESPONSE
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED_RESPONSE
DULOXETINE;ANO2;rs61908404;C;EFFICACY;DECREASED_RESPONSE
DULOXETINE;ANO2;rs61908408;A;EFFICACY;DECREASED_RESPONSE
DULOXETINE;ANO2;rs61908407;A;EFFICACY;DECREASED_RESPONSE
DULOXETINE;ANO2;rs17786412;G;EFFICACY;DECREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE
DULOXETINE;ANO2;rs17786400;A;EFFICACY;DECREASED_RESPONSE
METHADONE;ABCB1;rs9282564;C;LADME_PK;DECREASED_CONCENTRATIONS
DULOXETINE;ANO2;rs61908403;G;EFFICACY;DECREASED_RESPONSE
DULOXETINE;ANO2;rs61908402;T;EFFICACY;DECREASED_RESPONSE
DULOXETINE;ANO2;rs17724452;C;EFFICACY;DECREASED_RESPONSE
GLATIRAMER ACETATE;PVT1;rs2114358;A;EFFICACY;INCREASED_RESPONSE
DULOXETINE;;rs7316769;G;EFFICACY;DECREASED_RESPONSE
DULOXETINE;ANO2;rs17724494;C;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP2C9;rs56165452;CT;DOSAGE;DECREASED_DOSE
METHADONE;ABCB1;rs1045642;A;LADME_PK;DECREASED_CONCENTRATIONS
DULOXETINE;ANO2;rs17786394;T;EFFICACY;DECREASED_RESPONSE
DULOXETINE;ANO2;rs17724464;G;EFFICACY;DECREASED_RESPONSE
METHADONE;UGT2B7;rs7439366;CT;LADME_PK;INCREASED_CONCENTRATIONS
TENOFOVIR;ABCC4;rs1751034;TT;LADME_PK;DECREASED_CLEARANCE
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_DOSE
PEMETREXED, PLATINUM COMPOUNDS;CCND1;rs9344;A;EFFICACY;INCREASED_CLINICAL BENEFIT
WARFARIN;VKORC1;rs2359612;A;DOSAGE;DECREASED_DOSE
METOPROLOL;ADRB1;rs1801253;CC;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs7294;T;DOSAGE;INCREASED_DOSE
LIRAGLUTIDE;GLP1R;rs10305420;CT + TT;EFFICACY;DECREASED_RESPONSE
LAMOTRIGINE;CACNA1H;rs2753325;A;EFFICACY;INCREASED_CLINICAL BENEFIT
AZATHIOPRINE;TPMT;TPMT low activity;;LADME_PK;DECREASED_DOSE
FLUOROURACIL;DPYD;rs3918290;CT;LADME_PK;DECREASED_METABOLISM
FLUOROURACIL;DPYD;rs2297595;CC + CT;LADME_PK;DECREASED_METABOLISM
ASPIRIN;GP1BA;rs6065;CT + TT;EFFICACY;INCREASED_RESPONSE
FLUOROURACIL;DPYD;rs1801160;CT + TT;LADME_PK;DECREASED_METABOLISM
FLUOROURACIL;DPYD;rs1801265;GG;LADME_PK;DECREASED_METABOLISM
LACOSAMIDE;ABCC2;rs717620;CC;LADME_PK;INCREASED_CONCENTRATIONS
ANASTROZOLE;;rs11648166;G;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE
LACOSAMIDE;ABCC2;rs2273697;A;EFFICACY;INCREASED_RESISTANCE
LACOSAMIDE;ABCC2;rs717620;T;EFFICACY;INCREASED_RESISTANCE
ANASTROZOLE;;rs28845026;T;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;CYP2C9;rs1057910;AC + CC;DOSAGE;DECREASED_DOSE
CYCLOPHOSPHAMIDE;CYP2B6;rs4802101;C;LADME_PK;DECREASED_METABOLISM
APIXABAN;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_CLEARANCE
METHOTREXATE;ARID5B;rs10994982;A;LADME_PK;DECREASED_CLEARANCE
OXYCODONE;OPRM1;rs1799971;AG + GG;EFFICACY;DECREASED_RESPONSE
CYCLOPHOSPHAMIDE;CYP2C19;rs4244285;A;LADME_PK;DECREASED_METABOLISM
IMATINIB;ABCB1;rs1045642;AG + GG;LADME_PK;INCREASED_TROUGH CONCENTRATION
FENOFIBRATE;PPARA;rs4253778;GG;EFFICACY;INCREASED_RESPONSE
METHOTREXATE;SLC22A11;rs11231809;AT + TT;EFFICACY;DECREASED_RESPONSE
METHOTREXATE;ABCC1;rs246240;AG + GG;EFFICACY;DECREASED_RESPONSE
HMG COA REDUCTASE INHIBITORS;HMGCR;rs3846662;AA;EFFICACY;DECREASED_RESPONSE
METHOTREXATE;ABCC1;rs3784864;AG + GG;EFFICACY;DECREASED_RESPONSE
CYCLOPHOSPHAMIDE;CYP2C19;rs4244285;AG + GG;EFFICACY;DECREASED_RESPONSE
4-HYDROXYCYCLOPHOSPHAMIDE;CYP3A5;rs776746;CC + CT;LADME_PK;DECREASED_CONCENTRATIONS
CYCLOPHOSPHAMIDE;CYP2B6;rs7254579;C;LADME_PK;METABOLISM
HMG COA REDUCTASE INHIBITORS;;rs445925;A;EFFICACY;INCREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;DECREASED_METABOLISM
EFAVIRENZ;CYP2B6;rs3745274;GT;LADME_PK;DECREASED_METABOLISM
HMG COA REDUCTASE INHIBITORS;LPA;rs10455872;G;EFFICACY;DECREASED_RESPONSE
FENOFIBRATE;IL6;rs1800795;CC + CG;EFFICACY;INCREASED_RESPONSE
RANIBIZUMAB;NRP1;rs2070296;T;EFFICACY;DECREASED_RESPONSE
ATORVASTATIN;CETP;rs708272;GG;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;MICB;rs3828913;CC;EFFICACY;INCREASED_RESPONSE
METHOTREXATE;ABCG2;rs13120400;CC;EFFICACY;INCREASED_RESPONSE
NICOTINE;DBH;rs77905;GG;DOSAGE;DECREASED_DOSE
WARFARIN;VKORC1;rs9923231;CC + CT;DOSAGE;INCREASED_DOSE
NICOTINE;MAOA;rs1137070;TT;DOSAGE;INCREASED_DOSE
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;DOSAGE;DECREASED_DOSE
OMEPRAZOLE, PANTOPRAZOLE;ABCB1;rs1045642;AA;EFFICACY;INCREASED_RESPONSE
DEFERASIROX;CYP24A1;rs2248359;TT;LADME_PK;METABOLISM
DEFERASIROX;VDR;rs7975232;AA;LADME_PK;METABOLISM
FLUVOXAMINE, MILNACIPRAN, PAROXETINE;HTR1A;rs1364043;TT;EFFICACY;INCREASED_RESPONSE
DEFERASIROX;VDR;rs2228570;G;LADME_PK;METABOLISM
ANTIPSYCHOTICS;GRM3;rs6465084;AA;TOXICITY;INCREASED_RESPONSE
METFORMIN;SLC47A1;rs2289669;AA;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP4F2;rs2108622;CC + CT;DOSAGE;DECREASED_DOSE
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;DECREASED_METABOLISM
METFORMIN;SLC47A1;rs2289669;AA;LADME_PK;DECREASED_CLEARANCE
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_DOSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
BETA BLOCKING AGENTS;GRK5;rs2230345;AA + AT;EFFICACY;RESPONSE
EFAVIRENZ;CYP2B6;rs3745274;T;LADME_PK;DECREASED_METABOLISM
EFAVIRENZ;NR1I3;rs2307424;G;LADME_PK;DECREASED_METABOLISM
EFAVIRENZ;NR1I3;rs2307424;AG;LADME_PK;DECREASED_METABOLISM
ANTIHYPERTENSIVES;ATP2B1;rs12817819;CT + TT;EFFICACY;INCREASED_RESISTANCE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE
WARFARIN;EPHX1;rs1051741;CT;DOSAGE;DECREASED_DOSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8103142;TT;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs12980275;AA;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs11881222;AA;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_DOSE
ISONIAZID;NAT2;rs1799930;AA;LADME_PK;INCREASED_EXPOSURE
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE
MERCAPTOPURINE;NUDT15;rs73189762;T;DOSAGE;DECREASED_DOSE
WARFARIN;PRSS53, VKORC1;rs7294;CT;DOSAGE;INCREASED_DOSE
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;DECREASED_METABOLISM
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
ISONIAZID;NR1I2;rs2472677;TT;LADME_PK;INCREASED_EXPOSURE
AMLODIPINE, FELODIPINE;CACNA1C;rs2238032;TT;EFFICACY;INCREASED_RESPONSE
ISONIAZID;SLCO1B1;rs4149032;CC;LADME_PK;DECREASED_EXPOSURE
CALCIUM CHANNEL BLOCKERS;CACNA1C;rs2239128;C;EFFICACY;INCREASED_RESPONSE
MORPHINE;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_DOSE
GEFITINIB;EGFR;rs121434568;G;EFFICACY;RESPONSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;RESPONSE
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs2900478;A;EFFICACY;DECREASED_RESPONSE
CALCIUM CHANNEL BLOCKERS;CACNA1C;rs2239050;GG;EFFICACY;INCREASED_RESPONSE
HMG COA REDUCTASE INHIBITORS;CELSR2;rs646776;C;EFFICACY;INCREASED_RESPONSE
VALPROIC ACID;UGT2B7;rs12233719;GG;LADME_PK;INCREASED_CONCENTRATIONS
EFAVIRENZ;CYP2A6;rs28399454;T;LADME_PK;METABOLISM
EFAVIRENZ;CYP2B6;rs3745274;T;LADME_PK;METABOLISM
EFAVIRENZ;CYP2B6;rs28399499;C;LADME_PK;METABOLISM
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;DECREASED_METABOLISM
CALCIUM CHANNEL BLOCKERS;CACNA1C;rs2238032;TT;EFFICACY;INCREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs3745274;GT;LADME_PK;DECREASED_METABOLISM
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE
PHENPROCOUMON, WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE
EFAVIRENZ;CYP2B6;rs2279343;GG;LADME_PK;DECREASED_METABOLISM
ATAZANAVIR;ABCB1;rs1045642;GG;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;rs7900194;A;DOSAGE;DECREASED_DOSE
EFAVIRENZ;CYP2B6;rs2279343;AG;LADME_PK;DECREASED_METABOLISM
VALPROIC ACID;UGT2B7;rs7668258;CT;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;rs28371686;G;DOSAGE;DECREASED_DOSE
WARFARIN;APOC1, APOE;rs429358;T;DOSAGE;DECREASED_DOSE
VALPROIC ACID;UGT2B7;rs7668258;TT;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;APOC1, APOE;rs7412;T;DOSAGE;DECREASED_DOSE
INFLIXIMAB;;rs2097432;CC + CT;EFFICACY;INCREASED_DISCONTINUATION
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE
PHOTODYNAMIC THERAPY;CFH;rs1061170;TT;EFFICACY;DECREASED_RESPONSE
VALPROIC ACID;UGT2B7;rs7439366;TT;LADME_PK;CONCENTRATIONS
RISPERIDONE;ABCG2;rs2231142;GT + TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
FLUOXETINE;HTR1B;rs9361233;CC + TT;EFFICACY;INCREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs8192709;CC;LADME_PK;DECREASED_METABOLISM
INFLIXIMAB;;rs73277969;T;EFFICACY;INCREASED_DISCONTINUATION
IVACAFTOR;CFTR;rs121908757;C;EFFICACY;RESPONSE
IVACAFTOR;CFTR;rs121909005;G;EFFICACY;RESPONSE
ASPIRIN, CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED_RESPONSE
ASPIRIN, CLOPIDOGREL;CYP2C19;rs12248560;T;;INCREASED_RESPONSE
IVACAFTOR;CFTR;rs121908755;A;EFFICACY;RESPONSE
ASPIRIN, PRASUGREL;PEAR1;rs2768759;AC + CC;EFFICACY;DECREASED_RESPONSE
CYCLOSPORINE;ABCB1;rs2032582;AC + CC;DOSAGE;INCREASED_DOSE
ASPIRIN, CLOPIDOGREL, PRASUGREL;PEAR1;rs12041331;AA + AG;EFFICACY;INCREASED_RESPONSE
CYCLOSPORINE;CYP3A4;rs4646437;AG + GG;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
HYDRALAZINE / ISOSORBIDE DINITRATE;GNB3;rs5443;TT;EFFICACY;INCREASED_RESPONSE
IVACAFTOR;CFTR;rs397508453;C;EFFICACY;RESPONSE
WARFARIN;VKORC1;rs72547529;T;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;INCREASED_CONCENTRATIONS
IVACAFTOR;CFTR;rs121909013;A;EFFICACY;RESPONSE
IVACAFTOR;CFTR;rs121909041;C;EFFICACY;RESPONSE
TACROLIMUS;CYP3A4;rs2242480;T;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
ASPIRIN, CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED_RESPONSE
IVACAFTOR;CFTR;rs74503330;A;EFFICACY;RESPONSE
NEVIRAPINE;CYP1A2;rs762551;CC;EFFICACY;INCREASED_RESPONSE
FENTANYL;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_RESPONSE
ANASTROZOLE, LETROZOLE, TAMOXIFEN;CYP19A1;rs4646;AA;EFFICACY;DECREASED_RESPONSE
IVACAFTOR;CFTR;rs267606723;A;EFFICACY;RESPONSE
SEROTONIN;ERICH3;rs696692;T;OTHER;DECREASED_CONCENTRATIONS
IVACAFTOR;CFTR;rs80282562;A;EFFICACY;RESPONSE
TACROLIMUS;ABCB1;rs1045642;AG + GG;DOSAGE;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
CYCLOSPORINE;CYP3A4;rs4646437;AG + GG;EFFICACY;INCREASED_RESPONSE
ANASTROZOLE, LETROZOLE, TAMOXIFEN;CYP19A1;rs4646;AA;EFFICACY;INCREASED_RESPONSE
PLATINUM COMPOUNDS;ERCC2;rs1799793;CT + TT;EFFICACY;INCREASED_RESISTANCE
SEROTONIN;TSPAN5;rs11947402;G;OTHER;DECREASED_CONCENTRATIONS
NEVIRAPINE;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_DOSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TRAF1;rs3761847;G;EFFICACY;DECREASED_RESPONSE
THALIDOMIDE;CTNNB1;rs4533622;AA;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9934438;AG;DOSAGE;INCREASED_DOSE
FENTANYL;OPRM1;rs1799971;AG + GG;DOSAGE;DECREASED_DOSE
IVACAFTOR;CFTR;rs193922525;A;EFFICACY;RESPONSE
CYCLOPHOSPHAMIDE, DEXAMETHASONE, THALIDOMIDE;CTNNB1;rs4135385;AA;EFFICACY;INCREASED_RESPONSE
OPIOIDS;IL17A;rs2275913;A;DOSAGE, EFFICACY;INCREASED_DOSE
PLATINUM COMPOUNDS;CYP1A1;rs1048943;CC + CT;EFFICACY;INCREASED_RESISTANCE
WARFARIN;CYP4F2;rs2108622;C;DOSAGE;DECREASED_DOSE
TACROLIMUS;ABCB1;rs2032582;AC + CC;DOSAGE;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE
ANTIDEPRESSANTS, CITALOPRAM, ESCITALOPRAM;ERICH3;rs11580409;C;EFFICACY;INCREASED_RESPONSE
ETHANOL;OPRM1;rs1799971;AG + GG;OTHER;DECREASED_DOSE
CYCLOSPORINE;ABCB1;rs2032582;AC + CC;DOSAGE;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TACROLIMUS;CYP3A7;rs10211;TT;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;VKORC1;rs9923231;C;DOSAGE, EFFICACY;INCREASED_DOSE
WARFARIN;VKORC1;rs9923231;T;DOSAGE, EFFICACY;INCREASED_RESPONSE
TACROLIMUS;ABCB1;rs1045642;GG;LADME_PK;INCREASED_DOSE
ACETAMINOPHEN, TRAMADOL;OPRM1;rs1799971;AA;EFFICACY;INCREASED_RESPONSE
RITUXIMAB;FCGR2A;rs1801274;AA;EFFICACY;INCREASED_RESPONSE
METHADONE;CYP2B6;rs3745274;T;LADME_PK;DECREASED_CLEARANCE
COTININE;UGT2B10;rs2942857;CC;LADME_PK;DECREASED_CLEARANCE
FENTANYL;;rs6961071;GG;EFFICACY;INCREASED_RESPONSE
RITUXIMAB;FCGR3A;rs396991;AC + CC;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs2359612;G;DOSAGE;INCREASED_DOSE
CYCLOPHOSPHAMIDE, DOXORUBICIN, FEC100, FLUOROURACIL;ALDH1A1;rs13959;AG + GG;EFFICACY;INCREASED_CLINICAL BENEFIT
TACROLIMUS;POR;rs1057868;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
COUMARIN;CYP2A6;rs1801272;TT;OTHER, LADME_PK;DECREASED_METABOLISM
COUMARIN;CYP2A6;rs1801272;TT;LADME_PK;DECREASED_METABOLISM
METHADONE;ABCB1;rs2032582;CC;LADME_PK;DECREASED_CLEARANCE
NICOTINE;CYP2A6;rs5031016;G;LADME_PK;DECREASED_METABOLISM
TOCILIZUMAB;FCGR3A;rs396991;AA;EFFICACY;INCREASED_RESPONSE
CARVEDILOL;ADRB2;rs1042714;GG;EFFICACY;INCREASED_RESPONSE
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE
FENTANYL;;rs13093031;GG;EFFICACY;INCREASED_RESPONSE
ATORVASTATIN, LOVASTATIN, SIMVASTATIN;CYP3A5;rs776746;CC;EFFICACY;INCREASED_RESPONSE
COTININE;UGT2B10;rs2942857;CC;LADME_PK;INCREASED_EXPOSURE
CLOPIDOGREL;ABCB1;rs1045642;A;EFFICACY;INCREASED_RESPONSE
CISPLATIN;ERCC1;rs11615;A;EFFICACY;DECREASED_RESPONSE
WARFARIN;VKORC1;rs2884737;C;DOSAGE;DECREASED_DOSE
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE
WARFARIN;PRSS53, VKORC1;rs7294;TT;DOSAGE;INCREASED_DOSE
WARFARIN;VKORC1;rs8050894;G;DOSAGE;DECREASED_DOSE
PHENOBARBITAL;ABCB1;rs1045642;GG;EFFICACY;INCREASED_RESISTANCE
TACROLIMUS;FMO3;rs1800822;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE
FENOFIBRATE;CRP;rs1417938;TT;EFFICACY;INCREASED_RESPONSE
PRAVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE
IVACAFTOR;CFTR;rs397508442;T;EFFICACY;RESPONSE
FLUOXETINE;HTR1B;rs9361235;CC + TT;EFFICACY;INCREASED_RESPONSE
N-DESMETHYLCLOZAPINE;UGT2B10;rs61750900;T;LADME_PK;DECREASED_CONCENTRATIONS
WARFARIN;NQO1;rs10517;GG;DOSAGE;DECREASED_DOSE
FENOFIBRATE;CRP;rs3091244;AG + GG;EFFICACY;INCREASED_RESPONSE
PRAVASTATIN;MMP3;rs35068180;A/del + AA;EFFICACY;INCREASED_RESPONSE
N-DESMETHYLCLOZAPINE;UGT1A4;rs2011425;G;LADME_PK;DECREASED_CONCENTRATIONS
FENOFIBRATE;CRP;rs3091244;GG + GT;EFFICACY;INCREASED_RESPONSE
FENTANYL;ABCB1;rs1128503;AA;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE
CLOZAPINE;CYP2C18;rs1126545;T;LADME_PK;DECREASED_METABOLISM
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_DOSE
SIMVASTATIN;SLCO1B1;rs4149056;C;EFFICACY;DECREASED_RESPONSE
DESLORATADINE, MIZOLASTINE;FCER1A;rs2298805;AA;EFFICACY;INCREASED_RESPONSE
ATORVASTATIN;CYP3A5;rs17161788;TT;EFFICACY;DECREASED_RESPONSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;G;EFFICACY;DECREASED_RESPONSE
CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;SELE;rs3917412;CC;EFFICACY;DECREASED_RESPONSE
ATORVASTATIN;CYP3A5;rs776746;CC;EFFICACY;DECREASED_RESPONSE
OPIOIDS;;rs2952768;CC;EFFICACY;DECREASED_RESPONSE
HMG COA REDUCTASE INHIBITORS;PCSK9;rs11591147;T;EFFICACY;INCREASED_RESPONSE
IMATINIB;CYP3A4;rs28371759;AG;EFFICACY;INCREASED_RESPONSE
DIGOXIN;ABCB1;rs2032582;CC;LADME_PK;INCREASED_CLEARANCE
CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MTHFR;rs1801133;AA;EFFICACY;DECREASED_RESPONSE
PLATINUM;ERCC5;rs17655;GG;EFFICACY;INCREASED_RESPONSE
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR, IVACAFTOR / TEZACAFTOR;CFTR;rs75389940;AG + GG;EFFICACY;INCREASED_CLINICAL BENEFIT
CARVEDILOL;UGT2B7;rs12233719;T;LADME_PK;DECREASED_CLEARANCE
BUPROPION, NICOTINE, VARENICLINE;CHRNA5;rs2036527;AA + AG;EFFICACY;INCREASED_RESPONSE
BUPROPION, NICOTINE, VARENICLINE;CHRNA5;rs16969968;AA + AG;EFFICACY;INCREASED_RESPONSE
CARVEDILOL;UGT2B7;rs28365063;G;LADME_PK;DECREASED_CLEARANCE
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TACROLIMUS;FMO3;rs909530;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
DIGOXIN;ABCB1;rs2032582;AA + AT;LADME_PK;DECREASED_CLEARANCE
LUMACAFTOR;CFTR;rs121909047;AA;EFFICACY;RESPONSE
METHADONE;CDH2;rs8094439;AA;EFFICACY;INCREASED_RESPONSE
PERTUSSIS VACCINES;TLR4;rs4986790;AA;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;POR;rs1057868;CT + TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE
METHADONE;CDH2;rs17446819;CC;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE
SORAFENIB;ABCG2;rs2231137;CT;LADME_PK;CONCENTRATIONS
NICOTINE;CYP2A6;rs376817657;CT + TT;LADME_PK;DECREASED_METABOLISM
SORAFENIB;ABCG2;rs2231142;GT;LADME_PK;CONCENTRATIONS
IVACAFTOR;CFTR;rs397508602;A;EFFICACY;RESPONSE
IMATINIB;SLC22A1;rs683369;CC;EFFICACY;DECREASED_RESPONSE
FENOFIBRATE;GCKR;rs780094;CT + TT;EFFICACY;INCREASED_RESPONSE
IVACAFTOR / LUMACAFTOR;CFTR;rs121909011;T;EFFICACY;RESPONSE
IMATINIB;ABCB1;rs1045642;GG;EFFICACY;DECREASED_RESPONSE
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE
FENTANYL;OPRM1;rs1799971;GG;DOSAGE, EFFICACY;INCREASED_DOSE
IVACAFTOR / LUMACAFTOR;CFTR;rs74551128;A;EFFICACY;RESPONSE
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_DOSE
BILIRUBIN;UGT1A1;rs887829;TT;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;CYP2C9;rs1799853;CT;DOSAGE;DECREASED_DOSE
METHOTREXATE;GGH;rs3758149;AA + AG;EFFICACY;INCREASED_RESPONSE
MERCAPTOPURINE;NUDT15;rs186364861;A;DOSAGE;DECREASED_DOSE
FENOFIBRATE;APOA5;rs662799;AG + GG;EFFICACY;INCREASED_RESPONSE
IMIQUIMOD;TLR7;rs179008;A;EFFICACY;INCREASED_RESPONSE
MERCAPTOPURINE;NUDT15;rs116855232;T;DOSAGE;DECREASED_DOSE
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE
METHOTREXATE;GGH;rs11545077;CC + CT;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;T;DOSAGE, OTHER;DECREASED_DOSE
FENOFIBRATE;APOA5;rs3135506;CG + GG;EFFICACY;INCREASED_RESPONSE
CLONIDINE;GNB3;rs5443;CT + TT;EFFICACY;INCREASED_RESPONSE
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE
CLOZAPINE;UGT2B10;rs61750900;T;LADME_PK;DECREASED_METABOLISM
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE
OPIOIDS;TAOK3;rs1277441;AG + GG;DOSAGE;INCREASED_DOSE
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE
OPIOIDS;TAOK3;rs795484;TT;DOSAGE;DECREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_CONCENTRATIONS
FENTANYL;OPRM1;rs1799971;GG;DOSAGE;INCREASED_DOSE
WARFARIN;CYP2C9;rs1799853;T;LADME_PK;DECREASED_METABOLISM
IVACAFTOR;CFTR;rs121909005;G;EFFICACY;RESPONSE
OPIOIDS;TAOK3;rs795484;CT + TT;DOSAGE;INCREASED_DOSE
FENTANYL;ABCB1;rs1128503;AA;DOSAGE;INCREASED_DOSE
IVACAFTOR;CFTR;rs121908757;C;EFFICACY;RESPONSE
TENOFOVIR;ABCC4;rs3742106;AC + CC;LADME_PK;INCREASED_CONCENTRATIONS
VITAMIN B12 AND FOLIC ACID;MTHFR;rs1801133;A;EFFICACY;DECREASED_CLINICAL BENEFIT
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY, LADME_PK;INCREASED_EXPOSURE
CAPTOPRIL;AGTR1;rs5186;AC + CC;EFFICACY;INCREASED_RESPONSE
ANTHRACYCLINES AND RELATED SUBSTANCES;GSTP1;rs1695;A;EFFICACY;INCREASED_RESPONSE
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE
DAUNORUBICIN;CBR1;rs25678;CC;LADME_PK;DECREASED_EXPOSURE
IVACAFTOR;CFTR;rs78655421;A;EFFICACY;RESPONSE
MERCAPTOPURINE;TPMT;rs1142345;CC;DOSAGE;DECREASED_DOSE
CITALOPRAM;CYP2C19;rs4244285;AG;EFFICACY;DECREASED_RESPONSE
BILIRUBIN;SLCO1B1, SLCO1B3, SLCO1B7;rs1910167;C;LADME_PK;INCREASED_CONCENTRATIONS
CITALOPRAM;CYP2C19;rs4244285;AG;LADME_PK;INCREASED_CONCENTRATIONS
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE
ATENOLOL;GNB3;rs5443;CC;EFFICACY;INCREASED_RESPONSE
ETANERCEPT;PSORS1C1;rs2233945;C;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;POR;rs1057868;CT + TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
MERCAPTOPURINE;ABCC4;rs2274407;AA;DOSAGE;DECREASED_DOSE
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_CONCENTRATIONS
DISULFIRAM;TPH2;rs4290270;AA + AT;EFFICACY;INCREASED_RESPONSE
ATENOLOL;GNB3;rs11064426;AA;EFFICACY;INCREASED_RESPONSE
ENALAPRIL;NR3C2;rs5522;TT;EFFICACY;INCREASED_RESPONSE
ATENOLOL;GNB3;rs2301339;GG;EFFICACY;INCREASED_RESPONSE
ATENOLOL;GNB3;rs5443;CC;EFFICACY;INCREASED_RESPONSE
MERCAPTOPURINE;NUDT15;rs116855232;TT;DOSAGE;DECREASED_DOSE
ATENOLOL;GNB3;rs11064426;AA;EFFICACY;INCREASED_RESPONSE
ACENOCOUMAROL;CYP2C9;rs4086116;T;DOSAGE;DECREASED_DOSE
ATENOLOL;GNB3;rs11064426;AA;EFFICACY;INCREASED_RESPONSE
ETANERCEPT;STAT4;rs7574865;T;EFFICACY;DECREASED_RESPONSE
ATENOLOL;GNB3;rs2301339;GG;EFFICACY;INCREASED_RESPONSE
METHOTREXATE;GGH;rs11545076;AC + CC;EFFICACY;INCREASED_RESPONSE
ALLOPURINOL;ABCG2;rs2231142;T;EFFICACY;DECREASED_RESPONSE
PRAVASTATIN;SLCO1B1;rs4149015;AG;EFFICACY, LADME_PK;DECREASED_RESPONSE
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE
IVACAFTOR, TEZACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE
ATORVASTATIN, HMG COA REDUCTASE INHIBITORS, PRAVASTATIN, SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE
FENOFIBRATE;ABCA1;rs2230806;CT;EFFICACY;INCREASED_RESPONSE
SERTRALINE;HTR2A;rs6313;AA + AG;DOSAGE;INCREASED_DOSE
FENOFIBRATE;ABCA1;rs2230808;CC;EFFICACY;INCREASED_RESPONSE
PLATINUM COMPOUNDS;NUP107;rs79419059;C;EFFICACY;INCREASED_RESISTANCE
FENOFIBRATE;ABCA1;rs2230806;TT;EFFICACY;INCREASED_RESPONSE
VENLAFAXINE;COMT;rs4680;AA + AG;EFFICACY;INCREASED_RESPONSE
WARFARIN;NQO1;rs1800566;AA;DOSAGE;DECREASED_DOSE
KETOPROFEN;CYP2C9;rs1799853;CC;EFFICACY;INCREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_TROUGH CONCENTRATION
ETANERCEPT;TNF;rs1800629;AG + GG;EFFICACY;INCREASED_RESPONSE
ANTIDEPRESSANTS;CHL1;rs1516338;TT;EFFICACY;INCREASED_RESPONSE
ADALIMUMAB;TANK;rs1267067;CC;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;rs15524;AA;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
ADALIMUMAB;VEGFA;rs25648;T;EFFICACY;INCREASED_RESPONSE
DACLATASVIR, PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
CARVEDILOL;ADRB1;rs1801253;GG;DOSAGE;INCREASED_DOSE
TACROLIMUS;CYP3A5;rs4646450;GG;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
INFLIXIMAB;TNF;rs361525;GG;EFFICACY;INCREASED_RESPONSE
METHOTREXATE;SLCO1B1;rs11045879;CC + CT;LADME_PK;INCREASED_EXPOSURE
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A4;rs4646437;GG;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
HYDROCHLOROTHIAZIDE;VASP;rs10995;AG + GG;EFFICACY;INCREASED_RESPONSE
ADALIMUMAB;TNFAIP3;rs2230926;T;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
METHOTREXATE;SLC19A1;rs2838958;AA + AG;LADME_PK;INCREASED_CONCENTRATIONS
SIMVASTATIN, SIMVASTATIN ACID;SLCO1B1;rs4149056;C;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_DOSE
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE
IVACAFTOR;CFTR;rs121908757;C;EFFICACY;RESPONSE
METHOTREXATE;SLC19A1;rs3788200;AG + GG;LADME_PK;INCREASED_CONCENTRATIONS
LITHIUM;NR1D1, THRA;rs2314339;T;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP4F2;rs2108622;TT;DOSAGE;INCREASED_DOSE
NALTREXONE;OPRM1;rs1799971;AG;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE
ATENOLOL;GNB3;rs2301339;GG;EFFICACY;INCREASED_RESPONSE
BEVACIZUMAB, CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, OXALIPLATIN, TRASTUZUMAB;ERCC2;rs13181;GG;EFFICACY;INCREASED_RESPONSE
ACENOCOUMAROL;APOE;rs429358;C;DOSAGE;DECREASED_DOSE
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE
WARFARIN;VKORC1;rs8050894;CG + GG;DOSAGE;DECREASED_DOSE
WARFARIN;CYP4F2;rs2108622;CC;DOSAGE;DECREASED_DOSE
WARFARIN;VKORC1;rs2359612;AA + AG;DOSAGE;DECREASED_DOSE
ATAZANAVIR;SORCS2;rs73208473;A;LADME_PK;DECREASED_EXPOSURE
ROSUVASTATIN;ABCG2;rs2231142;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS
BEVACIZUMAB, CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, OXALIPLATIN, TRASTUZUMAB;ERCC1;rs11615;GG;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE
BEVACIZUMAB, CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, OXALIPLATIN, TRASTUZUMAB;MTHFR;rs1801133;AA;EFFICACY;DECREASED_RESPONSE
METHADONE;CNR1;rs806368;CT + TT;DOSAGE;INCREASED_DOSE
METHADONE;TPH2;rs1386493;GG;DOSAGE;INCREASED_DOSE
MORPHINE;UGT2B7;rs7439366;CT + TT;LADME_PK;DECREASED_CONCENTRATIONS
ATORVASTATIN, SIMVASTATIN;KIF6;rs20455;GG;EFFICACY;DECREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs35303484;GG;LADME_PK;INCREASED_CONCENTRATIONS
METHADONE;CYP2B6;rs16974799;CT;DOSAGE;INCREASED_DOSE
LAMIVUDINE, NEVIRAPINE;ABCB1;rs1045642;A;EFFICACY;RESPONSE
METHADONE;OPRL1;rs2229205;CT;DOSAGE;INCREASED_DOSE
ROSUVASTATIN;KIF6;rs20455;GG;EFFICACY;DECREASED_RESPONSE
ADRENERGICS, INHALANTS;;rs34548976;T;EFFICACY;DECREASED_RESPONSE
TOPIRAMATE;GRIK1;rs2832407;AA + AC;LADME_PK;INCREASED_CONCENTRATIONS
CISPLATIN, GEMCITABINE;CDA;rs2072671;AA;EFFICACY;INCREASED_RESPONSE
TOPIRAMATE;GRIK1;rs2832407;AA + AC;EFFICACY;DECREASED_RESPONSE
LAMIVUDINE, NEVIRAPINE, ZIDOVUDINE;ABCB1;rs2032582;A;EFFICACY;RESPONSE
ATORVASTATIN;KIF6;rs20455;GG;EFFICACY;DECREASED_RESPONSE
CISPLATIN, GEMCITABINE;ERCC1;rs11615;AA;EFFICACY;INCREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_CONCENTRATIONS
FLUVASTATIN;ABCB1;rs1922242;AA;EFFICACY;INCREASED_RESPONSE
GLICLAZIDE;KCNQ1;rs2237897;CT + TT;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP4F11;rs1060467;G;DOSAGE;DECREASED_DOSE
CARBOPLATIN, TAXANES;VEGFA;rs9369421;CC + CT;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A4;rs35599367;AA + AG;LADME_PK;DECREASED_CLEARANCE
EFAVIRENZ;CYP2A6;rs28399433;AC;LADME_PK;INCREASED_CONCENTRATIONS
FLUVASTATIN;CETP;rs4783961;GG;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_CLEARANCE
TACROLIMUS;ABCB1;rs9282564;CC + CT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
METHOTREXATE;MTRR;rs1801394;AG + GG;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE
TENOFOVIR;IFNL3, IFNL4;rs12979860;C;LADME_PK;INCREASED_CLEARANCE
GLUCOCORTICOIDS;ABCB1;rs1128503;GG;EFFICACY;DECREASED_RESPONSE
METFORMIN;SLC22A1;rs622342;A;EFFICACY;INCREASED_RESPONSE
GLUCOCORTICOIDS;ABCB1;rs1045642;GG;EFFICACY;DECREASED_RESPONSE
HYDROXYUREA;BCL11A;rs1427407;T;EFFICACY;INCREASED_RESPONSE
HYDROXYUREA;BCL11A;rs766432;C;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C9;rs2860905;A;DOSAGE;DECREASED_DOSE
FENTANYL;UGT2B7;rs7439366;TT;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP2C9;rs1057910;AC + CC;DOSAGE, EFFICACY;DECREASED_DOSE
TIOTROPIUM;ADRB2;rs1042713;AA;EFFICACY;INCREASED_RESPONSE
LUMEFANTRINE;ABCC2;rs8187710;AA;LADME_PK;INCREASED_CONCENTRATIONS
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs80034486;G;EFFICACY;INCREASED_CLINICAL BENEFIT
ATORVASTATIN;APOE;rs7412;CT;EFFICACY;INCREASED_RESPONSE
METHADONE;ABCB1;rs1045642;AG;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_DOSE
CLOPIDOGREL;ABCB1;rs1045642;GG;EFFICACY;INCREASED_RESISTANCE
MORPHINE;UGT2B7;rs7439366;CT + TT;EFFICACY;DECREASED_RESPONSE
VALPROIC ACID;UGT1A6;rs2070959;AG + GG;LADME_PK;DECREASED_CONCENTRATIONS
VALPROIC ACID;UGT1A6;rs1105879;AC + CC;LADME_PK;DECREASED_CONCENTRATIONS
CLOZAPINE;HTR2A;rs6314;AA + AG;EFFICACY;INCREASED_CLINICAL BENEFIT
FLUVASTATIN;SLCO1B1;rs4149056;TT;EFFICACY;INCREASED_RESPONSE
PRAVASTATIN;ACE;rs4341;CG + GG;EFFICACY;INCREASED_RESPONSE
PRAVASTATIN;LPL;rs328;GG;EFFICACY;INCREASED_RESPONSE
LOVASTATIN;CETP;rs708272;AG;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE
FENTANYL;UGT2B7;rs10028494;CC;EFFICACY;DECREASED_RESPONSE
METHOTREXATE;MTHFR;rs1801133;AA;LADME_PK;INCREASED_CONCENTRATIONS
NICOTINE;CHRNA3;rs1051730;A;LADME_PK;INCREASED_DOSE
FLUVASTATIN;LIPC;rs1800588;CC + CT;EFFICACY;INCREASED_RESPONSE
CLOZAPINE;CYP1A1;rs2472297;T;LADME_PK;DECREASED_CONCENTRATIONS
METHYLPHENIDATE;CES1;rs114119971;CG;DOSAGE;DECREASED_DOSE
SIMVASTATIN;LIPC;rs1800588;CT;EFFICACY;INCREASED_RESPONSE
CISPLATIN, FLUOROURACIL, OXALIPLATIN;VEGFA;rs25648;CT + TT;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE
ATORVASTATIN;ABCB1;rs2032582;CC;EFFICACY;INCREASED_RESPONSE
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE
ATORVASTATIN;SLCO1B1;rs4149036;AC + CC;EFFICACY;INCREASED_RESPONSE
ATORVASTATIN;CYP3A5;rs776746;CC + CT;EFFICACY;INCREASED_RESPONSE
PERTUSSIS VACCINES;TLR4;rs2770150;GG;EFFICACY;DECREASED_RESPONSE
CISPLATIN, FLUOROURACIL, MITOXANTRONE;;rs6025211;CC + TT;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;ABCB1;rs2032582;AA + TT;EFFICACY;INCREASED_RESPONSE
LOVASTATIN;SLCO1B1;rs2291073;GT + TT;EFFICACY;INCREASED_RESPONSE
SUFENTANIL;CYP3A4;rs2242480;CT + TT;DOSAGE;DECREASED_DOSE
TACROLIMUS;ABCB1;rs1128503;AA;EFFICACY;INCREASED_RESPONSE
CATECHOLAMINES, METFORMIN;SLC22A3;rs8187725;T;OTHER, LADME_PK;DECREASED_METABOLISM
LOVASTATIN;LDLR;rs688;TT;EFFICACY;INCREASED_RESPONSE
AMLODIPINE;CACNA1C;rs2239050;GG;EFFICACY;INCREASED_CLINICAL BENEFIT
FLUVASTATIN;CYP3A4;rs4986910;AG;EFFICACY;INCREASED_RESPONSE
NALTREXONE;ADH1C;rs698;C;EFFICACY;INCREASED_RESPONSE
NALTREXONE;ADH1B;rs2066702;A;EFFICACY;DECREASED_RESPONSE
LOVASTATIN;LDLR;rs5925;CC;EFFICACY;INCREASED_RESPONSE
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;rs9679162;TT;EFFICACY;INCREASED_RESPONSE
FLUOXETINE;HTR2A;rs6313;GG;EFFICACY;DECREASED_TIME TO RESPONSE
NALTREXONE;ALDH2;rs671;G;EFFICACY;INCREASED_RESPONSE
VARENICLINE;CYP2B6;rs8109525;AG + GG;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;ABCB1;rs1128503;AG;DOSAGE;INCREASED_DOSE
WARFARIN;CYP2C9;rs7089580;T;DOSAGE;INCREASED_DOSE
CLOPIDOGREL;P2RY12;rs2046934;AA;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;ABCB1;rs1045642;AA;DOSAGE;INCREASED_DOSE
WARFARIN;CYP2C19;rs3814637;C;DOSAGE;DOSE
TACROLIMUS;ABCB1;rs2032582;AA;DOSAGE;INCREASED_DOSE
WARFARIN;CYP2C9;rs4917639;A;DOSAGE;DOSE
WARFARIN;VKORC1;rs2359612;A;DOSAGE;DOSE
TACROLIMUS;CYP3A7;rs2257401;CG + GG;LADME_PK;DECREASED_CONCENTRATIONS
CLOPIDOGREL;P2RY12;rs3732759;GG;EFFICACY;DECREASED_RESPONSE
ANTIBIOTICS, ESOMEPRAZOLE;ABCB1;rs1045642;AA;EFFICACY;DECREASED_CLINICAL BENEFIT
CARFILZOMIB, DEXAMETHASONE, LENALIDOMIDE;VEGFA;rs833061;CT + TT;EFFICACY;INCREASED_RESPONSE
DOLUTEGRAVIR;ABCG2;rs2231142;TT;LADME_PK;INCREASED_CONCENTRATIONS
CLOPIDOGREL;ABCB1;rs1128503;AA + AG;EFFICACY;INCREASED_RESISTANCE
CISPLATIN, FLUOROURACIL;GALNT14;rs9679162;GG;EFFICACY;INCREASED_RESPONSE
CARFILZOMIB, DEXAMETHASONE, LENALIDOMIDE;KDR;rs2305948;CT + TT;EFFICACY;INCREASED_RESPONSE
CARFILZOMIB, DEXAMETHASONE, LENALIDOMIDE;KDR;rs1870377;AT + TT;EFFICACY;INCREASED_RESPONSE
MORPHINE;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE
SORAFENIB;GALNT14;rs9679162;GG;EFFICACY;INCREASED_RESPONSE
MYCOPHENOLIC ACID;ABCC2;rs2273697;A;LADME_PK;DECREASED_EXPOSURE
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE
MYCOPHENOLIC ACID;ABCC2;rs717620;T;LADME_PK;EXPOSURE
FENTANYL;ATF2;rs7583431;A;EFFICACY;INCREASED_RESPONSE
MYCOPHENOLIC ACID;ABCC2;rs717620;T;LADME_PK;EXPOSURE
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE
TACROLIMUS;NR1I2;rs3814055;CT + TT;DOSAGE;DECREASED_DOSE
AFLIBERCEPT, RANIBIZUMAB;ANO2;rs2110166;TT;EFFICACY;INCREASED_CLINICAL BENEFIT
TACROLIMUS;NR1I2;rs3814055;CT + TT;LADME_PK;INCREASED_CONCENTRATIONS
VENLAFAXINE;SLC6A2;rs2242446;CC;EFFICACY;INCREASED_RESPONSE
MYCOPHENOLIC ACID;ABCC2;rs2273697;A;LADME_PK;DECREASED_EXPOSURE
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE
BOCEPREVIR, PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;rs12979860;C;EFFICACY;INCREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1799724;TT;EFFICACY;INCREASED_RESPONSE
DONEPEZIL, GALANTAMINE, RIVASTIGMINE;CHRNA7;rs6494223;T;EFFICACY;INCREASED_RESPONSE
ADALIMUMAB;FCGR2A;rs1801274;A;EFFICACY;INCREASED_RESPONSE
FLUOROURACIL;ENOSF1;rs2612091;CC;EFFICACY;INCREASED_RESPONSE
ALLOPURINOL;SLC22A12;rs505802;T;DOSAGE;INCREASED_DOSE
ALLOPURINOL;PDZK1;rs12129861;C;DOSAGE;INCREASED_DOSE
DACLATASVIR, SOFOSBUVIR;HINT1;rs7728773;CT + TT;EFFICACY;INCREASED_CLINICAL BENEFIT
MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;DOSAGE;DECREASED_DOSE
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;IL6;rs1800795;G;EFFICACY;INCREASED_RESPONSE
LITHIUM;;rs78015114;T;EFFICACY;INCREASED_RESPONSE
BUPRENORPHINE;OPRD1;rs678849;CC;EFFICACY;DECREASED_RESPONSE
CARBAMAZEPINE, PHENOBARBITAL, PHENYTOIN, VALPROIC ACID;SCN2A;rs17183814;A;EFFICACY;RESISTANCE
LITHIUM;;rs79663003;T;EFFICACY;INCREASED_RESPONSE
APREMILAST;CYP3A4, TMEM130;rs1203844;C;EFFICACY;INCREASED_CLINICAL BENEFIT
APREMILAST;CYP3A4;rs35599367;A;EFFICACY;INCREASED_CLINICAL BENEFIT
ATORVASTATIN;MYLIP;rs9370867;AA;EFFICACY;INCREASED_RESPONSE
LITHIUM;;rs75222709;T;EFFICACY;INCREASED_RESPONSE
LITHIUM;;rs74795342;G;EFFICACY;INCREASED_RESPONSE
APREMILAST;PDE4D;rs295943;T;EFFICACY;DECREASED_CLINICAL BENEFIT
METHYLPHENIDATE;ADRA2A;rs1800544;CG + GG;EFFICACY;INCREASED_RESPONSE
SIMVASTATIN;SCAP;rs12487736;TT;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE
CAFFEINE;CYP1A2;rs2069514;AA + AG;OTHER, LADME_PK;DECREASED_METABOLISM
APREMILAST;CDKN2B, CDKN2B-AS1;rs1063192;G;EFFICACY;INCREASED_CLINICAL BENEFIT
PRAVASTATIN;LIPC;rs1800588;CT + TT;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_DOSE
EFAVIRENZ;CYP2B6;rs28399499;CT;LADME_PK;INCREASED_CONCENTRATIONS
(R)-METHADONE;NR1I3;rs2307424;GG;LADME_PK;INCREASED_CLEARANCE
OLANZAPINE;HTR2A;rs6314;GG;EFFICACY;INCREASED_RESPONSE
(S)-METHADONE;CYP2B6;rs2279343;G;LADME_PK;DECREASED_CLEARANCE
SIMVASTATIN;ABCB1;rs1128503;GG;EFFICACY;DECREASED_RESPONSE
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;CT;TOXICITY;INCREASED_DISCONTINUATION
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE
(R)-METHADONE;NR1I3;rs3003596;GG;LADME_PK;INCREASED_CLEARANCE
BEVACIZUMAB;CFH;rs1061170;CT;DOSAGE;INCREASED_DOSE
METHADONE;OPRD1;rs678849;CC;EFFICACY;INCREASED_RESPONSE
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;CT;DOSAGE;DECREASED_DOSE
BEVACIZUMAB;ARMS2;rs10490924;GT + TT;EFFICACY;INCREASED_RESPONSE
SIMVASTATIN;ABCB1;rs2032582;CC;EFFICACY;DECREASED_RESPONSE
WARFARIN;NQO1;rs1800566;AA + AG;DOSAGE;INCREASED_DOSE
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS
DEFERASIROX;ABCC2;rs2273697;AG;LADME_PK;INCREASED_CONCENTRATIONS
BUDESONIDE;;rs2392165;AG + GG;EFFICACY;INCREASED_RESPONSE
THIORIDAZINE;CYP2D6;rs1080985;CC + CG;LADME_PK;DECREASED_METABOLISM
DEFERASIROX;CYP1A2;rs2470890;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS
MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;DOSAGE;DECREASED_DOSE
DEFERASIROX;CYP1A2;rs762551;AC + CC;LADME_PK;INCREASED_CONCENTRATIONS
OLANZAPINE;DRD2;rs1076560;AA + AC;EFFICACY;INCREASED_RESPONSE
DEFERASIROX;CYP1A1;rs2606345;AC + CC;LADME_PK;INCREASED_CONCENTRATIONS
DEFERASIROX;UGT1A1;rs887829;TT;LADME_PK;INCREASED_CONCENTRATIONS
CARBAMAZEPINE;ABCB1;rs1128503;A;LADME_PK;INCREASED_CLEARANCE
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;FCGR2A;rs1801274;GG;EFFICACY;DECREASED_RESPONSE
CAPECITABINE;MTHFR;rs1801133;GG;LADME_PK;INCREASED_EXPOSURE
DACLATASVIR, SOFOSBUVIR;IFNL3;rs12979860;CC;EFFICACY;INCREASED_CLINICAL BENEFIT
BUPRENORPHINE;;rs6973474;T;EFFICACY;INCREASED_RESPONSE
CARBAMAZEPINE;ABCB1;rs2032582;A;LADME_PK;INCREASED_CLEARANCE
METHOTREXATE;SLC19A1;rs2838958;A;LADME_PK;DECREASED_CLEARANCE
BUPRENORPHINE;;rs13169373;T;EFFICACY;INCREASED_RESPONSE
HALOPERIDOL;CYP2D6;rs3892097;CC;EFFICACY;DECREASED_RESPONSE
CARBAMAZEPINE;ABCB1;rs1045642;A;LADME_PK;INCREASED_CLEARANCE
NEVIRAPINE;CYP2B6;rs28399499;C;LADME_PK;INCREASED_CONCENTRATIONS
IMATINIB;SLC22A1;rs628031;GG;LADME_PK;DECREASED_CLEARANCE
NICOTINE;CHRNA5;rs16969968;A;DOSAGE;INCREASED_DOSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE
BUPRENORPHINE;;rs62368105;G;EFFICACY;INCREASED_RESPONSE
BUPRENORPHINE;;rs11782370;T;EFFICACY;INCREASED_RESPONSE
METHOTREXATE;ABCC4;rs7317112;G;LADME_PK;DECREASED_CLEARANCE
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;FCGR3A;rs396991;AA;EFFICACY;DECREASED_RESPONSE
METHOTREXATE;SLCO1B1;rs2306283;G;LADME_PK;INCREASED_CLEARANCE
BUPRENORPHINE;;rs7205113;T;EFFICACY;INCREASED_RESPONSE
ETANERCEPT;IL10;rs1800896;CC;EFFICACY;INCREASED_RESPONSE
BUPRENORPHINE;ADAMTSL2;rs756770;A;EFFICACY;INCREASED_RESPONSE
(R)-METHADONE;ABCB1;rs2032582;AA;LADME_PK;DECREASED_CLEARANCE
ETANERCEPT;TGFB1;rs1800471;CG;EFFICACY;DECREASED_RESPONSE
ATORVASTATIN;SLCO1B1;rs2306283;AG + GG;EFFICACY;INCREASED_RESPONSE
EFAVIRENZ, NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS;CYP2B6;rs3745274;T;EFFICACY;INCREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs2279345;CC + CT;LADME_PK;INCREASED_CLEARANCE
EFAVIRENZ;CYP2B6;rs3745274;TT;EFFICACY;INCREASED_RESPONSE
METHOTREXATE;SLCO1B1;rs4149056;TT;LADME_PK;INCREASED_EXPOSURE
XK469;AOX1;rs10931910;G;LADME_PK;DECREASED_CLEARANCE
SIMVASTATIN;PON1;rs662;CC;EFFICACY;INCREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_CONCENTRATIONS
MERCAPTOPURINE;NUDT15;rs116855232;T;DOSAGE;DECREASED_DOSE
ETANERCEPT;TNF;rs1800629;GG;EFFICACY;INCREASED_RESPONSE
MERCAPTOPURINE;TPMT;rs1142345;CT;DOSAGE;DECREASED_DOSE
NEVIRAPINE;CYP2B6;rs3745274;T;LADME_PK;INCREASED_CONCENTRATIONS
BUCINDOLOL;ADRB1;rs1801253;CC;EFFICACY;INCREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A4;rs4986907;CT;LADME_PK;INCREASED_CONCENTRATIONS
NEVIRAPINE;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_CONCENTRATIONS
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_CONCENTRATIONS
PHENPROCOUMON;VKORC1;rs9923231;CC;DOSAGE;INCREASED_DOSE
WARFARIN;CYP4F2;rs2189784;AG + GG;DOSAGE;INCREASED_DOSE
PHENPROCOUMON;EPHX1;rs1051740;CC;DOSAGE, LADME_PK;DECREASED_DOSE
ASPIRIN, DICLOFENAC, IBUPROFEN, INDOMETHACIN, KETOROLAC, NAPROXEN;TNF;rs1800629;A;EFFICACY;DECREASED_CLINICAL BENEFIT
PHENPROCOUMON;PROC;rs1799808;CC;DOSAGE, LADME_PK;INCREASED_DOSE
LAMOTRIGINE;UGT2B7;rs7668258;CT + TT;LADME_PK;INCREASED_STEADY_STATE CONCENTRATION
INFLIXIMAB;TNF;rs1800629;GG;EFFICACY;INCREASED_RESPONSE
IMATINIB;SLC22A4;rs1050152;TT;EFFICACY;DECREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE
IMATINIB;SLC22A5;rs2631367;CG + GG;EFFICACY;INCREASED_RESPONSE
IMATINIB;SLC22A5;rs2631372;CG + GG;EFFICACY;INCREASED_RESPONSE
ETANERCEPT;TNF;rs1799724;CT + TT;EFFICACY;INCREASED_RESPONSE
WARFARIN;EPHX1;rs2260863;CG;DOSAGE;INCREASED_DOSE
WARFARIN;APOE;rs7412;CC;DOSAGE;DECREASED_DOSE
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE
CYCLOPHOSPHAMIDE;CYP2B6;rs2279343;AG + GG;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP3A4;rs28371759;AA;DOSAGE;DECREASED_DOSE
CLOPIDOGREL;ABCB1;rs1045642;AA;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP1A2;rs2069514;GG;DOSAGE;DECREASED_DOSE
IMATINIB;ABCC4;rs9561765;AG;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;CC;DOSAGE;INCREASED_DOSE
WARFARIN;SLC15A2;rs1143671;TT;DOSAGE;DECREASED_DOSE
LAMOTRIGINE;UGT1A4;rs2011425;GG + GT;LADME_PK;DECREASED_STEADY_STATE CONCENTRATION
WARFARIN;EPHX1;rs2260863;CC;DOSAGE;DECREASED_DOSE
RITONAVIR;NR1I2;rs1523130;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE
L-TRYPTOPHAN;SLC22A2;rs316019;CC;LADME_PK;INCREASED_CLEARANCE
WARFARIN;VKORC1;rs9923231;AA;DOSAGE;INCREASED_DOSE
PHENPROCOUMON;VKORC1;rs9934438;A;DOSAGE;DECREASED_DOSE
RITONAVIR;SLCO1B1;rs4149056;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS
RITONAVIR;ABCB1;rs2032582;AC + CC;LADME_PK;CONCENTRATIONS
ERENUMAB;RAMP1;rs13386048;A;EFFICACY;DECREASED_CLINICAL BENEFIT
ADALIMUMAB, INFLIXIMAB;TNF;rs1800629;GG;EFFICACY;INCREASED_RESPONSE
SIROLIMUS;POR;rs1057868;CT + TT;LADME_PK;DECREASED_TROUGH CONCENTRATION
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_DOSE
OLANZAPINE;BDNF;rs6265;CC;EFFICACY;INCREASED_RESPONSE
RITONAVIR;NR1I2;rs6785049;AA + AG;LADME_PK;CONCENTRATIONS
ERENUMAB;RAMP1;rs6431564;G;EFFICACY;INCREASED_CLINICAL BENEFIT
INFLIXIMAB;TNF;rs1800629;GG;EFFICACY;INCREASED_RESPONSE
LOSARTAN;SLC22A12;rs1529909;CC + CT;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE
ERENUMAB;RAMP1;rs12465864;G;EFFICACY;DECREASED_CLINICAL BENEFIT
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;TNF;rs1800629;GG;EFFICACY;INCREASED_RESPONSE
LOSARTAN;SLC22A12;rs3825016;CT + TT;EFFICACY;DECREASED_RESPONSE
ADALIMUMAB;TNF;rs1800629;GG;EFFICACY;INCREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS
SIROLIMUS;IL10;rs1800896;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
CYCLOSPORINE;ABCB1;rs9282564;CT;TOXICITY, LADME_PK;INCREASED_CONCENTRATIONS
CLADRIBINE, CYTARABINE;RRM1;rs1042919;AT;EFFICACY;DECREASED_RESPONSE
CLADRIBINE, CYTARABINE;RRM2B;rs1265138;AA;EFFICACY;INCREASED_RESPONSE
FLUOROURACIL;DPYD;rs1801265;AA;EFFICACY;INCREASED_RESPONSE
FLUOROURACIL;DPYD;rs67376798;AT;TOXICITY;INCREASED_EXPOSURE
CLADRIBINE, CYTARABINE;RRM1;rs2898950;AC + CC;EFFICACY;INCREASED_RESPONSE
INTERFERON ALFA-2A, RECOMBINANT, INTERFERON ALFA-2B, RECOMBINANT, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
BUPROPION;CYP2B6;rs2279343;AA;EFFICACY;INCREASED_RESPONSE
INTERFERON ALFA-2A, RECOMBINANT, INTERFERON ALFA-2B, RECOMBINANT, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE
CLADRIBINE, CYTARABINE;RRM1;rs1561876;GG;EFFICACY;DECREASED_RESPONSE
COTININE;PSMA4;rs57064725;A;LADME_PK;INCREASED_CONCENTRATIONS
METHOTREXATE;ATIC;rs16853826;GG;TOXICITY;INCREASED_DISCONTINUATION
METHOTREXATE;ABCC1;rs35592;TT;EFFICACY;INCREASED_RESPONSE
COTININE;CHRNA5;rs16969968;A;LADME_PK;INCREASED_CONCENTRATIONS
INFLIXIMAB;TNFRSF10A;rs20575;CC;EFFICACY;INCREASED_RESPONSE
CLADRIBINE, CYTARABINE;RRM2;rs1130609;GT + TT;EFFICACY;DECREASED_RESPONSE
INTERFERON ALFA-2A, RECOMBINANT, INTERFERON ALFA-2B, RECOMBINANT, RIBAVIRIN;FTO;rs9939609;AA + AT;EFFICACY;DECREASED_RESPONSE
VITAMIN K AND ANALOGUES;CYP4F2;rs2108622;T;LADME_PK;DECREASED_METABOLISM
COTININE;;rs77107237;G;LADME_PK;INCREASED_CONCENTRATIONS
CLOZAPINE;DTNBP1;rs742105;CT + TT;EFFICACY;INCREASED_RESPONSE
CLADRIBINE, CYTARABINE;RRM2;rs5030743;CG + GG;EFFICACY;DECREASED_RESPONSE
COTININE;CHRNB4;rs10851907;A;LADME_PK;INCREASED_CONCENTRATIONS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
SIROLIMUS;ABCB1;rs1045642;AA + AG;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
WARFARIN;SLCO1B3;rs7311358;AA;DOSAGE;DECREASED_DOSE
WARFARIN;SLC15A2;rs1143672;AA;DOSAGE;DECREASED_DOSE
INTERFERON ALFA-2A, RECOMBINANT, INTERFERON ALFA-2B, RECOMBINANT, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE
WARFARIN;SLCO1B3;rs4149117;GG;DOSAGE;DECREASED_DOSE
ETANERCEPT;TNF;rs1800629;GG;EFFICACY;INCREASED_RESPONSE
COTININE;CHRNA3;rs7170068;A;LADME_PK;INCREASED_CONCENTRATIONS
SUNITINIB;ABCB1;rs1045642;AA;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP4F2;rs2108622;CC;DOSAGE, EFFICACY;DECREASED_DOSE
INTERFERON ALFA-2A, RECOMBINANT, INTERFERON ALFA-2B, RECOMBINANT, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
FLUPENTHIXOL;NFKB1;rs230504;CT + TT;EFFICACY;INCREASED_RESPONSE
MONTELUKAST;SLCO2B1;rs12422149;AG;EFFICACY, LADME_PK;DECREASED_RESPONSE
DEFERASIROX;CYP24A1;rs927650;CT + TT;LADME_PK;DECREASED_METABOLISM
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE
DEFERASIROX;CYP24A1;rs2585428;CT + TT;LADME_PK;DECREASED_METABOLISM
FLUPENTHIXOL;NFKB1;rs3774959;AG;EFFICACY;INCREASED_RESPONSE
ANTIDEPRESSANTS;TPH2;rs10879346;C;EFFICACY;INCREASED_RESPONSE
METHOTREXATE POLYGLUTAMATE;IMPDH1;rs4731448;GG;LADME_PK;INCREASED_CONCENTRATIONS
CARBOPLATIN, CISPLATIN;EIF3A;rs3740556;AA + AG;EFFICACY;INCREASED_RESPONSE
METHOTREXATE POLYGLUTAMATE;CEP72;rs924607;TT;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;IL10;rs1800896;TT;DOSAGE;DECREASED_DOSE
MIRTAZAPINE, VENLAFAXINE;TPH2;rs1487278;C;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;ABCB1;rs1045642;GG;DOSAGE;INCREASED_DOSE
BILIRUBIN;UGT1A1;rs4124874;GG + GT;LADME_PK;INCREASED_CONCENTRATIONS
CARBOPLATIN, CISPLATIN;EIF3A;rs3740556;AA + AG;EFFICACY;INCREASED_RESPONSE
DEFERASIROX;CYP24A1;rs2248359;CT + TT;LADME_PK;DECREASED_METABOLISM
FLUPENTHIXOL;NFKB1;rs230493;AT;EFFICACY;INCREASED_RESPONSE
METHOTREXATE POLYGLUTAMATE;SLCO1B3;rs7311358;AA + AG;LADME_PK;INCREASED_CONCENTRATIONS
NICOTINE;FMO3;rs2266780;AA;LADME_PK;INCREASED_METABOLISM
PAZOPANIB;VEGFA;rs699947;A;EFFICACY;DECREASED_RESPONSE
METHOTREXATE POLYGLUTAMATE;FSTL5;rs3749598;AA + AC;LADME_PK;INCREASED_CONCENTRATIONS
METHOTREXATE POLYGLUTAMATE;ATG16L1;rs2241880;AG + GG;LADME_PK;INCREASED_CONCENTRATIONS
FLUOROURACIL;DPYD;rs3918290;CC;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT;LADME_PK;INCREASED_METABOLISM
THEOPHYLLINE;CYP1A2;rs2069514;AA + AG;OTHER, LADME_PK;DECREASED_METABOLISM
INFLIXIMAB;TNFRSF10A;rs20575;CC;EFFICACY;INCREASED_RESPONSE
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;TNFRSF1A;rs767455;TT;EFFICACY;INCREASED_RESPONSE
PAZOPANIB;VEGFA;rs2010963;G;EFFICACY;DECREASED_RESPONSE
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;TNFRSF10A;rs20575;CC;EFFICACY;INCREASED_RESPONSE
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;TNFRSF1A;rs767455;TT;EFFICACY;DECREASED_RESPONSE
PAZOPANIB;VEGFA;rs833061;T;EFFICACY;DECREASED_RESPONSE
ETANERCEPT;PTTG1;rs2431697;CC + CT;EFFICACY;DECREASED_RESPONSE
CISPLATIN, GEMCITABINE;CMPK1;rs4492666;CC;EFFICACY;DECREASED_RESPONSE
BUPROPION, NICOTINE, VARENICLINE;CHRNA5;rs503464;A;EFFICACY;INCREASED_RESPONSE
VORICONAZOLE;NR1I2;rs6785049;GG;LADME_PK;INCREASED_CONCENTRATIONS
ETANERCEPT;HLA-B;rs13437088;TT;EFFICACY;DECREASED_RESPONSE
ETANERCEPT;MAP3K1;rs96844;AG + GG;EFFICACY;INCREASED_RESPONSE
CLOZAPINE;COMT;rs4680;GG;EFFICACY;INCREASED_RESPONSE
CLOZAPINE;HTR1A;rs6295;GG;EFFICACY;INCREASED_RESPONSE
ETANERCEPT;GBP6;rs928655;AG + GG;EFFICACY;INCREASED_RESPONSE
ATORVASTATIN;SLCO1B1;rs4149056;TT;EFFICACY;DECREASED_RESPONSE
ETANERCEPT;IL12B;rs2546890;AG + GG;EFFICACY;DECREASED_RESPONSE
TEMOZOLOMIDE;ABCB1;rs1128503;AA + AG;LADME_PK;DECREASED_CONCENTRATIONS
IVACAFTOR;SLC26A9;rs7512462;CC + CT;EFFICACY;INCREASED_RESPONSE
GEMCITABINE;DCK;rs66878317;AG + GG;LADME_PK;INCREASED_CLEARANCE
VORICONAZOLE;NR1I2;rs3814057;CC;LADME_PK;INCREASED_CONCENTRATIONS
NICOTINE;COMT;rs4680;GG;EFFICACY;INCREASED_RESPONSE
MILNACIPRAN;ADRA2A;rs1800544;CC + CG;EFFICACY;INCREASED_RESPONSE
PLATINUM COMPOUNDS;IGF2, IGF2-AS, INS-IGF2;rs4244809;GG;EFFICACY;DECREASED_RESISTANCE
VORICONAZOLE;FMO3;rs2266780;AA;LADME_PK;INCREASED_CONCENTRATIONS
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs2306283;GG;EFFICACY;INCREASED_RESPONSE
FLUVOXAMINE;FGF2;rs1449683;CC + CT;EFFICACY;DECREASED_RESPONSE
VORICONAZOLE;POR;rs10954732;GG;LADME_PK;INCREASED_CONCENTRATIONS
PLATINUM COMPOUNDS;INS-IGF2;rs3842761;GG;EFFICACY;DECREASED_RESISTANCE
MILNACIPRAN;HTR1A;rs6295;CC + CG;EFFICACY;INCREASED_RESPONSE
VALPROIC ACID;SCN2A;rs17183814;AA + AG;EFFICACY;INCREASED_RESISTANCE
VALPROIC ACID;SCN1A;rs2298771;TT;EFFICACY;INCREASED_CLINICAL BENEFIT
VORICONAZOLE;NR1I2;rs2461817;AA;LADME_PK;DECREASED_CONCENTRATIONS
VORICONAZOLE;NR1I2;rs3732359;GG;LADME_PK;INCREASED_CONCENTRATIONS
METHOTREXATE;ABCC2;rs3740066;TT;LADME_PK;DECREASED_CONCENTRATIONS
CISPLATIN, GEMCITABINE;RRM1;rs720106;TT;EFFICACY;DECREASED_RESPONSE
VORICONAZOLE;NR1I2;rs7643645;AA;LADME_PK;INCREASED_CONCENTRATIONS
SIMVASTATIN;SLCO1B1;rs2306283;AA;EFFICACY;INCREASED_RESPONSE
CISPLATIN, GEMCITABINE;RRM1;rs232043;AA;EFFICACY;DECREASED_RESPONSE
CISPLATIN, GEMCITABINE;CMPK1;rs11211524;CC;EFFICACY;DECREASED_RESPONSE
SIMVASTATIN;SLCO1B1;rs2306283;GG;EFFICACY;INCREASED_RESPONSE
CISPLATIN, GEMCITABINE;RRM1;rs2284449;TT;EFFICACY;DECREASED_RESPONSE
ACENOCOUMAROL;GGCX;rs11676382;G;DOSAGE;DECREASED_DOSE
ACENOCOUMAROL;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE
ACENOCOUMAROL;VKORC1;rs7294;T;DOSAGE;INCREASED_DOSE
METHOTREXATE;NR1I2;rs6785049;G;LADME_PK;INCREASED_CONCENTRATIONS
RITUXIMAB;TGFB1;rs1800470;AG;EFFICACY;INCREASED_RESPONSE
RITUXIMAB;TGFB1;rs1800471;CG;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs12980275;A;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;T;EFFICACY;INCREASED_RESPONSE
SIMVASTATIN;CYP3A4;rs35599367;A;EFFICACY;INCREASED_RESPONSE
PIOGLITAZONE;ADIPOQ;rs2241766;GT;EFFICACY;INCREASED_RESPONSE
MORPHINE;OPRM1;rs1799971;GG;DOSAGE, EFFICACY;INCREASED_DOSE
MORPHINE;OPRM1;rs1799971;GG;DOSAGE, EFFICACY;INCREASED_DOSE
ACENOCOUMAROL;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE
ROSUVASTATIN;CYP3A5;rs776746;C;EFFICACY;INCREASED_RESPONSE
METHOTREXATE;GSK3B;rs3732361;A;LADME_PK;INCREASED_CONCENTRATIONS
NALOXONE;OPRM1;rs1799971;AG + GG;OTHER;INCREASED_RESPONSE
TIPIFARNIB;ABCB1;rs1128503;AA;OTHER, LADME_PK;DECREASED_METABOLISM
ETANERCEPT;ZNF816;rs9304742;CC;EFFICACY;DECREASED_RESPONSE
ROSUVASTATIN;ABCG2;rs2231142;T;EFFICACY;INCREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs3745274;GG;DOSAGE;INCREASED_DOSE
NALTREXONE;OPRM1;rs1799971;G;EFFICACY;INCREASED_RESPONSE
ANTIPSYCHOTICS;NRG1;rs13250975;G;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE
METHOTREXATE;SLCO1A2;rs4149009;CC + CT;LADME_PK;DECREASED_CLEARANCE
ANTIPSYCHOTICS;;rs2513265;A;EFFICACY;INCREASED_RESPONSE
ANTIPSYCHOTICS;ADCY2;rs1544938;C;EFFICACY;INCREASED_RESPONSE
ANTIPSYCHOTICS;NRG1;rs17716295;A;EFFICACY;DECREASED_RESPONSE
NICOTINE;CHRNA5;rs16969968;GG;OTHER;DECREASED_DOSE
METHADONE;DAO;rs55944529;TT;DOSAGE;INCREASED_DOSE
ANTIPSYCHOTICS;CCL2;rs4795893;G;EFFICACY;DECREASED_RESPONSE
ANTIPSYCHOTICS;CCL2;rs4586;T;EFFICACY;DECREASED_RESPONSE
METHADONE;DAO;rs55944529;TT;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;DECREASED_METABOLISM
ESCITALOPRAM, FLUOXETINE, FLUVOXAMINE, SERTRALINE;HTR2A;rs3803189;GG + GT;EFFICACY;INCREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs3745274;T;LADME_PK;INCREASED_CONCENTRATIONS
IVACAFTOR;CFTR;rs121908755;A;EFFICACY;INCREASED_RESPONSE
METHADONE;DRD1;rs5326;TT;DOSAGE;INCREASED_DOSE
IVACAFTOR;CFTR;rs121908757;C;EFFICACY;INCREASED_RESPONSE
IVACAFTOR;CFTR;rs80282562;A;EFFICACY;INCREASED_RESPONSE
RIFAMPIN;SLCO1B1;rs4149056;CT;LADME_PK;INCREASED_CONCENTRATIONS
METHYLPHENIDATE;CYP2D6;rs1065852;GG;EFFICACY;INCREASED_CLINICAL BENEFIT
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs11045819;CC;EFFICACY;DECREASED_RESPONSE
METHYLPHENIDATE;CYP2D6;rs1135840;CG;EFFICACY;INCREASED_CLINICAL BENEFIT
IVACAFTOR;CFTR;rs121909041;C;EFFICACY;INCREASED_RESPONSE
PRAVASTATIN;SLCO1B1;rs2306283;GG;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP2C9;rs1057910;AA;DOSAGE;INCREASED_DOSE
IVACAFTOR;CFTR;rs193922525;A;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs7196161;AA + AG;DOSAGE;INCREASED_DOSE
IVACAFTOR;CFTR;rs267606723;A;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE
IVACAFTOR;CFTR;rs74503330;A;EFFICACY;INCREASED_RESPONSE
IVACAFTOR;CFTR;rs121909005;G;EFFICACY;INCREASED_RESPONSE
IVACAFTOR;CFTR;rs121909013;A;EFFICACY;INCREASED_RESPONSE
SUNITINIB;GLP1R;rs6923761;A;LADME_PK;DECREASED_CONCENTRATIONS
DOXORUBICIN;ABCB1;rs1128503;AA;LADME_PK;DECREASED_METABOLISM
ATOMOXETINE;CYP2D6;rs1135840;CC;EFFICACY;INCREASED_CLINICAL BENEFIT
BETA BLOCKING AGENTS;GRK5;rs3740563;A;EFFICACY;DECREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNG;rs2069705;G;EFFICACY;INCREASED_RESPONSE
MONTELUKAST;MLLT3;rs6475448;AA;EFFICACY;INCREASED_RESPONSE
BETA BLOCKING AGENTS;GRK5;rs10787959;A;EFFICACY;DECREASED_RESPONSE
BUPROPION;;rs1908557;C;EFFICACY;DECREASED_RESPONSE
BETA BLOCKING AGENTS;GRK5;rs11198893;A;EFFICACY;DECREASED_RESPONSE
RIFAMPIN;CYP27B1;rs4646536;AG + GG;LADME_PK;INCREASED_CONCENTRATIONS
CORTICOSTEROIDS;ST13;rs138335;G;EFFICACY;DECREASED_RESPONSE
RIFAMPIN;VDR;rs1544410;TT;LADME_PK;INCREASED_CONCENTRATIONS
DOCETAXEL;CYP3A4;rs2740574;C;LADME_PK;INCREASED_CLEARANCE
BETA BLOCKING AGENTS;ADRB1;rs1801253;GG;EFFICACY;DECREASED_RESPONSE
METHADONE;CYP2B6;rs3745274;GG + GT;DOSAGE;INCREASED_DOSE
DOCETAXEL;CYP3A5;rs776746;T;LADME_PK;INCREASED_CLEARANCE
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;C;EFFICACY;DECREASED_RESPONSE
RAMIPRIL;ADRB2;rs2053044;AA + AG;EFFICACY;INCREASED_RESPONSE
OPIOIDS;COMT;rs4680;GG;DOSAGE;INCREASED_DOSE
METHADONE;NGF;rs2239622;AA;DOSAGE;DECREASED_DOSE
NICOTINE;CYP1A2;rs35694136;T/del + del/del;EFFICACY;INCREASED_EXPOSURE
METHADONE;CYP2B6;rs2279343;AA + AG;DOSAGE;INCREASED_DOSE
GEMCITABINE;NT5C3A;rs3750117;AA;OTHER, LADME_PK;INCREASED_CLEARANCE
GEMCITABINE;NT5C2;rs11598702;TT;OTHER, LADME_PK;DECREASED_CLEARANCE
FENTANYL, REMIFENTANIL;PGAP6;rs199670311;T;EFFICACY;INCREASED_DOSE
OLANZAPINE;UGT1A4;rs2011425;GT;LADME_PK;DECREASED_CONCENTRATIONS
ANTIDEPRESSANTS;ADCY9;rs2230739;CC;EFFICACY;INCREASED_RESPONSE
DABIGATRAN;CES1;rs2244613;GG + GT;LADME_PK;DECREASED_CONCENTRATIONS
ANTIPSYCHOTICS;PI4KA;rs165854;AG + GG;EFFICACY;DECREASED_RESPONSE
ANTIPSYCHOTICS;GRM3;rs1468412;AA + AT;EFFICACY;DECREASED_RESPONSE
BUDESONIDE, CORTICOSTEROIDS, FLUTICASONE / SALMETEROL, FLUTICASONE PROPIONATE;ZNF432;rs3752120;TT;EFFICACY;DECREASED_RESPONSE
AZATHIOPRINE;ITPA;rs1127354;AA + AC;EFFICACY;INCREASED_RESPONSE
CARBOPLATIN, DOCETAXEL, TRASTUZUMAB;ERBB2;rs1136201;G;EFFICACY;DECREASED_RESPONSE
ANTIPSYCHOTICS;SLC1A3;rs1529461;AA + AG;EFFICACY;DECREASED_RESPONSE
ANTIPSYCHOTICS;GRM3;rs2299214;CC;EFFICACY;INCREASED_RESPONSE
CARBOPLATIN, DOCETAXEL, TRASTUZUMAB;RNF8;rs2284922;A;EFFICACY;INCREASED_RESPONSE
ANTIPSYCHOTICS;GRM3;rs6465084;AG + GG;EFFICACY;INCREASED_RESPONSE
CARBOPLATIN, DOCETAXEL, TRASTUZUMAB;BARD1;rs2070096;A;EFFICACY;DECREASED_RESPONSE
GEMCITABINE;CDA;rs1048977;CC;EFFICACY;INCREASED_RESPONSE
CARBOPLATIN, DOCETAXEL, TRASTUZUMAB;ERBB3;rs2229046;C;EFFICACY;DECREASED_RESPONSE
CORTICOSTEROIDS;ST13;rs138337;G;EFFICACY;DECREASED_RESPONSE
CARBOPLATIN, DOCETAXEL, TRASTUZUMAB;ERBB3;rs773123;A;EFFICACY;DECREASED_RESPONSE
ANTIPSYCHOTICS;SLC1A4;rs10211524;AA;EFFICACY;DECREASED_RESPONSE
RISPERIDONE;GRM3;rs2299214;CC + CT;EFFICACY;DECREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs3745274;GT;LADME_PK;INCREASED_CONCENTRATIONS
PRAVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE
SUFENTANIL;COMT;rs4680;AA;DOSAGE, EFFICACY;DECREASED_DOSE
FLUINDIONE;VKORC1;rs9923231;TT;LADME_PK;DOSE
APREMILAST;LEPR, LEPROT;rs1045895;AA + AG;EFFICACY;DECREASED_CLINICAL BENEFIT
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_DOSE
OPIOIDS;ABCB1;rs1045642;AA;DOSAGE, EFFICACY;DECREASED_DOSE
CARBOPLATIN, CISPLATIN;AKT1;rs2494752;AG;EFFICACY;DECREASED_RESPONSE
QUINAPRIL;AGT;rs699;GG;EFFICACY;INCREASED_RESPONSE
OPIOIDS;KCNJ6;rs6517442;CC;DOSAGE;INCREASED_DOSE
OLANZAPINE;CYP1A2;rs35694136;T/del;LADME_PK;INCREASED_CONCENTRATIONS
OPIOIDS;OPRM1;rs1799971;AG + GG;DOSAGE, EFFICACY;INCREASED_DOSE
OLANZAPINE;CYP1A2;rs762551;AA;LADME_PK;DECREASED_CONCENTRATIONS
FENTANYL;OPRM1;rs1799971;GG;DOSAGE, EFFICACY;INCREASED_DOSE
PHENPROCOUMON;CYP4F2;rs2108622;TT;DOSAGE;INCREASED_DOSE
CAPECITABINE, FLUOROURACIL, TEGAFUR;TYMS;rs183205964;C;TOXICITY;INCREASED_DISCONTINUATION
KETOPROFEN;CYP2C9;rs1057910;AC;EFFICACY;INCREASED_RESPONSE
ATORVASTATIN;ABCB1;rs1045642;GG;EFFICACY;DECREASED_RESPONSE
IMATINIB;SLC22A1;rs683369;CC;LADME_PK;INCREASED_CLEARANCE
CAFFEINE;CYP1A2;rs762551;AA;OTHER, LADME_PK;INCREASED_METABOLISM
IMATINIB;SLC22A1;rs683369;CC;LADME_PK;DECREASED_CONCENTRATIONS
ETANERCEPT;TNFRSF1B;rs1061622;GT;EFFICACY;DECREASED_RESPONSE
FENTANYL, REMIFENTANIL;SLC9A9;rs4839603;GG;EFFICACY;DECREASED_DOSE
EFAVIRENZ;ABCB1;rs1045642;GG;EFFICACY, LADME_PK;DECREASED_CLEARANCE
EFAVIRENZ;CYP2B6;rs3745274;T;EFFICACY;DECREASED_CLEARANCE
EFAVIRENZ;ABCB1;rs1045642;AA;EFFICACY, LADME_PK;INCREASED_CLEARANCE
APREMILAST;PDE4B;rs12745871;T;EFFICACY;INCREASED_CLINICAL BENEFIT
ATORVASTATIN;SCARB1;rs5888;AA;EFFICACY;INCREASED_RESPONSE
APREMILAST;TSPAN16;rs322144;C;EFFICACY;DECREASED_CLINICAL BENEFIT
PRAVASTATIN;FCAR;rs11666735;AA + AG;EFFICACY;INCREASED_RESPONSE
CYCLOPHOSPHAMIDE, EPIRUBICIN;GSTP1;rs1695;AA + AG;EFFICACY;INCREASED_RESPONSE
FENOFIBRATE;APOA1;rs964184;G;EFFICACY;INCREASED_RESPONSE
ANTIEPILEPTICS;SCN1A;rs10188577;CT;EFFICACY;INCREASED_RESISTANCE
APREMILAST;DOCK6;rs12979813;G;EFFICACY;INCREASED_CLINICAL BENEFIT
DAPTOMYCIN;ABCB1;rs1045642;AA;LADME_PK;INCREASED_CONCENTRATIONS
DAPTOMYCIN;ABCB1;rs1045642;AA;LADME_PK;DECREASED_CLEARANCE
NALTREXONE;DBH;rs1611115;CT + TT;EFFICACY;INCREASED_RESPONSE
GEMCITABINE;SLC28A2;rs11854484;CC;EFFICACY;DECREASED_RESPONSE
ANTINEOPLASTIC AGENTS;ABCG2;rs2231142;GG;EFFICACY;DECREASED_RESPONSE
GEMCITABINE;SLC28A2;rs1060896;CC;EFFICACY;DECREASED_RESPONSE
APREMILAST;EIF3G, P2RY11, PPAN-P2RY11;rs2305795;G;EFFICACY;INCREASED_CLINICAL BENEFIT
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1A;rs767455;TT;EFFICACY;DECREASED_RESPONSE
ACENOCOUMAROL;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE
METHOTREXATE;SLCO1B1;rs4149056;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS
DRUGS FOR TREATMENT OF TUBERCULOSIS;METTL3;rs1139130;GG;EFFICACY;INCREASED_RESISTANCE
METHOTREXATE;SLCO1B1;rs11045879;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS
SUFENTANIL;OPRM1;rs1799971;AG;DOSAGE;INCREASED_DOSE
APREMILAST;ILF3;rs76966440;T;EFFICACY;INCREASED_CLINICAL BENEFIT
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;GSTP1;rs1695;A;EFFICACY;INCREASED_RESPONSE
SULFASALAZINE;ABCG2;rs2231142;GT + TT;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;T;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;CC + CT;DOSAGE;INCREASED_DOSE
TACROLIMUS;ABCB1;rs1128503;AG + GG;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP4F2;rs2108622;TT;DOSAGE;INCREASED_DOSE
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE
WARFARIN;PRSS53, VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_DOSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;T;EFFICACY;DECREASED_RESPONSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;VDR;rs2228570;A;EFFICACY;INCREASED_RESPONSE
NORTRIPTYLINE;NOS3;rs1799983;TT;EFFICACY;INCREASED_RESPONSE
ALLOPURINOL;GREM2;rs1934341;T;EFFICACY;INCREASED_RESPONSE
COTININE;NAT1;rs13253389;AG + GG;LADME_PK;INCREASED_CONCENTRATIONS
ALLOPURINOL;GREM2;rs77567654;G;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;ABCB1;rs2032582;CC;DOSAGE;INCREASED_DOSE
ALLOPURINOL;ABCG2;rs45499402;C;EFFICACY;DECREASED_RESPONSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;DECREASED_RESPONSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
ALLOPURINOL;ABCG2;rs2231142;T;EFFICACY;DECREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE
EXENATIDE;GLP1R;rs10305420;T;EFFICACY;DECREASED_RESPONSE
TOPIRAMATE;ABCB1;rs1045642;AA;EFFICACY;INCREASED_RESPONSE
LAMOTRIGINE;UGT2B7;rs7668258;TT;LADME_PK;DECREASED_CLEARANCE
WARFARIN;VKORC1;rs7294;TT;DOSAGE;INCREASED_DOSE
BENAZEPRIL;AGT;rs4762;GG;EFFICACY;RESPONSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
IMATINIB;ABCB1;rs1128503;GG;EFFICACY;INCREASED_RESPONSE
LAMOTRIGINE;UGT2B7;rs28365063;GG;LADME_PK;INCREASED_CLEARANCE
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE
METHOTREXATE;ABCC4;rs7317112;GG;LADME_PK;INCREASED_CLEARANCE
BENAZEPRIL;AGTR1;rs2640543;GG;EFFICACY;RESPONSE
ALENDRONATE;MVK;rs10161126;GG;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs1127354;A;EFFICACY;INCREASED_RESPONSE
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs80034486;G;EFFICACY;INCREASED_CLINICAL BENEFIT
SARILUMAB;IL6R;rs11265618;CC;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;LDLR;rs14158;GG;EFFICACY;INCREASED_RESPONSE
BENAZEPRIL;SPTA1;rs2106089;G;EFFICACY;RESPONSE
IMATINIB;ABCB1;rs1045642;GG;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;TT;LADME_PK;INCREASED_CLEARANCE
SARILUMAB;IL6R;rs4329505;TT;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
IMATINIB;ABCB1;rs2032582;C;EFFICACY;DECREASED_RESPONSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE
BUPRENORPHINE;OPRD1;rs678849;CC;EFFICACY;DECREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs3745274;GT;LADME_PK;INCREASED_CONCENTRATIONS
PHENPROCOUMON;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;DECREASED_CLEARANCE
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;NCR3;rs1052248;AT + TT;EFFICACY;INCREASED_CLINICAL BENEFIT
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE
SALBUTAMOL;COL2A1;rs3809324;GT + TT;LADME_PD;DECREASED_RESPONSE
ANTIPSYCHOTICS;CACNA1C;rs2238087;CC;EFFICACY;INCREASED_RESPONSE
DIURETICS, HYDROCHLOROTHIAZIDE, THIAZIDES, PLAIN;PRKCA;rs4791040;T;EFFICACY;DECREASED_RESPONSE
ANTIPSYCHOTICS;CACNA1B;rs2229949;CC;EFFICACY;INCREASED_RESPONSE
ACENOCOUMAROL;STX4;rs10871454;T;DOSAGE;DECREASED_DOSE
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE
WARFARIN;;rs12777823;AA + AG;DOSAGE;DECREASED_DOSE
CORTICOSTEROIDS;GLCCI1;rs37973;GG;EFFICACY;DECREASED_CLINICAL BENEFIT
DEFERASIROX;GC;rs7041;AA;EFFICACY;INCREASED_RESPONSE
ACENOCOUMAROL;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE
ACENOCOUMAROL;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_DOSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;GG + GT;EFFICACY;DECREASED_RESPONSE
ASPIRIN, CLOPIDOGREL;CYP4F2;rs2108622;CC + CT;EFFICACY;DECREASED_RESPONSE
ACENOCOUMAROL;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE
WARFARIN;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_DOSE
WARFARIN;VKORC1;rs7294;CT + TT;DOSAGE;INCREASED_DOSE
INTERFERON BETA-1A, INTERFERON BETA-1B;CD58;rs12044852;CC;EFFICACY;DECREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;rs610604;GG + GT;EFFICACY;INCREASED_RESPONSE
MORPHINE;OPRM1;rs1799971;AG + GG;EFFICACY;DECREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;rs6920220;AA;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP4F2;rs2108622;CC + CT;DOSAGE;DECREASED_DOSE
ANTIPSYCHOTICS;CACNB2;rs12245847;TT;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A7;rs2257401;C;LADME_PK;TROUGH CONCENTRATION
DEFERASIROX;UGT1A1;rs887829;CC;EFFICACY;DECREASED_RESPONSE
ANTIPSYCHOTICS;CACNG3;rs1859204;TT;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;C;LADME_PK;TROUGH CONCENTRATION
DEFERASIROX;UGT1A3;rs1983023;TT;EFFICACY;INCREASED_RESPONSE
DEFERASIROX;CYP27B1;rs10877012;GG;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A4;rs4646437;A;LADME_PK;TROUGH CONCENTRATION
ADALIMUMAB;ATG16L1;rs10210302;CT + TT;EFFICACY;INCREASED_RESPONSE
ANTIPSYCHOTICS;CACNB2;rs982003;CC;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A4;rs2242480;T;LADME_PK;TROUGH CONCENTRATION
DEFERASIROX;VDR;rs731236;GG;EFFICACY;INCREASED_RESPONSE
DEFERASIROX;VDR;rs1544410;TT;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs41303343;A;LADME_PK;TROUGH CONCENTRATION
CAPECITABINE, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;SLC19A1;rs1051266;CC;EFFICACY;INCREASED_RESPONSE
CAPECITABINE, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;SLCO1B1;rs2306283;AA + AG;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs4646450;A;LADME_PK;TROUGH CONCENTRATION
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_CONCENTRATIONS
SIMVASTATIN ACID;SLCO1B1;rs4149056;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS
DIURETICS, HYDROCHLOROTHIAZIDE, THIAZIDES, PLAIN;;rs2776546;A;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C9;rs28371686;CG;DOSAGE;DECREASED_DOSE
ANTIPSYCHOTICS;CACNB2;rs10741058;TT;EFFICACY;INCREASED_RESPONSE
ATAZANAVIR;UGT1A1;rs887829;TT;TOXICITY;INCREASED_DISCONTINUATION
DIURETICS, HYDROCHLOROTHIAZIDE, THIAZIDES, PLAIN;;rs238;A;EFFICACY;DECREASED_RESPONSE
ANTIPSYCHOTICS;CACNA2D3;rs4505744;AA;EFFICACY;INCREASED_RESPONSE
DIURETICS, HYDROCHLOROTHIAZIDE, THIAZIDES, PLAIN;;rs4815273;T;EFFICACY;INCREASED_RESPONSE
IBUPROFEN;CYP2C9;rs1057910;AC;EFFICACY;DECREASED_TIME TO RESPONSE
ANTIPSYCHOTICS;CACNA1E;rs12060765;TT;EFFICACY;INCREASED_RESPONSE
CORTICOSTEROIDS;TAAR6;rs7772821;GG;EFFICACY;INCREASED_RESPONSE
SALBUTAMOL;VEGFA;rs3025039;CT + TT;LADME_PD;DECREASED_RESPONSE
BEVACIZUMAB, RANIBIZUMAB;CFH;rs1061170;CC;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE
MORPHINE;TAOK3;rs795484;TT;DOSAGE, EFFICACY;INCREASED_DOSE
PREDNISONE;NR3C1;rs6196;G;EFFICACY;DECREASED_RESISTANCE
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE
SN-38;UGT1A1;rs4148323;AA;LADME_PK;DECREASED_METABOLISM
DOCETAXEL;;rs4842198;G;LADME_PK;INCREASED_METABOLISM
FLUVOXAMINE;HTR2A;rs6311;CC;EFFICACY;INCREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLCO1C1;rs3794271;AG + GG;EFFICACY;INCREASED_RESPONSE
ACENOCOUMAROL;VKORC1;rs9934438;AA + AG;DOSAGE, EFFICACY;DECREASED_DOSE
PREDNISONE;NR3C1;rs258751;A;EFFICACY;DECREASED_RESISTANCE
LEDIPASVIR, SOFOSBUVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
SN-38;UGT1A9;rs3832043;del/del;LADME_PK;DECREASED_METABOLISM
PHENYTOIN;CYP2C9;rs28371686;G;OTHER, LADME_PK;DECREASED_METABOLISM
IMATINIB;ABCG2;rs2231137;CT + TT;DOSAGE;DECREASED_DOSE
PREDNISONE;NR3C1;rs10052957;A;EFFICACY;DECREASED_RESISTANCE
IMATINIB;CYP1A2;rs762551;CC;DOSAGE;DECREASED_DOSE
PHENYTOIN;CYP2C9;rs7900194;A;OTHER, LADME_PK;DECREASED_METABOLISM
LURASIDONE;HTR1A;rs6295;CG + GG;EFFICACY;DECREASED_RESPONSE
PHENYTOIN;CYP2C9;rs28371685;T;OTHER, LADME_PK;INCREASED_METABOLISM
PHENYTOIN;CYP2C9;rs9332131;del;OTHER, LADME_PK;DECREASED_METABOLISM
DOCETAXEL;RXRA;rs3132291;A;LADME_PK;INCREASED_METABOLISM
INFLIXIMAB;TNFRSF1B;rs1061622;G;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;DECREASED_METABOLISM
CODEINE;OPRM1;rs1799971;AA;DOSAGE;DECREASED_DOSE
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
CODEINE;UGT2B7;rs7439366;TT;DOSAGE;DECREASED_DOSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE
ANTIPSYCHOTICS;CACNB2;rs4237348;CC;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A4;rs2740574;T;LADME_PK;TROUGH CONCENTRATION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE
ANTIPSYCHOTICS;CACNB4;rs3768652;AA + AC;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A4;rs35599367;A;LADME_PK;TROUGH CONCENTRATION
ANTIPSYCHOTICS;CACNA2D3;rs7427395;CC;EFFICACY;INCREASED_RESPONSE
ANTIPSYCHOTICS;CACNB2;rs1277733;TT;EFFICACY;INCREASED_RESPONSE
SOFOSBUVIR;CES1;rs4513095;A;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT;LADME_PK;INCREASED_CLEARANCE
PROPOFOL;SCN9A;rs6746030;AA + AG;OTHER;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE
SALBUTAMOL;PRKG1;rs7081864;A;EFFICACY;DECREASED_CLINICAL BENEFIT
TACROLIMUS;CYP3A5;rs776746;C;DOSAGE;DECREASED_DOSE
TOCILIZUMAB;IL6R;rs12083537;AA;EFFICACY;INCREASED_RESPONSE
ANTIPSYCHOTICS;BDNF;rs11030104;AG + GG;EFFICACY;INCREASED_RESISTANCE
SUNITINIB;ABCB1;rs1045642;GG;LADME_PK;INCREASED_EXPOSURE
PROPOFOL;HTR2A;rs6313;AA;DOSAGE;DECREASED_DOSE
ANTIPSYCHOTICS;BDNF-AS;rs10501087;CC + CT;EFFICACY;INCREASED_RESISTANCE
PROPOFOL;GABRA1;rs2279020;GG;OTHER;INCREASED_RESPONSE
SUNITINIB;ABCB1;rs1045642;GG;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;DECREASED_CLEARANCE
OPIOIDS;COMT;rs4680;AA + AG;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT;DOSAGE;INCREASED_DOSE
DOXORUBICIN, METHOTREXATE, PREDNISOLONE, VINCRISTINE;ABCB1;rs1045642;AA;EFFICACY;DECREASED_RESISTANCE
ANTIPSYCHOTICS;BDNF;rs6265;CT + TT;EFFICACY;INCREASED_RESISTANCE
OPIOIDS;COMT;rs4680;AG;DOSAGE;DECREASED_DOSE
METFORMIN, SULFONAMIDES, UREA DERIVATIVES;ABCC8, KCNJ11;rs5219;CT + TT;EFFICACY;INCREASED_CLINICAL BENEFIT
PALIPERIDONE, RISPERIDONE;NFIB;rs28379954;CT;LADME_PK;INCREASED_CONCENTRATIONS
REMIFENTANIL, SEVOFLURANE;ABCB1;rs1128503;GG;EFFICACY;INCREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS
MORPHINE;TAOK3;rs1277441;GG;DOSAGE, EFFICACY;INCREASED_DOSE
DOXORUBICIN, METHOTREXATE, PREDNISOLONE, VINCRISTINE;ABCB1;rs2229109;CT;EFFICACY;INCREASED_RESISTANCE
HYDROXYUREA;KLF4;rs2236599;C;EFFICACY;INCREASED_RESPONSE
OXYCODONE;OPRM1;rs1799971;GG;DOSAGE;INCREASED_DOSE
TACROLIMUS;CYP3A4;rs2242480;CT + TT;LADME_PK;INCREASED_CLEARANCE
METHOTREXATE;SLCO1B1;rs11045821;A;EFFICACY, TOXICITY, LADME_PK;DECREASED_CLEARANCE
METHYLPHENIDATE;SLC6A2;rs28386840;AT + TT;EFFICACY;INCREASED_RESPONSE
BILIRUBIN;UGT1A;rs11563250;AG + GG;LADME_PK;DECREASED_CONCENTRATIONS
DEFERASIROX;UGT1A3;rs1983023;CT + TT;LADME_PK;DECREASED_CONCENTRATIONS
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CERS6;rs13393173;A;EFFICACY;INCREASED_RESPONSE
MORPHINE;SLC22A1;rs12208357;CT + TT;LADME_PK;DECREASED_CLEARANCE
MIDAZOLAM;CYP3A4;rs35599367;AG;LADME_PK;DECREASED_METABOLISM
MORPHINE;SLC22A1;rs55918055;CC + CT;LADME_PK;DECREASED_CLEARANCE
BUPROPION, DRUGS USED IN NICOTINE DEPENDENCE;CYP2A6;rs4803381;T;EFFICACY;INCREASED_RESPONSE
METFORMIN;SRR;rs391300;CC + CT;EFFICACY;INCREASED_RESPONSE
METHYLPHENIDATE;SLC6A2;rs5569;AG + GG;EFFICACY;INCREASED_RESPONSE
ERYTHROMYCIN;CYP3A4;rs35599367;AG;LADME_PK;DECREASED_METABOLISM
NICOTINE;CYP2A6;rs4803381;T;LADME_PK;DECREASED_METABOLISM
CLOZAPINE;ABCB1;rs7787082;G;EFFICACY;DECREASED_RESPONSE
CAFFEINE;CYP1A2;rs762551;AA + AC;LADME_PK;INCREASED_METABOLISM
ATENOLOL;;rs12346562;AA + AC;EFFICACY;INCREASED_RESPONSE
HYDROCHLOROTHIAZIDE;;rs12346562;AA + AC;EFFICACY;DECREASED_RESPONSE
ATENOLOL;;rs1104514;AA + AG;EFFICACY;INCREASED_RESPONSE
IVACAFTOR;CFTR;rs121908755;A;EFFICACY;RESPONSE
MORPHINE;SLC22A1;rs34130495;AA + AG;LADME_PK;DECREASED_CLEARANCE
ATENOLOL;;rs10739150;GG + GT;EFFICACY;INCREASED_RESPONSE
CLOZAPINE;ABCB1;rs10248420;A;EFFICACY;DECREASED_RESPONSE
DEFERASIROX;UGT1A3;rs3806596;CC;EFFICACY, LADME_PK;INCREASED_RESPONSE
TRANDOLAPRIL, VERAPAMIL;PTPRD;rs4742610;T;EFFICACY;RESISTANCE
DEFERASIROX;ABCG2;rs13120400;CC;LADME_PK;INCREASED_CONCENTRATIONS
EFAVIRENZ;ABCB1;rs3842;CC + CT;LADME_PK;INCREASED_TROUGH CONCENTRATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE
METFORMIN, SULFONAMIDES, UREA DERIVATIVES;SLC47A1;rs2289669;A;EFFICACY;INCREASED_CLINICAL BENEFIT
SUNITINIB;ABCG2;rs2231142;GT + TT;LADME_PK;INCREASED_EXPOSURE
WARFARIN;VDR;rs11168292;GG;DOSAGE;INCREASED_DOSE
4-HYDROXYTAMOXIFEN, ENDOXIFEN;SULT1A2;rs1136703;AA;LADME_PK;DECREASED_CONCENTRATIONS
ARA-CTP;SLC28A3;rs17343066;AA;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;VDR;rs4760658;GG;DOSAGE;INCREASED_DOSE
WARFARIN;VDR;rs11168293;TT;DOSAGE;INCREASED_DOSE
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;ALPL;rs885814;T;EFFICACY;DECREASED_RESPONSE
ETOPOSIDE;SLIT1;rs2784917;AA;LADME_PK;DECREASED_INHIBITION
METHOTREXATE;SLCO1B1;rs4149056;C;EFFICACY, TOXICITY, LADME_PK;DECREASED_CLEARANCE
METHYLPHENIDATE;SLC6A2;rs5569;GG;EFFICACY;INCREASED_RESPONSE
METHOTREXATE;SLCO1B1;rs2306283;A;EFFICACY, TOXICITY, LADME_PK;DECREASED_CLEARANCE
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;;rs1350948;A;EFFICACY;INCREASED_RESPONSE
4-HYDROXYTAMOXIFEN, ENDOXIFEN;SULT1A2;rs1059491;TT;LADME_PK;DECREASED_CONCENTRATIONS
METHYLPHENIDATE;SLC6A2;rs28386840;AT + TT;EFFICACY;INCREASED_RESPONSE
METHOTREXATE;SLCO1B1;rs4149081;A;EFFICACY, TOXICITY, LADME_PK;DECREASED_CLEARANCE
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;EYA4;rs17301249;C;EFFICACY;DECREASED_RESPONSE
METHYLPHENIDATE;SLC6A2;rs28386840;AT + TT;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;;rs12081765;G;EFFICACY;INCREASED_RESPONSE
METHOTREXATE;SLCO1B1;rs11045879;C;EFFICACY, TOXICITY, LADME_PK;DECREASED_CLEARANCE
PHENYLEPHRINE;ADRB2;rs1042713;AA;DOSAGE;INCREASED_DOSE
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE, EFFICACY;INCREASED_DOSE
ANASTROZOLE;CSMD1;rs6990851;G;EFFICACY;INCREASED_RESPONSE
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;ABCC2;rs2273697;AA;LADME_PK;INCREASED_CONCENTRATIONS
PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs6806020;C;EFFICACY;DECREASED_RESPONSE
NICOTINE;CYP2A6;rs28399433;C;LADME_PK;DECREASED_METABOLISM
ATORVASTATIN;ABCB1;rs2032582;AA + AC;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs7294;CT + TT;DOSAGE, EFFICACY;INCREASED_DOSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs1931704;A;EFFICACY;DECREASED_RESPONSE
ACAMPROSATE;CHDH, IL17RB;rs6801605;A;EFFICACY;INCREASED_CLINICAL BENEFIT
WARFARIN;VKORC1;rs9923231;TT;DOSAGE, EFFICACY;DECREASED_DOSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;GG;EFFICACY;DECREASED_RESPONSE
CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;GG;EFFICACY;INCREASED_CLINICAL BENEFIT
PRAVASTATIN;MTTP;rs1800591;GT + TT;EFFICACY;RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT;LADME_PK;INCREASED_DOSE
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE
WARFARIN;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_DOSE
COUMARIN;CYP2A6;rs28399433;C;LADME_PK;DECREASED_METABOLISM
PEGINTERFERON ALFA-2B, RIBAVIRIN;IL21R;rs3093390;C;EFFICACY;DECREASED_RESPONSE
BEVACIZUMAB, IRINOTECAN;VEGFA;rs1570360;GG;EFFICACY;DECREASED_RESPONSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs7512595;A;EFFICACY;DECREASED_RESPONSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;CARD16;rs1792774;C;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP2C19;rs3814637;CC;DOSAGE;INCREASED_DOSE
WARFARIN;CYP2C9;rs1057910;AA + AC;DOSAGE;INCREASED_DOSE
N-DESMETHYLTRAMADOL;ABCC2;rs3740066;TT;LADME_PK;INCREASED_CONCENTRATIONS
PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs7750468;G;EFFICACY;DECREASED_RESPONSE
WARFARIN;GGCX;rs699664;CT + TT;DOSAGE;INCREASED_DOSE
IVACAFTOR;CFTR;rs75527207;AG;EFFICACY;INCREASED_CLINICAL BENEFIT
ATORVASTATIN;SLCO1B1;rs2306283;AA;EFFICACY;INCREASED_RESPONSE
FENTANYL;ABCC3;rs11079921;C;LADME_PK;INCREASED_CLEARANCE
PEGINTERFERON ALFA-2B, RIBAVIRIN;CARD16;rs1503391;A;EFFICACY;DECREASED_RESPONSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;CASP1;rs557905;T;EFFICACY;DECREASED_RESPONSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs2066911;A;EFFICACY;DECREASED_RESPONSE
HMG COA REDUCTASE INHIBITORS;CFAP44;rs13064411;G;EFFICACY;DECREASED_RESPONSE
ATORVASTATIN;CYP7A1;rs3808607;TT;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;CASP1;rs568910;A;EFFICACY;DECREASED_RESPONSE
CODEINE;CYP2D6;rs3892097;TT;LADME_PK;DECREASED_METABOLISM
NICOTINE;CHRNB2;rs2072658;AG;OTHER;INCREASED_RESPONSE
METFORMIN;SLC22A1;rs622342;AC + CC;EFFICACY;DECREASED_RESPONSE
N-DESMETHYLTRAMADOL;UGT1A8;rs8330;CC;LADME_PK;DECREASED_CONCENTRATIONS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC + CT;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC + CT;EFFICACY;INCREASED_RESPONSE
NICOTINE;CHRNA4;rs2229959;C;OTHER;INCREASED_RESPONSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;TUT7;rs17461620;C;EFFICACY;DECREASED_RESPONSE
ACETYLCYSTEINE;TOLLIP;rs3750920;TT;EFFICACY;INCREASED_RESPONSE
OXCARBAZEPINE;ABCB1;rs1045642;A;EFFICACY;DECREASED_RESPONSE
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
OXCARBAZEPINE;UGT2B7;rs7439366;C;EFFICACY;DECREASED_RESPONSE
ARA-CTP;CDA;rs12404655;AG + GG;LADME_PK;INCREASED_CONCENTRATIONS
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE
ARA-CTP;RRM1;rs11030918;CT + TT;LADME_PK;DECREASED_CONCENTRATIONS
CLOZAPINE;CYP1A2;rs762551;AA;LADME_PK;INCREASED_CONCENTRATIONS
CLOPIDOGREL;CYP3A5;rs776746;CC + CT;EFFICACY;INCREASED_RESISTANCE
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE
ARA-CTP;CTPS1;rs11577910;AG;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_METABOLISM
ARA-CTP;CTPS1;rs12067645;AA + AG;LADME_PK;INCREASED_CONCENTRATIONS
ARA-CTP;CTPS1;rs4364871;CT + TT;LADME_PK;DECREASED_CONCENTRATIONS
N-DESMETHYLTRAMADOL;UGT1A8;rs10929303;CC;LADME_PK;DECREASED_CONCENTRATIONS
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;UGT1A8;rs34650714;CC;LADME_PK;DECREASED_CONCENTRATIONS
ARA-CTP;SLC28A1;rs11853372;TT;LADME_PK;DECREASED_CONCENTRATIONS
ARA-CTP;DCTD;rs4742;GG;LADME_PK;DECREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_METABOLISM
ALLOPURINOL;ABCG2;rs2231142;GT + TT;EFFICACY;DECREASED_RESPONSE
OXCARBAZEPINE;ABCB1;rs1045642;GG;LADME_PK;INCREASED_CONCENTRATIONS
AMANTADINE, ANTICHOLINERGICS, LEVODOPA, SELEGILINE;SLC22A1;rs622342;C;DOSAGE, EFFICACY;INCREASED_DOSE
ARA-CTP;DCK;rs4643786;CC + CT;LADME_PK;DECREASED_CONCENTRATIONS
CLOZAPINE;CYP1A2;rs762551;AA;LADME_PK;DECREASED_CONCENTRATIONS
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs12980275;AA;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
MORPHINE-3-GLUCURONIDE, MORPHINE-6-GLUCURONIDE;ABCC3;rs4793665;CC;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;ABCB1;rs1128503;GG;LADME_PK;DECREASED_CONCENTRATIONS
MORPHINE-3-GLUCURONIDE;ABCC3;rs4148412;TT;LADME_PK;INCREASED_CONCENTRATIONS
GLUCOSE;CRTC2;rs8450;AA + AG;TOXICITY;INCREASED_CONCENTRATIONS
ACENOCOUMAROL;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLCO1C1;rs3794271;AG + GG;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;ABCB1;rs1128503;GG;LADME_PK;INCREASED_DOSE
SERTRALINE;GNB3;rs5441;GG;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS
FENTANYL;CYP3A4;rs2242480;TT;EFFICACY;INCREASED_RESPONSE
SUFENTANIL;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE
SUFENTANIL;OPRM1;rs1323040;AG + GG;DOSAGE;INCREASED_DOSE
SUFENTANIL;ABCB1;rs1128503;AA + AG;DOSAGE;INCREASED_DOSE
CYCLOSPORINE;ABCB1;rs1045642;A;EFFICACY;DECREASED_RESPONSE
SUFENTANIL;ABCB1;rs2032582;AA + AC;DOSAGE;INCREASED_DOSE
MORPHINE;OPRM1;rs1799971;GG;DOSAGE;INCREASED_DOSE
HDL CHOLESTEROL;CRTC2;rs8450;AA;TOXICITY;DECREASED_CONCENTRATIONS
O-DESMETHYLTRAMADOL;SLC22A1;rs34130495;GG;LADME_PK;DECREASED_CONCENTRATIONS
MYCOPHENOLIC ACID;ABCC2;rs717620;TT;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
METHYLPHENIDATE;COMT;rs4680;GG;EFFICACY;INCREASED_RESPONSE
METHYLPHENIDATE;COMT;rs4680;GG;EFFICACY;INCREASED_RESPONSE
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;SLC22A1;rs1867351;TT;LADME_PK;DECREASED_CONCENTRATIONS
PHENYTOIN;CYP2C9;rs12782374;AA + AG;DOSAGE, LADME_PK;DECREASED_DOSE
WARFARIN;CYP2C9;rs1057910;C;DOSAGE, LADME_PK;DECREASED_DOSE
FENTANYL;ABCC3;rs8077268;T;LADME_PK;INCREASED_CLEARANCE
METHYLPHENIDATE;COMT;rs4680;G;EFFICACY;INCREASED_CLEARANCE
WARFARIN;CYP2C9;rs1799853;T;DOSAGE, LADME_PK;DECREASED_DOSE
PLATINUM COMPOUNDS;XRCC1;rs25487;CC;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE
CYCLOSPORINE;ABCB1;rs1045642;GG;LADME_PK;DECREASED_CONCENTRATIONS
NICOTINE;CYP1A2;rs35694136;T/del + del/del;EFFICACY;DECREASED_EXPOSURE
SIROLIMUS;CYP3A5;rs776746;CC;DOSAGE, LADME_PK;DECREASED_METABOLISM
PLATINUM COMPOUNDS;ERCC1;rs3212986;CC;EFFICACY;INCREASED_RESPONSE
MYCOPHENOLIC ACID;UGT2B7;rs7662029;G;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
METHYLPHENIDATE;TH;rs2070762;GG;EFFICACY;DECREASED_RESPONSE
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;IL18;rs5744247;CC + CG;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
SIROLIMUS;CYP3A4;rs2740574;CC + CT;DOSAGE, LADME_PK;INCREASED_DOSE
SIROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME_PK;INCREASED_DOSE
CETUXIMAB;FCGR2A;rs1801274;AA;EFFICACY;INCREASED_RESPONSE
CARBAMAZEPINE;CYP3A4;rs2242480;CC;LADME_PK;INCREASED_CONCENTRATIONS
RISPERIDONE;HTR2C;rs518147;CC;EFFICACY;INCREASED_RESPONSE
CARBAMAZEPINE;CYP3A5;rs776746;CC;LADME_PK;INCREASED_CONCENTRATIONS
SITAGLIPTIN, VILDAGLIPTIN;GLP1R;rs6923761;AA;EFFICACY;DECREASED_CLINICAL BENEFIT
DESETHYLCHLOROQUINE, HYDROXYCHLOROQUINE;CYP2C8;rs7910936;C;LADME_PK;INCREASED_CONCENTRATIONS
CARBAMAZEPINE;ABCB1;rs1045642;GG;LADME_PK;INCREASED_CONCENTRATIONS
CARBAMAZEPINE;EPHX1;rs3738046;CG;LADME_PK;CONCENTRATIONS
ROSUVASTATIN;SLCO1B1;rs4149056;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS
PHENYTOIN;CYP2C9;rs1057910;AC;OTHER, LADME_PK;DECREASED_METABOLISM
PHENYTOIN;CYP2C9;rs1799853;CT;LADME_PK;DECREASED_METABOLISM
PHENYTOIN;CYP2C19;rs4244285;AG;OTHER, LADME_PK;DECREASED_METABOLISM
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
CLOZAPINE;HTR2C;rs6318;C;EFFICACY;INCREASED_RESPONSE
CARBAMAZEPINE;EPHX1;rs2234922;AG + GG;LADME_PK;CONCENTRATIONS
CARBAMAZEPINE;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE
SULFONAMIDES, UREA DERIVATIVES;TCF7L2;rs12255372;TT;EFFICACY;DECREASED_RESPONSE
SIMVASTATIN;SLCO1B1;rs4149056;TT;EFFICACY;INCREASED_RESPONSE
CARBOPLATIN, CISPLATIN, FLUOROURACIL;XRCC1;rs25487;T;EFFICACY;DECREASED_RESPONSE
TRAMADOL;ABCB1;rs2032582;AA;LADME_PK;INCREASED_EXPOSURE
TRAMADOL;ABCB1;rs1045642;AA;LADME_PK;INCREASED_EXPOSURE
CARBOPLATIN, CISPLATIN, FLUOROURACIL;SLC19A1;rs12659;A;EFFICACY;DECREASED_RESPONSE
TRAMADOL;ABCB1;rs1128503;AA;LADME_PK;INCREASED_EXPOSURE
TOCILIZUMAB;IL6R;rs12083537;AA;EFFICACY;DECREASED_RESPONSE
CAFFEINE;ADORA1;rs16851030;CC;EFFICACY;INCREASED_RESPONSE
TOCILIZUMAB;IL6R;rs4329505;CC + CT;EFFICACY;DECREASED_RESPONSE
RISPERIDONE;HTR2C;rs1023574;CC;EFFICACY;INCREASED_RESPONSE
RISPERIDONE;HTR2C;rs9698290;TT;EFFICACY;INCREASED_RESPONSE
DIURETICS, HYDROCHLOROTHIAZIDE, THIAZIDES, PLAIN;PRKCA;rs16960228;A;EFFICACY;INCREASED_RESPONSE
ANTIDEPRESSANTS;RGS17;rs672170;A;EFFICACY;INCREASED_RESPONSE
LITHIUM;NTRK2;rs1387923;AA;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C9;rs7089580;AT;DOSAGE;INCREASED_DOSE
WARFARIN;CYP2C9;rs7089580;AT;DOSAGE;INCREASED_CLEARANCE
VORICONAZOLE;SLCO1B3;rs4149117;GT + TT;LADME_PK;DECREASED_TROUGH CONCENTRATION
LITHIUM;GSK3B;rs334558;G;EFFICACY;INCREASED_RESPONSE
OXALIPLATIN;TP53;rs1042522;CG + GG;EFFICACY;DECREASED_RESPONSE
ANTIDEPRESSANTS;NBEA;rs9315310;T;EFFICACY;INCREASED_RESPONSE
ANTIDEPRESSANTS;CRH;rs4737771;C;EFFICACY;DECREASED_RESPONSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
ANTIDEPRESSANTS;FHIT;rs49411;C;EFFICACY;DECREASED_RESPONSE
ANTIDEPRESSANTS;PARP11;rs2532560;G;EFFICACY;INCREASED_RESPONSE
ANTIDEPRESSANTS;;rs2831440;T;EFFICACY;INCREASED_RESPONSE
SILDENAFIL;GNB3;rs5443;TT;EFFICACY;INCREASED_RESPONSE
ANTIDEPRESSANTS;MTRF1L;rs766127;G;EFFICACY;INCREASED_RESPONSE
ATORVASTATIN;POR;rs1057868;CT + TT;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;HSD11B1;rs846908;AA;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
SARILUMAB;IL6R;rs4845625;CC;EFFICACY;DECREASED_RESPONSE
SALVIANOLIC ACID B;NOS3;rs1799983;GG;EFFICACY;INCREASED_RESPONSE
BUPROPION;COMT;rs165599;AA + AG;EFFICACY;INCREASED_RESPONSE
LITHIUM;TPH1;rs1799913;TT;EFFICACY;DECREASED_RESPONSE
BUPROPION;COMT;rs737865;AA;EFFICACY;DECREASED_RESPONSE
LITHIUM;TPH1;rs1800532;TT;EFFICACY;DECREASED_RESPONSE
LITHIUM;CACNG2;rs2284017;CC;EFFICACY;INCREASED_RESPONSE
SALBUTAMOL;CRHR2;rs2267715;G;EFFICACY;DECREASED_RESPONSE
DESETHYLCHLOROQUINE, HYDROXYCHLOROQUINE;CYP2C8;rs10882521;T;LADME_PK;DECREASED_CONCENTRATIONS
LITHIUM;BCR;rs140504;A;EFFICACY;DECREASED_RESPONSE
SALMETEROL;ADRB2;rs1042713;AA;EFFICACY;DECREASED_RESPONSE
WARFARIN;STX1B;rs4889606;AG + GG;DOSAGE;INCREASED_DOSE
ADALIMUMAB;HFE;rs2071303;CC + CT;EFFICACY;INCREASED_RESPONSE
ROSIGLITAZONE;LPIN1;rs10192566;G;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;HSD11B1;rs4844880;AA;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
DESETHYLCHLOROQUINE, HYDROXYCHLOROQUINE;CYP2D6;rs1065852;AA;LADME_PK;DECREASED_CONCENTRATIONS
TACROLIMUS;HSD11B1;rs846910;AA;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE
ACENOCOUMAROL;GATA4;rs3735814;AG + GG;DOSAGE;DECREASED_DOSE
BETA BLOCKING AGENTS, SELECTIVE, DIURETICS;NEDD4L;rs4149601;AG + GG;EFFICACY;INCREASED_RESPONSE
ANTIDEPRESSANTS;CTNNA3;rs10997242;C;EFFICACY;DECREASED_RESPONSE
ALDOSTERONE ANTAGONISTS, AMILORIDE;NEDD4L;rs4149601;G;EFFICACY;INCREASED_RESPONSE
LITHIUM;DRD1;rs4532;C;EFFICACY;DECREASED_RESPONSE
ANTIDEPRESSANTS;HTR2A;rs7997012;AG + GG;EFFICACY;INCREASED_RESPONSE
SALBUTAMOL;CRHR2;rs255100;A;EFFICACY;DECREASED_RESPONSE
ANTIDEPRESSANTS;HTR2A;rs6313;GG;EFFICACY;INCREASED_RESPONSE
ANTIDEPRESSANTS;CACNA1A;rs2112460;A;EFFICACY;INCREASED_RESPONSE
SALBUTAMOL;CRHR2;rs2284220;G;EFFICACY;DECREASED_RESPONSE
WARFARIN;ORM1;rs17650;AG + GG;DOSAGE;DECREASED_DOSE
ANTIDEPRESSANTS;;rs521093;T;EFFICACY;INCREASED_RESPONSE
MORPHINE;UGT2B7;rs7439366;CC;DOSAGE;DECREASED_DOSE
WARFARIN;VKORC1;rs7294;C;DOSAGE;DECREASED_DOSE
ANTIDEPRESSANTS;RAPGEF5;rs16873129;C;EFFICACY;DECREASED_RESPONSE
VALPROIC ACID;ABCB1;rs1128503;AA;EFFICACY;DECREASED_CLINICAL BENEFIT
ANTIDEPRESSANTS;PON2;rs2299267;G;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;C;LADME_PK;DECREASED_METABOLISM
TACROLIMUS;CYP3A5;rs776746;C;LADME_PK;DECREASED_METABOLISM
CISPLATIN;GALNT18;rs7937567;GG;EFFICACY;INCREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs2279343;AG + GG;LADME_PK;INCREASED_CONCENTRATIONS
RITUXIMAB;;rs3759467;CC;EFFICACY;DECREASED_RESPONSE
ANTIPSYCHOTICS, ARIPIPRAZOLE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE;CYP3A43;rs680055;CG;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME_PK;INCREASED_METABOLISM
TACROLIMUS;CYP3A5;rs776746;CT;LADME_PK;INCREASED_CLEARANCE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME_PK;INCREASED_CLEARANCE
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_STEADY_STATE CONCENTRATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_METABOLISM
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_METABOLISM
WARFARIN;VKORC1;rs9923231;A;DOSAGE;DOSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_METABOLISM
CORTICOSTEROIDS;HDAC1;rs1741981;CC;EFFICACY;DECREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS
VINCRISTINE;MTNR1B;rs8192552;AG;LADME_PK;INCREASED_EXPOSURE
MORPHINE;TLR2;rs3804100;CC + CT;DOSAGE, EFFICACY;DECREASED_DOSE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;rs776746;CT;OTHER, LADME_PK;INCREASED_METABOLISM
DOCETAXEL, THALIDOMIDE;CHST3;rs4148947;T;EFFICACY;INCREASED_RESPONSE
MORPHINE;IL1B;rs1143634;A;DOSAGE, EFFICACY;DECREASED_DOSE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS
CISPLATIN;MLLT3;rs10964552;AA + AC;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME_PK;INCREASED_METABOLISM
TACROLIMUS;CYP3A5;rs776746;T;DOSAGE, LADME_PK;INCREASED_METABOLISM
MORPHINE;IL1B;rs1143634;A;DOSAGE, EFFICACY;INCREASED_DOSE
EFAVIRENZ;CYP2B6;rs28399499;CT;LADME_PK;INCREASED_CONCENTRATIONS
DOCETAXEL, THALIDOMIDE;CHST3;rs4148950;A;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME_PK;INCREASED_METABOLISM
TACROLIMUS;CYP3A5;rs776746;TT;DOSAGE, LADME_PK;INCREASED_CLEARANCE
ATORVASTATIN;MTTP;rs1800591;TT;EFFICACY;INCREASED_RESPONSE
NITROGLYCERIN;ALDH2;rs671;AA + AG;EFFICACY;DECREASED_RESPONSE
TOCILIZUMAB;GALNT18;rs4910008;CC;EFFICACY;INCREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS
CISPLATIN;RARS1;rs244898;TT;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT;DOSAGE, LADME_PK;INCREASED_CLEARANCE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE, LADME_PK;DECREASED_CLEARANCE
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DOSE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS
RISPERIDONE;ABCB1;rs2235048;AG + GG;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT;LADME_PK;INCREASED_DOSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_METABOLISM
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE, LADME_PK;DECREASED_DOSE
NITROGLYCERIN;ALDH2;rs671;AA + AG;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_METABOLISM
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;DECREASED_CLEARANCE
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE
TOCILIZUMAB;CD69;rs11052877;A;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_METABOLISM
PHENAZEPAM;CYP2C19;rs12248560;CC + CT;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME_PK;INCREASED_CLEARANCE
TACROLIMUS;CYP3A5;rs776746;TT;LADME_PK;INCREASED_CLEARANCE
VINCRISTINE;SNU13;rs6519270;G;LADME_PK;INCREASED_CONCENTRATIONS
ATENOLOL;;rs7184292;A;EFFICACY;INCREASED_RESPONSE
ATENOLOL;XIRP2;rs7606603;C;EFFICACY;DECREASED_RESPONSE
CYCLOSPORINE;CYP3A7;rs10211;TT;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DOSE
CYCLOSPORINE;CYP3A7;rs2257401;CC;LADME_PK;INCREASED_CONCENTRATIONS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;JAK2;rs12343867;CC;EFFICACY;DECREASED_RESPONSE
NILOTINIB;GSTP1;rs1695;A;EFFICACY;INCREASED_RESPONSE
HYDROCHLOROTHIAZIDE;;rs16872401;C;EFFICACY;INCREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL12B;rs3212217;GG;EFFICACY;INCREASED_RESPONSE
CYCLOSPORINE;CYP3A4;rs4646437;GG;LADME_PK;INCREASED_CONCENTRATIONS
PAROXETINE;ABCB1;rs2032582;CC + CT;EFFICACY;DECREASED_RESPONSE
NILOTINIB;CYP1A1;rs1048943;CT + TT;EFFICACY;INCREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;NLRP3;rs10754558;CG + GG;EFFICACY;INCREASED_RESPONSE
ATENOLOL;;rs7184292;GG;DOSAGE;DECREASED_DOSE
ATORVASTATIN;SLCO1B1;rs2306283;GG;EFFICACY;DECREASED_CLINICAL BENEFIT
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL18;rs1946518;GT + TT;EFFICACY;INCREASED_RESPONSE
RISPERIDONE;AKT1;rs3803300;CT;EFFICACY;INCREASED_RESPONSE
RISPERIDONE;AKT1;rs2494732;TT;EFFICACY;INCREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNGR1;rs2234711;AG;EFFICACY;DECREASED_RESPONSE
IMATINIB;CYP2B6;rs3745274;GG + TT;EFFICACY;INCREASED_RESISTANCE
WARFARIN;CYP2C19;rs4986893;AA + AG;DOSAGE;DECREASED_DOSE
CYCLOSPORINE;CYP3A5;rs776746;CC;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;CYP2C19;rs3814637;CT + TT;DOSAGE;DECREASED_DOSE
CANNABIDIOL;AOC1;rs12539;CT + TT;EFFICACY;INCREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TBX21;rs17250932;CC;EFFICACY;DECREASED_RESPONSE
VINCRISTINE;RAB7A;rs4548;CT;LADME_PK;INCREASED_EXPOSURE
DOCETAXEL, THALIDOMIDE;CHST3;rs730720;C;EFFICACY;INCREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNGR2;rs8126756;CC;EFFICACY;DECREASED_RESPONSE
CANNABIDIOL;SLC15A1;rs1339067;TT;EFFICACY;DECREASED_RESPONSE
WARFARIN;;rs12772169;T;DOSAGE;DOSE
ROSIGLITAZONE;SLCO1B1;rs4149056;C;EFFICACY;INCREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL12B;rs3212217;CG + GG;EFFICACY;DECREASED_RESPONSE
CORTICOSTEROIDS FOR SYSTEMIC USE;HDAC1;rs1741981;CC;EFFICACY;DECREASED_RESPONSE
WARFARIN;NQO1;rs1800566;A;EFFICACY;DECREASED_RESPONSE
RISPERIDONE;COMT;rs165599;G;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;A;DOSAGE;DOSE
RISPERIDONE;GRM3;rs724226;G;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;DOSE
ATENOLOL, BISOPROLOL, CELIPROLOL, DOXAZOSIN;KCNH2;rs1137617;GG;EFFICACY;RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR5;rs5744174;AG;EFFICACY;DECREASED_RESPONSE
MORPHINE;KCNJ6;rs6517442;CC;EFFICACY;INCREASED_RESPONSE
METHOTREXATE;ABCG2;rs2231142;GT;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE
TACROLIMUS;POR;rs1057868;CT + TT;LADME_PK;DECREASED_TROUGH CONCENTRATION
MORPHINE, REMIFENTANIL;KCNJ6;rs6517442;TT;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE
LOW DENSITY LIPOPROTEIN;SH2B1;rs3888190;CC;OTHER;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;rs776746;T;DOSAGE;INCREASED_DOSE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;DECREASED_CLEARANCE
ENALAPRIL;VEGFA;rs699947;AA + AC;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS
LITHIUM;CACNG2;rs2284018;TT;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE
EFAVIRENZ;ABCB1;rs1045642;GG;LADME_PK;INCREASED_CONCENTRATIONS
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS
ANASTROZOLE;;rs1437153;T;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_DOSE
DOCETAXEL;ORM2;rs2250242;AA;LADME_PK;INCREASED_CLEARANCE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE
ETANERCEPT, INFLIXIMAB;CARD8;rs2043211;TT;EFFICACY;DECREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_CONCENTRATIONS
METHOTREXATE;ABCB1;rs1045642;AA + AG;EFFICACY;DECREASED_RESPONSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;TT;DOSAGE, LADME_PK;INCREASED_DOSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNGR1;rs2234711;AG;EFFICACY;DECREASED_RESPONSE
ETANERCEPT, INFLIXIMAB;NLRP3;rs4612666;TT;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE
ANASTROZOLE;DLG2;rs2449598;T;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;rs776746;T;DOSAGE;INCREASED_DOSE
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
EFAVIRENZ;CYP2B6;rs2279343;GG;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_METABOLISM
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE
TACROLIMUS;CYP3A4;rs2242480;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
METHOTREXATE;MTHFR;rs1801133;AA;LADME_PK;INCREASED_CONCENTRATIONS
PEGINTERFERON ALFA-2B;HLA-DPA1;rs3077;GG;EFFICACY;INCREASED_RESPONSE
RIVASTIGMINE;BCHE;rs1803274;CC;EFFICACY;INCREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;CYP4F2;rs2108622;CC;DOSAGE;DECREASED_DOSE
METHOTREXATE;ABCB1;rs1045642;AG;LADME_PK;INCREASED_CONCENTRATIONS
ADALIMUMAB, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1800629;A;EFFICACY;DECREASED_RESPONSE
PRAVASTATIN;LDLR;rs1433099;TT;EFFICACY;INCREASED_RESPONSE
PRAVASTATIN;LDLR;rs2738466;GG;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
CANNABIDIOL;ABCC5;rs3749442;AA + AG;EFFICACY;DECREASED_RESPONSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs4803217;CC;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_CLEARANCE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_CLEARANCE
SUFENTANIL;NFKBIA;rs696;TT;DOSAGE;INCREASED_DOSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs11881222;AA;EFFICACY;INCREASED_RESPONSE
GLUCOSE;RABEP1;rs1000940;AG + GG;OTHER;DECREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME_PK;INCREASED_DOSE
PAROXETINE;BDNF;rs6265;TT;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME_PK;INCREASED_DOSE
REMIFENTANIL;COMT;rs4680;AA;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT;LADME_PK;INCREASED_CLEARANCE
MORPHINE;COMT;rs4680;GG;EFFICACY;DECREASED_RESPONSE
MORPHINE, REMIFENTANIL;COMT;rs4680;AA + AG;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT;DOSAGE, LADME_PK;INCREASED_CLEARANCE
ANTIPSYCHOTICS;ABCB1;rs2032582;CC;DOSAGE, LADME_PK;INCREASED_DOSE
ADALIMUMAB, INFLIXIMAB;TLR2;rs3804099;T;EFFICACY;DECREASED_RESPONSE
ANTIPSYCHOTICS;ABCB1;rs2032582;C;EFFICACY;INCREASED_RESPONSE
INTERFERON ALFA-N1, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
MORPHINE;COMT;rs4680;G;DOSAGE, EFFICACY;INCREASED_DOSE
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_EXPOSURE
INTERFERON ALFA-N1, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8103142;TT;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;T;LADME_PK;INCREASED_METABOLISM
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_CLEARANCE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs28416813;CC;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_METABOLISM
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_METABOLISM
IMATINIB;ABCG2;rs2231142;GT;EFFICACY;INCREASED_CLINICAL BENEFIT
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;DECREASED_METABOLISM
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_CLEARANCE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS
PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs8113007;AA;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME_PK;INCREASED_CLEARANCE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
CLOZAPINE;CHRM1;rs2075748;CC;DOSAGE;DECREASED_DOSE
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;CYP1B1;rs1056836;CC;EFFICACY;DECREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_EXPOSURE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs28416813;G;EFFICACY;INCREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_CONCENTRATIONS
INTERFERON ALFA-N1, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
INTERFERON ALFA-N1, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
ERENUMAB, FREMANEZUMAB, GALCANEZUMAB;;rs12615320;G;EFFICACY;DECREASED_RESPONSE
ROSUVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_DOSE
HYDROXYUREA;ASS1;rs10901080;T;EFFICACY;INCREASED_RESPONSE
ANASTROZOLE;CSMD1;rs6981827;T;EFFICACY;DECREASED_RESPONSE
HYDROXYUREA;ASS1;rs10793902;T;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;GG + GT;EFFICACY;DECREASED_RESPONSE
DOXORUBICIN;ABCB1;rs2032582;AA;LADME_PK;DECREASED_METABOLISM
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;GG + GT;EFFICACY;DECREASED_RESPONSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8103142;T;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT;DOSAGE;INCREASED_DOSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME_PK;INCREASED_DOSE
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE
EPIRUBICIN;NQO1;rs1800566;AA;EFFICACY, TOXICITY;DECREASED_RESPONSE
DOCETAXEL, EPIRUBICIN;MDM4;rs1563828;AA;EFFICACY;INCREASED_RESPONSE
GEMCITABINE;CDA;rs2072671;C;LADME_PK;DECREASED_CLEARANCE
HYDROCHLOROTHIAZIDE;NEDD4L;rs75982813;AG + GG;EFFICACY;INCREASED_RESPONSE
GLICLAZIDE;KCNJ11;rs5219;TT;EFFICACY;INCREASED_RESPONSE
WARFARIN;;rs12777823;AA + AG;DOSAGE;DECREASED_DOSE
DOXORUBICIN;ABCB1;rs1045642;AA;LADME_PK;DECREASED_METABOLISM
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE
ARIPIPRAZOLE;DRD2;rs6277;GG;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE
CAPECITABINE, RADIOTHERAPY;AREG;rs11942466;AA + AC;EFFICACY;DECREASED_RESPONSE
(S)-METHADONE;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS
(R)-METHADONE;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS
CAPECITABINE, RADIOTHERAPY;ERCC1;rs11615;AG + GG;EFFICACY;DECREASED_RESPONSE
CAPECITABINE, OXALIPLATIN;VEGFA;rs2010963;CG;EFFICACY;DECREASED_RESPONSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
ARIPIPRAZOLE;ANKK1;rs1800497;AA + AG;EFFICACY;INCREASED_RESPONSE
MORPHINE;COMT;rs4633;C;DOSAGE, EFFICACY;INCREASED_DOSE
CLOZAPINE;HTR3A;rs1150226;G;EFFICACY;INCREASED_RESPONSE
RISPERIDONE;GRM7;rs2069062;CC;EFFICACY;INCREASED_RESPONSE
CLOPIDOGREL;ABCB1;rs1045642;AA + AG;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_CLEARANCE
CLOZAPINE;HTR3A;rs2276302;A;EFFICACY;INCREASED_RESPONSE
GLUCOSE;COMT;rs4680;AA + AG;TOXICITY;INCREASED_CONCENTRATIONS
CLOZAPINE;HTR3A;rs1062613;C;EFFICACY;INCREASED_RESPONSE
CLOPIDOGREL;ABCB1;rs1045642;AA + AG;LADME_PK;DECREASED_METABOLISM
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_METABOLISM
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;PTPRC;rs10919563;G;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_DISCONTINUATION
RISPERIDONE;GRID2;rs1875705;GG;EFFICACY;INCREASED_RESPONSE
CLOPIDOGREL;ABCB1;rs1045642;AA + AG;EFFICACY;DECREASED_RESPONSE
PACLITAXEL;ABCB1;rs2032582;CC;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;NR1I2;rs2276707;CC;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;rs776746;CT;DOSAGE, LADME_PK;INCREASED_CLEARANCE
CAPECITABINE, OXALIPLATIN;VEGFA;rs699947;AC;EFFICACY;DECREASED_RESPONSE
WARFARIN;PRSS53, VKORC1;rs17886199;A;DOSAGE;DECREASED_DOSE
4-HYDROXYATORVASTATIN, 4-HYDROXYATORVASTATIN LACTONE;SLCO2B1;rs12422149;AG;LADME_PK;INCREASED_CONCENTRATIONS
PACLITAXEL;ABCB1;rs2032582;AA + AT;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_CLEARANCE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs11881222;AG + GG;EFFICACY;DECREASED_RESPONSE
2-HYDROXYATORVASTATIN LACTONE, 4-HYDROXYATORVASTATIN LACTONE, ATORVASTATIN LACTONE;UGT1A1;rs887829;CC;LADME_PK;DECREASED_CONCENTRATIONS
BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;RGS5;rs1056515;TT;EFFICACY;INCREASED_RESPONSE
SN-38;UGT1A1;rs4148323;AA;DOSAGE;DECREASED_METABOLISM
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8105790;CC + CT;EFFICACY;DECREASED_RESPONSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs12980275;AG + GG;EFFICACY;DECREASED_RESPONSE
VALPROIC ACID;GABRA1;rs10068980;AA + AG;EFFICACY;INCREASED_CLINICAL BENEFIT
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CT + TT;EFFICACY;DECREASED_RESPONSE
CLOZAPINE;CHRM1;rs1942499;GG;DOSAGE;DECREASED_DOSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;GG + GT;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_CLEARANCE
ROSUVASTATIN;SCAP;rs12487736;C;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs4803219;CT;EFFICACY;DECREASED_RESPONSE
BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;RALBP1;rs329007;GG;EFFICACY;DECREASED_RESPONSE
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE
ROCURONIUM;ABCB1;rs1128503;AA;EFFICACY;DECREASED_RESPONSE
MYCOPHENOLIC ACID;UGT1A9;rs6714486;AA + AT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
ACENOCOUMAROL;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;DECREASED_CLEARANCE
ROCURONIUM;SLCO1B1;rs2306283;AA;EFFICACY;DECREASED_RESPONSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;G;EFFICACY;DECREASED_RESPONSE
PERAMPANEL;CYP3A5, ZSCAN25;rs776746;C;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_CLEARANCE
MORPHINE;UGT2B7;rs7438135;AA + AG;LADME_PK;DECREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;DECREASED_CLEARANCE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;GT;EFFICACY;DECREASED_RESPONSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs7248668;AA + AG;EFFICACY;DECREASED_RESPONSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs10853728;GG;EFFICACY;DECREASED_RESPONSE
PRAVASTATIN;SLCO1B1;rs4149056;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS
PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs10853728;CG + GG;EFFICACY;DECREASED_RESPONSE
ACENOCOUMAROL;CYP4F2;rs2108622;TT;DOSAGE;INCREASED_DOSE
IMATINIB;ABCG2;rs2725252;C;EFFICACY;INCREASED_RESPONSE
PHENPROCOUMON;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE
ATENOLOL, IRBESARTAN;EDN1;rs5370;GT;EFFICACY;INCREASED_RESPONSE
PAROXETINE;HTR2A;rs6311;CC;EFFICACY;INCREASED_RESPONSE
PHENPROCOUMON;CYP2C9;rs4086116;T;DOSAGE;DECREASED_DOSE
ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;APOE;rs7412;C;EFFICACY;DECREASED_RESPONSE
IMATINIB;ABCG2;rs2725252;C;EFFICACY;INCREASED_RESPONSE
ATAZANAVIR;NR1I2;rs2472677;CT;LADME_PK;DECREASED_CONCENTRATIONS
PRAVASTATIN;SLCO1B1;rs4149015;AG;LADME_PK;INCREASED_METABOLISM
APIXABAN;CYP3A5;rs776746;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS
IMATINIB;ABCG2;rs12505410;G;EFFICACY;INCREASED_RESPONSE
NIACIN;HCAR2;rs2454727;CT + TT;EFFICACY;DECREASED_RESPONSE
ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;ABCA1;rs12003906;C;EFFICACY;DECREASED_RESPONSE
CEFTRIAXONE;ABCG2;rs13120400;TT;LADME_PK;CONCENTRATIONS
RIBAVIRIN;ITPA;rs1127354;CC;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;rs776746;CT;LADME_PK;DECREASED_EXPOSURE
PRAVASTATIN;SLCO1B1;rs4149015;AG;LADME_PK;INCREASED_RESPONSE
CREATINE;MOBP;rs616147;AA + AG;EFFICACY;INCREASED_RESPONSE
PEMETREXED;EXO1;rs1047840;AA + AG;EFFICACY;DECREASED_CLINICAL BENEFIT
PRAVASTATIN;SLCO1B1;rs4149056;CT;EFFICACY;INCREASED_RESPONSE
PHENPROCOUMON;STX4;rs10871454;T;DOSAGE;DECREASED_DOSE
PRAVASTATIN;SLCO1B1;rs4149056;CT;LADME_PK;INCREASED_METABOLISM
PROPOFOL;CYP2B6;rs3745274;GT + TT;DOSAGE;DECREASED_DOSE
ADALIMUMAB, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR9;rs352139;CT + TT;EFFICACY;INCREASED_RESPONSE
VALPROIC ACID;CYP2C19;rs4244285;AA + AG;DOSAGE, LADME_PK;INCREASED_DOSE
APIXABAN;ABCG2;rs2231142;TT;LADME_PK;INCREASED_CONCENTRATIONS
IVACAFTOR;CFTR;rs121908755;A;EFFICACY;RESPONSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
3,4-METHYLENEDIOXYMETHAMPHETAMINE;SLC6A2;rs2242446;TT;OTHER;DECREASED_RESPONSE
ATENOLOL;AGT;rs699;AG + GG;EFFICACY;INCREASED_RESPONSE
3,4-METHYLENEDIOXYMETHAMPHETAMINE;SLC6A2;rs1861647;GG;OTHER;INCREASED_RESPONSE
3,4-METHYLENEDIOXYMETHAMPHETAMINE;SLC6A2;rs36029;AA;OTHER;INCREASED_RESPONSE
ATENOLOL;AGT;rs5051;CT + TT;EFFICACY;INCREASED_RESPONSE
TEMOZOLOMIDE;ABCB1;rs2229109;CT;EFFICACY;DECREASED_RESPONSE
FOLLITROPIN BETA, UROFOLLITROPIN;FSHR;rs6166;T;TOXICITY;INCREASED_RESPONSE
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, GLUCOCORTICOIDS, INFLIXIMAB, METHOTREXATE;HLA-E;rs1264457;AA;EFFICACY;INCREASED_RESPONSE
REPAGLINIDE;SLC30A8;rs13266634;CT + TT;EFFICACY;INCREASED_RESPONSE
DISULFIRAM;ADRA1A;rs1048101;AA + AG;EFFICACY;INCREASED_RESPONSE
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, GLUCOCORTICOIDS, INFLIXIMAB, METHOTREXATE;ATP5F1E;rs1059150;GG;EFFICACY;DECREASED_RESPONSE
SIROLIMUS;ABCB1;rs1045642;AG;LADME_PK;INCREASED_CONCENTRATIONS
MERCAPTOPURINE;NUDT15;rs116855232;TT;DOSAGE;DECREASED_DOSE
DEXMEDETOMIDINE;CYP2A6;rs28399433;C;LADME_PK;DECREASED_CLEARANCE
IRBESARTAN;CYP2C9;rs1799853;CT;EFFICACY;INCREASED_RESPONSE
FENTANYL;CALCA;rs145837941;GG;DOSAGE;INCREASED_DOSE
NITRIC OXIDE;NAMPT;rs1319501;TT;EFFICACY;INCREASED_CONCENTRATIONS
TOCILIZUMAB;GALNT18;rs4910008;CC + CT;EFFICACY;INCREASED_CLINICAL BENEFIT
BUPRENORPHINE;OPRD1;rs529520;AA;EFFICACY;DECREASED_RESPONSE
NICOTINE;;rs12459249;C;LADME_PK;DECREASED_METABOLISM
WARFARIN;GGCX;rs2592551;AA + AG;DOSAGE;INCREASED_DOSE
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR7;rs7905446;TT;EFFICACY;DECREASED_RESPONSE
ESCITALOPRAM;HTR7;rs7905446;TT;EFFICACY;DECREASED_RESPONSE
ATOMOXETINE, DESVENLAFAXINE, DULOXETINE, SELECTIVE SEROTONIN REUPTAKE INHIBITORS, VENLAFAXINE;HTR7;rs7905446;TT;EFFICACY;DECREASED_RESPONSE
TOCILIZUMAB;IL6;rs2069840;CC;EFFICACY;DECREASED_CLINICAL BENEFIT
ANTIDEPRESSANTS;HTR7;rs7905446;TT;EFFICACY;DECREASED_RESPONSE
BENAZEPRIL;MTHFR;rs1801131;G;EFFICACY;DECREASED_RESPONSE
FLUOXETINE, PAROXETINE;HTR7;rs7905446;TT;EFFICACY;DECREASED_RESPONSE
BENAZEPRIL;MTHFR;rs1801133;G;EFFICACY;DECREASED_RESPONSE
IRBESARTAN;CYP2C9;rs1057910;AC;LADME_PK;INCREASED_CONCENTRATIONS
PAROXETINE;HTR7;rs7905446;TT;EFFICACY;DECREASED_RESPONSE
FENTANYL;CALCA;rs145837941;AG + GG;DOSAGE;INCREASED_DOSE
EFAVIRENZ;CYP2B6;rs28399499;CC + CT;LADME_PK;DECREASED_CLEARANCE
PEMETREXED;CAMKK2;rs1653586;GT;EFFICACY;DECREASED_CLINICAL BENEFIT
ABIRATERONE;SRD5A2;rs523349;CC;EFFICACY;INCREASED_RESPONSE
BUPRENORPHINE;OPRD1;rs581111;AA + AG;EFFICACY;DECREASED_RESPONSE
CARBOPLATIN, LONAFARNIB, PACLITAXEL;FNTB;rs11623866;GG;EFFICACY;RESPONSE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;DECREASED_CLEARANCE
METHOTREXATE;ABCG2;rs12505410;GG;LADME_PK;INCREASED_CLEARANCE
ESCITALOPRAM;BMP5;rs41271330;A;EFFICACY;DECREASED_RESPONSE
ESCITALOPRAM;BMP5;rs41271330;AA + AG;EFFICACY;INCREASED_DOSE
METHOTREXATE;ABCG2;rs13137622;GT + TT;LADME_PK;INCREASED_CLEARANCE
METHOTREXATE;ABCG2;rs13120400;CC;LADME_PK;INCREASED_CLEARANCE
AMLODIPINE;CYP3A4;rs2740574;CT + TT;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;IL18;rs1946518;GG + GT;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TACROLIMUS;IL10;rs1800896;TT;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
RIVASTIGMINE;BCHE;rs1803274;CT + TT;EFFICACY;DECREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;CONCENTRATIONS
EFAVIRENZ;CYP2B6;rs35303484;G;LADME_PK;CONCENTRATIONS
VALPROIC ACID;CYP2C9;rs1057910;C;LADME_PK;INCREASED_CONCENTRATIONS
METHOTREXATE;MTHFR;rs1801133;AG + GG;LADME_PK;INCREASED_STEADY_STATE CONCENTRATION
AZATHIOPRINE;NUDT15;rs116855232;TT;TOXICITY;DECREASED_DOSE
CLOZAPINE;NFIB;rs28379954;CT;LADME_PK;DECREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
METFORMIN;SLC22A1;rs594709;AA + AG;EFFICACY;INCREASED_RESPONSE
IRINOTECAN;TDP1;rs2401863;GG;EFFICACY;INCREASED_RESPONSE
METFORMIN;SLC47A1;rs2289669;GG;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;IL18;rs5744247;CC + CG;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
METHOTREXATE;SLC19A1;rs1051266;TT;LADME_PK;INCREASED_STEADY_STATE CONCENTRATION
DEXMEDETOMIDINE;CYP2D6;rs16947;GG;DOSAGE;INCREASED_DOSE
CARBAMAZEPINE;CYP1A2;rs762551;AA;LADME_PK;INCREASED_CLEARANCE
RIVAROXABAN;CYP3A4;rs2242480;T;LADME_PK;INCREASED_CONCENTRATIONS
CYCLOSPORINE, TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE, LADME_PK;INCREASED_CONCENTRATIONS
METHOTREXATE;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs4148324;GG + GT;LADME_PK;DECREASED_CLEARANCE
EFAVIRENZ;ABCB1;rs3842;C;LADME_PK;CONCENTRATIONS
CYCLOSPORINE, TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE, LADME_PK;DECREASED_DOSE
DEXMEDETOMIDINE;WBP2NL;rs5758550;AG + GG;TOXICITY;INCREASED_RESPONSE
MEMANTINE, RIVASTIGMINE;BCHE;rs1803274;CT + TT;EFFICACY;DECREASED_RESPONSE
IVACAFTOR;CFTR;rs75527207;AA;EFFICACY;RESPONSE
WARFARIN;CYP4F2;rs2108622;CC;DOSAGE;DECREASED_DOSE
WARFARIN;GGCX;rs699664;CC;DOSAGE;INCREASED_DOSE
METHOTREXATE;MTHFR;rs1801131;GT;EFFICACY;DECREASED_RESPONSE
CLOPIDOGREL;ABCB1;rs1045642;AA;LADME_PK;DECREASED_EXPOSURE
TACROLIMUS;POR;rs1057868;CT + TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
WARFARIN;VKORC1;rs9934438;GG;DOSAGE;INCREASED_DOSE
RIVASTIGMINE;BCHE;rs1803274;CT;EFFICACY;INCREASED_RESPONSE
FENTANYL;CALCA;rs145837941;GG;DOSAGE;INCREASED_DOSE
APIXABAN;ABCG2;rs2231142;G;LADME_PK;DECREASED_CONCENTRATIONS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;rs1061622;GG;EFFICACY;DECREASED_RESPONSE
DEXMEDETOMIDINE;CYP1A2;rs762551;AC + CC;LADME_PK;INCREASED_CLEARANCE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;rs3397;CC;EFFICACY;DECREASED_RESPONSE
LATANOPROST;PTGFR;rs3766355;CC;EFFICACY;INCREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;rs1061631;AA;EFFICACY;DECREASED_RESPONSE
METHOTREXATE;MTHFR;rs1801133;AG;EFFICACY;DECREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;rs3397;C;EFFICACY;DECREASED_RESPONSE
METHADONE;NECTIN4;rs11265549;AA;LADME_PK;DECREASED_CONCENTRATIONS
OPIOID ANESTHETICS, OTHER GENERAL ANESTHETICS, VOLATILE ANESTHETICS;OPRM1;rs1799971;GG;EFFICACY;INCREASED_RESPONSE
OPIOID ANESTHETICS, OTHER GENERAL ANESTHETICS, VOLATILE ANESTHETICS;ABCG2;rs2231142;TT;EFFICACY;INCREASED_RESPONSE
METHADONE;NECTIN4;rs11265549;AA;DOSAGE;DECREASED_DOSE
DEXMEDETOMIDINE;KCNMA1;rs16934182;AA + AG;DOSAGE;DECREASED_DOSE
DABIGATRAN;CES1;rs2244613;GG + GT;LADME_PK;DECREASED_CONCENTRATIONS
ATORVASTATIN;ABCG8;rs11887534;CC + CG;EFFICACY;INCREASED_RESPONSE
CAPECITABINE;DPYD;rs3918290;CT;DOSAGE;DOSE
CAPECITABINE;DPYD;rs56038477;CT;DOSAGE;DOSE
CAPECITABINE;DPYD;rs67376798;AT;DOSAGE;DOSE
DEXMEDETOMIDINE;ADRA2A;rs1800544;GG;DOSAGE;DECREASED_DOSE
TAMOXIFEN-N-GLUCURONIDE;UGT1A4;rs2011425;GG + GT;LADME_PK;INCREASED_CONCENTRATIONS
IMATINIB;CYP2B6;rs3745274;GG + GT;EFFICACY;INCREASED_RESPONSE
ATORVASTATIN;CYP7A1;rs3808607;GG;EFFICACY;DECREASED_RESPONSE
METHOTREXATE;ATIC;rs4673993;CC;EFFICACY;INCREASED_RESPONSE
BENAZEPRIL;AGT;rs7079;GG;EFFICACY;RESPONSE
WARFARIN;CYP2C9;rs9332098;GG;DOSAGE;INCREASED_DOSE
CANNABIDIOL;;rs6729738;CC;EFFICACY;INCREASED_RESPONSE
METHOTREXATE;MTHFR;rs1801133;AG + GG;EFFICACY;INCREASED_RESPONSE
DEXMEDETOMIDINE;ADRB2;rs1042713;AA;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C9;rs9332092;TT;DOSAGE;INCREASED_DOSE
HYDROCHLOROTHIAZIDE;TXNDC11;rs3784921;G;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP2C9;rs1057910;CC;LADME_PK;DECREASED_CLEARANCE
PAROXETINE;CYP1A2;rs762551;A;LADME_PK;INCREASED_DOSE
WARFARIN;CYP2C9;rs1799853;TT;LADME_PK;DECREASED_CLEARANCE
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;DECREASED_CLEARANCE
DEXMEDETOMIDINE;KCNMA1;rs16934182;AA + AG;TOXICITY;INCREASED_RESPONSE
TOPOTECAN;ABCG2;rs4148157;AA + AG;LADME_PK;INCREASED_CONCENTRATIONS
EFAVIRENZ;CYP2B6;rs28399499;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS
RIVAROXABAN;CYP3A4;rs2246709;G;LADME_PK;INCREASED_CONCENTRATIONS
DULOXETINE;KMT2E;rs117986340;GG;EFFICACY;INCREASED_RESPONSE
RIVASTIGMINE;ACHE;rs2571598;TT;EFFICACY;INCREASED_RESPONSE
MORPHINE;OPRM1;rs1799971;AG + GG;DOSAGE, EFFICACY;INCREASED_DOSE
DULOXETINE;NCAM1;rs2303377;TT;EFFICACY;INCREASED_RESPONSE
RIVAROXABAN;CYP3A5;rs776746;T;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS
DULOXETINE;ZNF385D;rs4261893;TT;EFFICACY;INCREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs2279343;AG + GG;LADME_PK;INCREASED_CONCENTRATIONS
RIVAROXABAN;CYP3A4;rs3735451;C;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;VKORC1;rs2359612;GG;DOSAGE;INCREASED_DOSE
WARFARIN;VKORC1;rs7294;TT;DOSAGE;INCREASED_DOSE
DEXMEDETOMIDINE;;rs141294036;CC;TOXICITY;INCREASED_RESPONSE
AMPHETAMINE;CDH13;rs3784943;AG + GG;EFFICACY;INCREASED_RESPONSE
EVEROLIMUS;CYP3A4;rs35599367;AG;LADME_PK;INCREASED_CONCENTRATIONS
PRAVASTATIN;SLCO1B1;rs4149056;CT;EFFICACY;DECREASED_RESPONSE
DEXMEDETOMIDINE;KCNMB1;rs11739136;CC + CT;EFFICACY;INCREASED_RESPONSE
MORPHINE;UGT2B7;rs7668282;CC + CT;LADME_PK;DECREASED_METABOLISM
MIVACURIUM;BCHE;rs755648929;AG;EFFICACY;INCREASED_RESPONSE
SUCCINYLCHOLINE;BCHE;rs772583466;CT;EFFICACY;INCREASED_RESPONSE
EFAVIRENZ;CYP2A7P1, CYP2B6;rs3745274;T;LADME_PK;INCREASED_CONCENTRATIONS
DABIGATRAN;CES1;rs8192935;GG;LADME_PK;INCREASED_CONCENTRATIONS
ETHANOL;OPRM1;rs1799971;AG + GG;DOSAGE;DECREASED_DOSE
METHOTREXATE;CLCN6, MTHFR;rs1801133;AA;EFFICACY;DECREASED_RESPONSE
METHOTREXATE;C1orf167, CLCN6, MTHFR;rs1801131;TT;EFFICACY;DECREASED_RESPONSE
METHOTREXATE;MTR;rs1805087;AA;EFFICACY;DECREASED_RESPONSE
RANIBIZUMAB;CXCL8;rs4073;AA;EFFICACY;DECREASED_RESPONSE
ETHANOL;OPRM1;rs10485057;AA;DOSAGE;INCREASED_DOSE
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_DOSE
OPIOIDS;COMT;rs4680;AA + AG;DOSAGE;DECREASED_DOSE
METHOTREXATE;BIRC5;rs9904341;CG;EFFICACY;INCREASED_RESPONSE
ACENOCOUMAROL;VKORC1;rs9934438;GG;EFFICACY;DECREASED_RESPONSE
SALBUTAMOL;;rs17834628;A;EFFICACY;INCREASED_RESPONSE
NICOTINE;CHRNA3;rs1051730;A;DOSAGE;DECREASED_DOSE
ABIRATERONE, PREDNISOLONE;TSPYL1;rs3828743;A;EFFICACY;DECREASED_RESPONSE
PLATINUM;RICTOR;rs6878291;GG;EFFICACY;DECREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs3745274;GT;LADME_PK;DECREASED_CLEARANCE
CLOZAPINE;DRD2;rs2514218;T;EFFICACY;INCREASED_RESPONSE
METHOTREXATE;FASTKD3, MTRR;rs1801394;AA + AG;EFFICACY;DECREASED_RESPONSE
RANIBIZUMAB;KDR;rs2071559;AA + AG;EFFICACY;DECREASED_RESPONSE
ETHANOL;OPRM1;rs1799971;AG;OTHER;INCREASED_RESPONSE
BUSULFAN;GSTA1;rs3957356;CT;LADME_PK;DECREASED_CLEARANCE
METHOTREXATE;ATIC;rs12995526;CT + TT;EFFICACY;DECREASED_RESPONSE
CLOZAPINE;HTR3A;rs1062613;T;EFFICACY;INCREASED_RESPONSE
METHOTREXATE;ATIC;rs7563206;CT + TT;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP4F2;rs2108622;CC;DOSAGE;DECREASED_DOSE
METHOTREXATE;ATIC;rs2372536;CC + CG;EFFICACY;DECREASED_RESPONSE
METHOTREXATE;ATIC;rs4673993;CT + TT;EFFICACY;DECREASED_RESPONSE
CANDESARTAN;KCNK3;rs1275988;C;EFFICACY;INCREASED_RESPONSE
RISPERIDONE;NR1I2;rs1523130;CC;LADME_PK;DECREASED_CLEARANCE
SUFENTANIL;ABCB1;rs1045642;GG;DOSAGE;INCREASED_DOSE
ADALIMUMAB;IL17F;rs763780;TT;EFFICACY;INCREASED_RESPONSE
IMMUNOGLOBULINS;CASP3, PRIMPOL;rs113420705;CT + TT;EFFICACY;DECREASED_RESPONSE
SUFENTANIL;COMT;rs4680;AA;DOSAGE;INCREASED_DOSE
WARFARIN;VKORC1;rs7294;CC;DOSAGE;DECREASED_CONCENTRATIONS
IMMUNOGLOBULINS;COQ8B, ITPKC;rs28493229;CC + CG;EFFICACY;DECREASED_RESPONSE
USTEKINUMAB;IL17F;rs763780;TT;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP2C9;rs1057910;AA;DOSAGE;INCREASED_DOSE
INFLIXIMAB;IL17F;rs763780;CT;EFFICACY;INCREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs3745274;TT;DOSAGE, LADME_PK;DECREASED_DOSE
HYDROCHLOROTHIAZIDE;CSK;rs1378942;C;EFFICACY;DECREASED_RESPONSE
SALBUTAMOL;;rs35661809;G;EFFICACY;INCREASED_RESPONSE
ANTIPSYCHOTICS;DRD3;rs6280;CT + TT;EFFICACY;INCREASED_RESISTANCE
HYDROCHLOROTHIAZIDE;PDE3A;rs12579720;C;EFFICACY;INCREASED_RESPONSE
CANDESARTAN;SULT1C3;rs6722745;T;EFFICACY;DECREASED_RESPONSE
ATENOLOL;STN1;rs4387287;A;EFFICACY;DECREASED_RESPONSE
METFORMIN;;rs10783050;TT;EFFICACY;INCREASED_RESPONSE
METFORMIN;IL1B;rs1143623;GG;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE
WARFARIN;VKORC1;rs9923231;TT;LADME_PK;DECREASED_CONCENTRATIONS
CISPLATIN, PACLITAXEL;TP53;rs1042522;CG + GG;EFFICACY;DECREASED_RESPONSE
RIFAPENTINE;ABCB1;rs1045642;AA + AG;LADME_PK;INCREASED_CLEARANCE
BEVACIZUMAB, PEGAPTANIB, RANIBIZUMAB;VEGFA;rs2010963;CC;EFFICACY;DECREASED_RESPONSE
EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;NQO1;rs1800566;AA + AG;EFFICACY;DECREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;CT;EFFICACY;INCREASED_DOSE
EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;PON1;rs662;CC;EFFICACY;INCREASED_RESPONSE
RISPERIDONE;NR1I2;rs2276707;CC;LADME_PK;DECREASED_CLEARANCE
EFAVIRENZ;CYP2B6;rs28399499;C;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;VKORC1;rs9923231;CT;EFFICACY;DECREASED_RESPONSE
RITUXIMAB;FCGR3A;rs396991;C;EFFICACY;INCREASED_RESPONSE
NICOTINE;CHRNA3, CHRNA5;rs16969968;AA + AG;EFFICACY;INCREASED_RESPONSE
CLOZAPINE;HTR3A;rs2276302;G;EFFICACY;INCREASED_RESPONSE
IMATINIB;ABCB1;rs2032582;AT + TT;EFFICACY;DECREASED_RESPONSE
IMATINIB;ABCG2;rs2231142;T;EFFICACY;DECREASED_RESPONSE
TELMISARTAN;GNB3;rs5443;TT;EFFICACY;DECREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs8192719;T;LADME_PK;INCREASED_CONCENTRATIONS
LITHIUM, VALPROIC ACID;;rs2769605;CC;EFFICACY;DECREASED_RESPONSE
CISPLATIN, FLUOROURACIL;GNAS;rs7121;CC;EFFICACY;INCREASED_RESPONSE
ATENOLOL, METOPROLOL;ZMAT4;rs1367094;T;EFFICACY;INCREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs3745274;T;LADME_PK;INCREASED_CONCENTRATIONS
ATENOLOL, HYDROCHLOROTHIAZIDE, METOPROLOL;LRRC15;rs11313667;del;EFFICACY;INCREASED_RESPONSE
ONDANSETRON;CYP3A5;rs776746;CC;LADME_PK;DECREASED_METABOLISM
LITHIUM, OLANZAPINE;DRD2;rs1800497;GG;EFFICACY;INCREASED_CLINICAL BENEFIT
HMG COA REDUCTASE INHIBITORS;;rs247616;T;EFFICACY;INCREASED_RESPONSE
BOCEPREVIR, PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, GLUCOCORTICOIDS, INFLIXIMAB, METHOTREXATE;KLRC1;rs7301582;CC;EFFICACY;DECREASED_RESPONSE
HYDROCHLOROTHIAZIDE;PRKAG2;rs10224002;A;EFFICACY;INCREASED_RESPONSE
AGOMELATINE, MELATONIN RECEPTOR AGONISTS, SELECTIVE SEROTONIN REUPTAKE INHIBITORS, VENLAFAXINE;ABCB1;rs1045642;GG;EFFICACY;INCREASED_RESPONSE
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, GLUCOCORTICOIDS, INFLIXIMAB, METHOTREXATE;KLRD1;rs2302489;TT;EFFICACY;DECREASED_RESPONSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
HYDROCHLOROTHIAZIDE;PLCE1;rs932764;A;EFFICACY;DECREASED_RESPONSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE
METOPROLOL;;rs1446468;T;EFFICACY;INCREASED_RESPONSE
ATENOLOL;RRP1B;rs9306160;T;EFFICACY;INCREASED_RESPONSE
ATENOLOL;TBX2;rs8068318;C;EFFICACY;DECREASED_RESPONSE
AMISULPRIDE;DRD2;rs1079597;C;EFFICACY;INCREASED_RESPONSE
USTEKINUMAB;NFKBIA;rs2145623;CC;EFFICACY;DECREASED_RESPONSE
HYDROCHLOROTHIAZIDE;ADO;rs10995311;C;EFFICACY;DECREASED_RESPONSE
PLATINUM COMPOUNDS;XBP1;rs2269577;CC;EFFICACY;INCREASED_RESPONSE
CANDESARTAN;DOT1L, PLEKHJ1;rs740406;A;EFFICACY;DECREASED_RESPONSE
USTEKINUMAB;ADAM33;rs2787094;CC;EFFICACY;DECREASED_RESPONSE
HYDROCHLOROTHIAZIDE;NUCB2;rs757081;C;EFFICACY;DECREASED_RESPONSE
USTEKINUMAB;;rs1975974;AG + GG;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE
EXENATIDE;KCNQ1;rs163184;G;EFFICACY;DECREASED_CLINICAL BENEFIT
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;DECREASED_METABOLISM
USTEKINUMAB;AGBL4;rs191190;CC + CT;EFFICACY;DECREASED_RESPONSE
NORTRIPTYLINE;SLC39A14;rs17060812;C;EFFICACY;INCREASED_RESPONSE
ACENOCOUMAROL;VKORC1;rs9923231;CC;DOSAGE;INCREASED_DOSE
USTEKINUMAB;CHUK;rs11591741;CC + CG;EFFICACY;INCREASED_RESPONSE
USTEKINUMAB;HTR2A;rs6311;CT + TT;EFFICACY;DECREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;CC + CT;DOSAGE;INCREASED_DOSE
HYDROCHLOROTHIAZIDE;C5orf56;rs12521868;G;EFFICACY;DECREASED_RESPONSE
CANDESARTAN;SH2B3;rs3184504;T;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
CARBAMAZEPINE;CYP3A5;rs776746;CC;LADME_PK;INCREASED_CONCENTRATIONS
APIXABAN;ABCG2;rs2231142;GG + GT;LADME_PK;INCREASED_CLEARANCE
CARBAMAZEPINE;CYP3A5;rs15524;AA;LADME_PK;INCREASED_CONCENTRATIONS
PAROXETINE;COMT;rs4680;A;EFFICACY;INCREASED_RESPONSE
CAPECITABINE, PACLITAXEL;TP53;rs1042522;GG;EFFICACY;DECREASED_RESPONSE
SUFENTANIL;CYP3A4;rs2242480;CC;DOSAGE;INCREASED_DOSE
TRIGLYCERIDES;CYP19A1;rs749292;A;OTHER;DECREASED_CONCENTRATIONS
HDL CHOLESTEROL;CYP19A1;rs1062033;G;OTHER;INCREASED_CONCENTRATIONS
EFAVIRENZ;CYP2B6;rs28399499;C;LADME_PK;DECREASED_METABOLISM
CLOBAZAM;POR;rs1057868;TT;LADME_PK;INCREASED_CLEARANCE
WARFARIN;CYP2C9;rs1057910;AA;DOSAGE;INCREASED_DOSE
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE
EFAVIRENZ;CYP2B6;rs3745274;T;LADME_PK;DECREASED_METABOLISM
NORTRIPTYLINE;PPM1A;rs2273623;AA;EFFICACY;DECREASED_RESPONSE
AMILORIDE, SPIRONOLACTONE;CYP4A11;rs1126742;GG;EFFICACY;DECREASED_RESPONSE
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;TT;DOSAGE;DECREASED_DOSE
DEFERASIROX;UGT1A3;rs3806596;CC;LADME_PK;INCREASED_CONCENTRATIONS
LOPINAVIR;CYP3A5;rs776746;C;LADME_PK;INCREASED_TROUGH CONCENTRATION
PROPOFOL;CYP2B6;rs2279343;AA + AG;LADME_PK;DECREASED_CLEARANCE
SPIRONOLACTONE;CYP4A11;rs3890011;CC;EFFICACY;DECREASED_RESPONSE
OPIOIDS;OPRM1;rs1799971;AG + GG;DOSAGE, EFFICACY;INCREASED_DOSE
ATAZANAVIR;NR1I2;rs2472677;TT;LADME_PK;INCREASED_METABOLISM
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;DECREASED_CONCENTRATIONS
RIFAMPIN;AADAC;rs1803155;AA;LADME_PK;DECREASED_CLEARANCE
APATINIB, APATINIB METABOLITE M1-1;CYP2C9;rs1934968;GG;LADME_PK;INCREASED_EXPOSURE
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;FTO;rs11075995;AT + TT;EFFICACY;INCREASED_CLINICAL BENEFIT
AMPRENAVIR;SLCO1B1;rs4149056;C;LADME_PK;DECREASED_TROUGH CONCENTRATION
ACAMPROSATE;;rs77583603;G;EFFICACY;DECREASED_RESPONSE
EVEROLIMUS;CYP3A5;rs776746;CC + CT;LADME_PK;DECREASED_CLEARANCE
NALTREXONE;;rs12749274;A;EFFICACY;DECREASED_RESPONSE
DEFERASIROX;ABCG2;rs13120400;CC;LADME_PK;INCREASED_CONCENTRATIONS
FLUVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;INCREASED_CLINICAL BENEFIT
FLUVASTATIN;APOE;rs429358;CC;EFFICACY;INCREASED_CLINICAL BENEFIT
DOXORUBICIN;CBR1;rs20572;CC;LADME_PK;INCREASED_CLEARANCE
DEHYDROARIPIPRAZOLE;CYP1A2;rs762551;AA;LADME_PK;DECREASED_CONCENTRATIONS
CLOZAPINE;CYP1A2;rs762551;AA;LADME_PK;DECREASED_EXPOSURE
ETHANOL;OPRM1;rs1799971;AA;DOSAGE;INCREASED_DOSE
PREDNISOLONE;GATA3;rs3824662;AA;EFFICACY;DECREASED_CLINICAL BENEFIT
TACROLIMUS;GSTM3;rs7483;TT;LADME_PK;DECREASED_CONCENTRATIONS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MICA;rs1051792;AG;EFFICACY;INCREASED_RESPONSE
ADALIMUMAB;TNF;rs1799724;CC;EFFICACY;DECREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MICA;rs1051792;GG;EFFICACY;DECREASED_RESPONSE
FLUOXETINE;HTR1B;rs130058;AA + TT;EFFICACY;INCREASED_RESPONSE
ADALIMUMAB;TNF;rs1800629;GG;EFFICACY;DECREASED_RESPONSE
CLOZAPINE;CYP1A2;rs762551;AA;EFFICACY;DECREASED_CLINICAL BENEFIT
FLUVASTATIN;APOE;rs7412;TT;EFFICACY;INCREASED_CLINICAL BENEFIT
ADALIMUMAB;TNF;rs361525;GG;EFFICACY;DECREASED_RESPONSE
CARBAMAZEPINE;CYP1A2;rs762551;AA;LADME_PK;INCREASED_CLEARANCE
MORPHINE;SLC6A4;rs1042173;CC;DOSAGE;DECREASED_DOSE
FLUOROURACIL;ABCA2;rs2271862;G;LADME_PK;INCREASED_CLEARANCE
FLUOXETINE;TPH2;rs4570625;TT;EFFICACY;INCREASED_RESPONSE
5'-DEOXY-5-FLUOROURIDINE;ABCG5;rs6720173;C;LADME_PK;INCREASED_CLEARANCE
METHOTREXATE;ADORA2A-AS1;rs17004921;CT + TT;EFFICACY;INCREASED_RESPONSE
ANTIEPILEPTICS;ABCB1;rs2032582;AA;EFFICACY;INCREASED_CLINICAL BENEFIT
ANTIEPILEPTICS;ABCB1;rs1045642;AA;EFFICACY;INCREASED_CLINICAL BENEFIT
ATENOLOL, HYDROCHLOROTHIAZIDE;;rs35123024;C;EFFICACY;DECREASED_RESPONSE
ATENOLOL, HYDROCHLOROTHIAZIDE;ALDH1A2;rs261316;T;EFFICACY;DECREASED_RESPONSE
CISPLATIN;REV3L;rs462779;AG + GG;EFFICACY;DECREASED_RESPONSE
CISPLATIN;REV1;rs3087403;CT + TT;EFFICACY;INCREASED_RESPONSE
ANTIEPILEPTICS;SCN1A;rs2298771;CC + CT;EFFICACY;INCREASED_RESISTANCE
LOPINAVIR;SLCO1B1;rs4149056;C;LADME_PK;INCREASED_TROUGH CONCENTRATION
FENTANYL;OPRM1;rs9384179;AA;DOSAGE, EFFICACY;INCREASED_DOSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
FLUVASTATIN;CYP2C9;rs1057910;AC;LADME_PK;INCREASED_CONCENTRATIONS
FENTANYL;KCNJ6;rs2835859;TT;DOSAGE, EFFICACY;INCREASED_DOSE
ABIRATERONE;HSD3B1;rs1047303;AC;LADME_PK;INCREASED_METABOLISM
FENTANYL;;rs2952768;CC;DOSAGE, EFFICACY;INCREASED_DOSE
FENTANYL;;rs11959113;AA;DOSAGE, EFFICACY;INCREASED_DOSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE
CYCLOPHOSPHAMIDE;GSTA1;rs3957356;CT;EFFICACY, TOXICITY, LADME_PK;DECREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs3745274;T;LADME_PK;INCREASED_CONCENTRATIONS
BILIRUBIN;SOD2;rs4880;GG;TOXICITY;INCREASED_CONCENTRATIONS
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;DECREASED_CLEARANCE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
METHYLPHENIDATE;SLC6A2;rs5569;GG;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;POR;rs1057868;CT + TT;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
IVACAFTOR;CFTR;rs77010898;AA;EFFICACY;INCREASED_RESPONSE
DOCETAXEL, DOXORUBICIN;AKR1C3;rs1937840;GG;EFFICACY;INCREASED_RESPONSE
CYCLOPHOSPHAMIDE, DOXORUBICIN;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED_RESPONSE
ANTIDEPRESSANTS;GRIK4;rs1954787;TT;EFFICACY;DECREASED_CLINICAL BENEFIT
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
ANTIDEPRESSANTS;GRIK4;rs1954787;C;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_CLEARANCE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
WARFARIN;VKORC1;rs7294;T;DOSAGE;INCREASED_DOSE
WARFARIN;CYP2C9;rs1057910;A;DOSAGE;INCREASED_DOSE
WARFARIN;VKORC1;rs9934438;AG + GG;DOSAGE;INCREASED_DOSE
BUPRENORPHINE;OPRM1;rs2075572;CC + CG;LADME_PK;INCREASED_CONCENTRATIONS
SELECTIVE SEROTONIN (5HT1) AGONISTS;PRDM16;rs2651899;C;EFFICACY;INCREASED_RESPONSE
AFATINIB;NR1I2;rs6785049;AA + AG;LADME_PK;DECREASED_CLEARANCE
WARFARIN;CYP2C9;rs4917639;C;DOSAGE;DECREASED_DOSE
LOPINAVIR;SLCO1B1;rs4149056;CT;LADME_PK;INCREASED_EXPOSURE
NALTREXONE;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_RESPONSE
ANTIDEPRESSANTS;ABCB1;rs1128503;A;EFFICACY;INCREASED_RESPONSE
METHADONE;COMT;rs933271;CC + CT;EFFICACY;INCREASED_RESPONSE
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs2070959;AG;DOSAGE, LADME_PK;INCREASED_DOSE
METHOTREXATE;MTHFR;rs1801131;GT + TT;EFFICACY;INCREASED_RESPONSE
VALPROIC ACID;GRIN2B;rs1019385;AC;DOSAGE, LADME_PK;DECREASED_DOSE
VALPROIC ACID;GRIN2B;rs1019385;CC;DOSAGE, LADME_PK;DECREASED_DOSE
METHOTREXATE;SLC19A1;rs1051266;CT + TT;EFFICACY;INCREASED_RESPONSE
CARBAMAZEPINE, CLOBAZAM, ETHOSUXIMIDE, LAMOTRIGINE, LEVETIRACETAM, OXCARBAZEPINE, VALPROIC ACID;SCN1A;rs2298771;C;EFFICACY;INCREASED_RESPONSE
LOPINAVIR;SLCO1B1;rs4149056;C;LADME_PK;INCREASED_TROUGH CONCENTRATION
VALPROIC ACID;UGT1A6;rs1105879;AC;DOSAGE, LADME_PK;INCREASED_DOSE
FLUVASTATIN;SLCO1B1;rs4149056;TT;EFFICACY;INCREASED_RESPONSE
EVEROLIMUS;CYP3A5;rs776746;CT;LADME_PK;DECREASED_TROUGH CONCENTRATION
WARFARIN;CYP4F2;rs2108622;C;DOSAGE;DECREASED_DOSE
AMISULPRIDE;SNAP25;rs8636;CT;EFFICACY;INCREASED_RESPONSE
CLOPIDOGREL;ABCA1;rs2487032;A;LADME_PK;INCREASED_METABOLISM
CLOPIDOGREL;N6AMT1;rs2254638;G;LADME_PK;DECREASED_METABOLISM
TENOFOVIR;ABCG2;rs2231142;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS
SIROLIMUS;ABCB1;rs2032582;A;LADME_PK;INCREASED_CONCENTRATIONS
ANTIPSYCHOTICS;NRXN1;rs12467557;AA;EFFICACY;INCREASED_RESPONSE
ANTIPSYCHOTICS;NRXN1;rs10490162;TT;EFFICACY;INCREASED_RESPONSE
CLOPIDOGREL;CYP2C19;rs4986893;AA;EFFICACY;DECREASED_RESPONSE
DABIGATRAN;CES1;rs8192935;GG;LADME_PK;INCREASED_CONCENTRATIONS
ADALIMUMAB, CERTOLIZUMAB PEGOL, GOLIMUMAB, INFLIXIMAB;TNF;rs1800629;GG;EFFICACY;INCREASED_CLINICAL BENEFIT
CLOPIDOGREL;CYP2C19;rs4244285;AA;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CC;OTHER, LADME_PK;DECREASED_METABOLISM
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS
BEVACIZUMAB;CFH;rs1061170;CC;EFFICACY;DECREASED_RESPONSE
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs2070959;GG;DOSAGE, LADME_PK;INCREASED_DOSE
CISPLATIN, FLUOROURACIL;DPYD;rs3918290;CT;EFFICACY;DECREASED_RESPONSE
CISPLATIN, DOCETAXEL, IRINOTECAN;XRCC3;rs861539;AA;EFFICACY;DECREASED_RESPONSE
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs6759892;GG;DOSAGE, LADME_PK;INCREASED_DOSE
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs6759892;GT;DOSAGE, LADME_PK;INCREASED_DOSE
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
VALPROIC ACID;UGT1A6;rs1105879;CC;DOSAGE, LADME_PK;INCREASED_DOSE
10-MONOHYDROXY OXCARBAZEPINE;INSR;rs2396185;C;LADME_PK;DECREASED_CLEARANCE
ETHANOL;OPRM1;rs1799971;AG;EFFICACY;INCREASED_RESPONSE
RISPERIDONE;HTR1A;rs6295;GG;DOSAGE, EFFICACY;INCREASED_RESPONSE
FENTANYL;CACNA1E;rs3845446;CC + CT;DOSAGE;DECREASED_DOSE
FENTANYL;LAMB3;rs2076222;G;DOSAGE, EFFICACY;INCREASED_DOSE
CETUXIMAB;VEGFA;rs833061;TT;EFFICACY;INCREASED_RESPONSE
CETUXIMAB;VEGFA;rs1570360;GG;EFFICACY;INCREASED_RESPONSE
CISPLATIN, FLUOROURACIL, MITOXANTRONE;MECP2;rs1734791;A;EFFICACY;RESPONSE
CISPLATIN, FLUOROURACIL, MITOXANTRONE;MECP2;rs1734787;A;EFFICACY;RESPONSE
CISPLATIN, FLUOROURACIL, MITOXANTRONE;MECP2;rs17435;A;EFFICACY;RESPONSE
CISPLATIN, FLUOROURACIL, MITOXANTRONE;;rs5906072;T;EFFICACY;RESPONSE
PROCHLORPERAZINE;ANKK1, DRD2;rs1800497;AA + AG;EFFICACY;DECREASED_RESPONSE
PROCHLORPERAZINE;DRD2;rs1079597;CT + TT;EFFICACY;DECREASED_RESPONSE
METFORMIN;ATM;rs11212617;AC;EFFICACY;INCREASED_RESPONSE
MORPHINE;OPRK1;rs1051660;A;DOSAGE, EFFICACY;DECREASED_DOSE
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;rs12613732;G;EFFICACY;RESPONSE
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;rs5009910;C;EFFICACY;RESPONSE
ATORVASTATIN;HMGCR;rs17671591;CT + TT;EFFICACY;INCREASED_RESPONSE
ESCITALOPRAM;TPH1;rs1800532;GT + TT;EFFICACY;DECREASED_RESPONSE
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;rs6752303;C;EFFICACY;RESPONSE
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;rs10209881;C;EFFICACY;RESPONSE
DABIGATRAN;CES1;rs2244613;GG;LADME_PK;DECREASED_CONCENTRATIONS
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;rs12999804;A;EFFICACY;RESPONSE
TACROLIMUS;CYP3A4;rs2740574;TT;DOSAGE;DECREASED_DOSE
APATINIB, APATINIB METABOLITE M1-1;CYP2C9;rs34532201;TT;LADME_PK;INCREASED_EXPOSURE
CISPLATIN, FLUOROURACIL, MITOXANTRONE;;rs5934731;C;EFFICACY;RESPONSE
CISPLATIN, FLUOROURACIL, MITOXANTRONE;;rs715171;C;EFFICACY;RESPONSE
CISPLATIN, FLUOROURACIL, MITOXANTRONE;;rs4932551;C;EFFICACY;RESPONSE
CISPLATIN, FLUOROURACIL, MITOXANTRONE;;rs7170769;T;EFFICACY;RESPONSE
CISPLATIN, FLUOROURACIL, MITOXANTRONE;;rs6458232;C;EFFICACY;RESPONSE
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;rs7608731;C;EFFICACY;RESPONSE
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs758900656;A;LADME_PD;INCREASED_CLINICAL BENEFIT
ALLOPURINOL, FEBUXOSTAT;AOX1;rs3731722;G;DOSAGE;DOSE
PAZOPANIB;CYP3A4;rs35599367;AG;LADME_PK;DECREASED_CLEARANCE
RITUXIMAB;IL2;rs6822844;GG;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;TT;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
RITUXIMAB;IL2;rs6822844;GG;EFFICACY;INCREASED_RESPONSE
ALLOPURINOL, FEBUXOSTAT;AOX1;rs11678615;T;DOSAGE;DOSE
METHOTREXATE;MTHFR;rs1801131;GG;EFFICACY;DECREASED_RESPONSE
ALLOPURINOL, FEBUXOSTAT;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs34650714;T;DOSAGE;DECREASED_DOSE
ALLOPURINOL, FEBUXOSTAT;XDH;rs1884725;G;DOSAGE;DECREASED_DOSE
ALLOPURINOL, FEBUXOSTAT;AOX1;rs75995567;T;DOSAGE;INCREASED_DOSE
WARFARIN;CYP4F2;rs2108622;T;DOSAGE, LADME_PK;DOSE
WARFARIN;VKORC1;rs9923231;T;DOSAGE, LADME_PK;DOSE
WARFARIN;GGCX;rs699664;T;DOSAGE, LADME_PK;DOSE
METFORMIN;SLC22A1;rs622342;AC;EFFICACY;INCREASED_RESPONSE
PROPOFOL, REMIFENTANIL;ABCB1;rs1128503;GG;EFFICACY;INCREASED_RESPONSE
METHOTREXATE;ABCC3;rs4148416;TT;LADME_PK;INCREASED_CLEARANCE
TACROLIMUS;CYP3A4;rs2740574;TT;LADME_PK;INCREASED_CONCENTRATIONS
METHOTREXATE;SLC19A1;rs17004785;CG;LADME_PK;INCREASED_CLEARANCE
DONEPEZIL;BCHE;rs1803274;T;EFFICACY;INCREASED_RESPONSE
CISPLATIN, DOXORUBICIN, METHOTREXATE;MTHFD1;rs2236225;AA + AG;EFFICACY;INCREASED_RESPONSE
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;rs9679162;TT;EFFICACY;INCREASED_RESPONSE
PAROXETINE;GDNF;rs2973049;CT + TT;EFFICACY;DECREASED_RESPONSE
PAROXETINE;GDNF;rs2216711;AA + AG;EFFICACY;DECREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL17RA;rs4819554;AA;EFFICACY;INCREASED_RESPONSE
ATOMOXETINE;SLC6A2;rs3785143;T;EFFICACY;DECREASED_RESPONSE
PAROXETINE;BDNF;rs6265;CC + CT;EFFICACY;DECREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR3A;rs396991;AC + CC;EFFICACY;INCREASED_RESPONSE
ROSUVASTATIN;CETP;rs5882;G;EFFICACY;INCREASED_RESPONSE
DISULFIRAM;DBH;rs1611115;CC;EFFICACY;INCREASED_RESPONSE
RIVAROXABAN;CYP3A5;rs776746;TT;LADME_PK;INCREASED_STEADY_STATE CONCENTRATION
RISPERIDONE;COMT;rs9606186;GG;EFFICACY;INCREASED_RESPONSE
RIVAROXABAN;ABCB1;rs1045642;AA + AG;LADME_PK;INCREASED_CLEARANCE
TACROLIMUS;C6;rs10052999;CC + TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
WARFARIN;VKORC1;rs9934438;GG;DOSAGE;INCREASED_DOSE
TACROLIMUS;C6;rs9200;CC + CT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
CISPLATIN, DOXORUBICIN, METHOTREXATE;ABCC2;rs717620;CT + TT;EFFICACY;DECREASED_RESPONSE
RISPERIDONE;RGS4;rs2661319;C;EFFICACY;DECREASED_RESPONSE
LAMOTRIGINE;SLC22A1;rs628031;AA + AG;LADME_PK;INCREASED_CONCENTRATIONS
RISPERIDONE;ANKK1;rs1800497;A;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A4;rs2740574;CT;LADME_PK;INCREASED_DOSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;DECREASED_METABOLISM
CISPLATIN, DOXORUBICIN, METHOTREXATE;GSTP1;rs1695;AG + GG;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;DECREASED_METABOLISM
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
PHENYTOIN;CYP2C9;rs1057910;C;DOSAGE, LADME_PK;INCREASED_DOSE
CARBAMAZEPINE;SCN1A;rs3812718;TT;DOSAGE;INCREASED_DOSE
PHENYTOIN;SCN1A;rs3812718;T;DOSAGE;INCREASED_DOSE
ACENOCOUMAROL;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE
INDINAVIR;CYP3A4;rs2740574;CC;LADME_PK;DECREASED_METABOLISM
TACROLIMUS;ABCB1;rs2032582;T;LADME_PK;DECREASED_METABOLISM
ALPHA-HYDROXYMETOPROLOL;CYP2D6;rs28371738;A;LADME_PK;INCREASED_CONCENTRATIONS
RIVAROXABAN;ABCB1;rs1128503;AG + GG;LADME_PK;DECREASED_CONCENTRATIONS
FLUVOXAMINE, MILNACIPRAN, PAROXETINE;HTR1A;rs6295;GG;EFFICACY;INCREASED_RESPONSE
LANSOPRAZOLE;ABCB1;rs1045642;G;OTHER, LADME_PK;INCREASED_METABOLISM
FLUVOXAMINE, MILNACIPRAN, PAROXETINE;HTR1A;rs10042486;CC;EFFICACY;INCREASED_RESPONSE
LAMOTRIGINE;ABCG2;rs2231142;TT;LADME_PK;INCREASED_CONCENTRATIONS
RIVAROXABAN;ABCB1;rs1045642;AG + GG;LADME_PK;DECREASED_CONCENTRATIONS
RIVAROXABAN;ABCB1;rs4148738;T;LADME_PK;DECREASED_CONCENTRATIONS
PHENYTOIN;CYP2C9;rs1934969;AT + TT;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
DEXAMETHASONE, DIPHENHYDRAMINE, PACLITAXEL, RANITIDINE;ABCB1;rs1128503;AA + AG;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE
HMG COA REDUCTASE INHIBITORS;APOC1;rs4420638;G;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP2C9;rs1057910;AC + CC;DOSAGE;DECREASED_DOSE
PHOTODYNAMIC THERAPY;F13A1;rs5985;AA + AC;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP4F2;rs2108622;TT;DOSAGE;INCREASED_DOSE
CITALOPRAM;TPH1;rs1800532;GT + TT;EFFICACY;DECREASED_RESPONSE
HMG COA REDUCTASE INHIBITORS;NPC1L1;rs2072183;G;EFFICACY;DECREASED_RESPONSE
HMG COA REDUCTASE INHIBITORS;SORT1;rs629301;T;EFFICACY;DECREASED_RESPONSE
MERCAPTOPURINE;NUDT15;rs116855232;CT;DOSAGE;DECREASED_DOSE
MYCOPHENOLIC ACID;UGT1A9;rs3832043;del;LADME_PK;DECREASED_METABOLISM
BISOPROLOL;ACY3;rs2514036;T;EFFICACY;INCREASED_RESPONSE
MYCOPHENOLIC ACID;SLCO1B1;rs2306283;AA + AG;LADME_PK;DECREASED_CLEARANCE
IMATINIB;BCL2L11;rs724710;T;EFFICACY;DECREASED_RESPONSE
FLUOROURACIL;DPYD;rs3918290;CT;LADME_PK;DECREASED_CLEARANCE
METOPROLOL;SEPTIN3;rs56234624;G;LADME_PK;INCREASED_CONCENTRATIONS
ALEMTUZUMAB, CHLORAMBUCIL, CYCLOPHOSPHAMIDE, FLUDARABINE, PREDNISONE, RITUXIMAB, VINCRISTINE;CXCL12;rs1801157;CT + TT;EFFICACY;DECREASED_RESPONSE
MYCOPHENOLIC ACID;ABCC2;rs3740066;CT;LADME_PK;DECREASED_CONCENTRATIONS
GEMCITABINE;RRM1;rs9937;AA;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;ABCB1;rs1045642;AA + AG;LADME_PK;INCREASED_CONCENTRATIONS
BEVACIZUMAB;CXCL8;rs4073;AA;EFFICACY;DECREASED_RESPONSE
GEMCITABINE;RRM1;rs183484;AC;EFFICACY, TOXICITY;DECREASED_RESPONSE
HYDROCHLOROTHIAZIDE;NEDD4L;rs4149601;AG + GG;EFFICACY;INCREASED_RESPONSE
SN-38;UGT1A1;rs4148323;AA;DOSAGE;INCREASED_CONCENTRATIONS
COTININE GLUCURONIDE;UGT1A9;rs12471326;CT;LADME_PK;INCREASED_CONCENTRATIONS
NICOTINE;CYP2A6;rs145014075;GT;LADME_PK;INCREASED_CONCENTRATIONS
BEVACIZUMAB, RANIBIZUMAB;VEGFA;rs3025000;CT + TT;EFFICACY;INCREASED_RESPONSE
GRANISETRON;ABCB1;rs1045642;AA;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;CC + CT;DOSAGE;INCREASED_DOSE
CARBAMAZEPINE;SCN1A;rs3812718;CC + CT;EFFICACY;INCREASED_RESPONSE
BEVACIZUMAB, RANIBIZUMAB;VEGFA;rs3025000;CT + TT;EFFICACY;INCREASED_RESPONSE
CARBAMAZEPINE;SCN1A;rs3812718;TT;DOSAGE;INCREASED_DOSE
ETANERCEPT;CD84;rs6427528;AG;EFFICACY;INCREASED_RESPONSE
LOPINAVIR;SLCO1B1;rs4149056;CC + CT;LADME_PK;INCREASED_TROUGH CONCENTRATION
CARBAMAZEPINE;SCN1A;rs2298771;TT;EFFICACY;INCREASED_RESPONSE
METHADONE;OPRM1;rs10485058;AA;EFFICACY;INCREASED_RESPONSE
CARBAMAZEPINE;GABRA1;rs2290732;AA + AG;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE
USTEKINUMAB;IL12B;rs3213094;CT;EFFICACY;INCREASED_RESPONSE
GEMCITABINE;CDA;rs2072671;AA;EFFICACY;INCREASED_RESPONSE
TOCILIZUMAB;IL6R;rs11265618;CC;EFFICACY;INCREASED_RESPONSE
TOCILIZUMAB;IL6R;rs12083537;AA;EFFICACY;INCREASED_RESPONSE
EFAVIRENZ;ABCB1;rs2032582;AA;LADME_PK;DECREASED_CONCENTRATIONS
ALFENTANIL;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_CONCENTRATIONS
EFAVIRENZ;ABCB1;rs1045642;AA;LADME_PK;DECREASED_CONCENTRATIONS
CETUXIMAB;FCGR3A;rs396991;AA;EFFICACY;INCREASED_RESPONSE
CETUXIMAB;FCGR2A;rs1801274;GG;EFFICACY;INCREASED_RESPONSE
EFAVIRENZ;HNF4A;rs1884613;CC;LADME_PK;INCREASED_CONCENTRATIONS
METHADONE;ALDH5A1;rs2760118;CT + TT;EFFICACY;DECREASED_RESPONSE
ATAZANAVIR;UGT1A1;rs887829;TT;TOXICITY;INCREASED_DISCONTINUATION
PLATINUM COMPOUNDS;XRCC1;rs25487;CT + TT;EFFICACY;DECREASED_RESPONSE
OLANZAPINE;CHAT;rs1880676;A;DOSAGE, EFFICACY;INCREASED_RESPONSE
RAMIPRIL;ACE;rs4359;CC + TT;EFFICACY;INCREASED_RESPONSE
RAMIPRIL;ACE;rs4344;AA + GG;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;DOSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;EFFICACY;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE
OXYCODONE;OPRD1;rs581111;AA + AG;EFFICACY;DECREASED_RESPONSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;KLRK1;rs1049174;GG;EFFICACY;INCREASED_RESPONSE
CITALOPRAM;CRHR2;rs2270007;CC + CG;EFFICACY;DECREASED_RESPONSE
RIFAMPIN;NR1I2;rs3732357;AA + AG;LADME_PK;DECREASED_EXPOSURE
METHOTREXATE;SLC19A1;rs1051266;CT + TT;LADME_PK;DECREASED_CONCENTRATIONS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
OXYCODONE;;rs6848893;CT;EFFICACY;DECREASED_RESPONSE
PLATINUM COMPOUNDS;ATP7B;rs9535826;G;EFFICACY;INCREASED_RESPONSE
DEXAMETHASONE;NR3C1;rs6198;CC;EFFICACY;INCREASED_TIME TO RESPONSE
ANTIDEPRESSANTS;HTR2A;rs6313;AA + AG;EFFICACY;INCREASED_RESPONSE
PLATINUM COMPOUNDS;ATP7B;rs9535828;A;EFFICACY;INCREASED_RESPONSE
DEXAMETHASONE;NR3C1;rs33388;AA;EFFICACY;INCREASED_TIME TO RESPONSE
RISPERIDONE;CCL2;rs4795893;AA + AG;EFFICACY;INCREASED_RESPONSE
RISPERIDONE;CCL2;rs4586;CC + CT;EFFICACY;INCREASED_RESPONSE
METHOTREXATE;FPGS;rs1544105;TT;EFFICACY;INCREASED_RESPONSE
ACENOCOUMAROL;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE
METHOTREXATE;FPGS;rs1544105;TT;LADME_PK;INCREASED_CONCENTRATIONS
DEXAMETHASONE;NR3C1;rs33389;TT;EFFICACY;INCREASED_TIME TO RESPONSE
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE
ATORVASTATIN, ROSUVASTATIN, SIMVASTATIN;ABCA1;rs769705621;AAAA;EFFICACY;DECREASED_RESPONSE
CORTICOSTEROIDS, SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;ADRB2;rs1042713;A;EFFICACY;DECREASED_RESPONSE
RISPERIDONE;CCL2;rs2857657;GG;EFFICACY;INCREASED_RESPONSE
LAMOTRIGINE;UGT1A4;rs2011425;TT;EFFICACY;INCREASED_RESPONSE
MERCAPTOPURINE;ITPA;rs1127354;A;LADME_PK;METABOLISM
LAMOTRIGINE;UGT1A4;rs2011425;TT;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE
EFAVIRENZ;CYP2B6;rs28399499;CC;LADME_PK;INCREASED_CONCENTRATIONS
NICOTINE;CHRNB3;rs4950;G;EFFICACY, OTHER;INCREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs3745274;T;LADME_PK;DECREASED_CLEARANCE
PLATINUM COMPOUNDS;HMGB1;rs1412125;CC;EFFICACY;INCREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR9;rs352139;CT + TT;EFFICACY;INCREASED_RESPONSE
NICOTINE;CHRNB3;rs13280604;G;EFFICACY, OTHER;INCREASED_RESPONSE
WARFARIN;VKORC1;rs749671;G;DOSAGE;INCREASED_DOSE
DEXAMETHASONE;CYP3A4;rs35599367;AG;EFFICACY;INCREASED_TIME TO RESPONSE
PLATINUM COMPOUNDS;HMGB1;rs2249825;GG;EFFICACY;INCREASED_RESPONSE
EFAVIRENZ;CYP2B6;rs3745274;T;LADME_PK;INCREASED_CONCENTRATIONS
EFAVIRENZ;CYP2B6;rs2279343;G;LADME_PK;INCREASED_CONCENTRATIONS
CISPLATIN, RADIOTHERAPY;XRCC1;rs25487;TT;EFFICACY;DECREASED_RESPONSE
LOSARTAN;ACE;rs4291;AT + TT;EFFICACY;INCREASED_CLINICAL BENEFIT
VEGF/VEGFR (VASCULAR ENDOTHELIAL GROWTH FACTOR) INHIBITORS;VEGFA;rs699947;AC + CC;EFFICACY;INCREASED_RESPONSE
ACENOCOUMAROL;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE
OXYCODONE;COMT;rs4680;AA + AG;EFFICACY;INCREASED_RESPONSE
ADALIMUMAB, INFLIXIMAB;IL12B;rs2546890;AA + AG;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A4;rs2740574;T;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
ADALIMUMAB, INFLIXIMAB;IVL;rs6661932;CT + TT;EFFICACY;DECREASED_RESPONSE
OPIOIDS;COMT;rs4680;AA + AG;DOSAGE;INCREASED_DOSE
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE
USTEKINUMAB;TIRAP;rs8177374;CT + TT;EFFICACY;INCREASED_RESPONSE
NICOTINE;OPRM1;rs1799971;AG + GG;OTHER;INCREASED_EXPOSURE
USTEKINUMAB;TLR5;rs5744174;AG + GG;EFFICACY;INCREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;rs11938228;AA + AC;EFFICACY;DECREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;LY96;rs11465996;CG + GG;EFFICACY;DECREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;rs4696480;AT + TT;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;C;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS, USTEKINUMAB;IL1B;rs1143623;CG + GG;EFFICACY;DECREASED_RESPONSE
WARFARIN;ABCB1;rs1045642;A;DOSAGE;INCREASED_DOSE
WARFARIN;APOE;rs429358;CC + CT;DOSAGE;DECREASED_DOSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS, USTEKINUMAB;IL1B;rs1143627;AG + GG;EFFICACY;DECREASED_RESPONSE
REPAGLINIDE;NR1I2;rs2276706;GG;LADME_PK;DECREASED_METABOLISM
COTININE;OPRM1;rs510769;T;LADME_PK;INCREASED_CONCENTRATIONS
RISPERIDONE;COMT;rs9606186;C;EFFICACY;DECREASED_RESPONSE
REPAGLINIDE;NR1I2;rs3814058;CC;LADME_PK;DECREASED_METABOLISM
ATEZOLIZUMAB, BEVACIZUMAB;IL7;rs16906115;AA;EFFICACY;DECREASED_CLINICAL BENEFIT
COTININE;OPRM1;rs12209447;T;LADME_PK;INCREASED_CONCENTRATIONS
RISPERIDONE;COMT;rs2020917;C;EFFICACY;DECREASED_RESPONSE
COTININE;OPRM1;rs3798676;T;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;VKORC1;rs2359612;A;DOSAGE;DECREASED_DOSE
FENTANYL;ABCB1;rs1045642;AA;DOSAGE;DECREASED_DOSE
RISPERIDONE;COMT;rs933271;C;EFFICACY;DECREASED_RESPONSE
COTININE;OPRM1;rs553202;T;LADME_PK;INCREASED_CONCENTRATIONS
COTININE;OPRM1;rs1074287;G;LADME_PK;INCREASED_CONCENTRATIONS
METHADONE;OPRD1;rs529520;AA + AC;DOSAGE;INCREASED_DOSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
COTININE;OPRM1;rs1799971;A;LADME_PK;INCREASED_CONCENTRATIONS
COTININE;OPRM1;rs6912029;T;LADME_PK;INCREASED_CONCENTRATIONS
PREDNISONE;EDNRA;rs5333;CC + CT;EFFICACY;INCREASED_RESISTANCE
REPAGLINIDE;NR1I2;rs3814058;CC;LADME_PK;INCREASED_METABOLISM
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;TLR4;rs1927907;CC;LADME_PK;INCREASED_CONCENTRATIONS
PAZOPANIB;NR1I2;rs3814055;T;EFFICACY;DECREASED_RESPONSE
ACENOCOUMAROL;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE
ADALIMUMAB, INFLIXIMAB;ZNF816;rs9304742;CC + CT;EFFICACY;INCREASED_RESPONSE
ACENOCOUMAROL;CALU;rs1043550;G;DOSAGE;INCREASED_DOSE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;IL18;rs1946518;GG + GT;LADME_PK;INCREASED_CONCENTRATIONS
ADALIMUMAB, INFLIXIMAB;NFKBIA;rs2145623;CC + CG;EFFICACY;DECREASED_RESPONSE
ADALIMUMAB, INFLIXIMAB;TNFRSF1B;rs1061624;AG + GG;EFFICACY;DECREASED_RESPONSE
REPAGLINIDE;NR1I2;rs2276706;GG;LADME_PK;INCREASED_METABOLISM
ADALIMUMAB, INFLIXIMAB;SLC9A8;rs645544;GG;EFFICACY;DECREASED_RESPONSE
FLUOROURACIL, PLATINUM COMPOUNDS, RADIOTHERAPY;XRCC4;rs10040363;G;EFFICACY;DECREASED_RESPONSE
FENTANYL, REMIFENTANIL;OPRM1;rs79910351;TT;EFFICACY;DECREASED_RESPONSE
FLUOROURACIL, PLATINUM COMPOUNDS, RADIOTHERAPY;XRCC4;rs2075685;T;EFFICACY;DECREASED_RESPONSE
MYCOPHENOLIC ACID;SLCO1B1;rs4149056;TT;LADME_PK;INCREASED_EXPOSURE
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;TT;EFFICACY;INCREASED_RESPONSE
SIMVASTATIN;PPARA;rs4253728;AA + AG;LADME_PK;DECREASED_CLEARANCE
FLUOROURACIL, PLATINUM COMPOUNDS, RADIOTHERAPY;ERCC1;rs2298881;A;EFFICACY;INCREASED_RESPONSE
COTININE;OPRM1;rs563649;T;LADME_PK;INCREASED_CONCENTRATIONS
COTININE;OPRM1;rs2075572;G;LADME_PK;INCREASED_CONCENTRATIONS
SIMVASTATIN;SLCO1B1;rs4149056;TT;EFFICACY;INCREASED_RESPONSE
COTININE;OPRM1;rs7748401;G;LADME_PK;INCREASED_CONCENTRATIONS
COTININE;OPRM1;rs495491;G;LADME_PK;INCREASED_CONCENTRATIONS
COTININE;OPRM1;rs10457090;G;LADME_PK;INCREASED_CONCENTRATIONS
COTININE;OPRM1;rs3778152;G;LADME_PK;INCREASED_CONCENTRATIONS
PRAVASTATIN;SLCO1B1;rs4149056;TT;EFFICACY;INCREASED_RESPONSE
COTININE;OPRM1;rs589046;T;LADME_PK;INCREASED_CONCENTRATIONS
METHOTREXATE;NR1I2;rs3814055;T;LADME_PK;DECREASED_METABOLISM
METHOTREXATE;SLCO1B1;rs2306283;AA + AG;LADME_PK;DECREASED_CONCENTRATIONS
METHOTREXATE;ABCC3;rs4793665;C;LADME_PK;DECREASED_CONCENTRATIONS
METHOTREXATE;NR1I2;rs7643038;G;LADME_PK;DECREASED_METABOLISM
METHOTREXATE;ABCB1;rs9282564;C;LADME_PK;INCREASED_CONCENTRATIONS
METHOTREXATE;ABCG2;rs2231142;T;LADME_PK;DECREASED_METABOLISM
GLUCOCORTICOIDS;;rs17446593;AA;EFFICACY;INCREASED_CLINICAL BENEFIT
SUNITINIB;CYP3A5;rs776746;CC;LADME_PK;DECREASED_CLEARANCE
CLOZAPINE;NTRK2;rs10465180;CC;EFFICACY;DECREASED_RESPONSE
SIMVASTATIN;CYP3A5;rs776746;TT;LADME_PK;INCREASED_CLEARANCE
SIMVASTATIN ACID;SLCO1B1;rs4149056;CT;LADME_PK;DECREASED_CLEARANCE
SIMVASTATIN;SLCO2B1;rs12422149;AA;LADME_PK;INCREASED_CLEARANCE
WARFARIN;CYP2C9;rs9332238;G;DOSAGE;INCREASED_DOSE
CLOPIDOGREL;P2RY12;rs6809699;AA + AC;EFFICACY;INCREASED_RESISTANCE
EFAVIRENZ;CYP2B6;rs3745274;T;LADME_PK;INCREASED_CONCENTRATIONS
DOXORUBICIN;CBR1;rs20572;CC;LADME_PK;DECREASED_CONCENTRATIONS
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;ADRA2A;rs1800544;CG;EFFICACY;INCREASED_RESPONSE
ERLOTINIB;ABCB1;rs1045642;AA;TOXICITY, LADME_PK;DECREASED_CLEARANCE
ERLOTINIB;ABCB1;rs1128503;AA;TOXICITY, LADME_PK;DECREASED_CLEARANCE
NICOTINE;CYP2A6;rs28399468;A;LADME_PK;DECREASED_METABOLISM
METHOTREXATE;ABCC1;rs28364006;GG;EFFICACY;INCREASED_RESPONSE
DOLUTEGRAVIR;NR1I2;rs2472677;TT;LADME_PK;INCREASED_CONCENTRATIONS
ERLOTINIB;ABCB1;rs2032582;AA;TOXICITY, LADME_PK;DECREASED_CLEARANCE
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE
LOSARTAN;AGTR1;rs5186;CC;EFFICACY;DECREASED_RESPONSE
CLOPIDOGREL;KDR;rs2305948;T;EFFICACY;DECREASED_RESPONSE
LAMOTRIGINE;UGT2B7;rs7668258;CT + TT;DOSAGE;INCREASED_DOSE
MERCAPTOPURINE;NUDT15;rs73189762;T;DOSAGE;DECREASED_DOSE
METFORMIN;ARFGEF3;rs143276236;AC;EFFICACY;DECREASED_CLINICAL BENEFIT
TRASTUZUMAB;ERBB2;rs1136201;G;TOXICITY;RESPONSE
DOXORUBICIN;CBR1;rs9024;GG;LADME_PK;INCREASED_CLEARANCE
METFORMIN;PRKAB2;rs7541245;A;EFFICACY;DECREASED_RESPONSE
AZATHIOPRINE;NUDT15;rs116855232;CT + TT;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME_PK;INCREASED_DOSE
TACROLIMUS;POR;rs1057868;CT + TT;DOSAGE, LADME_PK;INCREASED_DOSE
DOXORUBICIN;CBR1;rs9024;GG;LADME_PK;DECREASED_CONCENTRATIONS
DOXORUBICIN;CBR1;rs9024;GG;LADME_PK;DECREASED_EXPOSURE
PRAMIPEXOLE;DRD3;rs6280;T;EFFICACY;INCREASED_RESPONSE
WARFARIN;CYP4F2;rs2108622;TT;DOSAGE;INCREASED_DOSE
WARFARIN;VKORC1;rs7196161;GG;DOSAGE;DECREASED_DOSE
ANTIDEPRESSANTS, BENZODIAZEPINE DERIVATIVES, MIRTAZAPINE, SELECTIVE SEROTONIN REUPTAKE INHIBITORS;GAL;rs948854;C;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;DECREASED_DOSE
WARFARIN;VKORC1;rs9934438;GG;DOSAGE;INCREASED_DOSE
SUFENTANIL;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE
WARFARIN;VKORC1;rs9923231;CC;DOSAGE;INCREASED_DOSE
TACROLIMUS;CYP3A5;rs41303343;A;DOSAGE, LADME_PK;DECREASED_CLEARANCE
METFORMIN;SLC22A1;rs628031;GG;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A5;rs10264272;T;DOSAGE, LADME_PK;DECREASED_CLEARANCE
WARFARIN;VKORC1;rs2884737;AA;DOSAGE;INCREASED_DOSE
WARFARIN;VKORC1;rs61742245;A;DOSAGE;INCREASED_DOSE
TACROLIMUS;CYP3A5;rs776746;C;DOSAGE, LADME_PK;DECREASED_CLEARANCE
MYCOPHENOLIC ACID;ABCC2;rs717620;CC;LADME_PK;INCREASED_EXPOSURE
WARFARIN;PRSS53, VKORC1;rs2359612;A;DOSAGE;DECREASED_DOSE
CAFFEINE;CYP1A2;rs762551;AA;OTHER, LADME_PK;INCREASED_METABOLISM
DOXORUBICIN;CBR1;rs20572;CC;LADME_PK;DECREASED_EXPOSURE
WARFARIN;GGCX;rs11676382;CG;DOSAGE;DECREASED_DOSE
CAFFEINE;CYP1A2;rs762551;AA;OTHER, LADME_PK;INCREASED_METABOLISM
METHOTREXATE;ATIC;rs2372536;GG;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A4;rs35599367;AA + AG;LADME_PK;DECREASED_CLEARANCE
TACROLIMUS;CYP3A4;rs2740574;C;LADME_PK;DECREASED_CONCENTRATIONS
TACROLIMUS;CYP3A4;rs35599367;A;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME_PK;INCREASED_CLEARANCE
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;PRSS53, VKORC1;rs7294;T;DOSAGE;INCREASED_DOSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL9;rs2069885;AA + AG;EFFICACY;INCREASED_RESPONSE
RITUXIMAB;FCGR3A;rs396991;AA;EFFICACY;DECREASED_RESPONSE
PREDNISOLONE;CD40;rs1883832;CC;EFFICACY;DECREASED_CLINICAL BENEFIT
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME_PK;INCREASED_METABOLISM
METFORMIN;SLC47A1;rs2289669;AA;EFFICACY;INCREASED_RESPONSE
ERENUMAB;CALCRL;rs6710852;G;EFFICACY;INCREASED_CLINICAL BENEFIT
TACROLIMUS;ABCB1;rs2032582;AA + TT;DOSAGE, LADME_PK;DECREASED_CLEARANCE
WARFARIN;VKORC1;rs7294;CC;DOSAGE;DECREASED_DOSE
HALOTHANE;RYR1;rs118192161;T;OTHER;INCREASED_RESPONSE
WARFARIN;VKORC1;rs8050894;CC;DOSAGE;INCREASED_DOSE
WARFARIN;VKORC1;rs2359612;GG;DOSAGE;INCREASED_DOSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL5;rs2069812;AA + AG;EFFICACY;INCREASED_RESPONSE
BETA BLOCKING AGENTS, SELECTIVE;BST1;rs28404156;A;EFFICACY;INCREASED_RESPONSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE
TAMOXIFEN;CYP19A1;rs4646;AA;EFFICACY;DECREASED_RESPONSE
BISPHOSPHONATES;FDPS;rs2297480;T;EFFICACY;INCREASED_RESPONSE
SIMVASTATIN;CETP;rs5882;A;EFFICACY;INCREASED_RESPONSE
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;APOE;rs405509;TT;EFFICACY;INCREASED_RESPONSE
METHOTREXATE;ABCG2;rs17731538;GG;EFFICACY;INCREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1799724;C;EFFICACY;INCREASED_RESPONSE
CYCLOSPORINE;UMOD;rs12917707;GT + TT;EFFICACY;INCREASED_RESPONSE
MODAFINIL;ABCB1;rs2032582;AC + CT;EFFICACY;INCREASED_RESPONSE
MODAFINIL;ABCB1;rs1045642;AG;EFFICACY;INCREASED_RESPONSE
WARFARIN;MYC;rs4645962;CT;DOSAGE;DECREASED_DOSE
WARFARIN;MYC;rs4645943;CT + TT;DOSAGE;INCREASED_DOSE
CARBAMAZEPINE;EPHX1;rs2234922;G;DOSAGE, LADME_PK;DECREASED_METABOLISM
MODAFINIL;ABCB1;rs1128503;AG;EFFICACY;INCREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs361525;G;EFFICACY;INCREASED_RESPONSE
BISPHOSPHONATES;FDPS;rs11264359;A;EFFICACY;INCREASED_RESPONSE
WARFARIN;MYC;rs4645974;CC;DOSAGE;INCREASED_DOSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1800629;G;EFFICACY;INCREASED_RESPONSE
ATORVASTATIN, SIMVASTATIN;ABCC2;rs717620;T;EFFICACY;DECREASED_DOSE
LEFLUNOMIDE;DHODH;rs3213422;CC;EFFICACY;INCREASED_CLINICAL BENEFIT
ANTIPSYCHOTICS;DRD2;rs1799732;G;EFFICACY;INCREASED_RESISTANCE
IMATINIB;SLC22A4;rs1050152;TT;EFFICACY;DECREASED_RESPONSE
RISPERIDONE;HTR2A;rs6313;AA + AG;EFFICACY;INCREASED_RESPONSE
ANTIPSYCHOTICS;HTR2A;rs7997012;AG;EFFICACY;INCREASED_RESISTANCE
METHADONE;CYP2B6;rs3745274;TT;DOSAGE, LADME_PK;DECREASED_DOSE
METHADONE;ABCB1;rs1045642;AA + AG;LADME_PK;INCREASED_CONCENTRATIONS
OLANZAPINE;HTR2A;rs6313;AG + GG;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DOSE
OLANZAPINE;HTR2A;rs6313;AA + AG;EFFICACY;INCREASED_RESPONSE
CARBAMAZEPINE;EPHX1;rs1051740;CC;LADME_PK;INCREASED_METABOLISM
EFAVIRENZ;CYP2B6;rs3745274;GG;LADME_PK;INCREASED_CLEARANCE
CARBAMAZEPINE;EPHX1;rs2234922;GG;LADME_PK;INCREASED_METABOLISM
AZATHIOPRINE, MERCAPTOPURINE;ITPA;rs7270101;AC + CC;TOXICITY, LADME_PK;INCREASED_METABOLISM
IMATINIB;ABCB1;rs1045642;AA + AG;EFFICACY;DECREASED_RESPONSE
IMATINIB;SLC22A4;rs1050152;TT;EFFICACY;DECREASED_RESPONSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME_PK;INCREASED_DOSE
ETHANOL;OPRM1;rs3778150;CC + CT;;DECREASED_RESPONSE
CARBAMAZEPINE;ABCB1;rs1045642;AG;LADME_PK;INCREASED_DOSE
ANTIEPILEPTICS;ABCB1;rs1045642;AG;EFFICACY;INCREASED_RESISTANCE
RALOXIFENE;COMT;rs737865;AG;EFFICACY;INCREASED_CLINICAL BENEFIT
PACLITAXEL;ABCC2;rs717620;CT;TOXICITY;DECREASED_DOSE
RALOXIFENE;COMT;rs737865;AA;EFFICACY;INCREASED_CLINICAL BENEFIT
BUPRENORPHINE;OPRD1;rs678849;CT + TT;EFFICACY;INCREASED_RESPONSE
METHADONE;ABCB1;rs2032582;AC;LADME_PK;INCREASED_CONCENTRATIONS
ETHANOL;OPRM1;rs1799971;AG + GG;OTHER;INCREASED_EXPOSURE
ANTIEPILEPTICS;ABCB1;rs1045642;AA;EFFICACY;INCREASED_RESISTANCE
RISPERIDONE;TNIK;rs7627954;CC;EFFICACY;INCREASED_RESPONSE
RALOXIFENE;COMT;rs4818;CG;EFFICACY;INCREASED_CLINICAL BENEFIT
METHADONE;CYP3A4;rs35599367;AG;LADME_PK;DECREASED_CLEARANCE
SUNITINIB;ABCB1;rs2032582;AA + AT;DOSAGE, TOXICITY;INCREASED_DOSE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;TNF;rs1800629;AG + GG;EFFICACY;INCREASED_RESPONSE
SUNITINIB;ABCB1;rs1128503;AA;DOSAGE, TOXICITY;INCREASED_DOSE
METHADONE;ABCB1;rs1045642;AA;LADME_PK;INCREASED_CLEARANCE
METHADONE;ABCB1;rs1128503;AG;LADME_PK;INCREASED_CONCENTRATIONS
METHADONE;POR;rs1057868;CT + TT;LADME_PK;INCREASED_CLEARANCE
METHADONE;CYP2B6;rs2279343;AA;DOSAGE;INCREASED_DOSE
DOLUTEGRAVIR;ABCG2;rs2231142;TT;LADME_PK;INCREASED_CONCENTRATIONS
METHADONE;CYP2B6;rs3745274;GG;DOSAGE;INCREASED_DOSE
PREDNISOLONE;TLR4;rs4986791;T;EFFICACY;DECREASED_CLINICAL BENEFIT
PERAMPANEL;CYP3A4;rs4986908;CG;EFFICACY;DECREASED_CLINICAL BENEFIT
TELBIVUDINE;TK2;rs3826160;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;EPHX1;rs1877724;TT;DOSAGE;DECREASED_DOSE
NEVIRAPINE;CYP2B6;rs3745274;TT;TOXICITY, LADME_PK;DECREASED_CLEARANCE
IVACAFTOR;CFTR;rs75527207;AA + AG;EFFICACY;RESPONSE
ETHANOL;OPRM1;rs3778150;CC + CT;DOSAGE;INCREASED_DOSE
IVACAFTOR;CFTR;rs75527207;AA + AG;EFFICACY;RESPONSE
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;INCREASED_RESPONSE
NEVIRAPINE;CYP2B6;rs3745274;T;OTHER, LADME_PK;DECREASED_CLEARANCE
NEVIRAPINE;CYP2C19;rs12768009;AA;OTHER, LADME_PK;DECREASED_CLEARANCE
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE
ESCITALOPRAM;CYP2C18;rs11188059;G;LADME_PK;DECREASED_CONCENTRATIONS
DONEPEZIL, GALANTAMINE, RIVASTIGMINE;PRKCE;rs6720975;T;EFFICACY;INCREASED_RESPONSE
ESCITALOPRAM;CYP2C18;rs2860840;T;LADME_PK;DECREASED_CONCENTRATIONS
EFAVIRENZ;CYP2B6;rs2279345;TT;LADME_PK;DECREASED_METABOLISM
PERAMPANEL;CYP3A4;rs2242480;CT + TT;EFFICACY;DECREASED_CLINICAL BENEFIT
DONEPEZIL, GALANTAMINE, RIVASTIGMINE;;rs17798800;T;EFFICACY;DECREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE
PREDNISOLONE;TLR4;rs4986790;G;EFFICACY;DECREASED_CLINICAL BENEFIT
METHADONE;ABCB1;rs2032582;CC;DOSAGE;DECREASED_DOSE
METHADONE;ABCB1;rs1045642;AA;DOSAGE, LADME_PK;INCREASED_DOSE
SN-38;ABCB1;rs12720066;AC + CC;LADME_PK;DECREASED_EXPOSURE
ANTIPSYCHOTICS;GABRB1;rs4627835;T;DOSAGE;INCREASED_DOSE
ANTIPSYCHOTICS;GABRB1;rs16860087;A;DOSAGE;INCREASED_DOSE
WARFARIN;VKORC1;rs9923231;CC;DOSAGE;INCREASED_DOSE
SN-38;ABCC1;rs35621;CT + TT;LADME_PK;INCREASED_EXPOSURE
CARBAMAZEPINE;ABCB1;rs1045642;AA;DOSAGE;INCREASED_DOSE
LITHIUM;ASIC2;rs11869731;CC;EFFICACY;INCREASED_RESPONSE
SN-38;ABCC1;rs6498588;AT + TT;LADME_PK;INCREASED_EXPOSURE
CAPECITABINE, FLUOROURACIL;HLA-G;rs9380142;GG;EFFICACY;DECREASED_RESPONSE
ANTIDEPRESSANTS;MAPK1;rs8136867;AG;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs8050894;G;DOSAGE;DECREASED_DOSE
CAPECITABINE, FLUOROURACIL;HLA-G;rs17179108;CT;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;CC;DOSAGE, EFFICACY;INCREASED_DOSE
PHENYTOIN;CYP2C9;rs9332238;A;LADME_PK;INCREASED_CONCENTRATIONS
DONEPEZIL, GALANTAMINE, RIVASTIGMINE;CHAT;rs3793790;G;EFFICACY;INCREASED_RESPONSE
FLUVOXAMINE;COMT;rs4680;GG;EFFICACY;DECREASED_RESPONSE
LITHIUM;OR52E2;rs16909440;TT;EFFICACY;INCREASED_RESPONSE
LITHIUM;OR52J3;rs2499984;GG;EFFICACY;INCREASED_RESPONSE
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;INCREASED_RESPONSE
ANTIDEPRESSANTS;CREB1;rs889895;GG;EFFICACY;INCREASED_RESPONSE
DOLUTEGRAVIR;UGT1A1;rs887829;CT + TT;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
LITHIUM;;rs16973410;CC;EFFICACY;INCREASED_RESPONSE
MERCAPTOPURINE;TPMT;rs1142345;C;EFFICACY;EXPOSURE
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;INCREASED_RESPONSE
DOLUTEGRAVIR;AADAC;rs1803155;AG + GG;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
DONEPEZIL, GALANTAMINE, RIVASTIGMINE;CHAT;rs2177370;A;EFFICACY;INCREASED_RESPONSE
METHOTREXATE;ATIC;rs2372536;GG;EFFICACY;INCREASED_RESPONSE
ZIDOVUDINE;UGT2B7;rs28365062;G;LADME_PK;INCREASED_METABOLISM
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DOSE
CHOLESTEROL;APOE;rs429358;TT;TOXICITY;INCREASED_CONCENTRATIONS
METHADONE;DRD2;rs6275;AA;DOSAGE, LADME_PK;DECREASED_DOSE
METFORMIN;SLC47A2;rs12943590;AA + AG;EFFICACY;INCREASED_RESPONSE
ATENOLOL, CARVEDILOL, DILTIAZEM, METOPROLOL, VERAPAMIL;ADRB1;rs1801253;CG + GG;EFFICACY;INCREASED_RESPONSE
METHADONE;DRD2;rs1799978;CC;DOSAGE, LADME_PK;DECREASED_DOSE
METFORMIN;SLC22A2;rs316019;AA + AC;EFFICACY;INCREASED_RESPONSE
CARBAMAZEPINE;ABCB1;rs1128503;AA + AG;EFFICACY;DECREASED_CLINICAL BENEFIT
CARBAMAZEPINE;ABCB1;rs2032582;AA + AC;EFFICACY;DECREASED_CLINICAL BENEFIT
ERYTHROMYCIN;ABCC2;rs717620;TT;OTHER, LADME_PK;INCREASED_METABOLISM
WARFARIN;GGCX;rs11676382;CG + GG;DOSAGE;DECREASED_DOSE
CARBAMAZEPINE;ABCB1;rs1045642;AA + AG;EFFICACY;DECREASED_CLINICAL BENEFIT
ABIRATERONE, DUTASTERIDE;HSD3B1;rs1047303;AC;EFFICACY;DECREASED_RESPONSE
AZATHIOPRINE;PACSIN2;rs2413739;CT + TT;EFFICACY;DECREASED_RESPONSE
SILDENAFIL;NOS3;rs2070744;CC + CT;EFFICACY;INCREASED_RESPONSE
NEVIRAPINE;CYP2B6;rs3745274;TT;TOXICITY, LADME_PK;DECREASED_CLEARANCE
ABIRATERONE;SRD5A2;rs523349;CC;LADME_PK;INCREASED_METABOLISM
TRIGLYCERIDES;CYP19A1;rs10046;A;OTHER;DECREASED_CONCENTRATIONS
TRIGLYCERIDES;CYP19A1;rs3759811;C;OTHER;DECREASED_CONCENTRATIONS
WARFARIN;VKORC1;rs7196161;A;DOSAGE;DOSE
HDL CHOLESTEROL;CYP19A1;rs1008805;G;OTHER;DECREASED_CONCENTRATIONS
OPIOIDS;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE
TRIGLYCERIDES;CYP19A1;rs2289105;C;OTHER;DECREASED_CONCENTRATIONS
WARFARIN;VKORC1;rs7196161;G;DOSAGE;DOSE
METHOTREXATE;SLC19A1;rs1051296;AC + CC;LADME_PK;DECREASED_CONCENTRATIONS
HDL CHOLESTEROL;CYP19A1;rs10046;G;OTHER;DECREASED_CONCENTRATIONS
FENTANYL;CYP3A4;rs2242480;T;DOSAGE;DECREASED_DOSE
HDL CHOLESTEROL;CYP19A1;rs2289105;T;OTHER;DECREASED_CONCENTRATIONS
LEFLUNOMIDE;ESR1;rs2234693;TT;EFFICACY;INCREASED_RESPONSE
NEVIRAPINE;CYP2B6;rs3745274;GT;TOXICITY, LADME_PK;DECREASED_CLEARANCE
LEFLUNOMIDE;ESR1;rs9340799;AA;EFFICACY;INCREASED_RESPONSE
USTEKINUMAB;C9orf72;rs774359;CC + CT;EFFICACY;INCREASED_RESPONSE
METHOTREXATE;GGH;rs3758149;GG;LADME_PK;DECREASED_CONCENTRATIONS
HDL CHOLESTEROL;CYP19A1;rs4646;A;OTHER;DECREASED_CONCENTRATIONS
USTEKINUMAB;IL13;rs848;AA + AC;EFFICACY;DECREASED_RESPONSE
TRIGLYCERIDES;CYP19A1;rs700518;C;OTHER;DECREASED_CONCENTRATIONS
USTEKINUMAB;ZNF816;rs9304742;CC + CT;EFFICACY;INCREASED_RESPONSE
TRIGLYCERIDES;CYP19A1;rs4775936;C;OTHER;DECREASED_CONCENTRATIONS
WARFARIN;GGCX;rs11676382;CG + GG;DOSAGE;DECREASED_DOSE
USTEKINUMAB;STAT4;rs7574865;GT + TT;EFFICACY;INCREASED_RESPONSE
USTEKINUMAB;SLC22A4;rs1050152;CT;EFFICACY;INCREASED_RESPONSE
ETHANOL;OPRM1;rs1799971;AG + GG;OTHER;INCREASED_RESPONSE
NICOTINE;CHRNA5;rs16969968;GG;EFFICACY;INCREASED_RESPONSE
WARFARIN;STX1B;rs72800847;AA + AG;DOSAGE;DECREASED_DOSE
WARFARIN;CYP1A1;rs3826041;CC;DOSAGE;INCREASED_DOSE
VARENICLINE;CHRNA5;rs16969968;AA + AG;EFFICACY;INCREASED_RESPONSE
WARFARIN;DNMT3A;rs2304429;TT;DOSAGE;INCREASED_DOSE
WARFARIN;NQO1;rs10517;AA;DOSAGE;INCREASED_DOSE
RALOXIFENE;ESR1;rs2234693;TT;EFFICACY;INCREASED_CLINICAL BENEFIT
ACENOCOUMAROL, PHENPROCOUMON;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_DOSE
FENTANYL;DRD1;rs966775;AG + GG;EFFICACY;INCREASED_CONCENTRATIONS
FLUTICASONE / SALMETEROL;CHRM2;rs8191992;A;EFFICACY;RESPONSE
METHOTREXATE;MTHFR;rs1801133;AA + AG;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;VKORC1;rs9923231;A;DOSAGE;DOSE
PHENPROCOUMON;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE
WARFARIN;CYP2C9;rs1057910;AA;DOSAGE;INCREASED_DOSE
WARFARIN;VKORC1;rs9934438;AG + GG;DOSAGE;INCREASED_DOSE
ARIPIPRAZOLE, RISPERIDONE;DRD2;rs2514218;CC;EFFICACY;INCREASED_RESPONSE
VORICONAZOLE;ABCG2;rs2231142;GT + TT;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
WARFARIN;STX1B;rs4889606;AG + GG;DOSAGE;DECREASED_DOSE
WARFARIN;UGT1A1;rs887829;CC;DOSAGE;DECREASED_DOSE
WARFARIN;CYP4F2;rs2108622;CC + CT;DOSAGE;DECREASED_DOSE
AZATHIOPRINE, MERCAPTOPURINE;ITPA;rs1127354;AA + AC;LADME_PK;DECREASED_METABOLISM
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE
BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;SHMT1;rs1979277;A;EFFICACY;INCREASED_RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL6;rs1800795;G;EFFICACY;DECREASED_RESPONSE
WARFARIN;CYP2C9;rs1057910;AC + CC;DOSAGE;INCREASED_DOSE
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE
PLATINUM COMPOUNDS;;rs6983267;GG + GT;EFFICACY;INCREASED_RESPONSE
METFORMIN;SLC22A2;rs316009;TT;EFFICACY;INCREASED_RESPONSE
OPIOIDS;OPRM1;rs1799971;AG + GG;DOSAGE, EFFICACY;INCREASED_DOSE
ATORVASTATIN;SLCO1B1;rs4149056;C;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
CYCLOSPORINE;CYP3A4;rs35599367;AA + AG;TOXICITY, LADME_PK;DECREASED_CLEARANCE
PLATINUM COMPOUNDS;MALAT1;rs619586;AG + GG;EFFICACY;DECREASED_RESPONSE
PLATINUM COMPOUNDS;HOTAIR;rs7958904;CC + CG;EFFICACY;DECREASED_RESPONSE
PLATINUM COMPOUNDS;H19;rs2839698;AA + AG;EFFICACY;INCREASED_RESPONSE
TACROLIMUS;CYP3A4;rs35599367;AG;DOSAGE;DECREASED_DOSE
CARBAMAZEPINE;EPHX1;rs1051740;C;DOSAGE, LADME_PK;INCREASED_DOSE
WARFARIN;VKORC1;rs9934438;AG + GG;DOSAGE;INCREASED_DOSE
FLUTICASONE / SALMETEROL;CHRM2;rs6962027;A;EFFICACY;RESPONSE
NICOTINE;OPRM1;rs1799971;AG + GG;OTHER;INCREASED_EXPOSURE
BETA BLOCKING AGENTS;ADRB1;rs1801253;C;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9934438;AG + GG;DOSAGE;INCREASED_DOSE
BETA BLOCKING AGENTS;ADRB2;rs1042713;A;EFFICACY;INCREASED_RESPONSE
FLUTICASONE / SALMETEROL;CHRM2;rs6962027;A;EFFICACY;RESPONSE
CARBAMAZEPINE;EPHX1;rs2234922;G;DOSAGE, LADME_PK;INCREASED_DOSE
FLUTICASONE PROPIONATE;CRHR1;rs1876831;T;EFFICACY;INCREASED_RESPONSE
RISPERIDONE;TNIK;rs2088885;AA;EFFICACY;INCREASED_RESPONSE
FLUTICASONE PROPIONATE;CRHR1;rs1876828;T;EFFICACY;INCREASED_RESPONSE
METFORMIN;CSMD1;rs2617102;AC + CC;EFFICACY;DECREASED_RESPONSE
FLUTICASONE PROPIONATE;CRHR1;rs1876829;C;EFFICACY;INCREASED_RESPONSE
FLUTICASONE PROPIONATE;CRHR1;rs739645;G;EFFICACY;INCREASED_RESPONSE
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DOSE
NEVIRAPINE;CYP2B6;rs3745274;T;TOXICITY, LADME_PK;DECREASED_CLEARANCE
NICOTINE;POR;rs1057868;CT + TT;LADME_PK;INCREASED_METABOLISM
CARBAMAZEPINE;SCN1A;rs3812718;TT;LADME_PK;INCREASED_METABOLISM
WARFARIN;CYP4F2;rs2108622;TT;DOSAGE;INCREASED_DOSE
VORICONAZOLE;CYP2C18;rs2860840;T;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
VORICONAZOLE;CYP2C18;rs11188059;G;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
REMIFENTANIL;ABCB1;rs1045642;GG;DOSAGE;INCREASED_DOSE
WARFARIN;GGCX;rs12714145;CT + TT;DOSAGE;DECREASED_DOSE
WARFARIN;VKORC1;rs9934438;AG + GG;DOSAGE;INCREASED_DOSE
REMIFENTANIL;ABCB1;rs1045642;GG;EFFICACY;DECREASED_RESPONSE
FLUOROURACIL;DPYD;rs1801159;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE
CARBAMAZEPINE;SCN1A;rs3812718;TT;LADME_PK;INCREASED_DOSE
NALTREXONE;OPRM1;rs1799971;AA;EFFICACY;INCREASED_CLINICAL BENEFIT
ASPIRIN;P2RY1;rs1371097;T;EFFICACY;DECREASED_CLINICAL BENEFIT
GEMCITABINE;CMPK1;rs1044457;TT;EFFICACY;DECREASED_CLINICAL BENEFIT
TACROLIMUS;SLC7A8;rs7141505;AC + CC;LADME_PK;DECREASED_METABOLISM
MERCAPTOPURINE;NUDT15;rs55713253;CC;DOSAGE;INCREASED_DOSE
CYCLOPHOSPHAMIDE, DOXORUBICIN, PACLITAXEL;ABCC2;rs145008610;AA;EFFICACY;DECREASED_CLINICAL BENEFIT
DEOXY-THIOGUANOSINE TRIPHOSPHATE, THIOGUANOSINE TRIPHOSPHATE;TPMT;rs1142345;CT;LADME_PK;INCREASED_CONCENTRATIONS
AZATHIOPRINE;PACSIN2;rs2413739;CC + CT;EFFICACY;INCREASED_CLINICAL BENEFIT
CLOPIDOGREL CARBOXYLIC ACID;ABCB1;rs1045642;AA + AG;LADME_PK;DECREASED_CONCENTRATIONS
BREXPIPRAZOLE;CYP2D6;CYP2D6;intermediate_metabolizer;LADME_PK;DECREASED_METABOLISM
BREXPIPRAZOLE;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;DECREASED_CONCENTRATIONS
THIORIDAZINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*3/*4 + *4/*4 + *4/*5 + *4/*6;LADME_PK;INCREASED_CONCENTRATIONS
PRIMAQUINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*17, CYP2D6*29, CYP2D6*34, CYP2D6*39, CYP2D6*41;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;EFFICACY;INCREASED_CONCENTRATIONS
CYCLOSPORINE;CYP3A5;rs776746;CT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
RISPERIDONE;CYP2D6;CYP2D6*17;*17;LADME_PK;INCREASED_METABOLISM
RISPERIDONE;CYP2D6;CYP2D6*29;*29;LADME_PK;DECREASED_METABOLISM
DULAGLUTIDE, LIRAGLUTIDE, SEMAGLUTIDE;GLP1R;rs6923761;GG;EFFICACY;INCREASED_CLINICAL BENEFIT
N-DESMETHYLCLOZAPINE;SLCO1B1;rs4149056;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS
NORCLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*2/*2 + *2/*3 + *3/*3;LADME_PK;DECREASED_CLEARANCE
ARTEMETHER, LUMEFANTRINE;CYP2B6;rs3745274;GT;EFFICACY;DECREASED_CLINICAL BENEFIT
4-ENE VALPROIC ACID;CPT1A;rs2228502;GG;LADME_PK;INCREASED_CONCENTRATIONS
TACROLIMUS;SULT1E1;rs3775770;CC;LADME_PK;DECREASED_METABOLISM
DEXTROMETHORPHAN;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;DECREASED_METABOLISM
METHOTREXATE;ATIC;rs4673991;CC + CT;EFFICACY;INCREASED_CLINICAL BENEFIT
QUETIAPINE;CYP3A4;CYP3A4*22;*22;LADME_PK;INCREASED_EXPOSURE
METHOTREXATE;ATIC;rs4673993;CT + TT;EFFICACY;INCREASED_CLINICAL BENEFIT
METHOTREXATE;ADA;rs2057638;GT + TT;EFFICACY;INCREASED_CLINICAL BENEFIT
METHOTREXATE;ATIC;rs2372536;CC + CG;EFFICACY;INCREASED_CLINICAL BENEFIT
METHOTREXATE;ADA;rs6017375;CG + GG;EFFICACY;INCREASED_CLINICAL BENEFIT
METHOTREXATE;ADA;rs371927;AA;EFFICACY;INCREASED_CLINICAL BENEFIT
PROPOFOL;UGT1A9;rs72551330;CT;LADME_PK;DECREASED_CLEARANCE
PROPOFOL;UGT1A9;rs2741045;CC;LADME_PK;INCREASED_CLEARANCE
LOSARTAN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*1;;INCREASED_CLINICAL BENEFIT
CODEINE, HYDROCODONE, OXYCODONE, TRAMADOL;CYP2D6;CYP2D6;poor_metabolizer;EFFICACY;DECREASED_CLINICAL BENEFIT
ZUCLOPENTHIXOL;CYP2D6;CYP2D6 normal metabolizer;;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS
SITAGLIPTIN;GLP1R;rs6923761;GG;EFFICACY;INCREASED_CLINICAL BENEFIT
SALBUTAMOL;ADRB2;rs1042717;AA;EFFICACY;DECREASED_CLINICAL BENEFIT
SALBUTAMOL;ADRB2;rs1042714;GG;EFFICACY;DECREASED_CLINICAL BENEFIT
THIORIDAZINE;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS
ZUCLOPENTHIXOL;CYP2D6;CYP2D6;intermediate_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS
PERPHENAZINE;CYP2D6;CYP2D6;intermediate_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;CDKAL1;rs7754840;CC;EFFICACY;INCREASED_RESPONSE
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;CDKAL1;rs7756992;GG;EFFICACY;INCREASED_RESPONSE
SITAGLIPTIN, VILDAGLIPTIN;GLP1R;rs6923761;AA;EFFICACY;DECREASED_RESPONSE
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;LADME_PK;INCREASED_CONCENTRATIONS
ANTIDEPRESSANTS, ANTIPSYCHOTICS;CYP2C19;CYP2C19*17;*17;EFFICACY;INCREASED_RESISTANCE
AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;LADME_PK;INCREASED_CONCENTRATIONS
ANTIDEPRESSANTS, ANTIPSYCHOTICS;CYP2D6;CYP2D6*3;*3;EFFICACY;INCREASED_RESISTANCE
ANTIDEPRESSANTS, ANTIPSYCHOTICS;CYP1A2;CYP1A2*30;*30;EFFICACY;INCREASED_RESISTANCE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*1/*1 + *1/*3 + *1/*6 + *1/*7;DOSAGE;INCREASED_DOSE
TACROLIMUS;CYP3A4;rs35599367;AG;DOSAGE;DECREASED_DOSE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE
TACROLIMUS;CYP3A4;rs2740574;CC + CT;DOSAGE;INCREASED_DOSE
EFAVIRENZ;CYP2B6;rs4803419;C;LADME_PK;DECREASED_CONCENTRATIONS
ANTIDEPRESSANTS;SLC22A3;rs2292334;AG + GG;DOSAGE;INCREASED_DOSE
KETANSERIN;HTR1B;rs130060;C;LADME_PD;DECREASED_AFFINITY
THIOXANTHINE;XDH;rs2295474;T;LADME_PK;DECREASED_CLEARANCE
PAROMOMYCIN;MT-RNR1;rs267606617;G;LADME_PD;DECREASED_ACTIVITY
THIOXANTHINE;XDH;rs45442092;T;LADME_PK;DECREASED_CLEARANCE
DIHYDROERGOTAMINE, METHYSERGIDE, SUMATRIPTAN;HTR1B;rs130060;C;LADME_PD;INCREASED_AFFINITY
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;LADME_PK;INCREASED_EXPRESSION
CISPLATIN, IRINOTECAN;UBE2I;rs9597;CG;LADME_PK;INCREASED_EXPRESSION
METHOTREXATE;SHMT1;rs1979277;AA;LADME_PK;INCREASED_CATALYTIC_ACTIVITY
IVACAFTOR;CFTR;rs113993960;del;EFFICACY;ACTIVITY
IVACAFTOR;CFTR;rs397508139;A;EFFICACY;ACTIVITY
FLUOROURACIL;DPYD;rs1335150891;C;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
IVACAFTOR;CFTR;rs141033578;T;EFFICACY;ACTIVITY
IVACAFTOR;CFTR;rs121909011;T;EFFICACY;ACTIVITY
IVACAFTOR;CFTR;rs77409459;T;EFFICACY;ACTIVITY
IVACAFTOR;CFTR;rs397508510;C;EFFICACY;ACTIVITY
PHENYTOIN;CYP2C9;rs12782374;A;;DECREASED_EXPRESSION
IVACAFTOR;CFTR;rs397508435;C;EFFICACY;ACTIVITY
IVACAFTOR;CFTR;rs77010898;A;EFFICACY;INCREASED_ACTIVITY
ESTRADIOL;TCL1A;rs7158782;G;OTHER;INCREASED_EXPRESSION
IVACAFTOR;CFTR;rs397508328;G;EFFICACY;ACTIVITY
IVACAFTOR;CFTR;rs77932196;A;EFFICACY;ACTIVITY
NIMESULIDE;PTGS2;rs5272;C;LADME_PK;INCREASED_ENZYME_ACTIVITY
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;ASSOCIATED_PROTEIN_STABILITY
IVACAFTOR;CFTR;rs1800111;C;EFFICACY;ACTIVITY
IVACAFTOR;CFTR;rs74551128;A;EFFICACY;ACTIVITY
IVACAFTOR;CFTR;rs186045772;A;EFFICACY;ACTIVITY
IVACAFTOR;CFTR;rs78769542;A;EFFICACY;ACTIVITY
IVACAFTOR;CFTR;rs397508537;A;EFFICACY;ACTIVITY
IVACAFTOR;CFTR;rs397508256;A;EFFICACY;ACTIVITY
IVACAFTOR;CFTR;rs121908751;A;EFFICACY;ACTIVITY
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;ACTIVITY
CISPLATIN;TPMT;TPMT*1, TPMT*3A;*3A;OTHER;INCREASED_EXPRESSION
IVACAFTOR;CFTR;rs368505753;T;EFFICACY;ACTIVITY
NIMESULIDE;PTGS2;rs5273;G;LADME_PK;INCREASED_ENZYME_ACTIVITY
IVACAFTOR;CFTR;rs115545701;T;EFFICACY;ACTIVITY
SACUBITRIL;CES1;rs71647871;CT;EFFICACY;DECREASED_CATALYTIC_ACTIVITY
IVACAFTOR;CFTR;rs1800100;T;EFFICACY;ACTIVITY
ESTRADIOL;TCL1A;rs7158782;A;OTHER;INCREASED_EXPRESSION
ESTRADIOL;TCL1A;rs7158782;G;OTHER;INCREASED_EXPRESSION
ANASTROZOLE, EXEMESTANE, LETROZOLE;CYP19A1;rs6493497;AG;OTHER;ACTIVITY
ANASTROZOLE, EXEMESTANE, LETROZOLE;CYP19A1;rs7176005;CT;OTHER;ACTIVITY
MERCAPTOPURINE, THIOGUANINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*9, TPMT*21, TPMT*32, TPMT*33, TPMT*34;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;LADME_PK;DECREASED_ACTIVITY
SITAGLIPTIN;DPP4;rs759717;CC;LADME_PD;INCREASED_ACTIVITY
SITAGLIPTIN;DPP4;rs2909451;TT;LADME_PD;INCREASED_ACTIVITY
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10, CYP2D6*14, CYP2D6*18, CYP2D6*21, CYP2D6*41;*5/*10 + *5/*21 + *41/*41 + *10/*10 + *10/*41;EFFICACY;INCREASED_EXPRESSION
ESTRADIOL;TCL1A;rs7158782;A;OTHER;INCREASED_EXPRESSION
ESTRADIOL;TCL1A;rs7158782;A;OTHER;INCREASED_EXPRESSION
ESTRADIOL;TCL1A;rs7159713;A;OTHER;INCREASED_EXPRESSION
ESTRADIOL;TCL1A;rs7159713;A;OTHER;INCREASED_EXPRESSION
ESTRADIOL;TCL1A;rs7159713;A;OTHER;INCREASED_EXPRESSION
ESTRADIOL;TCL1A;rs7159713;G;OTHER;INCREASED_EXPRESSION
IVACAFTOR;CFTR;rs78655421;A;EFFICACY;ACTIVITY
IVACAFTOR;CFTR;rs397508759;A;EFFICACY;ACTIVITY
IVACAFTOR;CFTR;rs150212784;G;EFFICACY;ACTIVITY
IVACAFTOR;CFTR;rs34911792;G;EFFICACY;ACTIVITY
IVACAFTOR;CFTR;rs397508513;C;EFFICACY;ACTIVITY
ESTRADIOL;TCL1A;rs7159713;G;OTHER;INCREASED_EXPRESSION
METHOXSALEN;CYP2A6;CYP2A6*15, CYP2A6*21, CYP2A6*22;*15 + *21 + *22;OTHER;DECREASED_ENZYME_ACTIVITY
ATORVASTATIN;SCAP;rs12487736;TT;OTHER;DECREASED_TRANSCRIPTION
IVACAFTOR;CFTR;rs202179988;T;EFFICACY;ACTIVITY
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2;*2;OTHER;DECREASED_ACTIVITY
VITAMIN E;CYP4F2;rs3093105;C;LADME_PK;INCREASED_CATALYTIC_ACTIVITY
ESTRADIOL;;rs11849538;C;OTHER;INCREASED_EXPRESSION
ESTRADIOL;;rs11849538;C;OTHER;INCREASED_EXPRESSION
IVACAFTOR / LUMACAFTOR;CFTR;rs78655421;A;EFFICACY;INCREASED_ACTIVITY
IVACAFTOR, NPPB;CFTR;rs75527207;A;EFFICACY;INCREASED_ACTIVITY
EFAVIRENZ;CYP2B6;CYP2B6*6;*6;LADME_PK;INCREASED_ACTIVITY
FLUOROURACIL;DPYD;rs56005131;T;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
ESTRADIOL;;rs2369049;G;OTHER;INCREASED_EXPRESSION
ESTRADIOL;;rs2369049;A;OTHER;INCREASED_EXPRESSION
ESTRADIOL;;rs2369049;A;OTHER;INCREASED_EXPRESSION
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs80034486;CG;LADME_PD;INCREASED_ACTIVITY
CORR-4A, IVACAFTOR, LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;INCREASED_ACTIVITY
ESTRADIOL;;rs2369049;A;OTHER;INCREASED_EXPRESSION
IVACAFTOR;CFTR;rs397508288;G;EFFICACY;ACTIVITY
IVACAFTOR;CFTR;rs75541969;C;EFFICACY;ACTIVITY
ESCITALOPRAM;IL11;rs1126757;CT + TT;OTHER;DECREASED_EXPRESSION
ESTRADIOL;;rs11849538;G;OTHER;INCREASED_EXPRESSION
METHOTREXATE;FASTKD3, MTRR;rs1801394;AG + GG;;INCREASED_CATALYTIC_ACTIVITY
ESTRADIOL;;rs11849538;G;OTHER;INCREASED_EXPRESSION
ESTRADIOL;;rs11849538;C;OTHER;INCREASED_EXPRESSION
IVACAFTOR;CFTR;rs11971167;T;EFFICACY;ACTIVITY
ESTRADIOL;;rs2369049;G;OTHER;INCREASED_EXPRESSION
IVACAFTOR;CFTR;rs121909019;A;EFFICACY;ACTIVITY
IVACAFTOR;CFTR;rs121908753;A;EFFICACY;ACTIVITY
PHENYTOIN;CYP2C9;rs71486745;del;;DECREASED_EXPRESSION
METHOTREXATE;MTHFR;rs1801131;GT;;INCREASED_CATALYTIC_ACTIVITY
IVACAFTOR;CFTR;rs77834169;T;EFFICACY;ACTIVITY
IVACAFTOR;CFTR;rs397508442;T;EFFICACY;ACTIVITY
IVACAFTOR;CFTR;rs121909047;A;EFFICACY;ACTIVITY
GLYBURIDE;KCNJ11;rs5219;T;LADME_PK;DECREASED_ACTIVITY
HYDROCHLOROTHIAZIDE;YEATS4;rs7297610;CC;LADME_PK;DECREASED_EXPRESSION
IVACAFTOR;CFTR;rs121908752;G;EFFICACY;ACTIVITY
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;INCREASED_ACTIVITY
VITAMIN E;CYP4F2;rs2108622;T;OTHER;DECREASED_ENZYME_ACTIVITY
IVACAFTOR;CFTR;rs121909020;A;EFFICACY;ACTIVITY
IVACAFTOR;CFTR;rs113993958;C;EFFICACY;ACTIVITY
DISOPYRAMIDE;KCNH2;rs104894021;T;EFFICACY;DECREASED_INHIBITION
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*10;*10;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
QUINIDINE;KCNH2;rs104894021;T;EFFICACY;DECREASED_INHIBITION
CHLOROCRESOL;RYR1;rs193922803;T;OTHER;INCREASED_ACTIVITY
TAMOXIFEN;NCOA1;rs1804645;T;;DECREASED_ACTIVITY
CYTARABINE;CDA;rs60369023;AA + AG;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
GENTAMICIN;MT-RNR1;rs267606619;T;LADME_PD;DECREASED_ACTIVITY
QUINIDINE;KCNH2;rs104894021;C;EFFICACY;DECREASED_INHIBITION
BUPROPION;CYP2B6;CYP2B6*1, CYP2B6*30;*1/*30;OTHER;DECREASED_ACTIVITY
GEMCITABINE;DCTD;rs35932500;C;LADME_PK;DECREASED_ENZYME_ACTIVITY
BUPROPION;POR;rs2868177;AG + GG;LADME_PK;INCREASED_ACTIVITY
GEMCITABINE;CDA;rs2072671;C;LADME_PK;DECREASED_ENZYME_ACTIVITY
ADALIMUMAB;TNF;rs1800629;AG;LADME_PK;DECREASED_STEADY_STATE_LEVEL
PAROMOMYCIN;MT-RNR1;rs267606617;G;LADME_PD;DECREASED_ACTIVITY
SIMVASTATIN;HLA-G;rs1063320;GG;OTHER;INCREASED_EXPRESSION
ACETAMINOPHEN;CYP2E1;rs2515641;T;OTHER;INCREASED_EXPRESSION
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*19;*19;OTHER;DECREASED_CATALYTIC_ACTIVITY
BUPRENORPHINE;OPRM1;rs1799971;G;EFFICACY;DECREASED_ACTIVITY
TAMOXIFEN;UGT1A4;rs8330;CC;LADME_PK;DECREASED_ACTIVITY
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*19;*19;LADME_PK;INCREASED_CATALYTIC_ACTIVITY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*28;*28;LADME_PK;INCREASED_CATALYTIC_ACTIVITY
GEMCITABINE;FKBP5;rs73748206;CT;OTHER;INCREASED_EXPRESSION
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*10, CYP2C19*14, CYP2C19*19, CYP2C19*25, CYP2C19*26;*10 + *14 + *19 + *25 + *26;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*10, CYP2C19*13, CYP2C19*14, CYP2C19*15, CYP2C19*18, CYP2C19*19, CYP2C19*23, CYP2C19*25, CYP2C19*26;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*26;*26;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
ACETAMINOPHEN;UGT1A;rs8330;CC;LADME_PK;DECREASED_ACTIVITY
ETHANOL;ADH1B;rs1229984;CT + TT;LADME_PK;INCREASED_ENZYME_ACTIVITY
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR;CFTR;rs113993960;del/del;OTHER;INCREASED_TRANSPORT
ACETAMINOPHEN;UGT1A;rs10929303;CC;LADME_PK;DECREASED_ACTIVITY
XENOBIOTICS;AHR;rs2066853;A;LADME_PK;INCREASED_EXPRESSION
OMEPRAZOLE, XENOBIOTICS;AHR;rs75519181;G;LADME_PK;DECREASED_EXPRESSION
ACETAMINOPHEN;UGT1A;rs1042640;CC;LADME_PK;DECREASED_ACTIVITY
GEMCITABINE;FKBP5;rs73748206;CT;OTHER;INCREASED_EXPRESSION
ESTRADIOL;;rs3802201;GG;OTHER;INCREASED_EXPRESSION
ALDOSTERONE, INSULIN RECOMBINANT;SCNN1B;rs34241435;A;OTHER;INCREASED_TRANSCRIPTION
ESTRADIOL;;rs4476990;CC;OTHER;INCREASED_EXPRESSION
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*9;*9;LADME_PK;DECREASED_ACTIVITY
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*10;*10;LADME_PK;DECREASED_ACTIVITY
BERBERINE, COPTISINE;CYP2D6;CYP2D6*1;*1/*1;LADME_PK;INCREASED_INHIBITION
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;CYP2C19*1, CYP2C19*8, CYP2C19*10;*8 + *10;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*23;*23;LADME_PK;INCREASED_CATALYTIC_ACTIVITY
BERBERINE, COPTISINE;CYP2D6;CYP2D6*1, CYP2D6*10;*1/*10;LADME_PK;INCREASED_INHIBITION
DISOPYRAMIDE;KCNH2;rs104894021;C;EFFICACY;DECREASED_INHIBITION
IVACAFTOR;CFTR;rs74503330;A;OTHER;INCREASED_ACTIVITY
FLUOROURACIL;DPYD;rs372307932;T;LADME_PK;DECREASED_ACTIVITY
MIDAZOLAM;CYP3A4;rs35599367;AG;LADME_PK;DECREASED_ACTIVITY
DEXTROMETHORPHAN;CYP3A4;rs35599367;AG;LADME_PK;DECREASED_ACTIVITY
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*10;*10;LADME_PK;DECREASED_ACTIVITY
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*16;*16;LADME_PK;DECREASED_ACTIVITY
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*19;*19;LADME_PK;DECREASED_ACTIVITY
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*18;*18;LADME_PK;DECREASED_ACTIVITY
FLUOROURACIL;DPYD;rs376073289;T;LADME_PK;DECREASED_ACTIVITY
FLUOROURACIL;DPYD;rs374527058;G;LADME_PK;DECREASED_ACTIVITY
FLUOROURACIL;DPYD;rs538336580;A;LADME_PK;DECREASED_ACTIVITY
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*9;*9;LADME_PK;DECREASED_ACTIVITY
FLUOROURACIL;DPYD;rs568367673;A;LADME_PK;DECREASED_ACTIVITY
FLUOROURACIL;DPYD;rs558354142;A;LADME_PK;DECREASED_ACTIVITY
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs770829708;A;LADME_PK;DECREASED_ACTIVITY
FLUOROURACIL;DPYD;rs374825099;T;LADME_PK;DECREASED_ACTIVITY
ESTRONE SULFATE, ROSUVASTATIN;SLCO2B1;rs199654337;T;LADME_PK;DECREASED_TRANSPORT
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*9, CYP2C19*10, CYP2C19*16;*9 + *10 + *16;LADME_PK;DECREASED_CLEARANCE
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*19;*19;LADME_PK;DECREASED_CLEARANCE
ESTRONE SULFATE, ROSUVASTATIN;SLCO2B1;rs1009122956;C;LADME_PK;DECREASED_TRANSPORT
ESTRONE SULFATE, ROSUVASTATIN;SLCO2B1;rs1621378;T;LADME_PK;DECREASED_TRANSPORT
ESTRONE SULFATE;SLCO2B1;rs2306168;T;LADME_PK;DECREASED_TRANSPORT
FLUOROURACIL;DPYD;rs548783838;T;LADME_PK;DECREASED_ACTIVITY
;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*1;EFFICACY;INCREASED_ACTIVITY
BUPROPION;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*1;EFFICACY;INCREASED_ACTIVITY
FLUOROURACIL;DPYD;rs140989814;G;LADME_PK;DECREASED_ACTIVITY
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*8;*8;LADME_PK;DECREASED_ACTIVITY
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*13;*13;LADME_PK;DECREASED_ACTIVITY
BLONANSERIN;CYP3A4;CYP3A4*1, CYP3A4*29;*29;LADME_PK;INCREASED_ACTIVITY
TESTOSTERONE;CYP3A4;rs35599367;AG;LADME_PK;DECREASED_ACTIVITY
ACALABRUTINIB;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*11, CYP3A4*29, CYP3A4*33;*2 + *3 + *11 + *29 + *33;LADME_PK;INCREASED_CATALYTIC_ACTIVITY
ACALABRUTINIB;CYP3A4;CYP3A4*1, CYP3A4*9, CYP3A4*14, CYP3A4*16, CYP3A4*19, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*32;*9 + *14 + *16 + *19 + *23 + *24 + *28 + *32;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
VANDETANIB;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*9, CYP3A4*15, CYP3A4*16, CYP3A4*29, CYP3A4*32, CYP3A4*33;*2 + *3 + *9 + *15 + *16 + *29 + *32 + *33;LADME_PK;INCREASED_CLEARANCE
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*10;*10;LADME_PK;DECREASED_ACTIVITY
FLUOROURACIL;DPYD;rs1801266;A;LADME_PK;DECREASED_ACTIVITY
DEXTROMETHORPHAN;SEPTIN3, WBP2NL;rs1062753;G;LADME_PK;INCREASED_ENZYME_ACTIVITY
BUMETANIDE;SLC17A3;rs34376145;A;LADME_PK;DECREASED_TRANSPORT
BUMETANIDE;SLC17A3;rs34902660;A;LADME_PK;DECREASED_TRANSPORT
BUMETANIDE;SLC17A3;rs11966370;A;LADME_PK;DECREASED_TRANSPORT
BUMETANIDE;SLC17A3;rs56027330;T;LADME_PK;DECREASED_TRANSPORT
OMEPRAZOLE;CYP2C19;rs148247410;G;LADME_PK;DECREASED_ACTIVITY
FLUOROURACIL;DPYD;rs528152707;A;LADME_PK;DECREASED_ACTIVITY
FLUOROURACIL;DPYD;rs570122671;A;LADME_PK;DECREASED_ACTIVITY
FLUOROURACIL;DPYD;rs201268750;T;LADME_PK;DECREASED_ACTIVITY
FLUOROURACIL;DPYD;rs527580106;C;LADME_PK;DECREASED_ACTIVITY
FLUOROURACIL;DPYD;rs55886062;C;LADME_PK;DECREASED_ACTIVITY
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs550527959;T;LADME_PK;DECREASED_ACTIVITY
FLUOROURACIL;DPYD;rs538703919;A;LADME_PK;DECREASED_ACTIVITY
IBUPROFEN;CYP3A4;CYP3A4*1, CYP3A4*4, CYP3A4*5, CYP3A4*18, CYP3A4*23, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*33, CYP3A4*34;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;OTHER;DECREASED_CLEARANCE
BLONANSERIN;CYP3A4;CYP3A4*1, CYP3A4*20;*20;LADME_PK;DECREASED_ACTIVITY
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs763625282;A;LADME_PK;DECREASED_ACTIVITY
BLONANSERIN;CYP3A4;CYP3A4*1, CYP3A4*4, CYP3A4*5, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*10, CYP3A4*12, CYP3A4*13, CYP3A4*14, CYP3A4*16, CYP3A4*17, CYP3A4*18, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*31, CYP3A4*33, CYP3A4*34;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;LADME_PK;DECREASED_ACTIVITY
REGORAFENIB;CYP3A4;CYP3A4*1, CYP3A4*20;*20;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
FLUOROURACIL;DPYD;rs72549307;C;LADME_PK;DECREASED_ACTIVITY
OMEPRAZOLE;CYP2C19;rs1431015009;T;LADME_PK;DECREASED_ACTIVITY
BUFURALOL;CYP2D6;rs1058171;T;LADME_PK;DECREASED_ACTIVITY
DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;CYP2C9*1, CYP2C9*72;*72;LADME_PK;DECREASED_ENZYME_ACTIVITY
SUMATRIPTAN;HTR1B;rs130060;C;LADME_PD;INCREASED_CONCENTRATIONS
BUFURALOL;CYP2D6;rs1230912765;A;LADME_PK;DECREASED_ACTIVITY
PURINE ANALOGUES;PACSIN2;rs2413739;C;OTHER, LADME_PK;INCREASED_ACTIVITY
L-PHENYLALANINE;PAH;rs76394784;A;LADME_PK;DECREASED_ACTIVITY
CARBOCISTEINE;PAH;rs62516101;T;LADME_PK;DECREASED_ACTIVITY
CARBOCISTEINE;PAH;rs75193786;G;LADME_PK;DECREASED_ACTIVITY
DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;CYP2C9*1, CYP2C9*3;*3;LADME_PK;DECREASED_ENZYME_ACTIVITY
LOSARTAN;CYP2C9;CYP2C9*1, CYP2C9*75;*75;LADME_PK;DECREASED_ENZYME_ACTIVITY
L-PHENYLALANINE;PAH;rs62516101;T;LADME_PK;DECREASED_ACTIVITY
CARBOCISTEINE;PAH;rs5030860;C;LADME_PK;DECREASED_ACTIVITY
L-PHENYLALANINE;PAH;rs5030849;T;LADME_PK;DECREASED_ACTIVITY
CARBOCISTEINE;PAH;rs76394784;A;LADME_PK;DECREASED_ACTIVITY
DICLOFENAC;CYP2C9;CYP2C9*3;*3;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*60;*60;LADME_PK;DECREASED_ENZYME_ACTIVITY
DICLOFENAC;CYP2C9;CYP2C9*37;*37;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
DICLOFENAC;CYP2C9;CYP2C9*46;*46;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
CARBOCISTEINE;PAH;rs5030849;T;LADME_PK;DECREASED_ACTIVITY
L-PHENYLALANINE;PAH;rs5030860;C;LADME_PK;DECREASED_ACTIVITY
DICLOFENAC;CYP2C9;CYP2C9*54;*54;LADME_PK;INCREASED_CATALYTIC_ACTIVITY
DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;CYP2C9*1, CYP2C9*74;*74;LADME_PK;DECREASED_ENZYME_ACTIVITY
TOLBUTAMIDE;CYP2C9;rs9332239;T;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*49, CYP2D6*55;*49 + *55;LADME_PK;DECREASED_ENZYME_ACTIVITY
TOLTERODINE;CYP2D6;CYP2D6*92, CYP2D6*96;*92 + *96;LADME_PK;DECREASED_ACTIVITY
GEFITINIB;CYP2D6;CYP2D6*92, CYP2D6*96;*92 + *96;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*10, CYP2D6*18, CYP2D6*36, CYP2D6*47, CYP2D6*49, CYP2D6*50, CYP2D6*51, CYP2D6*54, CYP2D6*55, CYP2D6*114;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;LADME_PK;DECREASED_ENZYME_ACTIVITY
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*18;*18;LADME_PK;DECREASED_ENZYME_ACTIVITY
HYDRALAZINE;NAT2;NAT2*4, NAT2*5, NAT2*6, NAT2*7;*4/*5 + *4/*6;OTHER;INCREASED_ACTIVITY
HYDRALAZINE;NAT2;NAT2*4, NAT2*5, NAT2*6;*4/*4;OTHER;INCREASED_ACTIVITY
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*36;*36;LADME_PK;DECREASED_ENZYME_ACTIVITY
DICLOFENAC, LOSARTAN;CYP2C9;CYP2C9*1, CYP2C9*73;*73;LADME_PK;DECREASED_ENZYME_ACTIVITY
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*36;*36;LADME_PK;DECREASED_ENZYME_ACTIVITY
FLUOXETINE;CYP2D6;CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*92, CYP2D6*93, CYP2D6*96;*10 + *92 + *93 + *96 + *87 + *2;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*89, CYP2D6*92, CYP2D6*93, CYP2D6*96;*2 + *10 + *89 + *92 + *93 + *96;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
TOLBUTAMIDE;CYP2C9;CYP2C9*1, CYP2C9*60;*60;LADME_PK;DECREASED_ENZYME_ACTIVITY
TOLBUTAMIDE;CYP2C9;CYP2C9*1, CYP2C9*3;*3;LADME_PK;DECREASED_ENZYME_ACTIVITY
DICLOFENAC;CYP2C9;CYP2C9*1, CYP2C9*3;*3;LADME_PK;DECREASED_ENZYME_ACTIVITY
DICLOFENAC;CYP2C9;CYP2C9*1, CYP2C9*60;*60;LADME_PK;DECREASED_ENZYME_ACTIVITY
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*10;*10;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;LADME_PK;DECREASED_ENZYME_ACTIVITY
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*50;*50;LADME_PK;DECREASED_ENZYME_ACTIVITY
DICLOFENAC;CYP2C9;CYP2C9*44;*44;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
DICLOFENAC;CYP2C9;CYP2C9*42;*42;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
DICLOFENAC;CYP2C9;CYP2C9*40;*40;LADME_PK;INCREASED_CATALYTIC_ACTIVITY
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs200346442;A;LADME_PK;DECREASED_ACTIVITY
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs200150287;G;LADME_PK;DECREASED_ACTIVITY
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs150152656;T;LADME_PK;DECREASED_ACTIVITY
BUPROPION;POR;rs2868177;AA;OTHER, LADME_PK;DECREASED_ENZYME_ACTIVITY
BUPROPION;POR;rs2868177;GG;OTHER, LADME_PK;INCREASED_ACTIVITY
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*51;*51;LADME_PK;DECREASED_ENZYME_ACTIVITY
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*32;*32;LADME_PK;DECREASED_ACTIVITY
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*29, CYP2C19*30, CYP2C19*31, CYP2C19*33;*29 + *30 + *31 + *33;LADME_PK;DECREASED_ACTIVITY
;POR;rs2868177;AA;OTHER, LADME_PK;DECREASED_ACTIVITY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*10;*10;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
OMEPRAZOLE;CYP2C19;rs140278421;A;LADME_PK;DECREASED_ACTIVITY
OMEPRAZOLE;CYP2C19;rs1361528097;G;LADME_PK;DECREASED_ACTIVITY
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*3;*3;LADME_PK;DECREASED_ACTIVITY
FLUOROURACIL;DPYD;rs536577604;C;LADME_PK;DECREASED_ACTIVITY
DEBRISOQUINE;CYP2D6;CYP2D6*1, CYP2D6*10;*10;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs1267723490;C;LADME_PK;DECREASED_ACTIVITY
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*54;*54;LADME_PK;DECREASED_ENZYME_ACTIVITY
BUFURALOL, DEBRISOQUINE;CYP2D6;CYP2D6*1, CYP2D6*29;*29;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*47;*47;LADME_PK;DECREASED_ENZYME_ACTIVITY
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs764137538;T;LADME_PK;DECREASED_ACTIVITY
IBUPROFEN;CYP2C19;CYP2C19*1, CYP2C19*3, CYP2C19*35;*3 + *35;OTHER;DECREASED_CATALYTIC_ACTIVITY
IBUPROFEN;CYP2C19;CYP2C19*1, CYP2C19*30, CYP2C19*31, CYP2C19*32, CYP2C19*33;*33 + *30 + *31 + *32;OTHER;DECREASED_CATALYTIC_ACTIVITY
DEXTROMETHORPHAN;PHETA2, SMDT1;rs1807493;G;LADME_PK;INCREASED_ENZYME_ACTIVITY
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*10;*10;LADME_PK;DECREASED_ENZYME_ACTIVITY
DICLOFENAC;CYP2C9;CYP2C9*52;*52;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
DICLOFENAC;CYP2C9;CYP2C9*43;*43;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
DICLOFENAC;CYP2C9;CYP2C9*45;*45;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
DICLOFENAC;CYP2C9;CYP2C9*36;*36;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
DICLOFENAC;CYP2C9;CYP2C9*55;*55;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
DICLOFENAC;CYP2C9;CYP2C9*39;*39;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
DICLOFENAC;CYP2C9;CYP2C9*50;*50;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
DICLOFENAC;CYP2C9;CYP2C9*47;*47;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
DICLOFENAC;CYP2C9;CYP2C9*53;*53;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
DICLOFENAC;CYP2C9;CYP2C9*38;*38;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
DICLOFENAC;CYP2C9;CYP2C9*48;*48;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs1463550071;T;LADME_PK;DECREASED_ACTIVITY
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs1349931378;A;LADME_PK;DECREASED_ACTIVITY
DEBRISOQUINE;CYP2D6;CYP2D6*1, CYP2D6*75;*75;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
OMEPRAZOLE;CYP2C19;rs1393133490;T;LADME_PK;DECREASED_ACTIVITY
OMEPRAZOLE;CYP2C19;rs1466428833;G;LADME_PK;DECREASED_ACTIVITY
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs749678783;C;LADME_PK;DECREASED_ACTIVITY
IBRUTINIB;CYP3A4;CYP3A4*1, CYP3A4*17, CYP3A4*24;*17 + *24;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
EFAVIRENZ;CYP2B6;rs58871670;A;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
FLUOROURACIL;DPYD;rs72547601;C;LADME_PK;DECREASED_ACTIVITY
BUPROPION;CYP2B6;rs201500445;C;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3B;*1/*3A + *1/*3B;LADME_PK;DECREASED_ENZYME_ACTIVITY
FLUOROURACIL;DPYD;rs188052243;C;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A;LADME_PK;DECREASED_ENZYME_ACTIVITY
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3C;*1/*3C;LADME_PK;DECREASED_ENZYME_ACTIVITY
DAUNORUBICIN, DOXORUBICIN;AKR7A2;rs1043657;T;LADME_PK;DECREASED_ENZYME_ACTIVITY
DAUNORUBICIN;AKR1C4;rs17134592;G;LADME_PK;DECREASED_ENZYME_ACTIVITY
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*1;LADME_PK;INCREASED_ENZYME_ACTIVITY
MERCAPTOPURINE;TPMT;rs3931660;AT;LADME_PK;DECREASED_ENZYME_ACTIVITY
MERCAPTOPURINE;TPMT;rs1142345;CT;LADME_PK;DECREASED_ENZYME_ACTIVITY
DAUNORUBICIN;AKR1C3;rs4987102;A;LADME_PK;DECREASED_ENZYME_ACTIVITY
DAUNORUBICIN, DOXORUBICIN;AKR1C3;rs35575889;T;LADME_PK;DECREASED_ENZYME_ACTIVITY
DAUNORUBICIN, DOXORUBICIN;AKR1C3;rs34186955;T;LADME_PK;DECREASED_ENZYME_ACTIVITY
;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*5, TPMT*12, TPMT*14, TPMT*18, TPMT*22;*2 + *3A + *5 + *12 + *14 + *18 + *22;LADME_PK;DECREASED_EXPRESSION
FLUOROURACIL;DPYD;rs72549306;A;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
SN-38;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*37;*1/*28 + *28/*28 + *1/*37;LADME_PK;DECREASED_ENZYME_ACTIVITY
SN-38;UGT1A1;rs4148323;A;LADME_PK;DECREASED_ENZYME_ACTIVITY
FLUOROURACIL;DPYD;rs137999090;T;LADME_PK;DECREASED_ACTIVITY
FLUOROURACIL;DPYD;rs145773863;T;LADME_PK;DECREASED_ACTIVITY
17BETA-ESTRADIOL GLUCURONIDE;ABCC4;rs200858900;T;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;*1/*2 + *1/*3A + *1/*3C;LADME_PK;DECREASED_ACTIVITY
FLUOROURACIL;DPYD;rs59086055;A;LADME_PK;DECREASED_ACTIVITY
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3B, TPMT*3C;*3B/*3C;LADME_PK;DECREASED_ENZYME_ACTIVITY
PURINE ANALOGUES;TPMT;rs1142345;CT;OTHER, LADME_PK;DECREASED_ACTIVITY
ELEXACAFTOR, TEZACAFTOR;CFTR;rs1792306355;T;EFFICACY;INCREASED_ACTIVITY
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs186089140;CT;LADME_PD;INCREASED_ACTIVITY
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR, IVACAFTOR / TEZACAFTOR;CFTR;rs35516286;A;LADME_PD;INCREASED_ACTIVITY
CLOPIDOGREL, ENALAPRIL, SACUBITRIL;CES1;rs143718310;G;LADME_PK;DECREASED_METABOLISM
ENALAPRIL;CES1;rs202121317;C;LADME_PK;DECREASED_ENZYME_ACTIVITY
REMIMAZOLAM;CES1;rs2307240;T;LADME_PK;INCREASED_CATALYTIC_ACTIVITY
CLOPIDOGREL;CES1;rs202001817;A;LADME_PK;DECREASED_ENZYME_ACTIVITY
REMIMAZOLAM;CES1;rs71647871;T;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
REMIMAZOLAM;CES1;rs151291296;C;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
CLOPIDOGREL, ENALAPRIL, SACUBITRIL;CES1;rs151291296;C;LADME_PK;DECREASED_ENZYME_ACTIVITY
CLOPIDOGREL, ENALAPRIL, SACUBITRIL;CES1;rs146456965;A;LADME_PK;DECREASED_METABOLISM
REMIMAZOLAM;CES1;rs143718310;G;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
CLOPIDOGREL, ENALAPRIL, SACUBITRIL;CES1;rs200707504;C;LADME_PK;DECREASED_ENZYME_ACTIVITY
ENALAPRIL;CES1;rs2307243;T;LADME_PK;DECREASED_ENZYME_ACTIVITY
REMIMAZOLAM;CES1;rs200707504;C;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
BUPROPION;CYP2B6;rs58871670;A;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
FLUOROURACIL;DPYD;rs755692084;G;LADME_PK;DECREASED_ACTIVITY
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C, TPMT*5, TPMT*6, TPMT*8, TPMT*10, TPMT*11, TPMT*12, TPMT*13;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;LADME_PK;DECREASED_ENZYME_ACTIVITY
THIOGUANINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C, TPMT*5, TPMT*6, TPMT*7, TPMT*9, TPMT*10, TPMT*12, TPMT*14, TPMT*17, TPMT*18, TPMT*19, TPMT*20, TPMT*21, TPMT*22, TPMT*23, TPMT*30;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;LADME_PK;DECREASED_ENZYME_ACTIVITY
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;*1/*3A + *1/*3B + *1/*3C;LADME_PK;DECREASED_ENZYME_ACTIVITY
ELEXACAFTOR, TEZACAFTOR;CFTR;rs758900656;T;EFFICACY;INCREASED_ACTIVITY
17BETA-ESTRADIOL GLUCURONIDE;ABCC4;rs11568681;T;LADME_PK;INCREASED_CATALYTIC_ACTIVITY
FLUOROURACIL;DPYD;rs183385770;T;LADME_PK;DECREASED_ACTIVITY
ESLICARBAZEPINE ACETATE;AADAC;rs35084477;A;LADME_PK;INCREASED_CATALYTIC_ACTIVITY
ESLICARBAZEPINE ACETATE;AADAC;rs1803155;A;LADME_PK;INCREASED_CATALYTIC_ACTIVITY
ESLICARBAZEPINE ACETATE;AADAC;rs61733692;C;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
FLUOROURACIL;DPYD;rs114096998;T;LADME_PK;INCREASED_ACTIVITY
FLUOROURACIL;DPYD;rs60139309;C;LADME_PK;INCREASED_ACTIVITY
FLUOROURACIL;DPYD;rs143986398;C;LADME_PK;DECREASED_ACTIVITY
SN-38;UGT1A9;rs11692021;C;LADME_PK;DECREASED_ENZYME_ACTIVITY
SN-38;UGT1A9;rs72551344;G;LADME_PK;DECREASED_ENZYME_ACTIVITY
SN-38;UGT1A9;rs34993780;G;LADME_PK;DECREASED_ENZYME_ACTIVITY
FLUOROURACIL;DPYD;rs72549308;G;LADME_PK;DECREASED_ACTIVITY
FLUOROURACIL;DPYD;rs1184321568;del;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
FLUOROURACIL;DPYD;rs143879757;A;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
FLUOROURACIL;DPYD;rs59086055;A;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
FLUOROURACIL;DPYD;rs148994843;T;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
DEXTROMETHORPHAN;;rs729559;GG;LADME_PK;INCREASED_ENZYME_ACTIVITY
FLUOROURACIL;DPYD;rs748620513;G;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
DEXTROMETHORPHAN;;rs4073010;TT;LADME_PK;INCREASED_ENZYME_ACTIVITY
FLUOROURACIL;DPYD;rs72549304;A;LADME_PK;DECREASED_ACTIVITY
FLUOROURACIL;DPYD;rs200687447;T;LADME_PK;INCREASED_ACTIVITY
ESLICARBAZEPINE ACETATE;AADAC;rs144650170;G;LADME_PK;INCREASED_CATALYTIC_ACTIVITY
FLUOROURACIL;DPYD;rs146356975;C;LADME_PK;DECREASED_ACTIVITY
ESLICARBAZEPINE ACETATE;AADAC;rs140197497;G;LADME_PK;INCREASED_CATALYTIC_ACTIVITY
FLUOROURACIL;DPYD;rs2297595;C;LADME_PK;INCREASED_ACTIVITY
FLUOROURACIL;DPYD;rs183105782;G;LADME_PK;DECREASED_ACTIVITY
FLUOROURACIL;DPYD;rs190577302;C;LADME_PK;DECREASED_ACTIVITY
17BETA-ESTRADIOL GLUCURONIDE;ABCC4;rs11568644;A;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
17BETA-ESTRADIOL GLUCURONIDE;ABCC4;rs142211148;T;LADME_PK;INCREASED_CATALYTIC_ACTIVITY
FLUOROURACIL;DPYD;rs186169810;C;LADME_PK;DECREASED_ACTIVITY
FLUOROURACIL;DPYD;rs143154602;A;LADME_PK;DECREASED_ACTIVITY
FLUOROURACIL;DPYD;rs368146607;G;LADME_PK;DECREASED_ACTIVITY
FLUOROURACIL;DPYD;rs371258350;T;LADME_PK;DECREASED_ACTIVITY
FLUOROURACIL;DPYD;rs575853463;T;LADME_PK;DECREASED_ACTIVITY
FLUOROURACIL;DPYD;rs569661196;G;LADME_PK;DECREASED_ACTIVITY
FLUOROURACIL;DPYD;rs138616379;T;LADME_PK;DECREASED_ACTIVITY
AMISULPRIDE, ARIPIPRAZOLE, OLANZAPINE, RISPERIDONE;ABCB1;rs2229109;T;LADME_PK;DECREASED_TRANSPORT
FLUOROURACIL;DPYD;rs115232898;C;LADME_PK;DECREASED_ACTIVITY
CLOZAPINE;UGT1A4;rs2011425;G;LADME_PK;INCREASED_CATALYTIC_ACTIVITY
FLUOROURACIL;DPYD;rs111858276;C;LADME_PK;DECREASED_ACTIVITY
ACETAMINOPHEN;UGT1A6;UGT1A6*1a, UGT1A6*2a;*2a;LADME_PK;INCREASED_ACTIVITY
FLUOROURACIL;DPYD;rs140039091;G;LADME_PK;DECREASED_ACTIVITY
FLUOROURACIL;DPYD;rs187713395;G;LADME_PK;DECREASED_ACTIVITY
SN-38;UGT1A9;rs35350960;A;LADME_PK;DECREASED_ENZYME_ACTIVITY
ESLICARBAZEPINE ACETATE;AADAC;rs186388618;T;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
ELEXACAFTOR, TEZACAFTOR;CFTR;rs397508139;A;EFFICACY;INCREASED_ACTIVITY
FLUOROURACIL;MIR27A;rs895819;C;LADME_PK;DECREASED_ENZYME_ACTIVITY
ELEXACAFTOR, TEZACAFTOR;CFTR;rs397508609;A;EFFICACY;INCREASED_ACTIVITY
FLUOROURACIL;DPYD;rs141044036;C;LADME_PK;DECREASED_ACTIVITY
ARACHIDONIC ACID;CYP4F2;rs753169154;G;LADME_PD;DECREASED_CATALYTIC_ACTIVITY
EFAVIRENZ;CYP2B6;rs201500445;C;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
BUPROPION;CYP2B6;rs535039125;T;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
EFAVIRENZ;CYP2B6;rs117872433;A;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
BUPROPION;CYP2B6;rs200238771;A;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
ARACHIDONIC ACID;CYP4F2;rs114396708;A;LADME_PD;DECREASED_CATALYTIC_ACTIVITY
COUMARIN, NICOTINE, TEGAFUR;CYP2A6;CYP2A6*1, CYP2A6*7, CYP2A6*19;*7 + *19;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
BUPROPION;CYP2B6;CYP2B6*47;*47;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
NICOTINE;CYP2A6;rs4803381;CC + CT;LADME_PK;INCREASED_ACTIVITY
EFAVIRENZ;CYP2B6;CYP2B6*47;*47;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
NICOTINE;CYP2A6;rs57837628;AG + GG;LADME_PK;INCREASED_ACTIVITY
COUMARIN, TEGAFUR;CYP2A6;CYP2A6*1, CYP2A6*18;*18;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
FLUOROURACIL;DPYD;rs67376798;A;LADME_PK;DECREASED_ACTIVITY
EFAVIRENZ;CYP2B6;CYP2B6*46;*46;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
NICOTINE;CYP2A6;rs72549435;C;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
EFAVIRENZ;CYP2B6;rs535039125;T;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
PREGNENOLONE;SULT2B1;rs746398875;T;LADME_PK;DECREASED_ENZYME_ACTIVITY
PREGNENOLONE;SULT2B1;rs762765702;A;LADME_PK;DECREASED_ENZYME_ACTIVITY
COUMARIN;CYP2A6;CYP2A6*4, CYP2A6*9;*4/*9;LADME_PK;DECREASED_ENZYME_ACTIVITY
BUPROPION;CYP2B6;rs374099483;A;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
BUPROPION;CYP2B6;rs764288403;A;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
BUPROPION;CYP2B6;CYP2B6*46;*46;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
EFAVIRENZ;CYP2B6;rs374099483;A;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
BUPROPION;CYP2B6;rs117872433;A;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
FLUOROURACIL;DPYD;rs112766203;A;LADME_PK;DECREASED_ACTIVITY
FLUOROURACIL;DPYD;rs1801158;TT;OTHER;INCREASED_ACTIVITY
FLUOROURACIL;DPYD;rs188052243;C;LADME_PK;DECREASED_ACTIVITY
PREGNENOLONE;SULT2B1;rs527454384;T;LADME_PK;DECREASED_ENZYME_ACTIVITY
FLUOROURACIL;DPYD;rs61757362;A;LADME_PK;DECREASED_ACTIVITY
ARACHIDONIC ACID;CYP4F2;rs2108622;T;LADME_PD;DECREASED_CATALYTIC_ACTIVITY
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*17, CYP2A6*35;*17 + *35;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
BUPROPION;CYP2B6;rs148009906;A;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
ELEXACAFTOR, TEZACAFTOR;CFTR;rs397508293;T;EFFICACY;INCREASED_ACTIVITY
FLUOROURACIL;DPYD;rs1801268;A;LADME_PK;DECREASED_ACTIVITY
BUPROPION;CYP2B6;rs200458614;A;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
EFAVIRENZ;CYP2B6;rs764288403;A;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
EFAVIRENZ;CYP2B6;rs200238771;A;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
FLUOROURACIL;DPYD;rs367619008;C;LADME_PK;DECREASED_ACTIVITY
EFAVIRENZ;CYP2B6;rs200458614;A;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
NICOTINE;CYP2A6;rs56113850;CC + CT;LADME_PK;INCREASED_ACTIVITY
FLUOROURACIL;DPYD;rs758649719;T;LADME_PK;DECREASED_ACTIVITY
NICOTINE;CYP2A6;rs7259706;TT;LADME_PK;INCREASED_ACTIVITY
FLUOROURACIL;DPYD;rs369103276;G;LADME_PK;DECREASED_ACTIVITY
VANDETANIB;CYP3A4;CYP3A4*1, CYP3A4*6, CYP3A4*30;*6 + *30;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
NICOTINE;CYP2A6;rs28399453;AA + AG;LADME_PK;INCREASED_ACTIVITY
NICOTINE;CYP2A6;rs8192733;CC + CG;LADME_PK;INCREASED_ACTIVITY
EFAVIRENZ;CYP2B6;rs148009906;A;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
PREGNENOLONE;SULT2B1;rs777924668;G;LADME_PK;DECREASED_ENZYME_ACTIVITY
FLUOROURACIL;DPYD;rs55674432;A;LADME_PK;DECREASED_ACTIVITY
FLUOROURACIL;DPYD;rs55886062;CC;OTHER;DECREASED_ACTIVITY
LETROZOLE;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;*1/*4 + *1/*7 + *4/*4 + *4/*9;LADME_PK;DECREASED_ENZYME_ACTIVITY
NICOTINE;CYP2A6;rs7260629;GG;LADME_PK;INCREASED_ACTIVITY
FLUOROURACIL;DPYD;rs1801265;GG;OTHER;INCREASED_ACTIVITY
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*89, CYP2D6*92, CYP2D6*93, CYP2D6*96;*89 + *92 + *93 + *96;LADME_PK;DECREASED_CATALYTIC_ACTIVITY
PREGNENOLONE;SULT2B1;rs777140014;A;LADME_PK;DECREASED_ENZYME_ACTIVITY
TESTOSTERONE;CYP3A5;rs55817950;A;LADME_PK;DECREASED_ENZYME_ACTIVITY
NIFEDIPINE;CYP3A5;rs72552791;C;LADME_PK;DECREASED_ENZYME_ACTIVITY
PREGNENOLONE;SULT2B1;rs774212320;T;LADME_PK;DECREASED_ENZYME_ACTIVITY
;CYP2C9;rs762081829;T;OTHER;DECREASED_EXPRESSION
;SLCO1B1;SLCO1B1*1, SLCO1B1*14;*14;OTHER;INCREASED_EXPRESSION
;VDR;rs11568820;T;OTHER;INCREASED_STEADY_STATE_LEVEL
;A2M;rs669;T;LADME_PK;INCREASED_STEADY_STATE_LEVEL
;SLCO1B1;SLCO1B1*1, SLCO1B1*37;*37;OTHER;INCREASED_EXPRESSION
;NAMPT;rs1319501;CC + CT;OTHER;DECREASED_STEADY_STATE_LEVEL
;DPYD;rs1801160;T;OTHER;INCREASED_EXPRESSION
;NAMPT;rs3801266;CC + CT;OTHER;INCREASED_STEADY_STATE_LEVEL
;SLCO1B1;SLCO1B1*1, SLCO1B1*20;*20;OTHER;INCREASED_EXPRESSION
;ABCC11;rs17822471;AA + AG;OTHER;DECREASED_EXPRESSION
;CYP2C9;rs771237265;C;OTHER;DECREASED_EXPRESSION
;CYP2C9;rs761895497;C;OTHER;DECREASED_EXPRESSION
;CYP2C19;rs183701923;T;OTHER;DECREASED_EXPRESSION
;DPYD;rs748620513;G;OTHER;INCREASED_EXPRESSION
;CYP2C19;rs61311738;T;OTHER;DECREASED_EXPRESSION
;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;*1/*2 + *1/*3A + *1/*3C;;DECREASED_ENZYME_ACTIVITY
;DPYD;rs143879757;A;OTHER;INCREASED_EXPRESSION
;DPYD;rs1212037891;T;OTHER;INCREASED_EXPRESSION
;DPYD;rs72549306;A;OTHER;INCREASED_EXPRESSION
;CYP2C19;rs140278421;A;OTHER;DECREASED_EXPRESSION
DOXORUBICIN;CBR1;rs9024;GG;LADME_PK;INCREASED_CATALYTIC_ACTIVITY
DOXORUBICIN;CBR1;rs9024;GG;LADME_PK;INCREASED_CATALYTIC_ACTIVITY
;ADRB2;rs1042713;G;OTHER;DECREASED_ACTIVITY
;NOS3;rs1799983;GT + TT;;DECREASED_EXPRESSION
;IL18;rs5744247;CC + CG;OTHER;INCREASED_EXPRESSION
;IL18;rs1946518;GG + GT;OTHER;INCREASED_EXPRESSION
;CYP3A5;rs776746;CC;OTHER;DECREASED_EXPRESSION
;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PD;DECREASED_EXPRESSION
;CYP3A5;rs776746;TT;OTHER;INCREASED_EXPRESSION
;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PD;DECREASED_EXPRESSION
;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PD;DECREASED_EXPRESSION
;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PD;DECREASED_EXPRESSION
;ERCC1;rs2298881;A;OTHER;DECREASED_EXPRESSION
;HSPA5;rs430397;TT;OTHER;INCREASED_EXPRESSION
;CCND1;rs9344;AA + AG;OTHER;INCREASED_TRANSCRIPTION
;ABCC2;rs113646094;CG;OTHER;INCREASED_EXPRESSION
;ABCB1;rs1128503;GG;;INCREASED_EXPRESSION
;XRCC4;rs2075685;T;OTHER;INCREASED_EXPRESSION
;XRCC4;rs10040363;G;OTHER;INCREASED_EXPRESSION
;GCLC;rs761142;CC;OTHER;DECREASED_EXPRESSION
;BCL2L11;rs724710;T;OTHER;DECREASED_EXPRESSION
;EPO;rs1617640;AA;OTHER;INCREASED_EXPRESSION
;KDR;rs34231037;G;OTHER;DECREASED_STEADY_STATE_LEVEL
METHOTREXATE;GGH;rs11545078;A;LADME_PK;DECREASED_CLEARANCE
;DPYD;rs1801265;G;LADME_PK;INCREASED_ACTIVITY
;FCER2;rs28364072;GG;;DECREASED_EXPRESSION
;DPYD;rs114096998;T;OTHER;DECREASED_CATALYTIC_ACTIVITY
;DPYD;rs55886062;AC;OTHER;DECREASED_ACTIVITY
;MGMT;rs4751104;G;LADME_PK;INCREASED_TRANSCRIPTION
;ERCC2;rs1799793;TT;;INCREASED_EXPRESSION
CISPLATIN;ERCC2;rs13181;GG;TOXICITY;DECREASED_SENSITIVITY
;ERCC2;rs13181;GG;;INCREASED_EXPRESSION
;GSTT1;rs1007888;T;LADME_PK;INCREASED_TRANSCRIPTION
;KCNQ3;rs7818112;AA;OTHER;INCREASED_TRANSCRIPTION
;GSK3B;rs334558;A;;INCREASED_TRANSCRIPTION
CISPLATIN;GSTP1;rs1695;AG;TOXICITY;DECREASED_SENSITIVITY
BUSULFAN;GSTM1;rs3754446;C;LADME_PK;INCREASED_CLEARANCE
;DPYD;rs780025995;A;OTHER;DECREASED_CATALYTIC_ACTIVITY
;F12;rs1801020;G;LADME_PK;INCREASED_ENZYME_ACTIVITY
;ERCC1;rs11615;GG;;INCREASED_EXPRESSION
;IL7;rs16906115;AA + AG;OTHER;INCREASED_EXPRESSION
;F3;rs841698;T;;INCREASED_EXPRESSION
;DPYD;rs56038477;CT + TT;LADME_PK;DECREASED_ACTIVITY
;DPYD;rs2297595;C;OTHER;DECREASED_ACTIVITY
;DPYD;rs1801160;CT + TT;LADME_PK;DECREASED_ACTIVITY
;DPYD;rs2297595;CC + CT;LADME_PK;DECREASED_ACTIVITY
;HPR;rs2000999;G;OTHER;INCREASED_EXPRESSION
FLUOROURACIL;DPYD;rs4294451;A;TOXICITY;INCREASED_SENSITIVITY
;DPYD;rs115232898;CT;OTHER;DECREASED_ACTIVITY
;DPYD;rs4294451;T;OTHER;INCREASED_EXPRESSION
TAMOXIFEN;E2F7;rs310786;CC;OTHER;INCREASED_SENSITIVITY
;ECHDC1;rs6569487;AA;OTHER;INCREASED_TRANSCRIPTION
;EGFR;rs712829;TT;;INCREASED_EXPRESSION
;HLA-G;rs1063320;C;OTHER;INCREASED_EXPRESSION
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*07:01;*07:01;OTHER;INCREASED_SENSITIVITY
;DPYD;rs3918290;CT;OTHER;DECREASED_ACTIVITY
;IFNL3;rs4803217;C;OTHER;INCREASED_EXPRESSION
;DPYD;rs3918290;CT;OTHER;DECREASED_ACTIVITY
CISPLATIN;ERCC1;rs11615;GG;TOXICITY;DECREASED_SENSITIVITY
;DPYD;rs748639205;G;OTHER;DECREASED_CATALYTIC_ACTIVITY
;DPYD;rs75017182;CG;OTHER;DECREASED_ACTIVITY
FLUOROURACIL;DPYD;rs3918290;CT;OTHER;DECREASED_CLEARANCE
;IFNL4;rs11322783;TT/TT;OTHER;INCREASED_EXPRESSION
;DPYD;rs75017182;C;LADME_PK;DECREASED_ACTIVITY
;IMPDH2;rs121434586;A;OTHER;DECREASED_ENZYME_ACTIVITY
;DPYD;rs67376798;A;OTHER;DECREASED_ACTIVITY
CALCIUM;RYR1;rs118192167;AG;OTHER;INCREASED_STEADY_STATE_LEVEL
;MIR6076;rs1463411;G;OTHER;DECREASED_EXPRESSION
DESMETHYLNAPROXEN;SULT1A1;rs28374453;G;LADME_PK;INCREASED_SULFATION
ACETAMINOPHEN;SULT1A1;rs28374453;G;LADME_PK;INCREASED_SULFATION
DESMETHYLNAPROXEN;SULT1A1;rs1042008;A;LADME_PK;DECREASED_SULFATION
ACETAMINOPHEN;SULT1A1;rs1042008;A;LADME_PK;DECREASED_SULFATION
DESMETHYLNAPROXEN;SULT1A1;rs758145522;T;LADME_PK;DECREASED_SULFATION
DESMETHYLNAPROXEN;SULT1A1;rs767487725;C;LADME_PK;DECREASED_SULFATION
ACETAMINOPHEN;SULT1A1;rs72547527;T;LADME_PK;DECREASED_SULFATION
TAPENTADOL;SULT1A1;rs1042008;A;LADME_PK;DECREASED_SULFATION
ACETAMINOPHEN;SULT1A1;rs767487725;C;LADME_PK;DECREASED_SULFATION
DESMETHYLNAPROXEN;SULT1A1;rs1042028;T;LADME_PK;DECREASED_SULFATION
ACETAMINOPHEN;SULT1A1;rs544820732;A;LADME_PK;DECREASED_SULFATION
;TBXAS1;rs6962291;AA;OTHER;DECREASED_STEADY_STATE_LEVEL
;TBXAS1;rs6962291;AA;OTHER;DECREASED_EXPRESSION
;TMPRSS11E;rs2168047;T;;INCREASED_EXPRESSION
;TNF;rs1800629;AA + AG;LADME_PK;INCREASED_ACTIVITY
;TPH2;rs7305115;AA;OTHER;INCREASED_EXPRESSION
;TPH2;rs4290270;T;OTHER;INCREASED_EXPRESSION
THIOGUANINE;TPMT;TPMT*1, TPMT*7, TPMT*10, TPMT*12, TPMT*13;*7 + *10 + *12 + *13;LADME_PK;DECREASED_CLEARANCE
;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*3A + *3C;OTHER;DECREASED_ACTIVITY
ACETAMINOPHEN;SULT1A1;rs765399160;T;LADME_PK;INCREASED_SULFATION
;TPMT;TPMT*1, TPMT*3A, TPMT*3C, TPMT*24;*3A + *3C + *24;OTHER;DECREASED_EXPRESSION
ACETAMINOPHEN;SULT1A1;rs552524124;G;LADME_PK;DECREASED_SULFATION
TAPENTADOL;SULT1A1;rs1042028;T;LADME_PK;DECREASED_SULFATION
ATORVASTATIN, CERIVASTATIN, PRAVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*15;*15;LADME_PK;DECREASED_UPTAKE
PACLITAXEL;SLCO1B3;rs7311358;A;OTHER;DECREASED_TRANSPORT
ROSUVASTATIN;SLCO2B1;rs2306168;T;LADME_PK;DECREASED_UPTAKE
ROSUVASTATIN;SLCO2B1;rs142693902;A;LADME_PK;DECREASED_UPTAKE
ROSUVASTATIN;SLCO2B1;rs35199625;A;LADME_PK;DECREASED_UPTAKE
METHOTREXATE;SOD2;rs4880;G;TOXICITY;DECREASED_SENSITIVITY
;SPAG16;rs35945601;CC;OTHER;INCREASED_TRANSCRIPTION
;SQSTM1;rs10277;C;LADME_PK;INCREASED_TRANSCRIPTION
;STXBP4;rs9303363;AA;OTHER;INCREASED_TRANSCRIPTION
DESMETHYLNAPROXEN;SULT1A1;rs552524124;G;LADME_PK;DECREASED_SULFATION
TAPENTADOL;SULT1A1;rs758145522;T;LADME_PK;DECREASED_SULFATION
TAPENTADOL;SULT1A1;rs72547527;T;LADME_PK;DECREASED_SULFATION
TAPENTADOL;SULT1A1;rs544820732;A;LADME_PK;DECREASED_SULFATION
TAPENTADOL;SULT1A1;rs767487725;C;LADME_PK;DECREASED_SULFATION
DESMETHYLNAPROXEN;SULT1A1;rs544820732;A;LADME_PK;DECREASED_SULFATION
ACETAMINOPHEN;SULT1A1;rs1042028;T;LADME_PK;DECREASED_SULFATION
DESMETHYLNAPROXEN;SULT1A1;rs72547527;T;LADME_PK;DECREASED_SULFATION
TAPENTADOL;SULT1A1;rs552524124;G;LADME_PK;DECREASED_SULFATION
TAPENTADOL;SULT1A1;rs28374453;G;LADME_PK;INCREASED_SULFATION
ACETAMINOPHEN;SULT1A1;rs758145522;T;LADME_PK;DECREASED_SULFATION
ATORVASTATIN, CERIVASTATIN, PRAVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*5;*5;LADME_PK;DECREASED_UPTAKE
MERCAPTOPURINE;TPMT;TPMT deficiency;;TOXICITY, LADME_PK;INCREASED_CONCENTRATIONS
CISPLATIN;TPMT;TPMT*1, TPMT*3A;*3A;TOXICITY;INCREASED_SENSITIVITY
SN-38;UGT1A9;rs2741049;CT + TT;LADME_PK;INCREASED_CLEARANCE
;UGT1A9;rs3832043;T/del + TT;LADME_PK;INCREASED_FORMATION
;UGT1A9;rs2741049;TT;LADME_PK;INCREASED_FORMATION
SN-38;UGT1A9;rs3806598;AA;LADME_PK;INCREASED_CLEARANCE
;UGT1A9;rs3832043;T/del + TT;LADME_PK;INCREASED_FORMATION
SN-38;UGT1A9;rs3832043;T/del + TT;LADME_PK;INCREASED_CLEARANCE
;UGT1A9;rs2741049;CT + TT;LADME_PK;INCREASED_FORMATION
OLANZAPINE;UGT2B10;rs61750900;GT + TT;LADME_PK;DECREASED_GLUCURONIDATION
LORAZEPAM;UGT2B15;rs1902023;AA;LADME_PK;DECREASED_CLEARANCE
OXAZEPAM;UGT2B15;rs1902023;A;OTHER;DECREASED_GLUCURONIDATION
;UGT2B17;rs6817882;C;OTHER;INCREASED_EXPRESSION
;UGT2B4;rs4557343;T;;INCREASED_EXPRESSION
BUPRENORPHINE;UGT2B7;rs7438135;A;LADME_PK;INCREASED_GLUCURONIDATION
;UMPS;rs1801019;C;LADME_PK;INCREASED_EXPRESSION
;VKORC1;rs56314408;C;OTHER;INCREASED_TRANSCRIPTION
;VKORC1;rs9923231;T;;DECREASED_EXPRESSION
;WBP2NL;rs5758550;AG + GG;OTHER;INCREASED_EXPRESSION
;YAP1;rs1820453;C;;DECREASED_TRANSCRIPTION
;YEATS4;rs7297610;CC;LADME_PK;INCREASED_EXPRESSION
RALOXIFENE;UGT1A8;UGT1A8*1a, UGT1A8*2;*2/*2;LADME_PK;INCREASED_CLEARANCE
THIOGUANINE;TPMT;TPMT*1, TPMT*16;*16;LADME_PK;DECREASED_CLEARANCE
VALPROIC ACID;UGT1A6;rs1105879;C;LADME_PK;INCREASED_GLUCURONIDATION
CLOZAPINE 5-N-GLUCURONIDE, DESMETHYLCLOZAPINE GLUCURONIDE;UGT1A4;rs2011425;G;LADME_PK;INCREASED_FORMATION
CISPLATIN;TPMT;TPMT*1, TPMT*3A;*3A;TOXICITY;INCREASED_SENSITIVITY
;TXLNB;rs9495425;CC;OTHER;INCREASED_TRANSCRIPTION
;UGT1A1;rs4124874;GG + GT;LADME_PK;DECREASED_FORMATION
SN-38;UGT1A1;rs4124874;GG + GT;LADME_PK;DECREASED_CLEARANCE
OXAZEPAM;UGT1A1;rs10929302;A;OTHER;DECREASED_GLUCURONIDATION
;UGT1A1;rs10929302;A;OTHER;DECREASED_CONCENTRATIONS
;UGT1A1;rs28967009;A;OTHER;INCREASED_EXPRESSION
SN-38;UGT1A1;rs4148323;AG;LADME_PK;DECREASED_CLEARANCE
;UGT1A1;rs4148323;AG;LADME_PK;DECREASED_FORMATION
OXAZEPAM;UGT1A1;rs887829;T;OTHER;DECREASED_GLUCURONIDATION
OXAZEPAM;UGT1A1;rs4124874;G;OTHER;ASSOCIATED_GLUCURONIDATION
;UGT1A1;UGT1A1*1, UGT1A1*28;*28;OTHER;DECREASED_CONCENTRATIONS
CLOZAPINE;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;LADME_PK;DECREASED_METABOLISM
BELINOSTAT;UGT1A1;UGT1A1*1, UGT1A1*28;*28;LADME_PK;DECREASED_METABOLISM
;UGT1A1;rs887829;T;OTHER;DECREASED_CONCENTRATIONS
;UGT1A1;rs4124874;G;OTHER;DECREASED_CONCENTRATIONS
RALOXIFENE 6-GLUCURONIDE;UGT1A1;UGT1A1*1, UGT1A1*28;*28;LADME_PK;DECREASED_FORMATION
;UGT1A1;rs11568319;CG;LADME_PK;DECREASED_FORMATION
;UGT1A3;rs7604115;T;OTHER;INCREASED_EXPRESSION
OLANZAPINE;UGT1A4;UGT1A4*1a, UGT1A4*3a;*3a;LADME_PK;INCREASED_GLUCURONIDATION
;SLCO1B1;SLCO1B1*1, SLCO1B1*15;*15;OTHER;DECREASED_EXPRESSION
ATRASENTAN;SLCO1B1;SLCO1B1*1, SLCO1B1*14, SLCO1B1*37;*14;LADME_PK;DECREASED_TRANSPORT
ATRASENTAN;SLCO1B1;SLCO1B1*1, SLCO1B1*9, SLCO1B1*37;*9;LADME_PK;DECREASED_TRANSPORT
;PACSIN2;rs2413739;CT + TT;LADME_PK;DECREASED_ACTIVITY
;PHETA2, SMDT1;rs1807493;G;LADME_PK;INCREASED_EXPRESSION
;PITPNM2;rs12425009;C;;DECREASED_EXPRESSION
;PKNOX1;rs2839629;A;OTHER;INCREASED_EXPRESSION
;PKNOX1;rs2839629;A;OTHER;INCREASED_EXPRESSION
;PLG;rs783145;G;LADME_PK;DECREASED_TRANSCRIPTION
;PLG;rs783145;G;LADME_PK;INCREASED_TRANSCRIPTION
;PLXNB3;rs4898439;A;;INCREASED_EXPRESSION
;POR;rs2868177;AG;EFFICACY;INCREASED_ENZYME_ACTIVITY
;PPARA;rs4253728;AA;LADME_PK;DECREASED_CONCENTRATIONS
;PROM1;rs2286455;CC;;DECREASED_EXPRESSION
;PSMB8, TAP1, TAP2;rs2071543;T;;INCREASED_EXPRESSION
;PSMB8, TAP2;rs9357155;A;;INCREASED_EXPRESSION
;RALGAPA2;rs3827963;GG;OTHER;INCREASED_TRANSCRIPTION
DOXORUBICIN;RARG;rs2229774;A;TOXICITY;INCREASED_SENSITIVITY
;RARG;rs2229774;A;OTHER;DECREASED_PROTEIN_STABILITY
;REDIC1;rs10783969;T;;INCREASED_EXPRESSION
;RGMA;rs7165938;GG;OTHER;INCREASED_TRANSCRIPTION
CAFFEINE;RYR1;rs193922753;T;OTHER;INCREASED_SENSITIVITY
;ORMDL3;rs2872507;AG + GG;LADME_PK;INCREASED_EXPRESSION
CAFFEINE, CHLOROCRESOL, HALOTHANE;RYR1;rs118204423;C;OTHER;INCREASED_SENSITIVITY
ETHANOL;OPRM1;rs1799971;GG;EFFICACY;DECREASED_SENSITIVITY
;NT5C2;rs11191612;GG;LADME_PK;INCREASED_TRANSCRIPTION
PAROMOMYCIN;MT-RNR1;rs267606619;T;LADME_PD;INCREASED_SENSITIVITY
GEMCITABINE;MTHFR;rs1801131;GG + GT;TOXICITY;INCREASED_SENSITIVITY
;NAF1;rs17571991;AA;OTHER;INCREASED_TRANSCRIPTION
SOLITHROMYCIN;NAT2;NAT2*4, NAT2*5, NAT2*6, NAT2*7, NAT2*14;*4;LADME_PK;INCREASED_METABOLISM
;NAT2;rs4646244;A;OTHER;DECREASED_TRANSCRIPTION
;NCOA1;rs1804645;T;;INCREASED_HALF_LIFE
;NFATC2;rs6021191;T;OTHER;INCREASED_EXPRESSION
;NHLH1;rs11265375;T;OTHER;INCREASED_LUCIFERASE_ACTIVITY
;NQO1;rs1800566;AA;;DECREASED_ENZYME_ACTIVITY
;NQO1;rs1800566;A;;DECREASED_EXPRESSION
MIDAZOLAM;NR1I2;rs1464602;G;LADME_PK;INCREASED_CLEARANCE
MIDAZOLAM;NR1I2;rs1464603;G;LADME_PK;INCREASED_CLEARANCE
;NRP2;rs10932125;C;;INCREASED_EXPRESSION
CLADRIBINE, FLUOROURACIL, GEMCITABINE;NT5C1A;rs201045130;G;OTHER;DECREASED_SENSITIVITY
CLADRIBINE, FLUOROURACIL, GEMCITABINE;NT5C1A;rs370457585;T;OTHER;DECREASED_SENSITIVITY
CLADRIBINE, FLUOROURACIL, GEMCITABINE;NT5C1A;rs374150125;A;OTHER;DECREASED_SENSITIVITY
CYTARABINE;NT5C2;rs1163075;G;EFFICACY;DECREASED_SENSITIVITY
;NT5C2;rs1163075;G;LADME_PK;INCREASED_TRANSCRIPTION
CYTARABINE;NT5C2;rs11191612;GG;EFFICACY;DECREASED_SENSITIVITY
;NT5E;rs9450278;A;;DECREASED_EXPRESSION
CHLOROCRESOL;RYR1;rs121918596;del;OTHER;INCREASED_SENSITIVITY
CAFFEINE;RYR1;rs193922843;T;DOSAGE;INCREASED_SENSITIVITY
CAFFEINE;RYR1;rs193922816;T;OTHER;INCREASED_SENSITIVITY
CAFFEINE;RYR1;rs118192176;A;OTHER;INCREASED_SENSITIVITY
;SEMA6A;rs3806915;A;OTHER;INCREASED_LUCIFERASE_ACTIVITY
;SEPTIN3, WBP2NL;rs1062753;G;LADME_PK;INCREASED_EXPRESSION
RANITIDINE;SLC22A1;rs12208357;T;LADME_PK;DECREASED_TRANSPORT
RANITIDINE;SLC22A1;rs72552763;del;LADME_PK;DECREASED_TRANSPORT
RANITIDINE;SLC22A1;rs34130495;A;LADME_PK;DECREASED_TRANSPORT
;SLC22A3;rs2076828;G;OTHER;DECREASED_EXPRESSION
;SLC22A3;rs884742;C;LADME_PK;INCREASED_TRANSCRIPTION
;SLC22A3;rs555754;AA;;INCREASED_EXPRESSION
ADEFOVIR DIPIVOXIL;SLC22A6;rs11568634;T;OTHER;DECREASED_UPTAKE
CEFOTAXIME;SLC22A8;rs11568482;A;LADME_PK;DECREASED_TRANSPORT
GEMCITABINE TRIPHOSPHATE;SLC28A3;rs7867504;CC;LADME_PK;INCREASED_FORMATION
DOXORUBICIN;SLC28A3;rs11140490;AA;TOXICITY;INCREASED_SENSITIVITY
;SLC29A1;rs731780;G;OTHER;INCREASED_EXPRESSION
;SLC29A1;rs70914;A;;INCREASED_EXPRESSION
;SLCO1A2;rs4148981;T;;DECREASED_EXPRESSION
ATRASENTAN;SLCO1B1;SLCO1B1*1, SLCO1B1*15, SLCO1B1*37;*15;LADME_PK;DECREASED_TRANSPORT
;SLCO1B1;rs4149056;C;OTHER;DECREASED_EXPRESSION
ATRASENTAN;SLCO1B1;SLCO1B1*1, SLCO1B1*5, SLCO1B1*37;*5;LADME_PK;DECREASED_TRANSPORT
CAFFEINE, HALOTHANE;RYR1;rs28933397;CT;OTHER;ASSOCIATED_SENSITIVITY
CAFFEINE, CHLOROCRESOL;RYR1;rs186983396;T;LADME_PK;INCREASED_SENSITIVITY
CAFFEINE, CHLOROCRESOL;RYR1;rs118192178;T;OTHER;INCREASED_SENSITIVITY
CHLOROCRESOL;RYR1;rs118192124;T;OTHER;INCREASED_SENSITIVITY
CAFFEINE;RYR1;rs118192167;G;OTHER;INCREASED_SENSITIVITY
CAFFEINE;RYR1;rs193922803;T;DOSAGE;INCREASED_SENSITIVITY
CAFFEINE;RYR1;rs118192122;A;OTHER;INCREASED_SENSITIVITY
CAFFEINE;RYR1;rs193922809;A;OTHER;INCREASED_SENSITIVITY
CAFFEINE;RYR1;rs118192168;A;DOSAGE;INCREASED_SENSITIVITY
CAFFEINE;RYR1;rs193922832;A;DOSAGE;INCREASED_SENSITIVITY
CAFFEINE;RYR1;rs112563513;A;DOSAGE;INCREASED_SENSITIVITY
CAFFEINE, CHLOROCRESOL, HALOTHANE;RYR1;rs121918594;A;OTHER;INCREASED_SENSITIVITY
CAFFEINE;RYR1;rs193922878;G;OTHER;INCREASED_SENSITIVITY
;MIR27A;rs895819;CC;OTHER;INCREASED_EXPRESSION
CAFFEINE;RYR1;rs118192161;T;OTHER;INCREASED_SENSITIVITY
CAFFEINE;RYR1;rs118192177;T;OTHER;INCREASED_SENSITIVITY
CAFFEINE;RYR1;rs118192167;AG;OTHER;INCREASED_SENSITIVITY
CAFFEINE, HALOTHANE;RYR1;rs118192172;CT;OTHER;ASSOCIATED_SENSITIVITY
CAFFEINE, HALOTHANE;RYR1;rs193922772;GT;OTHER;ASSOCIATED_SENSITIVITY
CAFFEINE, HALOTHANE;RYR1;rs118192175;CT;OTHER;ASSOCIATED_SENSITIVITY
CAFFEINE, HALOTHANE;RYR1;rs193922747;CT;OTHER;ASSOCIATED_SENSITIVITY
CAFFEINE, HALOTHANE;RYR1;rs118192176;AG;OTHER;ASSOCIATED_SENSITIVITY
CHLOROCRESOL;RYR1;rs118192124;T;OTHER;INCREASED_SENSITIVITY
CAFFEINE, CHLOROCRESOL;RYR1;rs118192178;G;OTHER;INCREASED_SENSITIVITY
CAFFEINE, CHLOROCRESOL;RYR1;rs193922818;A;OTHER;INCREASED_SENSITIVITY
;;rs2000068;G;;INCREASED_EXPRESSION
PRIMAQUINE;CYP2D6;CYP2D6*1, CYP2D6*17, CYP2D6*18, CYP2D6*35, CYP2D6*39, CYP2D6*53;*17 + *18 + *35 + *39 + *53;LADME_PK;DECREASED_CLEARANCE
;DPYD;rs1801158;T;OTHER;DECREASED_ACTIVITY
EFAVIRENZ;CYP2B6;rs142421637;T;LADME_PK;DECREASED_CLEARANCE
EFAVIRENZ;CYP2B6;rs373442191;A;LADME_PK;INCREASED_CLEARANCE
PROPOFOL;CYP2B6;rs752695347;T;LADME_PK;DECREASED_CLEARANCE
PROPOFOL;CYP2B6;rs142421637;T;LADME_PK;DECREASED_CLEARANCE
PROPOFOL;CYP2B6;rs1282926098;T;LADME_PK;INCREASED_CLEARANCE
PROPOFOL;CYP2B6;rs1969136524;C;LADME_PK;DECREASED_CLEARANCE
EFAVIRENZ;CYP2B6;rs773494867;C;LADME_PK;DECREASED_CLEARANCE
EFAVIRENZ;CYP2B6;rs1969376664;T;LADME_PK;DECREASED_CLEARANCE
PROPOFOL;CYP2B6;rs138264188;T;LADME_PK;DECREASED_CLEARANCE
PROPOFOL;CYP2B6;rs373442191;A;LADME_PK;INCREASED_CLEARANCE
EFAVIRENZ;CYP2B6;rs1969255598;T;LADME_PK;INCREASED_CLEARANCE
EFAVIRENZ;CYP2B6;rs1248477767;G;LADME_PK;INCREASED_CLEARANCE
EFAVIRENZ;CYP2B6;rs750671397;G;LADME_PK;INCREASED_CLEARANCE
EFAVIRENZ;CYP2B6;rs141666881;A;LADME_PK;INCREASED_CLEARANCE
EFAVIRENZ;CYP2B6;rs1968919352;G;LADME_PK;INCREASED_CLEARANCE
EFAVIRENZ;CYP2B6;rs1282926098;T;LADME_PK;INCREASED_CLEARANCE
R-EDDP, S-EDDP;CYP2B6;CYP2B6*1, CYP2B6*4;*4;LADME_PK;INCREASED_FORMATION
R-EDDP, S-EDDP;CYP2B6;CYP2B6*1, CYP2B6*5, CYP2B6*6, CYP2B6*7, CYP2B6*9, CYP2B6*17, CYP2B6*18, CYP2B6*19, CYP2B6*26;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;LADME_PK;DECREASED_FORMATION
;CYP2B6;rs70950385;CA/CA;OTHER;DECREASED_ACTIVITY
EFAVIRENZ;CYP2B6;rs1969136524;C;LADME_PK;DECREASED_CLEARANCE
EFAVIRENZ;CYP2B6;rs772413158;A;LADME_PK;DECREASED_CLEARANCE
EFAVIRENZ;CYP2B6;rs752695347;T;LADME_PK;DECREASED_CLEARANCE
EFAVIRENZ;CYP2B6;rs553968231;T;LADME_PK;DECREASED_CLEARANCE
;CYP1A2;rs762551;A;;INCREASED_ACTIVITY
;CYP1A2;rs35694136;del;;DECREASED_ACTIVITY
DACARBAZINE;CYP1A2;CYP1A2*1, CYP1A2*11;*11;LADME_PK;DECREASED_CLEARANCE
;CYP1A2;rs762551;AA + AC;LADME_PK;INCREASED_TRANSCRIPTION
DACARBAZINE;CYP1A2;CYP1A2*1, CYP1A2*3;*3;LADME_PK;DECREASED_CLEARANCE
;CYP2A6;rs8192720;AA + AG;;INCREASED_EXPRESSION
;CYP2A6;rs8192725;AG + GG;;INCREASED_EXPRESSION
;CYP2A6;rs28399433;AC + CC;;DECREASED_EXPRESSION
;CYP2A6;CYP2A6*4, CYP2A6*9;*4/*9;;DECREASED_EXPRESSION
;CYP2B6;CYP2B6*1, CYP2B6*27;*27;;DECREASED_EXPRESSION
COUMARIN;CYP2A6;rs28399454;T;LADME_PK;DECREASED_METABOLISM
COUMARIN;CYP2A6;CYP2A6*1, CYP2A6*4;*1/*4;LADME_PK;DECREASED_CLEARANCE
COUMARIN;CYP2A6;CYP2A6*1, CYP2A6*9;*1/*9;LADME_PK;DECREASED_CLEARANCE
;CYP2A6;CYP2A6*46;*46;;INCREASED_EXPRESSION
;CYP2A6;CYP2A6*1, CYP2A6*4;*4;;DECREASED_EXPRESSION
;CYP2A6;CYP2A6*46;*46;;INCREASED_TRANSCRIPTION
;CYP2B6;rs3745274;TT;OTHER;DECREASED_EXPRESSION
PROPOFOL;CYP2B6;rs553968231;T;LADME_PK;DECREASED_CLEARANCE
PROPOFOL;CYP2B6;rs1969376664;T;LADME_PK;DECREASED_CLEARANCE
PROPOFOL;CYP2B6;rs773494867;C;LADME_PK;DECREASED_CLEARANCE
;CYP2A6;CYP2A6*46;*46;;INCREASED_EXPRESSION
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;CYP2C19*1, CYP2C19*8, CYP2C19*9, CYP2C19*10, CYP2C19*16, CYP2C19*19;*8 + *9 + *10 + *16 + *19;LADME_PK;DECREASED_CLEARANCE
NEBIVOLOL;CYP2C19;CYP2C19*1, CYP2C19*6, CYP2C19*18, CYP2C19*30, CYP2C19*31, CYP2C19*32, CYP2C19*33;*30 + *31 + *32 + *33 + *6 + *18;LADME_PK;DECREASED_CLEARANCE
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*10, CYP2C19*14, CYP2C19*19, CYP2C19*25, CYP2C19*26;*10 + *14 + *19 + *25 + *26;LADME_PK;DECREASED_CLEARANCE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*6;*6;LADME_PK;DECREASED_CLEARANCE
FLUOXETINE;CYP2C19;rs550527959;T;LADME_PK;DECREASED_CLEARANCE
METHADONE;CYP2C19;rs1463550071;T;LADME_PK;DECREASED_CLEARANCE
FLUOXETINE;CYP2C19;rs200346442;A;LADME_PK;DECREASED_CLEARANCE
FLUOXETINE;CYP2C19;rs200150287;G;LADME_PK;DECREASED_CLEARANCE
FLUOXETINE;CYP2C19;rs118203756;C;LADME_PK;DECREASED_CLEARANCE
FLUVOXAMINE, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*15;*15;LADME_PK;INCREASED_SENSITIVITY
FLUVOXAMINE, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*18;*18;LADME_PK;INCREASED_SENSITIVITY
CELECOXIB, FLUOXETINE, KETOCONAZOLE, TICLOPIDINE;CYP2C19;CYP2C19*1, CYP2C19*18;*18;LADME_PK;DECREASED_SENSITIVITY
FLUOXETINE;CYP2C19;rs778258371;A;LADME_PK;DECREASED_CLEARANCE
CELECOXIB;CYP2C19;CYP2C19*1, CYP2C19*19;*19;LADME_PK;INCREASED_SENSITIVITY
CELECOXIB, FLUOXETINE, KETOCONAZOLE, SERTRALINE, TICLOPIDINE;CYP2C19;CYP2C19*1, CYP2C19*16;*16;LADME_PK;DECREASED_SENSITIVITY
FLUOXETINE, FLUVOXAMINE, KETOCONAZOLE, OMEPRAZOLE, SERTRALINE, TICLOPIDINE, TRANYLCYPROMINE;CYP2C19;CYP2C19*1, CYP2C19*19;*19;LADME_PK;DECREASED_SENSITIVITY
;CYP2C19;CYP2C19*1, CYP2C19*16;*16;OTHER;DECREASED_FORMATION
FLUCONAZOLE, FLUVOXAMINE, SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*11;*11;LADME_PK;INCREASED_SENSITIVITY
FLUOXETINE;CYP2C19;CYP2C19*1, CYP2C19*10;*10;LADME_PK;DECREASED_SENSITIVITY
CELECOXIB, FLUOXETINE, KETOCONAZOLE, SERTRALINE, TROGLITAZONE;CYP2C19;CYP2C19*1, CYP2C19*9;*9;LADME_PK;DECREASED_SENSITIVITY
FLUCONAZOLE, FLUVOXAMINE;CYP2C19;CYP2C19*1, CYP2C19*9;*9;LADME_PK;INCREASED_SENSITIVITY
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*10;*10;LADME_PK;DECREASED_CLEARANCE
FLUCONAZOLE, FLUOXETINE, FLUVOXAMINE, KETOCONAZOLE, OMEPRAZOLE, SERTRALINE, TICLOPIDINE, TRANYLCYPROMINE, TROGLITAZONE;CYP2C19;CYP2C19*1, CYP2C19*8;*8;LADME_PK;DECREASED_SENSITIVITY
FLUOXETINE, TRANYLCYPROMINE;CYP2C19;CYP2C19*1, CYP2C19*15;*15;LADME_PK;DECREASED_SENSITIVITY
;CYP1A2;rs2069514;A;;DECREASED_ACTIVITY
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*26;*26;LADME_PK;DECREASED_CLEARANCE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*23;*23;LADME_PK;DECREASED_CLEARANCE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*10, CYP2C19*14, CYP2C19*19, CYP2C19*23, CYP2C19*25, CYP2C19*26;*10 + *14 + *19 + *23 + *25 + *26;LADME_PK;DECREASED_CLEARANCE
FLUOXETINE;CYP2C19;rs370803989;A;LADME_PK;DECREASED_CLEARANCE
FLUOXETINE;CYP2C19;rs145328984;T;LADME_PK;DECREASED_CLEARANCE
FLUOXETINE;CYP2C19;rs763625282;A;LADME_PK;DECREASED_CLEARANCE
FLUOXETINE;CYP2C19;rs147255955;T;LADME_PK;DECREASED_CLEARANCE
FLUOXETINE;CYP2C19;rs3758581;G;LADME_PK;DECREASED_CLEARANCE
FLUOXETINE;CYP2C19;rs559628884;A;LADME_PK;DECREASED_CLEARANCE
FLUOXETINE;CYP2C19;rs764137538;T;LADME_PK;DECREASED_CLEARANCE
FLUOXETINE;CYP2C19;rs1349931378;A;LADME_PK;DECREASED_CLEARANCE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*33;*33;LADME_PK;DECREASED_CLEARANCE
FLUOXETINE;CYP2C19;rs1463550071;T;LADME_PK;DECREASED_CLEARANCE
METHADONE;CYP2C19;rs778258371;A;LADME_PK;DECREASED_CLEARANCE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*18;*18;LADME_PK;DECREASED_CLEARANCE
METHADONE;CYP2C19;rs72552267;A;LADME_PK;DECREASED_CLEARANCE
METHADONE;CYP2C19;rs118203756;C;LADME_PK;DECREASED_CLEARANCE
METHADONE;CYP2C19;rs764137538;T;LADME_PK;DECREASED_CLEARANCE
METHADONE;CYP2C19;rs550527959;T;LADME_PK;DECREASED_CLEARANCE
METHADONE;CYP2C19;rs1349931378;A;LADME_PK;DECREASED_CLEARANCE
FLUOXETINE;CYP2C19;rs770829708;A;LADME_PK;DECREASED_CLEARANCE
METHADONE;CYP2C19;rs1267723490;C;LADME_PK;DECREASED_CLEARANCE
FLUOXETINE;CYP2C19;rs1267723490;C;LADME_PK;DECREASED_CLEARANCE
DACARBAZINE;CYP1A1;CYP1A1*1, CYP1A1*2C;*2C;LADME_PK;DECREASED_CLEARANCE
DACARBAZINE;CYP1A1;CYP1A1*1, CYP1A1*4;*4;LADME_PK;DECREASED_CLEARANCE
;CHD2;rs28458425;TT;OTHER;INCREASED_TRANSCRIPTION
OXAZEPAM;;rs1976391;G;OTHER;DECREASED_GLUCURONIDATION
;;rs247616;T;OTHER;DECREASED_EXPRESSION
;ABCA1;rs2515629;G;;INCREASED_EXPRESSION
;ABCA1;rs4149297;G;;INCREASED_EXPRESSION
;ABCA1;rs2472507;C;;INCREASED_EXPRESSION
;ABCA12;rs10182702;C;;INCREASED_EXPRESSION
;ABCA12;rs2888327;A;;INCREASED_EXPRESSION
;ABCA8;rs11656365;T;;DECREASED_EXPRESSION
;ABCB1;rs1045642;AG + GG;LADME_PK;INCREASED_ACTIVITY
;;rs1976391;G;OTHER;DECREASED_CONCENTRATIONS
;ABCB1;rs1128503;AG + GG;LADME_PK;INCREASED_ACTIVITY
;ABCB1;rs1045642;AA;OTHER;DECREASED_EXPRESSION
;ABCB1;rs1128503;AA;OTHER;DECREASED_EXPRESSION
;ABCB1;rs2032582;AA;OTHER;DECREASED_EXPRESSION
;ABCB9;rs4148866;T;;INCREASED_EXPRESSION
;ABCC10;rs2185631;A;;DECREASED_EXPRESSION
DOCETAXEL;ABCC10;rs2125739;TT;TOXICITY;INCREASED_SENSITIVITY
;ABCC10;rs9394952;G;;DECREASED_EXPRESSION
;ABCC10;rs2487663;A;;DECREASED_EXPRESSION
;ABCC11;rs11861379;C;LADME_PK;INCREASED_TRANSCRIPTION
;ABCB1;rs2032582;AC + CC;LADME_PK;INCREASED_ACTIVITY
;ABCC2;rs717620;T;;INCREASED_TRANSCRIPTION
;;rs6822259;CC;;INCREASED_EXPRESSION
;;rs729559;GG;LADME_PK;INCREASED_EXPRESSION
;;rs6539870;GG;OTHER;INCREASED_EXPRESSION
;;rs478437;CC;OTHER;INCREASED_EXPRESSION
;;rs9999111;C;OTHER;DECREASED_EXPRESSION
;;rs149713212;A;OTHER;DECREASED_EXPRESSION
;;rs12508471;G;OTHER;DECREASED_EXPRESSION
ENDOXIFEN;;rs4386686;C;TOXICITY;INCREASED_SENSITIVITY
;;rs4073010;TT;LADME_PK;INCREASED_EXPRESSION
;;rs35283911;G;OTHER;INCREASED_EXPRESSION
;;rs4386686;C;TOXICITY, OTHER;INCREASED_EXPRESSION
TAMOXIFEN;;rs478437;CC;OTHER;INCREASED_SENSITIVITY
;;rs2784917;AA;OTHER;INCREASED_EXPRESSION
;;rs9999111;C;OTHER;DECREASED_EXPRESSION
;;rs10242455;AG;LADME_PK;INCREASED_TRANSCRIPTION
;;rs446112;AA;OTHER;INCREASED_EXPRESSION
;;rs10871454;C;LADME_PK;INCREASED_TRANSCRIPTION
;;rs2487030;T;;INCREASED_EXPRESSION
;;rs4355801;G;;INCREASED_EXPRESSION
;;rs4285917;G;;DECREASED_EXPRESSION
;;rs12195350;G;;DECREASED_EXPRESSION
;;rs4898437;C;;INCREASED_EXPRESSION
;;rs4386686;C;TOXICITY, OTHER;DECREASED_EXPRESSION
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*28;*28;LADME_PK;INCREASED_CLEARANCE
;ABCC4;rs11568658;A;LADME_PK;INCREASED_CATALYTIC_ACTIVITY
MERCAPTOPURINE;ABCC4;rs3765534;TT;TOXICITY, LADME_PK;INCREASED_SENSITIVITY
;CACNA1S;rs1800559;T;OTHER;INCREASED_ACTIVITY
CAFFEINE;CACNA1S;rs1800559;T;OTHER;INCREASED_SENSITIVITY
HALOTHANE, ISOFLURANE;CACNA1S;rs772226819;A;OTHER;INCREASED_SENSITIVITY
;CBR3;rs8133052;A;;DECREASED_EXPRESSION
;CBR3;rs1056892;A;;INCREASED_EXPRESSION
;CBS;rs915854;C;OTHER;INCREASED_EXPRESSION
;CD38;rs1130169;T;;DECREASED_EXPRESSION
;CDA;rs3215400;C/del + del/del;OTHER;INCREASED_EXPRESSION
;CDA;rs2072671;CC;OTHER;INCREASED_EXPRESSION
DEXAMETHASONE;BCL2L11;rs2241843;AA;TOXICITY;INCREASED_SENSITIVITY
;CDA;rs532545;CC;OTHER;DECREASED_ACTIVITY
;CDA;rs2072671;AA;OTHER;DECREASED_ACTIVITY
;CDA;rs1048977;TT;OTHER;INCREASED_EXPRESSION
;CDA;rs602950;AA;OTHER;DECREASED_ACTIVITY
;CDA;rs602950;GG;OTHER;INCREASED_EXPRESSION
;CDA;rs3215400;del/del;;INCREASED_EXPRESSION
PALBOCICLIB;CDKN2A;rs759922342;C;EFFICACY;INCREASED_SENSITIVITY
REMIMAZOLAM;CES1;rs71647871;T;LADME_PK;DECREASED_METABOLISM
CLOPIDOGREL, ENALAPRIL, SACUBITRIL;CES1;rs201065375;A;LADME_PK;DECREASED_METABOLISM
;CETP;rs708272;GG;OTHER;INCREASED_EXPRESSION
;CDA;rs532545;TT;OTHER;INCREASED_EXPRESSION
MERCAPTOPURINE;ABCC4;ABCC4 deficiency;;TOXICITY, LADME_PK;INCREASED_CONCENTRATIONS
DEXAMETHASONE;BCL2L11;rs724710;CC;TOXICITY;INCREASED_SENSITIVITY
;ARNT;rs2134688;GG;LADME_PK;DECREASED_CONCENTRATIONS
;ABCC4;rs11568684;C;LADME_PK;INCREASED_CATALYTIC_ACTIVITY
;ABCC4;rs4773866;T;;INCREASED_EXPRESSION
;ABCC9;rs704212;T;OTHER;INCREASED_EXPRESSION
;ABCD1, BCAP31;rs17091297;C;;INCREASED_EXPRESSION
;ABCD2;rs4284427;C;;DECREASED_EXPRESSION
;ABCG2;rs2725263;C;OTHER;INCREASED_EXPRESSION
;ACE;rs1799752;del;;INCREASED_ENZYME_ACTIVITY
;ADCYAP1;rs304400;AA;OTHER;INCREASED_TRANSCRIPTION
LOSARTAN;AGTR1;rs12721226;A;OTHER;DECREASED_AFFINITY
;ATP2B1;rs12817819;CT + TT;;DECREASED_EXPRESSION
DOXORUBICINOL;AKR1A1;rs2229540;G;LADME_PK;DECREASED_FORMATION
DAUNORUBICINOL;AKR1A1;rs6690497;C;LADME_PK;DECREASED_FORMATION
DAUNORUBICINOL;AKR1A1;rs2229540;G;LADME_PK;DECREASED_FORMATION
EXEMESTANE;AKR1C3;rs62621365;T;LADME_PK;DECREASED_AFFINITY
DOXORUBICIN;AKR1C3;rs62621365;T;LADME_PK;DECREASED_CLEARANCE
DOXORUBICIN;AKR1C3;rs34186955;T;LADME_PK;DECREASED_CLEARANCE
DOXORUBICIN;AKR1C3;rs28943579;A;LADME_PK;DECREASED_CLEARANCE
EXEMESTANE;AKR1C4;rs11253043;A;LADME_PK;DECREASED_AFFINITY
;ALDH1A2;rs12915901;AA + AG;OTHER;DECREASED_EXPRESSION
;AMPH;rs12701634;CC;OTHER;INCREASED_TRANSCRIPTION
DOXORUBICINOL;AKR1A1;rs6690497;C;LADME_PK;DECREASED_FORMATION
;DPYD;rs2297595;C;LADME_PK;DECREASED_ACTIVITY
;CYP2C19;CYP2C19*1, CYP2C19*19;*19;OTHER;DECREASED_EXPRESSION
SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*13;*13;LADME_PK;DECREASED_SENSITIVITY
EBASTINE, TERFENADINE;CYP2J2;rs201379188;A;LADME_PK;DECREASED_CLEARANCE
TERFENADINE;CYP2J2;rs199717190;A;LADME_PK;DECREASED_CLEARANCE
OXYCODONE;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*18, CYP3A4*19, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*33, CYP3A4*34;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;LADME_PK;DECREASED_CLEARANCE
OXYCODONE;CYP3A4;CYP3A4*1, CYP3A4*6, CYP3A4*17, CYP3A4*20, CYP3A4*21, CYP3A4*26, CYP3A4*30;*6 + *17 + *20 + *21 + *26 + *30;LADME_PK;DECREASED_CLEARANCE
SIROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME_PK;DECREASED_CLEARANCE
SILDENAFIL;CYP3A4;CYP3A4*1, CYP3A4*3, CYP3A4*10, CYP3A4*14, CYP3A4*32;*3 + *10 + *14 + *32;LADME_PK;INCREASED_CLEARANCE
IBRUTINIB;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*5, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;LADME_PK;DECREASED_CLEARANCE
;CYP3A4;rs2242480;TT;LADME_PK;DECREASED_ACTIVITY
TESTOSTERONE;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*11, CYP3A4*15, CYP3A4*31;*2 + *3 + *11 + *15 + *31;LADME_PK;INCREASED_CLEARANCE
TESTOSTERONE;CYP3A4;CYP3A4*1, CYP3A4*5, CYP3A4*10, CYP3A4*14, CYP3A4*16, CYP3A4*17, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*32, CYP3A4*33, CYP3A4*34;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;LADME_PK;DECREASED_CLEARANCE
LIDOCAINE;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*5, CYP3A4*9, CYP3A4*16, CYP3A4*24;*2 + *5 + *9 + *16 + *24;LADME_PK;DECREASED_CLEARANCE
MIDAZOLAM;CYP3A4;rs12721627;C;LADME_PK;DECREASED_CLEARANCE
FENTANYL;CYP3A4;rs2242480;T/T;LADME_PK;DECREASED_METABOLISM
REGORAFENIB;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*17, CYP3A4*18, CYP3A4*23, CYP3A4*32, CYP3A4*33, CYP3A4*34;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;LADME_PK;DECREASED_CLEARANCE
TICAGRELOR;CYP3A4;CYP3A4*1, CYP3A4*11, CYP3A4*18, CYP3A4*33;*11 + *18 + *33;LADME_PK;INCREASED_CLEARANCE
TICAGRELOR;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*9, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*19, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;LADME_PK;DECREASED_CLEARANCE
LURASIDONE;CYP3A4;CYP3A4*1, CYP3A4*12;*12;LADME_PK;DECREASED_CLEARANCE
LURASIDONE;CYP3A4;CYP3A4*1, CYP3A4*15, CYP3A4*19, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*32, CYP3A4*33;*15 + *19 + *23 + *24 + *28 + *29 + *32 + *33;LADME_PK;INCREASED_CLEARANCE
SAXAGLIPTIN;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*18, CYP3A4*19, CYP3A4*20, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*34;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;LADME_PK;DECREASED_CLEARANCE
EBASTINE, TERFENADINE;CYP2J2;rs759510111;A;LADME_PK;INCREASED_CLEARANCE
EBASTINE;CYP2J2;rs757528200;(CTC)1;LADME_PK;DECREASED_CLEARANCE
;CYP2E1;CYP2E1*7A, CYP2E1*7B;*7B;LADME_PK;INCREASED_TRANSCRIPTION
;CYP2E1;CYP2E1*7, CYP2E1*7A;*7A;LADME_PK;INCREASED_TRANSCRIPTION
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*28, CYP2D6*35;*2 + *28 + *35;LADME_PK;DECREASED_METABOLISM
BUFURALOL, DEBRISOQUINE, DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*17;*17;LADME_PK;DECREASED_CLEARANCE
;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4;LADME_PK;DECREASED_EXPRESSION
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*169;*169;LADME_PK;DECREASED_CLEARANCE
DEXTROMETHORPHAN;CYP2D6;rs76187628;G;LADME_PK;INCREASED_CLEARANCE
;CYP2D6;CYP2D6*1, CYP2D6*169;*169;LADME_PK;DECREASED_EXPRESSION
;CYP2D6;rs76187628;G;LADME_PK;INCREASED_EXPRESSION
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*2;*2;LADME_PK;DECREASED_CLEARANCE
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*10;*10;LADME_PK;DECREASED_CLEARANCE
IBRUTINIB;CYP3A4;CYP3A4*1, CYP3A4*3, CYP3A4*4, CYP3A4*9, CYP3A4*19, CYP3A4*34;*3 + *4 + *9 + *19 +*34;LADME_PK;INCREASED_CLEARANCE
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*28, CYP2D6*35;*2 + *28 + *35;LADME_PK;DECREASED_METABOLISM
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*26;*26;LADME_PK;DECREASED_CLEARANCE
BUFURALOL, DEXTROMETHORPHAN;CYP2D6;rs750996195;T;LADME_PK;DECREASED_CLEARANCE
BUFURALOL, DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*17;*17;LADME_PK;DECREASED_CLEARANCE
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*14;*14;LADME_PK;DECREASED_CLEARANCE
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*53;*53;LADME_PK;INCREASED_CLEARANCE
DAPOXETINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*91, CYP2D6*93, CYP2D6*95, CYP2D6*97, CYP2D6*98;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;LADME_PK;DECREASED_CLEARANCE
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*53;*53;LADME_PK;INCREASED_CLEARANCE
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;LADME_PK;DECREASED_CLEARANCE
;CYP2E1;rs2515641;T;OTHER;DECREASED_EXPRESSION
;ZBED5;rs10840501;GG;OTHER;INCREASED_TRANSCRIPTION
REGORAFENIB;CYP3A4;CYP3A4*1, CYP3A4*14, CYP3A4*15, CYP3A4*28, CYP3A4*31;*14 + *15 + *28 + *31;LADME_PK;INCREASED_CLEARANCE
LIDOCAINE;CYP3A4;CYP3A4*1, CYP3A4*11, CYP3A4*14, CYP3A4*15, CYP3A4*18, CYP3A4*19, CYP3A4*23, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*34;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;LADME_PK;INCREASED_CLEARANCE
CABOZANTINIB;CYP3A4;CYP3A4*1, CYP3A4*14, CYP3A4*15;*14 + *15;LADME_PK;INCREASED_CLEARANCE
VITAMIN E;CYP4F2;rs2108622;T;LADME_PK;INCREASED_STEADY_STATE_LEVEL
;CYP4F2;rs2189784;A;OTHER;INCREASED_EXPRESSION
;CYP4F2;rs2189784;A;OTHER;DECREASED_EXPRESSION
;CYP4F2;rs2108622;CT;OTHER;INCREASED_CONCENTRATIONS
VITAMIN K AND ANALOGUES;CYP4F2;rs2108622;CT + TT;OTHER, LADME_PK;INCREASED_CONCENTRATIONS
;CYP4F2;rs2108622;T;OTHER;INCREASED_EXPRESSION
;CYP4F2;rs2108622;T;OTHER;INCREASED_EXPRESSION
;DCK;rs2306744;T;OTHER;INCREASED_EXPRESSION
;DHRS4L1;rs10147475;GG;OTHER;INCREASED_TRANSCRIPTION
VITAMIN E;CYP4F2;rs2108622;T;LADME_PK;INCREASED_STEADY_STATE_LEVEL
;DISP1;rs61840266;TT;OTHER;INCREASED_TRANSCRIPTION
;DPYD;rs568132506;A;OTHER;DECREASED_CATALYTIC_ACTIVITY
;DPYD;rs760663364;A;OTHER;DECREASED_CATALYTIC_ACTIVITY
FLUOROURACIL;DPYD;rs1801159;CC;TOXICITY, LADME_PK;DECREASED_CLEARANCE
;DPYD;rs3918290;CT;OTHER;DECREASED_ACTIVITY
;DPYD;rs1801158;CT;OTHER;DECREASED_CATALYTIC_ACTIVITY
;DPYD;rs547099198;A;OTHER;DECREASED_CATALYTIC_ACTIVITY
;DPYD;rs67376798;AT;OTHER;DECREASED_CATALYTIC_ACTIVITY
;DPYD;rs1801265;G;OTHER;DECREASED_ACTIVITY
;DPYD;rs1801160;T;OTHER;DECREASED_ACTIVITY
;DISP1;rs17535305;GG;OTHER;INCREASED_TRANSCRIPTION
BUFURALOL, DEXTROMETHORPHAN;CYP2D6;rs777560972;A;LADME_PK;DECREASED_CLEARANCE
;CYP4F11;rs1060467;A;OTHER;INCREASED_EXPRESSION
;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;OTHER;DECREASED_EXPRESSION
BREXPIPRAZOLE;CYP3A4;CYP3A4*1, CYP3A4*14, CYP3A4*15;*14 + *15;LADME_PK;INCREASED_CLEARANCE
ALECTINIB;CYP3A4;CYP3A4*1, CYP3A4*4, CYP3A4*7, CYP3A4*8, CYP3A4*12, CYP3A4*14, CYP3A4*16, CYP3A4*17, CYP3A4*18, CYP3A4*19, CYP3A4*20, CYP3A4*23, CYP3A4*24;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;LADME_PK;DECREASED_METABOLISM
METHADONE;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*5, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*18, CYP3A4*19, CYP3A4*24, CYP3A4*29, CYP3A4*31;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;LADME_PK;DECREASED_CLEARANCE
METHADONE;CYP3A4;CYP3A4*1, CYP3A4*11, CYP3A4*32, CYP3A4*34;*11 + *32 + *34;LADME_PK;INCREASED_CLEARANCE
;CYP3A4;rs35599367;A;OTHER;DECREASED_EXPRESSION
MIDAZOLAM;CYP3A4;CYP3A4*1, CYP3A4*39, CYP3A4*40, CYP3A4*41, CYP3A4*42, CYP3A4*43, CYP3A4*44, CYP3A4*46;*39 + *40 + *41 + *42 + *43 + *44 + *46;LADME_PK;DECREASED_CLEARANCE
MACITENTAN;CYP3A4;CYP3A4*1, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*10, CYP3A4*15, CYP3A4*16;*3 + *4 + *5 + *10 +*15 + *16;LADME_PK;INCREASED_CLEARANCE
;CYP3A4;rs4986909;A;;DECREASED_STEADY_STATE_LEVEL
VANDETANIB;CYP3A4;CYP3A4*1, CYP3A4*5, CYP3A4*7, CYP3A4*8, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*14, CYP3A4*17, CYP3A4*18, CYP3A4*19, CYP3A4*20, CYP3A4*23, CYP3A4*24, CYP3A4*31, CYP3A4*34;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;LADME_PK;DECREASED_CLEARANCE
;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;OTHER;DECREASED_EXPRESSION
CABOZANTINIB;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*16, CYP3A4*17, CYP3A4*18, CYP3A4*19, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*33, CYP3A4*34;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;LADME_PK;DECREASED_CLEARANCE
AMIODARONE;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*16, CYP3A4*18, CYP3A4*19, CYP3A4*23, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*34;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;LADME_PK;INCREASED_CLEARANCE
SILDENAFIL;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*5, CYP3A4*24, CYP3A4*28, CYP3A4*29;*2 + *5 + *24 + *28 + *29;LADME_PK;DECREASED_CLEARANCE
;CYP3A4;CYP3A4*8;*8;;DECREASED_STEADY_STATE_LEVEL
BREXPIPRAZOLE;CYP3A4;CYP3A4*1, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*16, CYP3A4*18, CYP3A4*23, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*33, CYP3A4*34;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;LADME_PK;DECREASED_CLEARANCE
;CYP3A4;CYP3A4*12;*12;;DECREASED_ENZYME_ACTIVITY
BREXPIPRAZOLE;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*7, CYP3A4*8, CYP3A4*17, CYP3A4*20;*2 + *7 + *8 + *17 + *20;LADME_PK;DECREASED_CLEARANCE
;CYP3A4;CYP3A4*11;*11;;DECREASED_STEADY_STATE_LEVEL
AMIODARONE;CYP3A4;CYP3A4*1, CYP3A4*17, CYP3A4*24;*17 + *24;LADME_PK;DECREASED_CLEARANCE
MIDAZOLAM;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;LADME_PK;INCREASED_METABOLISM
MACITENTAN;CYP3A4;CYP3A4*1, CYP3A4*9, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*17, CYP3A4*20, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*33, CYP3A4*34;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;LADME_PK;DECREASED_CLEARANCE
BUFURALOL, DEXTROMETHORPHAN;CYP2D6;rs138417770;T;LADME_PK;DECREASED_CLEARANCE
BUFURALOL, DEXTROMETHORPHAN;CYP2D6;rs371793722;G;LADME_PK;DECREASED_CLEARANCE
;CYP2D6;rs1058164;G;OTHER;DECREASED_EXPRESSION
METHADONE;CYP2C19;rs181297724;C;LADME_PK;DECREASED_CLEARANCE
METHADONE;CYP2C19;CYP2C19*1, CYP2C19*29, CYP2C19*30, CYP2C19*31, CYP2C19*32, CYP2C19*33;*29 + *30 + *31 + *32 + *33;LADME_PK;DECREASED_CLEARANCE
VORICONAZOLE;CYP2C19;rs778258371;A;LADME_PK;DECREASED_CLEARANCE
FLUOXETINE;CYP2C19;CYP2C19*1, CYP2C19*32;*32;LADME_PK;DECREASED_CLEARANCE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*2;LADME_PK;DECREASED_CLEARANCE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*3;*3;LADME_PK;DECREASED_CLEARANCE
METHADONE;CYP2C19;rs138142612;A;LADME_PK;DECREASED_CLEARANCE
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*24;*24;LADME_PK;DECREASED_CLEARANCE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*32;*32;LADME_PK;DECREASED_CLEARANCE
FLUOXETINE;CYP2C19;CYP2C19*1, CYP2C19*31;*31;LADME_PK;DECREASED_CLEARANCE
16ALPHA-HYDROXYTESTOSTERONE;CYP2C19;CYP2C19*1, CYP2C19*11, CYP2C19*23;*11 + *23;LADME_PK;INCREASED_FORMATION
11ALPHA-HYDROXYTESTOSTERONE;CYP2C19;CYP2C19*1, CYP2C19*9, CYP2C19*11, CYP2C19*23;*9 + *11 + *23;LADME_PK;INCREASED_FORMATION
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*29;*29;LADME_PK;DECREASED_CLEARANCE
FLUOXETINE;CYP2C19;CYP2C19*1, CYP2C19*29;*29;LADME_PK;DECREASED_CLEARANCE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*31;*31;LADME_PK;DECREASED_CLEARANCE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*30;*30;LADME_PK;DECREASED_CLEARANCE
SIPONIMOD;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*3/*3 + *2/*2;LADME_PK;DECREASED_METABOLISM
DICLOFENAC;CYP2C9;CYP2C9*1, CYP2C9*13;*13;LADME_PK;DECREASED_CLEARANCE
DICLOFENAC;CYP2C9;CYP2C9*1, CYP2C9*3;*3;LADME_PK;DECREASED_CLEARANCE
TOLBUTAMIDE;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;LADME_PK;DECREASED_CLEARANCE
ANDROSTENEDIONE;CYP2C19;CYP2C19*1, CYP2C19*9, CYP2C19*11, CYP2C19*23;*9 + *11 + *23;LADME_PK;INCREASED_FORMATION
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*52;*52;LADME_PK;DECREASED_CLEARANCE
METHADONE;CYP2C19;rs749678783;C;LADME_PK;DECREASED_CLEARANCE
METHADONE;CYP2C19;rs770829708;A;LADME_PK;DECREASED_CLEARANCE
FLUOXETINE;CYP2C19;rs72552267;A;LADME_PK;DECREASED_CLEARANCE
METHADONE;CYP2C19;rs200150287;G;LADME_PK;DECREASED_CLEARANCE
FLUOXETINE;CYP2C19;rs749678783;C;LADME_PK;DECREASED_CLEARANCE
FLUOXETINE;CYP2C19;rs138142612;A;LADME_PK;DECREASED_CLEARANCE
FLUOXETINE;CYP2C19;rs181297724;C;LADME_PK;DECREASED_CLEARANCE
FLUOXETINE, KETOCONAZOLE, SERTRALINE, TICLOPIDINE;CYP2C19;rs181297724;C;LADME_PK;DECREASED_SENSITIVITY
FLUVOXAMINE, OMEPRAZOLE;CYP2C19;rs181297724;C;LADME_PK;INCREASED_SENSITIVITY
FLUOXETINE;CYP2C19;rs17878459;C;LADME_PK;DECREASED_SENSITIVITY
CELECOXIB, FLUCONAZOLE, FLUVOXAMINE;CYP2C19;rs17878459;C;LADME_PK;INCREASED_SENSITIVITY
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*23;*23;LADME_PK;INCREASED_CLEARANCE
FLUVOXAMINE;CYP2C19;rs3758581;G;LADME_PK;INCREASED_SENSITIVITY
VORICONAZOLE;CYP2C19;rs763625282;A;LADME_PK;DECREASED_CLEARANCE
VORICONAZOLE;CYP2C19;rs3758581;G;LADME_PK;DECREASED_CLEARANCE
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*19;*19;LADME_PK;DECREASED_AFFINITY
VORICONAZOLE;CYP2C19;rs770829708;A;LADME_PK;DECREASED_CLEARANCE
CELECOXIB, FLUCONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*14;*14;LADME_PK;INCREASED_SENSITIVITY
FLUOXETINE, SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*14;*14;LADME_PK;DECREASED_SENSITIVITY
FLUCONAZOLE, FLUVOXAMINE;CYP2C19;CYP2C19*1, CYP2C19*13;*13;LADME_PK;INCREASED_SENSITIVITY
VORICONAZOLE;CYP2C19;rs181297724;C;LADME_PK;DECREASED_CLEARANCE
METHADONE;CYP2C19;rs200346442;A;LADME_PK;DECREASED_CLEARANCE
VORICONAZOLE;CYP2C19;rs550527959;T;LADME_PK;DECREASED_CLEARANCE
;CYP2C19;rs7902257;A;OTHER;DECREASED_EXPRESSION
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*51;*51;LADME_PK;INCREASED_CLEARANCE
;CYP2C9;rs4918758;C;OTHER;DECREASED_TRANSCRIPTION
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*33;*33;LADME_PK;DECREASED_CLEARANCE
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*13;*13;LADME_PK;DECREASED_CLEARANCE
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*16;*16;LADME_PK;DECREASED_CLEARANCE
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*45;*45;LADME_PK;DECREASED_CLEARANCE
;CYP2D6;rs16947;AA + AG;OTHER;DECREASED_EXPRESSION
PRIMAQUINE;CYP2D6;CYP2D6*1, CYP2D6*22, CYP2D6*26, CYP2D6*48;*22 + *48;LADME_PK;INCREASED_CLEARANCE
METHADONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*89, CYP2D6*90, CYP2D6*93, CYP2D6*95, CYP2D6*97, CYP2D6*98;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;LADME_PK;DECREASED_CLEARANCE
;CYP2D6;CYP2D6*1, CYP2D6*92, CYP2D6*96;*92 + *96;LADME_PK;DECREASED_ACTIVITY
VENLAFAXINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*89, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*94, CYP2D6*95, CYP2D6*97, CYP2D6*98;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME_PK;DECREASED_CLEARANCE
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*36;*36;LADME_PK;DECREASED_CLEARANCE
GEFITINIB;CYP2D6;CYP2D6*1, CYP2D6*10, CYP2D6*87, CYP2D6*90, CYP2D6*93, CYP2D6*95, CYP2D6*98;*10 + *87 + *90 + *93 + *95 + *98;LADME_PK;DECREASED_CLEARANCE
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*89, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*94, CYP2D6*95, CYP2D6*97, CYP2D6*98, CYP2D6*134, CYP2D6*153;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;LADME_PK;DECREASED_CLEARANCE
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*89, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*94, CYP2D6*95, CYP2D6*97, CYP2D6*98;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME_PK;DECREASED_CLEARANCE
CITALOPRAM;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*89, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*98;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;LADME_PK;DECREASED_CLEARANCE
ATOMOXETINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*95, CYP2D6*97;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;LADME_PK;DECREASED_CLEARANCE
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*95, CYP2D6*98;*2 + *10 + *87 + *90 + *91 + *93 + *95 + *98;LADME_PK;DECREASED_CLEARANCE
TOLTERODINE;CYP2D6;CYP2D6*1, CYP2D6*10, CYP2D6*93, CYP2D6*94, CYP2D6*95;*10 + *93 + *94 + *95;LADME_PK;DECREASED_CLEARANCE
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*87, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*94, CYP2D6*95, CYP2D6*97, CYP2D6*98, CYP2D6*134, CYP2D6*153;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;LADME_PK;DECREASED_CLEARANCE
AMITRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*89, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*94, CYP2D6*95, CYP2D6*97, CYP2D6*98;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME_PK;DECREASED_CLEARANCE
BUFURALOL, DEXTROMETHORPHAN;CYP2D6;rs745746329;T;LADME_PK;DECREASED_CLEARANCE
OLANZAPINE;CYP2D6;CYP2D6*1, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*95, CYP2D6*97;*10 + *87 + *88 + *90 + *91 + *93 + *95 + *97;LADME_PK;DECREASED_CLEARANCE
;CYP2C9;rs9332094;C;OTHER;DECREASED_TRANSCRIPTION
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*37;*37;LADME_PK;DECREASED_CLEARANCE
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*42;*42;LADME_PK;DECREASED_CLEARANCE
;CYP2C9;rs7089580;AT + TT;OTHER;INCREASED_EXPRESSION
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*55;*55;LADME_PK;DECREASED_CLEARANCE
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*56;*56;LADME_PK;INCREASED_CLEARANCE
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*53;*53;LADME_PK;INCREASED_CLEARANCE
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*50;*50;LADME_PK;DECREASED_CLEARANCE
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*54;*54;LADME_PK;INCREASED_CLEARANCE
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*19;*19;LADME_PK;DECREASED_CLEARANCE
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*31;*31;LADME_PK;DECREASED_CLEARANCE
LOSARTAN;CYP2C9;rs1057910;C;LADME_PK;DECREASED_CLEARANCE
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*41;*41;LADME_PK;INCREASED_CLEARANCE
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*27;*27;LADME_PK;INCREASED_CLEARANCE
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*14;*14;LADME_PK;DECREASED_CLEARANCE
DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;CYP2C9*1, CYP2C9*62;*62;LADME_PK;DECREASED_CLEARANCE
DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;CYP2C9*1, CYP2C9*2;*2;LADME_PK;DECREASED_CLEARANCE
DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;CYP2C9*1, CYP2C9*3;*3;LADME_PK;DECREASED_CLEARANCE
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*47;*47;LADME_PK;INCREASED_CLEARANCE
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*49;*49;LADME_PK;INCREASED_CLEARANCE
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;LADME_PK;DECREASED_CLEARANCE
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*43;*43;LADME_PK;DECREASED_CLEARANCE
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*39;*39;LADME_PK;DECREASED_CLEARANCE
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*8;*8;LADME_PK;DECREASED_CLEARANCE
;ZNF890P;rs62442010;AA;OTHER;INCREASED_TRANSCRIPTION
NICOTINE;CYP2A6;rs1801272;AA + AT;TOXICITY;DECREASED_RISK
SACITUZUMAB GOVITECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_SEVERITY
TACROLIMUS;CYP3A4;rs2740574;T;LADME_PK;PK
ARIPIPRAZOLE;CYP2D6;CYP2D6;ultrarapid_metabolizer;TOXICITY;INCREASED_LIKELIHOOD
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;rs1799930;A;TOXICITY;INCREASED_RISK
ATORVASTATIN, FLUVASTATIN, HMG COA REDUCTASE INHIBITORS, PITAVASTATIN, PRAVASTATIN, ROSUVASTATIN, SIMVASTATIN;HLA-DRB1;HLA-DRB1*01:01, HLA-DRB1*04:06;*04:06;TOXICITY;INCREASED_RISK
ETHANOL;CHRNA5;rs615470;T;TOXICITY, OTHER;DECREASED_LIKELIHOOD
LIRAGLUTIDE;GLP1R;rs2254336;AT + TT;TOXICITY;INCREASED_LIKELIHOOD
PEGINTERFERON ALFA-2A, RIBAVIRIN, SIMEPREVIR;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED_EFFICACY
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;rs1041983;T;TOXICITY;INCREASED_LIKELIHOOD
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;rs1799931;A;TOXICITY;INCREASED_LIKELIHOOD
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_PK
GEFITINIB;ABCG2;rs2231142;GG;TOXICITY;INCREASED_LIKELIHOOD
LIRAGLUTIDE;GLP1R;rs3765467;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *3/*3;TOXICITY;INCREASED_RISK
WARFARIN;VKORC1;rs9923231;TT;TOXICITY;INCREASED_LIKELIHOOD
TAMOXIFEN;CYP2D6;CYP2D6*4;*4/*4;EFFICACY;DECREASED_EFFICACY
ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;HTR3B;rs2276307;G;TOXICITY;INCREASED_RISK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_LIKELIHOODPK
NORTRIPTYLINE;UST;rs2500535;A;EFFICACY;DECREASED_EFFICACY
TACROLIMUS;CYP3A4;rs1851426;G;LADME_PK;PK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;EFFICACY;EFFICACY
WARFARIN;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*17;TOXICITY;INCREASED_RISK
OSIMERTINIB;IL6;rs1800796;CG + GG;EFFICACY;DECREASED_LIKELIHOODEFFICACY
FLUCLOXACILLIN;HLA-DQB1;HLA-DQB1*03:03;*03:03;TOXICITY;INCREASED_RISK
RISPERIDONE;HTR2A;rs6311;CT + TT;TOXICITY;INCREASED_SEVERITY
TAMOXIFEN;CYP2D6;CYP2D6*6;*6/*6;EFFICACY;DECREASED_EFFICACY
TAMOXIFEN;CYP2D6;CYP2D6*5;*5/*5;EFFICACY;DECREASED_EFFICACY
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;TOXICITY;INCREASED_SEVERITY
RISPERIDONE;HTR2A;rs6313;AA + AG;TOXICITY;INCREASED_SEVERITY
OXAZEPAM;UGT2B15;rs1902023;AA;LADME_PK;DECREASED_PK
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
OXAZEPAM;UGT2B15;rs1902023;AA;LADME_PK;DECREASED_PK
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED_RISK
EFAVIRENZ, ISONIAZID;CYP2B6;CYP2B6;poor_metabolizer;TOXICITY;INCREASED_LIKELIHOOD
PHENYTOIN;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED_RISK
PHENYTOIN;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED_RISK
TACROLIMUS;PPARA;rs4823613;GG;TOXICITY;DECREASED_LIKELIHOOD
MERCAPTOPURINE, METHOTREXATE;TPMT;TPMT*1, TPMT*3A;*1/*3A;TOXICITY;INCREASED_LIKELIHOOD
NITROUS OXIDE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY
RISPERIDONE;DRD3;rs167771;G;TOXICITY;INCREASED_RISK
ANTIPSYCHOTICS;CYP2D6;CYP2D6*1, CYP2D6*10;*1/*10 + *10/*10;TOXICITY;INCREASED_RISK
FLUCLOXACILLIN;HLA-DQA1;HLA-DQA1*02:01;*02:01;TOXICITY;INCREASED_RISK
FLUCLOXACILLIN;HLA-A;HLA-A*01:01;*01:01;TOXICITY;INCREASED_RISK
AMOXICILLIN;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK
CISPLATIN, PACLITAXEL;GGT1;rs5751901;CC;TOXICITY;DECREASED_LIKELIHOOD
ANTITHYROID PREPARATIONS;HLA-B;HLA-B*27:05;*27:05;TOXICITY;INCREASED_RISK
FLUCLOXACILLIN;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_RISK
BUSULFAN;CYP2B6;CYP2B6*1, CYP2B6*5, CYP2B6*9;*1/*1 + *1/*5 + *1/*9;EFFICACY;INCREASED_EFFICACY
TAMOXIFEN;CYP2D6;CYP2D6;poor_metabolizer;TOXICITY;INCREASED_RISK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK
CAPECITABINE, FLUOROURACIL;ABCC11;rs17822471;AA + AG;TOXICITY;INCREASED_RISK
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
ANTIPSYCHOTICS;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5;*1/*4 + *1/*5;TOXICITY;INCREASED_RISK
FLUVOXAMINE;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*1/*10 + *1/*5 + *10/*10 + *5/*10;LADME_PK;PK
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;HLA-DQA1;HLA-DQA1*05;*05;TOXICITY;INCREASED_LIKELIHOOD
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;IDO1;rs9657182;CC;TOXICITY;INCREASED_
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;;rs3129763;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;HLA-DQB1;HLA-DQB1*03:01;*03:01;TOXICITY;INCREASED_LIKELIHOOD
NITROUS OXIDE;MTHFR;rs1801131;GG;TOXICITY;INCREASED_
CIPROFLOXACIN, LEVOFLOXACIN, MOXIFLOXACIN;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_LIKELIHOOD
OMEPRAZOLE;CYP2C19;rs11188072;TT;DOSAGE, LADME_PK;DECREASED_PK
METHADONE;CYP3A4;rs3735451;C;TOXICITY;INCREASED_SEVERITY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED_EFFICACY
CARBOPLATIN, PACLITAXEL;ABCB1;rs2032582;AA;EFFICACY;DECREASED_EFFICACY
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*1/*1;EFFICACY;DECREASED_EFFICACY
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6 + *6/*6;TOXICITY;INCREASED_RISK
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_RISK
ANTIPSYCHOTICS;CYP2D6;CYP2D6*1, CYP2D6*10;*10;TOXICITY;RISK_
ANTIDEPRESSANTS;CYP2D6;CYP2D6*2, CYP2D6*2xN;*2/*2xN;EFFICACY;INCREASED_RISKEFFICACY
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;EFFICACY;DECREASED_EFFICACY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK
ASPARAGINASE;ATL2;rs59569490;T;TOXICITY;INCREASED_LIKELIHOOD
AZATHIOPRINE, MERCAPTOPURINE;HLA-DQA1;HLA-DQA1*02:01;*02:01;TOXICITY;INCREASED_RISK
ASPIRIN, CILOSTAZOL, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*3;LADME_PK;INCREASED_EFFICACY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;TOXICITY;INCREASED_RISK
ESCITALOPRAM;CYP2C19;rs4986893;A;DOSAGE, LADME_PK;INCREASED_PK
PLATINUM COMPOUNDS;RETN;rs1862513;GG;TOXICITY;INCREASED_SEVERITY
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;EFFICACY;DECREASED_EFFICACY
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6 + *6/*6;TOXICITY;INCREASED_RISK
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4 + *1/*4;EFFICACY;DECREASED_EFFICACY
NILOTINIB;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*27, UGT1A1*28;*6/*6 + *6/*28;TOXICITY;INCREASED_RISK
PRIMAQUINE;MAOA;rs1137070;CC + CT;EFFICACY;INCREASED_LIKELIHOODEFFICACY
OMEPRAZOLE;CYP2C19;rs12248560;TT;DOSAGE, LADME_PK;DECREASED_PK
PRIMAQUINE;CYP2D6;CYP2D6 normal metabolizer;;EFFICACY;DECREASED_LIKELIHOODEFFICACY
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs746071566;GGAGTC;TOXICITY;INCREASED_SEVERITY
PRIMAQUINE;CYP2D6;CYP2D6*4;*4;EFFICACY;INCREASED_LIKELIHOODEFFICACY
ESCITALOPRAM;CYP2C19;rs11188072;TT;DOSAGE, LADME_PK;DECREASED_PK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_PK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;DECREASED_PK
TENOFOVIR;ABCC10;rs2125739;C;TOXICITY;INCREASED_
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;LADME_PK;INCREASED_PK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_PK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*5;*5;TOXICITY;INCREASED_RISK
EFAVIRENZ, ISONIAZID;CYP2B6;CYP2B6;poor_metabolizer;TOXICITY;INCREASED_LIKELIHOOD
ROSUVASTATIN;ABCG2;rs2231142;GT + TT;TOXICITY;INCREASED_LIKELIHOOD
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C;TOXICITY;INCREASED_LIKELIHOOD
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_LIKELIHOOD
TACROLIMUS;CYP3A4;rs2687116;A;LADME_PK;PK
CARBOPLATIN, PACLITAXEL;ABCB1;rs1128503;AG + GG;TOXICITY;INCREASED_RISK
CARBOPLATIN, PACLITAXEL;ABCB1;rs1128503;AG + GG;TOXICITY;INCREASED_RISK
ESCITALOPRAM;CYP2C19;rs4244285;A;DOSAGE, LADME_PK;INCREASED_PK
;IFNL4;rs11322783;TT/TT;OTHER;INCREASED_
MERCAPTOPURINE;SLC22A1;rs72552763;del;TOXICITY;INCREASED_SEVERITY
CARBOPLATIN, CISPLATIN;;rs6856089;AA + AG;TOXICITY;DECREASED_LIKELIHOOD
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;*1/*2 + *1/*3A + *1/*3C;LADME_PK;DECREASED_PK
;SOD1;rs36232792;GCCCAGTAAAGCATGGGGCCTGGGGCCAGGGACCCCCTTGTTCAGGTGTG/del + del/del;OTHER;DECREASED_LIKELIHOOD
AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TOXICITY;INCREASED_LIKELIHOOD
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;NAT2*1, NAT2*5, NAT2*6, NAT2*7, NAT2*14;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD
LACOSAMIDE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;EFFICACY, TOXICITY;INCREASED_LIKELIHOODEFFICACY
AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TOXICITY;INCREASED_LIKELIHOOD
;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;OTHER;INCREASED_LIKELIHOOD
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;LADME_PK;INCREASED_LIKELIHOOD
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;TOXICITY;INCREASED_RISK
SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;LADME_PK;INCREASED_LIKELIHOOD
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;*1/*3A + *1/*3B + *1/*3C;TOXICITY;DECREASED_
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*10;*10/*10;EFFICACY;DECREASED_EFFICACY
CYCLOSPORINE;TPMT;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;*1/*3A + *1/*3B + *1/*3C;TOXICITY;INCREASED_PK
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_EFFICACY
CISPLATIN, PEMETREXED;MTHFR;rs1801131;GG + GT;EFFICACY;DECREASED_EFFICACY
ESCITALOPRAM;CYP2C19;rs12248560;TT;DOSAGE, LADME_PK;DECREASED_PK
PHENYTOIN;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_RISK
SUFENTANIL;ADRB1;rs1801253;GG;EFFICACY;DECREASED_SEVERITYEFFICACY
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*35, CYP2D6*36, CYP2D6*41;*10/*5 + *10/*10 + *10/*41;EFFICACY;DECREASED_EFFICACY
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
TENOFOVIR;ABCC10;rs9349256;G;TOXICITY;INCREASED_
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*17;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;TOXICITY;INCREASED_RISK
IMATINIB;ABCB1;rs1045642;A;TOXICITY;INCREASED_SEVERITY
IMATINIB;NR1I2;rs3814055;TT;TOXICITY;INCREASED_SEVERITY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY, TOXICITY;INCREASED_RISK
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR1A;rs6295;C;EFFICACY;INCREASED_LIKELIHOODEFFICACY
FLUOROURACIL;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;LADME_PK;DECREASED_PK
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_EFFICACY
METHOTREXATE;MTRR;rs1801394;G;TOXICITY;INCREASED_LIKELIHOOD
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9, CYP2A6*10;*4 + *7 + *9 + *10;EFFICACY;DECREASED_EFFICACY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;TOXICITY;INCREASED_RISK
CLOPIDOGREL, ROSUVASTATIN;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;OTHER;INCREASED_
METHADONE;CYP3A4;rs4646437;A;TOXICITY;INCREASED_SEVERITY
TEGAFUR;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;LADME_PK;INCREASED_PK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17;TOXICITY;DECREASED_RISK
ANTIPSYCHOTICS;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*14;*3 + *4 + *5 + *6 + *7 + *14;TOXICITY;INCREASED_RISK
AZATHIOPRINE;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_LIKELIHOOD
LAMOTRIGINE;HLA-C;HLA-C*07:18;*07:18;TOXICITY;INCREASED_RISK
LAMOTRIGINE;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK
RIVAROXABAN;ABCB1;rs4148738;CC;TOXICITY;INCREASED_RISK
LAMOTRIGINE;HLA-DQB1;HLA-DQB1*06:09;*06:09;TOXICITY;INCREASED_RISK
RIVAROXABAN;ABCB1;rs1045642;AA;EFFICACY;INCREASED_RISK
TAMOXIFEN;CYP2D6;CYP2D6*10;*10;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK
METHOTREXATE;MTHFD1;rs2236225;A;TOXICITY;DECREASED_LIKELIHOOD
METHADONE;CYP3A4;rs2242480;T;TOXICITY;INCREASED_SEVERITY
CARBOPLATIN, CISPLATIN;CD274;rs2297136;AG + GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17;TOXICITY;INCREASED_RISK
CARBOPLATIN, CISPLATIN;CD274;rs822336;CC + CG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
CARBOPLATIN, CISPLATIN;CD274;rs2282055;GT + TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY
HYDROMORPHONE, MORPHINE;OPRM1;rs1799971;AA;TOXICITY;INCREASED_LIKELIHOOD
ANTIPSYCHOTICS;CYP2D6;CYP2D6*1, CYP2D6*2;*2;TOXICITY;INCREASED_LIKELIHOOD
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD
DOXORUBICIN;NCF4;rs1883112;AA + AG;TOXICITY;DECREASED_LIKELIHOOD
AZATHIOPRINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3;*1/*2 + *1/*3;TOXICITY;INCREASED_RISK
AZATHIOPRINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*8, TPMT*9, TPMT*12, TPMT*24;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TOXICITY;INCREASED_RISK
DOXORUBICIN;CBR1;rs3787728;CT + TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY
INFLIXIMAB;HLA-DRB1;HLA-DRB1*04:04;*04:04;TOXICITY;INCREASED_RISK
DOXORUBICIN;CBR1;rs1005695;CG + GG;EFFICACY;DECREASED_LIKELIHOODEFFICACY
ATORVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*5;*1/*5 + *5/*5;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;OTHER;INCREASED_
DABIGATRAN;CES1;rs2244613;GG + GT;TOXICITY;DECREASED_LIKELIHOOD
OLANZAPINE, QUETIAPINE, RISPERIDONE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);TOXICITY;INCREASED_RISK
RIVAROXABAN;ABCB1;rs1045642;AA + AG;TOXICITY;DECREASED_LIKELIHOOD
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
CAPECITABINE, PLATINUM;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED_EFFICACY
ONDANSETRON;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_
CHOP, RITUXIMAB;CBR3;rs8133052;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
LAMOTRIGINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
CHOP, RITUXIMAB;ABCC2;rs8187710;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;EFFICACY;DECREASED_EFFICACY
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*1, CYP2B6*5, CYP2B6*6;*5/*6;EFFICACY;DECREASED_EFFICACY
METHOTREXATE;SLC19A1;rs1051266;T;EFFICACY;EFFICACY
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);TOXICITY;INCREASED_RISK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*11;*1/*11;EFFICACY;INCREASED_EFFICACY
AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;TPMT*1, TPMT*3C;*1/*3C;TOXICITY;INCREASED_RISK
GEMCITABINE, PLATINUM COMPOUNDS;RRM1;rs1042927;C;EFFICACY;DECREASED_EFFICACY
METHOTREXATE;SLC19A1;rs1051266;CC;TOXICITY;INCREASED_RISK
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR2A;rs6311;CC + TT;TOXICITY;DECREASED_LIKELIHOOD
AMOXICILLIN, CLAVULANATE;HLA-B;HLA-B*15:18;*15:18;TOXICITY;INCREASED_LIKELIHOOD
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*37;*28/*28 + *28/*37;TOXICITY;INCREASED_SEVERITY
CAPECITABINE, PACLITAXEL;TYMS;rs11280056;TTAAAGTTA/TTAAAGTTA;EFFICACY;DECREASED_EFFICACY
AZATHIOPRINE, MERCAPTOPURINE;PTPN2;rs11664064;C;TOXICITY;INCREASED_LIKELIHOOD
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*41;*3/*4 + *4/*4 + *4/*5;EFFICACY;DECREASED_EFFICACY
BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;SHMT1;rs1979277;A;EFFICACY;INCREASED_EFFICACY
METHOTREXATE;MTHFD1;rs2236225;AA;TOXICITY;INCREASED_SEVERITY
TAMOXIFEN;CYP2D6;rs3892097;CT + TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY
METHOTREXATE;ABCB1;rs1045642;GG;TOXICITY;INCREASED_RISK
METHOTREXATE;GSTP1;rs1695;AA;TOXICITY;INCREASED_SEVERITY
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_SEVERITY
MERCAPTOPURINE, METHOTREXATE;TPMT;rs1142345;C;TOXICITY;INCREASED_
METHOTREXATE;SLCO1B1;rs11045879;T;TOXICITY;INCREASED_RISK
AMOXICILLIN, CLAVULANATE;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED_LIKELIHOOD
AMOXICILLIN, CLAVULANATE;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED_LIKELIHOOD
AMOXICILLIN, CLAVULANATE;ERAP1, ERAP2;rs1363907;G;TOXICITY;INCREASED_LIKELIHOOD
CYCLOPHOSPHAMIDE;GSTT1;GSTT1 non-null, GSTT1 null;;TOXICITY;INCREASED_LIKELIHOOD
AMOXICILLIN, CLAVULANATE;PTPN22;rs2476601;A;TOXICITY;INCREASED_LIKELIHOOD
CYCLOPHOSPHAMIDE;GSTM1;GSTM1 non-null, GSTM1 null;;TOXICITY;INCREASED_LIKELIHOOD
CAPECITABINE;TYMS;rs3786362;G;TOXICITY;DECREASED_LIKELIHOOD
CAPECITABINE;TYMS;rs699517;C;TOXICITY;INCREASED_LIKELIHOOD
CAPECITABINE;ENOSF1, TYMS;rs11280056;TTAAAGTTA;TOXICITY;INCREASED_LIKELIHOOD
CAPECITABINE;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_LIKELIHOOD
CAPECITABINE;ENOSF1, TYMS;rs2790;G;TOXICITY;DECREASED_LIKELIHOOD
;NME1, NME1-NME2;rs2302254;TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY
IRINOTECAN;UGT1A7;UGT1A7*1a, UGT1A7*2, UGT1A7*3;*1a/*3 + *2/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD
RIVAROXABAN;SUSD3;rs76292544;TT;TOXICITY;INCREASED_LIKELIHOOD
;CYP3A5, ZSCAN25;rs776746;CC;;
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6 + *6/*6;TOXICITY;INCREASED_LIKELIHOOD
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6 + *6/*6;TOXICITY;INCREASED_LIKELIHOOD
IRINOTECAN;UGT1A7;UGT1A7*1a, UGT1A7*2, UGT1A7*3;*1a/*3 + *2/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD
METHOTREXATE;SLCO1B1;rs4149081;G;TOXICITY;INCREASED_RISK
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-A;HLA-A*02:07;*02:07;TOXICITY;INCREASED_LIKELIHOOD
ASPIRIN;FCER1G;rs11587213;AA;TOXICITY;INCREASED_RISK
LAPATINIB;HLA-DQA1;HLA-DQA1*02:01;*02:01;TOXICITY;INCREASED_RISK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*1/*1 + *1/*3 + *1/*6 + *1/*7;EFFICACY;INCREASED_RISKEFFICACY
LAPATINIB;HLA-DQA1;HLA-DQA1*02:01;*02:01;TOXICITY;INCREASED_RISK
TACROLIMUS;CYP3A5;rs776746;C;LADME_PK;INCREASED_PK
LAPATINIB;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_RISK
;MS4A2;rs569108;AG + GG;TOXICITY;INCREASED_LIKELIHOOD
LAPATINIB;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_RISK
PACLITAXEL;ABCB1;rs2032582;AA;EFFICACY;INCREASED_EFFICACY
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;FECH;rs536560;CC;TOXICITY;INCREASED_LIKELIHOOD
;FCER1G;rs11587213;AG + GG;TOXICITY;INCREASED_LIKELIHOOD
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*3;EFFICACY;INCREASED_RISK
CISPLATIN, RADIOTHERAPY;EPHX1;rs1051740;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
CISPLATIN, RADIOTHERAPY;ERCC2;rs13181;GG + GT;EFFICACY;DECREASED_LIKELIHOODEFFICACY
CISPLATIN, RADIOTHERAPY;ERCC2;rs1799793;CT + TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY
GEMCITABINE, PLATINUM COMPOUNDS;CDA;rs2072671;C;TOXICITY;INCREASED_LIKELIHOOD
;CYP2A6;CYP2A6*4;*4/*4;OTHER;INCREASED_LIKELIHOOD
ANTHRACYCLINES AND RELATED SUBSTANCES;CYP3A5;rs4646450;AA;TOXICITY;INCREASED_LIKELIHOOD
MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*6;*1/*2 + *1/*3 + *1/*6 + *2/*2;TOXICITY;INCREASED_
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC28A3;rs7853758;AA;TOXICITY;INCREASED_LIKELIHOOD
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3C;*1/*3C;TOXICITY;INCREASED_LIKELIHOOD
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1 + *1/*2 + *1/*3;EFFICACY;DECREASED_
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;NAT2;slow_acetylator;TOXICITY;INCREASED_LIKELIHOOD
PHENPROCOUMON;VKORC1;rs9923231;TT;DOSAGE, OTHER;INCREASED_RISK
METHOTREXATE;TYMS;rs11280056;TTAAAGTTA/TTAAAGTTA;TOXICITY;INCREASED_LIKELIHOOD
CARBOPLATIN, GEMCITABINE;TYMS;rs11280056;TTAAAGTTA/TTAAAGTTA;TOXICITY;INCREASED_LIKELIHOOD
METHOTREXATE;SLCO1B1;rs4149056;C;OTHER, LADME_PK;DECREASED_PK
ASPARAGINASE;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_
ENALAPRIL;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED_LIKELIHOOD
SUCCINYLCHOLINE, VOLATILE ANESTHETICS;RYR1;rs193922752;G;TOXICITY;INCREASED_RISK
EGFR INHIBITORS;EGFR;rs2227983;GG;TOXICITY;INCREASED_LIKELIHOOD
GEMCITABINE, PLATINUM COMPOUNDS;RRM1;rs12806698;A;TOXICITY;DECREASED_LIKELIHOOD
GEMCITABINE, PLATINUM COMPOUNDS;RRM1;rs11030918;C;TOXICITY;DECREASED_LIKELIHOOD
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
VERAPAMIL;ADRB1;rs1801252;AA + AG;EFFICACY;INCREASED_RISK
HEROIN;DRD2;rs12364283;G;TOXICITY;INCREASED_RISK
REPAGLINIDE;CYP2C8;CYP2C8*3;*3;LADME_PK;DECREASED_PK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_EFFICACY
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3C;*1/*3C;TOXICITY;INCREASED_LIKELIHOOD
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;NAT2;slow_acetylator;TOXICITY;INCREASED_RISK
AZATHIOPRINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5, NUDT15*6;*3/*3;TOXICITY;INCREASED_RISK
TACROLIMUS;CYP3A7;rs2257401;C;LADME_PK;PK
SIMVASTATIN;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_EFFICACY
PHENYTOIN;CYP2C19;rs4986893;A;TOXICITY;INCREASED_LIKELIHOOD
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*5;*3/*5;DOSAGE, EFFICACY;INCREASED_RISKEFFICACY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;DOSAGE, EFFICACY;INCREASED_RISKEFFICACY
TACROLIMUS;CYP3A4;rs4646437;G;LADME_PK;PK
ISONIAZID, RIFAMPIN;NAT2;NAT2*4;*4;TOXICITY, LADME_PK;DECREASED_LIKELIHOOD
ASPARAGINASE;SOD2;rs4880;GG;TOXICITY;INCREASED_RISK
;CYP1A2;rs762551;AC + CC;OTHER;INCREASED_RISK
ANTITHYROID PREPARATIONS;HLA-B;HLA-B*39:01;*39:01;TOXICITY;INCREASED_RISK
TRASTUZUMAB;ERBB2;rs1136201;AG + GG;TOXICITY;INCREASED_RISK
SIMVASTATIN;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;TOXICITY;INCREASED_LIKELIHOOD
PHENYTOIN;CYP2C9;rs1799853;T;TOXICITY;INCREASED_LIKELIHOOD
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK
BETA BLOCKING AGENTS;ADRA2C;rs61767072;GGGGCGGGGCCG/GGGGCGGGGCCG;EFFICACY;INCREASED_RISKEFFICACY
PACLITAXEL;FZD3;rs7001034;A;TOXICITY;DECREASED_RISK
CAPECITABINE, FLUOROURACIL;TYMS;rs11280056;TTA/TTA;TOXICITY;INCREASED_RISK
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;RISK_
SERTRALINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);TOXICITY;INCREASED_LIKELIHOOD
CLOZAPINE;HLA-DRB1;HLA-DRB1*04:02;*04:02;TOXICITY;INCREASED_LIKELIHOOD
DIRECT ACTING ANTIVIRALS;IFNL3, IFNL4;rs12979860;TT;TOXICITY;INCREASED_LIKELIHOOD
GLICLAZIDE, GLIMEPIRIDE, GLIPIZIDE, GLIQUIDONE, GLYBURIDE;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;OTHER;INCREASED_RISK
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*5;*5/*5;DOSAGE, EFFICACY;INCREASED_RISKEFFICACY
ASPIRIN, BETA BLOCKING AGENTS, CLOPIDOGREL, HMG COA REDUCTASE INHIBITORS;NOS3;rs1799983;T;OTHER;INCREASED_RISK
CISPLATIN, IRINOTECAN;UGT1A1;rs4148323;AA;EFFICACY;DECREASED_EFFICACY
ANTHRACYCLINES AND RELATED SUBSTANCES, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;EFFICACY;DECREASED_EFFICACY
ASPIRIN, CLOPIDOGREL;CYP2C9;rs1057910;AC + CC;EFFICACY;INCREASED_RISK
TACROLIMUS;CYP3A4;rs6956344;C;LADME_PK;PK
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;EFFICACY;DECREASED_EFFICACY
CISPLATIN, IRINOTECAN;UGT1A1;rs4148323;AA;EFFICACY;DECREASED_EFFICACY
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28;TOXICITY;INCREASED_SEVERITY
CARBAMAZEPINE;HLA-B;HLA-B*15:21;*15:21;TOXICITY;INCREASED_RISK
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK
FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED_SEVERITY
PACLITAXEL;ABCB1;rs1045642;AG;EFFICACY;DECREASED_EFFICACY
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;LADME_PK;DECREASED_PK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_LIKELIHOODPK
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;INCREASED_EFFICACY
PACLITAXEL;CYP3A5;rs776746;C;TOXICITY;DECREASED_RISK
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;TOXICITY;DECREASED_RISK
INFLIXIMAB;HLA-DQB1;HLA-DQB1*02:01;*02:01;TOXICITY;INCREASED_RISK
INFLIXIMAB;HLA-DPB1;HLA-DPB1*10:01;*10:01;TOXICITY;INCREASED_RISK
INFLIXIMAB;HLA-DRB1;HLA-DRB1*03:01;*03:01;TOXICITY;INCREASED_RISK
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*10x2, CYP2D6*14, CYP2D6*21, CYP2D6*36, CYP2D6*41;*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41;EFFICACY;DECREASED_EFFICACY
;HLA-DPB1;HLA-DPB1*03:01;*03:01;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10;*4/*4 + *4/*5 + *4/*10;EFFICACY;INCREASED_RISKEFFICACY
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*6;*6/*6;DOSAGE, EFFICACY;INCREASED_RISKEFFICACY
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5;*4/*5;DOSAGE, EFFICACY;INCREASED_RISKEFFICACY
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2;EFFICACY;DECREASED_EFFICACY
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DOXORUBICIN, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, THIOGUANINE, VINCRISTINE;CPT1A, IGHMBP2;rs12283870;T;TOXICITY;INCREASED_LIKELIHOOD
FOLFIRINOX;UGT1A1;UGT1A1*1, UGT1A1*28;*28;TOXICITY;INCREASED_RISK
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*14, CYP2D6*21, CYP2D6*36, CYP2D6*41;*4 + *5 + *10 + *14 + *21 + *36 + *41;EFFICACY;INCREASED_RISKEFFICACY
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_PK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_PK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_PK
TACROLIMUS;CYP3A4;rs2242480;C;LADME_PK;PK
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;EFFICACY;INCREASED_RISKEFFICACY
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*2, TPMT*3A;*1/*2 + *1/*3A;TOXICITY;INCREASED_RISK
METHAZOLAMIDE;HLA-C;HLA-C*01:02;*01:02;TOXICITY;INCREASED_RISK
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_EFFICACY
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;OTHER;INCREASED_
FLECAINIDE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*21, CYP2D6*36;*4 + *5 + *10 + *21 + *36;LADME_PK;INCREASED_PK
TRANILAST;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED_RISK
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*3;*3;LADME_PK;INCREASED_PK
FLECAINIDE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*21, CYP2D6*36;*5/*36 + *10/*10 + *10/*36 + *21/*36;LADME_PK;DECREASED_PK
ANTITHYROID PREPARATIONS;HLA-DRB1;HLA-DRB1*08:03;*08:03;TOXICITY;INCREASED_RISK
ANTITHYROID PREPARATIONS;HLA-DQA1;HLA-DQA1*01:03;*01:03;TOXICITY;INCREASED_RISK
ANTITHYROID PREPARATIONS;HLA-DQB1;HLA-DQB1*06:01;*06:01;TOXICITY;INCREASED_RISK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;EFFICACY;DECREASED_EFFICACY
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*20, CYP2D6*35, CYP2D6*41;*4/*4 + *4/*41 + *1/*5 + *2/*5;EFFICACY;DECREASED_EFFICACY
CAPECITABINE;DPYD;rs67376798;AT;TOXICITY;INCREASED_LIKELIHOOD
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK
CYTARABINE, IDARUBICIN;ABCB1;rs2032582;CC;EFFICACY;INCREASED_LIKELIHOODEFFICACY
CLOPIDOGREL;CYP1A2;rs2069514;A;TOXICITY;INCREASED_RISK
OPIOIDS;OPRM1;rs548646;T;TOXICITY;DECREASED_RISK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_PK
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10;*10;LADME_PK;INCREASED_PK
TACROLIMUS;CYP3A4;rs2242480;C/T + T/T;TOXICITY;INCREASED_RISK
RHODAMINE 123;ABCB1;rs1045642;GG;LADME_PK;INCREASED_PK
ASPIRIN, CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_RISK
MERCAPTOPURINE, THIOGUANINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;TOXICITY;
ASPIRIN, CLOPIDOGREL, TICAGRELOR;PEAR1;rs2768759;AC;TOXICITY;INCREASED_RISK
LAMOTRIGINE;HLA-A;HLA-A*68:01;*68:01;TOXICITY;INCREASED_RISK
CELECOXIB;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;EFFICACY;DECREASED_EFFICACY
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4, NUDT15*5, NUDT15*6;*2 + *3 + *4 + *5 + *6;TOXICITY;INCREASED_LIKELIHOOD
CARBAMAZEPINE;HLA-A;HLA-A*01:01;*01:01;TOXICITY;INCREASED_RISK
TETANUS ANTITOXIN;HLA-A;HLA-A*02:06;*02:06;TOXICITY;INCREASED_LIKELIHOOD
CARBAMAZEPINE;HLA-A;HLA-A*11:01;*11:01;TOXICITY;INCREASED_RISK
ACETAMINOPHEN;HLA-A;HLA-A*24:02;*24:02;TOXICITY;DECREASED_LIKELIHOOD
CARBAMAZEPINE;HLA-A;HLA-A*24:02;*24:02;TOXICITY;INCREASED_RISK
INFLIXIMAB;HLA-B;HLA-B*08:01;*08:01;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK
VANCOMYCIN;HLA-A;HLA-A*32:01;*32:01;TOXICITY;INCREASED_RISK
PHENYTOIN;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED_RISK
NEVIRAPINE;HLA-B;HLA-B*14:02;*14:02;TOXICITY;INCREASED_RISK
PHENYTOIN;HLA-B;HLA-B*15:01;*15:01;TOXICITY;INCREASED_RISK
ANTIEPILEPTICS;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_PK
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
ANTIEPILEPTICS;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-B;HLA-B*15:11;*15:11;TOXICITY;INCREASED_RISK
PHENYTOIN;HLA-B;HLA-B*15:13;*15:13;TOXICITY;INCREASED_RISK
AZATHIOPRINE, MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*3A + *3C;TOXICITY;INCREASED_LIKELIHOOD
MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4, NUDT15*6;*1/*2 + *1/*3 + *1/*4 + *1/*6;TOXICITY;INCREASED_RISK
CLINDAMYCIN;HLA-B;HLA-B*15:27;*15:27;TOXICITY;INCREASED_RISK
NEVIRAPINE;HLA-B;HLA-B*35:01;*35:01;TOXICITY;INCREASED_RISK
CLOZAPINE;HLA-B;HLA-B*38:01;*38:01;TOXICITY;INCREASED_RISK
LAMOTRIGINE;HLA-B;HLA-B*38:01;*38:01;TOXICITY;INCREASED_RISK
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED_RISK
INFLIXIMAB;HLA-B;HLA-B*39:01;*39:01;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-B;HLA-B*40:01;*40:01;TOXICITY;DECREASED_RISK
OXCARBAZEPINE;HLA-B;HLA-B*40:02;*40:02;TOXICITY;INCREASED_RISK
MIRTAZAPINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*6;*3/*4 + *4/*6;LADME_PK;INCREASED_PK
PHENYTOIN;HLA-B;HLA-B*51:01;*51:01;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-B;HLA-B*51:01;*51:01;TOXICITY;INCREASED_RISK
NILOTINIB;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED_RISK
CLINDAMYCIN;HLA-B;HLA-B*51:01;*51:01;TOXICITY;INCREASED_RISK
PHENYTOIN;HLA-B;HLA-B*51:01;*51:01;TOXICITY;INCREASED_RISK
PHENYTOIN;HLA-B;HLA-B*51:01;*51:01;TOXICITY;INCREASED_RISK
ISONIAZID;HLA-B;HLA-B*52:01;*52:01;TOXICITY;INCREASED_RISK
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK
METHAZOLAMIDE;HLA-B;HLA-B*59:01;*59:01;TOXICITY;INCREASED_RISK
METHAZOLAMIDE;HLA-B;HLA-B*59:01;*59:01;TOXICITY;INCREASED_RISK
MIRTAZAPINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5;*4 + *5;LADME_PK;INCREASED_PK
OPIOIDS;OPRM1;rs609148;A;TOXICITY;DECREASED_RISK
ATAZANAVIR;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28;TOXICITY;INCREASED_RISK
METHAZOLAMIDE;HLA-C;HLA-C*01:02;*01:02;TOXICITY;INCREASED_RISK
CYCLOSPORINE;CYP3A4;CYP3A4*1, CYP3A4*18;*1/*1 + *1/*18;LADME_PK;INCREASED_PK
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;HLA-C*07:27;*07:27;TOXICITY;INCREASED_RISK
NEVIRAPINE;HLA-C;HLA-C*08:02;*08:02;TOXICITY;INCREASED_RISK
INFLIXIMAB;HLA-C;HLA-C*12:03;*12:03;TOXICITY;INCREASED_RISK
;HLA-DPB1;HLA-DPB1*03:01;*03:01;TOXICITY;INCREASED_RISK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_PK
PHENYTOIN;HLA-C;HLA-C*15:02;*15:02;TOXICITY;INCREASED_RISK
TACROLIMUS;CYP2J2;rs890293;AA + AC;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-DQB1;HLA-DQB1*03:03;*03:03;TOXICITY;INCREASED_RISK
ABACAVIR;HLA-DQB1;HLA-DQB1*03:03;*03:03;TOXICITY;INCREASED_RISK
NEVIRAPINE;HLA-DQB1;HLA-DQB1*05:01;*05:01;TOXICITY;DECREASED_RISK
FLUPIRTINE;HLA-DQB1;HLA-DQB1*05:02;*05:02;TOXICITY;INCREASED_RISK
AMOXICILLIN, CLAVULANATE;HLA-DQB1;HLA-DQB1*06:02;*06:02;TOXICITY;INCREASED_RISK
NEVIRAPINE;HLA-DRB1;HLA-DRB1*01:01;*01:01;TOXICITY;INCREASED_RISK
NEVIRAPINE;HLA-DRB1;HLA-DRB1*01:01;*01:01;TOXICITY;INCREASED_RISK
NEVIRAPINE;HLA-DRB1;HLA-DRB1*01:02;*01:02;TOXICITY;INCREASED_RISK
HYDRALAZINE;HLA-DRB1;HLA-DRB1*04:01;*04:01;TOXICITY;INCREASED_LIKELIHOOD
OXCARBAZEPINE;HLA-DRB1;HLA-DRB1*04:03;*04:03;TOXICITY;INCREASED_RISK
ABACAVIR;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_RISK
ASPARAGINASE;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_LIKELIHOOD
LAPATINIB;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_RISK
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs4969170;AA;TOXICITY;DECREASED_RISK
PRAVASTATIN;LDLR;rs2738466;G;EFFICACY;INCREASED_RISK
LAMOTRIGINE;HLA-DRB1;HLA-DRB1*13:01;*13:01;TOXICITY;INCREASED_RISK
FLUPIRTINE;HLA-DRB1;HLA-DRB1*16:01;*16:01;TOXICITY;INCREASED_RISK
THALIDOMIDE;GSTT1;rs4630;AA;TOXICITY;INCREASED_LIKELIHOOD
MINOCYCLINE;HLA-B;HLA-B*35:02;*35:02;TOXICITY;INCREASED_RISK
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3;LADME_PK;DECREASED_PK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;EFFICACY;INCREASED_EFFICACY
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK
ROSIGLITAZONE;CYP2C8;CYP2C8*1, CYP2C8*3;*3;TOXICITY;DECREASED_
TACROLIMUS;CYP2C8;CYP2C8*1, CYP2C8*3;*3;TOXICITY;INCREASED_RISK
CALCINEURIN INHIBITORS, CYCLOSPORINE, TACROLIMUS;CYP2C8;CYP2C8*1, CYP2C8*3;*3;TOXICITY;INCREASED_RISK
ASPIRIN, CILOSTAZOL, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*3;LADME_PK;INCREASED_EFFICACY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY, TOXICITY;INCREASED_RISK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3/*3;TOXICITY;INCREASED_RISK
PACLITAXEL, PLATINUM COMPOUNDS;NAT2;rs1799931;AA;EFFICACY;DECREASED_EFFICACY
CAFFEINE;CYP1A2;CYP1A2 low activity;;OTHER;INCREASED_
HMG COA REDUCTASE INHIBITORS;GNB3;rs5443;CT + TT;EFFICACY;DECREASED_RISK
;HMGCR;rs3846662;AA;OTHER;DECREASED_
ATAZANAVIR, RITONAVIR;UGT1A1;UGT1A1*28;*28;LADME_PK;
ACYCLOVIR;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4, NUDT15*5;*2/*2 +*2/*3 +*3/*3 + *5/*5;EFFICACY;INCREASED_LIKELIHOODEFFICACY
METHOTREXATE;SLCO1B1;SLCO1B1*15;*15;TOXICITY;INCREASED_LIKELIHOOD
CAFFEINE;ADORA2A;rs35320474;T/del + TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;EFFICACY;EFFICACY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;EFFICACY;EFFICACY
;DHFR;rs70991108;del/del;OTHER;INCREASED_
CISPLATIN, IRINOTECAN;UGT1A1;rs4148323;AA;TOXICITY;INCREASED_
FLUOXETINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*17 + *17/*17;EFFICACY;DECREASED_SEVERITYEFFICACY
FLUOXETINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;EFFICACY;DECREASED_SEVERITYEFFICACY
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*9, CYP2A6*17, CYP2A6*20, CYP2A6*24, CYP2A6*26, CYP2A6*27;*20 + *26 + *24+ *9 + *27 + *17;OTHER, LADME_PK;DECREASED_PK
COCAINE, ETHANOL, OPIOIDS;OPRM1;rs3823010;A;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-B;HLA-B*15:11;*15:11;TOXICITY;INCREASED_LIKELIHOOD
CAPECITABINE, FLUOROURACIL, FOLFOX, XELOX;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;TOXICITY;INCREASED_LIKELIHOOD
COCAINE, ETHANOL, OPIOIDS;OPRM1;rs495491;G;TOXICITY;INCREASED_RISK
INTERFERON BETA-1A, INTERFERON BETA-1B;HLA-DQA1;rs9272105;G;EFFICACY;INCREASED_EFFICACY
CAPECITABINE, FLUOROURACIL, FOLFOX, XELOX;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_LIKELIHOOD
REPAGLINIDE;SLCO1B1;SLCO1B1*1, SLCO1B1*5, SLCO1B1*15, SLCO1B1*37;*37/*37;LADME_PK;DECREASED_PK
NEVIRAPINE;HLA-C;HLA-C*04:01;*04:01;TOXICITY;INCREASED_RISK
EGFR INHIBITORS;EGFR;rs2227983;A;EFFICACY;EFFICACY
ATAZANAVIR, RITONAVIR;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28 + *1/*28;TOXICITY;INCREASED_LIKELIHOOD
NEVIRAPINE;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED_RISK
INTERFERON BETA-1A, INTERFERON BETA-1B;;rs4961252;G;EFFICACY;INCREASED_EFFICACY
METHOTREXATE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;TOXICITY;DECREASED_RISK
PEGASPARGASE;HLA-DRB1;HLA-DRB1*16:02;*16:02;TOXICITY;INCREASED_LIKELIHOOD
ASPARAGINASE, CYTARABINE, DAUNORUBICIN, ETOPOSIDE, MERCAPTOPURINE, METHOTREXATE, PREDNISONE, VINCRISTINE;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RISKEFFICACY
METHOTREXATE;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED_EFFICACY
GEMCITABINE;RRM1;rs9937;G;TOXICITY;DECREASED_RISK
;ACE;rs1799752;del/del;OTHER;INCREASED_SEVERITY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;PD;DECREASED_LIKELIHOOD
ETHANOL;OPRM1;rs1381376;T;TOXICITY;INCREASED_RISK
NEVIRAPINE;HLA-B;HLA-B*35:01;*35:01;TOXICITY;INCREASED_RISK
PEGASPARGASE;HLA-DQA1;HLA-DQA1*02:01;*02:01;TOXICITY;INCREASED_RISK
PEGASPARGASE;HLA-DQB1;HLA-DQB1*02:02;*02:02;TOXICITY;INCREASED_RISK
PEGASPARGASE;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_RISK
METHOTREXATE;DHFR, MSH3;rs70991108;TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT;TOXICITY;INCREASED_SEVERITY
METHOTREXATE;ENOSF1, TYMS;rs11280056;TTA/TTA + TTA/TTAAAGTTA;TOXICITY;INCREASED_RISK
;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;OTHER;DECREASED_LIKELIHOOD
CYCLOSPORINE, TACROLIMUS;ABCB1;rs1128503;GG;EFFICACY;INCREASED_RISKEFFICACY
;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;OTHER;DECREASED_SEVERITY
AMITRIPTYLINE, CLOMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*2/*2 + *2/*1 + *2/*17;EFFICACY;INCREASED_RISKEFFICACY
;ACE;rs1799752;del;OTHER;INCREASED_LIKELIHOOD
ASPIRIN, BETA BLOCKING AGENTS, CLOPIDOGREL, HMG COA REDUCTASE INHIBITORS;;rs1050450;A;OTHER;INCREASED_RISK
;ACE;rs1799752;del/del;OTHER;INCREASED_RISK
SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*2/*2 + *2/*1 + *2/*17;EFFICACY;INCREASED_RISKEFFICACY
MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5, NUDT15*6;*1/*2 + *1/*3 + *1/*5 + *1/*6;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;CYP2C19 poor metabolizers and intermediate metabolizers;;TOXICITY;DECREASED_
LEFLUNOMIDE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*17 + *17/*17;TOXICITY;DECREASED_LIKELIHOOD
ANAKINRA, CANAKINUMAB, RILONACEPT, TOCILIZUMAB;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED_LIKELIHOOD
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;GG;EFFICACY;INCREASED_RISKEFFICACY
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*3;*3;LADME_PK;INCREASED_PK
FLUCLOXACILLIN;HLA-B;HLA-B*57:03;*57:03;TOXICITY;INCREASED_RISK
CISPLATIN;TPMT;TPMT*1, TPMT*3B, TPMT*3C;*3B + *3C;TOXICITY;INCREASED_RISK
PREDNISONE, TACROLIMUS;ABCB1;rs1045642;GG;EFFICACY;INCREASED_RISK
CARBAMAZEPINE;HLA-A;HLA-A*11:01;*11:01;TOXICITY;INCREASED_RISK
FLUCLOXACILLIN;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
ATAZANAVIR;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *1/*1;LADME_PK;INCREASED_PK
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C;*1/*3A + *1/*3B + *1/*3C + *1/*2;TOXICITY;INCREASED_LIKELIHOOD
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED_LIKELIHOOD
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
EGFR INHIBITORS;EGFR;rs712829;T;TOXICITY;EFFICACY
ANTINEOPLASTIC AGENTS;TYMS;rs11280056;TTA;TOXICITY;DECREASED_LIKELIHOOD
CARBAMAZEPINE;HLA-A;HLA-A*74:01;*74:01;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-A;HLA-A*24:07;*24:07;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-A;HLA-A*24:02;*24:02;TOXICITY;INCREASED_RISK
AZATHIOPRINE;TPMT;TPMT*1, TPMT*2, TPMT*3A;*1/*3A;TOXICITY;INCREASED_RISK
AZATHIOPRINE;TPMT;TPMT*1, TPMT*2, TPMT*3A;*1/*1;EFFICACY;INCREASED_EFFICACY
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*4;*4;TOXICITY;INCREASED_RISK
ATAZANAVIR;UGT1A1;UGT1A1*28;*28;TOXICITY;INCREASED_RISK
ATORVASTATIN, PRAVASTATIN;APOE;rs429358;CC + CT;EFFICACY;INCREASED_EFFICACY
CLOZAPINE;GSTM1;GSTM1 non-null, GSTM1 null;null/null;TOXICITY;DECREASED_RISK
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;EFFICACY;INCREASED_LIKELIHOODEFFICACY
OPIOIDS;OPRM1;rs1799971;AA;TOXICITY;DECREASED_RISK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;TOXICITY;INCREASED_RISK
TAMOXIFEN;CYP2D6;CYP2D6*4, CYP2D6*5;*4/*5;EFFICACY;DECREASED_EFFICACY
TAMOXIFEN;CYP2D6;CYP2D6*4, CYP2D6*7;*4/*7;EFFICACY;DECREASED_EFFICACY
TRAMADOL;CYP2D6;CYP2D6;poor_metabolizer;EFFICACY, LADME_PK;DECREASED_EFFICACY
METHOTREXATE;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_LIKELIHOOD
TAMOXIFEN;CYP2D6;CYP2D6*4, CYP2D6*6;*4/*6;EFFICACY;DECREASED_EFFICACY
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_LIKELIHOOD
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*12:02;*12:02;TOXICITY;INCREASED_LIKELIHOOD
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;EFFICACY;INCREASED_RISKEFFICACY
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*04:05;*04:05;TOXICITY;DECREASED_LIKELIHOOD
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;EFFICACY;INCREASED_
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-B;HLA-B*46:01;*46:01;TOXICITY;INCREASED_LIKELIHOOD
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*5;*5;LADME_PK;INCREASED_PK
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*09:01;*09:01;TOXICITY;INCREASED_LIKELIHOOD
CARBAMAZEPINE;HLA-DQA1;HLA-DQA1*03:02;*03:02;TOXICITY;INCREASED_LIKELIHOOD
TICAGRELOR;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;EFFICACY;INCREASED_EFFICACY
EFAVIRENZ;HLA-DRB1;HLA-DRB1*08:03;*08:03;TOXICITY;DECREASED_LIKELIHOOD
EFAVIRENZ;HLA-C;HLA-C*01:02;*01:02;TOXICITY;INCREASED_LIKELIHOOD
NEVIRAPINE;HLA-DRB1;HLA-DRB1*04:05;*04:05;TOXICITY;INCREASED_LIKELIHOOD
TAMOXIFEN;CYP2D6;CYP2D6*4, CYP2D6*11;*4/*11;EFFICACY;DECREASED_EFFICACY
CYCLOSPORINE;ABCB1;rs1128503;AA;DOSAGE, LADME_PK;INCREASED_PK
;TMPRSS2;rs383510;CC;OTHER;INCREASED_LIKELIHOOD
LAPATINIB;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_RISK
TAMOXIFEN;CYP2D6;CYP2D6*3, CYP2D6*4;*3/*4;EFFICACY;DECREASED_EFFICACY
FLUVASTATIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED_LIKELIHOOD
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4;LADME_PK;INCREASED_PK
TAMOXIFEN;CYP2D6;CYP2D6*3, CYP2D6*5;*3/*5;EFFICACY;DECREASED_EFFICACY
ATAZANAVIR / RITONAVIR;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*36;*28/*28;TOXICITY;INCREASED_LIKELIHOOD
CYCLOSPORINE;ABCB1;rs2032582;AA;DOSAGE, LADME_PK;INCREASED_PK
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3;LADME_PK;INCREASED_PK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE, EFFICACY;INCREASED_EFFICACY
METHADONE;CYP3A4;rs2246709;G;TOXICITY;INCREASED_SEVERITY
FLUVOXAMINE;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*10/*10 + *5/*10;LADME_PK;INCREASED_PK
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*4;*2/*2 + *2/*4;LADME_PK;INCREASED_PK
PRAVASTATIN;KIF6;rs20455;AG + GG;EFFICACY;DECREASED_RISK
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*4/*4 + *4/*5 + *10/*41 + *4/*41;EFFICACY;INCREASED_RISKEFFICACY
METHAZOLAMIDE;HLA-B;HLA-B*55:02;*55:02;TOXICITY;INCREASED_RISK
METHAZOLAMIDE;HLA-B;HLA-B*59:01;*59:01;TOXICITY;INCREASED_RISK
ACETAMINOPHEN, CODEINE, LEVOMEPROMAZINE;CYP2D6;CYP2D6*1;*1/*1;EFFICACY, LADME_PK;PK
LAMOTRIGINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD
METHADONE;CYP3A4;rs2242480;T;OTHER;INCREASED_SEVERITY
DOCETAXEL, THALIDOMIDE;RPL13, SNORD68, SPG7;rs12960;G;TOXICITY;INCREASED_RISK
DOCETAXEL, THALIDOMIDE;CHST3;rs1871450;A;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2+ *2/*2+ *1/*3 + *3/*3 + *2/*3;EFFICACY;INCREASED_RISKEFFICACY
CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;LADME_PK;INCREASED_PK
PEGINTERFERON ALFA-2B, RIBAVIRIN;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);TOXICITY;DECREASED_RISK
METHADONE;CYP3A4;rs4646440;A;OTHER;INCREASED_SEVERITY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *1/*17;EFFICACY;INCREASED_LIKELIHOODEFFICACY
CARBAMAZEPINE;HLA-C;HLA-C*03:02;*03:02;TOXICITY;INCREASED_RISK
ETHANOL, OPIOIDS;OPRM1;rs511435;T;TOXICITY;INCREASED_RISK
DOCETAXEL, THALIDOMIDE;NAT2;rs1799931;G;TOXICITY;INCREASED_RISK
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;LADME_PK;DECREASED_PK
DOCETAXEL, THALIDOMIDE;CYP4B1;rs4646487;T;TOXICITY;INCREASED_RISK
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*07:02;*07:02;TOXICITY;INCREASED_RISK
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;HLA-C*07:02;*07:02;TOXICITY;INCREASED_RISK
SULFAMETHOXAZOLE / TRIMETHOPRIM;GSTM1;GSTM1 null;null/null;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_RISK
OLANZAPINE;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_LIKELIHOOD
FOLFIRINOX;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*1/*6 + *1/*28 + *6/*28 + *6/*6 + *28/*28;TOXICITY;INCREASED_LIKELIHOOD
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK
METHOTREXATE;DHFR;rs3045983;GGGAGCTGG/del + del/del;TOXICITY;DECREASED_LIKELIHOOD
OPIOIDS;OPRM1;rs589046;CC;TOXICITY;DECREASED_RISK
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK
ALLOPURINOL;HLA-C;HLA-C*03:02;*03:02;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK
EFAVIRENZ, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME_PK;INCREASED_PK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;TOXICITY;INCREASED_RISK
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C;TOXICITY;DECREASED_
EFAVIRENZ, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME_PK;INCREASED_PK
AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;LADME_PK;INCREASED_PK
ALPRAZOLAM;CYP3A4;CYP3A4 low activity;;EFFICACY;INCREASED_RISK
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2;EFFICACY;INCREASED_LIKELIHOODEFFICACY
PACLITAXEL;CYP3A4;CYP3A4*1, CYP3A4*8, CYP3A4*20;*1/*8 + *1/*20;TOXICITY;INCREASED_RISK
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*4/*4 + *4/*5 + *10/*41 + *4/*41;EFFICACY;DECREASED_EFFICACY
CARBAMAZEPINE;HLA-A;HLA-A*33:03;*33:03;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
DOCETAXEL;VEGFA;rs144854329;del/del;EFFICACY;DECREASED_EFFICACY
WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*3/*3 + *3/*2 + *2/*3;TOXICITY;INCREASED_RISK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;LADME_PK;DECREASED_PK
CITALOPRAM;SLC6A4;SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T;L allele-rs25531T/L allele-rs25531T;TOXICITY;DECREASED_
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*3, NUDT15*6;*1/*3 + *3/*3 + *1/*6;TOXICITY;INCREASED_LIKELIHOOD
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);TOXICITY;INCREASED_RISK
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_LIKELIHOOD
WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*2/*3 + *3/*3 + *2/*2;TOXICITY;INCREASED_RISK
HALOPERIDOL;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4;TOXICITY;INCREASED_LIKELIHOOD
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED_RISK
;HLA-DPB1;HLA-DPB1*04:01;*04:01;TOXICITY;DECREASED_RISK
CARBOPLATIN, CISPLATIN;DPYD;DPYD Reference;Reference;EFFICACY;INCREASED_EFFICACY
METHAMPHETAMINE;DAOA;rs947267;T;TOXICITY;INCREASED_LIKELIHOOD
CARBAMAZEPINE, OXCARBAZEPINE, PHENOBARBITAL;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*10x2, CYP2D6*36;*10/*10 + *5/*10 + *36;EFFICACY;INCREASED_SEVERITYEFFICACY
EFAVIRENZ, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME_PK;INCREASED_PK
TACROLIMUS;CYP3A5;rs776746;TT;DOSAGE, LADME_PK;
METHAMPHETAMINE;OPRM1;rs2075572;C;TOXICITY;DECREASED_RISK
ACETAMINOPHEN;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_LIKELIHOOD
ACETAMINOPHEN;HLA-A;HLA-A*02:06;*02:06;TOXICITY;INCREASED_LIKELIHOOD
ACETAMINOPHEN;HLA-B;HLA-B*44:03;*44:03;TOXICITY;INCREASED_LIKELIHOOD
EFAVIRENZ, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME_PK;INCREASED_PK
ACETAMINOPHEN;HLA-C;HLA-C*14:03;*14:03;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;TOXICITY;INCREASED_RISK
CARBAMAZEPINE, LAMOTRIGINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;EFFICACY;DECREASED_EFFICACY
MERCAPTOPURINE, THIOGUANINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*9, TPMT*21, TPMT*33, TPMT*34;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TOXICITY;INCREASED_RISK
METHADONE;CYP3A4;rs2246709;A;OTHER;DECREASED_SEVERITY
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED_EFFICACY
ATORVASTATIN, PRAVASTATIN;APOE;rs7412;CT + TT;EFFICACY;INCREASED_EFFICACY
ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*5;*5;TOXICITY;INCREASED_RISK
PHENYTOIN;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED_RISK
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS;UGT1A1;UGT1A1*1, UGT1A1*28;*28;TOXICITY;INCREASED_LIKELIHOOD
PHENYTOIN;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED_RISK
ATENOLOL, HYDROCHLOROTHIAZIDE, TRANDOLAPRIL, VERAPAMIL;GRK5;rs2230345;AT + TT;OTHER;DECREASED_RISK
DAPSONE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_RISK
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;rs4244285;A;TOXICITY;INCREASED_RISK
METHAMPHETAMINE;BDNF;rs6265;CC;TOXICITY;DECREASED_SEVERITY
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK
TACROLIMUS;ABCB1;rs1045642;GG;EFFICACY, LADME_PK;INCREASED_LIKELIHOOD
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2*4;*4;TOXICITY;DECREASED_RISK
ANTICHOLINERGIC AGENTS;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;INCREASED_PK
ANTIEPILEPTICS;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;INCREASED_PK
AZATHIOPRINE;NUDT15;NUDT15*2, NUDT15*3, NUDT15*5, NUDT15*6;*2 + *3 + *5 + *6;TOXICITY;INCREASED_LIKELIHOOD
;GSTT1;GSTT1 non-null, GSTT1 null;;OTHER;INCREASED_LIKELIHOOD
NEVIRAPINE;HLA-C;HLA-C*04:01;*04:01;TOXICITY;INCREASED_RISK
;GSTM1;GSTM1 non-null, GSTM1 null;;OTHER;INCREASED_LIKELIHOOD
METHAMPHETAMINE;DAOA;rs2391191;A;TOXICITY;DECREASED_LIKELIHOOD
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*1, CYP2B6*4, CYP2B6*5, CYP2B6*6, CYP2B6*22;*1/*6 + *6/*6 + *4/*6 + *5/*6;TOXICITY;DECREASED_SEVERITY
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*1, CYP2B6*4, CYP2B6*5, CYP2B6*6, CYP2B6*22;*1/*1 + *1/*5 + *1/*4 + *1/*22;TOXICITY;INCREASED_SEVERITY
IRINOTECAN;HLA-DQB3;rs2859101;C;TOXICITY;DECREASED_SEVERITY
CYCLOSPORINE, METHOTREXATE;MTHFR;rs3737967;GG;EFFICACY;INCREASED_RISK
NEVIRAPINE;HLA-DRB1;HLA-DRB1*01:01;*01:01;TOXICITY;INCREASED_RISK
ANTIDEPRESSANTS;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*1;LADME_PK;DECREASED_PK
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs55633228;T;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;rs4244285;AA;TOXICITY;INCREASED_RISK
CARBOPLATIN, DEXAMETHASONE, ETOPOSIDE, IRINOTECAN;UGT1A1;UGT1A1*6;*6;EFFICACY;INCREASED_EFFICACY
SULFASALAZINE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_RISK
ACENOCOUMAROL, WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;TOXICITY;INCREASED_RISK
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs746071566;GGAGTC;TOXICITY;INCREASED_RISK
CYCLOSPORINE, METHOTREXATE;MTHFR;rs2274976;CC;EFFICACY;INCREASED_RISK
;G6PD;rs1050828;T;;INCREASED_
TAMOXIFEN;CYP2D6;CYP2D6*4;*4/*4;EFFICACY;INCREASED_LIKELIHOOD
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PERP;rs117101815;T;TOXICITY;DECREASED_RISK
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;*3A + *3B + *3C;TOXICITY;INCREASED_LIKELIHOOD
CISPLATIN;ERCC1;rs11615;GG;TOXICITY;DECREASED_LIKELIHOOD
ATAZANAVIR / RITONAVIR;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*36;*28/*28;TOXICITY;INCREASED_LIKELIHOOD
PRAVASTATIN;SLCO1B1;SLCO1B1*15, SLCO1B1*37;*15/*15;LADME_PK;INCREASED_PK
CAPECITABINE, FLUOROURACIL;DPYD;DPYD low activity;;TOXICITY;INCREASED_LIKELIHOOD
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*3;EFFICACY;INCREASED_EFFICACY
CISPLATIN, RADIOTHERAPY;GSTM1;GSTM1 non-null, GSTM1 null;null/null;EFFICACY;DECREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *2/*3 + *1/*3 + *2/*17;TOXICITY;INCREASED_RISK
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;EFFICACY;DECREASED_EFFICACY
ANTIDEPRESSANTS, ANTIEPILEPTICS, BETA BLOCKING AGENTS, CALCIUM CHANNEL BLOCKERS;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;OTHER;DECREASED_
ANTIDEPRESSANTS, ANTIEPILEPTICS, BETA BLOCKING AGENTS, CALCIUM CHANNEL BLOCKERS;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;OTHER;DECREASED_
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;LADME_PK;DECREASED_PK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1;EFFICACY;INCREASED_RISKEFFICACY
IRINOTECAN;DPYD;rs1042482;T;TOXICITY;INCREASED_SEVERITY
PAZOPANIB;UGT1A1;UGT1A1*6, UGT1A1*28, UGT1A1*37;*28 + *37 + *6;TOXICITY;INCREASED_RISK
METHADONE;CYP3A4;rs4646440;A;TOXICITY;INCREASED_SEVERITY
WARFARIN;VKORC1;rs9923231;CC;OTHER;INCREASED_LIKELIHOOD
PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;EFFICACY;DECREASED_EFFICACY
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PPP2R5D;rs3805945;C;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED_RISKEFFICACY
ATAZANAVIR / RITONAVIR, LAMIVUDINE, ZIDOVUDINE;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*36, UGT1A1*37;*1/*36 + *28/*36 + *36/*37 + *1/*1;TOXICITY;DECREASED_SEVERITY
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;CCNK;rs77769901;G;TOXICITY;DECREASED_RISK
CARBAMAZEPINE;SCN1A;rs3812718;TT;EFFICACY;INCREASED_RISKEFFICACY
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_EFFICACY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;TOXICITY;INCREASED_RISK
;CHRNB2;rs2072661;GG;;INCREASED_LIKELIHOOD
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;TOXICITY;INCREASED_RISK
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED_SEVERITY
ROSIGLITAZONE;PLIN1;rs894160;CT + TT;TOXICITY;DECREASED_
PLATINUM;;rs836554;T;TOXICITY;INCREASED_LIKELIHOOD
CYCLOSPORINE, METHOTREXATE;ABCC1;rs17264736;GG + GT;EFFICACY;DECREASED_RISK
METHADONE;CYP2B6;CYP2B6*6;*6;TOXICITY;INCREASED_SEVERITY
OXCARBAZEPINE;HLA-B;HLA-B*15:01;*15:01;TOXICITY;DECREASED_RISK
;LRP5;rs3736228;T;;INCREASED_RISK
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs118129530;A;TOXICITY;INCREASED_RISK
CITALOPRAM;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4;LADME_PK;INCREASED_PK
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs148013902;T;TOXICITY;INCREASED_RISK
DRUGS USED IN NICOTINE DEPENDENCE;COMT;rs4680;AA;EFFICACY;INCREASED_LIKELIHOODEFFICACY
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;EFFICACY;DECREASED_RISKEFFICACY
NICOTINE;ANKK1;rs1800497;AA + AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
VALGANCICLOVIR;ABCC4;rs11568658;AC;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY;INCREASED_EFFICACY
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs145623321;T;TOXICITY;INCREASED_RISK
CYCLOSPORINE, METHOTREXATE;NFATC1;rs1017860;CC;EFFICACY;INCREASED_RISK
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;CYP2C8;rs117458836;A;TOXICITY;INCREASED_RISK
PRASUGREL;PEAR1;rs822442;AA;EFFICACY;DECREASED_EFFICACY
TACROLIMUS;CYP2C8;CYP2C8*1, CYP2C8*3;*3;EFFICACY;DECREASED_LIKELIHOODEFFICACY
CARBAMAZEPINE;HLA-B;HLA-B*07:02, HLA-B*15:21;*15:21;TOXICITY;INCREASED_LIKELIHOOD
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_EFFICACY
NICOTINE;COMT;rs4680;G;TOXICITY, OTHER;DECREASED_RISK
FLUOROURACIL;DPYD;DPYD deficiency;;TOXICITY;
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*3 + *4 + *5 + *10 + *41;EFFICACY;INCREASED_RISKEFFICACY
AMOXICILLIN, CLAVULANATE;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED_RISK
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;TOXICITY;INCREASED_RISK
RISPERIDONE;CYP2D6;CYP2D6*4, CYP2D6*5, CYP2D6*6;*4/*4 + *4/*5 + *4/*6;EFFICACY;DECREASED_EFFICACY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK
PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *2/*2 + *1/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD
PHENYTOIN;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED_RISK
LAMOTRIGINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD
BOSENTAN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;LADME_PK;DECREASED_PK
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *2/*2 + *3/*3 + *1/*3 + *2/*3;TOXICITY;INCREASED_RISK
CLOZAPINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2;TOXICITY;INCREASED_LIKELIHOOD
BOSENTAN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;LADME_PK;DECREASED_PK
CAPECITABINE, FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_
FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK
ATORVASTATIN;TNF;rs1800629;GG;EFFICACY;INCREASED_EFFICACY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;EFFICACY;DECREASED_EFFICACY
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK
LAMOTRIGINE;HLA-B;HLA-B*44:03;*44:03;TOXICITY;INCREASED_LIKELIHOOD
CARBAMAZEPINE;HLA-B;HLA-B*15:11;*15:11;TOXICITY;INCREASED_RISK
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;G/TT + GG;EFFICACY;INCREASED_RISKEFFICACY
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_EFFICACY
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
LAMOTRIGINE;HLA-A;HLA-A*02:07;*02:07;TOXICITY;INCREASED_RISK
FLUCLOXACILLIN;HLA-C;HLA-C*06:02;*06:02;TOXICITY;INCREASED_RISK
NICOTINE;CYP2A6;CYP2A6 low activity;;TOXICITY;DECREASED_RISK
FLUVOXAMINE, PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);EFFICACY;INCREASED_EFFICACY
NICOTINE;CYP2A6;CYP2A6 low activity;;TOXICITY;DECREASED_RISK
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;TOXICITY;INCREASED_RISK
METHAZOLAMIDE;HLA-C;HLA-C*01:02;*01:02;TOXICITY;INCREASED_RISK
METHAZOLAMIDE;HLA-B;HLA-B*59:01;*59:01;TOXICITY;INCREASED_RISK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*6;*6;TOXICITY;INCREASED_RISK
METHOTREXATE;SLCO1B1;rs11045879;T;OTHER, LADME_PK;INCREASED_PK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*17/*17;TOXICITY;INCREASED_RISK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*11;*11;TOXICITY;INCREASED_RISK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*5;*5;TOXICITY;INCREASED_RISK
CODEINE, TRAMADOL;CYP2D6;CYP2D6;poor_metabolizer;EFFICACY;INCREASED_LIKELIHOOD
BOSENTAN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;TOXICITY;INCREASED_RISK
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;TOXICITY;INCREASED_RISK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;TOXICITY;INCREASED_SEVERITY
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;DECREASED_PK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;TOXICITY;INCREASED_SEVERITY
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_PK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;DECREASED_PK
CLOPIDOGREL;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;EFFICACY;INCREASED_EFFICACY
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;TOXICITY;INCREASED_RISKPK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*1/*1 + *1/*3 + *1/*6 + *1/*7;EFFICACY;INCREASED_RISKEFFICACY
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;LADME_PK;INCREASED_PK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;TOXICITY;INCREASED_RISK
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *2/*2 + *2/*3 + *1/*3;TOXICITY;INCREASED_RISK
ACE INHIBITORS, PLAIN;BDKRB2;rs71103505;(GGTGGGGAC)2/(GGTGGGGAC)2 + (GGTGGGGAC)2/GGTGGGGACGGTGGGGACGGTGGGGAC;TOXICITY;INCREASED_LIKELIHOOD
CODEINE, TRAMADOL;CYP2D6;CYP2D6 poor and ultrarapid metabolizers;;EFFICACY, TOXICITY, LADME_PK;INCREASED_LIKELIHOOD
;KCNE1;rs727957;T;OTHER;INCREASED_
AMOXICILLIN, CLAVULANATE;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;DECREASED_RISK
OXCARBAZEPINE;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED_RISK
HYDROCHLOROTHIAZIDE;ACE;rs1799752;del/del;EFFICACY;INCREASED_EFFICACY
METHOTREXATE;TYMS;rs11280056;del/del;TOXICITY;INCREASED_SEVERITY
PERINDOPRIL;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;TOXICITY;INCREASED_LIKELIHOOD
METHOTREXATE;TYMS;rs11280056;del/del;TOXICITY;DECREASED_LIKELIHOOD
;RGS2;rs34717272;TC/del + del/del;OTHER;INCREASED_RISK
CARBAMAZEPINE;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED_RISK
METHOTREXATE;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_LIKELIHOOD
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*14:05;*14:05;TOXICITY;INCREASED_RISK
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;CBR3;rs74743371;T;TOXICITY;DECREASED_RISK
CARBAMAZEPINE;HLA-B;HLA-B*58:01;*58:01;TOXICITY;DECREASED_RISK
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;TOXICITY;INCREASED_RISK
METHOTREXATE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_RISK
LAMOTRIGINE;HLA-A;HLA-A*30:01;*30:01;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*03:01;*03:01;TOXICITY;DECREASED_RISK
OXCARBAZEPINE;HLA-B;HLA-B*13:02;*13:02;TOXICITY;INCREASED_RISK
OXCARBAZEPINE;HLA-B;HLA-B*15:27;*15:27;TOXICITY;INCREASED_RISK
OXCARBAZEPINE;HLA-B;HLA-B*15:19;*15:19;TOXICITY;INCREASED_RISK
OXCARBAZEPINE;HLA-B;HLA-B*48:04;*48:04;TOXICITY;INCREASED_RISK
RALOXIFENE;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;EFFICACY;INCREASED_EFFICACY
ASPIRIN;HLA-DQB1;HLA-DQB1*03:02;*03:02;EFFICACY, TOXICITY;DECREASED_SEVERITY
OXCARBAZEPINE;HLA-B;HLA-B*27:09;*27:09;TOXICITY;INCREASED_RISK
NEVIRAPINE;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK
TAMOXIFEN;ABCB1;rs1045642;AG;OTHER;INCREASED_RISK
NEVIRAPINE;HLA-B;HLA-B*58:02;*58:02;TOXICITY;DECREASED_RISK
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;EFFICACY
PRASUGREL;PEAR1;rs3737224;TT;EFFICACY;DECREASED_EFFICACY
NEVIRAPINE;HLA-C;HLA-C*02:10;*02:10;TOXICITY;DECREASED_RISK
CYCLOSPORINE, METHOTREXATE;ABCC1;rs4781712;AA + AG;EFFICACY;DECREASED_RISK
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK
CAPECITABINE, FLUOROURACIL;MIR27A;rs895819;CT;TOXICITY;INCREASED_SEVERITY
OLANZAPINE;ABCB1;rs4728709;GG;TOXICITY;INCREASED_LIKELIHOOD
BUPROPION;CYP2B6;rs3211371;TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;TP53AIP1;rs118088833;T;TOXICITY;DECREASED_RISK
ASPIRIN, SULFASALAZINE;CYP2D6;CYP2D6*3, CYP2D6*4, CYP2D6*5;*3 + *4;DOSAGE, TOXICITY;INCREASED_LIKELIHOOD
PRASUGREL;PEAR1;rs41273215;TT;EFFICACY;DECREASED_EFFICACY
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);EFFICACY;INCREASED_EFFICACY
TAMOXIFEN;ABCB1;rs1045642;AG;OTHER;INCREASED_RISK
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;GNL3;rs112242273;T;TOXICITY;DECREASED_RISK
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;DOSAGE;
PRASUGREL;PEAR1;rs822441;CC;EFFICACY;DECREASED_EFFICACY
FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY, LADME_PK;INCREASED_SEVERITY
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C9;CYP2C9*1, CYP2C9*2;*2;TOXICITY;INCREASED_RISK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3;TOXICITY;INCREASED_RISK
CYTARABINE, IDARUBICIN;ABCB1;rs2032582;CC;EFFICACY;INCREASED_LIKELIHOODEFFICACY
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;EFFICACY
CAFFEINE;CYP1A2;CYP1A2 high activity;;TOXICITY;INCREASED_RISK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;EFFICACY
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;EFFICACY
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;TOP2A;rs181501757;A;TOXICITY;INCREASED_RISK
LAMOTRIGINE;HLA-B;HLA-B*13:02;*13:02;TOXICITY;INCREASED_RISK
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_LIKELIHOODEFFICACY
LAMOTRIGINE;HLA-A;HLA-A*33:03;*33:03;TOXICITY;DECREASED_RISK
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;EFFICACY
BELINOSTAT;UGT1A1;UGT1A1*1, UGT1A1*60;*1/*60 + *60/*60;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_LIKELIHOODEFFICACY
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PERP;rs9402944;T;TOXICITY;DECREASED_RISK
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;EFFICACY
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;OAS1;rs2660;AG;TOXICITY;DECREASED_RISK
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;EFFICACY
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
;VDR;rs731236;A;;INCREASED_RISK
OLANZAPINE;ABCB1;rs3842;CC;TOXICITY;INCREASED_LIKELIHOOD
IRINOTECAN;UGT1A1;rs10929302;A;TOXICITY;INCREASED_SEVERITY
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;CBR3;rs112783657;T;TOXICITY;DECREASED_RISK
BUPROPION;GALR1;rs2717162;CC + CT;EFFICACY;DECREASED_LIKELIHOOD
CARBAMAZEPINE;HLA-B;HLA-B*46:01;*46:01;TOXICITY;DECREASED_RISK
HEROIN;OPRM1;rs1799971;AG;TOXICITY;INCREASED_RISK
CYCLOSPORINE, METHOTREXATE;NFATC1;rs8090560;GG;EFFICACY;INCREASED_RISK
VINCRISTINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;TOXICITY;DECREASED_LIKELIHOOD
ALLOPURINOL;HLA-A;HLA-A*33:03;*33:03;TOXICITY;INCREASED_RISK
ALLOPURINOL;HLA-C;HLA-C*03:02;*03:02;TOXICITY;INCREASED_RISK
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;TOXICITY;INCREASED_LIKELIHOOD
RISPERIDONE;LEP;rs7799039;A;TOXICITY;INCREASED_LIKELIHOOD
BUPROPION;GALR1;rs2717162;CC + CT;EFFICACY;INCREASED_RISKEFFICACY
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;CTLA4;rs231775;AG;TOXICITY;DECREASED_RISK
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;NOS1;rs149212925;G;TOXICITY;DECREASED_RISK
CYCLOSPORINE, METHOTREXATE;DHFR;rs34965641;GG;EFFICACY;DECREASED_RISK
ETRAVIRINE;CYP2C19;rs4244285;AA + AG;LADME_PK;DECREASED_PK
CISPLATIN;ERCC1;rs3212986;A;EFFICACY;INCREASED_EFFICACY
ROSUVASTATIN;ABCG2;rs2231142;T;EFFICACY;INCREASED_EFFICACY
FLUOROURACIL;MTHFR;rs1801131;TT;TOXICITY;INCREASED_RISK
FLUOXETINE, PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_EFFICACY
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs58695150;T;TOXICITY;INCREASED_RISK
PEMETREXED;GGH;rs11545078;A;TOXICITY;DECREASED_RISK
METFORMIN;SLC22A1;rs72552763;GAT/del;OTHER, LADME_PK;DECREASED_EFFICACY
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK
PHENAZEPAM;CYP2C19;CYP2C19*1, CYP2C19*2;*2;TOXICITY;INCREASED_
CAPECITABINE;CDA;rs602950;AG + GG;TOXICITY;INCREASED_RISK
METHOTREXATE;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED_EFFICACY
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;DPYD;DPYD low activity;;TOXICITY;INCREASED_RISK
PHENYTOIN;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED_RISK
FLUOROURACIL;DPYD;DPYD deficiency;;TOXICITY;
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs150688309;G;TOXICITY;INCREASED_RISK
CAPECITABINE;CDA;rs602950;AG + GG;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
TAMOXIFEN;CYP2D6;CYP2D6*2;*2;EFFICACY;DECREASED_LIKELIHOOD
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK
TAMOXIFEN;CYP3A4;CYP3A4*1, CYP3A4*22;*22;TOXICITY;DECREASED_
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-A;HLA-A*74:01;*74:01;TOXICITY;INCREASED_RISK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED_LIKELIHOODEFFICACY
CARBAMAZEPINE;HLA-A;HLA-A*02:01;*02:01;TOXICITY;DECREASED_RISK
CODEINE;SLC22A1;SLC22A1 low activity;;TOXICITY;INCREASED_LIKELIHOOD
DAPSONE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_RISK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;TOXICITY;INCREASED_LIKELIHOOD
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C + *3A/*3A;TOXICITY;INCREASED_RISK
OXCARBAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*6/*6;TOXICITY;INCREASED_RISK
ETHANOL;OPRM1;rs1799971;G;;INCREASED_
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*6/*6;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY;INCREASED_
AZATHIOPRINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;*1/*2 + *1/*3A + *1/*3C;TOXICITY;INCREASED_RISK
VENLAFAXINE;CYP2D6;CYP2D6*4;*4/*4;LADME_PK;INCREASED_PK
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;HMMR;rs299293;T;TOXICITY;INCREASED_RISK
EXEMESTANE;;rs934635;AA;TOXICITY;
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PERP;rs9389568;C;TOXICITY;DECREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY;INCREASED_
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;FOXO1;rs144991623;T;TOXICITY;INCREASED_RISK
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6;TOXICITY;INCREASED_RISK
PRASUGREL;PEAR1;rs12407843;AA;EFFICACY;DECREASED_EFFICACY
DIGOXIN;ABCB1;rs1045642;AA;TOXICITY;INCREASED_LIKELIHOOD
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_EFFICACY
PRASUGREL;PEAR1;rs77235035;AA;EFFICACY;DECREASED_EFFICACY
VENLAFAXINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;LADME_PK;INCREASED_PK
VENLAFAXINE;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4;LADME_PK;INCREASED_PK
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2 + *2/*2;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17 + *1/*17;EFFICACY;INCREASED_EFFICACY
DIGOXIN;ABCB1;rs2032582;AA;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;TOXICITY;INCREASED_RISK
IRINOTECAN;UGT1A1;UGT1A1*6, UGT1A1*28;*6 + *28;TOXICITY;RISK_
DIGOXIN;ABCB1;rs1128503;AA;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*2/*2 + *2/*3 + *3/*3;LADME_PK;DECREASED_PK
CAPECITABINE;MTHFR;rs1801131;GG;TOXICITY;INCREASED_RISK
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;TOXICITY;INCREASED_RISK
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6 + *6/*6;TOXICITY;INCREASED_RISK
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs8110364;A;TOXICITY;INCREASED_RISK
OLANZAPINE;ABCB1;rs10248420;G;TOXICITY;INCREASED_LIKELIHOOD
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*6/*6 + *28/*28 + *6/*28;TOXICITY;INCREASED_RISK
FLUOROURACIL;DPYD;rs56293913;AG + GG;TOXICITY;INCREASED_RISK
FLUTICASONE PROPIONATE;CD14, TMCO6;rs2569190;AA;EFFICACY;INCREASED_EFFICACY
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs117341846;T;TOXICITY;INCREASED_RISK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3;EFFICACY;EFFICACY
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_EFFICACY
ESCITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_LIKELIHOODEFFICACY
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;IRS1;rs115457081;A;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-B;HLA-B*40:01;*40:01;TOXICITY;DECREASED_RISK
LAMOTRIGINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*2/*2 + *2/*3 + *3/*3;EFFICACY;EFFICACY
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;EFFICACY;INCREASED_RISKEFFICACY
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;INSR;rs142244113;T;TOXICITY;INCREASED_RISK
CITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_LIKELIHOODEFFICACY
ASPIRIN, CLOPIDOGREL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;EFFICACY;INCREASED_RISK
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*3;TOXICITY;INCREASED_RISK
METHOTREXATE;ATIC;rs2372536;GG;EFFICACY;DECREASED_EFFICACY
DOXEPIN;CYP2D6;CYP2D6*4;*4/*4;LADME_PK;DECREASED_PK
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs79430272;T;TOXICITY;INCREASED_RISK
OLANZAPINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*1/*3 + *1/*4;TOXICITY;INCREASED_
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;TP53;rs4968187;T;TOXICITY;DECREASED_RISK
CITALOPRAM, FLUOXETINE, PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_LIKELIHOODEFFICACY
CISPLATIN;ERCC1;rs3212986;AA;TOXICITY;DECREASED_LIKELIHOOD
PALBOCICLIB;ABCG2;rs2231137;CT;TOXICITY;INCREASED_LIKELIHOOD
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs117951771;T;TOXICITY;INCREASED_RISK
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4;*2/*2 + *2/*3 + *3/*3 + *4/*4 + *2/*4 + *3/*4;EFFICACY;INCREASED_RISKEFFICACY
EXEMESTANE;;rs934635;AA;TOXICITY;
PRIMAQUINE;G6PD;G6PD deficiency;;TOXICITY;INCREASED_LIKELIHOOD
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs148235907;A;TOXICITY;INCREASED_RISK
METHAMPHETAMINE;DAOA;rs3916965;C;TOXICITY;DECREASED_LIKELIHOOD
;UGT1A1;rs34993780;G;OTHER;INCREASED_LIKELIHOOD
CYCLOPHOSPHAMIDE;CYP2C9;CYP2C9;poor_metabolizer;TOXICITY;INCREASED_LIKELIHOOD
CAPECITABINE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_RISK
DESIPRAMINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;*10/*10 + *5/*10;LADME_PK;INCREASED_PK
PHENYTOIN;CYP2C9;CYP2C9*1;*1/*1;LADME_PK;INCREASED_PK
PHENYTOIN;CYP2C9;CYP2C9*1;*1/*1;LADME_PK;INCREASED_PK
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_
ATAZANAVIR, RITONAVIR;UGT1A1;UGT1A1*28;*28;OTHER;INCREASED_RISK
ATAZANAVIR;UGT1A1;UGT1A1*28;*28;OTHER;INCREASED_RISK
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28;TOXICITY;INCREASED_RISK
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED_RISK
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK
PALBOCICLIB;SULT2A1;rs182420;CC;TOXICITY;INCREASED_LIKELIHOOD
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED_RISK
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4 + *4/*4;EFFICACY;INCREASED_EFFICACY
IMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;LADME_PK;DECREASED_PK
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;HMMR;rs299313;A;TOXICITY;INCREASED_RISK
PRIMAQUINE;G6PD;G6PD deficiency;;OTHER;INCREASED_
SULFANILAMIDE;G6PD;G6PD deficiency;;OTHER;INCREASED_
CHLORAMPHENICOL;G6PD;G6PD deficiency;;OTHER;INCREASED_
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*3;TOXICITY;INCREASED_RISK
FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*28/*28 + *6/*6 + *1/*6 + *1/*28;TOXICITY;INCREASED_LIKELIHOOD
CODEINE, MORPHINE, TRAMADOL;UGT2B7;rs73823859;A;EFFICACY;INCREASED_EFFICACY
CISPLATIN, DOCETAXEL;ALDH2;rs671;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;HMMR;rs299314;C;TOXICITY;INCREASED_RISK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*8;*8;LADME_PK;DECREASED_PK
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28;TOXICITY, LADME_PK;INCREASED_LIKELIHOOD
ANTHRACYCLINES AND RELATED SUBSTANCES;CBR3;rs1056892;G;TOXICITY;INCREASED_RISK
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED_RISK
CISPLATIN;ERCC2;rs13181;G;EFFICACY;INCREASED_EFFICACY
ALLOPURINOL;HLA-A;HLA-A*33:03;*33:03;TOXICITY;INCREASED_LIKELIHOOD
ALLOPURINOL;HLA-C;HLA-C*03:02;*03:02;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;TOXICITY;INCREASED_LIKELIHOOD
ALLOPURINOL;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED_LIKELIHOOD
ANTHRACYCLINES AND RELATED SUBSTANCES;CAT;rs10836235;CC;TOXICITY;INCREASED_RISK
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD
EXEMESTANE;UGT2B17;UGT2B17 deficiency;;TOXICITY;INCREASED_SEVERITY
PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T;HTTLPR short form (S allele) + L allele-rs25531C + L allele-rs25531T;TOXICITY;INCREASED_
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *3/*3 + *2/*3;TOXICITY;INCREASED_LIKELIHOOD
VALPROIC ACID;XBP1;rs2269577;G;EFFICACY;INCREASED_LIKELIHOODEFFICACY
ACE INHIBITORS, PLAIN;ACE;rs1799752;del;TOXICITY;INCREASED_
PACLITAXEL;CYP1B1;rs1056836;GG;EFFICACY;INCREASED_EFFICACY
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10;*10/*10 + *4/*10 + *5/*10;EFFICACY;INCREASED_RISKEFFICACY
DOCETAXEL;CYP1B1;rs1056836;CC;EFFICACY;DECREASED_EFFICACY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*8;*8;DOSAGE, LADME_PK;DECREASED_PK
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ABCC4;rs9561778;T;TOXICITY, LADME_PK;INCREASED_RISK
CYCLOPHOSPHAMIDE;ABCC4;rs9561778;T;TOXICITY, LADME_PK;INCREASED_SEVERITY
CYCLOPHOSPHAMIDE;ABCC4;rs9561778;T;TOXICITY, LADME_PK;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*3;EFFICACY;INCREASED_EFFICACY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*1/*3;EFFICACY;INCREASED_EFFICACY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;EFFICACY;INCREASED_EFFICACY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK
HYDROCHLOROTHIAZIDE;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;OTHER;INCREASED_
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;rs6025;T;TOXICITY;INCREASED_LIKELIHOOD
ENALAPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_EFFICACY
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;EFFICACY;INCREASED_RISKEFFICACY
CLOZAPINE;HLA-B;HLA-B*38:01;*38:01;TOXICITY;INCREASED_RISK
PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN;LADME_PK;DECREASED_PK
FLUCLOXACILLIN;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK
FLUCLOXACILLIN;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2*4;*4;TOXICITY;DECREASED_RISK
CAPECITABINE;ANK3;rs143414470;T;TOXICITY;INCREASED_LIKELIHOOD
GEFITINIB;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*14;*10/*10 + *5/*10;TOXICITY;INCREASED_RISK
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*9;*2 + *3 + *8 + *9;OTHER;INCREASED_RISK
NEVIRAPINE;CCHCR1;rs130072;T;TOXICITY;INCREASED_RISK
NEVIRAPINE;HLA-B;HLA-B*35:05;*35:05;TOXICITY;INCREASED_RISK
RITONAVIR;APOC3;rs5128;G;TOXICITY;INCREASED_
EFAVIRENZ;CYP2B6;rs3745274;T;TOXICITY, LADME_PK;INCREASED_PK
METFORMIN;BDNF;rs6265;C;EFFICACY;INCREASED_LIKELIHOOD
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*18;*1/*18;LADME_PK;INCREASED_PK
LUMIRACOXIB;HLA-DRB1;HLA-DRB1*01:01, HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED_RISK
METHADONE;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;LADME_PK;INCREASED_PK
MERCAPTOPURINE, METHOTREXATE;TPMT;TPMT*1, TPMT*12;*12;TOXICITY;INCREASED_SEVERITY
MYCOPHENOLATE MOFETIL;IMPDH1;rs2278293;CT + TT;TOXICITY;DECREASED_RISK
MITOXANTRONE;ABCB1;rs2032582;AA;OTHER;INCREASED_
LUMIRACOXIB;HLA-DQB1;HLA-DQB1*06:02;*06:02;TOXICITY;INCREASED_RISK
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;LADME_PK;INCREASED_RISK
ASPIRIN, CLOPIDOGREL;PON1;rs662;CT + TT;EFFICACY;DECREASED_EFFICACY
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;LADME_PK;INCREASED_RISK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;TOXICITY;INCREASED_RISK
METHADONE;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;TOXICITY;INCREASED_RISK
METHADONE;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;LADME_PK;INCREASED_PK
TRIMIPRAMINE;CYP2D6;CYP2D6*1, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5;*4/*4 + *3/*5 + *3/*3;TOXICITY;INCREASED_
CLOPIDOGREL;ABCB1;rs1045642;A;OTHER;INCREASED_RISK
NEVIRAPINE;HLA-C;rs9461684;T;TOXICITY;INCREASED_RISK
ASPIRIN;IL1B;rs1143627;A;TOXICITY;
PACLITAXEL;CYP3A4;rs35599367;AA + AG;TOXICITY;INCREASED_SEVERITY
CYCLOPHOSPHAMIDE, DOXORUBICIN;SLC22A16;rs714368;CC + CT;TOXICITY;DECREASED_LIKELIHOOD
PHENYTOIN;EPHX1;rs2234922;G;TOXICITY;INCREASED_RISK
PHENYTOIN;EPHX1;rs1051740;T;TOXICITY;INCREASED_RISK
NEVIRAPINE;TCF19;rs2073724;T;TOXICITY;INCREASED_RISK
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*10;*10;TOXICITY;INCREASED_SEVERITY
CARBOPLATIN, PACLITAXEL;NRG3;rs1649942;G;EFFICACY;DECREASED_EFFICACY
PHENPROCOUMON;EPHX1;rs1051740;CC;TOXICITY;INCREASED_LIKELIHOOD
;SLCO1B1;rs4149056;C;LADME_PK;INCREASED_PK
EFAVIRENZ;CYP2B6;CYP2B6*6;*6/*6;LADME_PK;INCREASED_PK
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;EFFICACY;INCREASED_EFFICACY
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;TOXICITY;INCREASED_RISK
CAFFEINE;ADORA2A;rs5751876;TT;TOXICITY;INCREASED_
PACLITAXEL, PLATINUM COMPOUNDS;NAT2;rs1208;AG + GG;EFFICACY;DECREASED_EFFICACY
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-DQB1;HLA-DQB1*05:01, HLA-DQB1*05:02, HLA-DQB1*05:03;*05:01 + *05:02 + *05:03;TOXICITY;INCREASED_RISK
VENLAFAXINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6;*5/*4 + *6/*6 + *6/*4;TOXICITY, LADME_PK;INCREASED_RISK
FLUVOXAMINE;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*1/*5 + *10/*10 + *5/*10;TOXICITY;INCREASED_RISK
NEMONAPRIDE;ANKK1;rs1800497;A;TOXICITY;INCREASED_
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*3/*3 + *4/*4;EFFICACY;INCREASED_LIKELIHOODEFFICACY
METHOTREXATE;SLC19A1;rs1051266;TT;OTHER, LADME_PK;INCREASED_PK
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
FLUVOXAMINE;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;INCREASED_PK
METHOTREXATE;GGH;rs3758149;AA;LADME_PK;DECREASED_PK
RISPERIDONE;DRD2;rs1799978;C;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;TOXICITY;INCREASED_RISK
RISPERIDONE;ANKK1;rs1800497;AA + AG;TOXICITY;INCREASED_RISK
MYCOPHENOLATE MOFETIL;IMPDH2;rs11706052;G;OTHER;INCREASED_
MERCAPTOPURINE;XDH;rs2281547;CC + CT;TOXICITY;INCREASED_SEVERITY
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2 + *1/*2;EFFICACY;INCREASED_EFFICACY
MYCOPHENOLATE MOFETIL;SLCO1B3;rs4149117;G;LADME_PK;DECREASED_PK
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;EFFICACY;DECREASED_EFFICACY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY;INCREASED_EFFICACY
INDINAVIR;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*6/*28;TOXICITY;INCREASED_RISK
ANASTROZOLE;ABCB1;rs1045642;AA;OTHER;DECREASED_LIKELIHOOD
METHOTREXATE;MTHFR;rs1801131;GG;EFFICACY;DECREASED_
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;EFFICACY;INCREASED_LIKELIHOODEFFICACY
;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_RISK
MERCAPTOPURINE;ITPA;rs1127354;AC;TOXICITY;INCREASED_SEVERITY
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;TOXICITY;INCREASED_RISK
FLECAINIDE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_PK
ETHANOL;ALDH2;rs671;GG;TOXICITY;INCREASED_RISK
DIDANOSINE;XDH;rs1429376;AA;TOXICITY;INCREASED_RISK
DAUNORUBICIN;SZRD1;rs6603859;T;OTHER, LADME_PK;DECREASED_PK
DIDANOSINE;NT5C2;rs11598702;CC + CT;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2 + *2/*2;EFFICACY;INCREASED_
DIDANOSINE;XDH;rs1594160;AA;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*6;*6;TOXICITY;INCREASED_RISK
DAUNORUBICIN;;rs7929521;GG;OTHER, LADME_PK;INCREASED_PK
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*37;*28/*28;TOXICITY;INCREASED_RISK
AZACITIDINE;TYMS;rs11280056;del/del;EFFICACY;DECREASED_EFFICACY
DAUNORUBICIN;MAN1B1;rs3750518;T;OTHER, LADME_PK;INCREASED_PK
OXYCODONE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;LADME_PK;DECREASED_PK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED_
DIDANOSINE;NT5C2;rs11191561;CG + GG;TOXICITY;INCREASED_RISK
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-DQA1;HLA-DQA1*01:02;*01:02;TOXICITY;DECREASED_LIKELIHOOD
IGURATIMOD;CYP2C19;rs4244285;A;TOXICITY;INCREASED_LIKELIHOOD
CYCLOSPORINE;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;EFFICACY;INCREASED_RISKEFFICACY
PHENYTOIN;HLA-C;HLA-C*14:02;*14:02;TOXICITY;INCREASED_RISK
PHENYTOIN;HLA-B;HLA-B*56:02;*56:02;TOXICITY;INCREASED_RISK
NICOTINE;CYP2A6;rs1801272;AT + TT;TOXICITY;INCREASED_SEVERITY
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK
OLANZAPINE;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*6;*1/*3 + *2/*3 + *3/*6;TOXICITY;INCREASED_LIKELIHOOD
DESIPRAMINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;*10/*10 + *5/*10;LADME_PK;INCREASED_PK
GEFITINIB;EGFR;rs11568315;(CA)16/(CA)16;EFFICACY;INCREASED_EFFICACY
OLANZAPINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C;TOXICITY;INCREASED_LIKELIHOOD
;NAT1;NAT1*4, NAT1*11B;*11B/*4;OTHER;INCREASED_RISK
MERCAPTOPURINE, THIOGUANINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*9, TPMT*21, TPMT*32, TPMT*33, TPMT*34;*1/*3C;EFFICACY;DECREASED_EFFICACY
OLANZAPINE;GSTM3;rs1799735;CCT/CCT;LADME_PK;DECREASED_PK
OLANZAPINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_PK
MERCAPTOPURINE;XDH;rs2281547;CC + CT;TOXICITY;INCREASED_SEVERITY
ANASTROZOLE;CYP19A1;rs727479;AA;EFFICACY;INCREASED_
OXYCODONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*6;*4/*4 + *4/*6;LADME_PK;DECREASED_PK
FLUVASTATIN;SLCO1B1;rs11045819;CC;EFFICACY;DECREASED_EFFICACY
OXYCODONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4;*4/*4 + *3/*4;LADME_PK;DECREASED_PK
EFAVIRENZ;CYP2B6;CYP2B6*18;*18/*18;LADME_PK;INCREASED_PK
CYCLOPHOSPHAMIDE, DOXORUBICIN;NQO2;rs1143684;C;EFFICACY;EFFICACY
PIOGLITAZONE;CYP2C8;CYP2C8*1, CYP2C8*2;*1/*2 + *2/*2;LADME_PK;DECREASED_PK
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;TOXICITY;INCREASED_RISK
DICLOFENAC;UGT2B7;rs7668258;T;TOXICITY;INCREASED_LIKELIHOOD
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;TOXICITY;INCREASED_RISK
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;EFFICACY;DECREASED_RISK
IBUPROFEN;CYP2C8;CYP2C8*1, CYP2C8*2;*1/*2;LADME_PK;INCREASED_PK
CISPLATIN, CYCLOPHOSPHAMIDE;GSTM3;rs36120609;TCCTC/TCCTC;TOXICITY;DECREASED_RISK
ASPIRIN, CLOPIDOGREL;CYP2C19;rs4244285;A;TOXICITY;
;IRS1;rs1801123;C;OTHER;
ESTRADIOL;;rs1864729;A;OTHER;INCREASED_
FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_SEVERITY
GEFITINIB;EGFR;rs11568315;(CA)16/(CA)16 + (CA)16/(CA)17;EFFICACY;INCREASED_EFFICACY
ACENOCOUMAROL, WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;TOXICITY;INCREASED_RISK
GEFITINIB;EGFR;rs11568315;(CA)16/(CA)16 + (CA)16/(CA)17;EFFICACY;INCREASED_EFFICACY
CARBIMAZOLE, METHIMAZOLE, PROPYLTHIOURACIL;HLA-DRB1;HLA-DRB1*08:03;*08:03;TOXICITY;INCREASED_RISK
ANTHRACYCLINES AND RELATED SUBSTANCES;GSTM1;GSTM1 non-null, GSTM1 null;;TOXICITY;INCREASED_LIKELIHOOD
;EGFR;rs11568315;(CA)16/(CA)16 + (CA)16/(CA)17;;INCREASED_EFFICACY
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2;slow_acetylator;TOXICITY;INCREASED_LIKELIHOOD
CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2;*2;LADME_PK;DECREASED_PK
DICLOFENAC;ABCC2;rs717620;T;TOXICITY;INCREASED_LIKELIHOOD
ANTIARRHYTHMICS, CLASS I AND III;;rs10033464;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
CARBIMAZOLE, METHIMAZOLE;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED_RISK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*3;EFFICACY;DECREASED_EFFICACY
GEFITINIB;EGFR;rs11568315;(CA)16/(CA)16 + (CA)16/(CA)17;EFFICACY;INCREASED_EFFICACY
HYDRALAZINE;NAT2;NAT2;slow_acetylator;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;EFFICACY;EFFICACY
GEFITINIB;EGFR;rs11568315;(CA)16/(CA)16 + (CA)16/(CA)17;EFFICACY;INCREASED_EFFICACY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;LADME_PK;DECREASED_PK
RIFAMPIN;SLCO1B1;SLCO1B1*15;*15;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;EFFICACY
FLUVOXAMINE, PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T;HTTLPR short form (S allele)/HTTLPR short form (S allele) + HTTLPR short form (S allele)/L allele-rs25531C;EFFICACY;DECREASED_EFFICACY
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*4/*5 + *4/*6 + *3/*4 + *4/*4;OTHER;DECREASED_
;IGFBP3;rs2854744;T;OTHER;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
IRINOTECAN;UGT1A1;UGT1A1*6, UGT1A1*28;*6 + *28;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-A;HLA-A*24:02;*24:02;TOXICITY;DECREASED_RISK
CARBAMAZEPINE;HLA-B;HLA-B*15:11;*15:11;TOXICITY;INCREASED_RISK
NEVIRAPINE;GSTM1;GSTM1 non-null, GSTM1 null;;TOXICITY;INCREASED_LIKELIHOOD
CISPLATIN, CYCLOPHOSPHAMIDE;GSTM3;rs36120609;TCCTC/TCCTC;TOXICITY;DECREASED_RISK
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-B;HLA-B*40:01;*40:01;TOXICITY;DECREASED_RISK
CISPLATIN, CYCLOPHOSPHAMIDE;GSTM3;rs36120609;TCCTC/TCCTC;TOXICITY;DECREASED_RISK
PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5;*4/*5;LADME_PK;INCREASED_PK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;TOXICITY;INCREASED_RISK
;GSTM3;rs36120609;TC/TC + TC/TCCTC;OTHER;INCREASED_LIKELIHOOD
FLUOXETINE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*5/*4 + *1/*3 + *1/*4 + *1/*5 + *1/*6;LADME_PK;INCREASED_PK
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;ITPA;rs1127354;CC;OTHER;
CARBOPLATIN, CYCLOPHOSPHAMIDE, THIOTEPA;ALDH1A1;rs6151031;CTGGTGAGGAGAGAACC/del;TOXICITY;INCREASED_SEVERITY
ANTITHYROID PREPARATIONS;HLA-B;HLA-B*27:05;*27:05;TOXICITY;INCREASED_LIKELIHOOD
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;EFFICACY;INCREASED_RISKEFFICACY
;IFNL3;rs8099917;TT;;INCREASED_
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*1/*28 + *6/*28;TOXICITY;INCREASED_RISK
PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5;*1/*4 + *1/*5;LADME_PK;INCREASED_PK
DICLOFENAC;CYP2C8;CYP2C8*1, CYP2C8*3;*1/*3 + *3/*3;LADME_PK;INCREASED_PK
PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*3/*4;LADME_PK;INCREASED_PK
HEPARIN;HLA-DRB3;HLA-DRB3*01:01;*01:01;TOXICITY;INCREASED_LIKELIHOOD
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2 + *2/*2;TOXICITY;INCREASED_RISK
IRINOTECAN;UGT1A1;UGT1A1*6, UGT1A1*28;*6 + *28;TOXICITY;INCREASED_RISK
PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL4;rs11322783;TT/TT;TOXICITY;INCREASED_EFFICACY
CITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RISKEFFICACY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK
IBUPROFEN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;LADME_PK;DECREASED_PK
TENOXICAM;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;LADME_PK;INCREASED_PK
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED_EFFICACY
TENOXICAM;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;LADME_PK;INCREASED_PK
EFAVIRENZ, LAMIVUDINE, STAVUDINE, ZIDOVUDINE;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME_PK;INCREASED_PK
TAMOXIFEN;CYP2D6;CYP2D6 low activity;;EFFICACY;INCREASED_RISKEFFICACY
PIROXICAM;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;EFFICACY;INCREASED_EFFICACY
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*9, CYP2A6*10;*4 + *10 + *9;LADME_PK;DECREASED_PK
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*17;EFFICACY;DECREASED_EFFICACY
LUMIRACOXIB;HLA-DQA1;HLA-DQA1*01:01, HLA-DQA1*01:02;*01:02;TOXICITY;INCREASED_RISK
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;TOXICITY;INCREASED_RISK
PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;LADME_PK;INCREASED_PK
IBUPROFEN;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;OTHER;DECREASED_
IRINOTECAN;UGT1A6;rs2070959;A;TOXICITY;INCREASED_RISK
IBUPROFEN;CYP2C8;CYP2C8*1, CYP2C8*3;*1/*3;LADME_PK;INCREASED_PK
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;EFFICACY;INCREASED_EFFICACY
IMATINIB;EGFR;rs2072454;CC;TOXICITY;INCREASED_LIKELIHOOD
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;TOXICITY;DECREASED_SEVERITY
KETOPROFEN, TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*41;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;TOXICITY;INCREASED_RISK
PIROXICAM;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;EFFICACY;INCREASED_EFFICACY
PIROXICAM;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;LADME_PK;INCREASED_PK
PIROXICAM;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;LADME_PK;INCREASED_PK
GEFITINIB;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*114;*10/*10;TOXICITY;INCREASED_RISK
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;G;EFFICACY;DECREASED_LIKELIHOODEFFICACY
CITALOPRAM, ESCITALOPRAM;CYP2D6;rs1065852;A;OTHER;
HYDROCHLOROTHIAZIDE;ACE;rs1799752;del/del;EFFICACY;INCREASED_EFFICACY
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*1;EFFICACY;DECREASED_EFFICACY
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;RISK_
MIRTAZAPINE;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN;LADME_PK;INCREASED_PK
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;TOXICITY;INCREASED_RISK
;CYP2D6;CYP2D6*2xN;*2xN;OTHER;INCREASED_RISK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_PK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3;EFFICACY;INCREASED_RISK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;TOXICITY;INCREASED_RISK
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED_RISK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;EFFICACY;DECREASED_EFFICACY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;EFFICACY;INCREASED_
MIRTAZAPINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;LADME_PK;DECREASED_PK
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;OTHER;DECREASED_SEVERITY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;EFFICACY;DECREASED_EFFICACY
IRINOTECAN;UGT1A9;rs11692021;C;TOXICITY;INCREASED_RISK
METOPROLOL;ADRB2;rs1042714;CG;TOXICITY;INCREASED_
LAMOTRIGINE;HLA-A;HLA-A*33:03;*33:03;TOXICITY;INCREASED_LIKELIHOOD
TAMOXIFEN;IGF1R;rs2016347;GG;EFFICACY;INCREASED_RISK
IRINOTECAN, RALTITREXED;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3;EFFICACY;DECREASED_EFFICACY
;CYP2D6;CYP2D6*1xN;*1xN;OTHER;INCREASED_RISK
ALLOPURINOL;HLA-B;HLA-B*48:01;*48:01;TOXICITY;INCREASED_RISK
PACLITAXEL;CYP2C8;rs10509681;C;TOXICITY;INCREASED_RISK
IRINOTECAN, RALTITREXED;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK
PAZOPANIB;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_LIKELIHOOD
IRINOTECAN, RALTITREXED;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_PK
CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2;*2;TOXICITY;INCREASED_
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_PK
QUETIAPINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*4;*1/*2 + *2/*2 + *2/*4;LADME_PK;INCREASED_SEVERITY
CAFFEINE;ADORA2A;rs35060421;TTTTTTT/TTTTTTT;TOXICITY;INCREASED_
ALLOPURINOL;HLA-DRB1;HLA-DRB1*14:01;*14:01;TOXICITY;INCREASED_RISK
ALLOPURINOL;HLA-DRB1;HLA-DRB1*09:01;*09:01;TOXICITY;INCREASED_RISK
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2;slow_acetylator;TOXICITY;INCREASED_RISK
ZONISAMIDE;HLA-A;HLA-A*02:07;*02:07;TOXICITY;
PHENOBARBITAL;HLA-B;HLA-B*51:01;*51:01;TOXICITY;
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17;LADME_PK;DECREASED_PK
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;EFFICACY;INCREASED_SEVERITY
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_PK
LAMIVUDINE, NEVIRAPINE, STAVUDINE;HLA-B;HLA-B*35:05;*35:05;TOXICITY;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_PK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_PK
FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_
METHOTREXATE;ABCC2;rs3740065;AG + GG;LADME_PK;INCREASED_PK
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_PK
METOPROLOL;ADRB2;rs1042714;CC;TOXICITY;DECREASED_
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK
METHOTREXATE;ABCC4;rs9516519;GG + GT;LADME_PK;DECREASED_PK
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_PK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_PK
AZATHIOPRINE, MERCAPTOPURINE, THIOGUANINE;NUDT15;rs746071566;del;TOXICITY;INCREASED_RISK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_PK
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_RISKEFFICACY
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;LADME_PK;INCREASED_PK
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK
FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_SEVERITY
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;LADME_PK;INCREASED_PK
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);EFFICACY;DECREASED_EFFICACY
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);TOXICITY;INCREASED_RISK
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);TOXICITY;INCREASED_RISK
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17;DOSAGE, LADME_PK;DECREASED_PK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK
MIRTAZAPINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);TOXICITY;INCREASED_RISK
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*3;*3;DOSAGE, LADME_PK;INCREASED_PK
LISINOPRIL;MMP3;rs35068180;del/del;EFFICACY;DECREASED_RISK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_RISK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_RISK
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);EFFICACY;EFFICACY
ACENOCOUMAROL, WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;TOXICITY;INCREASED_RISK
ESCITALOPRAM;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*41;*4/*41;LADME_PK;INCREASED_PK
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*3 + *2/*3;TOXICITY;INCREASED_EFFICACY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;TOXICITY;INCREASED_EFFICACY
FENTANYL;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;TOXICITY;INCREASED_RISK
DIRECT ACTING ANTIVIRALS, SOFOSBUVIR;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2;DOSAGE, LADME_PK;INCREASED_PK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED_
FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_LIKELIHOOD
CITALOPRAM;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;DECREASED_PK
ALLOPURINOL;HLA-C;HLA-C*03:02;*03:02;TOXICITY;INCREASED_RISK
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6;TOXICITY;INCREASED_RISK
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;TOXICITY;INCREASED_RISK
ALLOPURINOL;HLA-A;HLA-A*33:03;*33:03;TOXICITY;INCREASED_RISK
ALLOPURINOL;HLA-C;HLA-C*03:02;*03:02;TOXICITY;INCREASED_RISK
FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED_LIKELIHOOD
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*9;*9;EFFICACY;INCREASED_LIKELIHOODEFFICACY
CAPECITABINE, FLUOROURACIL;DPYD;rs56038477;CT;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2;EFFICACY;INCREASED_EFFICACY
IRINOTECAN, OXALIPLATIN, TEGAFUR / GIMERACIL / OTERACIL;UGT1A6;UGT1A6*2a;*2a;TOXICITY;INCREASED_LIKELIHOOD
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*6/*6 + *28/*28 + *6/*28;TOXICITY;INCREASED_RISK
IRINOTECAN, OXALIPLATIN, TEGAFUR / GIMERACIL / OTERACIL;UGT1A1;UGT1A1*28;*28;EFFICACY;DECREASED_EFFICACY
FOLFOX;TYMS;rs11280056;TTA/TTA;TOXICITY;INCREASED_SEVERITY
IRINOTECAN, OXALIPLATIN, TEGAFUR / GIMERACIL / OTERACIL;UGT1A1;UGT1A1*60;*60;EFFICACY;DECREASED_EFFICACY
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;EFFICACY;DECREASED_EFFICACY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;EFFICACY;DECREASED_EFFICACY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-C;HLA-C*04:01;*04:01;TOXICITY;INCREASED_RISK
ISONIAZID, RIFAMPIN;NAT2;NAT2*4;*4;TOXICITY, LADME_PK;DECREASED_LIKELIHOOD
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3/*3;TOXICITY;INCREASED_RISK
METHOTREXATE;TYMS;rs11280056;TTA/TTA;TOXICITY;INCREASED_LIKELIHOOD
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*9;*9/*9 + *1/*9;EFFICACY;INCREASED_RISKEFFICACY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*17;*2 + *3 + *8;EFFICACY;INCREASED_RISKEFFICACY
FOLFOX;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_SEVERITY
MERCAPTOPURINE, METHOTREXATE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B;*1/*2 + *1/*3A + *3A/*3B;TOXICITY;INCREASED_RISK
EGFR INHIBITORS;HLA-A;HLA-A*02:01;*02:01;TOXICITY;DECREASED_RISK
CYCLOPHOSPHAMIDE, FLUDARABINE;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*6 + *6/*6;TOXICITY;DECREASED_RISK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK
ANTINEOPLASTIC AGENTS, TAMOXIFEN;UGT2B15;UGT2B15*1, UGT2B15*2;*2/*2 + *1/*2;EFFICACY;INCREASED_EFFICACY
EGFR INHIBITORS;HLA-A;HLA-A*03:01;*03:01;TOXICITY;DECREASED_RISK
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_
DOCETAXEL;SLCO1B3;rs3834935;A;OTHER, LADME_PK;INCREASED_PK
CARBAMAZEPINE, PHENYTOIN, VALPROIC ACID;GABRA1;rs2279020;GG;EFFICACY;EFFICACY
PACLITAXEL;CYP2C8;CYP2C8*2, CYP2C8*3, CYP2C8*4;*2 + *3 + *4;TOXICITY;INCREASED_RISK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;TOXICITY;INCREASED_RISK
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;TOXICITY;DECREASED_RISK
AMOXICILLIN, CLAVULANATE;HLA-A;HLA-A*30:02;*30:02;TOXICITY;INCREASED_RISK
CITALOPRAM, ESCITALOPRAM;;rs1074145;A;OTHER;
NEVIRAPINE;HLA-DQB1;HLA-DQB1*06:02;*06:02;TOXICITY;DECREASED_RISK
NEVIRAPINE;HLA-DQB1;HLA-DQB1*06:03;*06:03;TOXICITY;DECREASED_RISK
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;EFFICACY;DECREASED_EFFICACY
NEVIRAPINE;HLA-DQB1;HLA-DQB1*06:02;*06:02;TOXICITY;DECREASED_RISK
NEVIRAPINE;HLA-DRB1;HLA-DRB1*15:03;*15:03;TOXICITY;DECREASED_RISK
NEVIRAPINE;HLA-DQB1;HLA-DQB1*06:09;*06:09;TOXICITY;DECREASED_RISK
NEVIRAPINE;HLA-DQB1;HLA-DQB1*02:01;*02:01;TOXICITY;DECREASED_RISK
IMATINIB;CYP1A2;rs11636419;AA;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED_
NEVIRAPINE;HLA-DQB1;HLA-DQB1*02:01;*02:01;TOXICITY;DECREASED_RISK
NEVIRAPINE;HLA-DQB1;HLA-DQB1*03:02;*03:02;TOXICITY;DECREASED_RISK
NEVIRAPINE;HLA-DQB1;HLA-DQB1*06:02;*06:02;TOXICITY;DECREASED_RISK
NEVIRAPINE;HLA-DQB1;HLA-DQB1*03:02;*03:02;TOXICITY;DECREASED_RISK
NEVIRAPINE;HLA-C;HLA-C*04:01;*04:01;TOXICITY;INCREASED_RISK
NEVIRAPINE;HLA-C;HLA-C*04:01;*04:01;TOXICITY;INCREASED_RISK
ETHANOL;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;EFFICACY;INCREASED_EFFICACY
NEVIRAPINE;HLA-DQB1;HLA-DQB1*05:01;*05:01;TOXICITY;DECREASED_RISK
CARBAMAZEPINE, PHENYTOIN, VALPROIC ACID;GABRA1;rs2279020;G;EFFICACY;EFFICACY
METOPROLOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*17, CYP2D6*41;*3/*17 + *3/*4 + *4/*10 + *4/*17 + *4/*4 + *4/*41 + *4/*5 + *4/*6 + *5/*10 + *5/*17;OTHER;
BUCILLAMINE;HLA-DRB1;HLA-DRB1*08:02;*08:02;TOXICITY;INCREASED_RISK
MERCAPTOPURINE;TPMT;TPMT deficiency;;TOXICITY;INCREASED_RISK
AZATHIOPRINE, CYCLOSPORINE, PREDNISONE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;*1/*2 + *1/*3A + *1/*3C;TOXICITY;INCREASED_LIKELIHOOD
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK
BUCILLAMINE;HLA-DQB1;HLA-DQB1*04:02;*04:02;TOXICITY;INCREASED_RISK
CYCLOPHOSPHAMIDE;CYP2B6;rs3211371;CT;EFFICACY;INCREASED_EFFICACY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2 + *2/*2 + *2/*17;EFFICACY;INCREASED_EFFICACY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;TOXICITY;INCREASED_RISK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*11;*2 + *3 + *5 + *6 + *11;TOXICITY;INCREASED_RISK
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;HLA-C*06:02;*06:02;TOXICITY;INCREASED_RISK
DAPSONE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_RISK
DAPSONE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
LAPATINIB;HLA-DQA1;HLA-DQA1*02:01;*02:01;TOXICITY;INCREASED_RISK
DAPSONE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
LAPATINIB;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_RISK
DAPSONE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;TOXICITY;INCREASED_RISK
MERCAPTOPURINE;ABCC4;ABCC4 deficiency;;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;
AMOXICILLIN, CLAVULANATE;HLA-DQB1;HLA-DQB1*06:02;*06:02;TOXICITY;INCREASED_RISK
CLOZAPINE;HLA-DQB1;HLA-DQB1*05:02;*05:02;TOXICITY;INCREASED_RISK
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED_RISKEFFICACY
ASPIRIN;HLA-DQB1;HLA-DQB1*06:09;*06:09;TOXICITY;INCREASED_RISK
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;EFFICACY;INCREASED_RISKEFFICACY
ASPIRIN;HLA-DRB1;HLA-DRB1*13:02;*13:02;TOXICITY;INCREASED_RISK
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK
CLOZAPINE;HLA-DQB1;HLA-DQB1*05:02;*05:02;TOXICITY;INCREASED_RISK
CLOZAPINE;HLA-DPB1;HLA-DPB1*04:01;*04:01;TOXICITY;INCREASED_RISK
CLOZAPINE;HLA-DRB5;HLA-DRB5*02:02;*02:02;TOXICITY;INCREASED_RISK
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED_RISK
ASPIRIN, CLOPIDOGREL, PRASUGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17 + *1/*17;EFFICACY;DECREASED_LIKELIHOOD
OXCARBAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD
AMOXICILLIN, CLAVULANATE;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED_RISK
PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T;L allele-rs25531T/L allele-rs25531T;OTHER;
AMOXICILLIN, CLAVULANATE;HLA-DRB5;HLA-DRB5*01:01;*01:01;TOXICITY;INCREASED_RISK
SORAFENIB;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_LIKELIHOOD
SORAFENIB;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_LIKELIHOOD
AMOXICILLIN, CLAVULANATE;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED_RISK
SUNITINIB;ABCB1;rs1128503;AA + AG;TOXICITY;DECREASED_RISK
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;TOXICITY;INCREASED_RISK
TICLOPIDINE;HLA-DRB1;HLA-DRB1*13:02;*13:02;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;DECREASED_EFFICACY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;EFFICACY;DECREASED_EFFICACY
AMITRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*41;*41;OTHER, LADME_PK;INCREASED_PK
TICLOPIDINE;HLA-C;HLA-C*14:03;*14:03;TOXICITY;INCREASED_RISK
CYCLOPHOSPHAMIDE;CYP2B6;rs3211371;CT;EFFICACY;DECREASED_EFFICACY
ATORVASTATIN;LEPR;rs1805094;GG;OTHER;INCREASED_
TICLOPIDINE;HLA-DQB1;HLA-DQB1*06:04;*06:04;TOXICITY;INCREASED_RISK
TICLOPIDINE;HLA-A;HLA-A*33:03;*33:03;TOXICITY;INCREASED_RISK
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED_RISK
BUSULFAN, CYTARABINE, ETOPOSIDE;ABCC3;rs4148405;G;EFFICACY, TOXICITY;DECREASED_
TICLOPIDINE;HLA-B;HLA-B*44:03;*44:03;TOXICITY;INCREASED_RISK
COCAINE, ETHANOL, NICOTINE;OPRM1;rs1799972;TT;TOXICITY;INCREASED_RISK
NEVIRAPINE;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED_RISK
ANTIPSYCHOTICS;COMT;rs4680;A;OTHER;INCREASED_
ISONIAZID;NAT2;NAT2;slow_acetylator;TOXICITY;INCREASED_RISK
ASPIRIN;HLA-DRB1;HLA-DRB1*09:01;*09:01;TOXICITY;DECREASED_RISK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;EFFICACY;DECREASED_EFFICACY
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;TOXICITY;INCREASED_LIKELIHOOD
ASPIRIN;HLA-DPB1;HLA-DPB1*05:01;*05:01;TOXICITY;DECREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;;TOXICITY;INCREASED_RISK
DRUGS FOR TREATMENT OF TUBERCULOSIS;CYP2E1;CYP2E1*1A, CYP2E1*5B;*1A/*5B;TOXICITY;INCREASED_RISK
ASPIRIN;HLA-DQB1;HLA-DQB1*03:03;*03:03;TOXICITY;DECREASED_RISK
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2;slow_acetylator;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
ASPIRIN;HLA-DRB1;HLA-DRB1*13:02;*13:02;TOXICITY;INCREASED_RISK
MERCAPTOPURINE, THIOGUANINE;TPMT;TPMT*1, TPMT*3C;*1/*3C;TOXICITY;
ASPIRIN;HLA-DQB1;HLA-DQB1*06:09;*06:09;TOXICITY;INCREASED_RISK
FLUTICASONE PROPIONATE;CD14, TMCO6;rs2569190;AA + AG;OTHER;DECREASED_EFFICACY
BLEOMYCIN, DACARBAZINE, DOXORUBICIN, VINBLASTINE;GSTM1;GSTM1 non-null, GSTM1 null;non-null/non-null;TOXICITY;DECREASED_RISK
EFAVIRENZ, NEVIRAPINE;HLA-DRB1;HLA-DRB1*01:01;*01:01;TOXICITY;INCREASED_RISK
NEVIRAPINE;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;DECREASED_RISK
ETHANOL;ADH1B;rs1229984;T;TOXICITY;DECREASED_RISK
NEVIRAPINE;HLA-C;HLA-C*04:01;*04:01;TOXICITY;INCREASED_RISK
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED_RISK
ISONIAZID, RIFAMPIN;GSTT1;GSTT1 null;;LADME_PK;DECREASED_PK
CAPECITABINE, FLUOROURACIL, TEGAFUR;DPYD;rs56038477;T;TOXICITY;INCREASED_RISK
ISONIAZID, RIFAMPIN;GSTM1;GSTM1 null;;LADME_PK;INCREASED_PK
ALLOPURINOL;HLA-DQB1;HLA-DQB1*05:02;*05:02;TOXICITY;INCREASED_LIKELIHOOD
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;GSTM1;GSTM1 null;;TOXICITY;INCREASED_LIKELIHOOD
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;TOXICITY;INCREASED_RISK
NEVIRAPINE;HLA-B;HLA-B*35:01;*35:01;TOXICITY;INCREASED_RISK
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;TOXICITY;INCREASED_LIKELIHOOD
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK
METHADONE;CYP3A4;rs3735451;C;OTHER;INCREASED_SEVERITY
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*27;*1/*27;TOXICITY;INCREASED_SEVERITY
CLOZAPINE;CYP2C19;CYP2C19*17;*17/*17;TOXICITY;DECREASED_LIKELIHOOD
NEVIRAPINE;HLA-DRB1;HLA-DRB1*01:01;*01:01;TOXICITY;INCREASED_RISK
CLOZAPINE;HLA-B;HLA-B*59:01;*59:01;TOXICITY;INCREASED_RISK
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6;TOXICITY;INCREASED_SEVERITY
NEVIRAPINE;HLA-C;HLA-C*04:01;*04:01;TOXICITY;INCREASED_RISK
PHENYTOIN;HLA-B;HLA-B*07:02, HLA-B*13:01;*13:01;TOXICITY;INCREASED_LIKELIHOOD
FLUOXETINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;LADME_PK;PK
;TRPA1;rs920829;CT + TT;OTHER;INCREASED_LIKELIHOOD
ETHANOL;ALDH2;rs671;A;TOXICITY;DECREASED_RISK
;NAT2;NAT2 deficiency;;OTHER;
FLUOXETINE;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3;LADME_PK;INCREASED_PK
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5;*1/*4 + *1/*5;LADME_PK;DECREASED_PK
RITODRINE;CACNA1C;rs10774053;AA + AG;OTHER;DECREASED_LIKELIHOOD
SPIRONOLACTONE;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del;EFFICACY;EFFICACY
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_EFFICACY
WARFARIN;APOE;rs429358;TT;EFFICACY;INCREASED_EFFICACY
WARFARIN;APOE;rs7412;CC;EFFICACY;INCREASED_EFFICACY
AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;HLA-DQB1;HLA-DQB1*06:02;*06:02;TOXICITY;INCREASED_RISK
ATORVASTATIN, QUINAPRIL;ACE;rs1799752;del/del;EFFICACY;DECREASED_EFFICACY
TIMOLOL;CYP2D6;CYP2D6;poor_metabolizer;EFFICACY, LADME_PK;INCREASED_PK
LANSOPRAZOLE;CYP2C19;CYP2C19 normal metabolizer;;LADME_PK;DECREASED_
AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;HLA-C;HLA-C*06:02;*06:02;TOXICITY;INCREASED_RISK
RABEPRAZOLE;CYP2C19;CYP2C19 normal metabolizer;;EFFICACY;DECREASED_
;AREG;rs1615111;A;OTHER;DECREASED_
CISPLATIN, EPIRUBICIN, FLUOROURACIL;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;EFFICACY;INCREASED_EFFICACY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY;INCREASED_RISKEFFICACY
ATORVASTATIN, QUINAPRIL;ACE;rs1799752;del/del;EFFICACY;DECREASED_EFFICACY
ATORVASTATIN, QUINAPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_EFFICACY
AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C9;CYP2C9*1, CYP2C9*2;*2/*2;EFFICACY;INCREASED_EFFICACY
VINCRISTINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;TOXICITY;DECREASED_
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*2;EFFICACY;INCREASED_EFFICACY
ETHANOL;CYP2E1;rs2031920;T;TOXICITY;INCREASED_RISK
CISPLATIN, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*3;OTHER;INCREASED_LIKELIHOOD
TOLTERODINE;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*10/*10 + *5/*10;LADME_PK;INCREASED_PK
AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;HLA-DQB1;HLA-DQB1*03:03;*03:03;TOXICITY;INCREASED_RISK
PHENYTOIN;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED_RISK
ANASTROZOLE;CYP19A1;rs1008805;GG;OTHER;DECREASED_LIKELIHOOD
ACE INHIBITORS, PLAIN;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;TOXICITY;INCREASED_LIKELIHOOD
OLANZAPINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;TOXICITY;INCREASED_LIKELIHOOD
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;INSR;rs41412545;A;TOXICITY;INCREASED_RISK
CYCLOSPORINE, METHOTREXATE;ATIC;rs2177735;AA;EFFICACY;INCREASED_RISK
LEVETIRACETAM;HLA-A;HLA-A*11:01;*11:01;TOXICITY;INCREASED_RISK
ALLOPURINOL;HLA-DRB1;HLA-DRB1*03:01;*03:01;TOXICITY;INCREASED_RISK
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs56022120;T;TOXICITY;INCREASED_RISK
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs6759892;G;DOSAGE, LADME_PK;INCREASED_PK
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs2070959;G;DOSAGE, LADME_PK;INCREASED_PK
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs138602176;A;TOXICITY;INCREASED_RISK
ALLOPURINOL;HLA-C;HLA-C*03:02;*03:02;TOXICITY;INCREASED_RISK
PHENYTOIN;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED_RISK
NEVIRAPINE;HLA-DRB1;HLA-DRB1*01:01;*01:01;TOXICITY;INCREASED_RISK
CLOPIDOGREL;MED12L, P2RY12;rs5853517;T/del;EFFICACY;DECREASED_EFFICACY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;EFFICACY;INCREASED_EFFICACY
PHENYTOIN;HLA-A;HLA-A*24:02;*24:02;TOXICITY;INCREASED_RISK
EXEMESTANE;;rs16964189;TT;TOXICITY;
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PERP;rs78428806;A;TOXICITY;DECREASED_RISK
ASPIRIN, CLOPIDOGREL, PRASUGREL;CYP2C9;CYP2C9*1, CYP2C9*2;*2;EFFICACY;INCREASED_LIKELIHOOD
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;EFFICACY;INCREASED_EFFICACY
FLUOROURACIL;DPYD;DPYD deficiency;;TOXICITY;INCREASED_RISK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK
ANTIPSYCHOTICS;INSIG2;rs11123469;CC;EFFICACY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;TOXICITY;INCREASED_RISK
FENOFIBRATE, SERTRALINE, TERBINAFINE, TICLOPIDINE;HLA-A;HLA-A*33:01;*33:01;TOXICITY;INCREASED_RISK
CARBAMAZEPINE, PHENYTOIN, VALPROIC ACID;ABCB1;rs2032582;T;EFFICACY;EFFICACY
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;TYMS;rs45445694;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3;EFFICACY;INCREASED_EFFICACY
WARFARIN;CYP4F2;CYP4F2*1, CYP4F2*3;*3;EFFICACY;EFFICACY
ASPIRIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;TOXICITY;INCREASED_RISK
CAPECITABINE, FLUOROURACIL, TEGAFUR;DPYD;rs67376798;A;TOXICITY;INCREASED_RISK
METOPROLOL;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4 + *4/*4;LADME_PK;INCREASED_PK
FLUOROURACIL;DPYD;DPYD deficiency;;TOXICITY;INCREASED_RISK
ATAZANAVIR;UGT1A1;UGT1A1*1, UGT1A1*28;*28;OTHER;INCREASED_LIKELIHOOD
;ACE2;rs2285666;C;OTHER;INCREASED_SEVERITY
"""ACE INHIBITORS, PLAIN"", ""BETA BLOCKING AGENTS"", ""CALCIUM CHANNEL BLOCKERS"", ""DIGOXIN"", ""DIURETICS""";ACE;rs1799752;del;EFFICACY;INCREASED_EFFICACY
IVACAFTOR, TEZACAFTOR;CFTR;rs113993960;del/del;OTHER;DECREASED_
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3C;*1/*3C;TOXICITY;INCREASED_RISK
DESIPRAMINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5;*1/*1;LADME_PK;DECREASED_PK
PAMAQUINE;G6PD;G6PD deficiency;;TOXICITY;
METOPROLOL;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4 + *4/*4;EFFICACY, OTHER;INCREASED_
PRIMAQUINE;G6PD;G6PD deficiency;;TOXICITY;
ITRACONAZOLE, KETOCONAZOLE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;OTHER, LADME_PK;DECREASED_SEVERITY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;TOXICITY;INCREASED_RISK
HMG COA REDUCTASE INHIBITORS;;rs3764261;A;EFFICACY;DECREASED_EFFICACY
CAPECITABINE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY;INCREASED_RISKEFFICACY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK
PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;EFFICACY;DECREASED_
OSIMERTINIB;CYP2A6;rs28399433;CC;EFFICACY;DECREASED_EFFICACY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY
AMITRIPTYLINE, FLUOXETINE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN;*1/*1xN + *2/*2xN;TOXICITY;INCREASED_LIKELIHOOD
PAZOPANIB, PEMETREXED;VEGFA;rs833061;CC + CT;TOXICITY;INCREASED_SEVERITY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3/*3 + *1/*3;TOXICITY;INCREASED_RISK
PENICILLIN G, PENICILLIN V;HLA-B;HLA-B*55:01;*55:01;TOXICITY;INCREASED_RISK
ETHANOL;GHSR;rs2948694;AG;OTHER;
OPIOIDS;OPRM1;rs495491;AG + GG;TOXICITY;INCREASED_RISK
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*46;*46/*46;;INCREASED_
OPIOIDS;OPRM1;rs10457090;AA + AG;TOXICITY;DECREASED_RISK
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;LADME_PK;INCREASED_PK
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01/*58:01;TOXICITY;INCREASED_RISK
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
CARBAMAZEPINE, PHENYTOIN, VALPROIC ACID;SCN2A;rs17183814;A;EFFICACY;EFFICACY
WARFARIN;CYP2C9;CYP2C9*2;*2;EFFICACY;EFFICACY
ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;HTR7;rs1935349;T;TOXICITY;INCREASED_RISK
METHOTREXATE;TYMS;rs45445694;CCGCGCCACTTGGCCTGCCTCCGTCCCGCCGCGCCACTTGGCCTGCCTCCGTCCCGCCGCGCCACTTCGCCTGCCTCCGTCCCCC;TOXICITY;INCREASED_RISK
NEVIRAPINE;CYP2B6;CYP2B6*1, CYP2B6*6, CYP2B6*18;*6/*18;TOXICITY, LADME_PK;INCREASED_LIKELIHOODPK
DOCETAXEL, TEGAFUR;CYP2A6;CYP2A6*1, CYP2A6*4;*4/*4;EFFICACY;DECREASED_LIKELIHOODEFFICACY
CISPLATIN;ERCC2;rs1799793;T;EFFICACY;INCREASED_EFFICACY
CARBAMAZEPINE;HLA-B;HLA-B*40:01;*40:01;TOXICITY;DECREASED_LIKELIHOOD
COCAINE;SLC6A3;rs3836790;CACATACCATGCAACATACACACTCAGACA/CACATACCATGCAACATACACACTCAGACA;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;EFFICACY
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;TOXICITY;INCREASED_RISK
PHENYTOIN;HLA-DRB1;HLA-DRB1*16:02;*16:02;TOXICITY;INCREASED_RISK
PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*41;*1/*4;LADME_PK;INCREASED_PK
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;TOXICITY;INCREASED_LIKELIHOOD
IBUPROFEN;CYP2C9;CYP2C9*3;*3;EFFICACY;INCREASED_EFFICACY
PHENYTOIN;CYP2C9;CYP2C9*1;*1/*1;LADME_PK;DECREASED_PK
PHENYTOIN;CYP2C9;CYP2C9*1;*1/*1;LADME_PK;INCREASED_PK
ACETAMINOPHEN;CYP2E1;CYP2E1*1, CYP2E1*5B;*1/*5B;LADME_PK;INCREASED_PK
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;TOXICITY;INCREASED_PK
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;DOSAGE;DECREASED_
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE, EFFICACY;EFFICACY
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;EFFICACY;INCREASED_EFFICACY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3, CYP2C9*4;*1/*3 + *1/*4;DOSAGE;DECREASED_
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK
MERCAPTOPURINE;CYP2A7;rs73032311;C;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;EFFICACY;DECREASED_EFFICACY
BUPROPION;CYP2B6;CYP2B6*18;*18;LADME_PK;DECREASED_PK
PHENYTOIN;CYP2C9;CYP2C9*1;*1/*1;LADME_PK;DECREASED_PK
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK
PHENYTOIN;CYP2C9;CYP2C9*1;*1/*1;LADME_PK;DECREASED_PK
ANTIEPILEPTICS, CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*3;LADME_PK;INCREASED_PK
PHENYTOIN;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;TOXICITY;INCREASED_RISK
;NAT1;NAT1*10, NAT1*11A;*10/*11A;OTHER;INCREASED_RISK
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_
;NAT1;NAT1*4, NAT1*10;*10/*4;OTHER;INCREASED_RISK
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;GSTT1;GSTT1 null;;TOXICITY;INCREASED_LIKELIHOOD
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2;slow_acetylator;TOXICITY;INCREASED_RISK
PACLITAXEL;CYP2C8;CYP2C8*3;*3;LADME_PK;DECREASED_PK
BUPROPION;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME_PK;DECREASED_PK
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;EFFICACY
IRINOTECAN, RALTITREXED;TYMS;rs45445694;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2;TOXICITY;DECREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*3;*3;EFFICACY;EFFICACY
TEMSIROLIMUS;NR1I2;rs6785049;AG + GG;TOXICITY;DECREASED_LIKELIHOOD
TACROLIMUS;CYP3A4;rs2242480;C/C;LADME_PK;INCREASED_PK
;NAT1;NAT1*3, NAT1*11B;*11B/*3;OTHER;INCREASED_RISK
;NAT1;NAT1*10;*10/*10;OTHER;INCREASED_RISK
OXCARBAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
CALCINEURIN INHIBITORS, CYCLOSPORINE, TACROLIMUS;CYP2C8;CYP2C8*3;*3;TOXICITY;INCREASED_RISK
DAUNORUBICIN;NRP2;rs10932125;C;DOSAGE, LADME_PK;INCREASED_PK
CISPLATIN, CYCLOPHOSPHAMIDE;GSTM3;rs1799735;CCT/CCT;TOXICITY, LADME_PK;DECREASED_RISK
CISPLATIN, CYCLOPHOSPHAMIDE;GSTM3;rs1799735;CCT/CCT;TOXICITY, LADME_PK;DECREASED_RISK
CISPLATIN, CYCLOPHOSPHAMIDE;GSTM3;rs1799735;CCT/CCT;TOXICITY, LADME_PK;DECREASED_RISK
METOPROLOL;CYP2D6;rs5030655;del/del;OTHER;INCREASED_PK
ANTIDEPRESSANTS;SLC6A4;rs57098334;(CCCACCCGA)12/(CCCACCCGA)12;;EFFICACY
ANTIDEPRESSANTS;SLC6A4;rs57098334;(CCCACCCGA)12/(CCCACCCGA)12;TOXICITY;INCREASED_RISK
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs1105879;C;LADME_PK;INCREASED_PK
NEVIRAPINE;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;TOXICITY, LADME_PK;INCREASED_LIKELIHOODPK
ISONIAZID, PYRIDOXAL PHOSPHATE;CYP2E1;CYP2E1*1A;*1A/*1A;TOXICITY;INCREASED_LIKELIHOOD
ATENOLOL;ADRB1;rs1801253;CC;EFFICACY;INCREASED_EFFICACY
AMITRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;LADME_PK;INCREASED_PK
AMITRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;LADME_PK;INCREASED_PK
REPAGLINIDE;SLCO1B1;SLCO1B1*1, SLCO1B1*37;*37/*37;LADME_PK;DECREASED_PK
PHENYTOIN;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED_RISK
BENZENE;NQO1;rs1800566;AA;TOXICITY;INCREASED_RISK
ATAZANAVIR, EFAVIRENZ;TPH2;rs4570625;TT;TOXICITY;INCREASED_SEVERITY
METHOTREXATE;DHFR;rs70991108;TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT;TOXICITY;INCREASED_RISK
ALLOPURINOL;HLA-C;HLA-C*03:02;*03:02;TOXICITY;INCREASED_RISK
EFAVIRENZ;CYP2B6;CYP2B6*1;*1;EFFICACY, LADME_PK;DECREASED_PK
ANTITHYROID PREPARATIONS;HLA-B;HLA-B*08:01;*08:01;TOXICITY;INCREASED_LIKELIHOOD
TEGAFUR;CYP2A6;CYP2A6*1;*1;OTHER, LADME_PK;INCREASED_PK
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3;TOXICITY;INCREASED_
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*6/*6;TOXICITY;INCREASED_RISK
CYCLOSPORINE;CYP3A4;CYP3A4*1, CYP3A4*18;*1/*1;TOXICITY;INCREASED_RISK
ANTIEPILEPTICS;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;EFFICACY;DECREASED_LIKELIHOOD
ATORVASTATIN;UGT1A3;UGT1A3*1, UGT1A3*2;*2/*2;EFFICACY, LADME_PK;INCREASED_PK
ATORVASTATIN;UGT1A3;UGT1A3*1, UGT1A3*2;*2;EFFICACY, LADME_PK;DECREASED_EFFICACY
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD
DOXEPIN;CYP2C9;CYP2C9*3;*3/*3;LADME_PK;DECREASED_PK
EFAVIRENZ, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME_PK;DECREASED_PK
TACROLIMUS;CYP2C19;CYP2C19*2;*2/*2;OTHER;INCREASED_
MERCAPTOPURINE;COMT;rs4680;A;TOXICITY;INCREASED_RISK
ROSIGLITAZONE;CYP2C8;CYP2C8*3;*3;EFFICACY;DECREASED_EFFICACY
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*2xN;*1/*2xN;LADME_PK;INCREASED_PK
PRAVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*15;*15;LADME_PK;INCREASED_PK
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*1/*3;EFFICACY;DECREASED_EFFICACY
AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;LADME_PK;INCREASED_PK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;EFFICACY;DECREASED_EFFICACY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;DECREASED_EFFICACY
;CYP2C19;CYP2C19*1, CYP2C19*17;*17;OTHER;RISK_
CAFFEINE;ADORA2A;rs5751876;TT;OTHER;INCREASED_
METHOTREXATE;TYMS;rs45445694;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_SEVERITY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;TOXICITY;INCREASED_RISK
EFAVIRENZ;CYP2B6;CYP2B6*6;*6/*6;TOXICITY, LADME_PK;INCREASED_PK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;TOXICITY;INCREASED_RISK
ATORVASTATIN;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;TOXICITY;INCREASED_
NEVIRAPINE;ABCC10;rs2125739;CC;EFFICACY, LADME_PK;INCREASED_LIKELIHOODPK
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
METFORMIN;SLC22A1;rs36056065;GTAAGTTG;TOXICITY, LADME_PK;
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD
DRUGS FOR TREATMENT OF TUBERCULOSIS;CYP2E1;CYP2E1*1A;*1A/*1A;TOXICITY;INCREASED_LIKELIHOOD
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*17;*17;EFFICACY;EFFICACY
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;EFFICACY;DECREASED_EFFICACY
;NAT1;NAT1*10, NAT1*11B;*10/*11B;OTHER;INCREASED_RISK
EFAVIRENZ, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME_PK;DECREASED_PK
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-DQB1;HLA-DQB1*02:01;*02:01;TOXICITY;INCREASED_LIKELIHOOD
;NAT1;NAT1*4, NAT1*11A;*11A/*4;OTHER;INCREASED_RISK
WARFARIN;CYP2C9;CYP2C9*3;*3;EFFICACY;EFFICACY
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;TOXICITY;INCREASED_PK
PRAVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*15, SLCO1B1*37;*1/*15;LADME_PK;INCREASED_PK
PRAVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*15;*1/*15;LADME_PK;INCREASED_PK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*13;*1/*13;DOSAGE;DECREASED_
PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE, TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*1/*3;EFFICACY;INCREASED_EFFICACY
METOPROLOL;CYP2D6;CYP2D6*4;*4;DOSAGE, TOXICITY;INCREASED_RISK
PRAVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*15;*15/*15;LADME_PK;INCREASED_PK
DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTM1;GSTM1 null;;TOXICITY;DECREASED_SEVERITY
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;INCREASED_RISKEFFICACY
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*3;*3;EFFICACY;INCREASED_RISKEFFICACY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_
DOXEPIN;CYP2D6;CYP2D6*3, CYP2D6*5;*3/*5;LADME_PK;DECREASED_PK
HALOPERIDOL;COMT;rs4680;AG;TOXICITY;INCREASED_LIKELIHOOD
ATORVASTATIN;CYP2D6;CYP2D6*4;*4;TOXICITY;INCREASED_LIKELIHOOD
DOXEPIN;CYP2D6;CYP2D6*4, CYP2D6*5;*4/*5;LADME_PK;DECREASED_PK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*13;*1/*13;EFFICACY;EFFICACY
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE, EFFICACY;EFFICACY
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*14;*1/*14;DOSAGE;DECREASED_
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;EFFICACY;INCREASED_EFFICACY
CLOPIDOGREL;CYP2B6;CYP2B6*5;*5;EFFICACY;EFFICACY
VENLAFAXINE;CYP2D6;CYP2D6*10;*10/*10;LADME_PK;INCREASED_PK
WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*2/*3;EFFICACY;INCREASED_EFFICACY
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_
VENLAFAXINE;CYP2D6;CYP2D6*1, CYP2D6*10;*1/*10;LADME_PK;INCREASED_PK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*14;*1/*14;EFFICACY;EFFICACY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;EFFICACY;EFFICACY
PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*3;*3;TOXICITY;INCREASED_RISK
PHENPROCOUMON;CYP2C9;CYP2C9*3;*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY
PHENPROCOUMON;CYP2C9;CYP2C9*2;*2;EFFICACY;INCREASED_LIKELIHOODEFFICACY
ESCITALOPRAM;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*10;*4/*10;EFFICACY;INCREASED_EFFICACY
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED_EFFICACY
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;LADME_PK;DECREASED_PK
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;EFFICACY, LADME_PK;DECREASED_EFFICACY
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;EFFICACY;INCREASED_
PAROXETINE;CYP2D6;CYP2D6*3, CYP2D6*4;*4/*4 + *3/*4;LADME_PK;INCREASED_PK
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;DOSAGE, EFFICACY;DECREASED_EFFICACY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*1/*3 + *3/*3;EFFICACY;DECREASED_EFFICACY
TAMOXIFEN;CYP2D6;CYP2D6*6, CYP2D6*7;*6/*7;EFFICACY;DECREASED_EFFICACY
ESCITALOPRAM;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*5/*10;EFFICACY;INCREASED_EFFICACY
TAMOXIFEN;CYP2D6;CYP2D6*3, CYP2D6*6;*3/*6;EFFICACY;DECREASED_EFFICACY
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*3/*4;DOSAGE, EFFICACY;DECREASED_EFFICACY
CLOMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED_EFFICACY
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4;LADME_PK;INCREASED_PK
OXYCODONE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*4/*4 + *3/*4;LADME_PK;PK
PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*41;*1/*1 + *1/*41;LADME_PK;DECREASED_PK
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*5/*10;LADME_PK;INCREASED_PK
DESIPRAMINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*1/*1;LADME_PK;DECREASED_PK
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10;*2/*10;LADME_PK;DECREASED_PK
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*5;*3/*5;DOSAGE, EFFICACY;DECREASED_EFFICACY
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5;*5;LADME_PK;INCREASED_PK
PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*1/*10 + *1/*5;LADME_PK;INCREASED_PK
COTININE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*9, CYP2A6*17, CYP2A6*20;*1/*1;LADME_PK;PK
MIRTAZAPINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;LADME_PK;DECREASED_PK
PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4;LADME_PK;INCREASED_PK
CLOMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*3;*3;EFFICACY;INCREASED_EFFICACY
CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;LADME_PK;DECREASED_PK
PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10 + *1/*10;LADME_PK;INCREASED_PK
MIRTAZAPINE;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN;LADME_PK;INCREASED_PK
CODEINE;CYP2D6;CYP2D6*1, CYP2D6*36;*36;LADME_PK;DECREASED_PK
CODEINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;*1/*1 + *1/*4;LADME_PK;INCREASED_PK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;EFFICACY;INCREASED_EFFICACY
WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK
;UGT1A1;rs34946978;T;OTHER;INCREASED_LIKELIHOOD
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK
FLURBIPROFEN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;LADME_PK;INCREASED_PK
DICLOFENAC;CYP2C8;CYP2C8*1, CYP2C8*4;*1/*4 + *4/*4;LADME_PK;INCREASED_PK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK
PYRIMIDINE ANALOGUES;MIR27A;rs895819;CC + CT;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK
CITALOPRAM;CYP2C19;CYP2C19;poor_metabolizer;LADME_PK;INCREASED_PK
TIMOLOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;*3/*3 + *3/*4 + *4/*4 + *5/*4;LADME_PK;INCREASED_PK
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
CLOPIDOGREL;PON1;rs662;C;EFFICACY;INCREASED_RISK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;TOXICITY;INCREASED_RISK
TENOXICAM;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*3;LADME_PK;INCREASED_PK
IBUPROFEN;CYP2C8;CYP2C8*1, CYP2C8*3;*1/*3;TOXICITY;DECREASED_
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK
CLOPIDOGREL;P2RY12;rs2046934;A;EFFICACY;INCREASED_RISK
ANTIEPILEPTICS;HLA-B;HLA-B*58:01;*58:01;TOXICITY;DECREASED_RISK
ASPIRIN;HLA-DPB1;HLA-DPB1*03:01;*03:01;TOXICITY;INCREASED_RISK
SULFONAMIDES, UREA DERIVATIVES;TCF7L2;rs7903146;CC;EFFICACY;INCREASED_EFFICACY
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK
LUMACAFTOR;CFTR;rs113993960;del/del;TOXICITY;INCREASED_EFFICACY
CAFFEINE;CYP1A2;rs762551;AA;TOXICITY;INCREASED_LIKELIHOOD
DAPSONE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_RISK
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_EFFICACY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;EFFICACY;INCREASED_EFFICACY
CODEINE;CYP2D6;CYP2D6*1, CYP2D6*10;*1/*10 + *10/*10;LADME_PK;DECREASED_PK
AZATHIOPRINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;*1/*2 + *1/*3A + *1/*3C;TOXICITY;INCREASED_RISK
BOSENTAN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;TOXICITY;INCREASED_RISK
CODEINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;*1/*1 + *1/*4;OTHER;INCREASED_
;CYP1B1;rs1056836;CC + CG;;DECREASED_EFFICACY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;TOXICITY;INCREASED_RISK
TETRABENAZINE;CYP2D6;CYP2D6;intermediate_metabolizer;EFFICACY;EFFICACY
WARFARIN;CYP4F2;CYP4F2*1, CYP4F2*3;*3;TOXICITY;DECREASED_RISK
CITALOPRAM;SLC6A4;SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T;HTTLPR short form (S allele)/L allele-rs25531C;TOXICITY;INCREASED_LIKELIHOOD
CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;LADME_PK;DECREASED_PK
CLOPIDOGREL;PTGS1;rs1330344;T;EFFICACY;INCREASED_RISK
CLOMIPRAMINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);TOXICITY;INCREASED_
CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;LADME_PK;INCREASED_PK
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);EFFICACY;INCREASED_EFFICACY
PHENOBARBITAL;CYP2C19;CYP2C19*2;*2;TOXICITY;INCREASED_RISK
OLANZAPINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;EFFICACY;INCREASED_EFFICACY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2 + *1/*2;TOXICITY;INCREASED_LIKELIHOOD
CARBAMAZEPINE;HLA-B;HLA-B*07:02, HLA-B*08:01;*07:02;TOXICITY;DECREASED_RISK
TRICHLOROETHYLENE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY, TOXICITY;INCREASED_RISK
AZATHIOPRINE, CYCLOSPORINE, PREDNISONE;TPMT;TPMT*3A, TPMT*3C;*3A/*3C;TOXICITY;SEVERITY_
ALLOPURINOL;HLA-A;HLA-A*02:01;*02:01;TOXICITY;DECREASED_RISK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;EFFICACY;INCREASED_RISKEFFICACY
ALLOPURINOL;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED_RISK
IRINOTECAN, OXALIPLATIN, TEGAFUR / GIMERACIL / OTERACIL;UGT1A7;UGT1A7*3;*3;TOXICITY;INCREASED_LIKELIHOOD
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;EFFICACY;INCREASED_RISK
OSIMERTINIB;CYP2C9;rs1057910;CC;TOXICITY;INCREASED_LIKELIHOOD
CITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_LIKELIHOODEFFICACY
MYCOPHENOLATE MOFETIL;CYP2C8;rs11572076;CC;TOXICITY;DECREASED_RISK
ALLOPURINOL;HLA-A;HLA-A*33:03;*33:03;TOXICITY;INCREASED_RISK
CLOZAPINE;HLA-DRB3;HLA-DRB3*02:02;*02:02;TOXICITY;INCREASED_RISK
MERCAPTOPURINE;TPMT;rs1142345;C;TOXICITY;INCREASED_RISK
MYCOPHENOLATE MOFETIL;UGT2B7;rs7438135;G;TOXICITY;INCREASED_RISK
CLOZAPINE;HLA-C;HLA-C*07:01;*07:01;TOXICITY;INCREASED_RISK
CLOZAPINE;HLA-DRB1;HLA-DRB1*01:01;*01:01;TOXICITY;DECREASED_RISK
AZATHIOPRINE, MERCAPTOPURINE;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED_
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;TOXICITY;INCREASED_RISK
SULFASALAZINE;HLA-B;HLA-B*39:01;*39:01;TOXICITY;INCREASED_RISK
METHAZOLAMIDE;HLA-C;HLA-C*01:02;*01:02;TOXICITY;INCREASED_RISK
CARBIMAZOLE, METHIMAZOLE, PROPYLTHIOURACIL;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED_RISK
PLATINUM COMPOUNDS, PYRIMIDINE ANALOGUES;DPYD;rs1801265;AG + GG;TOXICITY;INCREASED_LIKELIHOOD
CILOSTAZOL, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY;DECREASED_EFFICACY
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*3;EFFICACY;INCREASED_EFFICACY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
CAPECITABINE, FLUOROURACIL;DPYD;DPYD deficiency;;TOXICITY;INCREASED_RISK
DOLASETRON;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN;EFFICACY;INCREASED_LIKELIHOOD
CYCLOSPORINE, METHOTREXATE;NFATC2;rs6123048;AA;EFFICACY;INCREASED_RISK
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;CYP2C8;CYP2C8*1, CYP2C8*4;*4;TOXICITY;INCREASED_LIKELIHOOD
TAMOXIFEN;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;EFFICACY;INCREASED_EFFICACY
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;
IFOSFAMIDE;ALDH1A1;rs3764435;AA;EFFICACY;DECREASED_EFFICACY
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*17;TOXICITY;DECREASED_RISK
DAPSONE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_RISK
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_EFFICACY
CLOZAPINE;GSTT1;GSTT1 non-null, GSTT1 null;null/null;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;TOXICITY;INCREASED_RISK
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_EFFICACY
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs746071566;del;TOXICITY;INCREASED_RISK
HMG COA REDUCTASE INHIBITORS;ADAMTS1;rs402007;CC;EFFICACY;EFFICACY
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK
NICOTINE;CYP2B6;CYP2B6*1, CYP2B6*4;*1/*4 + *4/*4;TOXICITY;INCREASED_SEVERITY
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*12;*1/*1;TOXICITY;DECREASED_RISK
ANTITHYROID PREPARATIONS;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED_RISK
ANTITHYROID PREPARATIONS;HLA-DRB1;HLA-DRB1*08:03;*08:03;TOXICITY;INCREASED_RISK
AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED_RISK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;TOXICITY;INCREASED_RISK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;TOXICITY;INCREASED_RISK
GEFITINIB;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;TOXICITY;INCREASED_RISK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;EFFICACY;DECREASED_RISKEFFICACY
CARBOPLATIN, PACLITAXEL;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;TOXICITY;INCREASED_RISK
LAMOTRIGINE;SCN1A;rs3812718;C;EFFICACY;INCREASED_EFFICACY
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;INCREASED_PK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;EFFICACY;INCREASED_RISKEFFICACY
PEMETREXED;TYMS;rs11280056;TTAAAGTTA/TTAAAGTTA;EFFICACY;DECREASED_EFFICACY
METHOTREXATE;TYMS;rs11280056;del;TOXICITY;INCREASED_RISK
;SLCO1B1;rs4149056;C;OTHER;DECREASED_
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_LIKELIHOOD
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_LIKELIHOOD
LEVOFLOXACIN;HLA-B;HLA-B*13:01, HLA-B*13:02;*13:01 + *13:02;TOXICITY;INCREASED_LIKELIHOOD
PHENYTOIN;HLA-A;HLA-A*03:01;*03:01;TOXICITY;INCREASED_LIKELIHOOD
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19;intermediate_metabolizer;EFFICACY;INCREASED_RISK
BETA-LACTAM ANTIBACTERIALS, PENICILLINS;HLA-DRB1;HLA-DRB1*10:01;*10:01;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*17;*2 + *3 + *8;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL, PROTON PUMP INHIBITORS;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*1 + *1/*17 + *17/*17;TOXICITY;INCREASED_LIKELIHOOD
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10  + *1/*10;EFFICACY;DECREASED_EFFICACY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*1 + *1/*17 + *17/*17;TOXICITY;DECREASED_RISK
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19;poor_metabolizer;EFFICACY;INCREASED_RISK
CYCLOSPORINE, METHOTREXATE;SLC19A1;rs4818789;TT;EFFICACY;DECREASED_RISK
ATENOLOL, METOPROLOL;ADRB2;rs1042714;GG;TOXICITY;INCREASED_RISK
ZOLEDRONATE;;rs1152003;CC;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD
ANTIDEPRESSANTS, ANTIPSYCHOTICS;CYP2C19;CYP2C19;intermediate_metabolizer;TOXICITY;INCREASED_LIKELIHOOD
ATORVASTATIN;HMGCR;rs17671591;T;EFFICACY;EFFICACY
ANTIDEPRESSANTS, ANTIPSYCHOTICS;CYP2D6;CYP2D6;intermediate_metabolizer;TOXICITY;INCREASED_LIKELIHOOD
TACROLIMUS, VORICONAZOLE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_SEVERITY
CARBOPLATIN, PACLITAXEL;LIG3;rs1052536;T;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP1A2;rs2069514;A;TOXICITY;INCREASED_RISK
CYCLOSPORINE, METHOTREXATE;SLC19A1;rs4819128;TT;EFFICACY;DECREASED_RISK
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;NAT2;slow_acetylator;TOXICITY;INCREASED_LIKELIHOOD
ATORVASTATIN;HMGCR;rs10474433;T;EFFICACY;EFFICACY
VANCOMYCIN;HLA-A;HLA-A*32:01;*32:01;TOXICITY;INCREASED_RISK
MERCAPTOPURINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_RISK
ATORVASTATIN;PCSK9;rs11591147;T;EFFICACY;EFFICACY
"""BETA-LACTAM ANTIBACTERIALS, PENICILLINS"", ""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-A;HLA-A*02:07;*02:07;TOXICITY;DECREASED_LIKELIHOOD
"""BETA-LACTAM ANTIBACTERIALS, PENICILLINS"", ""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-A;HLA-A*01:01;*01:01;TOXICITY;INCREASED_LIKELIHOOD
"""BETA-LACTAM ANTIBACTERIALS, PENICILLINS"", ""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-C;HLA-C*06:02;*06:02;TOXICITY;INCREASED_LIKELIHOOD
"""BETA-LACTAM ANTIBACTERIALS, PENICILLINS"", ""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED_LIKELIHOOD
"""BETA-LACTAM ANTIBACTERIALS, PENICILLINS"", ""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-DQB1;HLA-DQB1*03:02;*03:02;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;CYP2C19;poor_metabolizer;EFFICACY;INCREASED_LIKELIHOODEFFICACY
VALPROIC ACID;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD
ATORVASTATIN;APOE;rs429358;T;EFFICACY;EFFICACY
ENALAPRIL;;rs495828;TT;TOXICITY;INCREASED_RISK
RIBAVIRIN, SOFOSBUVIR;ITPA;rs1127354;AC;EFFICACY;INCREASED_LIKELIHOODEFFICACY
ENALAPRIL;;rs495828;TT;TOXICITY;INCREASED_RISK
ATORVASTATIN;APOE;rs7412;T;EFFICACY;EFFICACY
;GSTT1;GSTT1 non-null, GSTT1 null;;EFFICACY, TOXICITY;INCREASED_LIKELIHOOD
SIMVASTATIN;ABCG2;rs2231142;TT;LADME_PK;INCREASED_PK
CISPLATIN, DOCETAXEL, FLUOROURACIL;TYMS;rs11280056;TTA/TTA;TOXICITY;INCREASED_SEVERITY
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_LIKELIHOOD
CARBAMAZEPINE;HLA-B;HLA-B*15:11;*15:11;TOXICITY;INCREASED_LIKELIHOOD
;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY;INCREASED_LIKELIHOOD
EFAVIRENZ;CYP2B6;CYP2B6;poor_metabolizer;TOXICITY;INCREASED_SEVERITY
CAPECITABINE, FLUOROURACIL;DPYS;rs143004875;(T)7/(T)8;TOXICITY;INCREASED_SEVERITY
FLUVASTATIN;ABCG2;rs2231142;TT;LADME_PK;INCREASED_PK
CAPECITABINE, FLUOROURACIL;DPYD;DPYD c.1129-5923C>G, c.1236G>A (HapB3);c.1129-5923C>G, c.1236G>A (HapB3);TOXICITY;INCREASED_SEVERITY
OSIMERTINIB;CYP2A6;CYP2A6*4;*4;TOXICITY;INCREASED_LIKELIHOOD
OSIMERTINIB;ABCG2;rs2622604;TT;TOXICITY;INCREASED_LIKELIHOOD
L-ASPARAGINE, PREDNISONE, VINCRISTINE;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*3/*3 + *3/*6 + *3/*7;TOXICITY;INCREASED_LIKELIHOOD
L-ASPARAGINE, PREDNISONE, VINCRISTINE;ASNS;rs3832526;(GCGGGGCGCAGGGC)3/(GCGGGGCGCAGGGC)3;TOXICITY;INCREASED_LIKELIHOOD
PRAVASTATIN;NPC1L1;rs17655652;CC;EFFICACY;DECREASED_EFFICACY
PRAVASTATIN;NPC1L1;rs17655652;CC;EFFICACY;INCREASED_EFFICACY
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;NAT2;slow_acetylator;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;TOXICITY;DECREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*17;*17;TOXICITY;DECREASED_RISK
TRAMADOL;CYP2B6;CYP2B6;poor_metabolizer;EFFICACY;DECREASED_SEVERITYEFFICACY
TRAMADOL;CYP3A4;CYP3A4;poor_metabolizer;TOXICITY;INCREASED_LIKELIHOOD
CITALOPRAM, ESCITALOPRAM;CYP2C19;CYP2C19;poor_metabolizer;TOXICITY;INCREASED_LIKELIHOOD
IRINOTECAN;HLA-B;rs9266271;C;TOXICITY;DECREASED_SEVERITY
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED_LIKELIHOOD
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;HLA-A;HLA-A*34:01;*34:01;TOXICITY;INCREASED_LIKELIHOOD
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;HLA-DRB1;HLA-DRB1*16:02;*16:02;TOXICITY;INCREASED_LIKELIHOOD
ATORVASTATIN;HMGCR;rs3846662;GG;EFFICACY;INCREASED_EFFICACY
CLOPIDOGREL;ABCB1;rs1128503;GG;EFFICACY;DECREASED_EFFICACY
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;TOXICITY;INCREASED_LIKELIHOOD
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2*4, NAT2*6;*6;TOXICITY;INCREASED_RISK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY
AZATHIOPRINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_RISK
BETA BLOCKING AGENTS, METOPROLOL;ADRB1;rs1801252;AG + GG;EFFICACY;INCREASED_EFFICACY
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD
FOLFIRI, FOLFOX, XELOX;TYMS;rs11280056;del/del;EFFICACY;DECREASED_EFFICACY
IRINOTECAN;ALOX5;rs1051713;T;TOXICITY;INCREASED_SEVERITY
ETOPOSIDE;;rs6539870;GG;OTHER;INCREASED_
"""INTERFERON ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";ITPA;rs1127354;CC;EFFICACY;DECREASED_EFFICACY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY;INCREASED_RISKEFFICACY
"""INTERFERON ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";ITPA;rs1127354;CC;EFFICACY;EFFICACY
ASPARAGINASE;F5;rs6025;CT;TOXICITY;INCREASED_RISK
DABIGATRAN;CES1;rs2244613;GG + GT;LADME_PK;DECREASED_PK
DESIPRAMINE;MC1R;rs2228478;G;EFFICACY;INCREASED_LIKELIHOODEFFICACY
;ABCB1;rs1045642;A;;INCREASED_
ACENOCOUMAROL;VKORC1;rs9934438;AA;DOSAGE, EFFICACY, TOXICITY;DECREASED_EFFICACY
DESIPRAMINE;MC1R;rs2228479;A;EFFICACY;INCREASED_LIKELIHOODEFFICACY
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*4, NAT2*7, NAT2*16;*16/*7;TOXICITY, LADME_PK;INCREASED_LIKELIHOOD
CARBAMAZEPINE;LTA, TNF;rs1800629;A;TOXICITY;INCREASED_LIKELIHOOD
ASPARAGINASE;IL16;rs11556218;GG + GT;TOXICITY;INCREASED_RISK
MERCAPTOPURINE;PACSIN2;rs2413739;TT;TOXICITY;INCREASED_RISK
GEMCITABINE;SLC29A1;rs9394992;CT + TT;TOXICITY;INCREASED_RISK
DOCETAXEL, THALIDOMIDE;SPG7;rs2292954;A;TOXICITY;INCREASED_RISK
ANTINEOPLASTIC AGENTS;CTH;rs648743;CC;TOXICITY;DECREASED_LIKELIHOOD
DOCETAXEL, THALIDOMIDE;ABCC6;rs2238472;C;TOXICITY;INCREASED_RISK
DOCETAXEL, THALIDOMIDE;ATP7A;rs2227291;G;TOXICITY;INCREASED_RISK
MERCAPTOPURINE;GNMT;rs10948059;CT + TT;TOXICITY;DECREASED_RISK
ACENOCOUMAROL;CYP4F2;rs2108622;CC;OTHER, LADME_PK;DECREASED_
ACENOCOUMAROL;CYP4F2;rs2108622;CT;OTHER, LADME_PK;DECREASED_
DABIGATRAN;CES1;rs2244613;GG + GT;TOXICITY;DECREASED_RISK
CLOPIDOGREL;CYP2C19;rs4244285;A;TOXICITY;INCREASED_RISK
ACENOCOUMAROL;CYP4F2;rs2108622;CC;DOSAGE, EFFICACY, TOXICITY;DECREASED_EFFICACY
CLOPIDOGREL;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*1/*4 + *1/*10 + *1/*5 + *1/*41 + *1/*3;EFFICACY;INCREASED_RISKEFFICACY
IRINOTECAN;SLCO1B1;rs4149015;AA + AG;TOXICITY;INCREASED_
;CHRM3;rs2165870;AA + AG;;INCREASED_RISK
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*4, NAT2*16;*16/*16;TOXICITY;INCREASED_LIKELIHOOD
SALBUTAMOL, SALMETEROL;ADRB2;rs1042713;AA;EFFICACY;INCREASED_RISKEFFICACY
IRINOTECAN;UGT1A9;rs3832043;del/del;TOXICITY;INCREASED_RISK
ANTIPSYCHOTICS, ARIPIPRAZOLE, CLOZAPINE, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR2C;rs1414334;C;TOXICITY;INCREASED_LIKELIHOOD
CISPLATIN;SLC16A5;rs4788863;T;TOXICITY;DECREASED_LIKELIHOOD
ISONIAZID, RIFAMPIN;NAT2;NAT2*1, NAT2*4, NAT2*5, NAT2*5G, NAT2*5J, NAT2*6, NAT2*7, NAT2*14, NAT2*16, NAT2*17, NAT2*30, NAT2*34;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;TOXICITY;INCREASED_LIKELIHOOD
IRINOTECAN;ABCC2;rs3740066;CC;TOXICITY;INCREASED_RISK
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_SEVERITY
ENALAPRIL, IMIDAPRIL, LISINOPRIL;BDKRB2;rs1799722;CT + TT;TOXICITY;INCREASED_RISK
IRINOTECAN;ABCG2;rs2231137;CT + TT;TOXICITY;INCREASED_RISK
CLOZAPINE, RISPERIDONE;HTR2C;rs1414334;C;TOXICITY;INCREASED_RISK
HMG COA REDUCTASE INHIBITORS;SREBF1;rs11868035;AA + AG;OTHER;INCREASED_
OXYCODONE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;DOSAGE;INCREASED_PK
CISPLATIN;GSTP1;rs1695;G;TOXICITY;INCREASED_LIKELIHOOD
ACE INHIBITORS, PLAIN;BDKRB2;rs1799722;T;TOXICITY;INCREASED_RISK
ATORVASTATIN;ABCG2;rs2231142;TT;DOSAGE, LADME_PK;INCREASED_PK
LANSOPRAZOLE;CYP2C19;CYP2C19 intermediate metabolizers;;LADME_PK;DECREASED_
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*5, NAT2*6, NAT2*7;*5/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY, LADME_PK;INCREASED_RISK
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*6, NAT2*7;*6/*7;TOXICITY;INCREASED_RISK
IRBESARTAN;AGTR1;rs5186;AC + CC;EFFICACY;INCREASED_EFFICACY
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*6;*6/*6;TOXICITY;INCREASED_RISK
OPIOIDS;PDE3A;rs12305038;A;TOXICITY;DECREASED_SEVERITY
ISONIAZID, RIFAMPIN;NAT2;NAT2*1, NAT2*4, NAT2*5, NAT2*6, NAT2*7;*5/*7 + *6/*6 + *6/*7;TOXICITY, LADME_PK;INCREASED_RISK
DEXMEDETOMIDINE;ADRA2A;rs1800544;G;EFFICACY;INCREASED_EFFICACY
PACLITAXEL;CYP2C8;rs1113129;G;TOXICITY;DECREASED_RISK
OPIOIDS;MUC16;rs11882256;T;TOXICITY;INCREASED_SEVERITY
ISONIAZID, RIFAMPIN;NAT2;NAT2*6;*6;TOXICITY, LADME_PK;INCREASED_LIKELIHOOD
ROSUVASTATIN;ABCG2;rs2231142;TT;DOSAGE, LADME_PK;INCREASED_PK
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*6;*6/*6;TOXICITY, LADME_PK;INCREASED_RISK
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;NAT2*5, NAT2*6, NAT2*7, NAT2*14, NAT2*16;*16 + *5 + *6 + *6 + *7 + *7 + *14 + *14;TOXICITY;INCREASED_RISK
IRINOTECAN;UGT1A1;rs4148323;AA;TOXICITY;INCREASED_RISK
ROSUVASTATIN;ABCG2;rs2231142;GG;DOSAGE, LADME_PK;DECREASED_PK
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2*6;*6;TOXICITY;INCREASED_RISK
ISONIAZID, RIFAMPIN;NAT2;NAT2*6, NAT2*7;*6/*7;TOXICITY, LADME_PK;INCREASED_LIKELIHOOD
SORAFENIB;TNF;rs1800629;GG;TOXICITY;INCREASED_RISK
OPIOIDS;PDE3A;rs12305038;A;TOXICITY;INCREASED_SEVERITY
IRINOTECAN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK
ALFENTANIL;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_RISK
ISONIAZID;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_RISK
"""INTERFERON ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";ITPA;rs1127354;CC;TOXICITY;DECREASED_
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*6;*6;TOXICITY;INCREASED_RISK
ALFENTANIL;OPRM1;rs1799971;AG + GG;LADME_PK;INCREASED_PK
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD
SALMETEROL;ADRB2;rs1042713;AA;EFFICACY;INCREASED_RISK
PEGINTERFERON ALFA-2B, RIBAVIRIN;DNAAF9, ITPA;rs6051702;C;TOXICITY;DECREASED_SEVERITY
CLOPIDOGREL;MIR6076;rs1463411;GG + GT;TOXICITY;INCREASED_LIKELIHOOD
LANSOPRAZOLE;CYP2C19;CYP2C19 intermediate metabolizers;;LADME_PK;DECREASED_
TAMOXIFEN;LRMDA;rs10509373;C;EFFICACY;DECREASED_
OPIOIDS;CRYBG2;rs36024412;T;TOXICITY;DECREASED_SEVERITY
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;rs1799930;G;TOXICITY;INCREASED_LIKELIHOOD
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*6, NAT2*7;*6/*7;TOXICITY, LADME_PK;INCREASED_LIKELIHOOD
OPIOIDS;CLCC1;rs168107;T;TOXICITY;DECREASED_SEVERITY
CAPECITABINE;CDA;rs1048977;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
BOCEPREVIR, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY
PLATINUM COMPOUNDS;SLC31A1;rs10759637;AC;TOXICITY;INCREASED_SEVERITY
OPIOIDS;POM121L2;rs41269255;T;TOXICITY;INCREASED_SEVERITY
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS"", ""DRUGS FOR TREATMENT OF TUBERCULOSIS""";NAT2;NAT2*1, NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;TOXICITY, LADME_PK;INCREASED_RISK
DIPYRONE;NAT2;NAT2*6, NAT2*7, NAT2*14, NAT2*16;*16 + *6 + *7 + *14;TOXICITY;INCREASED_RISK
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*6, NAT2*7, NAT2*14, NAT2*16;*16 + *6 + *7 + *14;TOXICITY, LADME_PK;INCREASED_LIKELIHOOD
METHOTREXATE;ABCC2;rs3740065;AG + GG;TOXICITY;INCREASED_RISK
IRINOTECAN;NR3C1;rs61754806;A;TOXICITY;DECREASED_SEVERITY
IRINOTECAN;VKORC1;rs7294;T;TOXICITY;INCREASED_SEVERITY
PLATINUM COMPOUNDS;SLC31A1;rs2233914;AA;TOXICITY;DECREASED_SEVERITY
OPIOIDS;ZNF165;rs9393888;C;TOXICITY;DECREASED_SEVERITY
CISPLATIN, CYCLOPHOSPHAMIDE;TPMT;rs1142345;CT;EFFICACY;DECREASED_EFFICACY
HMG COA REDUCTASE INHIBITORS;SLCO1B1;SLCO1B1*5;*5;TOXICITY;DECREASED_RISK
GEMCITABINE;RRM1;rs9937;AA;TOXICITY;INCREASED_RISK
OLANZAPINE, RISPERIDONE;DRD2;rs1799978;C;EFFICACY;DECREASED_EFFICACY
PLATINUM COMPOUNDS;SLC31A1;rs2233914;AA;EFFICACY;INCREASED_LIKELIHOODEFFICACY
CLOPIDOGREL;CYP2C19;rs12248560;CT + TT;TOXICITY;INCREASED_RISK
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;NAT2*5, NAT2*6, NAT2*6J, NAT2*7, NAT2*16;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD
METHOTREXATE;ABCC4;rs9516519;GG + GT;TOXICITY;DECREASED_RISK
ESCITALOPRAM;CYP2D6;CYP2D6;poor_metabolizer;TOXICITY;INCREASED_LIKELIHOOD
RISPERIDONE;CYP2D6;CYP2D6 normal metabolizer;;EFFICACY;INCREASED_LIKELIHOODEFFICACY
PALIPERIDONE;CYP2D6;CYP2D6;poor_metabolizer;TOXICITY;INCREASED_LIKELIHOOD
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;NAT2*4, NAT2*6, NAT2*7;*6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD
TRAMADOL;CYP2D6;CYP2D6*10;*10/*10;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;rs12248560;CT + TT;EFFICACY;DECREASED_EFFICACY
ISONIAZID;NAT2;NAT2*6, NAT2*7;*6 + *7;TOXICITY;INCREASED_RISK
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*4, NAT2*6, NAT2*7;*6 + *7;TOXICITY;INCREASED_LIKELIHOOD
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;TOXICITY;INCREASED_RISK
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*16;*16;TOXICITY;INCREASED_LIKELIHOOD
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*6, NAT2*7;*6/*6 + *6/*7;TOXICITY, LADME_PK;INCREASED_RISK
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;HLA-DRB1;HLA-DRB1*04:03;*04:03;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_RISKEFFICACY
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*4, NAT2*16;*16/*4;TOXICITY, LADME_PK;DECREASED_LIKELIHOOD
PLATINUM COMPOUNDS;SLC31A1;rs10759637;AC;EFFICACY;DECREASED_LIKELIHOODEFFICACY
CAPECITABINE;CDA;rs2072671;AC + CC;TOXICITY;DECREASED_LIKELIHOOD
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16/*7 + *6/*7;TOXICITY;INCREASED_RISK
ISONIAZID;NAT2;NAT2*16;*16;TOXICITY;DECREASED_LIKELIHOOD
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD
OLANZAPINE, RISPERIDONE;DRD2;rs1799732;del;EFFICACY;INCREASED_EFFICACY
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2*4, NAT2*5, NAT2*6, NAT2*7;*5/*6 + *5/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_RISK
OPIOIDS;CYP2A7P1, CYP2B6;rs3745274;GG;TOXICITY;INCREASED_RISK
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;HLA-B;HLA-B*35:03;*35:03;TOXICITY;INCREASED_LIKELIHOOD
PLATINUM COMPOUNDS;SLC31A1;rs4979223;AC;EFFICACY;DECREASED_LIKELIHOODEFFICACY
;CHRNA3;rs1051730;A;OTHER;INCREASED_LIKELIHOOD
RIBAVIRIN, SOFOSBUVIR;ITPA;rs1127354;CC;TOXICITY;INCREASED_LIKELIHOOD
PROTON PUMP INHIBITORS;CYP2C19;CYP2C19 rapid and ultrarapid metabolizer genotypes;;TOXICITY;DECREASED_RISK
ANTINEOPLASTIC AGENTS;TYMS;rs2853539;AG + GG;TOXICITY;INCREASED_LIKELIHOOD
CYCLOPHOSPHAMIDE, DACTINOMYCIN, VINCRISTINE;CYP2B6;rs2279343;AG + GG;EFFICACY;INCREASED_EFFICACY
ANTIPSYCHOTICS;CYP2D6;CYP2D6 poor metabolizer genotype;;TOXICITY;INCREASED_LIKELIHOOD
OMEPRAZOLE;CYP2C19;CYP2C19 normal metabolizers;;LADME_PK;DECREASED_
TAMOXIFEN;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;EFFICACY, TOXICITY;INCREASED_RISK
ANTINEOPLASTIC AGENTS;AKR1C3;rs1937840;G;TOXICITY;DECREASED_LIKELIHOOD
ANTIHYPERTENSIVES;ADIPOQ;rs266729;CG + GG;EFFICACY;INCREASED_SEVERITYEFFICACY
MYCOPHENOLIC ACID, TACROLIMUS;IMPDH1;rs2278293;T;EFFICACY;DECREASED_LIKELIHOOD
GEMCITABINE;CDA;rs2072671;AA;TOXICITY;DECREASED_RISK
ATOMOXETINE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*10, CYP2D6*17;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK
CODEINE;CYP2D6;CYP2D6 poor metabolizers;;TOXICITY;DECREASED_RISK
NICOTINE;CYP2D6;CYP2D6*2xN, CYP2D6*4, CYP2D6*5;*2xN;TOXICITY;INCREASED_RISK
GEMCITABINE;DCK;rs4694362;TT;TOXICITY;INCREASED_RISK
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;RBX1;rs141084494;A;TOXICITY;DECREASED_RISK
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;rs1801280;T;TOXICITY;DECREASED_LIKELIHOOD
PLATINUM COMPOUNDS;SLC31A1;rs4978536;AG + GG;TOXICITY;INCREASED_SEVERITY
OPIOIDS;BDNF-AS;rs11030096;CC + CT;TOXICITY;INCREASED_RISK
IRINOTECAN, PLATINUM COMPOUNDS;NAT2;rs1799930;AA;EFFICACY;INCREASED_EFFICACY
PLATINUM COMPOUNDS;SLC31A1;rs10817464;CC + CT;TOXICITY;INCREASED_SEVERITY
VORICONAZOLE;CYP2C19;CYP2C19 poor metabolizer genotype;;TOXICITY;INCREASED_LIKELIHOOD
PLATINUM COMPOUNDS;SLC31A1;rs4979223;AC;TOXICITY;INCREASED_SEVERITY
COCAINE;SYT1;rs2251214;G;TOXICITY;INCREASED_RISK
AZATHIOPRINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
VALGANCICLOVIR;ABCB1;rs2229109;CT;TOXICITY;INCREASED_RISK
FLUOXETINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;LADME_PK;INCREASED_PK
TETRABENAZINE;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;EFFICACY;
MYCOPHENOLATE MOFETIL;UGT1A9;rs3832043;T;LADME_PK;INCREASED_PK
OLANZAPINE;CYP2C9;CYP2C9 poor metabolizers;;TOXICITY;INCREASED_LIKELIHOOD
"""FOLIC ACID"", ""VITAMIN B-COMPLEX, PLAIN""";MTRR;rs1801394;AA + AG;EFFICACY;DECREASED_SEVERITY
NICOTINE;HTR3B;rs3758987;TT;TOXICITY;INCREASED_SEVERITY
CAPECITABINE;TYMS;rs11280056;TTAAAGTTA;TOXICITY;INCREASED_SEVERITY
CAPECITABINE;DPYD;rs67376798;AT;TOXICITY;INCREASED_SEVERITY
ANTIDEPRESSANTS;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*3/*4 + *4/*4 + *4/*5 + *4/*6;LADME_PK;INCREASED_PK
ENALAPRIL;PCGF3;rs1044147;A;TOXICITY;INCREASED_LIKELIHOOD
TAMOXIFEN;CYP2D6;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*11;*3/*4 + *3/*5 + *3/*6 + *4/*11 + *4/*4 + *4/*5 + *4/*6 + *4/*7 + *5/*5 + *6/*6 + *6/*7;EFFICACY;DECREASED_EFFICACY
PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;*3/*4 + *4/*4 + *4/*5;LADME_PK;INCREASED_PK
TRAMADOL;COMT;rs4680;AA + AG;TOXICITY;INCREASED_SEVERITY
ANTICHOLINERGIC AGENTS;CYP2C19;CYP2C19 poor metabolizers;;LADME_PK;INCREASED_PK
VENLAFAXINE;CYP2D6;CYP2D6 normal metabolizers;;TOXICITY;INCREASED_RISK
ANTINEOPLASTIC AGENTS;ABCG2;rs2231164;CC + CT;EFFICACY;INCREASED_EFFICACY
CITALOPRAM, CLOMIPRAMINE, DULOXETINE, ESCITALOPRAM, FLUOXETINE, FLUVOXAMINE, MIRTAZAPINE, PAROXETINE, SERTRALINE, VENLAFAXINE;CYP2D6;CYP2D6 normal metabolizers;;EFFICACY;DECREASED_EFFICACY
MYCOPHENOLATE MOFETIL;UGT1A9;rs3832043;T;LADME_PK;INCREASED_PK
MYCOPHENOLATE MOFETIL;ABCC2;rs2273697;AG;LADME_PK;INCREASED_PK
CAPECITABINE;DPYD;rs2297595;CT;EFFICACY;DECREASED_EFFICACY
OPIOIDS;OPRM1;rs1799971;GG;TOXICITY;DECREASED_
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*3 + *2/*2 + *3/*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*17 + *17/*17;TOXICITY;INCREASED_RISK
ATENOLOL;PAH;rs2245360;AA;TOXICITY;INCREASED_LIKELIHOOD
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;*3/*4 + *3/*5 + *4/*4 + *4/*5;EFFICACY;INCREASED_RISKEFFICACY
TAMOXIFEN;CYP2D6;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*7;*3/*4 + *3/*5 + *4/*4 + *4/*5 + *4/*7;EFFICACY;INCREASED_LIKELIHOOD
ASPIRIN, CLOPIDOGREL;PON1;rs662;CT + TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY
OPIOIDS;DRD2;rs1125394;CC + CT;TOXICITY;INCREASED_RISK
OPIOIDS;OPRM1;rs1799971;G;TOXICITY;DECREASED_
SORAFENIB;VEGFA;rs3025040;CC;TOXICITY;INCREASED_RISK
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;*5/*10;EFFICACY;DECREASED_EFFICACY
OPIOIDS;DRD2;rs1079596;CT + TT;TOXICITY;INCREASED_RISK
TRAMADOL;COMT;rs4680;AA + AG;TOXICITY;INCREASED_SEVERITY
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;*5/*10;EFFICACY;DECREASED_EFFICACY
EFAVIRENZ;CYP2B6;CYP2B6 poor metabolizer and intermediate metabolizer genotypes;;OTHER;INCREASED_RISK
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCC2;rs3740066;TT;TOXICITY;INCREASED_LIKELIHOOD
AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;TPMT intermediate metabolizers;;TOXICITY;INCREASED_LIKELIHOOD
FLUOROURACIL;TYMS;rs2847153;AG + GG;EFFICACY;DECREASED_LIKELIHOODEFFICACY
MORPHINE;ABCC3;rs4148412;T;TOXICITY;INCREASED_SEVERITY
SORAFENIB;UGT1A9;rs7574296;AA;TOXICITY;INCREASED_RISK
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*1 + *1/*28;TOXICITY;DECREASED_LIKELIHOOD
SORAFENIB;KDR;rs2071559;AA;EFFICACY;DECREASED_EFFICACY
TACROLIMUS;CYP3A5;CYP3A5 intermediate metabolizer and normal metabolizer;;DOSAGE;INCREASED_LIKELIHOOD
TRAMADOL;COMT;rs4680;GG;EFFICACY;INCREASED_SEVERITYEFFICACY
"""FOLIC ACID"", ""VITAMIN B-COMPLEX, PLAIN""";MTHFR;rs1801133;AG + GG;EFFICACY;EFFICACY
AMITRIPTYLINE, CLOMIPRAMINE, DOXEPIN, IMIPRAMINE, TRIMIPRAMINE;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;INCREASED_PK
SORAFENIB;SLC15A2;rs2257212;CC;EFFICACY;DECREASED_EFFICACY
FLUOROURACIL;CCND1;rs9344;AA;EFFICACY;DECREASED_EFFICACY
AZATHIOPRINE;TPMT;TPMT intermediate metabolizer genotype;;TOXICITY;INCREASED_LIKELIHOOD
CAPECITABINE;UMPS;rs2279199;CC + CT;TOXICITY;DECREASED_LIKELIHOOD
METFORMIN;;rs578427;TT;LADME_PK;INCREASED_PK
CAPECITABINE;TYMS;rs2853741;CT + TT;TOXICITY;DECREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;CYP2C19 rapid and ultrarapid metabolizer genotypes;;TOXICITY;INCREASED_LIKELIHOOD
CAPECITABINE;SLC22A7;rs4149178;AG + GG;TOXICITY;DECREASED_LIKELIHOOD
CISPLATIN;ABCC3;rs1051640;G;TOXICITY;INCREASED_RISK
GALANTAMINE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*41;*3/*4 + *4/*4 + *4/*5;LADME_PK;INCREASED_PK
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*35;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;EFFICACY;DECREASED_EFFICACY
CLOPIDOGREL;CYP2C19;CYP2C19 normal metabolizers;;OTHER;DECREASED_RISK
METHOTREXATE;SLC19A1;rs1051266;T;TOXICITY;INCREASED_
CLOPIDOGREL;CYP2C19;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;;EFFICACY;INCREASED_LIKELIHOODEFFICACY
ABT-751;UGT1A4;rs6755571;AC;LADME_PK;DECREASED_PK
CAPECITABINE;UMPS;rs4678145;CC + CG;TOXICITY;INCREASED_LIKELIHOOD
ABT-751;UGT1A8;rs6431558;CC + CT;LADME_PK;INCREASED_PK
IMIPRAMINE;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;INCREASED_PK
ANTINEOPLASTIC AGENTS;DPYD;rs1760217;AA + AG;EFFICACY;DECREASED_EFFICACY
AZATHIOPRINE;TPMT;rs1142345;CC + CT;TOXICITY;INCREASED_RISK
ANTINEOPLASTIC AGENTS;SERPINA3;rs17091162;AC + CC;EFFICACY;DECREASED_EFFICACY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2 + *2/*17;LADME_PK;DECREASED_PK
VALPROIC ACID;CYP2C19;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;;TOXICITY;INCREASED_RISK
ASPIRIN, CLOPIDOGREL;PTGS1;rs10306114;AG + GG;TOXICITY;INCREASED_RISK
METFORMIN;SLC47A2;rs12943590;AA;LADME_PK;INCREASED_PK
TAMOXIFEN;NCOA1;rs1804645;CT;OTHER;INCREASED_SEVERITY
CLOPIDOGREL;CYP2C19;CYP2C19 intermediate metabolizer genotype;;EFFICACY;INCREASED_RISK
CITALOPRAM, ESCITALOPRAM;;rs352428;A;EFFICACY;EFFICACY
CLOPIDOGREL;CYP2C19;CYP2C19 intermediate metabolizer genotype;;EFFICACY;INCREASED_RISK
CITALOPRAM;;rs352428;A;EFFICACY;EFFICACY
CLOPIDOGREL;CYP2C19;CYP2C19 poor metabolizer genotype;;EFFICACY;INCREASED_RISK
MIDAZOLAM;POR;rs1057868;CT;LADME_PK;DECREASED_PK
CLOPIDOGREL;CYP2C19;CYP2C19 poor metabolizer genotype;;EFFICACY;INCREASED_RISK
LENVATINIB;ABCG2;rs2231142;GG;TOXICITY;INCREASED_SEVERITY
NICOTINE;CHRNA3;rs578776;G;LADME_PK;INCREASED_PK
GALANTAMINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*41;*3/*4 + *4/*4 + *4/*5;LADME_PK;INCREASED_PK
TRAZODONE;CYP2D6;CYP2D6 normal metabolizer genotype;;TOXICITY;INCREASED_LIKELIHOOD
CAPECITABINE;DPYD;rs17376848;AG;TOXICITY;INCREASED_SEVERITY
RISPERIDONE;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;TOXICITY;DECREASED_SEVERITY
ASPIRIN, CLOPIDOGREL;CYP2C19;rs4244285;AA;TOXICITY;INCREASED_RISK
LENVATINIB;CYP3A4;rs2242480;C;TOXICITY;INCREASED_SEVERITY
LENVATINIB;CYP3A5;rs776746;C;TOXICITY;INCREASED_SEVERITY
CAPECITABINE;ENOSF1, TYMS;rs699517;TT;TOXICITY;INCREASED_LIKELIHOOD
HEROIN;OPRK1;rs6473797;C;TOXICITY;DECREASED_RISK
HEROIN;CSNK1E;rs1534891;T;TOXICITY;DECREASED_RISK
CAPECITABINE;DPYD;rs12119882;AG;TOXICITY;INCREASED_LIKELIHOOD
ETHANOL;CHRNA5;rs16969968;G;TOXICITY;INCREASED_LIKELIHOOD
HEROIN;GAL;rs694066;A;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *3/*3 + *2/*3;EFFICACY;INCREASED_
HEROIN;OPRD1;rs2236861;A;TOXICITY;INCREASED_RISK
CAPECITABINE;SLC22A7;rs2270860;TT;TOXICITY;INCREASED_LIKELIHOOD
HEROIN;OPRD1;rs3766951;C;TOXICITY;INCREASED_RISK
METHADONE;CRHBP;rs1500;G;OTHER;DECREASED_
METHAMPHETAMINE;FAAH;rs324420;A;OTHER;INCREASED_LIKELIHOOD
ETHANOL;CHRNA3;rs1051730;G;TOXICITY;INCREASED_LIKELIHOOD
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*35;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;EFFICACY;INCREASED_RISKEFFICACY
HEROIN;OPRD1;rs2236857;C;TOXICITY;INCREASED_RISK
NALOXONE;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_EFFICACY
TAMOXIFEN;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;TOXICITY;INCREASED_RISK
CAPECITABINE;ENOSF1, TYMS;rs699517;CT + TT;TOXICITY;DECREASED_LIKELIHOOD
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*1/*1 + *1/*10;TOXICITY;INCREASED_LIKELIHOOD
HEROIN;HTR3B;rs3758987;C;TOXICITY;INCREASED_RISK
METOPROLOL;CYP2D6;CYP2D6 poor metabolizer genotype;;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;TOXICITY;INCREASED_RISK
OSIMERTINIB;ABCG2;rs2231142;GG;TOXICITY;INCREASED_LIKELIHOOD
TAMOXIFEN;CYP2D6;CYP2D6 normal metabolizers;;EFFICACY;INCREASED_EFFICACY
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY
ESCITALOPRAM;HTR2C;rs6318;C;EFFICACY;DECREASED_
OXYCODONE;CYP2D6;CYP2D6 poor metabolizer phenotype;;LADME_PK;DECREASED_PK
OXYCODONE;CYP2D6;CYP2D6 poor metabolizer phenotype;;EFFICACY;DECREASED_EFFICACY
MERCAPTOPURINE;GNMT;rs10948059;CT + TT;TOXICITY;DECREASED_LIKELIHOOD
NICOTINE;CHRNA5;rs16969968;A;TOXICITY;INCREASED_LIKELIHOOD
OXYCODONE;CYP2D6;CYP2D6 poor metabolizer phenotype;;EFFICACY;DECREASED_PK
NICOTINE;CHRNA3;rs1051730;A;TOXICITY;INCREASED_LIKELIHOOD
PAROXETINE;CYP2D6;CYP2D6 normal metabolizers;;OTHER;INCREASED_
IRINOTECAN, PLATINUM COMPOUNDS;NAT2;rs1799931;AA;EFFICACY;DECREASED_EFFICACY
PAROXETINE;CYP2D6;CYP2D6 poor metabolizers;;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;INCREASED_
HEROIN;OPRM1;rs3778151;C;TOXICITY;INCREASED_RISK
ESCITALOPRAM;CYP2D6;CYP2D6 intermediate metabolizers;;LADME_PK;INCREASED_PK
PAROXETINE;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;INCREASED_PK
CAPECITABINE;DPYD;rs1801265;AG + GG;TOXICITY;INCREASED_RISK
PAROXETINE;CYP2D6;CYP2D6 poor metabolizers;;TOXICITY;INCREASED_RISK
FLUOXETINE;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1;LADME_PK;INCREASED_PK
CAPECITABINE;DPYD;rs1801265;AG + GG;TOXICITY;INCREASED_RISK
ALKYLATING AGENTS, CISPLATIN;ESR1;rs2207396;A;TOXICITY;INCREASED_RISK
HEROIN;OPRM1;rs510769;T;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *3/*3 + *2/*3;TOXICITY;INCREASED_RISK
ANTIDEPRESSANTS;CYP2D6;CYP2D6 poor metabolizers;;TOXICITY;INCREASED_RISK
CITALOPRAM;CYP2C19;CYP2C19 poor metabolizers;;EFFICACY;INCREASED_LIKELIHOODEFFICACY
TAMOXIFEN;CYP2D6;CYP2D6 normal metabolizers;*1/*1;EFFICACY;INCREASED_EFFICACY
TAMOXIFEN;CYP2D6;CYP2D6 normal metabolizers;;TOXICITY;INCREASED_LIKELIHOOD
ANTIPSYCHOTICS;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;TOXICITY;INCREASED_RISK
OSIMERTINIB;STAT3;rs4796793;GG;TOXICITY;INCREASED_LIKELIHOOD
ESCITALOPRAM;CYP2D6;rs1065852;AA;EFFICACY;DECREASED_EFFICACY
3,4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2C19;CYP2C19 poor metabolizer genotype;;TOXICITY;INCREASED_SEVERITY
DRUGS FOR TREATMENT OF TUBERCULOSIS;SLCO1B1;rs4149014;GG + GT;TOXICITY;DECREASED_LIKELIHOOD
DOCETAXEL, EPIRUBICIN;;poor metabolizer genotype;;TOXICITY;INCREASED_LIKELIHOOD
;;rs6968865;T;DOSAGE;INCREASED_
SULFAMETHOXAZOLE;GCLC;rs761142;AA;TOXICITY;DECREASED_RISK
AZATHIOPRINE, MERCAPTOPURINE;TPMT;TPMT intermediate metabolizer genotype;;EFFICACY, TOXICITY, LADME_PK;INCREASED_PK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK
;CYP1A1;rs2472297;T;DOSAGE;INCREASED_
SULFAMETHOXAZOLE;GCLC;rs761142;A;TOXICITY;DECREASED_RISK
APIXABAN, DABIGATRAN, EDOXABAN, RIVAROXABAN;CES1;rs2244613;GT + TT;TOXICITY;INCREASED_RISK
TRAMADOL;CYP2D6;CYP2D6 normal metabolizer and ultrarapid metabolizer;;TOXICITY;INCREASED_SEVERITY
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCC2;rs2273697;AG + GG;EFFICACY;INCREASED_EFFICACY
SORAFENIB;KDR;rs1870377;TT;EFFICACY;INCREASED_EFFICACY
TACROLIMUS;CYP3A4;rs35599367;AG;OTHER;INCREASED_PK
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCC2;rs3740066;TT;EFFICACY;DECREASED_EFFICACY
CLOPIDOGREL;PON1;rs662;CC;EFFICACY;DECREASED_EFFICACY
ANTIPSYCHOTICS;CYP2D6;CYP2D6 ultrarapid metabolizer genotype;;TOXICITY;INCREASED_LIKELIHOOD
ISONIAZID;ASTN2;rs117491755;C;TOXICITY;INCREASED_RISK
ALECTINIB;PPARA;rs4253728;AA + AG;TOXICITY;INCREASED_SEVERITY
VALPROIC ACID;SCN1A;rs2298771;TT;EFFICACY;DECREASED_LIKELIHOOD
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_LIKELIHOOD
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*6;TOXICITY;INCREASED_SEVERITY
ATOMOXETINE;CYP2D6;CYP2D6*10;*10/*10;EFFICACY;INCREASED_LIKELIHOOD
CISPLATIN;GSTT1;GSTT1 non-null, GSTT1 null;;TOXICITY;INCREASED_LIKELIHOOD
CISPLATIN;GSTM1;GSTM1 non-null, GSTM1 null;;TOXICITY;DECREASED_LIKELIHOOD
ARIPIPRAZOLE, OLANZAPINE, RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4 + *4/*4;TOXICITY;INCREASED_LIKELIHOOD
CODEINE;ABCB1;rs2032582;AA;TOXICITY, LADME_PK;INCREASED_LIKELIHOOD
ETHANOL;CRHBP;rs10055255;TT;TOXICITY;INCREASED_SEVERITY
SUNITINIB;NR1I2;rs2276707;TT;EFFICACY;DECREASED_EFFICACY
ANTIPSYCHOTICS;DRD2;rs1799732;del;TOXICITY;DECREASED_LIKELIHOOD
LAMOTRIGINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK
OXALIPLATIN;HLA-DRB1;HLA-DRB1*12:01;*12:01;TOXICITY;INCREASED_LIKELIHOOD
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9, CYP2A6*10;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOODEFFICACY
CEFACLOR;HLA-DRB1;HLA-DRB1*14:54;*14:54;TOXICITY;INCREASED_LIKELIHOOD
ETHANOL;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_SEVERITY
SULFASALAZINE;HLA-A;HLA-A*11:01;*11:01;TOXICITY;INCREASED_LIKELIHOOD
SULFASALAZINE;HLA-B;HLA-B*39:01;*39:01;TOXICITY;INCREASED_LIKELIHOOD
SULFASALAZINE;HLA-B;HLA-B*56:03;*56:03;TOXICITY;INCREASED_LIKELIHOOD
METOPROLOL;CYP2D6;CYP2D6*1, CYP2D6*2;*1/*2;EFFICACY;DECREASED_EFFICACY
METHAMPHETAMINE;DAOA;rs778293;C;TOXICITY;INCREASED_LIKELIHOOD
CEFACLOR;HLA-DRB1;HLA-DRB1*04:03;*04:03;TOXICITY;INCREASED_LIKELIHOOD
CEFACLOR;HLA-DRB1;HLA-DRB1*04:03;*04:03;TOXICITY;INCREASED_LIKELIHOOD
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_SEVERITY
ATORVASTATIN, SIMVASTATIN;SLCO1B1;SLCO1B1*15;*15;EFFICACY, TOXICITY;INCREASED_LIKELIHOOD
ATORVASTATIN, SIMVASTATIN;SLCO1B1;SLCO1B1*20;*20;TOXICITY;INCREASED_LIKELIHOOD
ATORVASTATIN, SIMVASTATIN;SLCO1B1;SLCO1B1*37;*37;EFFICACY;DECREASED_LIKELIHOODEFFICACY
ATORVASTATIN, SIMVASTATIN;SLCO1B1;SLCO1B1*5;*5;EFFICACY;INCREASED_SEVERITYEFFICACY
ATORVASTATIN, SIMVASTATIN;SLCO1B1;SLCO1B1*15;*15;EFFICACY;INCREASED_SEVERITYEFFICACY
ATORVASTATIN, SIMVASTATIN;SLCO1B1;SLCO1B1*5;*5;EFFICACY, TOXICITY;INCREASED_LIKELIHOOD
SORAFENIB;KDR;rs2071559;GG;EFFICACY;DECREASED_EFFICACY
ATORVASTATIN, SIMVASTATIN;SLCO1B1;SLCO1B1*15;*15;TOXICITY;INCREASED_LIKELIHOOD
ATORVASTATIN, SIMVASTATIN;SLCO1B1;SLCO1B1*14;*14;EFFICACY;DECREASED_SEVERITYEFFICACY
TACROLIMUS;ABCB1;rs1045642;AG;EFFICACY;INCREASED_RISK
RISPERIDONE;ADRB2;rs1042713;G;TOXICITY;INCREASED_LIKELIHOOD
BECLOMETHASONE, BUDESONIDE, FLUTICASONE, FLUTICASONE PROPIONATE, MOMETASONE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*1x2;*1/*1x2;TOXICITY;INCREASED_SEVERITY
CYTARABINE;GLI1;rs2228224;AA;EFFICACY;DECREASED_EFFICACY
CYTARABINE;ARHGAP9, GLI1;rs2229300;GT + TT;EFFICACY;DECREASED_EFFICACY
CODEINE;ABCB1;rs1128503;A;TOXICITY, LADME_PK;INCREASED_LIKELIHOOD
CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;TYMS;rs45445694;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_RISK
SORAFENIB;KDR;rs1870377;TT;EFFICACY;INCREASED_EFFICACY
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK
CODEINE;ABCB1;rs2032582;AA;TOXICITY, LADME_PK;INCREASED_LIKELIHOOD
CODEINE;ABCB1;rs1045642;A;TOXICITY, LADME_PK;INCREASED_LIKELIHOOD
CLOPIDOGREL, RESPIRATORY SYSTEM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY
;CELSR2, PSRC1;rs602633;T;LADME_PK;PK
COCAINE, ETHANOL, OPIOIDS;OPRM1;rs524731;A;TOXICITY;INCREASED_RISK
ATAZANAVIR, INDINAVIR;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED_LIKELIHOOD
ATAZANAVIR, RITONAVIR;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED_LIKELIHOOD
PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;TOXICITY;INCREASED_RISK
ATAZANAVIR / RITONAVIR;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_LIKELIHOOD
METHOTREXATE;SLCO1B1;rs4149081;G;OTHER, LADME_PK;INCREASED_PK
BETA BLOCKING AGENTS;GRK5;rs2230345;AA;EFFICACY;DECREASED_RISKEFFICACY
VALPROIC ACID;SCN1A;rs10167228;AA;EFFICACY;DECREASED_LIKELIHOOD
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY
TACROLIMUS;ABCB1;rs1045642;AG;EFFICACY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*5;*5;TOXICITY;INCREASED_RISK
MIRTAZAPINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*6;*4/*4 + *4/*6;LADME_PK;INCREASED_PK
TROGLITAZONE;;rs10811661;C;EFFICACY;INCREASED_EFFICACY
PLATINUM COMPOUNDS;ERCC2;rs1799793;CC + CT;TOXICITY;INCREASED_RISK
NEVIRAPINE;CYP2B6;rs3745274;T;LADME_PK;INCREASED_
CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*3;*3;LADME_PK;DECREASED_PK
METHAMPHETAMINE;PICK1;rs713729;T;TOXICITY;INCREASED_LIKELIHOOD
IMATINIB;ABCG2;rs2231142;T;TOXICITY;INCREASED_SEVERITY
CAFFEINE;DRD2;rs1110976;GG;OTHER;DECREASED_
OPIOIDS;;rs4530637;AG + GG;TOXICITY;INCREASED_RISK
NEVIRAPINE;ABCB1;rs1045642;A;TOXICITY;DECREASED_RISK
COCAINE, ETHANOL, OPIOIDS;OPRM1;rs3778156;G;TOXICITY;INCREASED_RISK
;;rs1111875;C;LADME_PK;DECREASED_PK
CISPLATIN;COMT;rs9332377;T;TOXICITY;INCREASED_RISK
FLUOXETINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*6;*4 + *6;LADME_PK;INCREASED_PK
OPIOIDS;TACR3;rs1384401;AG + GG;TOXICITY;INCREASED_RISK
CISPLATIN;COMT;rs4646316;C;TOXICITY;INCREASED_RISK
FOLFIRI;ABCC2;rs2273697;GG;TOXICITY;DECREASED_SEVERITY
CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;LADME_PK;INCREASED_PK
PLATINUM COMPOUNDS;SLC22A2;rs316003;CT + TT;EFFICACY;INCREASED_EFFICACY
METHOTREXATE;ABCC2;rs717620;T;TOXICITY;INCREASED_RISK
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;EFFICACY;INCREASED_EFFICACY
METHAMPHETAMINE;PICK1;rs713729;T;OTHER;INCREASED_LIKELIHOOD
OPIOIDS;CYP2D6;rs1065852;AA;TOXICITY;INCREASED_RISK
FOLFIRI;ABCC2;rs1885301;AA;TOXICITY;INCREASED_SEVERITY
CITALOPRAM, ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;LADME_PK;INCREASED_PK
OPIOIDS;DRD3;rs6280;CC + CT;TOXICITY;INCREASED_RISK
HYDROCHLOROTHIAZIDE;;rs17137967;CC + CT;TOXICITY;INCREASED_
;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;*4/*4 + *4/*7 + *4/*9 + *7/*7 + *7/*9 + *9/*9;OTHER;DECREASED_SEVERITY
OPIOIDS;DRD3;rs324029;AA + AG;TOXICITY;INCREASED_RISK
TAMOXIFEN;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;TOXICITY;DECREASED_SEVERITY
OPIOIDS;EXOC4;rs718656;TT;TOXICITY;INCREASED_RISK
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs4646244;A;TOXICITY, LADME_PK;INCREASED_RISK
AMISULPRIDE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE, ZIPRASIDONE, ZUCLOPENTHIXOL;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;TOXICITY;INCREASED_RISK
NICOTINE;CHRNB2;rs2072660;T;OTHER;INCREASED_SEVERITY
DIRECT ACTING ANTIVIRALS;IFNL4;rs11322783;GG;EFFICACY;DECREASED_EFFICACY
PLATINUM COMPOUNDS;APLF;rs3213239;CCGG/CCGG + CCGG/del;EFFICACY;DECREASED_EFFICACY
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs8099917;GG;EFFICACY;EFFICACY
ATAZANAVIR / RITONAVIR;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOODEFFICACY
PLATINUM COMPOUNDS;ERCC2;rs50872;GG;TOXICITY;INCREASED_RISK
PLATINUM COMPOUNDS;ABCG2;rs1448784;GG;EFFICACY;DECREASED_EFFICACY
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1799930;A;TOXICITY, LADME_PK;INCREASED_RISK
NICOTINE;CHRNB2;rs2072661;A;OTHER;INCREASED_SEVERITY
CODEINE, HYDROCODONE, OXYCODONE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*3/*3 + *4/*4;TOXICITY;DECREASED_RISK
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*1 + *1/*28;TOXICITY;DECREASED_SEVERITY
BOCEPREVIR, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY
PLATINUM COMPOUNDS;ERCC1;rs11615;AA + AG;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-B;HLA-B*15:11;*15:11;TOXICITY;INCREASED_RISK
HYDROXYCHLOROQUINE;CYP2C8;rs10882526;GG;TOXICITY;INCREASED_RISK
OPIUM ALKALOIDS AND DERIVATIVES;CHRNA5;rs660652;GG;TOXICITY;INCREASED_
METHAMPHETAMINE;;rs1421292;T;TOXICITY;INCREASED_LIKELIHOOD
ACE INHIBITORS, PLAIN;ABO;rs495828;GT + TT;TOXICITY;
AMITRIPTYLINE, CLOMIPRAMINE, DOXEPIN, IMIPRAMINE, MAPROTILINE, NORTRIPTYLINE, OPIPRAMOL;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;TOXICITY;INCREASED_RISK
GLICLAZIDE;KCNJ11;rs5219;CT + TT;EFFICACY;INCREASED_EFFICACY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1 + *17;EFFICACY;DECREASED_
PLATINUM COMPOUNDS;ABCB1;rs1128503;AA;TOXICITY;INCREASED_RISK
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2;slow_acetylator;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK
OPIOIDS;ZNF804A;rs7597593;CC;TOXICITY;INCREASED_RISK
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;LADME_PK;DECREASED_PK
OPIUM ALKALOIDS AND DERIVATIVES;CHRNA3;rs1051730;AA;TOXICITY;INCREASED_SEVERITY
HYDROXYCHLOROQUINE;CYP3A5;rs776746;TT;TOXICITY;INCREASED_RISK
PLATINUM COMPOUNDS;IL16;rs7170924;GT + TT;TOXICITY;INCREASED_RISK
INDOMETHACIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;EFFICACY;INCREASED_LIKELIHOODEFFICACY
;CHRNA3;rs1051730;AA + AG;OTHER;INCREASED_LIKELIHOOD
NEVIRAPINE;HLA-B;HLA-B*15:10;*15:10;TOXICITY;DECREASED_RISK
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*17;*2 + *3 + *8;EFFICACY;INCREASED_RISKEFFICACY
ASPIRIN;TBXA2R;rs1131882;A;EFFICACY, TOXICITY;INCREASED_RISK
OPIOIDS;CNR1;rs2023239;TT;TOXICITY;INCREASED_RISK
;NQO1;rs1800566;AA;OTHER;
BUSULFAN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;LADME_PK;INCREASED_PK
PLATINUM COMPOUNDS;ABCB1;rs1128503;AA;TOXICITY;INCREASED_RISK
METFORMIN;SLC29A4;rs3889348;G;TOXICITY;INCREASED_SEVERITY
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_SEVERITY
FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_SEVERITY
;NQO1;rs1800566;A;TOXICITY;INCREASED_RISK
HYDROCHLOROTHIAZIDE;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED_EFFICACY
DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTM1;GSTM1 null;;TOXICITY;INCREASED_RISK
DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTT1;GSTT1 null;;TOXICITY;INCREASED_RISK
OPIOIDS;CNR1;rs6928499;CC;TOXICITY;INCREASED_RISK
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;*5/*10;EFFICACY;DECREASED_EFFICACY
NEVIRAPINE;CYP2B6;rs58425034;CC + CG;OTHER;INCREASED_LIKELIHOOD
FLUOROURACIL;TYMS;rs11280056;TTAAAGTTA/TTAAAGTTA;EFFICACY;DECREASED_
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2;EFFICACY;INCREASED_RISK
DOCETAXEL, THALIDOMIDE;CHST3;rs4148945;C;TOXICITY;INCREASED_RISK
"""FOLIC ACID"", ""VITAMIN B-COMPLEX, PLAIN""";MTHFR;rs1801133;AG + GG;EFFICACY;DECREASED_SEVERITY
CARBAMAZEPINE;HLA-B;HLA-B*51:01;*51:01;TOXICITY;INCREASED_RISK
DOCETAXEL, THALIDOMIDE;SLC10A2;rs2301159;A;TOXICITY;INCREASED_RISK
AXITINIB, SORAFENIB;HIF1A;rs11549465;CT;EFFICACY;DECREASED_EFFICACY
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;TYMS;rs11280056;TTAAAGTTA/TTAAAGTTA;EFFICACY;INCREASED_RISKEFFICACY
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;TOXICITY, LADME_PK;INCREASED_RISK
METHOTREXATE;SLC19A1;rs1051266;CC + CT;EFFICACY;INCREASED_SEVERITY
SORAFENIB;KDR;rs2071559;AA;EFFICACY;DECREASED_EFFICACY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;EFFICACY;DECREASED_EFFICACY
NICOTINE;DBH;rs77905;AA + AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
METHOTREXATE;ADORA2A;rs2298383;GG;TOXICITY;INCREASED_RISK
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;*5/*10;EFFICACY;DECREASED_EFFICACY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;OTHER;INCREASED_
RISPERIDONE;CYP2D6;rs3892097;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
;CYP2B6;rs3211371;TT;OTHER;INCREASED_LIKELIHOOD
;CYP2B6;rs3211371;CT;OTHER;INCREASED_LIKELIHOOD
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*3 + *4 + *5 + *10 + *41;EFFICACY;DECREASED_EFFICACY
FLUOXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);TOXICITY;INCREASED_RISK
IRINOTECAN;UGT1A1;rs4124874;G;TOXICITY;INCREASED_RISK
;CYP24A1;rs2762939;C;OTHER;DECREASED_RISK
OPIUM ALKALOIDS AND DERIVATIVES;CHRNA5;rs16969968;A;TOXICITY;INCREASED_SEVERITY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*3;TOXICITY;INCREASED_RISK
MORPHINE;ABCC3;rs739923;G;TOXICITY;INCREASED_SEVERITY
CITALOPRAM;PAPLN;rs11628713;T;TOXICITY;INCREASED_RISK
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;TOXICITY;INCREASED_LIKELIHOOD
SULFONAMIDES, UREA DERIVATIVES;KCNJ11;rs5219;CT + TT;EFFICACY;INCREASED_EFFICACY
FLUOXETINE;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN;LADME_PK;DECREASED_PK
IMATINIB;SLC22A1;rs1867351;TT;TOXICITY;INCREASED_LIKELIHOOD
FLUOROURACIL, LEUCOVORIN;ERCC2;rs13181;GG + GT;EFFICACY;INCREASED_RISKEFFICACY
VERAPAMIL;KCNIP1, KCNMB1;rs11739136;CT + TT;EFFICACY;EFFICACY
OPIOIDS;DRD3;rs9288993;AG + GG;TOXICITY;INCREASED_RISK
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_EFFICACY
OSIMERTINIB;CYP2C9;rs1057910;AC;EFFICACY;DECREASED_EFFICACY
OPIOIDS;DRD3;rs2654754;AG + GG;TOXICITY;INCREASED_RISK
OPIOIDS;ZNF568;rs10405238;G;TOXICITY;INCREASED_SEVERITY
ANTIEPILEPTICS;HLA-B;HLA-B*53:01;*53:01;TOXICITY;INCREASED_LIKELIHOOD
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD
PENICILLIN G;HLA-DPB1;HLA-DPB1*05:01;*05:01;TOXICITY;INCREASED_LIKELIHOOD
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_LIKELIHOOD
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED_LIKELIHOOD
APIXABAN, DABIGATRAN, EDOXABAN, RIVAROXABAN;ABCB1;rs3842;CC;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY
METFORMIN;AMHR2;rs784892;G;LADME_PK;DECREASED_PK
MYCOPHENOLATE MOFETIL;SLCO1B3;rs4149117;GG;LADME_PK;INCREASED_PK
CLOPIDOGREL;CYP2C19;CYP2C19;intermediate_metabolizer;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*9, CYP2C19*13, CYP2C19*17;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;EFFICACY;INCREASED_RISKEFFICACY
ASPIRIN, CLOPIDOGREL;PON1;rs662;CT + TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY
OPIOIDS;OPRM1;rs1799971;AA;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*4, CYP2C19*17;*2 + *4;OTHER;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*8;*8;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*5;*5;TOXICITY;INCREASED_RISK
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2;*2;EFFICACY;INCREASED_LIKELIHOODEFFICACY
ATEZOLIZUMAB, DURVALUMAB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB;HLA-A;HLA-A*26:01;*26:01;TOXICITY;INCREASED_LIKELIHOOD
CARBOPLATIN, GEMCITABINE;RRM1;rs9937;GG;TOXICITY;RISK_
ETHANOL;OPRM1;rs1799971;AA;TOXICITY;INCREASED_SEVERITY
METFORMIN;SLC22A1;rs628031;A;TOXICITY, LADME_PK;
OPIOIDS;GABRB3;rs4906902;AA;TOXICITY;INCREASED_RISK
AMITRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4;OTHER, LADME_PK;INCREASED_PK
AMITRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*10;*10;OTHER, LADME_PK;INCREASED_PK
BECLOMETHASONE DIPROPIONATE, FLUTICASONE PROPIONATE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY
AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*3 + *2/*3;LADME_PK;INCREASED_PK
MYCOPHENOLATE MOFETIL;SLCO1B3;rs7311358;AA;LADME_PK;INCREASED_PK
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, SOFOSBUVIR;IFNL3, IFNL4;rs12979860;TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY
ISONIAZID, RIFAMPIN;HLA-DPB1;HLA-DPB1*05:01;*05:01;TOXICITY;INCREASED_LIKELIHOOD
ISONIAZID, RIFAMPIN;HLA-A;HLA-A*11:01;*11:01;TOXICITY;INCREASED_LIKELIHOOD
ETHANOL;DRD2;rs1799732;GG;TOXICITY;INCREASED_SEVERITY
SALBUTAMOL;THRB;rs892940;A;EFFICACY;INCREASED_EFFICACY
OPIOIDS;TACR1;rs735668;AA;TOXICITY;INCREASED_RISK
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*9, CYP2D6*10, CYP2D6*35, CYP2D6*41;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;EFFICACY;DECREASED_EFFICACY
ASPIRIN, CLOPIDOGREL;ABCB1;rs1045642;AA + AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
ASPIRIN, CLOPIDOGREL;ABCB1;rs1045642;AA + AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
APIXABAN, DABIGATRAN, EDOXABAN, RIVAROXABAN;APOB;rs13306198;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;EFFICACY;INCREASED_RISKEFFICACY
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;EFFICACY;DECREASED_EFFICACY
OPIOIDS;OPRM1;rs510769;CC;TOXICITY;INCREASED_RISK
ETHANOL;OPRM1;rs1799971;G;TOXICITY;INCREASED_RISK
FIRST-GENERATION CEPHALOSPORINS, FOURTH-GENERATION CEPHALOSPORINS, OTHER CEPHALOSPORINS, THIRD-GENERATION CEPHALOSPORINS;HLA-B;HLA-B*55:02;*55:02;TOXICITY;INCREASED_LIKELIHOOD
AMOXICILLIN;HLA-B;HLA-B*15:01;*15:01;TOXICITY;INCREASED_LIKELIHOOD
"""METFORMIN"", ""SULFONAMIDES, UREA DERIVATIVES""";SLC22A1;rs72552763;GAT/del;EFFICACY;INCREASED_LIKELIHOOD
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*4;*4;TOXICITY;DECREASED_RISK
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*6, NAT2*7, NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;TOXICITY, LADME_PK;INCREASED_RISK
FIRST-GENERATION CEPHALOSPORINS, FOURTH-GENERATION CEPHALOSPORINS, OTHER CEPHALOSPORINS, THIRD-GENERATION CEPHALOSPORINS;HLA-C;HLA-C*01:02;*01:02;TOXICITY;INCREASED_SEVERITY
FIRST-GENERATION CEPHALOSPORINS, FOURTH-GENERATION CEPHALOSPORINS, OTHER CEPHALOSPORINS, THIRD-GENERATION CEPHALOSPORINS;HLA-DQB1;HLA-DQB1*06:09;*06:09;TOXICITY;INCREASED_LIKELIHOOD
INFLIXIMAB;HLA-DQA1;HLA-DQA1*05;*05;EFFICACY;INCREASED_LIKELIHOODEFFICACY
NICOTINE;CYP2A13;rs72552266;CT;TOXICITY;INCREASED_SEVERITY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_EFFICACY
CYCLOPHOSPHAMIDE;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6;*1/*3 + *1/*6 + *3/*3 + *3/*6;TOXICITY;INCREASED_SEVERITY
;UGT1A1;UGT1A1*28;*28;OTHER;INCREASED_LIKELIHOOD
DOXORUBICIN;GSTT1;GSTT1 non-null, GSTT1 null;;TOXICITY;INCREASED_LIKELIHOOD
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;HLA-DQB1;HLA-DQB1*03:01;*03:01;TOXICITY;INCREASED_LIKELIHOOD
IRINOTECAN;UGT1A1;rs4148323;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;EFFICACY;INCREASED_LIKELIHOODEFFICACY
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6 + *6/*6;TOXICITY;INCREASED_SEVERITY
FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*28/*28 + *6/*6 + *6/*28;TOXICITY;INCREASED_SEVERITY
FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6 + *6/*6;TOXICITY;INCREASED_SEVERITY
FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED_SEVERITY
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY
SACITUZUMAB GOVITECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED_LIKELIHOOD
FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*28/*28 + *6/*6 + *6/*28;TOXICITY;INCREASED_SEVERITY
FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED_SEVERITY
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_SEVERITY
FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28 + *1/*28;TOXICITY;INCREASED_SEVERITY
FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28 + *1/*28;TOXICITY;INCREASED_LIKELIHOOD
SUNITINIB;KDR;rs1870377;TT;EFFICACY;DECREASED_EFFICACY
IRINOTECAN;UGT1A1;UGT1A1*6, UGT1A1*28;*28 + *6;TOXICITY;INCREASED_LIKELIHOOD
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28;TOXICITY;INCREASED_LIKELIHOOD
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*6/*6;TOXICITY;INCREASED_LIKELIHOOD
FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*1/*28 + *28/*28 + *1/*6 + *6/*6 + *6/*28;TOXICITY;INCREASED_SEVERITY
MIRABEGRON;CYP2D6;CYP2D6;intermediate_metabolizer;TOXICITY;INCREASED_LIKELIHOOD
MIRABEGRON;SLCO1B1;SLCO1B1 deficiency;;TOXICITY;INCREASED_LIKELIHOOD
TRAMADOL;CYP2D6;CYP2D6;ultrarapid_metabolizer;EFFICACY;DECREASED_SEVERITYEFFICACY
METHOTREXATE;MTR;rs3768142;GG;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_LIKELIHOOD
CARBAMAZEPINE;HLA-B;HLA-B*15:01;*15:01;TOXICITY;INCREASED_LIKELIHOOD
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_LIKELIHOOD
AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *3A/*3C;TOXICITY, LADME_PK;INCREASED_PK
CISPLATIN;GSTT1;GSTT1 non-null, GSTT1 null;non-null;TOXICITY;INCREASED_RISK
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;NAT2*4, NAT2*5, NAT2*6, NAT2*7, NAT2*16;*4;TOXICITY;DECREASED_RISK
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C + *3A/*3A;DOSAGE;INCREASED_LIKELIHOOD
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8;*2 + *3 + *8;EFFICACY;DECREASED_RISKEFFICACY
TACROLIMUS;CYP3A4;rs4646437;AG + GG;LADME_PK;INCREASED_PK
DIHYDROPYRIDINE DERIVATIVES;RYR3;rs877087;TT;EFFICACY;INCREASED_RISKEFFICACY
;CYP4A11;rs1126742;AG + GG;LADME_PK;DECREASED_PK
CODEINE;CYP2D6;CYP2D6*1, CYP2D6*1x2, CYP2D6*2, CYP2D6*2x2, CYP2D6*2xN, CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*41, CYP2D6*41x2;*1/*1x2  + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9;OTHER;INCREASED_LIKELIHOOD
TICAGRELOR;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *3/*17;TOXICITY;INCREASED_LIKELIHOOD
PEMETREXED;SLC19A1;rs914232;TT;EFFICACY;DECREASED_EFFICACY
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*6 + *28;TOXICITY;INCREASED_SEVERITY
FLUOROURACIL, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*1/*28 + *28/*28 + *6/*6;TOXICITY;INCREASED_SEVERITY
FLUOROURACIL, IRINOTECAN;DPYD;DPYD c.1627A>G (*5);c.1627A>G (*5);TOXICITY;INCREASED_SEVERITY
CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;LADME_PK;INCREASED_PK
PEMETREXED;SLC19A1;rs1051298;AA + AG;EFFICACY;DECREASED_EFFICACY
RISPERIDONE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*4;*1/*1 + *1/*2;TOXICITY;INCREASED_LIKELIHOOD
CETUXIMAB;FCGR2A;rs1801274;GG;EFFICACY;INCREASED_EFFICACY
AMOXICILLIN, AMPICILLIN, BACAMPICILLIN;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED_RISK
METHAMPHETAMINE;DRD3;rs6280;CC + CT;TOXICITY;INCREASED_RISK
NICOTINE;CYP2A6;CYP2A6 low activity;;OTHER;DECREASED_RISK
VINCRISTINE;ACTN1;rs2268979;T;TOXICITY;DECREASED_LIKELIHOOD
CAPECITABINE, FLUOROURACIL;UPB1;rs2070474;GG;TOXICITY;INCREASED_SEVERITY
PEMETREXED;MTHFR;rs1801133;AA + AG;EFFICACY;DECREASED_EFFICACY
CAPECITABINE, FLUOROURACIL, FOLFIRI, FOLFIRINOX, FOLFOX;DPYD;DPYD c.2194G>A (*6);c.2194G>A (*6);TOXICITY;INCREASED_LIKELIHOOD
VINCRISTINE;PAPPA;rs12235805;A;TOXICITY;DECREASED_LIKELIHOOD
CAPECITABINE, FLUOROURACIL;UPB1;rs2070474;GG;TOXICITY;DECREASED_SEVERITY
CAPECITABINE, FLUOROURACIL;DPYD;rs1801265;AA + AG;TOXICITY;INCREASED_RISK
PEMETREXED;SLC19A1;rs3788189;GG + GT;EFFICACY;DECREASED_EFFICACY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2;EFFICACY;INCREASED_LIKELIHOODEFFICACY
NICOTINE;ANKK1, DRD2;rs1800497;AA + AG;TOXICITY;DECREASED_SEVERITY
CAPECITABINE, FLUOROURACIL, FOLFOX;DPYD;DPYD c.1129-5923C>G, c.1236G>A (HapB3), DPYD c.1679T>G (*13), DPYD c.2846A>T;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);TOXICITY;INCREASED_RISK
AMITRIPTYLINE, ANTIDEPRESSANTS, CLOMIPRAMINE, DESIPRAMINE, FLUOXETINE, IMIPRAMINE, NORTRIPTYLINE, PAROXETINE, VENLAFAXINE;CYP2D6;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK
SIROLIMUS;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_
FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*28/*28 + *1/*28 + *1/*6 + *6/*28;TOXICITY;INCREASED_SEVERITY
FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*1/*1;TOXICITY;DECREASED_SEVERITY
ATOMOXETINE;CYP2D6;CYP2D6;poor_metabolizer;TOXICITY;INCREASED_LIKELIHOOD
VINCRISTINE;NRG3;rs12253008;T;TOXICITY;DECREASED_LIKELIHOOD
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*28/*28 + *6/*6 + *6/*28;EFFICACY;DECREASED_EFFICACY
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;*1/*3A + *1/*3B + *1/*3C + *3A/*3B;TOXICITY;INCREASED_LIKELIHOOD
MERCAPTOPURINE, METHOTREXATE;TPMT;TPMT;intermediate_metabolizer;TOXICITY;INCREASED_LIKELIHOOD
VINCRISTINE;LRRTM3;rs10997459;G;TOXICITY;DECREASED_LIKELIHOOD
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C;TOXICITY;INCREASED_SEVERITY
VINCRISTINE;ARHGAP5;rs8006511;G;TOXICITY;DECREASED_LIKELIHOOD
MERCAPTOPURINE, METHOTREXATE;TPMT;TPMT normal metabolizer;;EFFICACY;INCREASED_RISKEFFICACY
NICOTINE;CYP2A6;rs28399433;CC;TOXICITY;DECREASED_SEVERITY
VINCRISTINE;METTL8;rs79802223;G;TOXICITY;DECREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY
;UGT1A1;rs4148325;CT;LADME_PK;DECREASED_LIKELIHOOD
;UGT1A1;rs11888492;G;LADME_PK;DECREASED_LIKELIHOOD
NALOXONE;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_EFFICACY
CISPLATIN;CERS6;rs13022792;T;TOXICITY;INCREASED_LIKELIHOOD
CISPLATIN;TLR4;rs10759932;C;TOXICITY;DECREASED_LIKELIHOOD
VINCRISTINE;NFIB;rs10961381;G;TOXICITY;DECREASED_LIKELIHOOD
ANTIARRHYTHMICS, CLASS I AND III;;rs10033464;GT + TT;EFFICACY;INCREASED_EFFICACY
VINCRISTINE;MCM3AP;rs1815857;T;TOXICITY;INCREASED_LIKELIHOOD
VINCRISTINE;SPDYA;rs12474420;T;TOXICITY;DECREASED_LIKELIHOOD
VINCRISTINE;PDE4D;rs12658429;C;TOXICITY;DECREASED_LIKELIHOOD
VINCRISTINE;FBN2;rs12656510;T;TOXICITY;DECREASED_LIKELIHOOD
VINCRISTINE;VTI1A;rs17129858;T;TOXICITY;DECREASED_LIKELIHOOD
VINCRISTINE;ZFAND3;rs200858088;C;TOXICITY;DECREASED_LIKELIHOOD
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;HLA-DRB1;HLA-DRB1*11:01;*11:01;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;TOXICITY;INCREASED_RISKEFFICACY
MYCOPHENOLATE MOFETIL, PREDNISONE, TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;OTHER;INCREASED_LIKELIHOOD
SIROLIMUS;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_
ACETAMINOPHEN / CODEINE;CYP2D6;CYP2D6;poor_metabolizer;TOXICITY;DECREASED_SEVERITY
RASBURICASE;G6PD;G6PD deficiency;;TOXICITY;INCREASED_LIKELIHOOD
NEVIRAPINE;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*6 + *6/*6;TOXICITY;DECREASED_LIKELIHOOD
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*6 + *6/*6;TOXICITY;INCREASED_LIKELIHOOD
SIROLIMUS;ABCB1;rs1128503;AA;TOXICITY;INCREASED_
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD
RISPERIDONE;CYP2D6;CYP2D6;poor_metabolizer;TOXICITY;INCREASED_LIKELIHOOD
ISONIAZID;NAT2;NAT2*5, NAT2*6, NAT2*7;*5/*7 + *5/*6 + *6/*6;TOXICITY;INCREASED_LIKELIHOOD
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;TOXICITY;INCREASED_LIKELIHOOD
ADALIMUMAB, AMIODARONE, BEVACIZUMAB, BICALUTAMIDE, CARBOPLATIN, CYCLOPHOSPHAMIDE, DOCETAXEL, ERLOTINIB, EVEROLIMUS, FLUOROURACIL, GEFITINIB, GEMCITABINE, IRINOTECAN, LEUCOVORIN, METHOTREXATE, OXALIPLATIN, PACLITAXEL, PEMBROLIZUMAB, SITAGLIPTIN, TEGAFUR / GIMERACIL / OTERACIL, TRASTUZUMAB;HLA-DRB1;HLA-DRB1*04:05;*04:05;TOXICITY;INCREASED_RISK
TAMSULOSIN;CYP2D6;CYP2D6;intermediate_metabolizer;TOXICITY;INCREASED_LIKELIHOOD
ANASTROZOLE, EXEMESTANE, LETROZOLE;CCDC148;rs79048288;CT + TT;TOXICITY;DECREASED_LIKELIHOOD
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK
PEMETREXED;DHFR;rs1650697;AA + AG;TOXICITY;INCREASED_RISK
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*3/*3 + *3/*6 + *3/*7 + *6/*6 + *6/*7 + *7/*7;EFFICACY;EFFICACY
TACROLIMUS;CYP2C8;CYP2C8*1, CYP2C8*3;*1/*1;EFFICACY;EFFICACY
FLUOROURACIL, FOLFIRI, FOLFOX;DPYD;DPYD c.85T>C (*9A);c.85T>C (*9A)/c.85T>C (*9A);TOXICITY;INCREASED_LIKELIHOOD
LACOSAMIDE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD
FLUOROURACIL, FOLFIRI, FOLFOX;DPYD;DPYD c.1627A>G (*5);c.1627A>G (*5)/c.1627A>G (*5);TOXICITY;DECREASED_LIKELIHOOD
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK
ASPIRIN;PTGS2;rs12042763;GG;EFFICACY;DECREASED_RISK
METHOTREXATE;SLCO1B1;SLCO1B1*1, SLCO1B1*15, SLCO1B1*37;*37/*37 + *37/*15;TOXICITY;DECREASED_LIKELIHOOD
;CYP2A6;rs56267346;G;OTHER;DECREASED_LIKELIHOOD
;DBH;rs6479643;C;OTHER;DECREASED_LIKELIHOOD
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*6, NAT2*7, NAT2*16;*16 + *6 + *7;TOXICITY, LADME_PK;INCREASED_RISK
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD
ISONIAZID;NAT2;NAT2*1, NAT2*4, NAT2*5, NAT2*6, NAT2*7, NAT2*14, NAT2*16;*16 + *5 + *6 + *7 + *14;TOXICITY;INCREASED_LIKELIHOOD
FLURBIPROFEN, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*36;*1/*36;EFFICACY;DECREASED_EFFICACY
ISONIAZID, RIFAMPIN;NAT2;NAT2*1, NAT2*5, NAT2*6, NAT2*7, NAT2*14;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;EFFICACY;DECREASED_LIKELIHOODEFFICACY
IRINOTECAN;UGT1A1;rs4148323;A;TOXICITY;INCREASED_LIKELIHOOD
;CASP9;rs1052576;T;EFFICACY;INCREASED_SEVERITYEFFICACY
CAPECITABINE, FLUOROURACIL;DPYD;rs1801265;AA + AG;TOXICITY;DECREASED_
IRINOTECAN;UGT1A1;rs4148323;A;TOXICITY;INCREASED_LIKELIHOOD
CYCLOSPORINE, METHOTREXATE;SLC19A1;rs1051266;CC;EFFICACY;DECREASED_RISK
CYCLOSPORINE, METHOTREXATE;ATIC;rs17514110;CC;EFFICACY;INCREASED_RISK
CYCLOSPORINE, METHOTREXATE;NFATC2;rs3787186;TT;EFFICACY;INCREASED_RISK
CYCLOSPORINE, METHOTREXATE;ABCC2;rs3740065;AA;EFFICACY;INCREASED_RISK
CETUXIMAB;FCGR3A;rs396991;CC;EFFICACY;INCREASED_EFFICACY
CYCLOSPORINE, METHOTREXATE;ABCC1;rs8058040;AA;EFFICACY;INCREASED_RISK
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-A;HLA-A*24:02;*24:02;TOXICITY;INCREASED_LIKELIHOOD
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD
ATAZANAVIR, EFAVIRENZ;TPH2;rs7305115;GG;TOXICITY;INCREASED_SEVERITY
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-A;HLA-A*01:02;*01:02;TOXICITY;INCREASED_LIKELIHOOD
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-B;HLA-B*52:01;*52:01;TOXICITY;INCREASED_LIKELIHOOD
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-DRB1;HLA-DRB1*03:01;*03:01;TOXICITY;INCREASED_LIKELIHOOD
ATAZANAVIR, EFAVIRENZ;TPH2;rs1386493;GG;TOXICITY;INCREASED_SEVERITY
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-DRB1;HLA-DRB1*13:01;*13:01;TOXICITY;INCREASED_LIKELIHOOD
CAPECITABINE;ENOSF1;rs2612091;TT;EFFICACY;INCREASED_EFFICACY
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-A;HLA-A*02:01;*02:01;TOXICITY;DECREASED_LIKELIHOOD
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-B;HLA-B*40:02;*40:02;TOXICITY;INCREASED_LIKELIHOOD
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-A;HLA-A*31:03;*31:03;TOXICITY;DECREASED_LIKELIHOOD
CARBOPLATIN, PACLITAXEL;OPRM1;rs544093;GG + GT;EFFICACY;DECREASED_EFFICACY
MYCOPHENOLATE MOFETIL;IMPDH1;rs2228075;T;EFFICACY, TOXICITY;INCREASED_LIKELIHOOD
CAPECITABINE, FLUOROURACIL;DPYD;rs1801160;CT + TT;TOXICITY;INCREASED_RISK
ISONIAZID;NAT2;NAT2;slow_acetylator;TOXICITY;INCREASED_LIKELIHOOD
ERLOTINIB, GEFITINIB;USP36;rs3744797;CC;EFFICACY;INCREASED_LIKELIHOODEFFICACY
OSIMERTINIB;HLA-B;HLA-B*51:02;*51:02;TOXICITY;INCREASED_LIKELIHOOD
DEXMEDETOMIDINE;CACNB2;rs10764319;CT;TOXICITY;DECREASED_LIKELIHOOD
DEXMEDETOMIDINE;CACNA2D2;rs2236957;AA;TOXICITY;DECREASED_LIKELIHOOD
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2;slow_acetylator;TOXICITY;INCREASED_LIKELIHOOD
DEXMEDETOMIDINE;UGT2B10;rs1841042;AA;TOXICITY;DECREASED_LIKELIHOOD
DEXMEDETOMIDINE;ADRA2B;rs3813662;AA + CC;TOXICITY;INCREASED_LIKELIHOOD
METHYLPHENIDATE;CES1;rs2307227;T;TOXICITY;INCREASED_LIKELIHOOD
PURINE ANALOGUES;NUDT15;NUDT15*1, NUDT15*3;*1/*3;TOXICITY;INCREASED_RISK
CLOPIDOGREL;THSD7A;rs7807369;G;EFFICACY;INCREASED_LIKELIHOODEFFICACY
CLOPIDOGREL;;rs1149515;C;EFFICACY;INCREASED_LIKELIHOODEFFICACY
ONDANSETRON;CYP2D6;CYP2D6 normal metabolizer;;EFFICACY;INCREASED_LIKELIHOODEFFICACY
;ERAP2;rs17524572;TT;TOXICITY;INCREASED_LIKELIHOOD
MYCOPHENOLATE MOFETIL;UGT1A8;rs1042597;CC;TOXICITY;INCREASED_RISK
PEMBROLIZUMAB;HLA-DRB1;HLA-DRB1*13:01;*13:01;EFFICACY;DECREASED_LIKELIHOODEFFICACY
PEMBROLIZUMAB;HLA-DPB1;HLA-DPB1*02:02;*02:02;TOXICITY;INCREASED_LIKELIHOOD
CAPECITABINE, FLUOROURACIL;DPYD;rs1801158;CT;TOXICITY;INCREASED_RISK
MORPHINE;SLC22A1;rs72552763;del/del;TOXICITY;INCREASED_LIKELIHOOD
DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTM1;GSTM1 non-null, GSTM1 null;;TOXICITY;INCREASED_LIKELIHOOD
;CASP9;rs4661636;C;EFFICACY;INCREASED_SEVERITYEFFICACY
;CASP8;rs6736233;G;EFFICACY;INCREASED_LIKELIHOODEFFICACY
CLOZAPINE;LEPR;rs6657868;AG + GG;TOXICITY;INCREASED_RISK
CLOZAPINE;CYP1A2;rs762551;AA;TOXICITY;INCREASED_RISK
CISPLATIN, PACLITAXEL;GGT1;rs2017869;CC;TOXICITY;DECREASED_LIKELIHOOD
CISPLATIN;TPMT;rs12201199;T;TOXICITY;INCREASED_RISK
;UGT1A1;rs4148323;A;OTHER;INCREASED_LIKELIHOOD
CLOZAPINE;LEPR, LEPROT;rs1137101;AA;TOXICITY;INCREASED_RISK
DOLUTEGRAVIR;NR1I2;rs2472677;CT + TT;TOXICITY;DECREASED_LIKELIHOOD
CISPLATIN;TPMT;rs1800460;T;TOXICITY;INCREASED_RISK
CLOZAPINE;LEPR;rs1805096;GG;TOXICITY;INCREASED_RISK
CLOZAPINE;LEPR;rs9436746;AC + CC;TOXICITY;INCREASED_RISK
RISPERIDONE;DRD2;rs1800497;AA + AG;TOXICITY;INCREASED_SEVERITY
;UGT1A1;rs35350960;A;OTHER;INCREASED_LIKELIHOOD
CISPLATIN;TPMT;rs1142345;C;TOXICITY;INCREASED_RISK
WARFARIN;ASPH;rs4379440;T;EFFICACY;DECREASED_EFFICACY
CARBOPLATIN, PACLITAXEL;SLCO1B3;rs7311358;AA;TOXICITY;DECREASED_LIKELIHOOD
ASPIRIN, CLOPIDOGREL, TICAGRELOR;PEAR1;rs12041331;AA + AG;TOXICITY;INCREASED_RISK
CAPECITABINE, FLUOROURACIL;DPYD;rs67376798;AT;TOXICITY;INCREASED_
METHOTREXATE;MTHFR;rs1801131;G;TOXICITY;INCREASED_LIKELIHOOD
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs1127354;AC;TOXICITY;INCREASED_RISK
HMG COA REDUCTASE INHIBITORS;CETP;rs3764261;A;EFFICACY, LADME_PK;INCREASED_
PYRIMIDINE ANALOGUES;MTHFR;rs1801133;AA + AC;;INCREASED_EFFICACY
METHOTREXATE;ITPA;rs1127354;A;TOXICITY;
GEFITINIB;ABCB1;rs1128503;AA;TOXICITY;INCREASED_LIKELIHOOD
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;CTLA4;rs231775;A;EFFICACY;INCREASED_EFFICACY
CAFFEINE;;rs4410790;T;OTHER;
LIRAGLUTIDE;GLP1R;rs6923761;AA + AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
METHAMPHETAMINE;ESR1;rs2234693;CC;TOXICITY;INCREASED_LIKELIHOOD
;ABCG8;rs11887534;CG;OTHER;INCREASED_RISK
PLATINUM;ERCC5;rs17655;GG;EFFICACY;INCREASED_EFFICACY
PLATINUM;ERCC5;rs17655;GG;EFFICACY;DECREASED_EFFICACY
RISPERIDONE;HTR2C;rs3813929;T;TOXICITY;DECREASED_LIKELIHOOD
PACLITAXEL;FGD4;rs10771973;A;TOXICITY;INCREASED_RISK
CAFFEINE;CYP1A1;rs2470893;T;OTHER;
CITALOPRAM;SLC6A4;rs25531;C;TOXICITY;INCREASED_LIKELIHOOD
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;SOCS3;rs4969170;AG;TOXICITY;DECREASED_RISK
MIDAZOLAM;POR;rs1057868;TT;OTHER, LADME_PK;INCREASED_PK
ENALAPRIL;PNPT1;rs13009649;G;TOXICITY;DECREASED_LIKELIHOOD
METHOTREXATE;ITPA;rs1127354;A;EFFICACY;EFFICACY
NICOTINE;HTR3B;rs11606194;CT + TT;TOXICITY;INCREASED_SEVERITY
ASPIRIN;SLC6A12;rs499368;A;TOXICITY;INCREASED_LIKELIHOOD
GEFITINIB;ABCB1;rs1045642;AA;TOXICITY;INCREASED_LIKELIHOOD
WARFARIN;CYP4F2;rs2189784;GG;EFFICACY;DECREASED_EFFICACY
ASPIRIN;SLC6A12;rs557881;G;TOXICITY;INCREASED_LIKELIHOOD
PLATINUM COMPOUNDS;WIF1;rs10878232;GG + GT;EFFICACY;DECREASED_EFFICACY
ANTIEPILEPTICS;ABCB1;rs1045642;G;EFFICACY;INCREASED_LIKELIHOODEFFICACY
ANTHRACYCLINES AND RELATED SUBSTANCES;CBR3;rs1056892;AG;TOXICITY;INCREASED_RISK
PLATINUM COMPOUNDS;WNT5B;rs12819505;AG + GG;EFFICACY;DECREASED_EFFICACY
PLATINUM COMPOUNDS;AXIN2;rs4541111;AA + AC;EFFICACY;INCREASED_EFFICACY
MERCAPTOPURINE, METHOTREXATE;PACSIN2;rs2413739;T;TOXICITY;INCREASED_
MERCAPTOPURINE;SLCO1B1;rs11045879;T;TOXICITY;INCREASED_
MERCAPTOPURINE, METHOTREXATE;ITPA;rs1127354;CC;EFFICACY;INCREASED_EFFICACY
PLATINUM COMPOUNDS;CXXC4;rs4413407;AA + AG;EFFICACY;DECREASED_EFFICACY
ENALAPRIL;PNPT1;rs13015243;C;TOXICITY;DECREASED_LIKELIHOOD
AZATHIOPRINE, MERCAPTOPURINE, THIOGUANINE;;rs11969064;T;TOXICITY;INCREASED_RISK
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;T;EFFICACY;INCREASED_EFFICACY
PLATINUM COMPOUNDS;ERCC2;rs13181;GG;TOXICITY;INCREASED_LIKELIHOOD
PLATINUM COMPOUNDS;ERCC2;rs1799793;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
DOXORUBICIN;NCF4;rs1883112;AA + AG;TOXICITY;INCREASED_RISK
AMPHETAMINE;DRD2;rs12364283;AA;EFFICACY;DECREASED_
ANTIEPILEPTICS;ABCB1;rs1045642;AA;EFFICACY;INCREASED_LIKELIHOODEFFICACY
ANTIEPILEPTICS;ABCB1;rs1045642;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
PAROXETINE;HTR2A;rs6313;GG;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CD80;rs34394661;AA;EFFICACY;INCREASED_LIKELIHOODEFFICACY
MYCOPHENOLATE MOFETIL;UGT1A9;rs6714486;A;LADME_PK;PK
CARBAMAZEPINE;;rs1633021;TT;TOXICITY;INCREASED_LIKELIHOOD
PLATINUM COMPOUNDS;AXIN2;rs11868547;CC + CG;EFFICACY;INCREASED_EFFICACY
MYCOPHENOLATE MOFETIL;UGT1A9;rs17868320;T;LADME_PK;PK
MORPHINE;ABCB1;rs1045642;GG;TOXICITY;DECREASED_LIKELIHOOD
CYCLOSPORINE, MYCOPHENOLATE MOFETIL;UGT1A8;rs1042597;CC;TOXICITY;INCREASED_RISK
TACROLIMUS;IL10;rs1800871;AA;LADME_PK;INCREASED_LIKELIHOODPK
METHOTREXATE;ARID5B;rs4948496;CC + CT;TOXICITY;INCREASED_RISK
;CYP2B6;rs3760657;AA;OTHER;DECREASED_LIKELIHOOD
FOLLITROPIN BETA, THYROTROPIN ALFA, UROFOLLITROPIN;FSHR;rs6166;T;EFFICACY, LADME_PK;EFFICACY
ASPIRIN, CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY, OTHER;INCREASED_RISK
;UGT2B10;rs11726322;CC;OTHER;INCREASED_LIKELIHOOD
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;rs6025;T;TOXICITY;INCREASED_RISK
ASPIRIN, CLOPIDOGREL;CYP2C19;rs12248560;CT + TT;EFFICACY, OTHER;DECREASED_RISK
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F2;rs1799963;A;TOXICITY;INCREASED_RISK
CLOPIDOGREL;ABCB1;rs1045642;AG;EFFICACY;INCREASED_EFFICACY
CAPECITABINE, FLUOROURACIL;TYMP;rs11479;AA + AG;TOXICITY;INCREASED_RISK
WARFARIN;CYP4F2;rs2108622;CT + TT;LADME_PK;INCREASED_PK
CAPECITABINE, FLUOROURACIL;DPYD;rs67376798;AT;TOXICITY;INCREASED_RISK
CAPECITABINE, FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_RISK
CAPECITABINE, FLUOROURACIL;DPYD;rs75017182;CG;TOXICITY;INCREASED_RISK
ALENDRONATE;VDR;rs1544410;CC;EFFICACY;INCREASED_EFFICACY
FENOFIBRATE;PPARA;rs135543;TT;EFFICACY;INCREASED_EFFICACY
FENOFIBRATE;PPARA;rs9626730;CC + CT;EFFICACY;DECREASED_EFFICACY
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;DECREASED_
;VDR;rs1544410;CC;;DECREASED_EFFICACY
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_RISK
FENOFIBRATE;PPARA;rs135550;TT;EFFICACY;INCREASED_EFFICACY
ALENDRONATE;VDR;rs1544410;CC;EFFICACY;DECREASED_EFFICACY
EXEMESTANE;CYP19A1;rs7176005;TT;TOXICITY;
TACROLIMUS;PPARA;rs4253728;GG;TOXICITY;DECREASED_LIKELIHOOD
VINCRISTINE;SLC5A7;rs1013940;AG + GG;TOXICITY;INCREASED_RISK
ETHANOL;ADH1B;rs1229984;T;TOXICITY;INCREASED_LIKELIHOOD
VINCRISTINE;NKAIN3;rs10504361;A;TOXICITY;INCREASED_RISK
SIMVASTATIN;SLCO1B1;rs4149056;C;TOXICITY;INCREASED_LIKELIHOOD
ATENOLOL;PROX1;rs340874;C;TOXICITY;INCREASED_
TACROLIMUS;CYP3A4;rs35599367;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
ABEMACICLIB, PALBOCICLIB, RIBOCICLIB;ABCB1;rs1128503;AA;TOXICITY;INCREASED_LIKELIHOOD
SIMVASTATIN;ABCG2;rs2231142;GT;TOXICITY;INCREASED_LIKELIHOOD
VINCRISTINE;ABCC1;rs3784867;T;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;rs4244285;AG;EFFICACY;INCREASED_RISKEFFICACY
OPIOIDS;COMT;rs4680;AA + AG;TOXICITY;DECREASED_LIKELIHOOD
OPIOIDS;IL6;rs1800795;CG + GG;TOXICITY;DECREASED_LIKELIHOOD
FLUOROURACIL;DPYD;rs67376798;A;TOXICITY;INCREASED_SEVERITY
SUNITINIB;CYP3A5;rs776746;CT + TT;EFFICACY;INCREASED_EFFICACY
ABEMACICLIB, PALBOCICLIB, RIBOCICLIB;CYP3A4;rs35599367;AG;TOXICITY;INCREASED_LIKELIHOOD
VINCRISTINE;CEP72;rs924607;TT;TOXICITY;INCREASED_RISK
METOPROLOL;CYP2D6;rs1065852;GG;EFFICACY;DECREASED_EFFICACY
CONJUGATED ESTROGENS, MEDROXYPROGESTERONE;VDR;rs1544410;TT;EFFICACY;INCREASED_
VERAPAMIL;CACNB2;rs2357928;GG;EFFICACY, TOXICITY;INCREASED_RISKEFFICACY
METFORMIN;SLC47A1;rs2252281;CC;EFFICACY;INCREASED_EFFICACY
TACROLIMUS;CYP3A5;rs4646450;A;TOXICITY;INCREASED_LIKELIHOOD
METFORMIN;SLC47A1;rs2252281;CC;EFFICACY;INCREASED_EFFICACY
TRAZODONE;ABCB1;rs1045642;AA;TOXICITY;INCREASED_LIKELIHOOD
INTERFERONS, RIBAVIRIN;BCL2;rs1800477;T;EFFICACY;INCREASED_EFFICACY
CETUXIMAB, FLUOROURACIL, IRINOTECAN, OXALIPLATIN;KRAS;rs112445441;T;EFFICACY;INCREASED_EFFICACY
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MSH6;rs3136228;GG;TOXICITY;INCREASED_SEVERITY
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;XRCC3;rs1799794;CC;TOXICITY;INCREASED_SEVERITY
;NR1I2;rs7643645;GG;OTHER;INCREASED_RISK
PLATINUM COMPOUNDS;CCND1;rs9344;AA;TOXICITY;INCREASED_SEVERITY
VERAPAMIL;CACNB2;rs11014166;AT + TT;EFFICACY, TOXICITY;INCREASED_RISKEFFICACY
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ABCC1;rs2074087;C;TOXICITY;DECREASED_SEVERITY
FLUOROURACIL;;rs2960436;AA;EFFICACY;
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ABCC2;rs1885301;AA;TOXICITY;INCREASED_SEVERITY
FLUOROURACIL;IGFBP3;rs2854744;TT;EFFICACY;
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ABCC2;rs717620;TT;TOXICITY;INCREASED_SEVERITY
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ABCC2;rs3740066;TT;TOXICITY;INCREASED_SEVERITY
COCAINE;DRD2;rs1125394;C;TOXICITY;INCREASED_RISK
COCAINE;DRD2;rs1076560;A;TOXICITY;INCREASED_RISK
COCAINE;DRD2;rs2283265;A;TOXICITY;INCREASED_RISK
MYCOPHENOLATE MOFETIL;SLCO1B1;rs4149015;A;TOXICITY;INCREASED_RISK
TACROLIMUS;CYP3A5;rs4646453;CC;TOXICITY;INCREASED_LIKELIHOOD
TACROLIMUS;CYP3A5;rs776746;CC;EFFICACY;INCREASED_RISKEFFICACY
MYCOPHENOLATE MOFETIL;SLCO1B1;rs4149056;TT;TOXICITY, LADME_PK;INCREASED_RISK
OPIOIDS;COMT;rs4633;CC;TOXICITY;INCREASED_LIKELIHOOD
MYCOPHENOLATE MOFETIL;SLCO1B1;rs4149056;C;TOXICITY, LADME_PK;DECREASED_RISK
ACETAMINOPHEN / TRAMADOL;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_LIKELIHOOD
;VDR;rs2228570;AA + AG;;DECREASED_EFFICACY
OPIOIDS;COMT;rs4633;CT;TOXICITY;INCREASED_LIKELIHOOD
CAPECITABINE;ABCB1;rs1128503;AA;TOXICITY;DECREASED_RISK
OPIOIDS;OPRM1;rs1799971;G;TOXICITY;DECREASED_LIKELIHOOD
CAPECITABINE;ABCB1;rs2032582;CC;TOXICITY;INCREASED_RISK
OPIOIDS;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_LIKELIHOOD
FLUOROURACIL;ABCB1;rs1045642;GG;TOXICITY;DECREASED_RISK
CAPECITABINE;ABCB1;rs1045642;GG;TOXICITY;INCREASED_RISK
WARFARIN;CYP2C9;rs7900194;A;DOSAGE, LADME_PK;
SUNITINIB;NR1I2;rs3814055;TT;EFFICACY;DECREASED_EFFICACY
AMPHETAMINE;OPRM1;rs510769;TT;OTHER;DECREASED_
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK
SUNITINIB;ABCG2;rs2231137;CT;EFFICACY;INCREASED_EFFICACY
;LRP5;rs3736228;T;;DECREASED_
CISPLATIN;NHLH1;rs11265375;CT + TT;EFFICACY;INCREASED_EFFICACY
;;rs4355801;A;;DECREASED_
;;rs4355801;A;;INCREASED_RISK
;LRP5;rs3736228;T;;INCREASED_RISK
BORTEZOMIB;CBS;rs915854;TT;TOXICITY;INCREASED_LIKELIHOOD
;UGT2B15;rs3100;AA;OTHER;INCREASED_LIKELIHOOD
AMPHETAMINE;OPRM1;rs2281617;CC;OTHER;INCREASED_
WARFARIN;HNF4A;rs6130615;CC;TOXICITY;INCREASED_RISK
CISPLATIN;SEMA6A;rs3806915;A;EFFICACY;INCREASED_EFFICACY
ASPIRIN, CLOPIDOGREL;ABCB1;rs1045642;AA;EFFICACY, OTHER;INCREASED_RISK
WARFARIN;HNF4A;rs1884613;GG;TOXICITY;INCREASED_RISK
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY
ASPIRIN, CLOPIDOGREL;ITGB3;rs5918;CC + CT;EFFICACY, OTHER;DECREASED_RISK
WARFARIN;HNF4A;rs3212191;TT;TOXICITY;INCREASED_RISK
ONDANSETRON;SLC6A4;rs1042173;AA;EFFICACY;INCREASED_EFFICACY
WARFARIN;;rs61162043;G;OTHER;INCREASED_LIKELIHOOD
RISPERIDONE;HTR2A;rs6313;GG;TOXICITY;DECREASED_SEVERITY
HEROIN;OPRM1;rs2075572;G;TOXICITY;INCREASED_RISK
RISPERIDONE;;rs1805054;TT;TOXICITY;DECREASED_SEVERITY
ANTIHYPERTENSIVES;NEDD4L;rs4149601;AA;EFFICACY;INCREASED_LIKELIHOODEFFICACY
ANTIHYPERTENSIVES;ADRB1;rs1801252;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
FLUOROURACIL;MTHFR;rs1801133;AA + AG;TOXICITY;DECREASED_RISK
RISPERIDONE;HTR2C;rs3813929;CT + TT;TOXICITY;DECREASED_SEVERITY
HEROIN;OPRM1;rs1799971;G;TOXICITY;INCREASED_RISK
BLEOMYCIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE, RITUXIMAB, VINCRISTINE, VINDESINE;ABCB1;rs2229109;CT;TOXICITY;INCREASED_RISK
CYCLOPHOSPHAMIDE;CYP2B6;rs4802101;C;TOXICITY;DECREASED_RISK
ANTIHYPERTENSIVES;CYP3A5, ZSCAN25;rs776746;CC;EFFICACY;DECREASED_LIKELIHOODEFFICACY
CISPLATIN;XPC;rs2228001;GG + GT;TOXICITY;INCREASED_RISK
METHADONE;OPRM1;rs1799971;G;OTHER;DECREASED_LIKELIHOOD
;CYP2C9;rs1057910;C;;DECREASED_RISK
;CYP2C9;rs1057910;C;;INCREASED_RISK
SUFENTANIL;CYP3A4;rs2242480;TT;TOXICITY;INCREASED_LIKELIHOOD
;ADRA2A;rs3750625;A;OTHER;INCREASED_LIKELIHOOD
;ADRA2A;rs11195418;G;OTHER;DECREASED_LIKELIHOOD
MURAGLITAZAR;REN;rs2368564;TT;TOXICITY;DECREASED_RISK
CHLOROQUINE, PRIMAQUINE;SLCO2B1;rs12422149;GG;EFFICACY;INCREASED_SEVERITYEFFICACY
ASPIRIN;IL4;rs2243250;TT;OTHER;DECREASED_
ANTIPSYCHOTICS;CNR1;rs806374;CC;TOXICITY;INCREASED_LIKELIHOOD
WARFARIN;CYP2C9;rs1057910;AC + CC;TOXICITY;INCREASED_LIKELIHOOD
METHOTREXATE;SLC16A7;rs3763980;A;EFFICACY;INCREASED_RISKEFFICACY
METFORMIN;AMHR2;rs784892;G;EFFICACY;DECREASED_EFFICACY
ACETAMINOPHEN, ASPIRIN, DICLOFENAC, PROPIONIC ACID DERIVATIVES, PYRAZOLONES;PLA2G4A;rs12746200;G;TOXICITY;INCREASED_RISK
ANTIPSYCHOTICS;CNR1;rs806374;CC;TOXICITY;INCREASED_SEVERITY
WARFARIN;VKORC1;rs9923231;TT;EFFICACY;EFFICACY
FLUOROURACIL;DPYD;rs75017182;C;TOXICITY;INCREASED_SEVERITY
ETHANOL;OPRM1;rs1799971;AA;TOXICITY;INCREASED_RISK
NEVIRAPINE;CYCSP5;rs3099844;A;TOXICITY, OTHER;INCREASED_RISK
ACETAMINOPHEN, ASPIRIN, DICLOFENAC, PROPIONIC ACID DERIVATIVES, PYRAZOLONES;PLCG1;rs2228246;G;TOXICITY;INCREASED_RISK
ACETAMINOPHEN, ASPIRIN, DICLOFENAC, PROPIONIC ACID DERIVATIVES, PYRAZOLONES;TNFRSF11A;rs1805034;C;TOXICITY;INCREASED_RISK
ANTIHYPERTENSIVES;NOS3;rs1799983;G;EFFICACY;INCREASED_LIKELIHOODEFFICACY
ANTIHYPERTENSIVES;NOS3;rs2070744;C;EFFICACY;INCREASED_LIKELIHOODEFFICACY
METHOTREXATE;ABCB1;rs1045642;AG;TOXICITY;INCREASED_LIKELIHOOD
;ADRA2A;rs1800038;A;OTHER;INCREASED_LIKELIHOOD
TACROLIMUS;CYP3A5;rs776746;T;TOXICITY;INCREASED_LIKELIHOOD
CISPLATIN;SLC22A1;rs683369;CG + GG;EFFICACY;INCREASED_EFFICACY
NICOTINE;;rs4887074;G;TOXICITY;DECREASED_RISK
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;ABCC5;rs10937158;T;TOXICITY;DECREASED_RISK
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;ABCC5;rs3749438;A;TOXICITY;INCREASED_RISK
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;ABCG1;rs225440;T;TOXICITY;INCREASED_RISK
CLOPIDOGREL;PON1;rs854552;CC;EFFICACY;INCREASED_EFFICACY
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;;rs2292997;A;TOXICITY;INCREASED_RISK
CISPLATIN;PPARD;rs2038067;AG + GG;EFFICACY;DECREASED_EFFICACY
TACROLIMUS;CYP3A5;rs6977165;C;TOXICITY;INCREASED_LIKELIHOOD
CYCLOPHOSPHAMIDE;CYP2C19;rs4244285;A;TOXICITY;DECREASED_RISK
WARFARIN;VKORC1;rs9923231;CT;TOXICITY;INCREASED_RISK
WARFARIN;VKORC1;rs9923231;T;EFFICACY;INCREASED_EFFICACY
FLUOROURACIL;DPYD;rs3918290;CT + TT;TOXICITY;INCREASED_SEVERITY
;OPRM1;rs1799971;AA;TOXICITY;INCREASED_SEVERITY
FLUOROURACIL;DPYD;rs3918290;CT + TT;TOXICITY;INCREASED_SEVERITY
FLUOROURACIL;DPYD;rs3918290;CT + TT;TOXICITY;INCREASED_SEVERITY
FLUOROURACIL;DPYD;rs17376848;G;TOXICITY;INCREASED_RISK
OPIOIDS;CYP3A5;rs776746;CC + CT;TOXICITY;INCREASED_RISK
ACETAMINOPHEN / TRAMADOL;MIR107;rs2296616;AA + AG;TOXICITY;DECREASED_LIKELIHOOD
LITHIUM;GSK3B;rs334558;AA;EFFICACY;DECREASED_EFFICACY
CYCLOPHOSPHAMIDE, DOXORUBICIN, EPIRUBICIN, FLUOROURACIL, METHOTREXATE;NQO1;rs1800566;AA;TOXICITY;DECREASED_RISK
ACETAMINOPHEN / TRAMADOL;MIR23B;rs1011784;GG;TOXICITY;INCREASED_LIKELIHOOD
ACETAMINOPHEN / TRAMADOL;MIR23B;rs1011784;CG + GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
OPIOIDS;CYP1A2;rs2069514;AA + AG;TOXICITY;DECREASED_RISK
OPIOIDS;DRD3;rs2654754;AA + AG;TOXICITY;INCREASED_RISK
SIMVASTATIN;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED_RISK
OPIOIDS;DRD3;rs324029;AG + GG;TOXICITY;INCREASED_RISK
METHAMPHETAMINE;FAAH;rs324420;A;TOXICITY;INCREASED_RISK
OPIOIDS;CYP3A4;rs2740574;CC + CT;TOXICITY;DECREASED_RISK
RISPERIDONE;ABCG2;rs2231142;GT + TT;TOXICITY;INCREASED_RISK
ASPIRIN;UGT1A6;rs1105879;AC + CC;EFFICACY;INCREASED_RISK
ACETAMINOPHEN / TRAMADOL;OPRM1;rs677830;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
OPIOIDS;CYP3A5;rs15524;AA + AG;TOXICITY;INCREASED_RISK
REGORAFENIB;KDR;rs4864950;A;TOXICITY;INCREASED_RISK
EFAVIRENZ, ETHAMBUTOL, ISONIAZID, RIFAMPIN;NR1I2;rs2472677;TT;TOXICITY;INCREASED_LIKELIHOOD
WARFARIN;VKORC1;rs9923231;TT;TOXICITY;INCREASED_RISK
EFAVIRENZ, ETHAMBUTOL, ISONIAZID, RIFAMPIN;NR1I2;rs2472677;TT;TOXICITY;INCREASED_SEVERITY
CYCLOPHOSPHAMIDE, DOXORUBICIN;ABCB1;rs2032582;AA + TT;TOXICITY;INCREASED_RISK
TAXANES;NR1I3;rs11584174;CC;TOXICITY;DECREASED_LIKELIHOOD
ATAZANAVIR, RITONAVIR;UGT1A1;rs8330;G;OTHER;INCREASED_RISK
CYCLOPHOSPHAMIDE, DOXORUBICIN;ABCB1;rs2032582;AC + CT;TOXICITY;INCREASED_RISK
EFAVIRENZ;CYP2B6;rs28399499;TT;TOXICITY;INCREASED_RISK
NEVIRAPINE;ABCB1;rs10276036;TT;TOXICITY;INCREASED_RISK
TAXANES;UGT2B7;rs7438284;AA;TOXICITY;DECREASED_LIKELIHOOD
ATAZANAVIR, RITONAVIR;UGT1A1;rs10929303;T;OTHER;INCREASED_RISK
TAXANES;UGT2B7;rs7439366;TT;TOXICITY;DECREASED_LIKELIHOOD
ATAZANAVIR, RITONAVIR;UGT1A1;rs1042640;G;OTHER;INCREASED_RISK
TAXANES;UGT2B7;rs7662029;AA;TOXICITY;DECREASED_LIKELIHOOD
TAXANES;UGT2B7;rs7668258;TT;TOXICITY;DECREASED_LIKELIHOOD
EFAVIRENZ;CYP2B6;rs3745274;TT;TOXICITY;INCREASED_RISK
ANTIPSYCHOTICS;GRM3;rs1468412;TT;TOXICITY;INCREASED_RISK
ASPIRIN, CLOPIDOGREL;PON1;rs662;CT + TT;EFFICACY;INCREASED_EFFICACY
WARFARIN;VKORC1;rs9923231;TT;TOXICITY;INCREASED_RISK
RISPERIDONE;BDNF;rs6265;TT;TOXICITY;DECREASED_SEVERITY
CORTICOSTEROIDS;FCER2;rs28364072;G;EFFICACY;INCREASED_LIKELIHOOD
FLUOROURACIL, RADIOTHERAPY;CXCL8;rs4073;AA;EFFICACY;DECREASED_RISK
METHOTREXATE;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
FLUOROURACIL, RADIOTHERAPY;KDR;rs1870377;AA;TOXICITY;RISK_
PEGINTERFERON ALFA-2B, RIBAVIRIN;IL6;rs1800795;CC;TOXICITY;DECREASED_RISK
ATORVASTATIN;CYP7A1;rs3808607;TT;EFFICACY;INCREASED_EFFICACY
CANGRELOR;P2RY12;rs6787801;G;OTHER;
;APOC1, APOE;rs445925;A;LADME_PK;PK
SUNITINIB;FGFR2;rs2981582;AA;EFFICACY;DECREASED_EFFICACY
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;rs1799931;A;TOXICITY;INCREASED_RISK
SUNITINIB;FLT4;rs307826;CC + CT;EFFICACY;DECREASED_
HEROIN;OPRM1;rs1799971;AG + GG;TOXICITY;DECREASED_RISK
SUNITINIB;NR1I3;rs2307424;AA + AG;EFFICACY;DECREASED_
;FADS1, FEN1, MIR611, TMEM258;rs174541;T;LADME_PK;PK
;;rs258494;C;LADME_PK;PK
;LDLR;rs6511720;T;OTHER;PK
;PNMT;rs2934965;T;OTHER;DECREASED_RISK
FLUOROURACIL, LEUCOVORIN, LEVAMISOLE, RADIOTHERAPY;GSTP1;rs1695;GG;EFFICACY;DECREASED_EFFICACY
DEXAMETHASONE, LENALIDOMIDE;ABCB1;rs2229109;CT;EFFICACY;INCREASED_LIKELIHOODEFFICACY
AZATHIOPRINE;DDRGK1, ITPA;rs1127354;AC;EFFICACY;INCREASED_LIKELIHOODEFFICACY
;PNMT;rs2941523;GG;OTHER;DECREASED_RISK
MYCOPHENOLIC ACID;SLCO1B3;rs4149117;GT + TT;EFFICACY;INCREASED_RISK
;PNMT;rs876493;AA + AG;OTHER;DECREASED_RISK
ATENOLOL, BISOPROLOL;ACY3;rs2514036;C;EFFICACY;DECREASED_SEVERITYEFFICACY
LOSARTAN;KIRREL2, NPHS1;rs3814995;T;EFFICACY;DECREASED_SEVERITYEFFICACY
ASPIRIN;ADORA1;rs16851030;TT;TOXICITY;INCREASED_RISK
ANTINEOPLASTIC AGENTS;FPGS;rs1544105;TT;TOXICITY;DECREASED_LIKELIHOOD
SUNITINIB;NR1I3;rs4073054;AA;EFFICACY;DECREASED_EFFICACY
SUNITINIB;FLT4;rs307821;AA + AC;EFFICACY;DECREASED_EFFICACY
ALPRAZOLAM;CYP3A4;rs35599367;AG;TOXICITY;INCREASED_RISK
MYCOPHENOLIC ACID;SLCO1B3;rs7311358;AG + GG;EFFICACY;INCREASED_RISK
MYCOPHENOLIC ACID;SLCO1B3;rs7311358;AG + GG;EFFICACY;DECREASED_LIKELIHOOD
SUNITINIB;ABCB1;rs1128503;AG + GG;EFFICACY;INCREASED_EFFICACY
OLANZAPINE;CYP1A1;rs2472297;T;LADME_PK;PK
MYCOPHENOLIC ACID;SLCO1B3;rs4149117;GT + TT;EFFICACY;INCREASED_RISK
BEVACIZUMAB, CAPECITABINE, CETUXIMAB, OXALIPLATIN;MGAT4A;rs885036;G;EFFICACY;INCREASED_
OPIOIDS;ADGRV1;rs2366929;C;TOXICITY;INCREASED_RISK
BEVACIZUMAB, CAPECITABINE, OXALIPLATIN;MGAT4A;rs885036;G;EFFICACY;DECREASED_
CLOPIDOGREL;FMO3;rs1736557;AA;EFFICACY;DECREASED_RISKEFFICACY
MYCOPHENOLIC ACID;SLCO1B3;rs4149117;GT + TT;EFFICACY;DECREASED_LIKELIHOOD
IRINOTECAN;UGT1A1;rs10929302;AA;TOXICITY;INCREASED_RISK
ASPIRIN, CLOPIDOGREL;PEAR1;rs2644592;G;EFFICACY;EFFICACY
ASPIRIN, CLOPIDOGREL;PEAR1;rs11264580;C;EFFICACY;EFFICACY
BUPROPION, NICOTINE;APOE;rs429358;CC + CT;OTHER;INCREASED_LIKELIHOOD
ASPIRIN, CLOPIDOGREL;PEAR1;rs57731889;TT;EFFICACY;EFFICACY
ALENDRONATE, IBANDRONATE, RISEDRONATE, ZOLEDRONATE;SIRT1;rs932658;A;TOXICITY;DECREASED_LIKELIHOOD
VALPROIC ACID;LEPR;rs1137101;AG + GG;TOXICITY;INCREASED_SEVERITY
ANTINEOPLASTIC AGENTS;GSTM5;rs3754446;C;TOXICITY;INCREASED_LIKELIHOOD
ATORVASTATIN, BEZAFIBRATE;APOE;rs449647;AT + TT;EFFICACY;INCREASED_EFFICACY
HALOPERIDOL;SLC6A5;rs2298826;AA;TOXICITY;
OLANZAPINE;AHR;rs4410790;T;LADME_PK;PK
CLOPIDOGREL;P2RY12;rs6785930;AA + AG;TOXICITY;INCREASED_RISK
ASPIRIN, CLOPIDOGREL;PEAR1;rs3737224;T;EFFICACY;EFFICACY
ASPIRIN, CLOPIDOGREL;CYP4F2;rs3093135;T;EFFICACY;INCREASED_LIKELIHOOD
ETHANOL;OPRM1;rs1799971;G;TOXICITY;INCREASED_SEVERITY
VENLAFAXINE;CYP2D6;rs5030655;del;LADME_PK;PK
ASPIRIN, TICAGRELOR;CYP4F2;rs3093135;T;EFFICACY;INCREASED_LIKELIHOOD
CLOPIDOGREL;P2RY12;rs6809699;AA + AC;TOXICITY;INCREASED_RISK
CISPLATIN, DOXORUBICIN;CASP3;rs2720376;C;EFFICACY;INCREASED_EFFICACY
ACE INHIBITORS, PLAIN;XPNPEP2;rs3788853;A;TOXICITY;INCREASED_LIKELIHOOD
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs59502379;C;TOXICITY;INCREASED_LIKELIHOOD
CAPECITABINE;CES1;rs2244613;GG + GT;TOXICITY;INCREASED_SEVERITY
NEVIRAPINE;CCHCR1;rs1265112;C;TOXICITY;INCREASED_RISK
CISPLATIN, DOXORUBICIN;CYP3A4;rs4646437;A;EFFICACY;INCREASED_EFFICACY
;GLI1;rs2228226;CC;EFFICACY;DECREASED_EFFICACY
NICOTINE;ANKK1, DRD2;rs1800497;AA + AG;TOXICITY;INCREASED_SEVERITY
VALPROIC ACID;UGT1A6;rs2070959;AG + GG;TOXICITY;INCREASED_LIKELIHOOD
ESCITALOPRAM;CYP1A2;rs4646425;T;TOXICITY;INCREASED_
CLOZAPINE;ACKR1;rs2814778;CC;TOXICITY;INCREASED_LIKELIHOOD
ESCITALOPRAM;;rs2069521;A;TOXICITY;INCREASED_
ASPIRIN, CLOPIDOGREL;PEAR1;rs41273215;T;EFFICACY;EFFICACY
ESCITALOPRAM;CYP1A2;rs4646427;C;TOXICITY;INCREASED_
ESCITALOPRAM;;rs2069521;A;TOXICITY;INCREASED_
ESCITALOPRAM;CYP1A2;rs4646425;T;TOXICITY;INCREASED_
ESCITALOPRAM;CYP1A2;rs4646427;C;TOXICITY;INCREASED_
ALLOPURINOL;CYCSP5;rs3099844;AA + AC;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP1A2;rs762551;AA + AC;EFFICACY, LADME_PK;DECREASED_EFFICACY
ETHANOL;OPRK1;rs6473797;CC + CT;TOXICITY;INCREASED_SEVERITY
CYCLOPHOSPHAMIDE, DOXORUBICIN;NQO1;rs1800566;A;EFFICACY;EFFICACY
HEROIN;GRM3;rs274618;T;OTHER;INCREASED_RISK
THIAZOLIDINEDIONES;AQP2;rs296766;T;TOXICITY;INCREASED_RISK
ETHANOL;CHRNA3;rs578776;G;TOXICITY, OTHER;DECREASED_LIKELIHOOD
CISPLATIN, DOXORUBICIN;ABCC5;rs939338;G;EFFICACY;DECREASED_EFFICACY
CISPLATIN, DOXORUBICIN;FASLG;rs763110;T;EFFICACY;DECREASED_EFFICACY
CISPLATIN, DOXORUBICIN;MSH2;rs4638843;C;EFFICACY;DECREASED_EFFICACY
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;SLC1A1;rs3087879;C;EFFICACY;INCREASED_SEVERITYEFFICACY
COCAINE;CHRNA5;rs684513;G;OTHER;INCREASED_LIKELIHOOD
ACE INHIBITORS, PLAIN;XPNPEP2;rs3788853;A;TOXICITY;INCREASED_LIKELIHOOD
ALLOPURINOL;;rs2734583;AG + GG;TOXICITY;INCREASED_RISK
METHOTREXATE;ABCC2;rs717620;CT + TT;TOXICITY;INCREASED_RISK
ALLOPURINOL;PSORS1C1;rs9263726;AA + AG;TOXICITY;INCREASED_RISK
FEXOFENADINE;SLCO2B1;rs2306168;T;LADME_PK;DECREASED_PK
ANTINEOPLASTIC AGENTS;SLC28A3;rs17343066;AA;TOXICITY;DECREASED_LIKELIHOOD
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_PK
CLOZAPINE;TRAT1;rs116982346;C;TOXICITY;INCREASED_LIKELIHOOD
MERCAPTOPURINE;NUDT15;rs116855232;CT;TOXICITY;INCREASED_LIKELIHOOD
EFAVIRENZ;CYP2A6;rs8192726;AC + CC;LADME_PK;INCREASED_PK
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;CYP3A4;rs2740574;CC;EFFICACY;DECREASED_EFFICACY
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;CYP3A4;rs2740574;CT;EFFICACY;DECREASED_EFFICACY
;ADH1B;rs1789891;A;OTHER;INCREASED_
ANTINEOPLASTIC AGENTS;DCTD;rs12067645;AA;TOXICITY;INCREASED_LIKELIHOOD
EFAVIRENZ;UGT2B7;rs7439366;CC + CT;LADME_PK;INCREASED_PK
MERCAPTOPURINE;SLC19A1;rs1051266;TT;TOXICITY;INCREASED_LIKELIHOOD
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ERCC2;rs13181;G;TOXICITY;INCREASED_RISK
CLOZAPINE;TRAC;rs377360;A;TOXICITY;INCREASED_LIKELIHOOD
NEVIRAPINE;CCHCR1;rs746647;G;TOXICITY;INCREASED_RISK
;FGFBP1;rs2245964;CC;OTHER;INCREASED_
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;EFFICACY;INCREASED_RISK
;FGFBP1;rs16892645;TT;OTHER;INCREASED_
ATORVASTATIN;SLCO1B1;rs2306283;GG;EFFICACY;INCREASED_EFFICACY
;;rs2824292;G;OTHER;INCREASED_RISK
NEVIRAPINE;;rs6545803;G;TOXICITY;INCREASED_RISK
NICOTINE;FMO1;rs10912675;C;OTHER;INCREASED_SEVERITY
NEVIRAPINE;POLR3G;rs2562519;T;TOXICITY;INCREASED_RISK
NICOTINE;FMO1;rs7877;T;OTHER;INCREASED_SEVERITY
ASPARAGINASE;GRIA1;rs4958381;T;TOXICITY;INCREASED_RISK
PACLITAXEL;CYP17A1;rs743572;AG + GG;TOXICITY;INCREASED_SEVERITY
ACENOCOUMAROL;CYP2C9;rs1057910;C;EFFICACY;INCREASED_RISK
CISPLATIN, FLUOROURACIL;ERCC1;rs3212986;AA + AC;EFFICACY;INCREASED_EFFICACY
DOXORUBICIN;CYP2C19;rs4244285;AA + AG;TOXICITY;INCREASED_SEVERITY
ANASTROZOLE, LETROZOLE;TNFRSF11B;rs2073618;CC;TOXICITY;INCREASED_LIKELIHOOD
CARBOPLATIN, DOCETAXEL, PACLITAXEL;SOX10;rs139887;CG;TOXICITY;INCREASED_RISK
ANASTROZOLE, LETROZOLE;TNFRSF11B;rs2073618;CC;TOXICITY;INCREASED_LIKELIHOOD
ANASTROZOLE, LETROZOLE;TNFSF11;rs7984870;CC;TOXICITY;INCREASED_LIKELIHOOD
ANTINEOPLASTIC AGENTS;CTPS1;rs12067645;A;TOXICITY;INCREASED_LIKELIHOOD
DOXORUBICIN;CYP2C19;rs4244285;AA + AG;TOXICITY;INCREASED_SEVERITY
ANTINEOPLASTIC AGENTS;CTPS1;rs12067645;A;TOXICITY;INCREASED_LIKELIHOOD
CAPECITABINE;CES2;rs11075646;CG + GG;TOXICITY;INCREASED_LIKELIHOOD
WARFARIN;VKORC1;rs9923231;T;EFFICACY;EFFICACY
ANASTROZOLE, LETROZOLE;TNFSF11;rs7984870;CC;TOXICITY;INCREASED_LIKELIHOOD
DRUGS FOR TREATMENT OF TUBERCULOSIS;SOD2;rs4880;AG + GG;TOXICITY;INCREASED_LIKELIHOOD
"""ANALGESICS AND ANESTHETICS"", ""ANTIBIOTICS"", ""ANTIEPILEPTICS"", ""ANTIFUNGALS FOR SYSTEMIC USE"", ""ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS"", ""ANTIMYCOBACTERIALS"", ""ANTITHYROID PREPARATIONS""";SOD2;rs4880;AG + GG;TOXICITY;INCREASED_RISK
DOXORUBICIN;CYP2C19;rs4244285;AA + AG;TOXICITY;INCREASED_SEVERITY
METFORMIN;PPARG;rs1801282;G;OTHER;INCREASED_LIKELIHOOD
MITOTANE;CYP2B6;rs3745274;GT + TT;LADME_PK;PK
BORTEZOMIB, MELPHALAN, PREDNISONE;CTLA4;rs4553808;GG;TOXICITY;
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_PK
;CRHR1;rs1876828;TT;LADME_PK;DECREASED_PK
EFAVIRENZ;CYP2B6;rs3745274;TT;TOXICITY, LADME_PK;INCREASED_PK
VALPROIC ACID;SOD2;rs4880;AG + GG;TOXICITY;DECREASED_LIKELIHOOD
;ABCB1;rs1045642;AA;OTHER;INCREASED_LIKELIHOOD
VALPROIC ACID;LEPR;rs1137101;AG + GG;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_
CAPECITABINE;CDA;rs10916825;AG + GG;TOXICITY;INCREASED_SEVERITY
ANTINEOPLASTIC AGENTS;ABCB1;rs4148737;CC + CT;TOXICITY;DECREASED_LIKELIHOOD
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;C;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL, TICAGRELOR;CYP4F2;rs3093135;TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY
EFAVIRENZ;CYP2B6;rs28399499;CT;LADME_PK;INCREASED_PK
DEFERASIROX;UGT1A3;rs3806596;CC;EFFICACY;DECREASED_RISKEFFICACY
CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, GEMCITABINE;ERCC2;rs13181;GG;EFFICACY;DECREASED_EFFICACY
DEFERASIROX;UGT1A1;rs887829;TT;EFFICACY;DECREASED_RISK
METFORMIN;SLC47A2;rs12943590;AA + AG;LADME_PK;INCREASED_PK
METFORMIN;SLC47A2;rs12943590;AA;EFFICACY;DECREASED_EFFICACY
CAPECITABINE;CES1;rs2244613;GG + GT;TOXICITY;INCREASED_SEVERITY
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;LADME_PK;DECREASED_PK
CAPECITABINE;CES1;rs2244613;GG + GT;TOXICITY;INCREASED_LIKELIHOOD
DEFERASIROX;CYP1A2;rs762551;AA;EFFICACY;DECREASED_RISKEFFICACY
ANTINEOPLASTIC AGENTS;CYP3A5;rs776746;T;TOXICITY;INCREASED_LIKELIHOOD
CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, GEMCITABINE;ERCC2;rs13181;GG;EFFICACY;DECREASED_EFFICACY
DEFERASIROX;CYP1A1;rs2606345;CC;EFFICACY;DECREASED_RISKEFFICACY
HEROIN;GRM3;rs274622;C;OTHER;INCREASED_RISK
EFAVIRENZ;ABCB1;rs3842;CC + CT;LADME_PK;INCREASED_PK
ETHANOL;CHRNA4;rs1044394;G;TOXICITY;DECREASED_RISK
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F2;rs1799963;AG;TOXICITY;INCREASED_RISK
OPIOIDS;ENPP2;rs2249015;AA;EFFICACY;INCREASED_SEVERITYEFFICACY
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;rs6025;CT;TOXICITY;INCREASED_RISK
CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, GEMCITABINE;XRCC1;rs25487;CT + TT;EFFICACY;DECREASED_EFFICACY
ASPIRIN;ADORA1;rs2228079;GG + GT;TOXICITY;DECREASED_RISK
LOVASTATIN;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED_RISK
METHOTREXATE;MTHFR;rs1801131;GG + GT;TOXICITY;DECREASED_RISK
METHOTREXATE;FASTKD3, MTRR;rs1801394;AG + GG;TOXICITY;INCREASED_LIKELIHOOD
FLUOROURACIL;DPYD;rs56038477;T;TOXICITY;INCREASED_SEVERITY
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_RISK
PROPRANOLOL;CYP2D6;rs1065852;AA;LADME_PK;INCREASED_PK
CAPECITABINE, FLUOROURACIL;DPYD;rs6668296;T;TOXICITY;INCREASED_SEVERITY
CLOZAPINE;HLA-DQB1;rs113332494;G;TOXICITY;INCREASED_LIKELIHOOD
CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, GEMCITABINE;ERCC2;rs1799793;CC;EFFICACY;INCREASED_EFFICACY
;APOE;rs7412;CT + TT;OTHER;INCREASED_
CAPECITABINE, FLUOROURACIL;DPYD;rs115349832;C;TOXICITY;INCREASED_SEVERITY
METFORMIN;PPARG;rs1801282;G;OTHER;INCREASED_LIKELIHOOD
;APOE;rs429358;CC + CT;OTHER;INCREASED_
CLOZAPINE;HLA-DQB1;rs113332494;G;TOXICITY;INCREASED_LIKELIHOOD
SIMVASTATIN;APOE;rs429358;C;EFFICACY;INCREASED_RISK
CLOZAPINE, HALOPERIDOL, OLANZAPINE, RISPERIDONE;HTR2C;rs518147;G;OTHER;INCREASED_LIKELIHOOD
AMISULPRIDE, CLOZAPINE, HALOPERIDOL, ILOPERIDONE, OLANZAPINE, QUETIAPINE, RISPERIDONE, ZIPRASIDONE;HTR2C;rs3813929;C;OTHER;INCREASED_RISK
HEROIN;SOD2;rs5746136;TT;TOXICITY;INCREASED_RISK
OPIOIDS;ENPP2;rs7832704;A;EFFICACY;INCREASED_SEVERITYEFFICACY
CARBOPLATIN, DOCETAXEL, PACLITAXEL;BCL2;rs2849380;TT;TOXICITY;INCREASED_RISK
CARBOPLATIN, DOCETAXEL, PACLITAXEL;OPRM1;rs544093;TT;TOXICITY;INCREASED_RISK
CARBOPLATIN, DOCETAXEL, PACLITAXEL;;rs879207;AG;TOXICITY;INCREASED_RISK
TOLCAPONE;;rs4680;GG;EFFICACY;INCREASED_EFFICACY
DOLASETRON, GRANISETRON;NOS1AP;rs10494366;GT + TT;TOXICITY;INCREASED_RISK
SUNITINIB;ABCB1;rs2032582;A;TOXICITY;DECREASED_RISK
CAPECITABINE, FLUOROURACIL;DPYD;rs56276561;T;TOXICITY;INCREASED_SEVERITY
CLOZAPINE;ELAVL2;rs73482673;A;TOXICITY;INCREASED_LIKELIHOOD
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_PK
FLUOROURACIL;DPYD;rs2297595;CC + CT;TOXICITY;DECREASED_LIKELIHOOD
DOCETAXEL;SLCO1B3;rs4149118;G;OTHER, LADME_PK;INCREASED_PK
NEVIRAPINE;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_PK
TOLCAPONE;COMT;rs4680;AG;EFFICACY;DECREASED_EFFICACY
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_PK
HEROIN;SOD2;rs2758339;AC + CC;TOXICITY;DECREASED_RISK
DOCETAXEL;SLCO1B3;rs11045585;G;OTHER, LADME_PK;INCREASED_PK
DOCETAXEL;SLCO1B3;rs7311358;A;OTHER, LADME_PK;INCREASED_PK
IRINOTECAN;TOP1;rs6072262;GG;TOXICITY;DECREASED_SEVERITY
WARFARIN;APOB;rs679899;G;TOXICITY;INCREASED_RISK
ERLOTINIB;EGFR;rs712829;GG;TOXICITY;INCREASED_SEVERITY
ERLOTINIB;ABCG2;rs2622604;CC;OTHER, LADME_PK;DECREASED_PK
WARFARIN;APOB;rs1367117;G;TOXICITY;INCREASED_RISK
CAPECITABINE, FLUOROURACIL;DPYD;rs56038477;T;TOXICITY;INCREASED_SEVERITY
MORPHINE;OPRM1;rs1799971;AA;EFFICACY;INCREASED_EFFICACY
MORPHINE;ABCB1;rs1045642;AA;EFFICACY;INCREASED_EFFICACY
PHENYTOIN;ABCB1;rs1045642;G;EFFICACY;INCREASED_LIKELIHOODEFFICACY
ATORVASTATIN, FLUVASTATIN, HMG COA REDUCTASE INHIBITORS, PRAVASTATIN, ROSUVASTATIN, SIMVASTATIN;SLCO1B1;rs4149056;C;TOXICITY;
ASPIRIN, CLOPIDOGREL;B4GALT2;rs1061781;CT + TT;EFFICACY;DECREASED_EFFICACY
LEFLUNOMIDE;CYB5A;rs1790834;AA + AG;EFFICACY;DECREASED_EFFICACY
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;rs6025;CT;TOXICITY;INCREASED_RISK
NEVIRAPINE;CYP2B6;rs28399499;CT;LADME_PK;INCREASED_PK
NEVIRAPINE;CYP2B6;rs3745274;T;LADME_PK;INCREASED_PK
CETUXIMAB, PANITUMUMAB;KRAS;rs61764370;C;EFFICACY;EFFICACY
EDOXABAN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_LIKELIHOOD
CYCLOSPORINE;ABCB1;rs1045642;GG;EFFICACY, LADME_PK;DECREASED_PK
BLEOMYCIN;BLMH;rs1050565;CC;EFFICACY;DECREASED_EFFICACY
CISPLATIN;GSTP1;rs1695;AA + AG;TOXICITY;INCREASED_RISK
CITALOPRAM;FKBP5;rs4713916;A;EFFICACY;INCREASED_LIKELIHOODEFFICACY
OPIOIDS;TH;rs10770141;AA + AG;TOXICITY;INCREASED_RISK
DISULFIRAM;DBH;rs1611115;CC;EFFICACY;DECREASED_SEVERITYEFFICACY
OPIOIDS;COMT;rs4680;AA;TOXICITY;DECREASED_RISK
;VEGFA;rs2010963;CC + CG;EFFICACY;INCREASED_EFFICACY
SOFOSBUVIR, VELPATASVIR, VOXILAPREVIR;IFNL3, IFNL4;rs12979860;CT + TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY
OPIOIDS;TH;rs10770140;CT + TT;TOXICITY;INCREASED_RISK
PHENYTOIN;ABCB1;rs1128503;A;OTHER, LADME_PK;INCREASED_PK
PHENYTOIN;ABCB1;rs1045642;A;OTHER, LADME_PK;INCREASED_PK
ANTHRACYCLINES AND RELATED SUBSTANCES;CBR3;rs1056892;GG;TOXICITY;INCREASED_RISK
DEXMEDETOMIDINE;PRKCB;rs9922316;T;OTHER;INCREASED_
PRASUGREL;CYP2C19;rs12248560;T;EFFICACY;DECREASED_EFFICACY
CYCLOSPORINE;ABCB1;rs2229109;CC;EFFICACY, LADME_PK;INCREASED_PK
PRASUGREL;CYP2C19;rs12248560;T;EFFICACY;DECREASED_EFFICACY
HMG COA REDUCTASE INHIBITORS;LPA;rs10455872;G;TOXICITY;INCREASED_RISK
EFAVIRENZ;CYP2B6;rs28399499;C;TOXICITY, LADME_PK;INCREASED_PK
PRASUGREL;CYP2C19;rs12248560;T;TOXICITY;INCREASED_RISK
NICOTINE;DRD1;rs686;A;EFFICACY, TOXICITY, OTHER;INCREASED_RISK
PRASUGREL;CYP2C19;rs12248560;T;EFFICACY;INCREASED_EFFICACY
ANTIPSYCHOTICS;DRD2;rs1799732;del;TOXICITY;INCREASED_RISK
MITOTANE;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_PK
NICOTINE;DRD1;rs4532;T;EFFICACY, TOXICITY, OTHER;INCREASED_RISK
REPAGLINIDE;SLC30A8;rs16889462;AG;EFFICACY;INCREASED_EFFICACY
ATAZANAVIR, RITONAVIR;UGT1A7;rs17863778;AA;TOXICITY, OTHER;INCREASED_LIKELIHOOD
BEVACIZUMAB;EDN1;rs5370;TT;EFFICACY;DECREASED_EFFICACY
;G6PD, IKBKG;rs5030868;A;;
MYCOPHENOLATE MOFETIL;IMPDH1;rs2278294;T;EFFICACY;DECREASED_RISK
ATAZANAVIR, RITONAVIR;UGT1A3;rs3806596;CC;TOXICITY, OTHER;INCREASED_LIKELIHOOD
GEFITINIB;ABCB1;rs1128503;AA;TOXICITY;INCREASED_RISK
MYCOPHENOLATE MOFETIL;IMPDH1;rs2278294;T;TOXICITY;INCREASED_RISK
ATAZANAVIR, RITONAVIR;UGT1A7;rs7586110;GG;TOXICITY, OTHER;INCREASED_LIKELIHOOD
OXALIPLATIN;ERCC2, KLC3;rs13181;GG + GT;EFFICACY;DECREASED_EFFICACY
APREPITANT, OLANZAPINE;HTR3C;rs6766410;CC;EFFICACY;INCREASED_LIKELIHOODEFFICACY
ATAZANAVIR, RITONAVIR;UGT1A7;rs17868323;GG;TOXICITY, OTHER;INCREASED_LIKELIHOOD
BEVACIZUMAB;VEGFA;rs3025039;TT;EFFICACY;DECREASED_EFFICACY
APREPITANT, OLANZAPINE;MTHFR;rs1801131;TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY
APREPITANT, OLANZAPINE;HTR3B;rs7943062;GG;EFFICACY;DECREASED_LIKELIHOODEFFICACY
TAFENOQUINE;;rs62103056;A;EFFICACY;INCREASED_LIKELIHOODEFFICACY
METHOTREXATE;GGH;rs719235;CC;EFFICACY, TOXICITY;INCREASED_RISK
TIMOLOL;ADRB1;rs1801252;AA;OTHER;INCREASED_
CISPLATIN;LRP2;rs2228171;G;TOXICITY;INCREASED_RISK
DISULFIRAM;DBH;rs1611115;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
FENTANYL, PROPOFOL, REMIFENTANIL, SEVOFLURANE;ADRB2;rs1042718;AA;TOXICITY;INCREASED_SEVERITY
ROSUVASTATIN;ABCG2;rs2231142;T;EFFICACY;SEVERITY_EFFICACY
;SLC30A8;rs13266634;C;OTHER;INCREASED_RISK
THIAZIDES, PLAIN;SLCO2A1;rs34550074;T;TOXICITY;INCREASED_LIKELIHOOD
ROSUVASTATIN;FMO3;rs1736557;A;EFFICACY;SEVERITY_EFFICACY
WARFARIN;GGCX;rs699664;C;EFFICACY;INCREASED_EFFICACY
CISPLATIN;GSTP1;rs1695;AG + GG;TOXICITY;INCREASED_RISK
WARFARIN;GGCX;rs11676382;G;EFFICACY;DECREASED_EFFICACY
METHYLPHENIDATE;COMT;rs4680;A;TOXICITY;INCREASED_LIKELIHOOD
ANTIEPILEPTICS;SCN2A;rs2304016;A;EFFICACY;EFFICACY
WARFARIN;GGCX;rs11676382;G;EFFICACY;INCREASED_EFFICACY
WARFARIN;NQO1;rs1800566;AA + AG;TOXICITY;INCREASED_RISK
;G6PD;rs1050828;T;;INCREASED_
ANTITHYROID PREPARATIONS, METHIMAZOLE, PROPYLTHIOURACIL;KLRC4;rs2734565;C;TOXICITY;INCREASED_LIKELIHOOD
OXALIPLATIN;ERCC1;rs11615;AA;EFFICACY;DECREASED_EFFICACY
FLUOROURACIL;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_RISK
ACE INHIBITORS, PLAIN;;rs4267385;CC + CT;OTHER;
ACE INHIBITORS, PLAIN;;rs4459610;AA + AT;OTHER;
;G6PD;rs1050828;T;;INCREASED_
METHOTREXATE;MTHFR;rs1801133;AG;TOXICITY;INCREASED_RISK
ACE INHIBITORS, PLAIN;BDKRB2;rs8016905;AG;TOXICITY;
;F5;rs6025;C;OTHER;INCREASED_LIKELIHOOD
CARBOPLATIN, PACLITAXEL;TRIM5;rs7950311;C;EFFICACY;DECREASED_EFFICACY
;MTHFR;rs1801131;G;OTHER;INCREASED_LIKELIHOOD
ANTINEOPLASTIC AGENTS;;rs6674079;G;EFFICACY;DECREASED_EFFICACY
;MTHFR;rs1801133;G;OTHER;INCREASED_LIKELIHOOD
CARBOPLATIN, PACLITAXEL;;rs2549714;C;EFFICACY;DECREASED_EFFICACY
;SERPINE1;rs2227631;A;OTHER;INCREASED_LIKELIHOOD
ANTINEOPLASTIC AGENTS;;rs4910232;G;EFFICACY;DECREASED_EFFICACY
WARFARIN;CYP4F2;rs2108622;CT + TT;EFFICACY;DECREASED_EFFICACY
ASPIRIN;PPARG;rs3856806;TT;TOXICITY;INCREASED_RISK
CYCLOSPORINE;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK
ANTINEOPLASTIC AGENTS;ZNF100;rs3795247;C;EFFICACY;DECREASED_EFFICACY
WARFARIN;VKORC1;rs9923231;T;EFFICACY;INCREASED_EFFICACY
ASPIRIN;PTGIR;rs1126510;AG + GG;OTHER;DECREASED_RISK
WARFARIN;VKORC1;rs9923231;CT + TT;EFFICACY;INCREASED_EFFICACY
ASPIRIN;TBXA2R;rs1131882;GG;TOXICITY;INCREASED_RISK
ASPIRIN;PTGER3;rs7551789;A;OTHER;INCREASED_RISK
WARFARIN;VKORC1;rs9923231;CT + TT;EFFICACY;DECREASED_EFFICACY
ASPIRIN;PTGER2;rs1353411;GG;OTHER;INCREASED_RISK
ASPIRIN;PTGER2;rs2075797;G;OTHER;DECREASED_RISK
DOCETAXEL, PACLITAXEL;CYP3A4;rs2740574;CC;TOXICITY;INCREASED_RISK
DOXORUBICIN;ABCB1;rs1045642;AA + AG;TOXICITY;DECREASED_SEVERITY
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_
CLOPIDOGREL;CYP2C19;rs4244285;AG + GG;EFFICACY;INCREASED_EFFICACY
ASPIRIN;PPARG;rs3856806;TT;TOXICITY;INCREASED_
CLOPIDOGREL;CYP2C19;rs4986893;AG + GG;EFFICACY;EFFICACY
ASPIRIN, CLOPIDOGREL;NECAB1;rs74569896;G;EFFICACY;INCREASED_RISKEFFICACY
CLOPIDOGREL;CYP2C19;rs4244285;AG + GG;EFFICACY;EFFICACY
WARFARIN;VKORC1;rs9923231;T;TOXICITY;INCREASED_RISK
WARFARIN;CYP2C9;rs1799853;T;EFFICACY, TOXICITY;INCREASED_
ASPIRIN, CLOPIDOGREL;EFR3A;rs4736529;G;EFFICACY;INCREASED_RISKEFFICACY
DOCETAXEL, PACLITAXEL;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK
GEMCITABINE;SLC28A1;rs2242046;GG;TOXICITY;DECREASED_RISK
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_
WARFARIN;CYP2C9;rs1057910;C;EFFICACY, TOXICITY;INCREASED_
GEMCITABINE;CDA;rs1048977;CC + CT;OTHER, LADME_PK;INCREASED_PK
PACLITAXEL;ABCB1;rs1045642;AA + AG;TOXICITY;DECREASED_SEVERITY
HMG COA REDUCTASE INHIBITORS;LPA;rs10455872;AG + GG;TOXICITY;INCREASED_RISK
HMG COA REDUCTASE INHIBITORS;LPA;rs10455872;AG + GG;TOXICITY;INCREASED_RISK
CYTARABINE;ABCB1;rs1128503;GG;EFFICACY;DECREASED_EFFICACY
HMG COA REDUCTASE INHIBITORS;LPA;rs10455872;AG + GG;EFFICACY;EFFICACY
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;rs1799930;AA;TOXICITY;INCREASED_LIKELIHOOD
HMG COA REDUCTASE INHIBITORS;LPA;rs10455872;AG + GG;EFFICACY;EFFICACY
PRAVASTATIN;ABCB1;rs2032582;CC;EFFICACY;INCREASED_EFFICACY
GEMCITABINE;CMPK1;rs1044457;CC;OTHER, LADME_PK;DECREASED_PK
ASPIRIN, CLOPIDOGREL;WDR24;rs11640115;G;EFFICACY;INCREASED_RISKEFFICACY
GEMCITABINE;CDA;rs4655226;CC;OTHER, LADME_PK;INCREASED_PK
CARBOPLATIN, PACLITAXEL;MAD1L1;rs1801368;CT + TT;OTHER;DECREASED_
VARENICLINE;ICAM5;rs901886;T;TOXICITY;INCREASED_LIKELIHOOD
METHOTREXATE;ABCC1;rs2238476;AG;TOXICITY;INCREASED_LIKELIHOOD
MITOXANTRONE;ABCB1;rs1128503;AA;OTHER;INCREASED_
MERCAPTOPURINE, METHOTREXATE;FOLH1;rs61886492;A;TOXICITY;INCREASED_RISK
CYTARABINE;ABCB1;rs2032582;CC;EFFICACY;DECREASED_EFFICACY
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;rs1041983;TT;TOXICITY;INCREASED_LIKELIHOOD
NEVIRAPINE;CYP2B6;rs28399499;C;TOXICITY;INCREASED_RISK
;PPARA;rs135561;AA + AG;OTHER;DECREASED_RISK
CLOZAPINE;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK
DRUGS FOR TREATMENT OF TUBERCULOSIS, ISONIAZID;;rs1495741;AA;TOXICITY;DECREASED_
METHOTREXATE;ATIC;rs4673993;C;EFFICACY;DECREASED_RISKEFFICACY
DRUGS FOR TREATMENT OF TUBERCULOSIS, ISONIAZID;;rs1495741;AA;TOXICITY;DECREASED_
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS;APOC3;rs5128;CG + GG;TOXICITY;INCREASED_LIKELIHOOD
FLUTICASONE PROPIONATE;CYP3A4;rs35599367;AA + AG;EFFICACY;EFFICACY
ALLOPURINOL;CCHCR1;rs9263745;A;TOXICITY;INCREASED_SEVERITY
LETROZOLE;;rs74418677;C;TOXICITY;INCREASED_LIKELIHOOD
ACE INHIBITORS, PLAIN;AGTR1;rs5186;C;TOXICITY;INCREASED_
CYTARABINE, DAUNORUBICIN, ETOPOSIDE, MITOXANTRONE;SLCO1B1;rs2291075;CT + TT;EFFICACY;INCREASED_EFFICACY
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_PK
CYCLOSPORINE;CYP3A4;rs35599367;AA + AG;TOXICITY;INCREASED_RISK
ALLOPURINOL;CYCSP5;rs3099844;A;TOXICITY;INCREASED_SEVERITY
METHOTREXATE;FOXP3;rs3761548;GT;TOXICITY;INCREASED_LIKELIHOOD
;CHAT;rs1880676;G;OTHER;INCREASED_RISK
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS;SIK3;rs139961185;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
OXALIPLATIN;XRCC1;rs25487;TT;EFFICACY;DECREASED_EFFICACY
CYCLOSPORINE;CYP3A4;rs35599367;AA + AG;TOXICITY;DECREASED_
METFORMIN;SLC22A1;rs622342;AA;LADME_PK;DECREASED_PK
ALLOPURINOL;PSORS1C2;rs9263733;T;TOXICITY;INCREASED_SEVERITY
CYCLOSPORINE;ABCB1;rs1045642;AA + AG;TOXICITY;DECREASED_RISK
METHOTREXATE;ABCG2;rs13120400;CT + TT;TOXICITY;INCREASED_SEVERITY
ALLOPURINOL;PSORS1C1, PSORS1C2;rs9263726;A;TOXICITY;INCREASED_SEVERITY
DRUGS FOR TREATMENT OF TUBERCULOSIS;;rs1495741;AA;TOXICITY;INCREASED_RISK
EXEMESTANE, LETROZOLE;;rs912571;G;TOXICITY;DECREASED_LIKELIHOOD
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS;APOA5;rs964184;CG + GG;TOXICITY;INCREASED_LIKELIHOOD
VALPROIC ACID;POLG;rs2307441;C;TOXICITY;INCREASED_RISK
CISPLATIN, CYCLOPHOSPHAMIDE;ADH1C;rs698;CT;EFFICACY;DECREASED_LIKELIHOODEFFICACY
EXEMESTANE, LETROZOLE;CCDC148;rs79048288;T;TOXICITY;INCREASED_LIKELIHOOD
OXALIPLATIN;GSTP1;rs1695;GG;EFFICACY;INCREASED_EFFICACY
;DRD2;rs6277;G;;INCREASED_RISK
ATORVASTATIN, LOVASTATIN, SIMVASTATIN;CYP3A4;rs35599367;AA + AG;DOSAGE, LADME_PK;DECREASED_
;DRD2;rs1799732;G;;INCREASED_RISK
VALPROIC ACID;POLG;rs3087374;A;TOXICITY;INCREASED_RISK
EDOXABAN;SLCO1B1;rs2306283;GG;TOXICITY;DECREASED_LIKELIHOOD
EDOXABAN;ABCB1;rs3842;CC;TOXICITY;INCREASED_LIKELIHOOD
HYDROCHLOROTHIAZIDE;ADD1;rs4961;TT;OTHER;INCREASED_
EDOXABAN;SLCO1B1;rs999278;AA + AC;TOXICITY;INCREASED_LIKELIHOOD
LEVODOPA;DRD3;rs6280;TT;TOXICITY;INCREASED_RISK
LEVODOPA;DRD2;rs1799732;GG;TOXICITY;INCREASED_RISK
BUSULFAN, CYCLOPHOSPHAMIDE;CTH;rs1021737;TT;TOXICITY;INCREASED_RISK
FUROSEMIDE, SPIRONOLACTONE;CYP11B2;rs1799998;AA + AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
EDOXABAN;SLCO1B1;rs4149057;CC + CT;TOXICITY;INCREASED_LIKELIHOOD
SIMVASTATIN;ABCB1;rs2032582;AA;EFFICACY;INCREASED_EFFICACY
SIMVASTATIN;ABCB1;rs2032582;AC;EFFICACY;INCREASED_EFFICACY
FUROSEMIDE, SPIRONOLACTONE;ACE;rs4341;CG + GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
SIMVASTATIN;ABCB1;rs1045642;AA;EFFICACY;INCREASED_EFFICACY
ATORVASTATIN;NOS3;rs2070744;CC;EFFICACY;INCREASED_EFFICACY
ATORVASTATIN;NOS3;rs2070744;CC;OTHER;INCREASED_
PAROXETINE;CYP1A2;rs2472304;A;EFFICACY;INCREASED_LIKELIHOODEFFICACY
FUROSEMIDE, SPIRONOLACTONE;ADD1;rs4961;GT + TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY
PAROXETINE;CYP1A2;rs4646425;T;EFFICACY;DECREASED_LIKELIHOODEFFICACY
ATORVASTATIN;ABCB1;rs2032582;AA;OTHER, LADME_PK;INCREASED_PK
CISPLATIN, DOXORUBICIN;ERCC1;rs11615;AA;TOXICITY;DECREASED_RISK
METHAMPHETAMINE;ARRB2;rs4790694;C;OTHER;INCREASED_LIKELIHOOD
METHOTREXATE;ABCG2;rs2231142;GT;TOXICITY;DECREASED_RISK
PAROXETINE;CYP1A2;rs2470890;T;EFFICACY;INCREASED_LIKELIHOODEFFICACY
PEGINTERFERON ALFA-2A, RIBAVIRIN;SCARB1;rs10846744;GG;EFFICACY;DECREASED_EFFICACY
PLATINUM COMPOUNDS, RADIOTHERAPY;;rs1829346;AA;TOXICITY;INCREASED_RISK
CISPLATIN, DOXORUBICIN;CYBA;rs4673;AA + AG;TOXICITY;DECREASED_RISK
ATORVASTATIN;ABCB1;rs1128503;AA;OTHER, LADME_PK;INCREASED_PK
CLOZAPINE;CYP2C19;rs4244285;AA;OTHER, LADME_PK;INCREASED_PK
ATORVASTATIN;ABCB1;rs1045642;AA;OTHER, LADME_PK;INCREASED_PK
PRASUGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_RISKEFFICACY
IRINOTECAN;SLCO1B1;rs2306283;GG;TOXICITY;INCREASED_RISK
PLATINUM COMPOUNDS, RADIOTHERAPY;;rs2027701;AG + GG;TOXICITY;DECREASED_RISK
SIMVASTATIN;ABCB1;rs1128503;AA;OTHER, LADME_PK;INCREASED_PK
PRASUGREL;CYP2C19;rs4244285;A;EFFICACY;EFFICACY
ANTIPSYCHOTICS;SLC18A2;rs363341;TT;TOXICITY;INCREASED_RISK
PLATINUM COMPOUNDS, RADIOTHERAPY;;rs1059698;CC;TOXICITY;DECREASED_RISK
ANTIPSYCHOTICS;GRIK3;rs1334802;CT;TOXICITY;INCREASED_RISK
PLATINUM COMPOUNDS, RADIOTHERAPY;;rs73594404;AA + AG;TOXICITY;INCREASED_RISK
PAROXETINE;CYP1A2;rs4646427;TT;EFFICACY;EFFICACY
METHOTREXATE;SHMT1;rs1979277;AG + GG;TOXICITY;INCREASED_LIKELIHOOD
PAROXETINE;CYP1A2;rs762551;A;TOXICITY;INCREASED_RISK
ANTIPSYCHOTICS;HTR2A;rs9567733;AG + GG;TOXICITY;INCREASED_RISK
PLATINUM COMPOUNDS, RADIOTHERAPY;;rs36080650;CC;TOXICITY;INCREASED_RISK
METHOTREXATE;ABCB1;rs1045642;AG + GG;TOXICITY;INCREASED_RISK
ANTIPSYCHOTICS;DRD2;rs1124491;AA + AG;TOXICITY;DECREASED_RISK
PLATINUM COMPOUNDS, RADIOTHERAPY;MEG3;rs10132552;CC;TOXICITY;INCREASED_RISK
WARFARIN;CYP4F2;rs2108622;CT + TT;LADME_PK;INCREASED_PK
MYCOPHENOLATE MOFETIL;UGT1A9;rs72551330;C;TOXICITY;
METHOTREXATE;ABCC2;rs17222723;AT + TT;TOXICITY;INCREASED_RISK
METHAMPHETAMINE;SLC6A9;rs2486001;T;TOXICITY, OTHER;INCREASED_RISK
MYCOPHENOLATE MOFETIL;UGT1A9;rs72551330;C;TOXICITY;INCREASED_RISK
ANTIPSYCHOTICS, CLOZAPINE, OLANZAPINE, RISPERIDONE;HTR2C;rs1414334;C;TOXICITY;INCREASED_LIKELIHOOD
;KCNH2;rs1805123;T;OTHER;INCREASED_LIKELIHOOD
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED_EFFICACY
METHAMPHETAMINE;ARRB2;rs2036657;A;OTHER;INCREASED_LIKELIHOOD
METHOTREXATE;MTHFR;rs1801133;AA + AG;EFFICACY;DECREASED_EFFICACY
ASPIRIN;P2RY1;rs1065776;CT;EFFICACY;INCREASED_RISKEFFICACY
ROSUVASTATIN;SLCO1B1;rs4149056;C;TOXICITY;INCREASED_LIKELIHOOD
;CRHR1;rs110402;AA;OTHER;INCREASED_RISK
NICOTINE;ARRB2;rs4790694;A;OTHER;INCREASED_RISK
WARFARIN;CYP2C9;rs7900194;A;DOSAGE;DECREASED_EFFICACY
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_RISK
ATORVASTATIN;ABCB1;rs1045642;A;TOXICITY;INCREASED_LIKELIHOOD
CAPECITABINE;MTHFR;rs1801133;GG;TOXICITY;INCREASED_LIKELIHOOD
CARVEDILOL;ADRB2;rs1042714;C;EFFICACY;INCREASED_EFFICACY
CLOPIDOGREL;PON1;rs662;CC + CT;EFFICACY;INCREASED_LIKELIHOODEFFICACY
ANTIDEPRESSANTS;NTRK2;rs1439050;G;TOXICITY;INCREASED_RISK
IRINOTECAN;UGT1A1;rs10929302;AA;TOXICITY;INCREASED_RISK
BEVACIZUMAB;;rs1478947;CT + TT;TOXICITY;INCREASED_RISK
ASPIRIN;TBXA2R;rs4523;AA;TOXICITY;INCREASED_RISK
METHAMPHETAMINE;ARRB2;rs1045280;T;OTHER;INCREASED_LIKELIHOOD
ASPIRIN;GP1BA;rs6065;CC;TOXICITY;INCREASED_RISK
OLANZAPINE;PMCH;rs7973796;G;OTHER;INCREASED_LIKELIHOOD
IRINOTECAN;UGT1A1;rs10929302;AA;TOXICITY;INCREASED_
WARFARIN;VKORC1;rs9934438;AA;TOXICITY;INCREASED_RISK
ASPIRIN;TGFB1;rs1800469;AA + AG;TOXICITY;INCREASED_RISK
WARFARIN;F7;rs6046;AA;EFFICACY;INCREASED_EFFICACY
WARFARIN;F7;rs6046;AA;TOXICITY;INCREASED_RISK
CARBOPLATIN, CISPLATIN, DOCETAXEL, GEMCITABINE, PACLITAXEL, VINORELBINE;MTHFR;rs1801133;AA;EFFICACY;INCREASED_LIKELIHOODEFFICACY
ASPIRIN, CLOPIDOGREL;KRTAP10-4, TSPEAR;rs201441480;A;EFFICACY;INCREASED_RISKEFFICACY
CAPECITABINE, FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_LIKELIHOOD
METHOTREXATE;MTHFD1;rs2236225;AA + AG;TOXICITY;INCREASED_RISK
PACLITAXEL;ABCB1;rs1128503;AA;TOXICITY;INCREASED_SEVERITY
METHOTREXATE;MTHFR;rs1801131;GT + TT;TOXICITY;INCREASED_RISK
ATORVASTATIN;NOS3;rs2070744;CC;OTHER;DECREASED_
WARFARIN;CYP2C9;rs7900194;A;LADME_PK;DECREASED_PK
ASPIRIN, CLOPIDOGREL;ECHS1;rs140410716;T;EFFICACY;INCREASED_RISKEFFICACY
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIGB;rs12050587;G;TOXICITY;INCREASED_LIKELIHOOD
ATORVASTATIN, FLUVASTATIN, LOVASTATIN, PITAVASTATIN, SIMVASTATIN;SLCO1B1;rs4149035;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
ASPIRIN, CLOPIDOGREL;AGAP3;rs75750968;A;EFFICACY;INCREASED_RISKEFFICACY
ATORVASTATIN, FLUVASTATIN, LOVASTATIN, PITAVASTATIN, SIMVASTATIN;SLCO1B1;rs11045818;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
GEMCITABINE;SLC28A2;rs11854484;CC;TOXICITY;DECREASED_RISK
SIMVASTATIN;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED_RISK
ACETAMINOPHEN;TLR4;rs1927911;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
TIMOLOL;;rs16947;AA + AG;TOXICITY;INCREASED_RISK
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;;rs11636687;C;TOXICITY;INCREASED_LIKELIHOOD
GEMCITABINE;SLC28A2;rs1060896;CC;TOXICITY;DECREASED_RISK
ATORVASTATIN, FLUVASTATIN, LOVASTATIN, PITAVASTATIN, SIMVASTATIN;ABCG2;rs2622629;TT;TOXICITY;INCREASED_LIKELIHOOD
PRAVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK
ASPIRIN, CLOPIDOGREL;ZDHHC3;rs3749187;A;EFFICACY;INCREASED_RISKEFFICACY
VENLAFAXINE;CYP2D6;rs3892097;CT + TT;LADME_PK;INCREASED_PK
;ADORA2A;rs5996696;AC + CC;OTHER;DECREASED_RISK
;ADORA2A;rs71651683;CT;OTHER;DECREASED_RISK
;IFITM3;rs12252;GG;OTHER;INCREASED_SEVERITY
METHOTREXATE;ABCB1;rs1128503;AG + GG;TOXICITY;INCREASED_LIKELIHOOD
CAFFEINE;CYP1A2;rs762551;CC;OTHER;DECREASED_RISK
CAFFEINE;CYP1A2;rs2470890;CC;OTHER;DECREASED_RISK
CLOZAPINE;ABCB1;rs1045642;AA;LADME_PK;INCREASED_PK
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED_LIKELIHOOD
WARFARIN;VKORC1;rs9934438;AA;EFFICACY;INCREASED_EFFICACY
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs1127354;CC;EFFICACY;INCREASED_LIKELIHOOD
;KCNJ11;rs5219;TT;;INCREASED_LIKELIHOOD
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED_EFFICACY
ATORVASTATIN, SIMVASTATIN;SLCO1B1;rs374113543;A;EFFICACY;INCREASED_SEVERITYEFFICACY
ATORVASTATIN, SIMVASTATIN;SLCO1B1;rs373327528;A;EFFICACY;INCREASED_SEVERITYEFFICACY
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;DNAAF9;rs6051702;AA;EFFICACY;DECREASED_LIKELIHOOD
DEXAMETHASONE;SERPINE1;rs6092;AA + AG;TOXICITY;INCREASED_RISK
GEMCITABINE;CDA;rs2072671;AA + AC;TOXICITY;INCREASED_SEVERITY
NICOTINE;CHRNB2;rs2072661;GG;EFFICACY, TOXICITY, OTHER;INCREASED_
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC28A3;rs7853758;A;TOXICITY;DECREASED_LIKELIHOOD
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_RISK
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED_EFFICACY
CLOZAPINE;CYP1A2;rs2069514;A;OTHER;INCREASED_LIKELIHOOD
CISPLATIN, DOXORUBICIN, METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_RISK
CISPLATIN, DOXORUBICIN, METHOTREXATE;GSTP1;rs1695;AG + GG;TOXICITY;INCREASED_RISK
EVEROLIMUS;MTOR;rs2024627;C;EFFICACY;DECREASED_LIKELIHOODEFFICACY
CAPECITABINE;DPYD;rs3918290;CT;TOXICITY;INCREASED_RISK
CISPLATIN, DOXORUBICIN, METHOTREXATE;ERCC2;rs13181;GG + GT;TOXICITY;INCREASED_RISK
NICOTINE;CHRM2;rs324650;T;TOXICITY, OTHER;INCREASED_RISK
CETUXIMAB, PANITUMUMAB;EGFR;rs712829;GT + TT;EFFICACY;INCREASED_EFFICACY
;VDR;rs1544410;C;;INCREASED_RISK
CLOZAPINE;CYP1A2;rs35694136;del;OTHER;INCREASED_LIKELIHOOD
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY
CETUXIMAB, PANITUMUMAB;AREG;rs9996584;AA + AG;EFFICACY;INCREASED_EFFICACY
BEVACIZUMAB, IRINOTECAN;VEGFA;rs1570360;GG;EFFICACY;DECREASED_EFFICACY
CLOPIDOGREL;PON1;rs662;CT + TT;OTHER;INCREASED_
PROTON PUMP INHIBITORS;TRPM6;rs3750425;T;TOXICITY;INCREASED_RISK
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_RISK
;FKBP5;rs1360780;CC + CT;EFFICACY;INCREASED_LIKELIHOOD
CLOZAPINE, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR2C, MIR1264, MIR1912;rs12836771;GG;TOXICITY;INCREASED_LIKELIHOOD
METHOTREXATE;GGH;rs3758149;AA;TOXICITY;INCREASED_LIKELIHOOD
HALOTHANE, SUCCINYLCHOLINE;RYR1;rs193922803;T;OTHER;INCREASED_RISK
CETUXIMAB, PANITUMUMAB;AREG;rs11942466;AA;EFFICACY;DECREASED_EFFICACY
SIMVASTATIN;ABCB1;rs1045642;AA;OTHER, LADME_PK;INCREASED_PK
PROTON PUMP INHIBITORS;TRPM6;rs2274924;C;TOXICITY;INCREASED_RISK
DOXORUBICIN;GSTP1;rs1695;AG + GG;TOXICITY;INCREASED_RISK
DOXORUBICIN;ERCC1;rs3212986;AA + AC;TOXICITY;DECREASED_RISK
CLOZAPINE, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR2C;rs518147;CC;TOXICITY;INCREASED_LIKELIHOOD
SIMVASTATIN;ABCB1;rs2032582;AA;OTHER, LADME_PK;INCREASED_PK
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs118192172;T;OTHER;INCREASED_RISK
NEVIRAPINE;CYP2B6;rs2054675;C;TOXICITY;INCREASED_RISK
ASUNAPREVIR, DACLATASVIR, DIRECT ACTING ANTIVIRALS, LEDIPASVIR / SOFOSBUVIR, OMBITASVIR / PARITAPREVIR / RITONAVIR;IFNL3, IFNL4;rs8099917;GG + GT;TOXICITY;INCREASED_RISK
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs118192176;A;OTHER;INCREASED_RISK
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs118192177;T;OTHER;INCREASED_RISK
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs121918593;A;OTHER;INCREASED_RISK
NEVIRAPINE;CYP2B6;rs3786547;C;TOXICITY;INCREASED_RISK
CAPECITABINE;DPYD;rs1801160;CC + CT;TOXICITY;INCREASED_LIKELIHOOD
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs121918592;A;OTHER;INCREASED_RISK
CAPECITABINE;DPYD;rs1801159;C;TOXICITY;INCREASED_RISK
METHYLPHENIDATE;DRD3;rs6280;CT + TT;TOXICITY;INCREASED_
CISPLATIN;ACYP2;rs1872328;AA + AG;TOXICITY;INCREASED_RISK
CLOPIDOGREL;PON1;rs662;CT + TT;TOXICITY;INCREASED_RISK
DOXORUBICIN;XPC;rs2228001;GG + GT;TOXICITY;DECREASED_RISK
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY
HEROIN;OPRM1;rs9479757;GG;TOXICITY;INCREASED_SEVERITY
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED_EFFICACY
NALTREXONE;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_EFFICACY
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3;rs8099917;TT;EFFICACY;EFFICACY
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;FTO;rs1125338;CC;EFFICACY;INCREASED_LIKELIHOODEFFICACY
BETA-LACTAM ANTIBACTERIALS, PENICILLINS;;rs71542416;T;TOXICITY;INCREASED_LIKELIHOOD
IRINOTECAN;ABCG1;rs425215;GG;TOXICITY;INCREASED_LIKELIHOOD
XELOX;ABCA2;rs2271862;AA;TOXICITY;DECREASED_LIKELIHOOD
IRINOTECAN;ABCC5;rs562;CC;TOXICITY;INCREASED_LIKELIHOOD
OPIOIDS;TACR1;rs6715729;AG + GG;TOXICITY;DECREASED_LIKELIHOOD
OPIOIDS;DRD2;rs4436578;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
OPIOIDS;CYP3A5;rs776746;CC + CT;TOXICITY;INCREASED_LIKELIHOOD
IRINOTECAN;SLCO1B1;rs2306283;AG;TOXICITY;DECREASED_LIKELIHOOD
TRAMADOL;ABCB1;rs1045642;AA;TOXICITY;DECREASED_RISK
;ABCB1;rs2032582;CC + TT;EFFICACY;DECREASED_EFFICACY
CARBOPLATIN, PACLITAXEL;SLCO1B3;rs7311358;AA;TOXICITY;INCREASED_RISK
METHOTREXATE;FPGS;rs10106;CC + CT;TOXICITY;DECREASED_LIKELIHOOD
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_LIKELIHOOD
;HIF1A;rs11549467;AG;EFFICACY;DECREASED_EFFICACY
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;FTO;rs12596638;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
COUMARIN, NICOTINE;CYP2A6;rs28399433;C;OTHER, LADME_PK;DECREASED_
SUNITINIB;ABCG2;rs2231142;TT;TOXICITY;INCREASED_RISK
;PEMT;rs7946;T;;INCREASED_RISK
ANTIBIOTICS;LGALS3;rs11125;AT + TT;TOXICITY;INCREASED_RISK
SUNITINIB;ABCG2;rs2231142;TT;TOXICITY;INCREASED_RISK
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;;rs12600192;CG + GG;TOXICITY;INCREASED_LIKELIHOOD
SUNITINIB;ABCG2;rs2231142;TT;TOXICITY;INCREASED_RISK
;VKORC1;rs9934438;AA + AG;TOXICITY;INCREASED_RISK
SUNITINIB;ABCG2;rs2231142;TT;TOXICITY;INCREASED_RISK
METHOTREXATE;DHFR;rs1650723;T;TOXICITY;INCREASED_SEVERITY
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;;rs12600192;CC;EFFICACY;INCREASED_LIKELIHOODEFFICACY
METHOTREXATE;ABCG2;rs2231135;AG;TOXICITY;INCREASED_RISK
NICOTINE;HINT1;rs3852209;CC;OTHER;INCREASED_LIKELIHOOD
METHOTREXATE;SLC19A1;rs1051266;TT;EFFICACY;INCREASED_RISKEFFICACY
;VDR;rs1544410;CC;OTHER;DECREASED_LIKELIHOOD
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;ALAS1;rs352139;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
RISPERIDONE;SLC6A4;rs3813034;AA;OTHER;INCREASED_LIKELIHOOD
ISONIAZID, RIFAMPIN;GSTP1;rs1695;AA;TOXICITY;INCREASED_LIKELIHOOD
CYCLOPHOSPHAMIDE, DOXORUBICIN;ALDH1A1;rs3764435;A;TOXICITY;INCREASED_RISK
CYCLOPHOSPHAMIDE, DOXORUBICIN;ALDH1A1;rs168351;A;TOXICITY;INCREASED_RISK
METHOTREXATE;MTHFR;rs1801133;A;TOXICITY;INCREASED_LIKELIHOOD
CARBOPLATIN, PACLITAXEL;SLCO1B3;rs4149117;GG;TOXICITY;INCREASED_RISK
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs117648444;AA + AG;EFFICACY;INCREASED_EFFICACY
ETHANOL, NALTREXONE;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_SEVERITYEFFICACY
ISONIAZID, RIFAMPIN;NAT2;rs1799929;TT;TOXICITY, LADME_PK;INCREASED_LIKELIHOOD
OPIOIDS;COMT;rs4680;AG;TOXICITY;INCREASED_LIKELIHOOD
ISONIAZID, RIFAMPIN;NAT2;rs1799930;AA;TOXICITY, LADME_PK;INCREASED_LIKELIHOOD
METHOTREXATE;SLC19A1;rs1051266;CC;EFFICACY;INCREASED_EFFICACY
METHOTREXATE;DHFR;rs1053129;CC;TOXICITY;INCREASED_RISKEFFICACY
METHOTREXATE;MTHFR;rs1801133;GG;TOXICITY;INCREASED_RISK
TAMOXIFEN;HS6ST3;rs118042719;A;EFFICACY;DECREASED_RISKEFFICACY
PHENYTOIN;ABCB1;rs2229107;A;OTHER, LADME_PK;INCREASED_PK
"""3,4-METHYLENEDIOXYMETHAMPHETAMINE"", ""COCAINE"", ""ETHANOL"", ""OPIOIDS""";OPRM1;rs1799971;AG;TOXICITY;INCREASED_RISK
TRASTUZUMAB;FCGR3A;rs396991;CC;EFFICACY;INCREASED_EFFICACY
MYCOPHENOLIC ACID, TACROLIMUS;ABCC2;rs717620;C;EFFICACY;INCREASED_LIKELIHOODEFFICACY
METHADONE;CYP2B6;rs1038376;TT;TOXICITY;INCREASED_LIKELIHOOD
TRASTUZUMAB;FCGR2A;rs1801274;AA;EFFICACY;INCREASED_EFFICACY
METHOTREXATE;SLC19A1;rs1051266;CC + CT;TOXICITY;INCREASED_LIKELIHOOD
SUCCINYLCHOLINE;BCHE;rs1799807;C;LADME_PK;
SUCCINYLCHOLINE;BCHE;rs1803274;T;LADME_PK;
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C18;rs1042192;A;EFFICACY;INCREASED_EFFICACY
CLOZAPINE;HNMT;rs2737385;GG;TOXICITY;DECREASED_SEVERITY
FLUOROURACIL;DPYD;rs1801160;CT;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_EFFICACY
METHADONE;CYP2B6;rs2279343;AG + GG;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;NOC3L;rs12572897;A;EFFICACY;INCREASED_EFFICACY
TAMOXIFEN;LPP;rs6790761;A;EFFICACY;DECREASED_RISKEFFICACY
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;rs1799929;T;TOXICITY;DECREASED_SEVERITY
SUNITINIB;ABCB1;rs1128503;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
NICOTINE;CHRNA5;rs16969968;A;TOXICITY, OTHER;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C8;rs1058932;A;EFFICACY;INCREASED_EFFICACY
SUNITINIB;ABCB1;rs2032582;AA + AC;TOXICITY;INCREASED_LIKELIHOOD
NICOTINE;CHRNA3;rs578776;A;TOXICITY, OTHER;DECREASED_LIKELIHOOD
TAMOXIFEN;LPP;rs77693286;A;EFFICACY;DECREASED_RISKEFFICACY
ANTHRACYCLINES AND RELATED SUBSTANCES;UGT1A6;rs17863783;T;TOXICITY;INCREASED_LIKELIHOOD
TACROLIMUS;CYP3A5;rs776746;CT + TT;EFFICACY;INCREASED_RISK
RIFAMPIN;RIPOR2;rs10946739;C;TOXICITY;INCREASED_RISK
ANTHRACYCLINES AND RELATED SUBSTANCES;RARG;rs2229774;A;TOXICITY;INCREASED_LIKELIHOOD
;EGFR;rs763317;AA;EFFICACY;INCREASED_RISKEFFICACY
;GAL;rs948854;C;OTHER;INCREASED_SEVERITY
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;ZNRD1-AS1;rs3869066;AG + GG;TOXICITY;INCREASED_LIKELIHOOD
ATAZANAVIR;ABCB1;rs2032582;AA;TOXICITY;INCREASED_RISK
HMG COA REDUCTASE INHIBITORS;EYS;rs1337512;G;TOXICITY;INCREASED_LIKELIHOOD
RIFAMPIN;AGBL4;rs393994;A;TOXICITY;INCREASED_RISK
ATAZANAVIR;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK
PHENYTOIN;CYP2C9;rs1799853;T;TOXICITY;INCREASED_LIKELIHOOD
HMG COA REDUCTASE INHIBITORS, OTHER COMBINATIONS;EYS;rs9342288;A;TOXICITY;INCREASED_LIKELIHOOD
ASPIRIN;SLC30A9;rs1047626;A;TOXICITY, OTHER;DECREASED_RISK
ESCITALOPRAM, NORTRIPTYLINE;BDNF;rs962369;C;EFFICACY, TOXICITY;INCREASED_LIKELIHOOD
ACE INHIBITORS, PLAIN;KCNMA1;rs2253201;G;TOXICITY;INCREASED_RISK
HMG COA REDUCTASE INHIBITORS, OTHER COMBINATIONS;EYS;rs3857532;A;TOXICITY;INCREASED_LIKELIHOOD
ASPIRIN;TSC1;rs7862221;C;TOXICITY, OTHER;INCREASED_RISK
RIFAMPIN;AGBL4;rs320003;G;TOXICITY;INCREASED_RISK
ASPIRIN;THRA;rs11819745;G;TOXICITY, OTHER;INCREASED_RISK
RIFAMPIN;CUX2;rs7958375;G;TOXICITY;INCREASED_RISK
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC28A3;rs7853758;A;TOXICITY;DECREASED_LIKELIHOOD
HMG COA REDUCTASE INHIBITORS;GATM;rs9806699;A;TOXICITY;DECREASED_LIKELIHOOD
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4363657;CC + CT;TOXICITY;INCREASED_LIKELIHOOD
ASPIRIN;CHIA;rs3818822;A;TOXICITY, OTHER;INCREASED_RISK
ATAZANAVIR;ABCB1;rs1128503;AA;TOXICITY;INCREASED_RISK
ASPIRIN;;rs1074373;C;TOXICITY, OTHER;DECREASED_RISK
PHENYTOIN;CYP2C9;rs1799853;T;TOXICITY, LADME_PK;INCREASED_PK
PHENYTOIN;CYP2C9;rs1057910;C;TOXICITY, LADME_PK;INCREASED_PK
HEROIN;GRM3;rs1990040;A;OTHER;INCREASED_RISK
ASPIRIN;ZBTB22;rs3130100;C;TOXICITY, OTHER;INCREASED_RISK
CYCLOSPORINE, SIROLIMUS, TACROLIMUS;TCF7L2;rs7903146;T;TOXICITY;INCREASED_LIKELIHOOD
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_LIKELIHOOD
PHENYTOIN;CYP2C9;rs1057910;C;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY, TOXICITY;INCREASED_RISK
ASPIRIN;HLA-DPB1;rs3097671;C;TOXICITY, OTHER;INCREASED_RISK
ASPIRIN;HLA-DPB2;rs3129294;C;TOXICITY, OTHER;INCREASED_RISK
ASPIRIN;HLA-DPB1;rs1042151;G;TOXICITY, OTHER;INCREASED_RISK
ASPIRIN;HLA-DPB1;rs1042136;C;TOXICITY, OTHER;INCREASED_RISK
ATORVASTATIN, SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_LIKELIHOOD
RIFAMPIN;RIPOR2;rs10946737;A;TOXICITY;INCREASED_RISK
PREDNISOLONE;GATA3;rs3824662;AA;PD;INCREASED_RISK
RIFAMPIN;AGBL4;rs319952;A;TOXICITY;INCREASED_RISK
NICOTINE;OPRM1;rs10485057;AA;TOXICITY;INCREASED_RISK
ETHANOL;DPP6;rs2533200;C;TOXICITY;DECREASED_RISK
CISPLATIN, CYCLOPHOSPHAMIDE;EPHX1;rs1051740;CT;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;;rs192543598;G;TOXICITY;INCREASED_RISK
ETHANOL;;rs7900002;T;TOXICITY;INCREASED_RISK
ETHANOL;;rs2582405;T;TOXICITY;INCREASED_RISK
CISPLATIN, CYCLOPHOSPHAMIDE;NAT2;rs1801280;CT;TOXICITY;INCREASED_RISK
ETHANOL;;rs56722963;T;TOXICITY;DECREASED_RISK
CISPLATIN, CYCLOPHOSPHAMIDE;MUTYH;rs3219484;CT;TOXICITY;DECREASED_RISK
CARBAMAZEPINE;ALK;rs187926838;G;TOXICITY;INCREASED_RISK
ETHANOL;MED19, TMX2;rs576859;A;TOXICITY;INCREASED_RISK
METHOTREXATE;ATIC;rs7563206;CC;TOXICITY;INCREASED_LIKELIHOOD
ENZYMES;A2M;rs669;TT;TOXICITY;INCREASED_RISK
METHOTREXATE;ATIC;rs3821353;GT + TT;TOXICITY;INCREASED_LIKELIHOOD
CHOP, RITUXIMAB;NCF4;rs1883112;AA;EFFICACY;DECREASED_EFFICACY
ENZYMES;F12;rs1801020;GG;TOXICITY;INCREASED_RISK
SUNITINIB;ABCB1;rs1128503;A;EFFICACY;DECREASED_EFFICACY
METHOTREXATE;ATIC;rs2372536;CG + GG;TOXICITY;INCREASED_LIKELIHOOD
ETHANOL;;rs6589386;T;TOXICITY;DECREASED_RISK
ETHANOL;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_RISK
ETHANOL;ADH1C;rs13125415;A;TOXICITY;DECREASED_RISK
METHOTREXATE;ATIC;rs12995526;CC;TOXICITY;INCREASED_LIKELIHOOD
CISPLATIN, CYCLOPHOSPHAMIDE;RAD52;rs11226;AG;TOXICITY;DECREASED_RISK
ETHANOL;SLC39A8;rs13135092;A;TOXICITY;INCREASED_RISK
CISPLATIN, CYCLOPHOSPHAMIDE;LIG3;rs1052536;CC;TOXICITY;INCREASED_RISK
ABIRATERONE, PREDNISOLONE;TSPYL1;rs3828743;AA;EFFICACY;DECREASED_EFFICACY
OPIOIDS;COMT;rs4680;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
CISPLATIN, FLUOROURACIL, RADIOTHERAPY;XRCC1;rs1799782;AA + AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
INDINAVIR;UGT1A1;rs4148323;AG;TOXICITY;INCREASED_RISK
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY
ETHANOL;ADH1B;rs1229984;T;TOXICITY;DECREASED_RISK
METHOTREXATE;FPGS;rs10760502;AA;EFFICACY, TOXICITY, OTHER;DECREASED_LIKELIHOOD
METHOTREXATE;FPGS;rs10106;TT;EFFICACY, TOXICITY, OTHER;DECREASED_LIKELIHOOD
CAPECITABINE, FLUOROURACIL, TEGAFUR;DPYD;rs55886062;AC + CC;TOXICITY;INCREASED_RISK
METHOTREXATE;FPGS;rs10106;TT;TOXICITY;INCREASED_LIKELIHOOD
ETHANOL;;rs9679319;T;TOXICITY;DECREASED_RISK
ETHANOL;;rs1402398;A;TOXICITY;INCREASED_RISK
ETHANOL;THSD7B;rs13382553;A;TOXICITY;DECREASED_RISK
PEGINTERFERON ALFA-2A, RIBAVIRIN;;rs4273729;GG;EFFICACY;INCREASED_EFFICACY
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs12980275;AA;EFFICACY;INCREASED_EFFICACY
METHOTREXATE;ABCB1;rs868755;TT;TOXICITY;INCREASED_LIKELIHOOD
ETHANOL;;rs2673136;A;TOXICITY;DECREASED_RISK
ETHANOL;;rs13129401;A;TOXICITY;DECREASED_RISK
METHOTREXATE;ABCB1;rs10280623;TT;TOXICITY;INCREASED_LIKELIHOOD
ETHANOL;CADM2;rs62250713;A;TOXICITY;INCREASED_RISK
ETHANOL;ADH1B;rs75967634;T;TOXICITY;DECREASED_RISK
CARBOPLATIN, CYCLOPHOSPHAMIDE, ETOPOSIDE, LOMUSTINE, METHOTREXATE, VINCRISTINE;METTL3;rs1139130;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
HEROIN;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_SEVERITY
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs4273729;GG;EFFICACY;INCREASED_EFFICACY
;CYP2A6;rs56113850;T;OTHER;DECREASED_LIKELIHOOD
ETHANOL;PDE4B;rs6421482;A;TOXICITY;DECREASED_RISK
ETHANOL;;rs61767420;A;TOXICITY;INCREASED_RISK
ETHANOL;GCKR;rs1260326;T;TOXICITY;DECREASED_RISK
ETHANOL;;rs494904;T;TOXICITY;DECREASED_RISK
;CHRNA5;rs503464;AA + AT;OTHER;INCREASED_LIKELIHOOD
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY
METHOTREXATE;SPATA9;rs72783407;A;TOXICITY;INCREASED_LIKELIHOOD
METHOTREXATE;BIRC5;rs9904341;GG;EFFICACY;INCREASED_EFFICACY
PROTEIN KINASE INHIBITORS;STAT6;rs324011;TT;TOXICITY;INCREASED_SEVERITY
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED_EFFICACY
FLUOROURACIL;DPYD;rs3918290;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
CAPECITABINE, FLUOROURACIL, TEGAFUR;DPYD;rs3918290;CT + TT;TOXICITY;INCREASED_RISK
OPIOIDS;ANKK1, DRD2;rs1800497;AA + AG;TOXICITY;INCREASED_RISK
TAMOXIFEN;C1QTNF6;rs114557570;C;EFFICACY;DECREASED_RISKEFFICACY
;CHRNA5;rs637137;AA + AT;OTHER;INCREASED_LIKELIHOOD
DOCETAXEL;VEGFA;rs833061;CC;EFFICACY;INCREASED_EFFICACY
DOCETAXEL;VEGFA;rs13207351;GG;EFFICACY;DECREASED_EFFICACY
DOCETAXEL;VEGFA;rs35864111;GG;EFFICACY;INCREASED_EFFICACY
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, LEUCOVORIN, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;GATA3;rs3824662;A;EFFICACY;INCREASED_LIKELIHOODEFFICACY
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, LEUCOVORIN, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;GATA3;rs3824662;A;EFFICACY;INCREASED_EFFICACY
DOCETAXEL;VEGFA;rs699947;AA;EFFICACY;INCREASED_EFFICACY
EXEMESTANE;;rs62293499;C;EFFICACY;DECREASED_RISKEFFICACY
ASPIRIN, CLOPIDOGREL;CYP4F2;rs2108622;CT;OTHER;INCREASED_
FLUOROURACIL;DPYD;rs4294451;AT + TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY
CITALOPRAM;COL26A1;rs17135437;T;TOXICITY;INCREASED_
CITALOPRAM;;rs16965962;A;TOXICITY;INCREASED_
ALLOPURINOL;PSORS1C1, PSORS1C2;rs9263726;A;TOXICITY;INCREASED_LIKELIHOOD
ASPIRIN;ACE;rs4292;CC + CT;TOXICITY;INCREASED_RISK
CLOPIDOGREL;P2RY12;rs6809699;AA;EFFICACY;EFFICACY
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC22A17;rs4982753;T;TOXICITY;DECREASED_RISK
TACROLIMUS;CYP3A5;rs776746;T;TOXICITY;INCREASED_LIKELIHOOD
FLUOROURACIL;DPYD;rs4294451;AT + TT;TOXICITY;DECREASED_LIKELIHOOD
;ACE2;rs2074192;T;OTHER;INCREASED_SEVERITY
CLOPIDOGREL;P2RY12;rs6809699;AA;EFFICACY;INCREASED_RISKEFFICACY
ASPIRIN, CLOPIDOGREL;F2R;rs168753;T;EFFICACY;DECREASED_EFFICACY
CLOPIDOGREL;P2RY12;rs6809699;AA;EFFICACY;INCREASED_RISKEFFICACY
ASPIRIN;P2RY1;rs1065776;CT;EFFICACY;INCREASED_EFFICACY
MERCAPTOPURINE;ITPA;rs1127354;AC;LADME_PK;INCREASED_PK
;FGFR2;rs1219648;G;TOXICITY, OTHER;INCREASED_RISK
ANASTROZOLE;;rs6735923;T;EFFICACY;INCREASED_RISKEFFICACY
ACENOCOUMAROL;CYP2C9;rs1799853;CT + TT;TOXICITY;INCREASED_RISK
ASPIRIN, CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_EFFICACY
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC10A2;rs7319981;A;TOXICITY;INCREASED_RISK
;AGT;rs699;AG;OTHER;INCREASED_LIKELIHOOD
ANASTROZOLE;;rs1877193;C;EFFICACY;INCREASED_RISKEFFICACY
CAPECITABINE;DPYD;rs2786783;A;TOXICITY;INCREASED_SEVERITY
;COMT;rs4818;CC + CG;OTHER;INCREASED_SEVERITY
DRUGS FOR TREATMENT OF TUBERCULOSIS;UGT2B7;rs7662029;G;TOXICITY;INCREASED_LIKELIHOOD
DRUGS FOR TREATMENT OF TUBERCULOSIS;UGT2B7;rs7439366;C;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY, TOXICITY;INCREASED_
CEFACLOR;LIMD1;rs62242178;C;TOXICITY;INCREASED_LIKELIHOOD
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_
CEFACLOR;LIMD1;rs62242177;G;TOXICITY;INCREASED_LIKELIHOOD
REPAGLINIDE;SLCO1B1;rs4149056;CC;OTHER, LADME_PK;INCREASED_PK
DIHYDROPYRIDINE DERIVATIVES;ADRA1A;rs1048101;AG + GG;EFFICACY;DECREASED_RISKEFFICACY
THALIDOMIDE;XRCC5;rs1051685;AG;EFFICACY;INCREASED_EFFICACY
THALIDOMIDE;ERCC1;rs735482;AC + CC;EFFICACY;INCREASED_EFFICACY
CLOZAPINE, OLANZAPINE;GCG;rs13429709;C;OTHER;INCREASED_
CLOZAPINE, OLANZAPINE;GLP1R;rs2268639;T;OTHER;INCREASED_
NICOTINE;OPRM1;rs1799971;AA + AG;DOSAGE;INCREASED_
NICOTINE;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_
TOLCAPONE;COMT;rs4680;AA;EFFICACY;INCREASED_SEVERITYEFFICACY
NICOTINE;UGT2B10;rs112561475;AG + GG;LADME_PK;INCREASED_PK
NICOTINE;UGT2B10;rs61750900;T;LADME_PK;DECREASED_PK
CLOZAPINE, OLANZAPINE;GCG;rs13429709;CC;OTHER;INCREASED_
DIHYDROPYRIDINE DERIVATIVES;CYP3A5;rs776746;TT;EFFICACY;INCREASED_RISKEFFICACY
METHAMPHETAMINE;HTR1A;rs878567;A;TOXICITY, OTHER;
METHOTREXATE;MTHFR;rs1801133;A;TOXICITY;INCREASED_RISK
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;rs9679162;TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY
CAPTOPRIL;ACE;rs4291;AA;EFFICACY;DECREASED_SEVERITY
ANTIEPILEPTICS;;rs4471527;T;TOXICITY;INCREASED_LIKELIHOOD
ANTIPSYCHOTICS;LEPR;rs1137101;G;OTHER;INCREASED_LIKELIHOOD
ANTHRACYCLINES AND RELATED SUBSTANCES;HAS3;rs2232228;A;TOXICITY;DECREASED_RISK
ETHANOL;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_RISK
ANTIEPILEPTICS;;rs77542827;T;TOXICITY;INCREASED_LIKELIHOOD
STAVUDINE;SAMHD1;rs8124728;A;TOXICITY;DECREASED_RISK
CARVEDILOL;ADRB1;rs1801253;CC;EFFICACY;DECREASED_EFFICACY
IRINOTECAN;TGFB1;rs1800469;AG + GG;TOXICITY;INCREASED_RISK
ANTHRACYCLINES AND RELATED SUBSTANCES;RARG;rs2229774;A;TOXICITY;INCREASED_RISK
CYTARABINE, DAUNORUBICIN, MITOXANTRONE;DCK;rs4643786;CT;EFFICACY;INCREASED_EFFICACY
ANTIEPILEPTICS;NIPAL2;rs199755581;A;TOXICITY;INCREASED_LIKELIHOOD
OXALIPLATIN, PACLITAXEL;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
AMLODIPINE, CHLORTHALIDONE, LISINOPRIL;ACE;rs4291;AA + AT;OTHER;DECREASED_
SORAFENIB;KDR;rs1870377;T;TOXICITY;INCREASED_RISK
IRINOTECAN;TGFBR2;rs3087465;GG;TOXICITY;INCREASED_RISK
SORAFENIB;KDR;rs1870377;T;TOXICITY;INCREASED_RISK
SUNITINIB;FLT4;rs307826;CT;EFFICACY;EFFICACY
SUNITINIB;CYP3A5;rs776746;TT;TOXICITY;INCREASED_RISK
RITODRINE;PDE4B;rs17128809;AA;TOXICITY;INCREASED_RISK
CYCLOPHOSPHAMIDE, DOCETAXEL, EPIRUBICIN;ABCC1;rs246221;CC;TOXICITY;INCREASED_LIKELIHOOD
SUNITINIB;FLT4;rs307821;AC;EFFICACY;DECREASED_EFFICACY
BETA BLOCKING AGENTS;ADRB2;rs1042713;AG + GG;EFFICACY;INCREASED_RISKEFFICACY
SALBUTAMOL;;rs9552679;C;EFFICACY;DECREASED_EFFICACY
SALBUTAMOL;COL22A1;rs6988229;T;EFFICACY;INCREASED_EFFICACY
SALBUTAMOL;;rs17495520;T;EFFICACY;INCREASED_EFFICACY
ASPIRIN, CLOPIDOGREL;CDH15;rs72819363;C;EFFICACY;INCREASED_LIKELIHOODEFFICACY
ANTIEPILEPTICS;DDX12P;rs77491650;C;TOXICITY;DECREASED_LIKELIHOOD
SALBUTAMOL;;rs1663332;T;EFFICACY;INCREASED_EFFICACY
SALBUTAMOL;;rs1663330;G;EFFICACY;INCREASED_EFFICACY
SALBUTAMOL;;rs17701271;A;EFFICACY;INCREASED_EFFICACY
SALBUTAMOL;;rs518350;T;EFFICACY;INCREASED_EFFICACY
SALBUTAMOL;;rs10511905;G;EFFICACY;DECREASED_EFFICACY
SORAFENIB;ABCC2;rs717620;CC;TOXICITY;INCREASED_RISK
SALBUTAMOL;CLOCK;rs1522113;A;EFFICACY;INCREASED_EFFICACY
SALBUTAMOL;;rs1423515;A;EFFICACY;INCREASED_EFFICACY
SALBUTAMOL;;rs1419555;T;EFFICACY;INCREASED_EFFICACY
SALBUTAMOL;;rs6002674;C;EFFICACY;DECREASED_EFFICACY
;ACE2;rs2106809;A;OTHER;INCREASED_LIKELIHOOD
DOXORUBICIN;GSTP1;rs1695;AG + GG;TOXICITY;INCREASED_LIKELIHOOD
METHOTREXATE;ABCB1;rs1045642;A;TOXICITY;INCREASED_RISK
ASPIRIN, CLOPIDOGREL;CDH13;rs11859453;AA + AG;EFFICACY;DECREASED_LIKELIHOODEFFICACY
ALLOPURINOL;CYCSP5;rs3099844;A;TOXICITY;INCREASED_LIKELIHOOD
ALLOPURINOL;;rs1634776;T;TOXICITY;INCREASED_LIKELIHOOD
PACLITAXEL;ABCB1;rs1128503;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
SALBUTAMOL;;rs11252394;A;EFFICACY;INCREASED_EFFICACY
SORAFENIB;SLCO1B1;rs4149056;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
COCAINE;GABRA2;rs11503014;G;TOXICITY;INCREASED_SEVERITY
COCAINE;OPRM1;rs2236256;C;TOXICITY;DECREASED_SEVERITY
SORAFENIB;SLCO1B1;rs2306283;AG + GG;TOXICITY;INCREASED_LIKELIHOOD
SORAFENIB;SLCO1B1;rs2306283;AG + GG;TOXICITY;DECREASED_LIKELIHOOD
METHOTREXATE;ABCB1;rs1128503;A;TOXICITY;INCREASED_RISK
;AGT;rs699;A;OTHER;DECREASED_SEVERITY
CANGRELOR;P2RY12;rs9859552;TT;OTHER;
SORAFENIB;NOS3;rs2070744;TT;EFFICACY;DECREASED_EFFICACY
RADIOTHERAPY;TANC1;rs10497203;C;TOXICITY;INCREASED_RISK
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_RISK
SORAFENIB;NOS3;rs1799983;GG;EFFICACY;DECREASED_EFFICACY
SORAFENIB;NOS3;rs1799983;GG;EFFICACY;DECREASED_EFFICACY
GLUCOCORTICOIDS;GLCCI1;rs37973;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;ABCG2;rs7699188;A;EFFICACY;INCREASED_EFFICACY
SORAFENIB;NOS3;rs2070744;TT;EFFICACY;DECREASED_EFFICACY
AZATHIOPRINE;NUDT15;rs116855232;T;TOXICITY;DECREASED_
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CTLA4;rs3087243;AG + GG;TOXICITY;DECREASED_RISK
WARFARIN;VKORC1;rs8050894;G;DOSAGE;DECREASED_
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_RISK
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FBXL19;rs10782001;GG;TOXICITY;INCREASED_RISK
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL23R;rs11209026;AG;TOXICITY;INCREASED_RISK
AZATHIOPRINE;NUDT15;rs116855232;TT;TOXICITY;INCREASED_SEVERITY
METHOTREXATE;MTHFR;rs1801133;A;LADME_PK;INCREASED_RISKPK
WARFARIN;VKORC1;rs8050894;G;DOSAGE;DECREASED_
ETHANOL;OPRM1;rs1799971;G;TOXICITY;INCREASED_RISK
MORPHINE;ABCB1;rs2032582;CC;TOXICITY;DECREASED_LIKELIHOOD
COLISTIMETHATE;SLC15A2;rs2257212;T;TOXICITY;INCREASED_LIKELIHOOD
HEROIN;OPRM1;rs1799971;G;TOXICITY;INCREASED_RISK
ASPARAGINASE, DAUNORUBICIN, METHOTREXATE, PREDNISOLONE, VINCRISTINE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_SEVERITY
ASPARAGINASE, DAUNORUBICIN, METHOTREXATE, PREDNISOLONE, VINCRISTINE;MTHFR;rs1801131;GT + TT;TOXICITY;INCREASED_RISK
WARFARIN;GGCX;rs699664;CT + TT;DOSAGE;DECREASED_
CETUXIMAB;FCGR3A;rs396991;A;EFFICACY;INCREASED_EFFICACY
WARFARIN;CYP2C9;rs28371685;CT;DOSAGE;DECREASED_
CETUXIMAB;CCND1;rs9344;G;EFFICACY;DECREASED_EFFICACY
WARFARIN;F7;rs510335;GT + TT;DOSAGE;DECREASED_
TACROLIMUS;IL10;rs1800871;AA;EFFICACY;INCREASED_LIKELIHOODEFFICACY
ESCITALOPRAM;HTR1B;rs11568817;AC + CC;TOXICITY;INCREASED_RISK
CETUXIMAB;CCND1;rs9344;AA;EFFICACY;DECREASED_EFFICACY
METHOTREXATE;SLC19A1;rs1051266;TT;TOXICITY;DECREASED_RISK
FLUVOXAMINE, MILNACIPRAN, PAROXETINE;MDGA2;rs1160351;A;TOXICITY;INCREASED_RISK
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS"", ""RITONAVIR""";APOC1, APOE, TOMM40;rs429358;CC + CT;TOXICITY;INCREASED_
ESCITALOPRAM;HTR2A;rs6311;CT + TT;TOXICITY;INCREASED_RISK
TACROLIMUS;IL10;rs1800872;TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY
;;rs17234657;G;;INCREASED_RISK
WARFARIN;VKORC1;rs9934438;AG + GG;DOSAGE;INCREASED_
LEVODOPA;HOMER1;rs4704559;AG + GG;TOXICITY;DECREASED_RISK
CYCLOPHOSPHAMIDE, DOCETAXEL, EPIRUBICIN;SOD2;rs4880;AG + GG;TOXICITY;INCREASED_LIKELIHOOD
LEVODOPA;HOMER1;rs4704559;AG + GG;TOXICITY;DECREASED_RISK
;;rs2200733;T;;INCREASED_RISK
ESTRADIOL;NFE2L2;rs6721961;T;TOXICITY;INCREASED_RISK
HYDROCHLOROTHIAZIDE;YEATS4;rs7297610;CC;EFFICACY;INCREASED_EFFICACY
CAPECITABINE;DPYD;rs3918290;CT;TOXICITY;INCREASED_LIKELIHOOD
WARFARIN;F2;rs5896;CT + TT;DOSAGE;DECREASED_
;HLA-DRA;rs3135388;A;;INCREASED_RISK
VINCRISTINE;CEP72;rs924607;TT;TOXICITY;INCREASED_LIKELIHOOD
;NOD2;rs17221417;G;;INCREASED_RISK
CISPLATIN, PACLITAXEL;TP53;rs1042522;CG + GG;EFFICACY;DECREASED_EFFICACY
AZATHIOPRINE;ITPA;rs1127354;AC;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CES1;rs71647871;CT;PD;INCREASED_LIKELIHOODEFFICACY
;TCF7L2;rs12255372;T;;INCREASED_RISK
;IL6;rs1800797;AG + GG;OTHER;INCREASED_SEVERITY
;TCF7L2;rs12243326;C;;INCREASED_RISK
;TCF7L2;rs4506565;T;;INCREASED_RISK
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_
ETHANOL;ADH1B;rs1229984;T;TOXICITY;DECREASED_RISK
WARFARIN;VKORC1;rs9934438;AG;DOSAGE;INCREASED_
;CDKN2B-AS1;rs10965219;G;OTHER;INCREASED_
MORPHINE;COMT;rs4680;AA;EFFICACY;INCREASED_EFFICACY
ETHANOL;RABGAP1L;rs61826952;G;TOXICITY;DECREASED_RISK
MORPHINE;COMT;rs4680;AA;EFFICACY;INCREASED_EFFICACY
;CDKN2B-AS1;rs10965219;G;OTHER;INCREASED_RISK
TRAMADOL;CYP2D6;rs1058172;CC;TOXICITY;INCREASED_LIKELIHOOD
CLOZAPINE;CYP2D6;rs16947;GG;TOXICITY;INCREASED_SEVERITY
TRAMADOL;CYP2B6;rs4803419;CC;TOXICITY;INCREASED_LIKELIHOOD
;ACE2;rs4240157;CC;OTHER;INCREASED_RISK
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_PK
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;DECREASED_PK
;ACE2;rs4240157;C;OTHER;INCREASED_LIKELIHOOD
CLOZAPINE;CYP2D6;rs1065852;AA;TOXICITY;INCREASED_SEVERITY
CLOZAPINE;CYP2D6;rs1065852;AA;TOXICITY;INCREASED_SEVERITY
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_PK
METHOTREXATE;SLC19A1;rs1051266;TT;TOXICITY;INCREASED_LIKELIHOOD
CLOZAPINE;CYP2D6;rs16947;GG;TOXICITY;INCREASED_SEVERITY
HMG COA REDUCTASE INHIBITORS;COQ5;rs10849757;AA + AG;EFFICACY;INCREASED_LIKELIHOOD
AZATHIOPRINE;ITPA;rs1127354;AC;TOXICITY;INCREASED_LIKELIHOOD
ZOLEDRONATE;FDPS;rs2297480;TT;TOXICITY;INCREASED_LIKELIHOOD
HMG COA REDUCTASE INHIBITORS;COQ3;rs11548336;TT;EFFICACY;INCREASED_LIKELIHOOD
IMATINIB;CYP2B6;rs3745274;GG;TOXICITY;INCREASED_RISK
HMG COA REDUCTASE INHIBITORS;COQ2;rs4693075;CG + GG;EFFICACY;INCREASED_LIKELIHOOD
CYCLOPHOSPHAMIDE, DOXORUBICIN;ABCB1;rs2032582;CT + TT;EFFICACY;DECREASED_EFFICACY
CYCLOPHOSPHAMIDE, DOXORUBICIN;CYP2B6;rs3211371;T;TOXICITY;INCREASED_LIKELIHOOD
ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;CLMN;rs8014194;A;EFFICACY;EFFICACY
CYCLOPHOSPHAMIDE, DOXORUBICIN;CYP2B6;rs12721655;AG;EFFICACY;DECREASED_EFFICACY
NINTEDANIB;DSP;rs2076295;TT;EFFICACY;DECREASED_EFFICACY
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_
CYCLOPHOSPHAMIDE, DOXORUBICIN;CYP2B6;rs8192709;CT;EFFICACY;DECREASED_EFFICACY
FLUOROURACIL, LEUCOVORIN;MTHFR;rs1801133;GG;TOXICITY;DECREASED_SEVERITY
WARFARIN;F2;rs5896;CT + TT;DOSAGE;DECREASED_
BUSULFAN;CYP2C19;rs12248560;CC;LADME_PK;INCREASED_PK
CAPECITABINE;MTHFR;rs1801131;TT;TOXICITY;DECREASED_
WARFARIN;F7;rs510317;GG;DOSAGE;DECREASED_
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TAP1;rs1135216;CT;TOXICITY;DECREASED_RISK
OLANZAPINE, QUETIAPINE, RISPERIDONE;ANKK1;rs1800497;AA;TOXICITY;INCREASED_RISK
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLC12A8;rs651630;AA;TOXICITY;DECREASED_RISK
RADIOTHERAPY;TANC1;rs264588;A;TOXICITY;INCREASED_RISK
EFAVIRENZ;CYP2B6;rs3745274;TT;TOXICITY, LADME_PK;INCREASED_PK
RADIOTHERAPY;TANC1;rs264631;G;TOXICITY;INCREASED_RISK
BUSULFAN;CYP2C9;rs1799853;CT + TT;LADME_PK;INCREASED_PK
CYCLOPHOSPHAMIDE, DOXORUBICIN;SLC22A16;rs714368;C;TOXICITY;DECREASED_LIKELIHOOD
RADIOTHERAPY;TANC1;rs7582141;T;TOXICITY;INCREASED_RISK
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;ABCG2;rs7699188;A;TOXICITY;INCREASED_RISK
RADIOTHERAPY;TANC1;rs6432512;T;TOXICITY;INCREASED_RISK
RADIOTHERAPY;TANC1;rs264663;T;TOXICITY;INCREASED_RISK
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;ABCB1;rs2032582;CC;EFFICACY;EFFICACY
RADIOTHERAPY;TANC1;rs264651;G;TOXICITY;INCREASED_RISK
CYCLOPHOSPHAMIDE, DOXORUBICIN;CYP2B6;rs3745274;T;TOXICITY;DECREASED_LIKELIHOOD
CYCLOPHOSPHAMIDE, DOXORUBICIN;CYP2B6;rs8192709;T;TOXICITY;INCREASED_LIKELIHOOD
PLATINUM COMPOUNDS;XPC;rs2228000;AA + AG;TOXICITY;DECREASED_RISK
SECUKINUMAB;ERAP2;rs2248374;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
CYCLOPHOSPHAMIDE, DOXORUBICIN;SLC22A16;rs12210538;G;TOXICITY;INCREASED_LIKELIHOOD
CYCLOPHOSPHAMIDE, DOXORUBICIN;SLC22A16;rs723685;G;TOXICITY;DECREASED_LIKELIHOOD
CYCLOPHOSPHAMIDE, DOXORUBICIN;SLC22A16;rs6907567;G;TOXICITY;DECREASED_LIKELIHOOD
ASPIRIN;LTC4S;rs730012;C;TOXICITY;INCREASED_RISK
ATORVASTATIN, ROSUVASTATIN;COQ2;rs4693075;G;TOXICITY;INCREASED_RISK
ATEZOLIZUMAB, AVELUMAB, DURVALUMAB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB;SEMA5A;rs35719165;A;TOXICITY;INCREASED_LIKELIHOOD
METHOTREXATE;MTHFD1;rs2236225;AA + AG;TOXICITY;DECREASED_RISK
WARFARIN;VKORC1;rs2884737;CC;TOXICITY;INCREASED_RISK
EFAVIRENZ, NELFINAVIR;ABCB1;rs1045642;AA;EFFICACY, OTHER;INCREASED_EFFICACY
EFAVIRENZ;ABCB1;rs1045642;AA;EFFICACY;INCREASED_LIKELIHOODEFFICACY
ATEZOLIZUMAB, AVELUMAB, DURVALUMAB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB;EDIL3;rs1862167;T;TOXICITY;INCREASED_LIKELIHOOD
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_PK
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_PK
DOXORUBICIN;ABCC2;rs17222723;A;TOXICITY, LADME_PK;INCREASED_RISK
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs2032583;AG + GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
AZATHIOPRINE;XDH;rs2295475;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
AZATHIOPRINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
;ATP8B3;rs10421558;G;TOXICITY;DECREASED_LIKELIHOOD
;ABCB1;rs1045642;AA;OTHER;INCREASED_LIKELIHOOD
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1799929;T;TOXICITY, LADME_PK;INCREASED_RISK
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1799930;A;TOXICITY, LADME_PK;INCREASED_RISK
ANTHRACYCLINES AND RELATED SUBSTANCES, DOXORUBICIN, EPIRUBICIN;ABCB1;rs1045642;GG;EFFICACY;INCREASED_EFFICACY
RITONAVIR;APOC3;rs2854117;T;TOXICITY;INCREASED_RISK
;AGTR1;rs5186;CC;OTHER;INCREASED_RISK
IMATINIB;ARID5B;rs10821936;TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1041983;T;TOXICITY, LADME_PK;INCREASED_RISK
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1801280;C;TOXICITY, LADME_PK;INCREASED_RISK
FEXOFENADINE;ABCB1;rs1045642;AA;DOSAGE, LADME_PK;DECREASED_PK
EFAVIRENZ;CYP2B6;rs28399499;C;LADME_PK;INCREASED_PK
EFAVIRENZ;CYP2B6;rs4803419;T;LADME_PK;INCREASED_PK
IMATINIB;ATIC;rs2372536;G;EFFICACY;INCREASED_LIKELIHOODEFFICACY
ATORVASTATIN, SIMVASTATIN;CYP3A4;rs2740574;CC + CT;OTHER;DECREASED_RISK
FEXOFENADINE;ABCB1;rs2032582;AA;DOSAGE, LADME_PK;DECREASED_PK
RITODRINE;KCNMB2;rs7625907;GG;TOXICITY;DECREASED_LIKELIHOOD
EFAVIRENZ;CYP2B6;rs3745274;T;LADME_PK;INCREASED_PK
DOXORUBICIN;ABCC1;rs45511401;T;TOXICITY, LADME_PK;INCREASED_RISK
DOXORUBICIN;ABCC2;rs8187710;A;TOXICITY, LADME_PK;INCREASED_RISK
CAPECITABINE, FOLFOX, TEGAFUR;SMAD7;rs4939827;CC;EFFICACY;DECREASED_EFFICACY
DOXORUBICIN;NCF4;rs1883112;AA;TOXICITY;INCREASED_RISK
;ATP8B3;rs10403288;A;TOXICITY;DECREASED_LIKELIHOOD
SIMVASTATIN;ABCB1;rs1128503;A;EFFICACY;DECREASED_RISK
;ACE2;rs2074192;T;OTHER;INCREASED_SEVERITY
DOXORUBICIN;CYBA;rs4673;A;TOXICITY;INCREASED_RISK
SIMVASTATIN;ABCB1;rs1045642;A;EFFICACY;DECREASED_RISK
DOXORUBICIN;RAC2;rs13058338;T;TOXICITY;INCREASED_RISK
SIMVASTATIN;ABCB1;rs2032582;C;EFFICACY;INCREASED_RISK
;ABO;rs8176746;T;;INCREASED_
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;DECREASED_PK
ATORVASTATIN, SIMVASTATIN;PON1;rs705379;AA + AG;EFFICACY;EFFICACY
ATORVASTATIN, SIMVASTATIN;PON1;rs662;CC + CT;EFFICACY;EFFICACY
ATORVASTATIN;PON1;rs705379;GG;OTHER;DECREASED_
CLOZAPINE;TACR1;rs58933792;C;TOXICITY;INCREASED_LIKELIHOOD
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;DECREASED_PK
FLUCONAZOLE, TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_PK
FLUCONAZOLE, TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_PK
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_PK
TAMOXIFEN;SLCO1A2;rs10841795;AG + GG;TOXICITY;DECREASED_SEVERITY
CLOZAPINE;ERBB4;rs3942465;C;TOXICITY;INCREASED_LIKELIHOOD
DIAZEPAM;CYP2C19;rs4244285;AA + AG;TOXICITY;INCREASED_SEVERITY
"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS"", ""BETA BLOCKING AGENTS"", ""DIGOXIN"", ""DIURETICS"", ""SPIRONOLACTONE""";ADRB2;rs1042713;GG;OTHER;INCREASED_RISK
PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs1127354;AA + AC;EFFICACY;INCREASED_EFFICACY
L-ASPARAGINE, PREDNISONE, VINCRISTINE;ASNS;rs1049674;AT;TOXICITY;INCREASED_LIKELIHOOD
"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS"", ""BETA BLOCKING AGENTS"", ""DIGOXIN"", ""DIURETICS"", ""SPIRONOLACTONE""";NOS3;rs1799983;TT;OTHER;INCREASED_RISK
EFAVIRENZ, LOPINAVIR, NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS, RITONAVIR;;rs2853826;G;TOXICITY;INCREASED_
DIAZEPAM;CYP2C19;rs12248560;CT + TT;TOXICITY;DECREASED_SEVERITY
"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS"", ""BETA BLOCKING AGENTS"", ""DIGOXIN"", ""DIURETICS"", ""SPIRONOLACTONE""";ADRB1;rs1801253;GG;OTHER;DECREASED_RISK
L-ASPARAGINE, PREDNISONE, VINCRISTINE;ABCB1;rs9282564;CT;TOXICITY;INCREASED_LIKELIHOOD
OLANZAPINE;UGT1A4;rs2011425;GG + GT;TOXICITY;DECREASED_SEVERITY
OLANZAPINE;CYP3A4;rs2740574;CC + CT;TOXICITY;INCREASED_LIKELIHOOD
CABAZITAXEL;ABCB1;rs17327624;T;TOXICITY;INCREASED_LIKELIHOOD
SIMVASTATIN;ABCB1;rs1128503;AA;EFFICACY;INCREASED_EFFICACY
OLANZAPINE;UGT1A4;rs2011425;GG + GT;LADME_PK;INCREASED_PK
;COL1A1;rs1800012;AA + AC;;INCREASED_RISK
CYCLOSPORINE;ABCB1;rs1045642;AG;TOXICITY;INCREASED_SEVERITY
TACROLIMUS;CYP3A5;rs776746;CT;EFFICACY;INCREASED_RISKEFFICACY
CLOPIDOGREL;P2RY12;rs6785930;AA + AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
CABAZITAXEL;ABCB1;rs2235040;T;TOXICITY;DECREASED_LIKELIHOOD
TACROLIMUS;NOD2;rs2066844;CC;OTHER;INCREASED_
TACROLIMUS;CYP3A5;rs776746;TT;EFFICACY;INCREASED_RISK
TACROLIMUS;CYP3A5;rs776746;CT;EFFICACY;INCREASED_RISK
CYCLOSPORINE, TACROLIMUS;CYP3A4;rs2740574;CT;TOXICITY;INCREASED_LIKELIHOOD
WARFARIN;VKORC1;rs2359612;AA + AG;EFFICACY;DECREASED_EFFICACY
AZATHIOPRINE, MERCAPTOPURINE;FTO;rs16952570;CC;TOXICITY;DECREASED_RISK
OSELTAMIVIR;CES1;rs121912777;CT + TT;LADME_PK;PK
AZATHIOPRINE, MERCAPTOPURINE;FTO;rs16952570;CT;TOXICITY;INCREASED_RISK
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_PK
CABAZITAXEL;CYP2C8;rs11572093;T;TOXICITY;INCREASED_LIKELIHOOD
WARFARIN;VKORC1;rs9923231;CT + TT;EFFICACY;DECREASED_EFFICACY
CITALOPRAM;CYP2C19;rs4244285;A;TOXICITY;INCREASED_
WARFARIN;VKORC1;rs9934438;AA + AG;EFFICACY;DECREASED_EFFICACY
NORTRIPTYLINE;GNB3;rs5443;TT;TOXICITY;
WARFARIN;VKORC1;rs8050894;CG + GG;EFFICACY;DECREASED_EFFICACY
NORTRIPTYLINE;GNB3;rs5443;TT;TOXICITY;DECREASED_LIKELIHOOD
WARFARIN;VKORC1;rs2884737;AC + CC;EFFICACY;DECREASED_EFFICACY
NORTRIPTYLINE;GNB3;rs5443;TT;EFFICACY;EFFICACY
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_PK
WARFARIN;VKORC1;rs9934438;A;EFFICACY;DECREASED_EFFICACY
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_PK
;SLC19A1;rs1051266;C;OTHER;INCREASED_LIKELIHOOD
DIGOXIN;ABCB1;rs1045642;AA;LADME_PK;DECREASED_PK
OLANZAPINE;HTR2A;rs7997012;AA;TOXICITY;INCREASED_RISK
CAPECITABINE, FLUOROURACIL, TEGAFUR;DPYD;rs3918290;T;TOXICITY;INCREASED_RISK
CAPECITABINE, FLUOROURACIL, TEGAFUR;DPYD;rs67376798;A;TOXICITY;INCREASED_RISK
OLANZAPINE;ABCB1;rs1045642;A;EFFICACY;EFFICACY
OLANZAPINE;CYP1A2;rs762551;AA;LADME_PK;DECREASED_PK
NICOTINE;OPRM1;rs1799971;AA;EFFICACY;INCREASED_LIKELIHOODEFFICACY
OLANZAPINE;DRD2;rs6275;A;OTHER, LADME_PK;INCREASED_
ANTHRACYCLINES AND RELATED SUBSTANCES;CBR1;rs9024;GG;TOXICITY;INCREASED_RISK
OLANZAPINE;DRD2;rs6279;G;OTHER, LADME_PK;INCREASED_
CEPHALEXIN;;rs34545984;T;TOXICITY;INCREASED_RISK
OLANZAPINE;DRD2;rs1124493;T;OTHER, LADME_PK;INCREASED_
OLANZAPINE;DRD2;rs2734841;A;OTHER, LADME_PK;INCREASED_
ASPIRIN;;rs115346678;A;TOXICITY;INCREASED_RISK
METHOTREXATE;MTHFD1;rs2236225;A;EFFICACY;DECREASED_LIKELIHOODEFFICACY
SIMVASTATIN;PPARA;rs4253728;AA;EFFICACY;INCREASED_EFFICACY
METHOTREXATE;MTHFR;rs1801133;A;EFFICACY;INCREASED_RISKEFFICACY
CODEINE;WBP2NL;rs9620007;G;TOXICITY;DECREASED_RISK
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_
CODEINE, HYDROCODONE, OXYCODONE, TRAMADOL;OPRM1;rs62436463;T;TOXICITY;DECREASED_RISK
METFORMIN;SLC22A2;rs316009;CC;TOXICITY;INCREASED_LIKELIHOOD
METFORMIN;SLC22A2;rs316019;CC;TOXICITY;INCREASED_LIKELIHOOD
SIMVASTATIN;PPARA;rs4823613;GG;EFFICACY;INCREASED_EFFICACY
;ANKK1;rs1800497;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
NICOTINE;COMT;rs4680;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
ESCITALOPRAM;HTR2A;rs6311;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
NICOTINE;ANKK1;rs1800497;AA + AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
AMIODARONE, ANTIBIOTICS, ANTIPSYCHOTICS, DIURETICS, QUINIDINE, SOTALOL;KCNE1;rs1805128;T;TOXICITY;INCREASED_RISK
NICOTINE;OPRM1;rs1799971;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
NICOTINE;OPRM1;rs1799971;AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
BUPROPION;ANKK1;rs1800497;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
OLANZAPINE;DRD2;rs2734842;G;OTHER, LADME_PK;INCREASED_
METHOTREXATE;MTHFR;rs1801133;A;TOXICITY;INCREASED_LIKELIHOOD
PYRIMIDINE ANALOGUES;DPYD;rs1801160;CT + TT;TOXICITY;INCREASED_RISK
ROSUVASTATIN;ABCG2;rs2231142;GG;EFFICACY;DECREASED_EFFICACY
AMITRIPTYLINE;CYP2C19;rs4244285;AA;OTHER, LADME_PK;INCREASED_PK
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_RISKEFFICACY
ROSUVASTATIN;SLCO1B1;rs4149056;TT;LADME_PK;DECREASED_PK
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;INCREASED_RISKEFFICACY
ROSUVASTATIN;ABCG2;rs2231142;TT;LADME_PK;INCREASED_PK
CLOPIDOGREL;ABCB1;rs1045642;AA;EFFICACY;INCREASED_RISKEFFICACY
CLOPIDOGREL;ABCB1;rs1045642;AA;EFFICACY;INCREASED_LIKELIHOODEFFICACY
CISPLATIN, DOCETAXEL, FLUOROURACIL;CCL2;rs1024611;GG;TOXICITY;INCREASED_SEVERITY
;SERPINE1;rs7242;T;OTHER;INCREASED_LIKELIHOOD
;SERPINE1;rs2227684;G;OTHER;INCREASED_LIKELIHOOD
METHOTREXATE;MTHFR;rs1801131;G;EFFICACY;INCREASED_LIKELIHOODEFFICACY
GEMCITABINE;CDA;rs60369023;A;TOXICITY, LADME_PK;INCREASED_SEVERITY
METHOTREXATE;GGH;rs3758149;AA;TOXICITY;INCREASED_LIKELIHOOD
BISPHOSPHONATES;IL1B;rs16944;GG;EFFICACY;INCREASED_LIKELIHOODPK
CLODRONATE;VDR;rs1544410;C;EFFICACY;INCREASED_LIKELIHOODEFFICACY
WARFARIN;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
CLODRONATE;VDR;rs731236;A;EFFICACY;INCREASED_LIKELIHOODEFFICACY
CYTARABINE, IDARUBICIN;NT5C3A;rs3750117;GG;EFFICACY;INCREASED_RISKEFFICACY
ATORVASTATIN, LOVASTATIN, SIMVASTATIN;APOA5;rs662799;AG + GG;EFFICACY;DECREASED_EFFICACY
CITALOPRAM, SERTRALINE;HTR2A;rs6311;T;TOXICITY;INCREASED_LIKELIHOOD
CISPLATIN, DOCETAXEL, FLUOROURACIL;IL6;rs1800796;CC;TOXICITY;INCREASED_LIKELIHOOD
CITALOPRAM;HTR2A;rs6313;AA;TOXICITY;INCREASED_LIKELIHOOD
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_LIKELIHOOD
BUPRENORPHINE / NALOXONE;OPRM1;rs648893;AG + GG;TOXICITY;DECREASED_SEVERITY
METHOTREXATE;ADORA2A;rs2267076;T;TOXICITY;INCREASED_RISK
METHOTREXATE;ADORA2A;rs2236624;T;TOXICITY;INCREASED_RISK
METHOTREXATE;ADORA2A;rs2298383;T;TOXICITY;INCREASED_RISK
TACROLIMUS;CYP3A5;rs776746;CT + TT;OTHER;INCREASED_PK
METHOTREXATE;ADORA2A;rs3761422;T;TOXICITY;INCREASED_RISK
CISPLATIN, DOCETAXEL, FLUOROURACIL;TNF;rs1799964;CC + CT;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;ABCB1;rs1045642;AA;EFFICACY;INCREASED_LIKELIHOODEFFICACY
ASPIRIN, CLOPIDOGREL;PEAR1;rs12041331;AA + AG;EFFICACY;DECREASED_EFFICACY
CISPLATIN, DOCETAXEL, FLUOROURACIL;ABCC2;rs717620;CT + TT;TOXICITY;INCREASED_SEVERITY
HYDROCHLOROTHIAZIDE;NELL1;rs12279250;C;LADME_PK;INCREASED_
BUPRENORPHINE / NALOXONE;OPRD1;rs678849;TT;TOXICITY;DECREASED_SEVERITY
ARIPIPRAZOLE;DAOA;rs2391191;A;EFFICACY;DECREASED_EFFICACY
BUPRENORPHINE / NALOXONE;OPRD1;rs569356;A;EFFICACY;DECREASED_LIKELIHOODEFFICACY
OLANZAPINE;HTR2C;rs6318;C;TOXICITY;INCREASED_SEVERITY
TACROLIMUS;CYP3A5;rs776746;T;TOXICITY;INCREASED_RISK
TACROLIMUS;CYP3A5;rs776746;CC;EFFICACY, TOXICITY;INCREASED_RISK
SIMVASTATIN;CYBA;rs4673;AA + AG;EFFICACY;INCREASED_EFFICACY
BUPROPION;CYP2B6;rs3211371;CT;EFFICACY;INCREASED_LIKELIHOODEFFICACY
ASPIRIN;ABCB1;rs1045642;AG + GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
OLANZAPINE;DRD3;rs6280;CC;EFFICACY;EFFICACY
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_RISK
OLANZAPINE;RGS4;rs951439;CT;EFFICACY;INCREASED_LIKELIHOODEFFICACY
CABAZITAXEL;TUBB1;rs151352;G;EFFICACY;INCREASED_EFFICACY
RISPERIDONE;RGS4;rs951439;TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY
OLANZAPINE, PERPHENAZINE;RGS4;rs951439;CC;EFFICACY;INCREASED_LIKELIHOODEFFICACY
CABAZITAXEL;CYP2C8;rs1341164;C;EFFICACY;INCREASED_EFFICACY
OLANZAPINE;LEP;rs4731426;GG;TOXICITY;INCREASED_RISK
HEROIN;GRM3;rs13242038;T;OTHER;INCREASED_RISK
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs2235015;A;EFFICACY;INCREASED_LIKELIHOODEFFICACY
;ACE;rs4343;G;LADME_PK;INCREASED_
ANTIDEPRESSANTS;HTR1A;rs6295;GG;EFFICACY;DECREASED_EFFICACY
OPIOIDS;ABCB1;rs9282564;CC + CT;TOXICITY;DECREASED_RISK
ANTHRACYCLINES AND RELATED SUBSTANCES, TAXANES;ABCB1;rs1045642;AA;EFFICACY, LADME_PK;INCREASED_LIKELIHOODEFFICACY
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED_EFFICACY
PAROXETINE, SERTRALINE;HTR1A;rs6295;CC;EFFICACY;INCREASED_LIKELIHOODEFFICACY
OPIOIDS;KCNJ6;rs2070995;TT;EFFICACY;INCREASED_EFFICACY
WARFARIN;VKORC1;rs8050894;G;DOSAGE, EFFICACY;EFFICACY
WARFARIN;VKORC1;rs9923231;T;DOSAGE, EFFICACY;EFFICACY
NEVIRAPINE;CYP2B6;rs28399499;CT;OTHER;INCREASED_LIKELIHOOD
NEVIRAPINE;CYP3A5;rs776746;CC + CT;OTHER;INCREASED_LIKELIHOOD
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;C9orf72;rs3849942;T;EFFICACY;INCREASED_RISKEFFICACY
METHAMPHETAMINE;DTNBP1;rs3213207;C;TOXICITY;INCREASED_RISK
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MOB3B;rs2814707;T;EFFICACY;INCREASED_RISKEFFICACY
METHAMPHETAMINE;PICK1;rs2076369;T;TOXICITY;INCREASED_LIKELIHOOD
NEVIRAPINE;CYP2B6;rs12721646;CT + TT;OTHER;INCREASED_LIKELIHOOD
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;GBP6;rs928655;A;EFFICACY;INCREASED_RISKEFFICACY
FLUOROURACIL;DPYD;rs1801265;AG + GG;TOXICITY;DECREASED_LIKELIHOOD
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;C9orf72;rs774359;C;EFFICACY;INCREASED_RISKEFFICACY
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CSRP3;rs983332;T;EFFICACY;INCREASED_RISKEFFICACY
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MOB3B;rs868856;A;EFFICACY;INCREASED_RISKEFFICACY
METHOTREXATE;MTHFR;rs1801131;G;TOXICITY;INCREASED_RISK
METHOTREXATE;MTHFR;rs1801131;TT;EFFICACY;INCREASED_EFFICACY
METHOTREXATE;SLC19A1;rs1051266;TT;EFFICACY;DECREASED_EFFICACY
GEFITINIB;EGFR;rs712829;GT + TT;EFFICACY;INCREASED_EFFICACY
ANTIANDROGENS;AKR1C3;rs12529;CC;EFFICACY;INCREASED_RISKEFFICACY
WARFARIN;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_
CISPLATIN, CYCLOPHOSPHAMIDE;ERCC1;rs11615;AG;TOXICITY;INCREASED_RISK
CISPLATIN, CYCLOPHOSPHAMIDE;TP53;rs1042522;GG;TOXICITY;INCREASED_SEVERITY
PACLITAXEL;CYP2C8;rs11572080;TT;TOXICITY;INCREASED_RISK
METHOTREXATE;ABCC1;rs2238476;GG;TOXICITY;INCREASED_RISK
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MAFB;rs6028945;T;EFFICACY;INCREASED_RISKEFFICACY
OLANZAPINE;HTR2C;rs3813929;T;TOXICITY;DECREASED_RISK
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MAFB;rs6071980;C;EFFICACY;INCREASED_RISKEFFICACY
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_LIKELIHOOD
OLANZAPINE;HTR2C;rs3813929;T;TOXICITY;DECREASED_RISK
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CST5;rs6138150;T;EFFICACY;INCREASED_RISKEFFICACY
OLANZAPINE;HTR2C;rs3813929;T;TOXICITY;DECREASED_RISK
CISPLATIN, CYCLOPHOSPHAMIDE;GSTP1;rs1695;AA;EFFICACY, LADME_PK;INCREASED_EFFICACY
ANTIPSYCHOTICS;CLCN6, MTHFR;rs1801133;A;TOXICITY;INCREASED_LIKELIHOOD
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;PON1;rs854548;A;EFFICACY;INCREASED_RISKEFFICACY
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;PON1;rs854555;A;EFFICACY;INCREASED_RISKEFFICACY
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MOB3B;rs7046653;A;EFFICACY;INCREASED_RISKEFFICACY
BUPRENORPHINE;CYP3A4;rs2740574;CC + CT;EFFICACY;INCREASED_RISK
WARFARIN;VKORC1;rs9934438;AG;EFFICACY;DECREASED_EFFICACY
DOCETAXEL;;rs11185648;CT;TOXICITY;INCREASED_SEVERITY
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_
DOCETAXEL;RXRA;rs11185647;AG;TOXICITY;INCREASED_SEVERITY
CISPLATIN;TPMT;rs12201199;T;TOXICITY;INCREASED_RISK
DOCETAXEL;RXRA;rs2234753;AG;TOXICITY;INCREASED_SEVERITY
DOCETAXEL;RXRA;rs6413517;GT;TOXICITY;INCREASED_SEVERITY
DOCETAXEL;RXRA;rs62576288;GG;TOXICITY;INCREASED_SEVERITY
;DRD2;rs1799732;GG;;INCREASED_LIKELIHOOD
;SCN1A;rs2298771;CT;OTHER;INCREASED_LIKELIHOOD
METHOTREXATE;;rs9345389;G;TOXICITY;
DOCETAXEL;HNF4A;rs6130615;TT;TOXICITY;INCREASED_SEVERITY
ANTIPSYCHOTICS;HTR2A;rs7997012;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
SIMVASTATIN;;rs76103438;A;TOXICITY;INCREASED_RISK
DIAZEPAM;CYP3A4;rs35599367;GG;TOXICITY;INCREASED_SEVERITY
ANTIPSYCHOTICS;HTR2A;rs6314;AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
DOCETAXEL;HNF4A;rs2273618;CT;TOXICITY;INCREASED_SEVERITY
DOCETAXEL;HNF4A;rs3746574;CT;TOXICITY;INCREASED_SEVERITY
WARFARIN;VKORC1;rs9934438;A;DOSAGE, EFFICACY;
DOCETAXEL;NR1I2;rs3732360;TT;TOXICITY;INCREASED_SEVERITY
;NRXN1;rs985919;C;OTHER;INCREASED_LIKELIHOOD
"""BETA BLOCKING AGENTS, SELECTIVE"", ""DIURETICS""";NEDD4L;rs4149601;AG + GG;EFFICACY;DECREASED_RISK
MEPERIDINE;SERINC5;rs185462714;C;TOXICITY;INCREASED_RISK
CISPLATIN, CYCLOPHOSPHAMIDE;GSTA1;rs3957357;AA;EFFICACY;INCREASED_EFFICACY
DOCETAXEL;NR1I2;rs3732359;AA;TOXICITY;INCREASED_SEVERITY
;CHRNA5;rs17408276;C;OTHER;INCREASED_LIKELIHOOD
BETA BLOCKING AGENTS;;rs139945292;T;TOXICITY;INCREASED_RISK
NICOTINE;COMT;rs4680;AA;EFFICACY;INCREASED_LIKELIHOODEFFICACY
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK
PENICILLIN G, PENICILLIN V;;rs115200108;A;TOXICITY;INCREASED_RISK
NICOTINE;COMT;rs4680;AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_
DOCETAXEL;NR1I2;rs3814058;CC + TT;TOXICITY;INCREASED_SEVERITY
;CHRNA5;rs16969968;A;OTHER;INCREASED_LIKELIHOOD
;NRXN1;rs1882296;C;OTHER;INCREASED_LIKELIHOOD
DOCETAXEL;NR1I3;rs10538494;TT;TOXICITY;INCREASED_SEVERITY
CODEINE, HYDROCODONE, OXYCODONE, TRAMADOL;SEPTIN3, WBP2NL;rs739296;A;TOXICITY;DECREASED_RISK
MEPERIDINE;FIP1L1;rs113100019;G;TOXICITY;INCREASED_RISK
DOCETAXEL;NR1I3;rs75114882;AG;TOXICITY;INCREASED_SEVERITY
;NRXN1;rs10865246;C;OTHER;INCREASED_SEVERITY
CISPLATIN;COMT;rs9332377;T;TOXICITY;INCREASED_RISK
DOCETAXEL;NR1I3;rs2501873;CC;TOXICITY;DECREASED_SEVERITY
CISPLATIN, CYCLOPHOSPHAMIDE;ERCC2;rs1799793;CT;TOXICITY;INCREASED_SEVERITY
CISPLATIN, CYCLOPHOSPHAMIDE;ERCC1;rs3212986;AC;TOXICITY;INCREASED_RISK
CISPLATIN, CYCLOPHOSPHAMIDE;XRCC1;rs25487;CC;TOXICITY;INCREASED_SEVERITY
MEPERIDINE;;rs11049274;A;TOXICITY;INCREASED_RISK
DOCETAXEL;RXRA;rs1536475;AG;TOXICITY;INCREASED_SEVERITY
CISPLATIN;XPC;rs2228001;G;TOXICITY;INCREASED_RISK
DOCETAXEL;NR1I3;rs2502815;GG;TOXICITY;INCREASED_SEVERITY
DOCETAXEL;NR1I3;rs9725457;AA;TOXICITY;INCREASED_SEVERITY
CISPLATIN;ERCC2, KLC3;rs13181;G;EFFICACY;DECREASED_EFFICACY
ETHANOL;ACSS2;rs6088638;T;TOXICITY;INCREASED_RISK
CAPECITABINE, FLUOROURACIL;DPYD;rs17376848;AG;TOXICITY;INCREASED_RISK
ETHANOL;OPRM1;rs1799971;G;TOXICITY;INCREASED_RISK
ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs1058164;C;EFFICACY;DECREASED_SEVERITYEFFICACY
CISPLATIN;ERCC1;rs11615;G;EFFICACY;INCREASED_EFFICACY
;APOE;rs429358;CC;OTHER;INCREASED_SEVERITY
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY, TOXICITY;INCREASED_RISK
ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs1985842;T;EFFICACY;DECREASED_SEVERITYEFFICACY
;NAT2;rs1801280;T;OTHER;INCREASED_SEVERITY
ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs1135840;G;EFFICACY;DECREASED_SEVERITYEFFICACY
CLOPIDOGREL;CYP2C19;rs28399504;G;EFFICACY, TOXICITY;INCREASED_RISK
ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs28371713;G;EFFICACY;DECREASED_SEVERITYEFFICACY
;NAT2;rs1208;A;OTHER;INCREASED_SEVERITY
AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;;rs72631546;C;TOXICITY;INCREASED_RISK
GEFITINIB;ABCG2;rs2231142;GT;TOXICITY;INCREASED_LIKELIHOOD
ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs112568578;G;EFFICACY;DECREASED_SEVERITYEFFICACY
CAPECITABINE, FLUOROURACIL;MIR23A, MIR24-2, MIR27A;rs895819;C;TOXICITY;INCREASED_LIKELIHOOD
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;
AMOXICILLIN, CLAVULANATE;PTPN22;rs2476601;A;TOXICITY;INCREASED_RISK
MORPHINE;OPRM1;rs1799971;AA;TOXICITY;INCREASED_SEVERITY
COCAINE;CNR1;rs6454674;GT + TT;OTHER;INCREASED_RISK
;PTGS2;rs20417;G;;INCREASED_RISK
ATENOLOL, BETA BLOCKING AGENTS, CARVEDILOL, METOPROLOL;PPARA;rs4253778;GG;EFFICACY;DECREASED_
DOXORUBICIN;RARG;rs2229774;AG;TOXICITY;INCREASED_LIKELIHOOD
FLUVASTATIN;ABCG2;rs2231142;GT + TT;TOXICITY;INCREASED_LIKELIHOOD
ASPIRIN;TMEM196;rs9886152;T;TOXICITY;DECREASED_RISK
PAZOPANIB;HIF1A;rs11549467;AG;EFFICACY;DECREASED_EFFICACY
;CLOCK;rs1801260;AA + AG;OTHER;INCREASED_LIKELIHOOD
MERCAPTOPURINE, METHOTREXATE;ITPA;rs7270101;CC;TOXICITY;INCREASED_RISK
COCAINE;CNR1;rs6454674;GT + TT;OTHER;INCREASED_RISK
RITUXIMAB;FCGR3A;rs396991;C;EFFICACY;INCREASED_EFFICACY
MERCAPTOPURINE, METHOTREXATE;IMPDH1;rs2278293;CT;TOXICITY;INCREASED_RISK
RITUXIMAB;FCGR3A;rs396991;AA;;DECREASED_
COCAINE;CNR1;rs806368;C;OTHER;DECREASED_RISK
MERCAPTOPURINE, METHOTREXATE;ITPA;rs1127354;CC;TOXICITY;INCREASED_RISK
ALENDRONATE, RALOXIFENE;VDR;rs1544410;CC;EFFICACY;INCREASED_EFFICACY
ASPARAGINASE, DEXAMETHASONE, METHOTREXATE;PYGL;rs7142143;CC + CT;DOSAGE;INCREASED_RISKEFFICACY
INTERFERONS;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY
PAZOPANIB;CXCL8;rs4073;AA;EFFICACY;DECREASED_EFFICACY
ERLOTINIB;EGFR;rs121434569;T;EFFICACY;DECREASED_EFFICACY
ERLOTINIB, GEFITINIB;EGFR;rs121434569;T;EFFICACY;DECREASED_EFFICACY
INTERFERONS;IFNL3;rs8099917;TT;EFFICACY;INCREASED_EFFICACY
CAPECITABINE, IRINOTECAN, OXALIPLATIN;DPYD;rs17376848;AG;TOXICITY;INCREASED_SEVERITY
METHOTREXATE;;rs4888024;G;TOXICITY;
TACROLIMUS;ABCB1;rs1128503;AG;LADME_PK;INCREASED_PK
TACROLIMUS;ABCB1;rs2032582;AC + CT;LADME_PK;INCREASED_PK
METHOTREXATE;ABCC1;rs3784862;AA;TOXICITY;INCREASED_LIKELIHOOD
ETHANOL;OPRM1;rs1799971;A;TOXICITY;INCREASED_RISK
CAPECITABINE;DPYD;rs2297595;CT;TOXICITY;INCREASED_SEVERITY
CLOPIDOGREL;ABCB1;rs1045642;A;TOXICITY;INCREASED_RISK
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;CTBP2;rs945665113;A;EFFICACY;INCREASED_EFFICACY
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_EFFICACY
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_EFFICACY
CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MTHFR;rs1801133;AG;TOXICITY;INCREASED_RISK
ANTIDEPRESSANTS;HTR2A;rs6313;AA + AG;TOXICITY;DECREASED_RISK
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY
SUNITINIB;SLC22A5;rs2631367;C;EFFICACY;DECREASED_EFFICACY
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
CLOPIDOGREL;CYP2C19;rs4244285;AA;EFFICACY, TOXICITY;INCREASED_RISK
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
SUNITINIB;SLC22A5;rs2631370;C;EFFICACY;DECREASED_EFFICACY
;PTGS2;rs20417;CG + GG;;DECREASED_RISK
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;CTBP2;rs376695472;G;EFFICACY;INCREASED_EFFICACY
ANTIDEPRESSANTS;HTR2A;rs6311;CC;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;rs4244285;A;TOXICITY;INCREASED_RISK
BETA BLOCKING AGENTS;ADRB2;rs1042713;GG;EFFICACY;DECREASED_RISKEFFICACY
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED_LIKELIHOOD
FLUOROURACIL;DPYS;rs2959023;G;TOXICITY;INCREASED_LIKELIHOOD
SUNITINIB;IL4R;rs1805015;C;EFFICACY;DECREASED_EFFICACY
OMEGA-3 POLYUNSATURATED FATTY ACIDS;PTGS2;rs20417;CG + GG;OTHER;INCREASED_RISK
;PTGS2;rs20417;CG + GG;OTHER;DECREASED_RISK
FLUOROURACIL;DPYS;rs2669429;G;TOXICITY;DECREASED_LIKELIHOOD
METHOTREXATE;CLCN6, MTHFR;rs1801133;AG;TOXICITY;INCREASED_RISK
CAPECITABINE, FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_RISK
SUNITINIB;SLC22A5;rs2631372;C;EFFICACY;DECREASED_EFFICACY
CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MTHFR;rs1801131;GG;TOXICITY;INCREASED_RISK
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
SUNITINIB;IL4R;rs1801275;G;EFFICACY;DECREASED_EFFICACY
HEROIN;BDNF;rs16917234;TT;TOXICITY;DECREASED_AGE AT ONSET
AMINOGLYCOSIDE ANTIBACTERIALS;MT-RNR1;rs267606619;T;TOXICITY;INCREASED_RISK
TENOFOVIR;ABCC4;rs1751034;CC + CT;LADME_PK;INCREASED_PK
AZITHROMYCIN, ERYTHROMYCIN;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
CORTICOSTEROIDS;DTNBP1;rs35514893;T;EFFICACY;DECREASED_SEVERITY
;CYP1B1;rs1056836;CC + CG;OTHER;INCREASED_RISK
THIOTEPA;GSTP1;rs1138272;T;OTHER;INCREASED_PK
TENOFOVIR;ABCC4;rs1751034;TT;OTHER;INCREASED_PK
FLUOROURACIL;DPYD;rs2786783;A;TOXICITY;INCREASED_LIKELIHOOD
;G6PD;rs72554664;T;OTHER;INCREASED_LIKELIHOOD
OPIOIDS;;rs12442183;T;TOXICITY;INCREASED_LIKELIHOOD
CORTICOSTEROIDS;KL;rs450789;G;EFFICACY;DECREASED_SEVERITY
INTERFERON BETA-1A, INTERFERON BETA-1B;IRF6;rs2205986;G;TOXICITY;INCREASED_RISK
METHOTREXATE;NR1I2;rs3814058;C;TOXICITY;DECREASED_RISK
METHOTREXATE;ABCC2;rs2273697;A;TOXICITY;INCREASED_RISK
FLUOROURACIL;WNT5B;rs2010851;CC;EFFICACY;DECREASED_
CORTICOSTEROIDS;ME3;rs2125362;A;EFFICACY;INCREASED_SEVERITY
HEROIN;OPRD1;rs508448;GG;TOXICITY;DECREASED_AGE AT ONSET
METHOTREXATE;NR1I2;rs6785049;G;TOXICITY;DECREASED_RISK
CORTICOSTEROIDS;LHX2;rs7851998;A;EFFICACY;DECREASED_SEVERITY
FLUOROURACIL;DPYD;rs2811178;C;TOXICITY;INCREASED_LIKELIHOOD
CORTICOSTEROIDS;LHFPL3;rs61585310;G;EFFICACY;DECREASED_SEVERITY
ASPARAGINASE, CORTICOSTEROIDS, CYCLOPHOSPHAMIDE, CYTARABINE, MERCAPTOPURINE, METHOTREXATE, VINCRISTINE;IL10;rs1800896;CC;EFFICACY;INCREASED_EFFICACY
METHOTREXATE;GSK3B;rs3732361;A;LADME_PK;DECREASED_RISK
HEROIN;BDNF;rs6265;TT;TOXICITY;DECREASED_AGE AT ONSET
MORPHINE;SLC22A1;rs12208357;T;TOXICITY;INCREASED_LIKELIHOOD
CORTICOSTEROIDS;TRDN;rs4897302;T;EFFICACY;INCREASED_SEVERITY
NICOTINE;CHRNA5;rs55781567;G;TOXICITY;INCREASED_
HEROIN;OPRD1;rs4654327;AA;TOXICITY;DECREASED_RISK
OLANZAPINE;GIPR;rs10423928;AA + AT;TOXICITY;INCREASED_SEVERITY
NICOTINE;CHRNA5;rs16969968;A;TOXICITY;INCREASED_
NICOTINE;CHRNA5;rs503464;A;TOXICITY;INCREASED_
ALLOPURINOL;CYCSP5;rs9469003;C;TOXICITY;INCREASED_RISK
FLUOROURACIL;DPYD;rs1801265;G;TOXICITY;INCREASED_LIKELIHOOD
DAUNORUBICIN, DOXORUBICIN;SLC22A17;rs4982753;T;TOXICITY;DECREASED_LIKELIHOOD
WARFARIN;VKORC1;rs9923231;TT;EFFICACY;INCREASED_EFFICACY
ALLOPURINOL, CARBAMAZEPINE, PHENYTOIN;CYCSP5;rs9469003;C;TOXICITY;INCREASED_RISK
NICOTINE;CHRNA5;rs55853698;G;TOXICITY;INCREASED_
AMANTADINE, ANTICHOLINERGICS, DOPAMINE AGONISTS, LEVODOPA, SELEGILINE;SLC22A1;rs622342;C;DOSAGE, EFFICACY, TOXICITY;INCREASED_RISK
MELPHALAN;POLR1G;rs967591;A;EFFICACY, TOXICITY;INCREASED_EFFICACY
CORTICOSTEROIDS;ACOT7;rs11121611;G;EFFICACY;DECREASED_SEVERITY
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;ITPA;rs1127354;CC;TOXICITY;INCREASED_RISK
MORPHINE;TLR2;rs3804100;CC + CT;TOXICITY;DECREASED_LIKELIHOOD
DAUNORUBICIN, DOXORUBICIN;SLC22A7;rs4149178;G;TOXICITY;DECREASED_LIKELIHOOD
ROSUVASTATIN;SCAP;rs12487736;CC + CT;EFFICACY;DECREASED_SEVERITYEFFICACY
ALLOPURINOL;PSORS1C3;rs3094188;A;TOXICITY;INCREASED_RISK
CORTICOSTEROIDS;APOBEC3B;rs5995653;A;EFFICACY;DECREASED_SEVERITY
ALLOPURINOL, CARBAMAZEPINE, PHENYTOIN;PSORS1C3;rs3094188;A;TOXICITY;INCREASED_RISK
MORPHINE;COMT;rs4680;AA + AG;TOXICITY;DECREASED_LIKELIHOOD
GEMCITABINE, PACLITAXEL;CDA;rs2072671;CC;TOXICITY;INCREASED_RISK
MONTELUKAST;ABCC1;rs119774;CT;EFFICACY;INCREASED_EFFICACY
TRIAMCINOLONE;HCG22;rs2523864;T;TOXICITY;INCREASED_
ANTIDEPRESSANTS;CREB1, METTL21A;rs7569963;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
MORPHINE;IL6;rs10499563;CC;TOXICITY;INCREASED_LIKELIHOOD
ALLOPURINOL;POU5F1;rs3130501;G;TOXICITY;INCREASED_RISK
ALLOPURINOL, CARBAMAZEPINE, PHENYTOIN;POU5F1;rs3130501;G;TOXICITY;INCREASED_RISK
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;HLA-DRB5;rs184278615;A;EFFICACY;DECREASED_EFFICACY
CITALOPRAM;;rs4675690;T;TOXICITY;INCREASED_LIKELIHOOD
CITALOPRAM;CREB1, METTL21A;rs7569963;A;TOXICITY;DECREASED_LIKELIHOOD
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;HLA-DRB5;rs201469165;T;EFFICACY;DECREASED_EFFICACY
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS"", ""RITONAVIR""";APOE;rs7412;T;TOXICITY;INCREASED_RISK
ALLOPURINOL;POU5F1;rs3130931;C;TOXICITY;INCREASED_RISK
TRIAMCINOLONE;HCG22;rs3873352;G;TOXICITY;INCREASED_
ALLOPURINOL, CARBAMAZEPINE, PHENYTOIN;PSORS1C1;rs3815087;A;TOXICITY;INCREASED_RISK
MORPHINE;IL6R;rs2228145;AC + CC;TOXICITY;DECREASED_LIKELIHOOD
ALLOPURINOL, CARBAMAZEPINE, PHENYTOIN;POU5F1;rs3130931;C;TOXICITY;INCREASED_RISK
MORPHINE;BDNF;rs6265;TT;TOXICITY;DECREASED_LIKELIHOOD
ALLOPURINOL;PSORS1C1;rs3815087;A;TOXICITY;INCREASED_RISK
MORPHINE;IL2;rs2069762;AC + CC;TOXICITY;DECREASED_LIKELIHOOD
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;HLA-DRB5;rs1071748;C;EFFICACY;DECREASED_EFFICACY
ASPIRIN, CLOPIDOGREL;B4GALT2;rs1061781;CT + TT;EFFICACY;DECREASED_EFFICACY
METHOTREXATE;ABCB1;rs1128503;AA + AG;TOXICITY;INCREASED_RISK
ALLOPURINOL;;rs2844665;C;TOXICITY;INCREASED_RISK
MERCAPTOPURINE, METHOTREXATE;SLC28A2;rs2413775;AA;TOXICITY;INCREASED_RISK
CHLORTHALIDONE;NPPA;rs5065;G;EFFICACY;DECREASED_EFFICACY
METHOTREXATE;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_RISK
MERCAPTOPURINE, METHOTREXATE;SLC28A2;rs2413775;AT;TOXICITY;INCREASED_RISK
CYCLOPHOSPHAMIDE;SOD2;rs4880;G;EFFICACY;DECREASED_EFFICACY
CYCLOPHOSPHAMIDE;CYP3A4;rs2740574;C;TOXICITY;DECREASED_RISK
DOXORUBICIN;SLC22A16;rs714368;CC;TOXICITY, LADME_PK;INCREASED_PK
MERCAPTOPURINE, METHOTREXATE;SLC29A1;rs747199;CC;TOXICITY;DECREASED_RISK
ALLOPURINOL, CARBAMAZEPINE, PHENYTOIN;;rs2844665;C;TOXICITY;INCREASED_RISK
CYCLOPHOSPHAMIDE;CYP2B6;rs2279343;AG + GG;TOXICITY, LADME_PK;INCREASED_RISK
CYCLOPHOSPHAMIDE;CYP2B6;rs8192709;CT + TT;TOXICITY, LADME_PK;INCREASED_RISK
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;KIR3DL2;rs973541788;G;EFFICACY;DECREASED_EFFICACY
AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;HLA-DRA;rs3129880;T;TOXICITY;INCREASED_RISK
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_RISK
CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;GT + TT;TOXICITY, LADME_PK;DECREASED_RISK
ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs28371725;C;EFFICACY;DECREASED_SEVERITYEFFICACY
OPIOIDS;OPRM1;rs1799971;GG;TOXICITY;INCREASED_SEVERITY
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_EFFICACY
CYCLOSPORINE, METHOTREXATE;MTHFR;rs1801133;A;OTHER;
CARBOPLATIN, CISPLATIN, GEMCITABINE;GSTP1;rs1695;AG + GG;EFFICACY;INCREASED_RISKEFFICACY
ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs2004511;T;EFFICACY;DECREASED_SEVERITYEFFICACY
MERCAPTOPURINE, METHOTREXATE;ABCC4;rs2274407;CC;TOXICITY;INCREASED_RISK
DOXORUBICIN;CBR3;rs8133052;G;EFFICACY;DECREASED_EFFICACY
DOXORUBICIN;CBR3;rs8133052;G;TOXICITY, LADME_PK;DECREASED_SEVERITY
DOXORUBICIN;CBR3;rs1056892;A;DOSAGE, LADME_PK;INCREASED_PK
ANTIHYPERTENSIVES;ATP2B1;rs1401982;AA + AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs28371702;A;EFFICACY;DECREASED_SEVERITYEFFICACY
MORPHINE;OPRM1;rs1799971;AA;TOXICITY;INCREASED_LIKELIHOOD
MERCAPTOPURINE, METHOTREXATE;SLC28A3;rs10868138;CC + CT;TOXICITY;INCREASED_RISK
HEROIN;GRM3;rs724226;A;OTHER;INCREASED_RISK
ACENOCOUMAROL;VKORC1;rs7294;T;OTHER;DECREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_EFFICACY
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_
CORTICOSTEROIDS;CRHR1;rs242941;AA;EFFICACY;INCREASED_EFFICACY
METHOTREXATE;CLCN6, MTHFR;rs1801133;AA;EFFICACY;INCREASED_LIKELIHOODEFFICACY
CORTICOSTEROIDS;FKBP5;rs4713916;AA + AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
BUDESONIDE, FLUTICASONE PROPIONATE;CRHR1;rs242941;AA;EFFICACY;PK
OPIOIDS;ABCB1;rs1045642;G;TOXICITY;INCREASED_LIKELIHOOD
CORTICOSTEROIDS;CRHR1;rs1876828;TT;EFFICACY;INCREASED_EFFICACY
GEMCITABINE;;rs1155463;C;TOXICITY;INCREASED_RISK
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;TOXICITY;INCREASED_LIKELIHOOD
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;rs212090;AA + AT;TOXICITY;DECREASED_SEVERITY
BUDESONIDE, FLUTICASONE PROPIONATE;CRHR1;rs1876828;TT;EFFICACY;PK
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;SLC22A6;rs4149171;CC + CT;TOXICITY;DECREASED_SEVERITY
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;;rs955434;AA + AG;TOXICITY;DECREASED_SEVERITY
CHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE;;rs61824877;A;EFFICACY, TOXICITY;INCREASED_SEVERITY
WARFARIN;VKORC1;rs9923231;CT + TT;EFFICACY;DECREASED_EFFICACY
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;SLC22A6;rs4149170;CT + TT;TOXICITY;DECREASED_SEVERITY
TRAMADOL;OPRM1;rs1799971;GG;TOXICITY;DECREASED_LIKELIHOOD
CHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE;HMGCS2;rs9943291;G;EFFICACY, TOXICITY;INCREASED_SEVERITY
METHOTREXATE;CLCN6, MTHFR;rs1801133;AG;TOXICITY;INCREASED_RISK
METHADONE;DAO;rs55944529;TT;EFFICACY;INCREASED_SEVERITYEFFICACY
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs4148579;CC;TOXICITY;INCREASED_SEVERITY
;KCNIP1, KCNMB1;rs11739136;CT + TT;OTHER;DECREASED_RISK
INFLIXIMAB;IL1B;rs1143634;GG;EFFICACY;DECREASED_LIKELIHOODEFFICACY
IRINOTECAN;UGT1A1;rs10929302;AA;TOXICITY;INCREASED_RISK
ATAZANAVIR;ABCB1;rs2032582;AT;TOXICITY;INCREASED_RISK
DABIGATRAN;ABCB1;rs4148738;CC + CT;TOXICITY;INCREASED_LIKELIHOOD
NICOTINE;CHRNA5;rs16969968;A;OTHER;INCREASED_RISK
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;rs212087;AA + AG;TOXICITY;DECREASED_SEVERITY
INFLIXIMAB;IL23R;rs10489629;TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY
IRINOTECAN;UGT1A1;rs10929302;AA;TOXICITY;INCREASED_RISK
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs4148580;CC;TOXICITY;INCREASED_SEVERITY
INFLIXIMAB;SLCO1C1;rs3794271;GG;EFFICACY;DECREASED_LIKELIHOODEFFICACY
NICOTINE;CHRNA3;rs578776;A;OTHER;DECREASED_RISK
CARVEDILOL;ADRB1;rs1801253;CC;EFFICACY;INCREASED_EFFICACY
PEGINTERFERON ALFA-2A;ABCB1;rs1045642;AA + AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;IL7;rs16906115;A;TOXICITY;INCREASED_LIKELIHOOD
IRINOTECAN;ABCC1;rs3743527;CT + TT;TOXICITY;DECREASED_SEVERITY
NICOTINE;CHRNA3;rs1051730;A;OTHER;INCREASED_RISK
IRINOTECAN;ABCB1;rs12720066;AC + CC;TOXICITY;INCREASED_SEVERITY
NICOTINE;CHRNA3;rs3743078;C;OTHER;DECREASED_RISK
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs4148575;GG;TOXICITY;INCREASED_SEVERITY
NICOTINE;CHRNB4;rs3813567;G;OTHER;DECREASED_RISK
IRINOTECAN;ABCC1;rs17501331;AG + GG;TOXICITY;DECREASED_SEVERITY
CARVEDILOL;ADRB1;rs1801253;CC;EFFICACY;EFFICACY
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOODEFFICACY
PEGINTERFERON ALFA-2A;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY
;UGT1A1;rs4148323;AA;EFFICACY;INCREASED_LIKELIHOOD
PEGINTERFERON ALFA-2A;NT5C2;rs10883841;CT;EFFICACY;DECREASED_LIKELIHOODEFFICACY
WARFARIN;VKORC1;rs9923231;TT;TOXICITY;INCREASED_RISK
INFLIXIMAB;ADAM17;rs10929587;TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY
CLOPIDOGREL;MED12L, P2RY12;rs10935838;AG;EFFICACY;DECREASED_EFFICACY
;ago-02;rs4961280;AA + AC;OTHER;DECREASED_
STAVUDINE;TNF;rs1799964;C;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;MED12L, P2RY12;rs2046934;AG;EFFICACY;DECREASED_EFFICACY
CLOPIDOGREL;MED12L, P2RY12;rs6809699;AC;EFFICACY;DECREASED_EFFICACY
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs3749442;AA;TOXICITY;INCREASED_SEVERITY
NICOTINE;CHRNA5;rs684513;G;OTHER;DECREASED_RISK
AMINOGLYCOSIDE ANTIBACTERIALS;MT-RNR1;rs267606618;C;TOXICITY;INCREASED_RISK
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs1132776;GG;TOXICITY;INCREASED_SEVERITY
NICOTINE;CHRNA5;rs637137;A;OTHER;DECREASED_RISK
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY
;IL1A;rs1800587;A;OTHER;INCREASED_SEVERITY
FLUTICASONE / SALMETEROL;CRHR1;rs242941;CC;EFFICACY;INCREASED_EFFICACY
PROPRANOLOL;COMT;rs4680;G;EFFICACY;INCREASED_SEVERITYEFFICACY
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs939338;AA;TOXICITY;INCREASED_SEVERITY
PEGINTERFERON ALFA-2A;CYP27B1, METTL1;rs10877012;GT + TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY
PROPRANOLOL;COMT;rs4818;G;EFFICACY;INCREASED_SEVERITYEFFICACY
CORTICOSTEROIDS;APOBEC3B;rs6001366;T;EFFICACY;DECREASED_SEVERITY
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY
CORTICOSTEROIDS;KCNN1;rs2278992;C;EFFICACY;DECREASED_SEVERITY
PEGINTERFERON ALFA-2A;VDR;rs7975232;AA;EFFICACY;DECREASED_LIKELIHOODEFFICACY
CORTICOSTEROIDS;ANKRD30B;rs12959468;A;EFFICACY;DECREASED_SEVERITY
ROSUVASTATIN;CRP;rs1205;CT + TT;EFFICACY, OTHER, LADME_PK;DECREASED_
PROPRANOLOL;COMT;rs6269;G;EFFICACY;INCREASED_SEVERITYEFFICACY
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;rs129081;CC + CG;TOXICITY;INCREASED_SEVERITY
RISPERIDONE;HTR2A;rs6311;TT;TOXICITY;DECREASED_LIKELIHOOD
HEROIN;GRM3;rs2189814;T;OTHER;INCREASED_RISK
ROSUVASTATIN;;rs2808630;CC + CT;EFFICACY, OTHER, LADME_PK;DECREASED_
METHADONE;OPRD1;rs204076;AT + TT;EFFICACY;INCREASED_EFFICACY
ROSUVASTATIN;HNF1A;rs1169288;AC + CC;EFFICACY, OTHER, LADME_PK;DECREASED_
METOPROLOL;ADRB1;rs1801253;CC;EFFICACY;INCREASED_EFFICACY
PROPRANOLOL;COMT;rs4633;C;EFFICACY;INCREASED_SEVERITYEFFICACY
BUCINDOLOL;ADRB1;rs1801253;CC;EFFICACY;INCREASED_EFFICACY
ERYTHROMYCIN;CYP3A4;rs35599367;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_RISKEFFICACY
ASPIRIN;PEAR1;rs12041331;AA + AG;TOXICITY;INCREASED_RISK
;KCNIP1, KCNMB1;rs11739136;CT + TT;OTHER;DECREASED_
TACROLIMUS;ABCB1;rs2032582;A;EFFICACY;INCREASED_LIKELIHOODEFFICACY
CAFFEINE, ISOFLURANE;RYR1;rs118192162;AC;TOXICITY;
RISPERIDONE;NR1I2;rs7643645;GG;LADME_PK;DECREASED_PK
REPAGLINIDE;SLCO1B1;rs2306283;GG;OTHER, LADME_PK;DECREASED_PK
HALOTHANE;RYR1;rs118192161;CT;TOXICITY;
RISPERIDONE;NR1I2;rs7643645;GG;LADME_PK;DECREASED_PK
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY, TOXICITY;INCREASED_RISK
TACROLIMUS;ABCB1;rs1045642;G;EFFICACY;INCREASED_LIKELIHOODEFFICACY
GEFITINIB;CYP2D6;rs1065852;AA + AG;EFFICACY;DECREASED_EFFICACY
DALCETRAPIB;ADCY9;rs1967309;AA;EFFICACY;DECREASED_RISKEFFICACY
EGFR INHIBITORS;PIK3CA;rs6443624;C;TOXICITY;DECREASED_LIKELIHOOD
EGFR INHIBITORS;PIK3CA;rs2677760;T;TOXICITY;DECREASED_LIKELIHOOD
MISOPROSTOL;SLCO1B1;rs4149087;GG;TOXICITY;INCREASED_LIKELIHOOD
MISOPROSTOL;ABCC4;rs11568658;AA;TOXICITY;INCREASED_LIKELIHOOD
ASPIRIN, CLOPIDOGREL;PEAR1;rs12041331;A;EFFICACY;DECREASED_EFFICACY
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2E1;rs2031920;TT;TOXICITY;INCREASED_LIKELIHOOD
CARBOPLATIN, CISPLATIN, DOCETAXEL, GEMCITABINE, PACLITAXEL;RAF1;rs11710163;AG;EFFICACY;INCREASED_EFFICACY
CLOPIDOGREL;CYP2C19;rs12248560;T;TOXICITY;DECREASED_RISK
ASPIRIN, CLOPIDOGREL;PEAR1;rs12041331;AA + AG;TOXICITY;INCREASED_
MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_RISK
OLANZAPINE;GSTP1;rs1695;AG + GG;TOXICITY;INCREASED_SEVERITY
ASPIRIN, CLOPIDOGREL;PEAR1;rs12041331;AA + AG;TOXICITY;INCREASED_
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;ALOX15;rs3892408;C;TOXICITY;INCREASED_LIKELIHOOD
METHADONE;CCL11;rs1129844;A;TOXICITY;INCREASED_
EGFR INHIBITORS;PIK3CA;rs2699905;C;TOXICITY;DECREASED_LIKELIHOOD
FLUOXETINE;;rs2433320;GG;EFFICACY;DECREASED_EFFICACY
ANTIPSYCHOTICS;MTHFR;rs1801133;G;TOXICITY;INCREASED_
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, MERCAPTOPURINE, PREDNISOLONE, VINCRISTINE;PNPLA3;rs738409;CG + GG;TOXICITY;INCREASED_RISK
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;PTGS1;rs5789;C;TOXICITY;DECREASED_LIKELIHOOD
CLOZAPINE, OLANZAPINE;MTHFR;rs1801131;GG;TOXICITY;INCREASED_
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;rs1799929;CT;TOXICITY;INCREASED_RISK
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DOXORUBICIN, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, THIOGUANINE, VINCRISTINE;PNPLA3;rs738409;G;TOXICITY;INCREASED_LIKELIHOOD
LEUCOVORIN, TEGAFUR;UMPS;rs1801019;CC;TOXICITY;INCREASED_SEVERITY
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
GEFITINIB;EGFR;rs121434568;T;EFFICACY;DECREASED_EFFICACY
CARBOPLATIN, CISPLATIN, DOCETAXEL, PACLITAXEL;MAP3K1;rs726501;AA + AG;EFFICACY;DECREASED_EFFICACY
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2C9;rs9332096;CT + TT;TOXICITY;DECREASED_LIKELIHOOD
ANTHRACYCLINES AND RELATED SUBSTANCES, CYCLOPHOSPHAMIDE, FLUOROURACIL, TAXANES;CYP4X1;rs17102977;AA;EFFICACY;INCREASED_EFFICACY
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DOXORUBICIN, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, THIOGUANINE, VINCRISTINE;TPMT;rs1142345;C;TOXICITY;DECREASED_LIKELIHOOD
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2C19;rs4986893;AA + AG;TOXICITY;DECREASED_LIKELIHOOD
SIMVASTATIN;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED_RISK
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;PTGS1;rs10306135;A;TOXICITY;INCREASED_LIKELIHOOD
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
IMATINIB;SLC22A1;rs683369;CG + GG;EFFICACY;DECREASED_
ANTIPSYCHOTICS;GABRG3;rs2061051;A;TOXICITY;INCREASED_SEVERITY
GEMCITABINE;;rs642990;CT + TT;TOXICITY;DECREASED_RISK
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
CARBOPLATIN, CISPLATIN, DOCETAXEL, PACLITAXEL;MAP3K1;rs16886403;CC + CT;EFFICACY;DECREASED_EFFICACY
GEMCITABINE;RRM1;rs1042858;A;DOSAGE;DECREASED_RISK
CARBOPLATIN, CISPLATIN, DOCETAXEL, PACLITAXEL;;rs17661089;AG + GG;EFFICACY;DECREASED_EFFICACY
CARBOPLATIN, CISPLATIN, DOCETAXEL, GEMCITABINE, PACLITAXEL;ACSS2;rs17309872;AT;EFFICACY;DECREASED_EFFICACY
METHOTREXATE;ABCC1;rs246240;AG + GG;TOXICITY;DECREASED_RISK
BUPROPION, NICOTINE;EPB41;rs6702335;AA;EFFICACY;INCREASED_EFFICACY
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
DRUGS FOR TREATMENT OF TUBERCULOSIS;METTL14;rs62328061;G;TOXICITY;DECREASED_RISK
;IL17F;rs763780;CC;OTHER;INCREASED_LIKELIHOOD
DAUNORUBICIN;NOS3;rs1799983;GG;EFFICACY;INCREASED_EFFICACY
;IL17A;rs2275913;AA;OTHER;INCREASED_LIKELIHOOD
ACE INHIBITORS, PLAIN;KCNIP4;rs145489027;A;OTHER;INCREASED_LIKELIHOOD
PEMETREXED;ATIC;rs12995526;C;EFFICACY;INCREASED_EFFICACY
OPIOIDS;PDYN;rs910080;A;TOXICITY;INCREASED_RISK
IRINOTECAN;UGT1A1;rs4148323;AA + AG;TOXICITY;INCREASED_RISK
ACE INHIBITORS, PLAIN;KCNIP4;rs1495509;C;OTHER;INCREASED_LIKELIHOOD
FOLFIRI, FOLFOX, XELOX;MTHFR;rs1801131;GG;EFFICACY;DECREASED_EFFICACY
GEMCITABINE;ALG10;rs1705772;AA + AG;TOXICITY;DECREASED_RISK
MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_RISK
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DOXORUBICIN, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, THIOGUANINE, VINCRISTINE;UGT1A1;rs887829;T;TOXICITY;INCREASED_LIKELIHOOD
RITONAVIR;APOC3;rs2854116;C;OTHER;INCREASED_RISK
PEMETREXED;GGH;rs16930092;CT + TT;EFFICACY;INCREASED_EFFICACY
ANASTROZOLE;UGT1A4;rs3732218;GG;LADME_PK;INCREASED_PK
HALOPERIDOL;CYP2D6;rs3892097;CT;TOXICITY;INCREASED_LIKELIHOOD
FOLFIRI, FOLFOX, XELOX;ABCB1;rs1045642;GG;EFFICACY;DECREASED_EFFICACY
ACE INHIBITORS, PLAIN;KCNIP4;rs7675300;A;OTHER;INCREASED_LIKELIHOOD
CYCLOPHOSPHAMIDE;VEGFA;rs2010963;CC;EFFICACY;DECREASED_EFFICACY
NICOTINE;CHRNA3;rs1051730;A;OTHER;INCREASED_LIKELIHOOD
NEVIRAPINE;TRAF3IP2;rs76228616;C;TOXICITY;INCREASED_RISK
GEMCITABINE;ALOX5AP;rs4769060;AG + GG;LADME_PK;DECREASED_PK
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
SUFENTANIL;OPRM1;rs1799971;AG;TOXICITY;INCREASED_LIKELIHOOD
IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB;IL7;rs16906115;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
GEMTUZUMAB OZOGAMICIN;CD33;rs1803254;CC + CG;TOXICITY;INCREASED_
FOLFIRI, FOLFOX, XELOX;BRAF;rs113488022;T;EFFICACY;DECREASED_EFFICACY
METHOTREXATE;CLCN6, MTHFR;rs1801133;AG + GG;TOXICITY;INCREASED_SEVERITY
OPIOIDS;TH;rs2070762;G;TOXICITY;INCREASED_RISK
GEMTUZUMAB OZOGAMICIN;CD33;rs35112940;GG;EFFICACY;INCREASED_EFFICACY
ISONIAZID, RIFAMPIN;CYP2E1, DUX1;rs6413432;AT;TOXICITY;INCREASED_LIKELIHOOD
CISPLATIN;SLC22A2;rs316019;A;TOXICITY;DECREASED_RISK
ANTINEOPLASTIC AGENTS, FLUOROURACIL, LEUCOVORIN;SPARC;rs1059829;AG + GG;EFFICACY;INCREASED_EFFICACY
OPIOIDS;DBH;rs1611131;G;TOXICITY;DECREASED_RISK
ANTIPSYCHOTICS;HSPG2;rs2445142;C;TOXICITY;INCREASED_SEVERITY
FOLFIRI, FOLFOX, XELOX;DPYD;rs1801265;AG + GG;EFFICACY;DECREASED_EFFICACY
ANTIPSYCHOTICS;HSPG2;rs878949;T;TOXICITY;INCREASED_RISK
QUETIAPINE;RIMS1;rs502046;CC + CT;EFFICACY, TOXICITY;DECREASED_LIKELIHOODEFFICACY
ETHANOL;TAS2R16;rs846664;C;OTHER;INCREASED_RISK
DRUGS FOR TREATMENT OF TUBERCULOSIS;METTL3;rs1139130;G;TOXICITY;DECREASED_LIKELIHOOD
METHOTREXATE;C1orf167, CLCN6, MTHFR;rs1801131;GG + GT;TOXICITY;INCREASED_SEVERITY
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;rs6025;T;TOXICITY;INCREASED_RISK
SORAFENIB;KDR;rs2239702;CT + TT;EFFICACY;DECREASED_EFFICACY
FLUOROURACIL;SCN1A;rs3812718;CC;OTHER;DECREASED_
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY
"""ACETAMINOPHEN"", ""ANTIEPILEPTICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""OPIOIDS""";OPRM1;rs510769;CT + TT;EFFICACY;DECREASED_SEVERITYEFFICACY
WARFARIN;VKORC1;rs9934438;A;EFFICACY;DECREASED_EFFICACY
OPIOIDS;DRD2;rs1076560;A;TOXICITY;INCREASED_RISK
EFAVIRENZ;NR1I2;rs2472677;TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY
EFAVIRENZ;CYP2B6;rs3745274;TT;EFFICACY;INCREASED_EFFICACY
CETUXIMAB;KRAS;rs112445441;T;EFFICACY;INCREASED_EFFICACY
CISPLATIN, CYCLOPHOSPHAMIDE, DACTINOMYCIN, DOXORUBICIN, METHOTREXATE, VINCRISTINE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_LIKELIHOOD
SORAFENIB;VEGFA;rs2010963;CG + GG;TOXICITY;INCREASED_RISK
CISPLATIN, CYCLOPHOSPHAMIDE, DACTINOMYCIN, DOXORUBICIN, METHOTREXATE, VINCRISTINE;MTR;rs1805087;GG;TOXICITY;INCREASED_LIKELIHOOD
SORAFENIB;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_RISK
SORAFENIB;VEGFA;rs1570360;AA + AG;EFFICACY;DECREASED_EFFICACY
ATORVASTATIN;ABCG2;rs2231142;GT + TT;TOXICITY;INCREASED_LIKELIHOOD
COCAINE, HEROIN;OPRM1;rs62638690;T;TOXICITY;DECREASED_LIKELIHOOD
SORAFENIB;KDR;rs2239702;CT + TT;EFFICACY;DECREASED_EFFICACY
EFAVIRENZ;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK
CETUXIMAB, PANITUMUMAB;KRAS;rs112445441;A;EFFICACY;INCREASED_EFFICACY
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;CYP2C9;rs1799853;T;TOXICITY;INCREASED_RISK
;MTR;rs1805087;GG;OTHER;INCREASED_LIKELIHOOD
METHOTREXATE;MTR;rs1805087;GG;TOXICITY;INCREASED_LIKELIHOOD
"""ACETAMINOPHEN"", ""ANTIEPILEPTICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""OPIOIDS""";OPRD1;rs2236861;AG + GG;TOXICITY;INCREASED_LIKELIHOOD
PRAVASTATIN;SLCO1B1;rs4149056;CT;LADME_PK;INCREASED_PK
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F2;rs1799963;A;TOXICITY;INCREASED_RISK
EFAVIRENZ;CYP2B6;rs3745274;TT;EFFICACY;INCREASED_RISKEFFICACY
FLUOROURACIL;SCN1A;rs3812718;TT;OTHER;DECREASED_
ATAZANAVIR;UGT1A1;rs887829;T;TOXICITY;INCREASED_LIKELIHOOD
SIMVASTATIN;SLCO1B1;rs4363657;CC;TOXICITY;INCREASED_LIKELIHOOD
EFAVIRENZ;CYP2B6;rs28399499;CC + CT;TOXICITY;DECREASED_RISK
WARFARIN;VKORC1;rs9923231;TT;TOXICITY;INCREASED_RISK
TACROLIMUS;CYP3A5;rs776746;CT;TOXICITY;INCREASED_RISK
SIMVASTATIN;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED_LIKELIHOOD
EFAVIRENZ;CYP2B6;rs4803419;CT + TT;TOXICITY;INCREASED_RISK
WARFARIN;VKORC1;rs9923231;TT;TOXICITY;INCREASED_RISK
FLUOROURACIL;DPYD;rs1801160;CT;LADME_PK;DECREASED_PK
ALLOPURINOL;PSORS1C1;rs3131003;AG + GG;TOXICITY;INCREASED_RISK
FLUOROURACIL;MTHFR;rs1801133;GG;EFFICACY;INCREASED_
OPIOIDS;PDYN;rs1997794;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
ONDANSETRON;ABCB1;rs1045642;GG;EFFICACY;INCREASED_LIKELIHOOD
DEXMEDETOMIDINE;CYP2A6;rs8192733;GG;TOXICITY;INCREASED_LIKELIHOOD
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY
"""ACETAMINOPHEN"", ""ANTIEPILEPTICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""OPIOIDS""";OPRM1;rs1799971;AA;EFFICACY;INCREASED_LIKELIHOODEFFICACY
OPIOIDS;PDYN;rs1022563;CC;TOXICITY;INCREASED_LIKELIHOOD
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;EFFICACY
RISPERIDONE;LEP;rs7799039;GG;TOXICITY;INCREASED_LIKELIHOOD
PERINDOPRIL;AGTR1;rs5182;TT;EFFICACY;DECREASED_RISKEFFICACY
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;EFFICACY
GEMCITABINE;CDA;rs2072671;AC + CC;TOXICITY;INCREASED_RISK
CYTARABINE;CDA;rs602950;GG;EFFICACY, LADME_PK;INCREASED_EFFICACY
HALOPERIDOL;CYP2D6;rs3892097;CC;TOXICITY;DECREASED_LIKELIHOOD
CYTARABINE;CDA;rs532545;TT;EFFICACY, LADME_PK;INCREASED_EFFICACY
ALLOPURINOL;CYCSP5;rs3099844;AA + AC;TOXICITY;INCREASED_RISK
BISPHOSPHONATES;RBMS3;rs17024608;A;TOXICITY;INCREASED_LIKELIHOOD
;NEDD4L;rs4149601;AG;OTHER;INCREASED_RISK
FLUOROURACIL;DPYD;rs55886062;AC;LADME_PK;DECREASED_PK
ANTIPSYCHOTICS;INSIG2;rs17587100;C;OTHER;INCREASED_SEVERITY
ONDANSETRON;ABCB1;rs2032582;CC;EFFICACY;INCREASED_LIKELIHOOD
;CTLA4;rs3087243;A;OTHER;DECREASED_RISK
EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;GCKR;rs780094;CC + CT;EFFICACY;INCREASED_EFFICACY
FLUOROURACIL;DPYD;rs115232898;CT;LADME_PK;DECREASED_PK
RIBAVIRIN, SOFOSBUVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY
TENOFOVIR;ABCC4;rs1059751;G;TOXICITY;INCREASED_LIKELIHOOD
EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;IGF2BP2;rs6769511;C;EFFICACY;INCREASED_LIKELIHOODEFFICACY
WARFARIN;VKORC1;rs9934438;A;EFFICACY;DECREASED_EFFICACY
CYTARABINE;CDA;rs2072671;CC;EFFICACY, LADME_PK;INCREASED_EFFICACY
WARFARIN;VKORC1;rs9934438;A;TOXICITY;INCREASED_RISK
ALLOPURINOL;NOTCH4;rs367398;AA + AG;TOXICITY;DECREASED_RISK
EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;KCNQ1;rs163182;CC + GG;EFFICACY;DECREASED_LIKELIHOODEFFICACY
;NQO1;rs1800566;AA;OTHER;DECREASED_LIKELIHOOD
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;EFFICACY
EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;IGF2BP2;rs4402960;G;EFFICACY;DECREASED_LIKELIHOODEFFICACY
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;EFFICACY
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
ERLOTINIB, GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
EFAVIRENZ;CYP2B6;rs3745274;GG;EFFICACY;INCREASED_RISKEFFICACY
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_RISK
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;NQO1;rs1800566;AA;TOXICITY;DECREASED_LIKELIHOOD
METHOTREXATE;SLCO1B1;rs2306283;AG + GG;TOXICITY;INCREASED_LIKELIHOOD
EFAVIRENZ;CYP2B6;rs3745274;GT;TOXICITY;INCREASED_LIKELIHOOD
SUNITINIB;ABCB1;rs1045642;AA;TOXICITY;DECREASED_RISK
VERAPAMIL;CACNA1C;rs1051375;AA;EFFICACY;DECREASED_RISK
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
CISPLATIN, IRINOTECAN;UGT1A1;rs4148323;AA + AG;TOXICITY;INCREASED_SEVERITY
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
SUNITINIB;ABCB1;rs1045642;AA + AG;TOXICITY;DECREASED_RISK
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
EFAVIRENZ;CYP2B6;rs3745274;GT;LADME_PK;INCREASED_PK
CISPLATIN, IRINOTECAN;UGT1A1;rs4148323;AA + AG;TOXICITY;INCREASED_SEVERITY
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
EFAVIRENZ;CYP2A6;rs28399433;AC + CC;LADME_PK;INCREASED_PK
;DRD2;rs1800497;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
EFAVIRENZ;CYP2B6;rs28399499;CC + CT;LADME_PK;INCREASED_PK
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_PK
VERAPAMIL;CACNA1C;rs1051375;GG;EFFICACY;INCREASED_RISKEFFICACY
EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;GCKR;rs780093;CC + CT;EFFICACY;INCREASED_EFFICACY
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
SIMVASTATIN;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED_RISK
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK
CARBOPLATIN, CISPLATIN, GEMCITABINE;;rs12118636;AG;EFFICACY;DECREASED_EFFICACY
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_RISK
CISPLATIN, IRINOTECAN;UGT1A1;rs4148323;AA + AG;TOXICITY;INCREASED_SEVERITY
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;TT;TOXICITY;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
ANTINEOPLASTIC AGENTS;ABCB1;rs1045642;AG;TOXICITY;INCREASED_SEVERITY
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
CARBOPLATIN, CISPLATIN, GEMCITABINE;NRAS;rs1065634;CT;EFFICACY;DECREASED_EFFICACY
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
CARBOPLATIN, CISPLATIN, GEMCITABINE;GPX5;rs451774;AG + GG;EFFICACY;INCREASED_EFFICACY
VINCRISTINE;ACTG1;rs1135989;A;TOXICITY;INCREASED_RISK
ACENOCOUMAROL, WARFARIN;VKORC1;rs9923231;T;TOXICITY;INCREASED_LIKELIHOOD
METHADONE;CYP2B6;rs3745274;GG;TOXICITY;INCREASED_SEVERITY
CARBOPLATIN, TAXANES;ATP7B;rs1801249;AA;TOXICITY;INCREASED_LIKELIHOOD
VINCRISTINE;CAPG;rs3770102;T;TOXICITY;DECREASED_RISK
VALPROIC ACID;COL1A1;rs1800012;AA + AC;TOXICITY;DECREASED_
VINCRISTINE;ABCB1;rs4728709;A;TOXICITY;DECREASED_RISK
DOXORUBICIN;AKR1C3;rs1937840;GG;OTHER;DECREASED_
METHADONE;CYP2B6;rs2279343;AA;TOXICITY;INCREASED_SEVERITY
KETOPROFEN;CYP2C9;rs1799853;CC;TOXICITY;DECREASED_SEVERITY
ACENOCOUMAROL, WARFARIN;VKORC1;rs9923231;T;EFFICACY;INCREASED_
MYCOPHENOLATE MOFETIL;SLCO1B3;rs4149117;GG;TOXICITY;INCREASED_LIKELIHOOD
REMIFENTANIL;OPRM1;rs1799971;GG;TOXICITY;DECREASED_SEVERITY
WARFARIN;VKORC1;rs9934438;AA + AG;TOXICITY;INCREASED_RISK
MERCAPTOPURINE;ITPA;rs1127354;AA + AC;TOXICITY;INCREASED_SEVERITY
CARBOPLATIN, TAXANES;GSR;rs3594;CC;TOXICITY;INCREASED_LIKELIHOOD
ACENOCOUMAROL, WARFARIN;APOE;rs429358;C;TOXICITY;INCREASED_LIKELIHOOD
ETHANOL;SLC6A4;rs4251417;T;TOXICITY;DECREASED_RISK
CARBOPLATIN, TAXANES;VEGFA;rs6900017;TT;TOXICITY;INCREASED_LIKELIHOOD
ACENOCOUMAROL, WARFARIN;CYP2C9;rs1057910;C;TOXICITY;INCREASED_LIKELIHOOD
METHYLPHENIDATE;COMT;rs4680;AA + AG;TOXICITY;DECREASED_LIKELIHOOD
NALOXONE;OPRM1;rs1799971;G;EFFICACY;INCREASED_EFFICACY
ETHANOL;SLC6A4;rs25531;C;TOXICITY;DECREASED_RISK
INTERFERONS, RIBAVIRIN;VDR;rs2228570;AG + GG;TOXICITY;DECREASED_RISK
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_
EGFR INHIBITORS;PIK3CA;rs2677760;C;TOXICITY;INCREASED_LIKELIHOOD
CETUXIMAB;EGFR;rs2227983;AA + AG;EFFICACY;DECREASED_EFFICACY
EGFR INHIBITORS;PIK3CA;rs2459693;T;TOXICITY;INCREASED_LIKELIHOOD
IRINOTECAN;CES1;rs7187684;CC;TOXICITY;DECREASED_LIKELIHOOD
METHOTREXATE;ATIC;rs2372536;GG;TOXICITY;INCREASED_LIKELIHOOD
ETHANOL;SLC6A4;rs2066713;A;TOXICITY;INCREASED_RISK
CORTICOSTEROIDS, SALMETEROL;ADRB2;rs1042713;AA;EFFICACY;INCREASED_RISKEFFICACY
ANTIPSYCHOTICS;IL1B;rs4849127;AA + AG;TOXICITY;INCREASED_
BETA BLOCKING AGENTS;CYP2D6;rs1065852;GG;TOXICITY;INCREASED_LIKELIHOOD
FLUOROURACIL;DPYD;rs1801265;GG;LADME_PK;INCREASED_PK
EGFR INHIBITORS;PIK3CA;rs6443624;C;EFFICACY;DECREASED_EFFICACY
ANTIPSYCHOTICS;IL1B;rs16944;AG;TOXICITY;INCREASED_
DAUNORUBICIN, DOXORUBICIN;SLC28A3;rs885004;A;TOXICITY;DECREASED_LIKELIHOOD
CYCLOSPORINE;ABCB1;rs1045642;AA;TOXICITY;INCREASED_LIKELIHOOD
EGFR INHIBITORS;PIK3CA;rs2677760;T;EFFICACY;DECREASED_EFFICACY
CORTICOSTEROIDS;ADRB2;rs1042713;AA;EFFICACY;INCREASED_RISKEFFICACY
IRINOTECAN;CES1;rs2244614;AA + AG;TOXICITY;DECREASED_LIKELIHOOD
EXEMESTANE, LETROZOLE;CYP19A1;rs6493497;AA;TOXICITY;DECREASED_
ANTIPSYCHOTICS;IL1B;rs1143634;AA;TOXICITY;DECREASED_
ANTIPSYCHOTICS;BDNF;rs6265;CT + TT;TOXICITY;DECREASED_
METHYLPHENIDATE;ADGRL3;rs2345039;CG + GG;TOXICITY;INCREASED_LIKELIHOOD
DAUNORUBICIN, DOXORUBICIN;SLC28A3;rs7853758;A;TOXICITY;DECREASED_LIKELIHOOD
MERCAPTOPURINE;NUDT15;rs116855232;CT;TOXICITY;INCREASED_SEVERITY
WARFARIN;CYP2C9;rs1799853;T;EFFICACY;EFFICACY
CARBOPLATIN, TAXANES;ATP7B;rs1061472;TT;TOXICITY;INCREASED_LIKELIHOOD
IRINOTECAN;UGT1A1;rs4148323;AG;TOXICITY;INCREASED_RISK
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;C;TOXICITY;INCREASED_RISK
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;SUGCT;rs4379368;T;TOXICITY;INCREASED_RISK
;FMO3;rs2266780;AG + GG;OTHER;DECREASED_SEVERITY
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;KNG1;rs710446;C;TOXICITY;INCREASED_RISK
FLUOROURACIL;DPYD;rs1801265;AA;EFFICACY;INCREASED_EFFICACY
IRINOTECAN;ABCG2;rs2231142;GT + TT;TOXICITY;INCREASED_LIKELIHOOD
ASPIRIN;LPA;rs3798220;CT;EFFICACY;DECREASED_RISK
METHOTREXATE;SLC19A1;rs1051266;TT;TOXICITY;INCREASED_LIKELIHOOD
BOCEPREVIR, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY
WARFARIN;CYP2C19;rs3814637;T;TOXICITY;RISK_
FLUOROURACIL;DPYD;rs72728438;CT;LADME_PK;DECREASED_PK
FLUOROURACIL;ABCC11;rs7194667;GG + GT;TOXICITY;INCREASED_RISK
EGFR INHIBITORS;PIK3CA;rs2699905;C;EFFICACY;DECREASED_EFFICACY
FLUOROURACIL;DPYD;rs115632870;CT;LADME_PK;DECREASED_PK
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;ABO;rs56392308;del;TOXICITY;DECREASED_RISK
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_SEVERITY
ETHANOL;SLC6A3;rs6350;AG;TOXICITY;INCREASED_RISK
CAPECITABINE, FLUOROURACIL;DPYD;rs67376798;AT;TOXICITY;INCREASED_SEVERITY
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;ABO;rs8176719;C;TOXICITY;INCREASED_RISK
METHOTREXATE;SLCO1B1;rs4149056;TT;TOXICITY;DECREASED_RISK
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;PROCR;rs9574;G;TOXICITY;INCREASED_RISK
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F11;rs2289252;T;TOXICITY;INCREASED_RISK
METHOTREXATE;SLCO1B1;rs2306283;AG + GG;TOXICITY;INCREASED_RISK
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_
DEXMEDETOMIDINE;NR1I2;rs3814057;CC;TOXICITY;INCREASED_LIKELIHOOD
;MAOA;rs1137070;TT;TOXICITY;DECREASED_RISK
;MAOB;rs1799836;CC;TOXICITY;INCREASED_RISK
CAPECITABINE;;rs9936750;C;TOXICITY;INCREASED_RISK
FLUOROURACIL;DPYD;rs1801265;AG + GG;TOXICITY;INCREASED_
DOXORUBICIN;ABCB1;rs1045642;A;TOXICITY;DECREASED_LIKELIHOOD
DOXORUBICIN;CBR3;rs1056892;A;TOXICITY;INCREASED_LIKELIHOOD
CAPECITABINE;DPYD;rs3918290;T;TOXICITY;INCREASED_RISK
FOLFIRI;UGT1A1;rs4124874;GG;TOXICITY;INCREASED_SEVERITY
CAPECITABINE;DPYD;rs67376798;A;TOXICITY;INCREASED_RISK
CETUXIMAB;EGF;rs4444903;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
AFATINIB, ERLOTINIB, GEFITINIB;UHRF1;rs2261988;TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY
;HAVCR2;rs10515746;AA + AC;EFFICACY;DECREASED_LIKELIHOOD
;HAVCR2;rs1036199;AC + CC;EFFICACY;DECREASED_LIKELIHOOD
AFATINIB, ERLOTINIB, GEFITINIB;DVL2;rs2074216;AA;EFFICACY;DECREASED_LIKELIHOODEFFICACY
GLATIRAMER ACETATE;;rs12459996;T;TOXICITY;INCREASED_RISK
WARFARIN;VKORC1;rs9923231;T;EFFICACY;DECREASED_EFFICACY
WARFARIN;VKORC1;rs9923231;T;TOXICITY;INCREASED_RISK
FLUOROURACIL;OR10AE3P, PSMB3P;rs10876844;A;TOXICITY;INCREASED_LIKELIHOOD
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK
HEROIN;BDNF;rs6265;TT;OTHER;INCREASED_RISK
METHAMPHETAMINE;BDNF;rs6265;T;OTHER;INCREASED_RISK
DOXORUBICIN, PACLITAXEL, TRASTUZUMAB;ABCB1;rs2235047;C;TOXICITY;INCREASED_RISK
DOXORUBICIN, PACLITAXEL, TRASTUZUMAB;CBR3;rs1056892;A;TOXICITY;INCREASED_RISK
FENTANYL;OPRM1;rs540825;T;TOXICITY;INCREASED_LIKELIHOOD
ASPIRIN, TICAGRELOR;CYP4F2;rs3093135;AA;EFFICACY;DECREASED_EFFICACY
CLOPIDOGREL;ABCB1;rs2032582;T;TOXICITY;INCREASED_RISK
AFATINIB, ERLOTINIB, GEFITINIB;NUP62;rs9523;CC;EFFICACY;DECREASED_LIKELIHOODEFFICACY
;;rs2207418;GG;OTHER;INCREASED_RISK
ALFENTANIL;OPRM1;rs1799971;GG;TOXICITY;DECREASED_SEVERITY
WARFARIN;CYP2C9;rs9332197;C;EFFICACY;EFFICACY
WARFARIN;CYP2C9;rs1057910;C;TOXICITY;RISK_
WARFARIN;CYP2C18;rs2901783;AG + GG;EFFICACY;INCREASED_EFFICACY
WARFARIN;F5;rs6018;G;TOXICITY;RISK_
WARFARIN;PROS1;rs8178607;AA;EFFICACY;DECREASED_EFFICACY
;CHRM3;rs2165870;GG;TOXICITY;INCREASED_RISK
WARFARIN;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_RISK
CISPLATIN, GEMCITABINE;CDA;rs2072671;AA;TOXICITY;INCREASED_RISK
CAPECITABINE;DPYD;rs1801265;G;TOXICITY;DECREASED_RISK
DOXORUBICIN;GSTP1;rs1695;GG;TOXICITY;INCREASED_
WARFARIN;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_RISK
METHOTREXATE;MTHFR;rs1801131;TT;EFFICACY;INCREASED_EFFICACY
METHOTREXATE;MTHFR;rs1801133;GG;EFFICACY;INCREASED_EFFICACY
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;rs1801274;AG;EFFICACY;DECREASED_EFFICACY
;SCN5A;rs7626962;GT + TT;OTHER;INCREASED_LIKELIHOOD
CARBOPLATIN, TAXANES;VEGFA;rs879825;GG;TOXICITY;INCREASED_LIKELIHOOD
EXEMESTANE, LETROZOLE;ESR1;rs4870061;CT + TT;TOXICITY;DECREASED_
METHOTREXATE;MTRR;rs1801394;AG + GG;LADME_PK;DECREASED_LIKELIHOOD
CARBOPLATIN, TAXANES;SCN10A;rs9825762;TT;TOXICITY;INCREASED_LIKELIHOOD
CARBOPLATIN, TAXANES;VEGFA;rs9369421;CC;TOXICITY;INCREASED_LIKELIHOOD
LETROZOLE;ESR1;rs4870061;TT;TOXICITY;DECREASED_
WARFARIN;CYP2C9;rs1057910;CC;TOXICITY;INCREASED_RISK
METHOTREXATE;ABCC2;rs2273697;AA + AG;LADME_PK;INCREASED_LIKELIHOOD
EXEMESTANE, LETROZOLE;ESR1;rs9322335;TT;TOXICITY;DECREASED_
LETROZOLE;ESR1;rs9322335;TT;TOXICITY;DECREASED_
CISPLATIN, ETOPOSIDE;NQO1;rs1800566;AA;OTHER;DECREASED_
CISPLATIN;SLC22A2;rs316019;AC;TOXICITY;INCREASED_SEVERITY
LETROZOLE;ESR2;rs10140457;CC;TOXICITY;DECREASED_
EXEMESTANE;ESR1;rs2813543;AA;TOXICITY;DECREASED_
EXEMESTANE;CYP19A1;rs6493497;AA;TOXICITY;DECREASED_
METHOTREXATE;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_LIKELIHOOD
METHOTREXATE;SLCO1B1;rs4149056;CC + CT;LADME_PK;INCREASED_LIKELIHOOD
BISPHOSPHONATES;;rs2736308;C;TOXICITY;INCREASED_RISK
METHOTREXATE;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_LIKELIHOOD
BISPHOSPHONATES;;rs2736308;C;TOXICITY;INCREASED_RISK
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;PTGS1;rs10306135;TT;TOXICITY;INCREASED_LIKELIHOOD
BEVACIZUMAB, CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, OXALIPLATIN, TRASTUZUMAB;DPYD;rs67376798;AT;TOXICITY;INCREASED_RISK
CARBOPLATIN, GEMCITABINE;TNF;rs1800629;A;TOXICITY;INCREASED_SEVERITY
SORAFENIB;KDR;rs2305948;CC;EFFICACY;INCREASED_EFFICACY
;COMT;rs4680;AG + GG;OTHER;DECREASED_
CARBOPLATIN, GEMCITABINE;PRRC2A;rs11229;G;TOXICITY;INCREASED_SEVERITY
CARBOPLATIN, GEMCITABINE;PRRC2A;rs10885;T;TOXICITY;INCREASED_SEVERITY
METHADONE, MORPHINE;COMT;rs4680;AG + GG;OTHER;DECREASED_LIKELIHOOD
SORAFENIB;FLT1;rs664393;TT;EFFICACY;DECREASED_EFFICACY
SORAFENIB;KDR;rs2071559;AA;EFFICACY;DECREASED_EFFICACY
CARBOPLATIN, GEMCITABINE;MSH5;rs3115672;T;TOXICITY;INCREASED_SEVERITY
CYCLOPHOSPHAMIDE, DOXORUBICIN, FEC100, FLUOROURACIL;ALDH1A1;rs13959;AA + AG;EFFICACY;INCREASED_LIKELIHOOD
HMG COA REDUCTASE INHIBITORS;ATP2B1;rs17381194;T;TOXICITY;INCREASED_RISK
CARBOPLATIN, GEMCITABINE;DOCK8;rs10491684;A;TOXICITY;INCREASED_SEVERITY
HMG COA REDUCTASE INHIBITORS;;rs4693570;C;TOXICITY;INCREASED_RISK
;EPO;rs1617640;A;OTHER;INCREASED_
HMG COA REDUCTASE INHIBITORS;DMPK;rs672348;G;TOXICITY;INCREASED_RISK
ASPIRIN;EYA1;rs12678747;T;TOXICITY;INCREASED_RISK
CARBOPLATIN, GEMCITABINE;CYP2C8;rs1058932;A;TOXICITY;DECREASED_SEVERITY
CARBOPLATIN, GEMCITABINE;CYP2C8;rs11572078;A;TOXICITY;DECREASED_SEVERITY
AZITHROMYCIN, CHLORPROMAZINE, CILOSTAZOL, CIPROFLOXACIN, CITALOPRAM, CLARITHROMYCIN, DOFETILIDE, DONEPEZIL, DRONEDARONE, ERYTHROMYCIN, ESCITALOPRAM, FLECAINIDE, FLUCONAZOLE, HALOPERIDOL, HYDROXYCHLOROQUINE, LEVOFLOXACIN, METHADONE, MOXIFLOXACIN, ONDANSETRON, OXALIPLATIN, PAPAVERINE, PENTAMIDINE, PROCAINAMIDE, PROPOFOL, QUINIDINE, SOTALOL;KCNE1;rs1805128;T;TOXICITY;INCREASED_LIKELIHOOD
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
CARBOPLATIN, GEMCITABINE;C6orf15;rs2233980;A;TOXICITY;INCREASED_SEVERITY
CARBOPLATIN, GEMCITABINE;CDSN;rs3130985;T;TOXICITY;INCREASED_SEVERITY
ETOPOSIDE, PLATINUM COMPOUNDS;DYNC2H1;rs716274;AG + GG;EFFICACY;INCREASED_RISK
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
METHADONE, MORPHINE;OPRM1;rs1799971;AG + GG;OTHER;DECREASED_LIKELIHOOD
CYCLOPHOSPHAMIDE, DOXORUBICIN, FEC100, FLUOROURACIL;NQO1;rs1800566;AA + AG;EFFICACY;DECREASED_LIKELIHOOD
ETOPOSIDE, PLATINUM COMPOUNDS;YAP1;rs10895256;GT + TT;EFFICACY;INCREASED_RISK
HMG COA REDUCTASE INHIBITORS;COQ2;rs6535454;A;TOXICITY;INCREASED_RISK
HMG COA REDUCTASE INHIBITORS;COQ2;rs4693075;G;TOXICITY;INCREASED_RISK
CARBOPLATIN, GEMCITABINE;HLA-C;rs1049709;C;TOXICITY;INCREASED_SEVERITY
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
CARBOPLATIN, GEMCITABINE;HCP5;rs3130907;G;TOXICITY;INCREASED_SEVERITY
LENALIDOMIDE;CTNNB1;rs4135385;AA;TOXICITY;INCREASED_RISK
CARBOPLATIN, ERLOTINIB, PACLITAXEL;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
CARBOPLATIN, GEMCITABINE;SERPINC1;rs5877;C;TOXICITY;DECREASED_SEVERITY
IBRUTINIB;KCNQ1;rs2237895;AA;TOXICITY;INCREASED_LIKELIHOOD
TAMOXIFEN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_EFFICACY
METHOTREXATE;SLC19A1;rs1051266;CC;TOXICITY;INCREASED_SEVERITY
;SCN5A;rs7626962;GG;OTHER;INCREASED_LIKELIHOOD
LENALIDOMIDE;CTNNB1;rs4533622;AA;TOXICITY;INCREASED_RISK
CARBOPLATIN, GEMCITABINE;;rs886423;C;TOXICITY;INCREASED_SEVERITY
CARBOPLATIN, GEMCITABINE;;rs886424;T;TOXICITY;INCREASED_SEVERITY
BETA BLOCKING AGENTS;ADRB1;rs1801252;AG + GG;EFFICACY;INCREASED_RISK
CARBOPLATIN, GEMCITABINE;ATAT1;rs9262132;C;TOXICITY;INCREASED_SEVERITY
SORAFENIB;VEGFA;rs2010963;GG;EFFICACY;DECREASED_EFFICACY
SORAFENIB;VEGFA;rs2010963;GG;EFFICACY;DECREASED_EFFICACY
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
;ABO;rs495828;GG;LADME_PK;INCREASED_
CARBOPLATIN, GEMCITABINE;PPP1R18;rs9262143;T;TOXICITY;INCREASED_SEVERITY
;OPRM1;rs1799971;AG + GG;OTHER;DECREASED_
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
SORAFENIB;;rs4604006;CC;EFFICACY;DECREASED_EFFICACY
IBRUTINIB;KCNQ1;rs163182;GG;TOXICITY;INCREASED_LIKELIHOOD
CARBOPLATIN, GEMCITABINE;MUCL3;rs3094086;A;TOXICITY;INCREASED_SEVERITY
OLANZAPINE;GIPR;rs10423928;AA;TOXICITY;INCREASED_
SORAFENIB;;rs4604006;CC;EFFICACY;DECREASED_EFFICACY
SORAFENIB;VEGFA;rs25648;CC;EFFICACY;INCREASED_EFFICACY
ANTHRACYCLINES AND RELATED SUBSTANCES;;rs28714259;A;TOXICITY;INCREASED_LIKELIHOOD
CYCLOSPORINE;CTLA4;rs231775;A;TOXICITY;INCREASED_LIKELIHOOD
SORAFENIB;VEGFA;rs833061;CC;EFFICACY;DECREASED_EFFICACY
SORAFENIB;VEGFA;rs699947;CC;EFFICACY;INCREASED_EFFICACY
SORAFENIB;VEGFA;rs25648;CC;EFFICACY;INCREASED_EFFICACY
FENTANYL;OPRM1;rs9397685;AG;TOXICITY;DECREASED_SEVERITY
SORAFENIB;VEGFA;rs833061;CC;EFFICACY;DECREASED_EFFICACY
TACROLIMUS;CYP3A5;rs776746;CT + TT;EFFICACY;EFFICACY
;ABCC4;rs2274407;AA + AC;EFFICACY;DECREASED_LIKELIHOODEFFICACY
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
ERLOTINIB, GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
ERLOTINIB, GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
WARFARIN;VKORC1;rs9923231;TT;DOSAGE, EFFICACY, TOXICITY;INCREASED_RISKEFFICACY
PAZOPANIB;HFE;rs2858996;TT;TOXICITY;INCREASED_LIKELIHOOD
PACLITAXEL;ABCB1;rs1128503;AA;TOXICITY;INCREASED_SEVERITY
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_RISK
;;rs2207418;GG;OTHER;INCREASED_RISK
TACROLIMUS;CYP3A5;rs776746;CT + TT;EFFICACY, LADME_PK;DECREASED_PK
GLATIRAMER ACETATE;;rs75041078;A;TOXICITY;INCREASED_RISK
GLATIRAMER ACETATE;;rs1056854;A;TOXICITY;INCREASED_RISK
METHAMPHETAMINE;GAD2;rs2236418;AG + GG;OTHER;INCREASED_LIKELIHOOD
GLICLAZIDE, GLYBURIDE;ABCC8, KCNJ11;rs757110;CC;EFFICACY;INCREASED_LIKELIHOODEFFICACY
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs4803217;AA + AC;EFFICACY;INCREASED_LIKELIHOODEFFICACY
TACROLIMUS;ABCB1;rs2229109;CT + TT;EFFICACY;INCREASED_RISKEFFICACY
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs4803217;CC;EFFICACY;INCREASED_EFFICACY
TACROLIMUS;CYP3A5;rs776746;CT + TT;EFFICACY;INCREASED_LIKELIHOOD
FENTANYL;ABCB1;rs1045642;AA;TOXICITY;INCREASED_LIKELIHOOD
TACROLIMUS;CYP3A5;rs776746;CT + TT;EFFICACY, LADME_PK;DECREASED_PK
AFATINIB, ERLOTINIB, GEFITINIB;ARF1;rs11541557;GT + TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY
DRUGS FOR TREATMENT OF TUBERCULOSIS;CYP2E1;rs2031920;CT + TT;TOXICITY;INCREASED_RISK
OSELTAMIVIR;ABCB1;rs1045642;AG + GG;TOXICITY;INCREASED_RISK
METHOTREXATE;ABCC3;rs9895420;AA + AT;TOXICITY, LADME_PK;INCREASED_
METHOTREXATE;ABCC3;rs9895420;AA + AT;EFFICACY;DECREASED_EFFICACY
COCAINE;OPRD1;rs678849;T;TOXICITY;DECREASED_RISK
CERIVASTATIN;RYR2;rs2819742;AA;TOXICITY;DECREASED_RISK
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;;rs1891059;A;TOXICITY;INCREASED_RISK
ANTIEPILEPTICS;ABCC2;rs2273697;A;EFFICACY;INCREASED_EFFICACY
METHOTREXATE;ABCC3;rs9895420;AA + AT;EFFICACY;INCREASED_RISKEFFICACY
;CYP1A2;rs35694136;T;OTHER;INCREASED_LIKELIHOOD
ANTITHYMOCYTE GLOBULIN;FCGR3A;rs396991;AC + CC;OTHER;INCREASED_
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;LINC00251;rs141059755;G;TOXICITY;INCREASED_RISK
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;;rs17021408;C;TOXICITY;INCREASED_RISK
PEGASPARGASE;ARHGAP28;rs9958628;T;TOXICITY;INCREASED_RISK
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;DOK5;rs117532069;A;TOXICITY;INCREASED_RISK
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;;rs80223967;G;TOXICITY;INCREASED_RISK
CARBOPLATIN, ETOPOSIDE, IFOSFAMIDE;ABCG2;rs3114020;CT + TT;EFFICACY;INCREASED_RISK
THEOPHYLLINE;CYP1A2;rs35694136;T/del + TT;EFFICACY;INCREASED_SEVERITY
THEOPHYLLINE;CYP1A2;rs35694136;T;EFFICACY, LADME_PK;DECREASED_PK
;CYP1A2;rs762551;C;OTHER;INCREASED_LIKELIHOOD
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;ATP7B;rs1061472;CC;TOXICITY;INCREASED_LIKELIHOOD
VERAPAMIL;NR1H3;rs2279238;T;EFFICACY;INCREASED_RISKEFFICACY
VERAPAMIL;NR1H3;rs12221497;A;EFFICACY;DECREASED_RISKEFFICACY
;DDC;rs921451;T;;SEVERITY_
ATENOLOL, VERAPAMIL;NR1H3;rs11039149;G;EFFICACY;DECREASED_RISKEFFICACY
;DDC;rs3735273;C;;SEVERITY_
SEVOFLURANE;KCNK2;rs6686529;CC + CG;EFFICACY;INCREASED_EFFICACY
;DDC;rs1451371;T;;SEVERITY_
CHOP, RITUXIMAB;SLC35F4;rs74832512;CC;EFFICACY;INCREASED_EFFICACY
PROTEASE INHIBITORS;APOC3;rs2854116;CC + CT;EFFICACY;DECREASED_SEVERITY
VARENICLINE;CHRNB1, ZBTB4;rs2302764;C;TOXICITY;INCREASED_SEVERITY
PROTEASE INHIBITORS;APOC3;rs2854117;CT + TT;TOXICITY;DECREASED_SEVERITY
VARENICLINE;CHRNB2;rs2072661;A;TOXICITY;INCREASED_SEVERITY
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;BMP7;rs79085477;T;TOXICITY;INCREASED_RISK
VARENICLINE;CHRNB2;rs4292956;T;TOXICITY;INCREASED_SEVERITY
VARENICLINE;CHRNB2;rs2072660;C;TOXICITY;INCREASED_SEVERITY
CARBOPLATIN, ETOPOSIDE, IFOSFAMIDE;ABCB1;rs1045642;AA + AG;EFFICACY;INCREASED_RISK
AZATHIOPRINE;DDRGK1, ITPA;rs1127354;A;TOXICITY;INCREASED_LIKELIHOOD
MORPHINE;FAAH;rs324420;AA;TOXICITY;INCREASED_LIKELIHOOD
CHOP, RITUXIMAB;OXNAD1;rs11721010;TT;EFFICACY;INCREASED_EFFICACY
MORPHINE;FAAH;rs11576941;TT;TOXICITY;INCREASED_LIKELIHOOD
PROTEASE INHIBITORS;APOC3;rs5128;CG + GG;TOXICITY;DECREASED_
SUNITINIB;ABCB1;rs2032582;AC;EFFICACY;INCREASED_EFFICACY
DOCETAXEL;SLCO1B3;rs11045585;G;TOXICITY;INCREASED_RISK
APIXABAN;ABCB1;rs4148738;CT + TT;TOXICITY;DECREASED_RISK
DOCETAXEL;ABCC2;rs12762549;G;TOXICITY;INCREASED_RISK
;DTNBP1;rs3213207;T;;DECREASED_RISK
ASPIRIN;ITGB3;rs5918;CT;OTHER;INCREASED_
CHOP, RITUXIMAB;CIDEA;rs75614943;TT;EFFICACY;INCREASED_EFFICACY
CYTARABINE;CDA;rs3215400;C/del + del/del;TOXICITY;INCREASED_
METHAMPHETAMINE;BDNF;rs6265;CC;OTHER;INCREASED_LIKELIHOOD
CHOP, RITUXIMAB;NOS1;rs77241831;GG;EFFICACY;INCREASED_EFFICACY
METHAMPHETAMINE;BDNF;rs6265;CC;OTHER;DECREASED_LIKELIHOOD
CYTARABINE;CDA;rs2072671;AC + CC;TOXICITY;INCREASED_
ANTIPSYCHOTICS;;rs9346455;GG + GT;TOXICITY;INCREASED_
;DTNBP1;rs3213207;T;;DECREASED_SEVERITY
SUFENTANIL;ABCB1;rs1045642;GG;EFFICACY;INCREASED_SEVERITYEFFICACY
;DTNBP1;rs2619539;C;;DECREASED_SEVERITY
CYTARABINE;CDA;rs602950;AG + GG;TOXICITY;INCREASED_
HEROIN;OPRD1;rs2236857;C;TOXICITY;INCREASED_RISK
CYTARABINE;CDA;rs532545;CT + TT;TOXICITY;INCREASED_
HEROIN;OPRD1;rs2236855;A;TOXICITY;INCREASED_RISK
SUNITINIB;ABCB1;rs1128503;AG;EFFICACY;INCREASED_EFFICACY
RIVAROXABAN;ABCB1;rs1045642;AA + AG;TOXICITY;DECREASED_RISK
HEROIN;OPRD1;rs3766951;C;TOXICITY;INCREASED_RISK
NICOTINE;NRXN1;rs2193225;C;OTHER;
HEROIN;OPRD1;rs2298897;C;TOXICITY;INCREASED_RISK
NICOTINE;NRXN1;rs2193225;C;OTHER;
NICOTINE;NRXN1;rs6721498;A;OTHER;
SUNITINIB;ABCB1;rs1045642;AG;EFFICACY;INCREASED_EFFICACY
CHOP, RITUXIMAB;;rs1607795;CC;EFFICACY;INCREASED_EFFICACY
SUFENTANIL;COMT;rs4680;AA;EFFICACY;INCREASED_SEVERITYEFFICACY
;DTNBP1;rs2619538;T;;DECREASED_SEVERITY
ETHANOL;FUT2;rs492602;A;TOXICITY;DECREASED_RISK
ETHANOL;FTO;rs9937709;A;TOXICITY;INCREASED_RISK
PLATINUM;RICTOR;rs6878291;GG;TOXICITY;DECREASED_EFFICACY
ANTIDEPRESSANTS;NR3C1;rs852977;G;EFFICACY;INCREASED_PK
CERIVASTATIN;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED_RISK
PAROXETINE;HTR3B;rs1176744;AA;TOXICITY;INCREASED_RISK
ETHANOL;;rs1783835;A;TOXICITY;DECREASED_RISK
CHOP, RITUXIMAB;TNIP3;rs116665727;CC;EFFICACY;INCREASED_EFFICACY
CISPLATIN, FLUOROURACIL, RADIOTHERAPY;APEX1;rs1760944;GG;EFFICACY;DECREASED_LIKELIHOODEFFICACY
CHOP, RITUXIMAB;IL10;rs1800871;AG + GG;EFFICACY;INCREASED_EFFICACY
SUNITINIB;ABCB1;rs2032582;A;EFFICACY;DECREASED_EFFICACY
CISPLATIN, FLUOROURACIL, RADIOTHERAPY;MUTYH;rs3219489;CG + GG;EFFICACY;DECREASED_LIKELIHOODEFFICACY
ETHANOL;SLC4A8;rs12296477;C;TOXICITY;INCREASED_RISK
ASPIRIN;ITGB3;rs5918;CC + CT;OTHER;
;NR3C1;rs10482633;G;;INCREASED_EFFICACY
ESCITALOPRAM;HTR2A;rs9316233;C;EFFICACY;INCREASED_EFFICACY
ETHANOL;ARID4A;rs61974485;T;TOXICITY;INCREASED_RISK
ETHANOL;;rs8008020;T;TOXICITY;INCREASED_RISK
NICOTINE;OPRM1;rs1799971;AG;TOXICITY;INCREASED_SEVERITY
ETHANOL;TNRC6A;rs72768626;A;TOXICITY;INCREASED_RISK
GLIMEPIRIDE, GLIPIZIDE, GLYBURIDE;NOS1AP;rs10494366;T;TOXICITY;INCREASED_RISK
KETOROLAC;;rs2562456;CC;EFFICACY;EFFICACY
OPIOIDS;OPRM1;rs1799971;AG + GG;DOSAGE;DECREASED_LIKELIHOOD
AZATHIOPRINE;ABCC1;rs2074087;CC + CG;TOXICITY;INCREASED_LIKELIHOOD
FLUVASTATIN;SREBF1;rs60282872;CC;EFFICACY;INCREASED_EFFICACY
BEVACIZUMAB, PEMETREXED;SLC19A1;rs1051298;G;EFFICACY;INCREASED_EFFICACY
CISPLATIN, RADIOTHERAPY;TP53;rs1042522;CG;EFFICACY;INCREASED_EFFICACY
;SLC30A8;rs13266634;C;OTHER, LADME_PK;INCREASED_
OPIOIDS;OPRM1;rs1799971;AG + GG;DOSAGE;DECREASED_LIKELIHOOD
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;AGT;rs943580;GG;TOXICITY;DECREASED_LIKELIHOOD
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;MMP1, MMP10;rs2071230;AG + GG;TOXICITY;INCREASED_LIKELIHOOD
LEVONORGESTREL;ADAMTS10;rs7255721;CG;TOXICITY;DECREASED_LIKELIHOOD
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;MMP1, MMP10;rs7945189;CT + TT;TOXICITY;DECREASED_LIKELIHOOD
CITALOPRAM;HTR2A;rs6313;AA;TOXICITY;DECREASED_RISK
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;PTGS1;rs12353214;TT;TOXICITY;INCREASED_LIKELIHOOD
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;KL;rs211247;CG + GG;TOXICITY;INCREASED_LIKELIHOOD
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;CRP;rs1205;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
NICOTINE;CHRNA4;rs1044396;AG;OTHER;INCREASED_LIKELIHOOD
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;CDKN2B-AS1;rs10757274;AA + AG;TOXICITY;DECREASED_LIKELIHOOD
NICOTINE;CHRNA4;rs1044396;GG;TOXICITY;INCREASED_LIKELIHOOD
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;AGT;rs699;GG;TOXICITY;DECREASED_LIKELIHOOD
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY
NICOTINE;CHRNA4;rs1044397;CC;TOXICITY;INCREASED_LIKELIHOOD
COXIBS;PTGS2;rs20417;CG + GG;TOXICITY;INCREASED_LIKELIHOOD
COXIBS;PTGS2;rs4648276;AG + GG;TOXICITY;INCREASED_LIKELIHOOD
SEVOFLURANE;FASTKD3, MTRR;rs3733784;CC + CT;EFFICACY;INCREASED_EFFICACY
HEROIN;OPRM1;rs524731;A;TOXICITY;INCREASED_RISK
HEROIN;OPRM1;rs511435;T;TOXICITY;INCREASED_RISK
HEROIN;OPRM1;rs495491;G;TOXICITY;INCREASED_RISK
AZATHIOPRINE;ADK;rs10824095;TT;TOXICITY;INCREASED_LIKELIHOOD
HEROIN;OPRM1;rs510769;T;TOXICITY;INCREASED_RISK
CISPLATIN;ACYP2;rs1872328;A;TOXICITY;INCREASED_RISK
AZATHIOPRINE;SLC29A1;rs747199;CG + GG;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_EFFICACY
AZATHIOPRINE;IMPDH2;rs11706052;AG + GG;TOXICITY;INCREASED_LIKELIHOOD
HEROIN;OPRM1;rs3778151;C;TOXICITY;INCREASED_RISK
AZATHIOPRINE;IMPDH1;rs2278294;CT + TT;TOXICITY;DECREASED_LIKELIHOOD
CLOZAPINE, OLANZAPINE, RISPERIDONE;SLC1A1;rs2228622;A;TOXICITY;INCREASED_RISK
HEROIN;OPRM1;rs3823010;A;TOXICITY;INCREASED_RISK
CLOZAPINE, OLANZAPINE, RISPERIDONE;SLC1A1;rs3780413;G;TOXICITY;INCREASED_RISK
CLOZAPINE, OLANZAPINE, RISPERIDONE;SLC1A1;rs3780412;C;TOXICITY;INCREASED_RISK
HEROIN;;rs9478495;A;TOXICITY;INCREASED_RISK
;;rs9424490;G;;INCREASED_RISK
;USH2A;rs12126638;C;;INCREASED_RISK
;AK4;rs1109374;C;;INCREASED_RISK
ASPIRIN, CLOPIDOGREL;ITGA2;rs1062535;AA + AG;EFFICACY;INCREASED_RISKEFFICACY
;ITGB1;rs1187075;AA;EFFICACY;INCREASED_RISKEFFICACY
HEROIN;OPRM1;rs562859;C;TOXICITY;INCREASED_RISK
FLUOROURACIL;DPYD;rs3918290;T;TOXICITY;INCREASED_SEVERITY
LETROZOLE;;rs1324052;A;TOXICITY;INCREASED_LIKELIHOOD
PLATINUM, VINORELBINE;STMN1;rs182455;AA;EFFICACY;DECREASED_EFFICACY
TEGAFUR;DPYD;rs1801159;TT;EFFICACY;DECREASED_EFFICACY
;ITGB1;rs2230395;GG;EFFICACY;INCREASED_RISKEFFICACY
HEROIN;OPRM1;rs3778150;C;TOXICITY;INCREASED_RISK
BEVACIZUMAB, PEMETREXED;GGH;rs3780126;G;EFFICACY;INCREASED_EFFICACY
;TPH2;rs1843809;TT;OTHER;DECREASED_LIKELIHOOD
ASPIRIN, CLOPIDOGREL;ITGA2;rs1126643;CT + TT;EFFICACY;INCREASED_RISKEFFICACY
HEROIN;;rs9384169;C;TOXICITY;INCREASED_RISK
ANTIPSYCHOTICS;CYP1A2;rs762551;AC + CC;TOXICITY;INCREASED_
PLATINUM COMPOUNDS;SLC22A2;rs316019;AA + AC;TOXICITY;INCREASED_SEVERITY
PLATINUM COMPOUNDS;SLC22A2;rs316019;AA + AC;TOXICITY;INCREASED_SEVERITY
ANTIDEPRESSANTS, ANTIPSYCHOTICS, BENZODIAZEPINE DERIVATIVES, OPIOIDS, SYMPATHOMIMETICS;OPRM1;rs1799971;G;TOXICITY;INCREASED_RISK
BEVACIZUMAB, PEMETREXED;GGH;rs11545077;CT;EFFICACY;INCREASED_EFFICACY
DIGOXIN;NOS1AP;rs10494366;GG;TOXICITY;INCREASED_
SUNITINIB;ABCB1;rs2032582;CC;TOXICITY;INCREASED_LIKELIHOOD
ASPIRIN, CLOPIDOGREL;ITGA2;rs1126643;CT + TT;EFFICACY;INCREASED_EFFICACY
FENTANYL;OPRM1;rs1799971;GG;DOSAGE;EFFICACY
CANNABINOIDS, COCAINE, ETHANOL, NICOTINE, OPIOIDS;OPRM1;rs1799971;G;TOXICITY;DECREASED_RISK
CAPECITABINE, FLUOROURACIL;MIR27A;rs895819;CT;TOXICITY;INCREASED_LIKELIHOOD
SUNITINIB;FLT1;rs7993418;GG;EFFICACY;DECREASED_EFFICACY
CISPLATIN;NFE2L2;rs6721961;GG + GT;TOXICITY;INCREASED_LIKELIHOOD
SUNITINIB;FLT1;rs9582036;CC;EFFICACY;DECREASED_EFFICACY
FENTANYL;OPRM1;rs1799971;AG + GG;DOSAGE, EFFICACY;EFFICACY
FLUVOXAMINE;HTR2A;rs6311;CC + CT;TOXICITY;INCREASED_RISK
FENTANYL;OPRM1;rs1799971;AG + GG;EFFICACY;EFFICACY
OLANZAPINE;FMO3;rs2266780;GG;LADME_PK;DECREASED_PK
METOPROLOL;CYP2D6;rs3892097;T;EFFICACY, LADME_PK;INCREASED_PK
SUNITINIB;FLT1;rs9554320;AA;EFFICACY;DECREASED_EFFICACY
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_EFFICACY
PLATINUM COMPOUNDS;CCN4;rs10956697;AA + AC;EFFICACY;DECREASED_RISKEFFICACY
ASPIRIN;ITGB3;rs5918;CC + CT;EFFICACY;INCREASED_RISKEFFICACY
SUNITINIB;FLT1;rs9554320;AA;EFFICACY;DECREASED_EFFICACY
OLANZAPINE;FMO1;rs12720462;AA + AC;LADME_PK;INCREASED_PK
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY, TOXICITY;INCREASED_RISK
PLATINUM COMPOUNDS;ERCC1;rs3212986;CC;EFFICACY;INCREASED_EFFICACY
ARIPIPRAZOLE;DRD2;rs2514218;CC;TOXICITY;INCREASED_SEVERITY
PLATINUM COMPOUNDS, TAXANES;GSTP1;rs1695;AA;TOXICITY, LADME_PK;INCREASED_RISK
PLATINUM, TAXANES;ABCB1;rs2032582;CC;TOXICITY, LADME_PK;DECREASED_RISK
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY, TOXICITY;INCREASED_RISK
SUNITINIB;FLT1;rs9582036;CC;EFFICACY;DECREASED_EFFICACY
OLANZAPINE;FMO1;rs7877;CT + TT;LADME_PK;INCREASED_PK
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;INCREASED_EFFICACY
BUMETANIDE, FUROSEMIDE, TORASEMIDE;SLC12A3;rs1529927;C;EFFICACY;INCREASED_EFFICACY
AMPHETAMINE, CANNABINOIDS, COCAINE, OPIOIDS;KAT2B;rs9829896;C;TOXICITY;DECREASED_RISK
PACLITAXEL;EPHA5;rs7349683;TT;TOXICITY;INCREASED_RISK
IMATINIB;ABCG2;rs2231142;TT;EFFICACY;INCREASED_EFFICACY
ASPIRIN;NAT2;rs4271002;C;TOXICITY;INCREASED_RISK
OPIOIDS;OPRM1;rs1799971;AG + GG;TOXICITY;DECREASED_LIKELIHOOD
METHADONE;ARRB2;rs3786047;AA;EFFICACY;INCREASED_RISKEFFICACY
BUMETANIDE, FUROSEMIDE, TORASEMIDE;SCNN1G;rs5723;G;EFFICACY;DECREASED_EFFICACY
PLATINUM COMPOUNDS;CCN4;rs2929973;GG + GT;EFFICACY;DECREASED_RISKEFFICACY
ENALAPRIL;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_LIKELIHOOD
ANTIPSYCHOTICS;HTR2A;rs6311;TT;TOXICITY;INCREASED_RISK
METHADONE;ARRB2;rs1045280;CC;EFFICACY;INCREASED_RISKEFFICACY
METHADONE;MYOCD;rs1714984;AA + AG;EFFICACY;EFFICACY
METHADONE;ARRB2;rs2036657;GG;EFFICACY;INCREASED_RISKEFFICACY
BUMETANIDE, FUROSEMIDE, TORASEMIDE;SCNN1G;rs5729;A;EFFICACY;DECREASED_EFFICACY
ANTIPSYCHOTICS;CYP1A2;rs762551;CC;TOXICITY;INCREASED_RISK
ANTIPSYCHOTICS;CYP2D6;rs1065852;A;TOXICITY;INCREASED_RISK
OLANZAPINE;HTR2C;rs518147;C;TOXICITY;DECREASED_RISK
PRAVASTATIN;CETP;rs708272;AG;EFFICACY;DECREASED_SEVERITYEFFICACY
ATORVASTATIN;KIF6;rs20455;AG + GG;EFFICACY;INCREASED_EFFICACY
ASPIRIN;ITGB3;rs5918;TT;EFFICACY;EFFICACY
ASPIRIN;F13A1;rs5985;AA + AC;EFFICACY;INCREASED_EFFICACY
VERAPAMIL;ADRB1;rs1801253;CC + CG;EFFICACY;INCREASED_RISK
AZATHIOPRINE;ITPA;rs1127354;C;EFFICACY;DECREASED_LIKELIHOODEFFICACY
CHOP, RITUXIMAB;NCF4;rs1883112;GG;EFFICACY;DECREASED_EFFICACY
IVACAFTOR;CFTR;rs75527207;AA + AG;EFFICACY;DECREASED_SEVERITY
CHOP, RITUXIMAB;ABCG2;rs2231137;CC;EFFICACY;DECREASED_EFFICACY
PRAVASTATIN;CETP;rs708272;GG;EFFICACY;DECREASED_EFFICACY
AMIODARONE, DIURETICS, SOTALOL;NOS1AP;rs10800397;T;TOXICITY;
ANTIPSYCHOTICS;;rs6977820;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
AMIODARONE;NOS1AP;rs10800397;T;TOXICITY;
WARFARIN;VKORC1;rs17880887;T;DOSAGE;EFFICACY
AMIODARONE;NOS1AP;rs10919035;T;TOXICITY;
ASPIRIN;HNMT;rs1050891;G;TOXICITY;DECREASED_RISK
AMIODARONE;NOS1AP;rs10919035;T;TOXICITY;
ASPIRIN;LTC4S;rs730012;AC + CC;TOXICITY;INCREASED_RISK
ANTIPSYCHOTICS;SMYD3;rs2485914;T;TOXICITY;INCREASED_LIKELIHOOD
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1799929;TT;TOXICITY;INCREASED_RISK
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1799929;CC;TOXICITY;DECREASED_RISK
CYTARABINE, IDARUBICIN;ABCB1;rs1045642;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_
LEVONORGESTREL;TP53;rs1042522;CG;TOXICITY;INCREASED_LIKELIHOOD
ASPIRIN;GP6;rs1613662;AG;EFFICACY;INCREASED_RISKEFFICACY
CISPLATIN, DOXORUBICIN, IFOSFAMIDE, METHOTREXATE;ERCC2;rs1799793;CT + TT;EFFICACY;INCREASED_EFFICACY
CYTARABINE, IDARUBICIN;ABCB1;rs1045642;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
CISPLATIN, DOXORUBICIN, IFOSFAMIDE, METHOTREXATE;ERCC2, KLC3;rs13181;GG;EFFICACY;INCREASED_EFFICACY
ACENOCOUMAROL, PHENPROCOUMON, WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;EFFICACY
ASPIRIN;ITGB3;rs5918;CT;TOXICITY;INCREASED_
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_RISK
SUNITINIB;KDR;rs2305948;C;TOXICITY;INCREASED_SEVERITY
CAPECITABINE, EPIRUBICIN, PLATINUM;GSTP1;rs1695;GG;EFFICACY;INCREASED_EFFICACY
CLOPIDOGREL;PON1;rs662;CT + TT;EFFICACY;INCREASED_EFFICACY
;ITGB3;rs5918;CC + CT;OTHER;
BETA BLOCKING AGENTS;GRK5;rs2230345;AA;OTHER;INCREASED_RISK
FENTANYL, HYDROMORPHONE, OXYCODONE;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
CLOPIDOGREL;PON1;rs662;CT + TT;EFFICACY;INCREASED_EFFICACY
BEVACIZUMAB;CXCR4;rs2228014;AA + AG;EFFICACY;DECREASED_EFFICACY
BETA BLOCKING AGENTS;ADRB1;rs1801253;CC;OTHER;DECREASED_RISK
DOCETAXEL, FEC100, GEMCITABINE, TRASTUZUMAB, ZOLEDRONATE;PPCDC;rs147451859;G;TOXICITY;DECREASED_LIKELIHOOD
SUNITINIB;FLT4;rs6877011;GG;EFFICACY;DECREASED_LIKELIHOODEFFICACY
HALOPERIDOL;ABCB5;rs17143212;CT;TOXICITY;INCREASED_
DOCETAXEL, FEC100, GEMCITABINE, TRASTUZUMAB, ZOLEDRONATE;;rs17587029;G;TOXICITY;DECREASED_LIKELIHOOD
SUNITINIB;ABCG2;rs2231142;T;TOXICITY;INCREASED_SEVERITY
OPIOIDS;CNIH3;rs10799590;A;TOXICITY;DECREASED_RISK
AZATHIOPRINE, MERCAPTOPURINE;ITPA;rs7270101;AC + CC;TOXICITY;INCREASED_LIKELIHOOD
SUNITINIB;VEGFA;rs3025039;CT + TT;TOXICITY;INCREASED_SEVERITY
ANTIPSYCHOTICS;CYP1A2;rs762551;CC;TOXICITY;INCREASED_SEVERITY
METHOTREXATE;MTHFR;rs1801133;A;EFFICACY;DECREASED_LIKELIHOODEFFICACY
CISPLATIN;SLC22A2;rs316019;A;TOXICITY;DECREASED_RISK
SUNITINIB;CYP3A4;rs4646437;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
ATORVASTATIN;ABCB1;rs2032582;C;TOXICITY;INCREASED_RISK
"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS""";F5;rs6025;CT + TT;TOXICITY;INCREASED_RISK
CISPLATIN;NFE2L2;rs6721961;T;TOXICITY;DECREASED_RISK
CARVEDILOL;ADRB2;rs1042714;CC;EFFICACY;DECREASED_LIKELIHOODEFFICACY
TACROLIMUS;FOXP3;rs3761548;GT + TT;TOXICITY;INCREASED_RISK
TACROLIMUS;CYP3A4;rs2740574;CC + CT;TOXICITY;DECREASED_LIKELIHOOD
METHOTREXATE;RAVER2;rs72675408;A;TOXICITY;INCREASED_LIKELIHOOD
PHENYTOIN;CYP2C9;rs1057910;C;EFFICACY;INCREASED_RISK
PHENYTOIN;CYP2C9;rs1799853;T;EFFICACY;INCREASED_RISK
CAPECITABINE, FLUOROURACIL;PPARD;rs2016520;T;TOXICITY;INCREASED_SEVERITY
EFAVIRENZ;CYP2B6;rs8192719;CT + TT;LADME_PK;INCREASED_PK
;SULT1A1, SULT1A2;rs1801030;CC + CT;OTHER;INCREASED_LIKELIHOOD
OPIOIDS;MCOLN1;rs116181528;A;TOXICITY;INCREASED_SEVERITY
CERIVASTATIN, HMG COA REDUCTASE INHIBITORS, ROSUVASTATIN, SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK
;AKT1;rs2494732;CC;OTHER;INCREASED_LIKELIHOOD
CAPECITABINE;MTHFR;rs1801131;GG;TOXICITY;INCREASED_RISK
WARFARIN;VKORC1;rs8050894;G;DOSAGE;DECREASED_
BEVACIZUMAB;KCNAB1;rs6770663;G;TOXICITY;INCREASED_RISK
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_
CYCLOPHOSPHAMIDE, EPIRUBICIN;GSTP1;rs1695;AA + AG;TOXICITY;DECREASED_SEVERITY
ASPIRIN;CEP68;rs7572857;AA;TOXICITY;INCREASED_
OPIOIDS;MCOLN1;rs114077267;T;TOXICITY;INCREASED_SEVERITY
ACENOCOUMAROL;VKORC1;rs9923231;TT;EFFICACY;DECREASED_EFFICACY
PLATINUM COMPOUNDS;MDM2;rs2279744;GT + TT;TOXICITY;INCREASED_SEVERITY
SUNITINIB;FLT3;rs1933437;AG + GG;TOXICITY;DECREASED_LIKELIHOOD
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_PK
ASPIRIN;ITGB3;rs5918;CT;EFFICACY;DECREASED_EFFICACY
;SLC2A9;rs62293298;AG;OTHER;DECREASED_LIKELIHOOD
EFAVIRENZ;CYP2B6;rs2279343;GG;LADME_PK;INCREASED_PK
ASPIRIN;TLR3;rs3775291;CT + TT;TOXICITY;INCREASED_RISK
EFAVIRENZ;CYP2B6;rs2279345;CC + CT;LADME_PK;DECREASED_PK
OPIOIDS;MCOLN1;rs115208233;G;TOXICITY;INCREASED_SEVERITY
TACROLIMUS;CYP3A4;rs2740574;CC + CT;EFFICACY;INCREASED_LIKELIHOODEFFICACY
NICOTINE;DRD2;rs1800497;AA + AG;TOXICITY;INCREASED_
NICOTINE;DRD2;rs1800497;GG;TOXICITY;INCREASED_SEVERITY
WARFARIN;VKORC1;rs2884737;CC;DOSAGE;DECREASED_
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IL6;rs1800795;CC;EFFICACY;INCREASED_EFFICACY
;ABCG2;rs2231142;GT + TT;OTHER;INCREASED_LIKELIHOOD
ACENOCOUMAROL, WARFARIN;CYP2C9;rs72558189;AG;EFFICACY;INCREASED_EFFICACY
TELBIVUDINE;TK2;rs3826160;CC + CT;TOXICITY;INCREASED_LIKELIHOOD
SUNITINIB;FLT1;rs9582036;CC;EFFICACY;DECREASED_EFFICACY
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_
;SLC22A12;rs3825017;CT;OTHER;INCREASED_LIKELIHOOD
ACENOCOUMAROL, WARFARIN;CYP4F2;rs2108622;CT + TT;EFFICACY;INCREASED_EFFICACY
SUNITINIB;CYP1A1;rs1048943;C;TOXICITY;INCREASED_LIKELIHOOD
OLANZAPINE;DRD2;rs2440390;T;TOXICITY;INCREASED_
PRAVASTATIN;ADAMTS1;rs428785;GG;EFFICACY;DECREASED_LIKELIHOODEFFICACY
OLANZAPINE;HTR2C;rs6318;G;TOXICITY;INCREASED_
CAFFEINE;CYP1A2;rs762551;AA;TOXICITY;INCREASED_LIKELIHOOD
OLANZAPINE;HTR2C;rs2497538;C;TOXICITY;INCREASED_
OLANZAPINE;HTR2C;rs1414334;G;TOXICITY;INCREASED_
VINCRISTINE;CEP72;rs924607;TT;TOXICITY;INCREASED_RISK
PIOGLITAZONE;LPL;rs328;CG + GG;EFFICACY;DECREASED_EFFICACY
PACLITAXEL;EPHA5;rs7349683;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
;SCN1A;rs3812718;T;OTHER;INCREASED_RISK
;UGT1A1;rs4148323;AA + AG;OTHER;INCREASED_SEVERITY
;CHRNA5;rs16969968;A;OTHER;INCREASED_SEVERITY
PACLITAXEL;ABCB1;rs3213619;AG + GG;TOXICITY;DECREASED_LIKELIHOOD
VERAPAMIL;NOS1AP;rs10494366;GG;TOXICITY;INCREASED_RISK
MERCAPTOPURINE;PACSIN2;rs2413739;TT;TOXICITY;INCREASED_RISK
;;rs1051730;A;OTHER;INCREASED_SEVERITY
;CYP2R1;rs12794714;A;OTHER;INCREASED_LIKELIHOOD
OLANZAPINE;ABCB1;rs1045642;AA;EFFICACY;INCREASED_EFFICACY
PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;rs1799930;A;TOXICITY;INCREASED_LIKELIHOOD
;CYP2R1;rs10741657;A;OTHER;DECREASED_LIKELIHOOD
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;rs1799929;T;TOXICITY;INCREASED_LIKELIHOOD
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK
PAROXETINE;HTR1A;rs6295;GG;EFFICACY;INCREASED_EFFICACY
TAMOXIFEN;E2F7;rs310786;CC;TOXICITY;INCREASED_
ALENDRONATE;DKK1;rs2241529;AA;EFFICACY;DECREASED_EFFICACY
CLOPIDOGREL;CES1;rs8192950;G;EFFICACY;DECREASED_RISKEFFICACY
ANTIPSYCHOTICS;DRD2;rs1799732;GG;TOXICITY;INCREASED_LIKELIHOOD
SUNITINIB;KDR;rs2305948;CC;EFFICACY;DECREASED_EFFICACY
WARFARIN;CYP2C9;rs4918758;C;DOSAGE;DECREASED_
SUNITINIB;VEGFA;rs3025039;CC;EFFICACY;DECREASED_EFFICACY
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK
OLANZAPINE;ANKK1;rs1800497;GG;OTHER;DECREASED_PK
EXEMESTANE;ESR1;rs9322336;CC;TOXICITY;INCREASED_LIKELIHOOD
WARFARIN;CYP2C9;rs9332096;T;DOSAGE;DECREASED_
OLANZAPINE;ANKK1;rs1800497;GG;OTHER;DECREASED_
SUNITINIB;VEGFA;rs2010963;G;TOXICITY;INCREASED_LIKELIHOOD
SUNITINIB;FLT4;rs6877011;C;EFFICACY;INCREASED_EFFICACY
OLANZAPINE;GSTP1;rs1695;AA;TOXICITY;INCREASED_LIKELIHOOD
SUNITINIB;NR1I2;rs2276707;TT;EFFICACY;DECREASED_EFFICACY
WARFARIN;VKORC1;rs9934438;AG + GG;DOSAGE;INCREASED_
ANTHRACYCLINES AND RELATED SUBSTANCES;HAS3;rs2232228;AA;TOXICITY;INCREASED_RISK
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_
SUNITINIB;FLT3;rs1933437;AG + GG;TOXICITY;DECREASED_LIKELIHOOD
NORTRIPTYLINE;ABCB1;rs1045642;AA;TOXICITY;INCREASED_LIKELIHOOD
WARFARIN;VKORC1;rs2359612;A;DOSAGE;DECREASED_
MORPHINE, OXYCODONE;OPRM1;rs1799971;GG;TOXICITY;DECREASED_LIKELIHOOD
MORPHINE, OXYCODONE;COMT;rs4680;GG;TOXICITY;INCREASED_LIKELIHOOD
CARBAMAZEPINE;HNF4A;rs2071197;GG;EFFICACY;INCREASED_PK
WARFARIN;VKORC1;rs8050894;G;DOSAGE;DECREASED_
PRAVASTATIN;MTHFR;rs1801133;GG;EFFICACY;DECREASED_LIKELIHOOD
SUNITINIB;ABCB1;rs1128503;AA;EFFICACY;DECREASED_EFFICACY
SUNITINIB;VEGFA;rs833061;CC + CT;EFFICACY;INCREASED_EFFICACY
CYCLOSPORINE, MYCOPHENOLATE MOFETIL;IMPDH2;rs11706052;AG + GG;EFFICACY;INCREASED_RISK
CYCLOSPORINE, MYCOPHENOLATE MOFETIL;TNF;rs1800629;AA + AG;EFFICACY;INCREASED_RISK
METHOTREXATE;MTHFR;rs1801131;GG;TOXICITY;INCREASED_RISK
CYCLOSPORINE, MYCOPHENOLATE MOFETIL;IL10;rs1800872;TT;EFFICACY;INCREASED_RISKEFFICACY
SUNITINIB;ABCB1;rs2032582;AA + AT;EFFICACY;DECREASED_EFFICACY
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;INCREASED_RISKEFFICACY
SUNITINIB;VEGFA;rs2010963;G;EFFICACY;INCREASED_EFFICACY
NICOTINE;CHRNA5;rs16969968;A;OTHER;INCREASED_SEVERITY
NICOTINE;CHRNA5;rs16969968;A;OTHER;INCREASED_SEVERITY
;CHRNA5;rs16969968;A;OTHER;INCREASED_LIKELIHOOD
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK
CLOPIDOGREL;N6AMT1;rs2254638;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
METHOTREXATE;MTHFR;rs1801133;AA;EFFICACY;INCREASED_EFFICACY
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK
NICOTINE;GALR1;rs2717162;CT + TT;OTHER;INCREASED_SEVERITY
CAPECITABINE, FLUOROURACIL;DPYD;rs67376798;A;TOXICITY;INCREASED_LIKELIHOOD
CAPECITABINE, FLUOROURACIL;DPYD;rs3918290;T;TOXICITY;INCREASED_LIKELIHOOD
ERYTHROMYCIN;SLCO1B1;rs4149056;C;LADME_PK;DECREASED_PK
PAZOPANIB, SIMVASTATIN;ABCG2;rs2231142;GT + TT;TOXICITY;INCREASED_LIKELIHOOD
GENTAMICIN;MT-RNR1;rs267606617;G;TOXICITY;INCREASED_RISK
CYCLOSPORINE, TACROLIMUS;LEP;rs2167270;A;TOXICITY;INCREASED_LIKELIHOOD
ERLOTINIB;ABCB1;rs1045642;AA;TOXICITY, LADME_PK;INCREASED_LIKELIHOOD
MERCAPTOPURINE;NUDT15;rs73189762;GT;DOSAGE;INCREASED_LIKELIHOOD
ETHANOL;HTR3B;rs1176744;C;OTHER;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;rs12248560;T;TOXICITY;DECREASED_
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_SEVERITY
METHOTREXATE;ADORA2A, SPECC1L;rs5760410;G;TOXICITY;INCREASED_RISK
CALCIUM CHANNEL BLOCKERS, NITRENDIPINE;KCNH2;rs1137617;AA + AG;EFFICACY;INCREASED_EFFICACY
CLOPIDOGREL;KDR;rs7667298;CC;TOXICITY;DECREASED_LIKELIHOOD
METHOTREXATE;MTHFR;rs1801131;G;EFFICACY;INCREASED_RISK
METHOTREXATE;MTHFR;rs1801133;AA;EFFICACY;DECREASED_RISK
NICOTINE;GALR1;rs2717162;CT + TT;OTHER;INCREASED_SEVERITY
ANTINEOPLASTIC AGENTS;CLCN6, MTHFR;rs1801133;GG;EFFICACY;INCREASED_EFFICACY
IRINOTECAN;UGT1A1;rs4148323;AG;TOXICITY;INCREASED_SEVERITY
;MTHFR;rs1801131;G;EFFICACY;INCREASED_EFFICACY
BUSULFAN, CYCLOPHOSPHAMIDE, METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK
ERLOTINIB;ABCB1;rs1128503;AA;TOXICITY, LADME_PK;INCREASED_LIKELIHOOD
METHOTREXATE;MTHFR;rs1801131;GG;EFFICACY;DECREASED_RISKEFFICACY
CLOPIDOGREL;KDR;rs2305948;TT;TOXICITY;INCREASED_RISK
METHOTREXATE;ABCB1;rs1128503;GG;TOXICITY;INCREASED_SEVERITY
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK
METHOTREXATE;MTHFR;rs1801131;GG;TOXICITY;DECREASED_SEVERITY
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK
WARFARIN;VKORC1;rs9923231;TT;TOXICITY;INCREASED_RISK
ERLOTINIB;ABCB1;rs2032582;AA;TOXICITY, LADME_PK;INCREASED_LIKELIHOOD
WARFARIN;VKORC1;rs9923231;TT;TOXICITY;INCREASED_RISK
PACLITAXEL;ARHGEF10;rs9657362;C;TOXICITY;DECREASED_LIKELIHOOD
;FKBP5;rs1360780;CC + CT;;INCREASED_RISK
;FKBP5;rs3800373;AA + AC;OTHER;INCREASED_RISK
PACLITAXEL;ARHGEF10;rs9657362;C;TOXICITY;DECREASED_LIKELIHOOD
;TBX21;rs17244587;A;;INCREASED_RISK
;PSMB4;rs2296840;T;OTHER;INCREASED_RISK
METFORMIN;SLC22A1;rs34059508;A;DOSAGE, LADME_PK;INCREASED_PK
METFORMIN;SLC22A1;rs12208357;C;DOSAGE, LADME_PK;INCREASED_PK
CLOPIDOGREL;CYP2C19;rs12248560;T;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;rs4244285;A;TOXICITY;INCREASED_RISK
;CHRNA5;rs680244;C;OTHER;INCREASED_RISK
CLOPIDOGREL;CYP2C19;rs4244285;A;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;rs4244285;A;TOXICITY;INCREASED_RISK
METHOTREXATE;PTPN22;rs2476601;AA;TOXICITY;INCREASED_LIKELIHOOD
;CHRNA3;rs1051730;G;;INCREASED_RISK
METHOTREXATE;TNFAIP3;rs6920220;A;TOXICITY;INCREASED_LIKELIHOOD
;CHRNA3, CHRNA5;rs578776;G;;INCREASED_RISK
SUNITINIB;ABCG2;rs2231142;TT;TOXICITY;DECREASED_RISK
;CHRNA5;rs16969968;A;;INCREASED_RISK
RISPERIDONE;ABCB1;rs1045642;AA;LADME_PK;INCREASED_SEVERITY
;CHRNA5;rs569207;C;;INCREASED_RISK
CARBAMAZEPINE, PHENOBARBITAL, PHENYTOIN, VALPROIC ACID;CYP1A1;rs2606345;A;EFFICACY, LADME_PK;INCREASED_RISK
;SLCO1B3;rs2417940;C;OTHER;INCREASED_SEVERITY
SERTRALINE;;rs13432159;G;TOXICITY;INCREASED_
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK
TAMOXIFEN;CYP2D6;rs3892097;TT;EFFICACY;INCREASED_EFFICACY
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK
TAMOXIFEN;CYP2D6;rs3892097;TT;EFFICACY;DECREASED_EFFICACY
TAMOXIFEN;CYP2D6;rs3892097;TT;EFFICACY;DECREASED_EFFICACY
;KIF6;rs20455;AG + GG;OTHER;INCREASED_RISK
PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs1127354;A;TOXICITY;DECREASED_
ROSUVASTATIN;GATM;rs9806699;AA + AG;TOXICITY;DECREASED_RISK
TAMOXIFEN;CYP2D6;rs3892097;T;EFFICACY;DECREASED_EFFICACY
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4363657;CC + CT;TOXICITY;DECREASED_RISK
PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs7270101;C;TOXICITY;DECREASED_
IRINOTECAN;UGT1A1;rs4148323;AA;TOXICITY;INCREASED_SEVERITY
FLUOROURACIL, IRINOTECAN, OXALIPLATIN;GSTP1;rs1695;AA;TOXICITY;INCREASED_RISK
PRAVASTATIN;IL1B;rs16944;GG;OTHER;INCREASED_
HMG COA REDUCTASE INHIBITORS;;rs116561224;G;TOXICITY;INCREASED_RISK
;KCNH2;rs3815459;T;OTHER;INCREASED_
FENOFIBRATE, SERTRALINE, TERBINAFINE, TICLOPIDINE;;rs114577328;C;TOXICITY;INCREASED_RISK
ANTIDEPRESSANTS;HTR2A;rs17288723;CC;EFFICACY;INCREASED_LIKELIHOODEFFICACY
;KCNH2;rs3807375;CT + TT;OTHER;INCREASED_
CITALOPRAM;GRIK4;rs1954787;C;EFFICACY;DECREASED_LIKELIHOODEFFICACY
;KCNH2;rs1805123;GT + TT;OTHER;INCREASED_
CYCLOSPORINE;NR1I2;rs2276707;C;DOSAGE, LADME_PK;DECREASED_PK
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;rs1799929;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;rs1799930;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
PLATINUM COMPOUNDS;GSTP1;rs1695;G;TOXICITY, LADME_PK;DECREASED_RISK
CLOZAPINE;;rs149104283;T;TOXICITY;INCREASED_RISK
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;rs1799931;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
;KCNH2;rs1805123;G;OTHER;DECREASED_
ASPARAGINASE, CYCLOPHOSPHAMIDE, DAUNORUBICIN, PREDNISOLONE, VINCRISTINE;PNPLA3;rs738409;CG + GG;TOXICITY;INCREASED_RISK
;KCNH2;rs3807375;T;OTHER;INCREASED_
OXALIPLATIN;GSTP1;rs1695;GG;TOXICITY;INCREASED_SEVERITY
;KCNQ1;rs757092;G;OTHER;INCREASED_
;KCNH2;rs3815459;T;OTHER;INCREASED_
PRAVASTATIN;IL1B;rs16944;GG;OTHER;INCREASED_
;VEGFA;rs2010963;CG + GG;OTHER;INCREASED_RISK
;KCNH2;rs1805123;GG;OTHER;DECREASED_
;KCNQ1;rs757092;G;OTHER;INCREASED_
OXALIPLATIN;GSTP1;rs1695;AA;TOXICITY, LADME_PK;INCREASED_SEVERITY
METHOTREXATE;SLCO1B1;rs4149056;TT;TOXICITY;INCREASED_SEVERITY
CYCLOSPORINE;NR1I2;rs2276707;T;DOSAGE, LADME_PK;INCREASED_PK
RIFAMPIN;NR1I2;rs3814055;TT;OTHER;INCREASED_PK
PLATINUM COMPOUNDS;CCN4;rs2977549;CC + CT;EFFICACY;DECREASED_RISKEFFICACY
CITALOPRAM;HTR2A;rs7997012;AA;EFFICACY;INCREASED_LIKELIHOODEFFICACY
TACROLIMUS;CYP3A4;rs2740574;CC + TT;TOXICITY, LADME_PK;INCREASED_RISK
CITALOPRAM;HTR2A;rs7997012;A;EFFICACY;INCREASED_LIKELIHOODEFFICACY
TACROLIMUS;CYP3A5;rs776746;T;TOXICITY, LADME_PK;INCREASED_RISK
CYCLOSPORINE;NR1I2;rs3814055;C;DOSAGE, LADME_PK;DECREASED_PK
ASPIRIN, CLOPIDOGREL;MYOM2;rs17064642;CC + CT;EFFICACY;INCREASED_RISKEFFICACY
ANTIDEPRESSANTS;HTR2A;rs7997012;G;EFFICACY;INCREASED_LIKELIHOODEFFICACY
CITALOPRAM;HTR2A;rs7997012;A;EFFICACY;INCREASED_LIKELIHOODEFFICACY
SUFENTANIL;COMT;rs4680;AA + AG;DOSAGE;INCREASED_SEVERITYEFFICACY
ANTIDEPRESSANTS;GRIK4;rs1954787;CC;EFFICACY;INCREASED_LIKELIHOODEFFICACY
SUFENTANIL;OPRM1;rs1799971;AG + GG;DOSAGE;DECREASED_SEVERITYEFFICACY
ANTIDEPRESSANTS;GRIK4;rs12800734;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
PRAVASTATIN;KIF6;rs20455;AG + GG;EFFICACY;DECREASED_RISK
;KIF6;rs20455;AG + GG;OTHER;INCREASED_RISK
PRAVASTATIN;SLCO1B1;rs2306283;G;LADME_PK;DECREASED_PK
PRAVASTATIN;SLCO1B1;rs4149015;AG;OTHER, LADME_PK;INCREASED_PK
MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
PLATINUM COMPOUNDS;CCN4;rs2977551;CC + CT;EFFICACY;DECREASED_RISKEFFICACY
CLOPIDOGREL;ABCB1;rs1045642;AA;EFFICACY;DECREASED_LIKELIHOODEFFICACY
FLUOROURACIL;TP53;rs1042522;GG;EFFICACY;DECREASED_EFFICACY
PEGINTERFERON ALFA-2A, RIBAVIRIN;ITPA;rs6051702;AC + CC;TOXICITY;DECREASED_RISK
NICOTINE;CHRNA3, CHRNA5;rs578776;GG;TOXICITY;INCREASED_LIKELIHOOD
NICOTINE;CHRNA4;rs1044396;AA;TOXICITY;INCREASED_LIKELIHOOD
NICOTINE;CHRNA4;rs2229959;CC;TOXICITY;INCREASED_LIKELIHOOD
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;COMT, TXNRD2;rs13306278;T;EFFICACY;DECREASED_LIKELIHOODEFFICACY
PRAVASTATIN;TLR4;rs4986790;AG + GG;EFFICACY;DECREASED_RISKEFFICACY
PHENPROCOUMON;VKORC1;rs9923231;TT;EFFICACY;INCREASED_RISK
AMINOGLYCOSIDE ANTIBACTERIALS;MT-RNR1;rs267606617;G;TOXICITY;INCREASED_RISK
PEGINTERFERON ALFA-2A, RIBAVIRIN;VDR;rs1544410;TT;TOXICITY;INCREASED_RISK
PHENPROCOUMON;VKORC1;rs9923231;TT;TOXICITY;INCREASED_
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
FLUOROURACIL;IGFBP3;rs2854746;CC;EFFICACY;
PHENPROCOUMON;VKORC1;rs9923231;TT;EFFICACY;INCREASED_EFFICACY
PLATINUM COMPOUNDS;GSTP1;rs1695;AA;EFFICACY;INCREASED_RISKEFFICACY
PLATINUM COMPOUNDS;ERCC2, KLC3;rs13181;GG;EFFICACY;INCREASED_RISKEFFICACY
PHENPROCOUMON;EPHX1;rs1051740;CC;TOXICITY;INCREASED_
PLATINUM COMPOUNDS;ERCC1;rs11615;AA;EFFICACY;INCREASED_RISKEFFICACY
CLOPIDOGREL;ABCB1;rs2032582;AA;EFFICACY;DECREASED_LIKELIHOODEFFICACY
PLATINUM COMPOUNDS;GSTP1;rs1695;AA;EFFICACY;INCREASED_RISKEFFICACY
CARBOPLATIN, PACLITAXEL;NR1I2;rs1523130;TT;TOXICITY;DECREASED_LIKELIHOOD
AZATHIOPRINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_RISK
CETUXIMAB;EGF;rs4444903;AA;EFFICACY;INCREASED_EFFICACY
CARBOPLATIN, PACLITAXEL;NR1I2;rs1523127;CC;TOXICITY;DECREASED_LIKELIHOOD
IRINOTECAN;UGT1A1;rs10929302;AA + AG;TOXICITY;INCREASED_SEVERITY
CARBOPLATIN, PACLITAXEL;SLCO1B3;rs4149117;GT + TT;TOXICITY;DECREASED_LIKELIHOOD
NICOTINE;CHRNA4;rs1044396;G;OTHER;INCREASED_RISK
CISPLATIN;LRP2;rs2075252;T;TOXICITY;INCREASED_RISK
CETUXIMAB;EGF;rs4444903;AA;EFFICACY;DECREASED_EFFICACY
CAPECITABINE;CDA;rs3215400;C/del + CC;TOXICITY;DECREASED_LIKELIHOOD
CLOPIDOGREL;POR;rs2286823;GG;EFFICACY;DECREASED_LIKELIHOODEFFICACY
SUNITINIB;POR;rs1057868;TT;EFFICACY;INCREASED_EFFICACY
SUNITINIB;SLCO1B3;rs4149117;GG;EFFICACY;DECREASED_EFFICACY
METHOTREXATE;SLC19A1;rs1051266;CC + CT;TOXICITY;INCREASED_RISK
PHENPROCOUMON;VKORC1;rs9923231;TT;TOXICITY;INCREASED_
CAPECITABINE;CDA;rs532545;T;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CES1P1;rs3785161;AC + CC;EFFICACY;INCREASED_EFFICACY
WARFARIN;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_RISK
METHOTREXATE;ATIC;rs2372536;G;;SEVERITY_
LEUCOVORIN, TEGAFUR;FASTKD3, MTRR;rs1801394;GG;TOXICITY;INCREASED_SEVERITY
CAPECITABINE;DPYD;rs67376798;A;TOXICITY;INCREASED_SEVERITY
LEUCOVORIN, TEGAFUR;UMPS;rs1801019;CC;TOXICITY;INCREASED_SEVERITY
LEUCOVORIN, TEGAFUR;UMPS;rs1801019;CC;TOXICITY;INCREASED_LIKELIHOOD
ASPIRIN, CLOPIDOGREL;F13A1;rs5985;AA + AC;EFFICACY;INCREASED_RISK
PAZOPANIB;CXCL8;rs1126647;TT;EFFICACY;DECREASED_EFFICACY
WARFARIN;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_RISK
NICOTINE;CHRNA4;rs2236196;G;OTHER;INCREASED_RISK
ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs111564371;CT;EFFICACY;DECREASED_SEVERITYEFFICACY
METHOTREXATE;SLC19A1;rs1051266;CT + TT;TOXICITY;DECREASED_RISK
NICOTINE;CHRNA3;rs1051730;AA + AG;TOXICITY;DECREASED_
CYCLOPHOSPHAMIDE, FLUOROURACIL;MTHFR;rs1801133;A;TOXICITY;INCREASED_LIKELIHOOD
LEDIPASVIR, SOFOSBUVIR;IFNL3, IFNL4;rs12979860;TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY
CARBAMAZEPINE;HSPA1A;rs1043620;T;TOXICITY;DECREASED_SEVERITY
ASPIRIN, CLOPIDOGREL;F13A1;rs5985;AA + AC;EFFICACY;INCREASED_RISK
LEDIPASVIR, SOFOSBUVIR;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED_EFFICACY
CARBAMAZEPINE;HSPA1A;rs506770;G;TOXICITY;DECREASED_SEVERITY
ASPIRIN, CLOPIDOGREL;F13A1;rs5985;AA;EFFICACY;DECREASED_EFFICACY
CYCLOPHOSPHAMIDE, FLUOROURACIL;TP53;rs1042522;G;TOXICITY;INCREASED_LIKELIHOOD
CARBAMAZEPINE;HSPA1L;rs2227956;G;TOXICITY;DECREASED_SEVERITY
CLOPIDOGREL;P2RY12;rs6787801;AG + GG;EFFICACY;EFFICACY
CLOZAPINE;ABCB1;rs1045642;AG + GG;TOXICITY;INCREASED_
RIBAVIRIN;ITPA;rs1127354;CC;TOXICITY;INCREASED_LIKELIHOOD
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_PK
CLOZAPINE;ABCC1;rs212090;AT + TT;TOXICITY;INCREASED_
CARBAMAZEPINE;MLN;rs2894342;A;TOXICITY;INCREASED_RISK
EFAVIRENZ;CYP2B6;rs28399499;CC + CT;LADME_PK;INCREASED_PK
CLOZAPINE;ABCB1;rs1045642;AG + GG;TOXICITY;INCREASED_
CLOZAPINE;ABCC1;rs212090;AT + TT;TOXICITY;INCREASED_
CAFFEINE;ADORA2A;rs5751876;TT;TOXICITY;INCREASED_
CAFFEINE;ADORA2A;rs2298383;CC;TOXICITY;INCREASED_
CAFFEINE;;rs4822492;CC;TOXICITY;INCREASED_
;MT-RNR1;rs267606617;G;OTHER;INCREASED_LIKELIHOOD
CARBAMAZEPINE;;rs3130690;T;TOXICITY;INCREASED_RISK
CAFFEINE;ADORA2A;rs5751876;CC;EFFICACY;INCREASED_LIKELIHOODEFFICACY
CAFFEINE;ADORA2A;rs5751876;CC;TOXICITY;INCREASED_LIKELIHOOD
ETHANOL, HEROIN, METHAMPHETAMINE;ANKS1B;rs2133896;T;TOXICITY;INCREASED_RISK
CARBAMAZEPINE;MICA;rs2848716;C;TOXICITY;INCREASED_RISK
"""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ASPIRIN""";;rs2965667;TT;OTHER;DECREASED_RISK
CAFFEINE;ADORA2A;rs5751876;TT;DOSAGE;DECREASED_
CARBAMAZEPINE;BAG6, PRRC2A;rs750332;C;TOXICITY;INCREASED_RISK
"""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ASPIRIN""";;rs16973225;AA;OTHER;DECREASED_LIKELIHOOD
;CHRNA5;rs588765;T;EFFICACY;EFFICACY
WARFARIN;VKORC1;rs9934438;AG + GG;DOSAGE;INCREASED_
RIBAVIRIN;ITPA;rs7270101;AA;TOXICITY;INCREASED_LIKELIHOOD
SIMVASTATIN;LEPR;rs1137101;GG;EFFICACY;INCREASED_EFFICACY
ALENDRONATE;SOST;rs1234612;CC;EFFICACY;INCREASED_EFFICACY
CYTARABINE, DAUNORUBICIN;ABCB1;rs1128503;GG;TOXICITY;INCREASED_LIKELIHOOD
CYTARABINE, DAUNORUBICIN;CDA;rs532545;CC;TOXICITY;DECREASED_LIKELIHOOD
CYTARABINE, DAUNORUBICIN;ABCB1;rs1045642;GG;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;EFFICACY
ALENDRONATE;SOST;rs865429;GG;EFFICACY;DECREASED_EFFICACY
RIBAVIRIN;ITPA;rs1127354;CC;TOXICITY;INCREASED_LIKELIHOOD
CYTARABINE;ABCB1;rs1128503;AA + AG;EFFICACY;INCREASED_EFFICACY
CLOPIDOGREL;MED12L, P2RY12;rs6801273;T;EFFICACY;DECREASED_EFFICACY
CYTARABINE;ABCB1;rs2032582;AA + AC;EFFICACY;INCREASED_EFFICACY
CLOPIDOGREL;MED12L;rs6798347;G;EFFICACY;DECREASED_EFFICACY
ERLOTINIB, GEFITINIB;EGFR;rs121434569;T;EFFICACY;DECREASED_EFFICACY
CYTARABINE;ABCB1;rs1045642;AA + AG;EFFICACY;INCREASED_EFFICACY
SEVOFLURANE;ABCB1;rs1128503;GG;OTHER;DECREASED_LIKELIHOOD
TACROLIMUS;KCNJ11;rs5219;CT + TT;TOXICITY;INCREASED_RISK
ACE INHIBITORS, PLAIN;ETV6;rs2724635;GG;TOXICITY;INCREASED_LIKELIHOOD
ERLOTINIB, GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
SUNITINIB;ABCB1;rs1128503;AA;TOXICITY;DECREASED_RISK
ASPIRIN;TAPBP;rs2071888;CC + CG;TOXICITY;INCREASED_
DRUGS FOR TREATMENT OF TUBERCULOSIS;ABCC2;rs3740065;AG + GG;TOXICITY;DECREASED_RISK
ESCITALOPRAM;HTR2A;rs6311;CT + TT;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;rs4244285;AA;TOXICITY;INCREASED_RISK
HYDROCHLOROTHIAZIDE;KCNJ1;rs12795437;C;TOXICITY;INCREASED_LIKELIHOOD
PHENPROCOUMON;VKORC1;rs9934438;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
VALPROIC ACID;LEPR;rs1137101;AA + AG;TOXICITY;INCREASED_
PHENYTOIN;CFHR4;rs78239784;G;TOXICITY;INCREASED_RISK
HYDROCHLOROTHIAZIDE;KCNJ1;rs11600347;A;TOXICITY;INCREASED_LIKELIHOOD
CABAZITAXEL;ABCB1;rs2032582;A;TOXICITY;DECREASED_LIKELIHOOD
VALPROIC ACID;ANKK1;rs1800497;AG + GG;TOXICITY;INCREASED_
HYDROCHLOROTHIAZIDE;KCNJ1;rs658903;A;TOXICITY;DECREASED_LIKELIHOOD
CABAZITAXEL;ABCB1;rs1045642;A;TOXICITY;DECREASED_LIKELIHOOD
CLOPIDOGREL;P2RY12;rs6787801;G;EFFICACY;DECREASED_EFFICACY
CABAZITAXEL;CYP3A5;rs776746;T;TOXICITY;DECREASED_LIKELIHOOD
ACE INHIBITORS, PLAIN;PRKCQ;rs500766;CT + TT;TOXICITY;DECREASED_LIKELIHOOD
HYDROCHLOROTHIAZIDE;KCNJ1;rs675388;A;TOXICITY;INCREASED_LIKELIHOOD
DOXORUBICIN;GSTP1;rs1695;GG;EFFICACY;DECREASED_RISKEFFICACY
CABAZITAXEL;ABCB1;rs1128503;A;TOXICITY;DECREASED_LIKELIHOOD
PROPOFOL;DRD2;rs2283265;AA + AC;OTHER;DECREASED_
NICOTINE;CHRNA4;rs2236196;A;OTHER;INCREASED_LIKELIHOOD
ACETAMINOPHEN;UGT1A;rs1042640;CG + GG;TOXICITY;DECREASED_RISK
CLOPIDOGREL;ABCB1;rs1045642;AA;TOXICITY;DECREASED_
ACETAMINOPHEN;UGT1A;rs8330;CG + GG;TOXICITY;DECREASED_RISK
GEFITINIB;EGFR;rs121434569;T;EFFICACY;DECREASED_EFFICACY
HYDROCHLOROTHIAZIDE;KCNJ1;rs59172778;AG;TOXICITY;INCREASED_
ETHANOL;CACNA1C;rs1034936;TT;TOXICITY;INCREASED_RISK
DOXORUBICIN, METHOTREXATE, PREDNISOLONE, VINCRISTINE;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;rs4244285;AA;TOXICITY;INCREASED_RISK
WARFARIN;EPHA7;rs114504854;A;TOXICITY;INCREASED_RISK
ACETAMINOPHEN;UGT1A;rs10929303;CT + TT;TOXICITY;DECREASED_RISK
ACE INHIBITORS, PLAIN;XPNPEP2;rs2050011;T;TOXICITY;INCREASED_LIKELIHOOD
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;TNF;rs1800629;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
NICOTINE;ADGRL3;rs2271339;AG;TOXICITY;INCREASED_RISK
NICOTINE;ADGRL3;rs1456862;AT;TOXICITY;INCREASED_RISK
GEFITINIB;EGFR;rs2293347;CC;EFFICACY;INCREASED_EFFICACY
GEFITINIB;EGFR;rs2293347;CC;EFFICACY;INCREASED_EFFICACY
ETHANOL;MAP2K4;rs2159140;CT;TOXICITY;INCREASED_RISK
SUNITINIB;ABCB1;rs1045642;GG;TOXICITY;INCREASED_RISK
SORAFENIB;UGT1A9;rs17868320;T;TOXICITY;INCREASED_RISK
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
GEFITINIB;EGFR;rs712829;GT + TT;EFFICACY;INCREASED_EFFICACY
ACENOCOUMAROL;VKORC1;rs9934438;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
MORPHINE;OPRM1;rs1799971;AA;TOXICITY;INCREASED_RISK
ACE INHIBITORS, PLAIN;XPNPEP2;rs3788853;A;TOXICITY;INCREASED_LIKELIHOOD
VINCRISTINE;CEP72;rs924607;TT;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_RISK
DOCETAXEL;ABCC10;rs2125739;CT;TOXICITY;DECREASED_SEVERITY
;ARNT;rs2228099;CG + GG;OTHER;DECREASED_LIKELIHOOD
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2E1;rs3813867;GG;TOXICITY;INCREASED_SEVERITY
CLOPIDOGREL;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_RISK
;DEPTOR;rs4871827;AA + AG;OTHER;INCREASED_
CISPLATIN, IRINOTECAN;SYNE3;rs8020368;CC;EFFICACY;DECREASED_EFFICACY
;DEPTOR;rs4871827;AG;OTHER;DECREASED_LIKELIHOOD
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS"", ""DRUGS FOR TREATMENT OF TUBERCULOSIS""";CYP2B6;rs3745274;TT;TOXICITY;INCREASED_RISK
;DEPTOR;rs4871827;AG;OTHER;DECREASED_LIKELIHOOD
LOSARTAN;STK39;rs6749447;GG + GT;EFFICACY;DECREASED_EFFICACY
CLOPIDOGREL;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK
;AHR;rs2066853;AA + AG;OTHER;INCREASED_RISK
RISPERIDONE;HTR6;rs9659997;CC + CT;TOXICITY;INCREASED_SEVERITY
CISPLATIN, IRINOTECAN;DCBLD1;rs17574269;AG;EFFICACY;DECREASED_EFFICACY
CISPLATIN, IRINOTECAN;;rs7186128;AG + GG;EFFICACY;DECREASED_EFFICACY
RISPERIDONE;TYMS;rs3786362;A;TOXICITY;INCREASED_RISK
;TNF;rs1800630;C;EFFICACY;INCREASED_SEVERITYEFFICACY
CISPLATIN, IRINOTECAN;;rs2166219;TT;EFFICACY;DECREASED_EFFICACY
RISPERIDONE;HTR2A;rs6311;CC;TOXICITY;INCREASED_SEVERITY
CISPLATIN, IRINOTECAN;;rs4655567;CC;EFFICACY;DECREASED_EFFICACY
ANTINEOPLASTIC AGENTS, CORTICOSTEROIDS;ITPA;rs1127354;AA + AC;TOXICITY;INCREASED_RISK
CISPLATIN, IRINOTECAN;;rs2018683;TT;EFFICACY;DECREASED_EFFICACY
RISPERIDONE;BDNF;rs6265;CT + TT;TOXICITY;INCREASED_SEVERITY
ANTINEOPLASTIC AGENTS, CORTICOSTEROIDS;ADORA2A;rs2236624;CC;TOXICITY;INCREASED_RISK
LEUCOVORIN, METHOTREXATE;ABCC2;rs717620;CT + TT;LADME_PK;INCREASED_PK
CISPLATIN, IRINOTECAN;;rs2018683;TT;EFFICACY;INCREASED_RISKEFFICACY
;OPRM1;rs1799971;G;TOXICITY;INCREASED_LIKELIHOOD
CISPLATIN, IRINOTECAN;SYNE3;rs8020368;CC;EFFICACY;INCREASED_RISKEFFICACY
CISPLATIN, IRINOTECAN;;rs4655567;CC;EFFICACY;INCREASED_RISKEFFICACY
METHOTREXATE;ABCC4;rs7317112;AA;TOXICITY;INCREASED_RISK
RISPERIDONE;UGT1A1;rs1976391;AG;TOXICITY;INCREASED_RISK
RISPERIDONE;HTR2C;rs6318;C;TOXICITY;INCREASED_SEVERITY
CYCLOSPORINE;;rs2275913;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
LENALIDOMIDE;ABCB1;rs2032582;AA;TOXICITY;DECREASED_LIKELIHOOD
HEROIN;DBH;rs1611114;TT;TOXICITY;DECREASED_RISK
DILTIAZEM;PLCD3;rs12946454;T;EFFICACY;INCREASED_EFFICACY
CAPECITABINE, FLUOROURACIL, OXALIPLATIN;MTHFR;rs1801131;GG;EFFICACY;DECREASED_EFFICACY
PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs1127354;AC;TOXICITY;DECREASED_SEVERITY
DOCETAXEL;ABCB1;rs1045642;AA;TOXICITY;INCREASED_LIKELIHOOD
"""BETA BLOCKING AGENTS"", ""THIAZIDES, PLAIN""";;rs11191548;C;EFFICACY;INCREASED_EFFICACY
NICOTINE;COMT;rs4680;GG;OTHER;INCREASED_SEVERITY
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_PK
MORPHINE;ABCB1;rs9282564;CC + CT;TOXICITY;INCREASED_RISK
ANTINEOPLASTIC AGENTS, CORTICOSTEROIDS;ABCC1;rs246240;GG;TOXICITY;INCREASED_RISK
LENALIDOMIDE;NCF4;rs1883112;AA + AG;TOXICITY;DECREASED_LIKELIHOOD
NICOTINE;COMT;rs4680;GG;OTHER;INCREASED_
LENALIDOMIDE;GSTP1;rs1695;GG;TOXICITY;DECREASED_LIKELIHOOD
CISPLATIN, IRINOTECAN;ABCC4;rs16950650;CT;EFFICACY;DECREASED_EFFICACY
ASPIRIN, CLOPIDOGREL;ITGA2;rs1126643;CT + TT;OTHER;INCREASED_
MYCOPHENOLATE MOFETIL;SLCO1B3;rs4149117;TT;TOXICITY;INCREASED_RISK
EFAVIRENZ, LAMIVUDINE, TENOFOVIR;ABCB1;rs1045642;GG;TOXICITY;DECREASED_LIKELIHOOD
GEMCITABINE;SLC29A3;rs780668;CT + TT;EFFICACY;INCREASED_EFFICACY
PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs1127354;A;TOXICITY;DECREASED_SEVERITY
MYCOPHENOLATE MOFETIL;SLCO1B3;rs4149117;TT;TOXICITY;INCREASED_RISK
ATORVASTATIN;SLCO1B1;rs4149056;C;TOXICITY;INCREASED_RISK
PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs7270101;C;TOXICITY;DECREASED_SEVERITY
CAFFEINE;CYP1A2;rs762551;AC + CC;TOXICITY;INCREASED_LIKELIHOOD
GEMCITABINE;ABCG2;rs2231142;GT + TT;TOXICITY;INCREASED_SEVERITY
PLATINUM COMPOUNDS;ERCC1;rs11615;AA;EFFICACY;INCREASED_RISK
CAPECITABINE;CDA;rs1048977;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C9;rs1799853;CT + TT;LADME_PK;DECREASED_PK
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_LIKELIHOOD
ALLOPURINOL;CFLAR;rs1594;A;TOXICITY;
OXYCODONE;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
CAPECITABINE;CES2;rs11075646;CG + GG;EFFICACY;INCREASED_EFFICACY
PLATINUM COMPOUNDS;ERCC1;rs11615;AA;EFFICACY;INCREASED_RISKEFFICACY
CLOPIDOGREL;CYP2C9;rs1799853;CT + TT;EFFICACY;DECREASED_EFFICACY
PLATINUM COMPOUNDS;HSPA5;rs430397;TT;EFFICACY;DECREASED_
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED_EFFICACY
ASPIRIN;AGT;rs5050;GG;TOXICITY;INCREASED_RISK
SUNITINIB;NR1I2;rs6785049;A;TOXICITY;INCREASED_RISK
BUPROPION;SACM1L;rs2251954;C;TOXICITY;DECREASED_
ROSUVASTATIN;GATM;rs9806699;AA;TOXICITY;DECREASED_RISK
CLOPIDOGREL;CYP2C19;rs4244285;A;LADME_PK;DECREASED_PK
BUPROPION;SACM1L;rs2742421;G;TOXICITY;DECREASED_
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;CYP3A4;rs28371759;AG;TOXICITY;INCREASED_LIKELIHOOD
ROSUVASTATIN;SLCO1B1;rs4149081;AG;EFFICACY;INCREASED_EFFICACY
BUPROPION;SACM1L;rs2742423;G;TOXICITY;DECREASED_
EFAVIRENZ;CYP2B6;rs3745274;TT;TOXICITY;
CLOPIDOGREL;CYP2C9;rs1057910;AC + CC;LADME_PK;DECREASED_PK
BUPROPION;SACM1L;rs1969624;T;TOXICITY;DECREASED_
EFAVIRENZ;NR1I3;rs2307424;GG;TOXICITY;
BUPROPION;SACM1L;rs2245705;C;TOXICITY;DECREASED_
BUPROPION;SACM1L;rs2742435;G;TOXICITY;DECREASED_
CLOPIDOGREL;CYP2C9;rs1057910;AC + CC;EFFICACY;DECREASED_EFFICACY
BUPROPION;SACM1L;rs2742390;A;TOXICITY;DECREASED_
SIMVASTATIN;SLCO1B1;rs4149081;AG;EFFICACY;INCREASED_EFFICACY
PLATINUM COMPOUNDS;HSPA5;rs430397;TT;EFFICACY;INCREASED_LIKELIHOOD
SIMVASTATIN;SLCO1B1;rs4149081;AA;EFFICACY;INCREASED_EFFICACY
PEMETREXED;DHFR;rs442767;GG;TOXICITY;INCREASED_RISK
FLUOROURACIL;MTHFR;rs1801131;GG;TOXICITY;INCREASED_LIKELIHOOD
BUPROPION;SACM1L;rs2742417;T;TOXICITY;DECREASED_
TEMSIROLIMUS;NR1I2;rs3814055;T;TOXICITY;DECREASED_LIKELIHOOD
PHENPROCOUMON;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_RISK
SUNITINIB;FLT3;rs1933437;AA;TOXICITY;INCREASED_RISK
CAPECITABINE;CES1;rs71647871;CT + TT;TOXICITY;INCREASED_SEVERITY
ROSUVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK
GEMCITABINE;ABCG2;rs2231142;GT + TT;EFFICACY;INCREASED_EFFICACY
PLATINUM COMPOUNDS;HSPA5;rs430397;TT;EFFICACY;INCREASED_RISK
ROSUVASTATIN;SLCO1B1;rs4149081;AA;EFFICACY;INCREASED_EFFICACY
NALTREXONE;OPRD1;rs4654327;A;EFFICACY;INCREASED_EFFICACY
IRINOTECAN;UGT1A;rs11563250;AG + GG;TOXICITY;DECREASED_RISK
ATORVASTATIN, SIMVASTATIN;RYR2;rs2819742;A;TOXICITY;INCREASED_LIKELIHOOD
CAPECITABINE, FLUOROURACIL, GEMCITABINE;SPARC;rs2347128;GG;EFFICACY;INCREASED_
;MET;rs40239;AG + GG;OTHER;INCREASED_
AZATHIOPRINE;ITPA;rs7270101;AC + CC;TOXICITY;INCREASED_LIKELIHOOD
CAPECITABINE, FLUOROURACIL, GEMCITABINE;SPARC;rs17718347;TT;EFFICACY;INCREASED_
;MET;rs40239;AG + GG;OTHER;INCREASED_
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS"", ""DRUGS FOR TREATMENT OF TUBERCULOSIS""";ABCB1;rs1045642;AA;TOXICITY, LADME_PK;INCREASED_RISK
EFAVIRENZ;CYP2B6;rs3745274;T;OTHER, LADME_PK;INCREASED_PK
EFAVIRENZ;CYP2B6;rs3745274;T;TOXICITY;INCREASED_RISK
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_LIKELIHOOD
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs112563513;A;OTHER;INCREASED_RISK
EFAVIRENZ;CYP3A4;rs2740574;C;OTHER, LADME_PK;INCREASED_PK
FLUOROURACIL;DPYD;rs67376798;AT;TOXICITY;INCREASED_LIKELIHOOD
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_RISK
EFAVIRENZ;CYP3A5;rs776746;C;LADME_PK;DECREASED_PK
CLOPIDOGREL;ABCB1;rs1045642;GG;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;rs4244285;AA;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;rs4986893;A;TOXICITY;INCREASED_RISK
ACE INHIBITORS, PLAIN;MME;rs989692;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
HMG COA REDUCTASE INHIBITORS;LILRB5;rs12975366;TT;DOSAGE, TOXICITY;INCREASED_LIKELIHOOD
ESCITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE, VENLAFAXINE;HTR2A;rs6311;TT;TOXICITY;INCREASED_LIKELIHOOD
CABAZITAXEL;CYP3A5;rs776746;CT;EFFICACY;DECREASED_EFFICACY
CLOPIDOGREL;CYP2C19;rs4986893;AA;EFFICACY;INCREASED_RISKEFFICACY
CITALOPRAM, ESCITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;HTR2A;rs6311;CC;TOXICITY;INCREASED_LIKELIHOOD
CABAZITAXEL;TUBB1;rs463312;AC;EFFICACY;DECREASED_EFFICACY
CLOPIDOGREL;CYP2C19;rs28399504;G;TOXICITY;INCREASED_RISK
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;rs4986893;AA;TOXICITY;INCREASED_RISK
NEVIRAPINE;CYP2B6;rs28399499;C;LADME_PK;INCREASED_
;SLC2A9;rs16890979;T;LADME_PK;DECREASED_PK
CYCLOPHOSPHAMIDE;IKZF3;rs9908694;CC;EFFICACY;INCREASED_
METHOTREXATE;ABCB1;rs1045642;AG;TOXICITY;DECREASED_RISK
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs118192122;A;OTHER;INCREASED_RISK
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs193922816;T;OTHER;INCREASED_RISK
METHAMPHETAMINE;DRD4;rs1800955;CC + CT;TOXICITY;DECREASED_LIKELIHOOD
BEVACIZUMAB;GC;rs4588;TT;EFFICACY;DECREASED_EFFICACY
CETUXIMAB;GC;rs4588;TT;EFFICACY;INCREASED_EFFICACY
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs28933397;T;OTHER;INCREASED_RISK
ASPIRIN;TAPBP;rs1059288;AG + GG;TOXICITY;INCREASED_
"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS""";F5;rs140530655;CT;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;rs4244285;AG;EFFICACY;INCREASED_RISKEFFICACY
GEFITINIB;IKBKB;rs2272733;CC;TOXICITY;DECREASED_RISK
"""METFORMIN"", ""SULFONAMIDES, UREA DERIVATIVES""";SLC22A1;rs628031;AA + AG;EFFICACY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;rs4244285;AA;EFFICACY;INCREASED_RISKEFFICACY
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs193922772;T;OTHER;INCREASED_RISK
CLOPIDOGREL;CYP2C19;rs4986893;AG;EFFICACY;INCREASED_RISKEFFICACY
FENOTEROL;SLC22A1;rs12208357;T;TOXICITY;INCREASED_LIKELIHOOD
FENOTEROL;SLC22A1;rs34130495;A;TOXICITY;INCREASED_LIKELIHOOD
ACE INHIBITORS, PLAIN;AGT;rs699;GG;EFFICACY;DECREASED_RISK
;P2RY12;rs2046934;G;OTHER;INCREASED_RISK
GEFITINIB;RELA;rs11227247;CC;TOXICITY;DECREASED_RISK
FENOTEROL;SLC22A1;rs55918055;C;TOXICITY;INCREASED_LIKELIHOOD
IRINOTECAN;KCNQ5;rs9351963;C;TOXICITY;INCREASED_LIKELIHOOD
FENOTEROL;SLC22A1;rs34059508;A;TOXICITY;INCREASED_LIKELIHOOD
;P2RY12;rs2046934;G;OTHER;INCREASED_EFFICACY
GEFITINIB;IKBKE;rs2151222;AG + GG;TOXICITY;DECREASED_RISK
ISONIAZID, PHENYTOIN;NAT2;rs1801280;C;TOXICITY;INCREASED_RISK
ISONIAZID, PHENYTOIN;NAT2;rs1799931;A;TOXICITY;INCREASED_RISK
TAMOXIFEN;CYP2D6;rs28371725;T;EFFICACY;INCREASED_RISKEFFICACY
TAMOXIFEN;CYP2D6;rs3892097;C;EFFICACY;INCREASED_RISKEFFICACY
TAMOXIFEN;CYP2D6;rs1065852;A;EFFICACY;INCREASED_RISKEFFICACY
PAROXETINE;HTR2A;rs6314;AG;EFFICACY;EFFICACY
GABAPENTIN, PREGABALIN;SLC7A5;rs4240803;AG;TOXICITY;INCREASED_RISK
BEVACIZUMAB, CYCLOPHOSPHAMIDE;CXCR2;rs2230054;TT;EFFICACY;DECREASED_EFFICACY
PAROXETINE;HTR2A;rs6314;AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
TAMOXIFEN;CYP2C19;rs12248560;T;EFFICACY;DECREASED_RISKEFFICACY
GEMCITABINE;SLCO1B1;rs4149086;AG + GG;EFFICACY;DECREASED_EFFICACY
PAROXETINE;HTR2A;rs6313;GG;TOXICITY;INCREASED_RISK
HYDROCHLOROTHIAZIDE;CDCA3, GNB3, USP5;rs5443;TT;EFFICACY;INCREASED_EFFICACY
BETA BLOCKING AGENTS;GRK5;rs2230345;AT + TT;OTHER;DECREASED_RISK
ACENOCOUMAROL, WARFARIN;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_RISK
;CHRNA3;rs1051730;A;OTHER;INCREASED_RISK
CITALOPRAM;GRIK2;rs2518224;CC;TOXICITY;INCREASED_RISK
ACENOCOUMAROL, WARFARIN;VKORC1;rs9934438;AA + AG;TOXICITY;INCREASED_RISK
IRINOTECAN;UGT1A9;rs7586110;G;TOXICITY;INCREASED_RISK
ACENOCOUMAROL, WARFARIN;CYP4F2;rs2108622;CT + TT;TOXICITY;DECREASED_RISK
;HYKK;rs8034191;C;OTHER;INCREASED_RISK
ISONIAZID, PHENYTOIN;NAT2;rs1041983;T;TOXICITY;INCREASED_RISK
TACROLIMUS;TCF7L2;rs290487;CC + CT;TOXICITY;INCREASED_RISK
ACE INHIBITORS, PLAIN;AGT;rs699;GG;EFFICACY;DECREASED_RISK
GEMCITABINE;POLR2A;rs2228130;CC;TOXICITY;INCREASED_SEVERITY
VALPROIC ACID;CYP2C9;rs1057910;AC;OTHER, LADME_PK;INCREASED_PK
CITALOPRAM;GRIA3;rs4825476;G;TOXICITY;INCREASED_RISK
IMATINIB;SLC22A5;rs274558;AA + AG;TOXICITY;DECREASED_RISK
ISONIAZID, PHENYTOIN;NAT2;rs1208;G;TOXICITY;INCREASED_RISK
ANTIPSYCHOTICS;COMT;rs4818;CC + CG;TOXICITY;INCREASED_SEVERITY
;CHRNA3;rs1051730;A;OTHER;INCREASED_LIKELIHOOD
;CHRNA3;rs1051730;A;OTHER;INCREASED_LIKELIHOOD
DACARBAZINE, PROCARBAZINE;EPM2AIP1;rs1800734;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
ISONIAZID, PHENYTOIN;NAT2;rs1799930;A;TOXICITY;INCREASED_RISK
;CHRNA3;rs1051730;A;OTHER;INCREASED_
ISONIAZID, PHENYTOIN;NAT2;rs1799929;T;TOXICITY;INCREASED_RISK
IMATINIB;ABCB1;rs2235040;CT;TOXICITY;DECREASED_RISK
DEXAMETHASONE, DOXORUBICIN, VINCRISTINE;ABCB1;rs2032582;AA + AC;EFFICACY;INCREASED_EFFICACY
DACARBAZINE, PROCARBAZINE;EPM2AIP1;rs1800734;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
IMATINIB;EGFR;rs10258429;CT + TT;TOXICITY;INCREASED_RISK
ANTIPSYCHOTICS;COMT;rs165599;AG;TOXICITY;INCREASED_SEVERITY
IMATINIB;SLC22A1;rs683369;CG + GG;TOXICITY;INCREASED_RISK
RISPERIDONE;CYP2D6;rs1065852;AA;TOXICITY;INCREASED_LIKELIHOOD
DACLATASVIR, SOFOSBUVIR;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED_EFFICACY
"""ANALGESICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ERGOT ALKALOIDS"", ""OPIOIDS"", ""SUMATRIPTAN""";HTR2A;rs6305;A;OTHER;INCREASED_LIKELIHOOD
ASPIRIN;TBXA2R;rs4523;AA;EFFICACY;INCREASED_RISK
"""ANALGESICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ERGOT ALKALOIDS"", ""OPIOIDS"", ""SUMATRIPTAN""";DBH;rs1611115;T;OTHER;DECREASED_LIKELIHOOD
RISPERIDONE;DRD2;rs1799978;CT;TOXICITY;INCREASED_LIKELIHOOD
PACLITAXEL;ABCB1;rs2032582;AA;TOXICITY;INCREASED_RISK
PACLITAXEL;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK
"""ANALGESICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ERGOT ALKALOIDS"", ""OPIOIDS"", ""SUMATRIPTAN""";OPRM1;rs1799971;G;OTHER;INCREASED_LIKELIHOOD
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY
"""ANALGESICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ERGOT ALKALOIDS"", ""OPIOIDS"", ""SUMATRIPTAN""";BDNF;rs6265;T;OTHER;DECREASED_LIKELIHOOD
ANTIPSYCHOTICS;COMT;rs4680;AA;TOXICITY;INCREASED_SEVERITY
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED_EFFICACY
"""ANALGESICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ERGOT ALKALOIDS"", ""OPIOIDS"", ""SUMATRIPTAN""";COMT;rs4680;AA;OTHER;DECREASED_LIKELIHOOD
RISPERIDONE;CYP2D6;rs1065852;AA;TOXICITY;INCREASED_LIKELIHOOD
TACROLIMUS;CAPN10;rs5030952;CT;TOXICITY;INCREASED_RISK
WARFARIN;CYP2C18;rs2901783;G;DOSAGE;
IDARUBICIN;RAC2;rs13058338;AA;TOXICITY;DECREASED_RISK
"""ANALGESICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ERGOT ALKALOIDS"", ""OPIOIDS"", ""SUMATRIPTAN""";DRD2;rs6275;AA;OTHER;DECREASED_LIKELIHOOD
IDARUBICIN;NCF4;rs1883112;AA;TOXICITY;INCREASED_RISK
OPIOIDS;OPRM1;rs9479757;AG;OTHER;DECREASED_RISK
TACROLIMUS;CYP3A5;rs776746;CC;TOXICITY;INCREASED_LIKELIHOOD
PEGINTERFERON ALFA-2B, PROTEASE INHIBITORS, RIBAVIRIN;ITPA;rs1127354;AA + AC;TOXICITY;DECREASED_RISK
OPIOIDS;GAL;rs948854;CC;OTHER;INCREASED_RISK
OPIOIDS;ABCB1;rs1045642;GG;OTHER;DECREASED_RISK
OPIOIDS;OPRD1;rs2236861;A;OTHER;DECREASED_RISK
IDARUBICIN;CYBA;rs4673;AG + GG;EFFICACY;INCREASED_EFFICACY
HYDROCHLOROTHIAZIDE;NOS3;rs1799983;GG;EFFICACY;INCREASED_EFFICACY
IDARUBICIN;CYBA;rs4673;AA + AG;TOXICITY;DECREASED_RISK
PRAVASTATIN;CETP;rs708272;A;EFFICACY;INCREASED_RISK
PEGINTERFERON ALFA-2B, PROTEASE INHIBITORS, RIBAVIRIN;SLC28A2;rs11854484;TT;TOXICITY;INCREASED_RISK
DACLATASVIR, SOFOSBUVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY
DIURETICS;PDE4D;rs702553;TT;EFFICACY;DECREASED_EFFICACY
CITALOPRAM, FLUVOXAMINE, PAROXETINE, SERTRALINE, VENLAFAXINE;ABCB1;rs2235040;T;TOXICITY;INCREASED_LIKELIHOOD
ESCITALOPRAM;KCNE1;rs1805127;C;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED_EFFICACY
ESCITALOPRAM;KCNE1;rs4817668;TT;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_RISK
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA5;rs588765;T;EFFICACY;EFFICACY
;CHRNA3;rs1051730;A;EFFICACY;EFFICACY
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_RISK
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA3;rs1051730;A;EFFICACY;EFFICACY
CITALOPRAM, FLUVOXAMINE, PAROXETINE, SERTRALINE, VENLAFAXINE;ABCB1;rs2032583;G;TOXICITY;INCREASED_LIKELIHOOD
FLUOROURACIL;DPYD;rs1801159;CC;TOXICITY, LADME_PK;INCREASED_LIKELIHOOD
FLUOROURACIL;DPYD;rs1801159;CC;TOXICITY, LADME_PK;INCREASED_LIKELIHOOD
CISPLATIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, METHOTREXATE, VINCRISTINE;ABCB1;rs4148737;C;EFFICACY;INCREASED_RISKEFFICACY
CISPLATIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, METHOTREXATE, VINCRISTINE;ABCC3;rs4148416;T;EFFICACY;INCREASED_RISKEFFICACY
;FOXO3;rs4946936;TT;EFFICACY;DECREASED_EFFICACY
NEVIRAPINE;ABCB1;rs1045642;A;TOXICITY;DECREASED_RISK
;FOXO3;rs17069665;GG;EFFICACY;DECREASED_EFFICACY
;ARNT;rs3215133;T/del + del/del;OTHER;DECREASED_LIKELIHOOD
METHADONE;ARRB2;rs2036657;GG;EFFICACY;INCREASED_SEVERITYEFFICACY
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;ABCB1;rs2032582;A;TOXICITY;INCREASED_LIKELIHOOD
ETHANOL;GHSR;rs2232165;AG;OTHER;
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;ABCB1;rs1045642;G;TOXICITY;DECREASED_LIKELIHOOD
CISPLATIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, METHOTREXATE, VINCRISTINE;ABCB1;rs10276036;C;EFFICACY;INCREASED_RISKEFFICACY
ANTIPSYCHOTICS;NEFM;rs1379357;G;EFFICACY;EFFICACY
CISPLATIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, METHOTREXATE, VINCRISTINE;ABCB1;rs1128503;G;EFFICACY;INCREASED_RISKEFFICACY
ANTIPSYCHOTICS;NEFM;rs1457266;G;EFFICACY;EFFICACY
;ARNT;rs12410394;AA + AG;OTHER;DECREASED_LIKELIHOOD
CELECOXIB;IL23R;rs7518660;A;TOXICITY;INCREASED_RISK
CELECOXIB;ALOX12;rs11078659;A;TOXICITY;INCREASED_RISK
;CYP1A2;rs2470890;CT + TT;OTHER;DECREASED_LIKELIHOOD
;;rs11072508;CT + TT;OTHER;DECREASED_LIKELIHOOD
CELECOXIB;PTGES;rs2302821;C;TOXICITY;INCREASED_RISK
;CSK;rs4886410;CG + GG;OTHER;DECREASED_LIKELIHOOD
CELECOXIB;PTGER4;rs4133101;T;TOXICITY;INCREASED_RISK
CARBOPLATIN, CYCLOPHOSPHAMIDE, THIOTEPA;ALDH3A1;rs2228100;CC + CG;TOXICITY;INCREASED_LIKELIHOOD
TAMOXIFEN;ABCC2;rs3740065;AA;EFFICACY, LADME_PK;INCREASED_RISKEFFICACY
CAFFEINE;CYP1A2;rs762551;AA;TOXICITY;INCREASED_LIKELIHOOD
DEXAMETHASONE, DOXORUBICIN, VINCRISTINE;ABCB1;rs1045642;GG;EFFICACY;DECREASED_EFFICACY
FARGLITAZAR, INSULINS AND ANALOGUES;SCNN1B;rs34241435;A;TOXICITY;
HYDROCHLOROTHIAZIDE;SCNN1G;rs5723;CC;EFFICACY;DECREASED_EFFICACY
FARGLITAZAR, GLYBURIDE;SCNN1B;rs889299;A;TOXICITY;
HYDROCHLOROTHIAZIDE;SCNN1G;rs5729;TT;EFFICACY;DECREASED_EFFICACY
GEFITINIB;IKBKE;rs12142086;CC;TOXICITY;INCREASED_RISK
NICOTINE;CHRNA5;rs680244;C;OTHER;DECREASED_LIKELIHOOD
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
METHADONE;ARRB2;rs1045280;CC;EFFICACY;INCREASED_SEVERITYEFFICACY
TACROLIMUS;CYP3A5;rs776746;CT;EFFICACY;DECREASED_EFFICACY
LORAZEPAM;UGT2B15;rs1902023;AA;LADME_PK;INCREASED_PK
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;ABCB1;rs3213619;G;TOXICITY;DECREASED_LIKELIHOOD
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;TUBB2A;rs9501929;C;TOXICITY;INCREASED_LIKELIHOOD
NALOXONE, OXYCODONE;COMT;rs4680;GG;TOXICITY;INCREASED_LIKELIHOOD
TACROLIMUS;CYP3A4;rs2740574;CT;LADME_PK;DECREASED_PK
NICOTINE;CHRNA5;rs16969968;A;OTHER;DECREASED_LIKELIHOOD
METHADONE;ARRB2;rs3786047;AA;EFFICACY;INCREASED_SEVERITYEFFICACY
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
BISOPROLOL;CYP3A5;rs776746;TT;EFFICACY;INCREASED_SEVERITYEFFICACY
NALOXONE, OXYCODONE;OPRM1;rs1799971;AA;TOXICITY;INCREASED_LIKELIHOOD
PAZOPANIB;VEGFA;rs2010963;CC;EFFICACY;INCREASED_EFFICACY
HYDROCHLOROTHIAZIDE;WNK1;rs1159744;GG;EFFICACY;INCREASED_EFFICACY
TAMOXIFEN;CYP2C19;rs12248560;T;EFFICACY;INCREASED_EFFICACY
CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;TT;TOXICITY;DECREASED_RISK
;SLC22A3;rs2504938;TT;EFFICACY;DECREASED_EFFICACY
NALOXONE, OXYCODONE;COMT;rs4680;AA;TOXICITY;INCREASED_LIKELIHOOD
CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;GT;TOXICITY;INCREASED_RISK
FLUOROURACIL, LEUCOVORIN;UMPS;rs1801019;CC + CG;TOXICITY, LADME_PK;
FLUOROURACIL, LEUCOVORIN;UMPS;rs1801019;CC;TOXICITY, LADME_PK;INCREASED_LIKELIHOOD
BUPRENORPHINE, METHADONE;COMT;rs4680;AG + GG;EFFICACY;DECREASED_SEVERITYEFFICACY
CAPECITABINE, FLUOROURACIL;DPYD;rs56038477;T;TOXICITY;INCREASED_SEVERITY
;SLC22A3;rs512077;AA;EFFICACY;INCREASED_EFFICACY
BUPRENORPHINE, METHADONE;OPRM1;rs1799971;AG + GG;EFFICACY;DECREASED_SEVERITYEFFICACY
CAPECITABINE, FLUOROURACIL;DPYD;rs2297595;CC + CT;TOXICITY;INCREASED_SEVERITY
GLUCARPIDASE;ABCC4;rs7317112;AG + GG;TOXICITY;INCREASED_RISK
HYDROCHLOROTHIAZIDE;ADRB2;rs2400707;AA + AG;EFFICACY;INCREASED_EFFICACY
CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;TT;TOXICITY;INCREASED_RISK
NICOTINE;CHRNA5;rs16969968;GG;OTHER;INCREASED_
HYDROCHLOROTHIAZIDE;WNK1;rs1159744;CC;OTHER;INCREASED_
HEROIN;DRD2;rs1076560;A;TOXICITY;INCREASED_LIKELIHOOD
SUFENTANIL;ABCB1;rs1128503;GG;EFFICACY;DECREASED_SEVERITYEFFICACY
HYDROCHLOROTHIAZIDE;WNK1;rs2107614;CC + CT;EFFICACY;INCREASED_EFFICACY
HYDROCHLOROTHIAZIDE;RAD52, WNK1;rs2277869;CC;EFFICACY;INCREASED_EFFICACY
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DOXORUBICIN, MERCAPTOPURINE, PREDNISONE, VINCRISTINE;XRCC1;rs1799782;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
METFORMIN;SLC47A2;rs34399035;T;LADME_PK;DECREASED_PK
OXALIPLATIN;ABCB1;rs1128503;AA;EFFICACY;INCREASED_EFFICACY
ANLOTINIB, APATINIB, AXITINIB, BEVACIZUMAB, SORAFENIB, SUNITINIB;KDR;rs1870377;A;TOXICITY;INCREASED_LIKELIHOOD
CYTARABINE, IDARUBICIN;CBR3;rs8133052;GG;TOXICITY;DECREASED_RISK
WARFARIN;;rs16871327;T;TOXICITY;INCREASED_RISK
WARFARIN;EPHA7;rs78132896;C;TOXICITY;INCREASED_RISK
FENOFIBRATE;FABP1;rs2241883;CC + CT;TOXICITY;INCREASED_RISK
ANTIPSYCHOTICS;SNAP25;rs1051312;TT;TOXICITY;DECREASED_LIKELIHOOD
GEFITINIB;TAB2;rs577001;CT + TT;TOXICITY;DECREASED_RISK
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFIT1;rs304478;TT;EFFICACY;INCREASED_EFFICACY
PEGINTERFERON ALFA-2B, RIBAVIRIN;OASL;rs12819210;T;EFFICACY;INCREASED_EFFICACY
OXALIPLATIN;ABCB1;rs1045642;AG;EFFICACY;INCREASED_EFFICACY
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY
PAZOPANIB;VEGFA;rs833061;TT;EFFICACY;INCREASED_EFFICACY
COCAINE;SLC6A3;rs6347;TT;TOXICITY;INCREASED_RISK
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
ATORVASTATIN;ABCB1;rs1045642;AA;TOXICITY;INCREASED_LIKELIHOOD
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;ABCC2;rs8187710;A;TOXICITY;DECREASED_LIKELIHOOD
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
COCAINE;DRD2;rs1076560;A;TOXICITY;INCREASED_RISK
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;ABCC2;rs17222723;A;TOXICITY;DECREASED_LIKELIHOOD
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;CYP1B1;rs1056836;C;TOXICITY;DECREASED_LIKELIHOOD
ANLOTINIB, APATINIB, AXITINIB, BEVACIZUMAB, SORAFENIB, SUNITINIB;KDR;rs1870377;A;EFFICACY;INCREASED_LIKELIHOODEFFICACY
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY
GEFITINIB;NFKBIA;rs2233407;AA + AT;TOXICITY;DECREASED_RISK
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;SPIDR;rs6473187;G;TOXICITY;INCREASED_LIKELIHOOD
GEFITINIB;NR1H2;rs2695121;CT + TT;TOXICITY;DECREASED_RISK
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;SLCO1B1;rs3829306;T;TOXICITY;DECREASED_LIKELIHOOD
SUNITINIB;VEGFA;rs2010963;CG + GG;EFFICACY;INCREASED_EFFICACY
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;EPHA6;rs301927;G;TOXICITY;INCREASED_LIKELIHOOD
WARFARIN;;rs115112393;G;TOXICITY;INCREASED_RISK
ANTIPSYCHOTICS;HTR2C;rs6318;GG;TOXICITY;INCREASED_LIKELIHOOD
ANTIPSYCHOTICS;HTR2C;rs3813929;CC;TOXICITY;INCREASED_LIKELIHOOD
ANTIPSYCHOTICS;HTR2C;rs518147;GG;TOXICITY;INCREASED_LIKELIHOOD
ATORVASTATIN;ABCB1;rs2032582;AA;TOXICITY;INCREASED_LIKELIHOOD
COCAINE;DRD2;rs2283265;A;TOXICITY;INCREASED_RISK
ANLOTINIB, APATINIB, AXITINIB, BEVACIZUMAB, SORAFENIB, SUNITINIB;KDR;rs2305948;CT + TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY
ANTIPSYCHOTICS;DRD2;rs6275;A;TOXICITY;INCREASED_LIKELIHOOD
ANTIPSYCHOTICS;DRD2;rs7131056;CC;TOXICITY;DECREASED_LIKELIHOOD
ANTIPSYCHOTICS;INSIG2;rs17047764;C;TOXICITY;INCREASED_LIKELIHOOD
ANTIPSYCHOTICS;GNB3;rs5443;TT;TOXICITY;INCREASED_LIKELIHOOD
ANTIPSYCHOTICS;MC4R;rs489693;AA;TOXICITY;INCREASED_LIKELIHOOD
TIANEPTINE;OPRM1;rs1799971;AA;TOXICITY;INCREASED_RISK
ATORVASTATIN;ABCB1;rs1128503;A;TOXICITY;INCREASED_LIKELIHOOD
ANTIPSYCHOTICS;BDNF, BDNF-AS;rs6265;CC;TOXICITY;INCREASED_LIKELIHOOD
ANTIPSYCHOTICS;ADRA2A;rs1800544;G;TOXICITY;INCREASED_LIKELIHOOD
ANLOTINIB, APATINIB, AXITINIB, BEVACIZUMAB, SORAFENIB, SUNITINIB;KDR;rs2071559;G;EFFICACY;DECREASED_LIKELIHOODEFFICACY
THEOPHYLLINE;CYP1A2;rs2069514;GG;LADME_PK;INCREASED_PK
ANTIPSYCHOTICS;DRD2;rs1799732;del;TOXICITY;INCREASED_LIKELIHOOD
GEFITINIB;NFKBIA;rs2233409;AG + GG;TOXICITY;DECREASED_RISK
GEFITINIB;NFKBIA;rs8904;AG + GG;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;INCREASED_RISKEFFICACY
GEFITINIB;NFKBIB;rs2053071;CC;TOXICITY;DECREASED_RISK
LEVODOPA;DRD3;rs6280;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
GEFITINIB;NFKBIA;rs2233406;AG + GG;TOXICITY;DECREASED_RISK
CLOPIDOGREL;ITGB3;rs5918;C;EFFICACY;EFFICACY
CLOPIDOGREL;ITGB3;rs5918;CT;EFFICACY;DECREASED_EFFICACY
CYTARABINE, FLUDARABINE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN;CYP2E1;rs2070673;A;TOXICITY;DECREASED_LIKELIHOOD
CYTARABINE, FLUDARABINE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN;CYP2E1;rs2515641;T;TOXICITY;DECREASED_LIKELIHOOD
CYTARABINE, FLUDARABINE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN;SLCO1B1;rs4149056;C;TOXICITY;INCREASED_LIKELIHOOD
PERINDOPRIL;AGTR1;rs275651;TT;EFFICACY;DECREASED_RISKEFFICACY
CYTARABINE, FLUDARABINE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN;SULT2B1;rs2302948;T;TOXICITY;DECREASED_LIKELIHOOD
ESCITALOPRAM;KCNH2;rs3807372;AA;TOXICITY;INCREASED_LIKELIHOOD
HEROIN;OPRM1;rs1799971;AA + AG;OTHER;DECREASED_LIKELIHOOD
GEFITINIB;IKBKB;rs9694958;AA;TOXICITY;INCREASED_RISK
CYTARABINE, FLUDARABINE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN;SLC22A12;rs11231825;TT;TOXICITY;INCREASED_LIKELIHOOD
GEFITINIB;IKBKE;rs3748022;CC + CT;TOXICITY;INCREASED_RISK
ASPIRIN;FSIP1;rs7179742;G;TOXICITY;INCREASED_RISK
ASPIRIN;PTGS1;rs10306114;G;EFFICACY;INCREASED_RISKEFFICACY
DRUGS FOR TREATMENT OF TUBERCULOSIS;XPO1;rs4430924;AA;TOXICITY;INCREASED_RISK
ASPIRIN;CEP68;rs7572857;AA + AG;TOXICITY;INCREASED_RISK
CYCLOSPORINE, MYCOPHENOLATE MOFETIL;ABCB1;rs2032582;A;EFFICACY;INCREASED_RISK
PAROXETINE;HTR2A;rs6311;CC;TOXICITY;INCREASED_SEVERITY
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;;rs10945919;G;EFFICACY;INCREASED_RISKEFFICACY
AMISULPRIDE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE, ZIPRASIDONE, ZUCLOPENTHIXOL;CYP2D6;rs5030655;A/DELA;TOXICITY;INCREASED_RISK
DAUNORUBICIN, DOXORUBICIN, EPIRUBICIN;SLC28A3;rs7853758;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1799930;AA;TOXICITY;INCREASED_RISK
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1799931;AG;TOXICITY;INCREASED_RISK
CETUXIMAB, PANITUMUMAB;KRAS;rs61764370;AC + CC;EFFICACY;INCREASED_
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1041983;TT;TOXICITY;INCREASED_RISK
CYCLOPHOSPHAMIDE, FLUOROURACIL, METHOTREXATE;FGFR4;rs351855;GG;EFFICACY;INCREASED_LIKELIHOOD
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CERS6;rs13393173;A;EFFICACY;INCREASED_RISKEFFICACY
CLOPIDOGREL;CES1;rs71647871;CT;LADME_PK;INCREASED_PK
CLOPIDOGREL;CES1;rs71647871;CT;EFFICACY;DECREASED_EFFICACY
CLOPIDOGREL;CES1;rs71647871;CT;EFFICACY;DECREASED_EFFICACY
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;DECREASED_PK
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED_PK
CARBOPLATIN, PEMETREXED;MTHFR;rs1801133;AA;EFFICACY;INCREASED_EFFICACY
VEMURAFENIB;ABCB1;rs1045642;AA;TOXICITY;INCREASED_LIKELIHOOD
VEMURAFENIB;CYP3A4;rs35599367;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_EFFICACY
CITALOPRAM, ESCITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;HTR2A;rs7997012;AA;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;INCREASED_EFFICACY
WARFARIN;VKORC1;rs9923231;TT;EFFICACY;DECREASED_EFFICACY
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;KLC1, XRCC3;rs861539;GG;EFFICACY;DECREASED_EFFICACY
TACROLIMUS;CYP3A5;rs776746;TT;DOSAGE, LADME_PK;PK
OPIOIDS;SLC18A2;rs363332;A;OTHER;INCREASED_LIKELIHOOD
OPIOIDS;SLC18A2;rs363334;G;OTHER;INCREASED_LIKELIHOOD
OPIOIDS;SLC18A2;rs363338;C;OTHER;INCREASED_LIKELIHOOD
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;MISP;rs8110536;G;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;rs4986893;AA + AG;EFFICACY;EFFICACY
PACLITAXEL;EPHA5;rs7349683;TT;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_RISKEFFICACY
SUNITINIB;VEGFA;rs699947;AA + AC;EFFICACY;INCREASED_EFFICACY
PAZOPANIB;VEGFA;rs699947;CC;EFFICACY;INCREASED_EFFICACY
CYTARABINE, IDARUBICIN;NQO2;rs1143684;CC;TOXICITY;INCREASED_RISK
PACLITAXEL;EPHA6;rs301927;G;TOXICITY;INCREASED_RISK
TACROLIMUS;CYP3A5;rs776746;CC;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;INCREASED_RISKEFFICACY
WARFARIN;VEGFA;rs35410204;CC;TOXICITY;INCREASED_LIKELIHOOD
PACLITAXEL;EPHA8;rs209709;G;TOXICITY;INCREASED_RISK
URSODEOXYCHOLIC ACID;MGAT5;rs661899;TT;TOXICITY;INCREASED_LIKELIHOOD
GLUCOCORTICOIDS, METHOTREXATE, RADIOTHERAPY;CDH2;rs1944294;AT + TT;TOXICITY;DECREASED_
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_EFFICACY
MYCOPHENOLATE MOFETIL;IMPDH2;rs11706052;AG;TOXICITY;DECREASED_RISK
PACLITAXEL;EPHA5;rs7349683;TT;TOXICITY;DECREASED_RISK
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;EFFICACY
CYTARABINE, IDARUBICIN;NQO1;rs1800566;AA;TOXICITY;INCREASED_RISK
WARFARIN;VEGFA;rs866236;AA;TOXICITY;INCREASED_LIKELIHOOD
PACLITAXEL;ABCG1;rs492338;AA;TOXICITY;INCREASED_RISK
CISPLATIN;AQP1;rs1049305;CC + CG;TOXICITY;INCREASED_RISK
OXALIPLATIN;ABCB1;rs1128503;AG;EFFICACY;INCREASED_EFFICACY
PACLITAXEL;EPHA6;rs301927;AA;TOXICITY;DECREASED_RISK
;SULT1A1;rs1042028;T;OTHER;INCREASED_LIKELIHOOD
;SULT1A1;rs1042028;T;OTHER;INCREASED_LIKELIHOOD
;SULT1A1;rs1042028;T;OTHER;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;rs4244285;AG;EFFICACY;DECREASED_EFFICACY
AMITRIPTYLINE, CLOMIPRAMINE, DOXEPIN, IMIPRAMINE, MAPROTILINE, NORTRIPTYLINE, OPIPRAMOL;CYP2D6;rs3892097;TT;TOXICITY;INCREASED_RISK
CALCIUM;VDR;rs731236;G;EFFICACY;INCREASED_RISK
;SULT1A1;rs1042028;T;OTHER;DECREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;rs4244285;AG;EFFICACY;DECREASED_EFFICACY
;SULT1A1;rs1042028;T;OTHER;INCREASED_LIKELIHOOD
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs2235040;T;EFFICACY;INCREASED_LIKELIHOODEFFICACY
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs12720067;T;EFFICACY;INCREASED_LIKELIHOODEFFICACY
ASPIRIN, CLOPIDOGREL;IRS1;rs13431554;AG + GG;EFFICACY;INCREASED_EFFICACY
DOCETAXEL;VAC14;rs875858;T;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP3A4;rs2242480;CT + TT;EFFICACY;EFFICACY
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs10280101;C;EFFICACY;INCREASED_LIKELIHOODEFFICACY
DIRECT FACTOR XA INHIBITORS, DIRECT THROMBIN INHIBITORS;FGG;rs1800792;CC;TOXICITY;INCREASED_LIKELIHOOD
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs7787082;A;EFFICACY;INCREASED_LIKELIHOODEFFICACY
OPIOIDS;COMT;rs6269;AG + GG;OTHER;INCREASED_LIKELIHOOD
FLUINDIONE;VKORC1;rs9934438;AA;EFFICACY;DECREASED_EFFICACY
FLUINDIONE;VKORC1;rs9934438;AA;EFFICACY;DECREASED_EFFICACY
OSIMERTINIB;EGFR;rs121434569;T;EFFICACY;INCREASED_LIKELIHOODEFFICACY
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs4148739;C;EFFICACY;INCREASED_LIKELIHOODEFFICACY
FLUINDIONE;VKORC1;rs9934438;AA;EFFICACY;EFFICACY
OPIOIDS;COMT;rs4680;AG + GG;OTHER;INCREASED_LIKELIHOOD
ETHANOL;ADH1B;rs1229984;TT;LADME_PK;INCREASED_PK
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs11983225;C;EFFICACY;INCREASED_LIKELIHOODEFFICACY
FLUINDIONE;VKORC1;rs9934438;AA;EFFICACY;EFFICACY
OPIOIDS;COMT;rs4818;CG + GG;OTHER;INCREASED_LIKELIHOOD
FLUINDIONE;VKORC1;rs9934438;AA;EFFICACY;DECREASED_EFFICACY
OPIOIDS;COMT;rs4633;CC + CT;OTHER;INCREASED_LIKELIHOOD
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs10248420;G;EFFICACY;INCREASED_LIKELIHOODEFFICACY
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1799931;A;TOXICITY, LADME_PK;INCREASED_RISK
ANTINEOPLASTIC AGENTS;UGT1A;rs6744284;TT;EFFICACY;INCREASED_EFFICACY
DIRECT FACTOR XA INHIBITORS, DIRECT THROMBIN INHIBITORS;F2;rs5896;TT;TOXICITY;INCREASED_LIKELIHOOD
BORTEZOMIB;PKNOX1;rs2839629;A;TOXICITY;INCREASED_SEVERITY
ANTINEOPLASTIC AGENTS;UGT1A;rs6744284;T;TOXICITY;INCREASED_LIKELIHOOD
SUNITINIB;VEGFA;rs699947;A;TOXICITY;INCREASED_
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs2235067;T;EFFICACY;INCREASED_LIKELIHOODEFFICACY
ATENOLOL;FTO;rs9940629;G;OTHER;
SUNITINIB;VEGFA;rs833061;C;TOXICITY;INCREASED_
ALFENTANIL, FENTANYL;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_SEVERITYEFFICACY
SUNITINIB;VEGFA;rs2010963;G;TOXICITY;INCREASED_
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs4148740;G;EFFICACY;INCREASED_LIKELIHOODEFFICACY
ATENOLOL;ABCB1;rs10267099;G;OTHER;INCREASED_RISK
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;OTHER;DECREASED_
ATENOLOL;ABCB1;rs3213619;G;OTHER;INCREASED_RISK
CORTICOSTEROIDS;DCAF4;rs7160796;CC;EFFICACY;INCREASED_EFFICACY
SUNITINIB;NOS3;rs2070744;CC + CT;TOXICITY;INCREASED_RISK
ATENOLOL;PRKCB;rs11649514;GT + TT;TOXICITY, OTHER;INCREASED_LIKELIHOOD
ATENOLOL;FTO;rs12595985;AA;OTHER;INCREASED_RISK
CYCLOPHOSPHAMIDE;ALDH1A1;rs8187996;CT + TT;TOXICITY;DECREASED_LIKELIHOOD
CLOPIDOGREL;P2RY12;rs2046934;AG + GG;OTHER;DECREASED_
ATENOLOL;GALNT2;rs2144297;T;OTHER;
ATENOLOL;GALNT2;rs2144300;C;OTHER;
ETHANOL;ANKK1, DRD2;rs1800497;A;TOXICITY;INCREASED_RISK
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE, LADME_PK;DECREASED_PK
ATENOLOL;PLA2G4A;rs10157410;C;OTHER;INCREASED_RISK
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_EFFICACY
ATENOLOL;PTGS2;rs4648287;G;OTHER;INCREASED_LIKELIHOOD
ISONIAZID, RIFAMPIN;NOS2;rs11080344;CC;TOXICITY;INCREASED_LIKELIHOOD
ENALAPRIL;SLCO1B1;rs2306283;AA;TOXICITY;INCREASED_LIKELIHOOD
ISONIAZID, RIFAMPIN;BACH1;rs2070401;GG;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;rs12248560;CT + TT;EFFICACY;DECREASED_EFFICACY
ISONIAZID, RIFAMPIN;MAFK;rs4720833;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
ISONIAZID, RIFAMPIN;XPO1;rs11125883;AC + CC;TOXICITY;DECREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;rs12248560;CC;EFFICACY;EFFICACY
ISONIAZID;NAT2;rs1041983;T;TOXICITY;INCREASED_RISK
ISONIAZID;NAT2;rs1495741;G;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C9;rs1057910;C;EFFICACY;DECREASED_EFFICACY
CAPECITABINE, FLUOROURACIL;DPYD;rs1801158;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED_LIKELIHOODEFFICACY
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs7270101;AA;TOXICITY;INCREASED_RISK
ANASTROZOLE, LETROZOLE;ESR1;rs9340799;A;OTHER;INCREASED_RISK
CLOPIDOGREL;CYP3A5;rs776746;CT + TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY
ANASTROZOLE, LETROZOLE;ESR1;rs2234693;C;OTHER;INCREASED_RISK
CLOPIDOGREL;P2RY12;rs2046934;AG + GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
;CYP3A4;rs2740574;CC;OTHER;INCREASED_LIKELIHOOD
OPIOIDS;OPRM1;rs1799971;AA + AG;OTHER;DECREASED_LIKELIHOOD
CAPECITABINE, FLUOROURACIL;DPYD;rs75017182;C;DOSAGE, TOXICITY;INCREASED_RISK
REPAGLINIDE;NEUROD1;rs1801262;CT + TT;EFFICACY;DECREASED_EFFICACY
REPAGLINIDE;PAX4;rs114202595;AA + AG;EFFICACY;DECREASED_EFFICACY
;CYP3A4;rs2740574;CT;OTHER;INCREASED_RISK
VINCRISTINE;COCH;rs1045644;CG + GG;TOXICITY;DECREASED_LIKELIHOOD
CETUXIMAB, IRINOTECAN, LEUCOVORIN, TEGAFUR;EGFR;rs712830;CC;TOXICITY;INCREASED_SEVERITY
TAMOXIFEN;CYP3A4;rs2740574;CT;OTHER;INCREASED_RISK
VINCRISTINE;;rs7963521;C;TOXICITY;INCREASED_LIKELIHOOD
REPAGLINIDE;NEUROD1;rs1801262;CT + TT;EFFICACY;DECREASED_EFFICACY
;VDR;rs3782905;G;OTHER;INCREASED_RISK
OPIOIDS;OPRL1;rs6090043;C;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_RISKEFFICACY
CLOPIDOGREL;P2RY12;rs6785930;A;EFFICACY;INCREASED_RISK
OPIOIDS;COMT;rs165599;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
DOCETAXEL, PACLITAXEL;ABCB1;rs2032582;A;TOXICITY;DECREASED_LIKELIHOOD
;VDR;rs2239185;G;;INCREASED_RISK
;VDR;rs1540339;T;;INCREASED_RISK
CISPLATIN;AQP1;rs1049305;CC + CG;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;rs4986893;AA + AG;EFFICACY;DECREASED_EFFICACY
CALCITRIOL;VDR;rs2228570;A;EFFICACY;INCREASED_RISK
CISPLATIN;AQP1;rs1049305;CC + CG;TOXICITY;DECREASED_RISK
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_RISKEFFICACY
PERINDOPRIL;BDKRB1;rs12050217;AA;EFFICACY;DECREASED_RISKEFFICACY
CISPLATIN;AQP1;rs1049305;CC;TOXICITY;INCREASED_RISK
ATENOLOL, VERAPAMIL;GRK4;rs1801058;TT;EFFICACY, TOXICITY, OTHER;INCREASED_RISK
CLOZAPINE;CYP1A2;rs762551;AA;TOXICITY;INCREASED_LIKELIHOOD
MYCOPHENOLATE MOFETIL;IMPDH1;rs2278294;CT + TT;TOXICITY;DECREASED_RISK
PLATINUM COMPOUNDS;HLA-DOB;rs2071554;CT + TT;EFFICACY;INCREASED_RISK
PLATINUM COMPOUNDS;;rs2900420;AA + AG;EFFICACY;DECREASED_RISK
CLOZAPINE;CYP1A2;rs762551;AA;TOXICITY;DECREASED_LIKELIHOOD
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, MERCAPTOPURINE, METHOTREXATE, PREDNISONE, VINCRISTINE;DROSHA;rs639174;T;TOXICITY;INCREASED_RISK
OPIOIDS;DRD2;rs6275;AG + GG;TOXICITY;INCREASED_LIKELIHOOD
CISPLATIN;TPMT;rs12201199;T;TOXICITY;INCREASED_RISK
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2E1;rs6413432;A;TOXICITY;INCREASED_LIKELIHOOD
CISPLATIN;;rs3746444;AG + GG;EFFICACY;DECREASED_EFFICACY
ACENOCOUMAROL, WARFARIN;CYP2C9;rs1057910;CC;TOXICITY;INCREASED_LIKELIHOOD
ASPIRIN;PTGS2;rs20417;G;OTHER;DECREASED_RISK
CISPLATIN;AQP1;rs28362731;AG;TOXICITY;INCREASED_RISK
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2E1;rs2031920;CC;TOXICITY;INCREASED_LIKELIHOOD
ASPIRIN;PTGS2;rs20417;G;OTHER;INCREASED_RISK
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;DECREASED_EFFICACY
FOLFIRI;ABCC1;rs17501011;AA + AG;EFFICACY;DECREASED_EFFICACY
OPIOIDS;OPRL1;rs6090041;G;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED_EFFICACY
ANTIDEPRESSANTS;CUX1;rs365836;G;EFFICACY;LIKELIHOOD_EFFICACY
;SULT1A1;rs1042028;CC + CT;;INCREASED_RISK
;SULT1A1;rs1042028;CT + TT;OTHER;INCREASED_RISK
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED_EFFICACY
;SULT1A1;rs1042028;CT + TT;OTHER;DECREASED_LIKELIHOOD
CLOZAPINE;LEPR;rs1137101;AG + GG;TOXICITY;INCREASED_LIKELIHOOD
ACENOCOUMAROL, WARFARIN;VKORC1;rs9923231;TT;TOXICITY;INCREASED_LIKELIHOOD
ANTIDEPRESSANTS;CUX1;rs201522;A;EFFICACY;LIKELIHOOD_EFFICACY
BORTEZOMIB;PKNOX1;rs2839629;AA;TOXICITY;INCREASED_LIKELIHOOD
CISPLATIN;COMT;rs9332377;T;TOXICITY;INCREASED_RISK
WARFARIN;VKORC1;rs9923231;CT + TT;EFFICACY;DECREASED_EFFICACY
CISPLATIN;COMT;rs4646316;C;TOXICITY;INCREASED_RISK
CAPECITABINE;ENOSF1;rs2741171;T;TOXICITY;INCREASED_RISK
CAPECITABINE;ENOSF1;rs2612091;C;TOXICITY;INCREASED_RISK
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_
CISPLATIN;ABCC3;rs1051640;G;TOXICITY;INCREASED_RISK
CAPECITABINE;DPYD;rs12022243;T;TOXICITY;INCREASED_SEVERITY
FOLFIRI;CES1;rs9921399;CC;EFFICACY;INCREASED_EFFICACY
DEXTROAMPHETAMINE, METHYLPHENIDATE;DRD1;rs4532;CC;TOXICITY;INCREASED_SEVERITY
CISPLATIN;TPMT;rs1142345;C;TOXICITY;INCREASED_RISK
METHAMPHETAMINE;GRIN1;rs1126442;GG;TOXICITY;INCREASED_RISK
FOLFIRI;UGT1A10, UGT1A8;rs1113193;AA;EFFICACY;DECREASED_EFFICACY
CISPLATIN;TPMT;rs1800460;T;TOXICITY;INCREASED_RISK
CAPECITABINE;ENOSF1;rs2741171;T;TOXICITY;INCREASED_RISK
CAPECITABINE;ENOSF1;rs2612091;C;TOXICITY;INCREASED_RISK
CAPECITABINE;DPYD;rs12022243;T;TOXICITY;INCREASED_SEVERITY
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY
IODINE (131I) COMPOUNDS, RADIOTHERAPY;TGFB1;rs1800469;AA;TOXICITY;INCREASED_LIKELIHOOD
NICOTINE;CHRNA5;rs588765;CT + TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;GG + GT;EFFICACY;INCREASED_RISKEFFICACY
CAPECITABINE;DPYD;rs76387818;A;TOXICITY;INCREASED_SEVERITY
CAPECITABINE;DPYD;rs12132152;A;TOXICITY;INCREASED_SEVERITY
CAPECITABINE;DPYD;rs76387818;A;TOXICITY;INCREASED_SEVERITY
ATENOLOL;DPYS;rs2669429;AG + GG;TOXICITY;INCREASED_SEVERITY
LENALIDOMIDE;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_SEVERITY
CAPECITABINE;DPYD;rs12132152;A;TOXICITY;INCREASED_SEVERITY
;IFNL3, IFNL4;rs12979860;CC;OTHER;INCREASED_
RISPERIDONE;LEP;rs7799039;G;OTHER;INCREASED_RISK
WARFARIN;VKORC1;rs9923231;T;EFFICACY, TOXICITY;INCREASED_
IODINE (131I) COMPOUNDS, RADIOTHERAPY;ATG10;rs10514231;CC;TOXICITY;INCREASED_LIKELIHOOD
VINCRISTINE;CEP72;rs924607;TT;TOXICITY;INCREASED_RISK
CARBOPLATIN, PACLITAXEL;EIF4E2, TIGD1;rs1656402;CC;EFFICACY;DECREASED_EFFICACY
IODINE (131I) COMPOUNDS, RADIOTHERAPY;ATM;rs11212570;AG;TOXICITY;DECREASED_LIKELIHOOD
NICOTINE;;rs2056527;CT + TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY
NICOTINE;;rs2056527;CT + TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY
CAPECITABINE, FLUOROURACIL;DPYD;rs67376798;AA + AT;TOXICITY;INCREASED_RISK
PIRFENIDONE;TOLLIP;rs5743890;CC + CT;EFFICACY;INCREASED_EFFICACY
CAPECITABINE, FLUOROURACIL;DPYD;rs1801160;CT + TT;TOXICITY;INCREASED_RISK
WARFARIN;VKORC1;rs9923231;T;EFFICACY;DECREASED_EFFICACY
IMATINIB;ABCB1;rs1045642;GG;TOXICITY;DECREASED_SEVERITY
PLATINUM COMPOUNDS;XBP1;rs2269577;GG;TOXICITY;INCREASED_RISK
IMATINIB;SLC22A1;rs683369;CC;TOXICITY;DECREASED_SEVERITY
CARBOPLATIN, PACLITAXEL;DSCAM;rs9981861;TT;EFFICACY;DECREASED_EFFICACY
CARBOPLATIN, PACLITAXEL;ETS2;rs1209950;CT + TT;EFFICACY;DECREASED_EFFICACY
IODINE (131I) COMPOUNDS, RADIOTHERAPY;ATG10;rs10514231;CC;TOXICITY;INCREASED_LIKELIHOOD
IODINE (131I) COMPOUNDS, RADIOTHERAPY;TGFB1;rs1800469;AA;TOXICITY;INCREASED_LIKELIHOOD
WARFARIN;VKORC1;rs9923231;T;EFFICACY;INCREASED_RISK
IODINE (131I) COMPOUNDS, RADIOTHERAPY;ATG10;rs1864183;TT;TOXICITY;INCREASED_LIKELIHOOD
MERCAPTOPURINE;NUDT15;rs186364861;A;TOXICITY;INCREASED_LIKELIHOOD
AMISULPRIDE, CLOZAPINE, OLANZAPINE, PALIPERIDONE, QUETIAPINE, RISPERIDONE;MC4R;rs17782313;CC;OTHER;INCREASED_RISK
AMISULPRIDE, ARIPIPRAZOLE, CLOZAPINE, HALOPERIDOL, QUETIAPINE, RISPERIDONE, ZIPRASIDONE;MC4R;rs489693;A;OTHER;INCREASED_RISK
MERCAPTOPURINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_LIKELIHOOD
AMISULPRIDE, ARIPIPRAZOLE, CLOZAPINE, HALOPERIDOL, QUETIAPINE, RISPERIDONE, ZIPRASIDONE;MC4R;rs489693;AA;OTHER;INCREASED_LIKELIHOOD
ATENOLOL, VERAPAMIL;PLEKHH2;rs11124945;G;TOXICITY;DECREASED_RISK
CLOPIDOGREL;CYP2C19;rs4244285;AG;EFFICACY;INCREASED_
REGADENOSON;AMPD1;rs17602729;AA + AG;EFFICACY;INCREASED_SEVERITY
EFAVIRENZ;CYP2B6;rs3745274;T;TOXICITY;INCREASED_SEVERITY
CLOPIDOGREL;CYP2C19;rs4244285;AA;EFFICACY;INCREASED_
CAPECITABINE, FLUOROURACIL;DPYD;rs3918290;CT + TT;TOXICITY;INCREASED_RISK
;;rs2952768;CC;EFFICACY;DECREASED_SEVERITY
CISPLATIN, CYCLOPHOSPHAMIDE;ERCC2;rs1799793;CT;EFFICACY;INCREASED_LIKELIHOODEFFICACY
ACENOCOUMAROL, WARFARIN;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_RISK
NICOTINE;DBH;rs1541333;CC;EFFICACY;DECREASED_LIKELIHOODEFFICACY
REGADENOSON;AMPD1;rs17602729;AA + AG;TOXICITY;INCREASED_RISK
RISPERIDONE;CNR1;rs806378;T;OTHER;INCREASED_RISK
RISPERIDONE;CNR1;rs1049353;C;OTHER;INCREASED_RISK
MERCAPTOPURINE;ABCC4;rs3765534;T;TOXICITY;INCREASED_LIKELIHOOD
ASPARAGINASE;NFATC2;rs6021191;T;TOXICITY;INCREASED_RISK
ASPARAGINASE;HLA-DRB1;rs17885382;T;TOXICITY;INCREASED_RISK
CYCLOPHOSPHAMIDE, EPIRUBICIN;GSTP1;rs1695;AA;TOXICITY;INCREASED_RISK
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;DECREASED_LIKELIHOOD
VANCOMYCIN;;rs2789047;A;TOXICITY;INCREASED_LIKELIHOOD
LISINOPRIL;MMP3;rs35068180;AA;EFFICACY;INCREASED_RISK
CARBOPLATIN, GEMCITABINE;SERPINA5;rs6113;C;TOXICITY;INCREASED_SEVERITY
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;EFFICACY
CARBOPLATIN, GEMCITABINE;SERPINA5;rs6118;T;TOXICITY;INCREASED_SEVERITY
CARBOPLATIN, GEMCITABINE;XYLT2;rs6504649;G;TOXICITY;INCREASED_SEVERITY
CARBOPLATIN, GEMCITABINE;SERPINA5;rs6119;G;TOXICITY;INCREASED_SEVERITY
ETHANOL;CAT;rs1001179;T;OTHER;INCREASED_RISK
CARBOPLATIN, GEMCITABINE;ETS2;rs73450548;A;TOXICITY;INCREASED_SEVERITY
BEVACIZUMAB, PEGAPTANIB, RANIBIZUMAB;VEGFA;rs2010963;CC;EFFICACY;INCREASED_EFFICACY
CLOPIDOGREL;ABCB1;rs1045642;AA;EFFICACY;INCREASED_
METHOTREXATE;MTHFR;rs1801133;AA;EFFICACY;INCREASED_LIKELIHOOD
DOXORUBICIN;GSTA1;rs3957357;AA;EFFICACY;INCREASED_EFFICACY
AMISULPRIDE, CLOZAPINE, OLANZAPINE, PALIPERIDONE, QUETIAPINE, RISPERIDONE;MC4R;rs489693;AA;OTHER;INCREASED_RISK
ETHANOL;CAT;rs1001179;T;OTHER;INCREASED_SEVERITY
;ERCC1;rs3212986;AC;OTHER;DECREASED_
DEXMEDETOMIDINE;GABRA2;rs279847;GG;TOXICITY;DECREASED_
TAMOXIFEN;ESR1;rs9340799;AG + GG;TOXICITY;INCREASED_RISK
"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS""";F5;rs149389480;AG;TOXICITY;INCREASED_RISK
MORPHINE;FAAH;rs3766246;AA + AG;TOXICITY;INCREASED_RISK
CLOZAPINE, OLANZAPINE;TBC1D1;rs9852;CC;TOXICITY;INCREASED_
FLUOROURACIL;DPYD;rs67376798;AT;EFFICACY;DECREASED_EFFICACY
MORPHINE;FAAH;rs4141964;CT + TT;TOXICITY;INCREASED_RISK
;ABCB11;rs2287622;GG;TOXICITY;INCREASED_RISK
HYDROCODONE;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_RISK
HYDROCODONE;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_RISK
;DRD2;rs1800497;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
OPIOIDS;GNB3;rs5443;CT + TT;TOXICITY, OTHER;INCREASED_LIKELIHOOD
ARIPIPRAZOLE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE;FAAH;rs324420;A;TOXICITY;INCREASED_LIKELIHOOD
MORPHINE;FAAH;rs2295632;GT + TT;TOXICITY;INCREASED_RISK
CAFFEINE;CYP1A2;rs762551;AC + CC;OTHER;DECREASED_RISK
MORPHINE;FAAH;rs324420;AA + AC;TOXICITY;INCREASED_RISK
PEGINTERFERON ALFA-2B, RIBAVIRIN;VDR;rs2228570;AA + AG;EFFICACY;INCREASED_EFFICACY
;ABCB11;rs2287622;GG;TOXICITY;INCREASED_RISK
PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;ITPA;rs1127354;CC;TOXICITY;INCREASED_RISK
DOCETAXEL;NR1I3;rs3003593;AA;TOXICITY;INCREASED_SEVERITY
ANTITHYROID PREPARATIONS;EHMT2;rs652888;G;TOXICITY;INCREASED_LIKELIHOOD
IODINE (131I) COMPOUNDS, RADIOTHERAPY;TNF;rs1800629;AG;TOXICITY;INCREASED_LIKELIHOOD
HYDROCODONE;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_RISK
HMG COA REDUCTASE INHIBITORS;HLA-G;rs1063320;G;OTHER;DECREASED_LIKELIHOOD
HYDROCODONE;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_RISK
DEXMEDETOMIDINE;CYP2A6;rs28399433;C;EFFICACY;INCREASED_EFFICACY
DEFERIPRONE;UGT1A6;rs6759892;GG;TOXICITY;INCREASED_RISK
DEFERIPRONE;UGT1A6;rs6759892;GG;TOXICITY;INCREASED_RISK
ANTITHYROID PREPARATIONS;;rs111618861;del;TOXICITY;INCREASED_LIKELIHOOD
ANTITHYROID PREPARATIONS;HLA-B;rs1071816;C;TOXICITY;INCREASED_LIKELIHOOD
IODINE (131I) COMPOUNDS, RADIOTHERAPY;ATM;rs11212570;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
EFAVIRENZ;IL10;rs1800896;TT;TOXICITY;INCREASED_LIKELIHOOD
ETHANOL;ANKK1, DRD2;rs1800497;A;OTHER;INCREASED_RISK
IODINE (131I) COMPOUNDS, RADIOTHERAPY;NFKB1;rs230493;AT;TOXICITY;DECREASED_LIKELIHOOD
OPIOIDS;OPRM1;rs1799971;G;TOXICITY;DECREASED_RISK
ETHANOL;DRD2;rs1800497;A;OTHER;INCREASED_RISK
IODINE (131I) COMPOUNDS, RADIOTHERAPY;TGFB1;rs2241716;TT;TOXICITY;INCREASED_LIKELIHOOD
MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
IODINE (131I) COMPOUNDS, RADIOTHERAPY;TGFB1;rs1800469;GG;TOXICITY;INCREASED_LIKELIHOOD
ANTITHYROID PREPARATIONS;FOXF2;rs199564443;del;TOXICITY;INCREASED_LIKELIHOOD
CAPECITABINE;CES1P1;rs7187684;T;TOXICITY;INCREASED_RISK
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, HYDROCORTISONE, METHOTREXATE, PREDNISONE, VINCRISTINE;;rs6977967;GG;TOXICITY;INCREASED_LIKELIHOOD
CAPECITABINE;CES1P1;rs11861118;G;TOXICITY;INCREASED_RISK
PLATINUM;XRCC1;rs25487;TT;EFFICACY;
PLATINUM;ERCC1;rs11615;AG + GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
CAPECITABINE;CES1;rs2244613;G;TOXICITY;INCREASED_RISK
PLATINUM;ERCC1;rs3212986;AA + AC;EFFICACY;INCREASED_EFFICACY
CLOZAPINE, ETHANOL;CYP1A2;rs2069514;GG;TOXICITY;INCREASED_LIKELIHOOD
MERCAPTOPURINE, METHOTREXATE;PACSIN2;rs2413739;CT + TT;EFFICACY;INCREASED_RISKEFFICACY
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, HYDROCORTISONE, METHOTREXATE, PREDNISONE, VINCRISTINE;MIR4268;rs4674470;CC + CT;TOXICITY;DECREASED_LIKELIHOOD
CAPECITABINE;CES1;rs2244614;G;TOXICITY;INCREASED_RISK
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CT + TT;EFFICACY;DECREASED_EFFICACY
CITALOPRAM;CYP2C19;rs4244285;AG;TOXICITY;INCREASED_LIKELIHOOD
IODINE (131I) COMPOUNDS, RADIOTHERAPY;ATM;rs620815;TT;TOXICITY;INCREASED_LIKELIHOOD
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;TT;EFFICACY;INCREASED_RISKEFFICACY
TENOFOVIR;ABCC2;rs17222723;A;TOXICITY;DECREASED_RISK
TENOFOVIR;ABCC2;rs2273697;A;TOXICITY;INCREASED_RISK
FLUOROURACIL;DPYD;rs1801160;CT;EFFICACY;DECREASED_EFFICACY
CYTARABINE, IDARUBICIN;;rs12036333;AA + AG;EFFICACY;DECREASED_EFFICACY
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, HYDROCORTISONE, METHOTREXATE, PREDNISONE, VINCRISTINE;ATF5;rs8667;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
NEVIRAPINE;CYP2B6;rs28399499;CC + CT;TOXICITY;INCREASED_RISK
PEGINTERFERON ALFA-2B, RIBAVIRIN;CYP2R1;rs10741657;AA + AG;EFFICACY;INCREASED_EFFICACY
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, HYDROCORTISONE, METHOTREXATE, PREDNISONE, VINCRISTINE;MIR3117;rs12402181;AA + AG;TOXICITY;DECREASED_LIKELIHOOD
NEVIRAPINE;CYP2B6;rs3745274;T;TOXICITY;INCREASED_LIKELIHOOD
TENOFOVIR DISOPROXIL FUMARATE;CYP24A1;rs2248359;TT;TOXICITY;INCREASED_SEVERITY
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_RISK
CYCLOPHOSPHAMIDE;CYP2C19;rs4244285;GG;TOXICITY;INCREASED_RISK
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3;rs8099917;TT;EFFICACY;INCREASED_EFFICACY
TENOFOVIR DISOPROXIL FUMARATE;CYP27B1;rs4646536;GG;TOXICITY;DECREASED_SEVERITY
NICOTINE;DDC;rs2060761;C;OTHER;INCREASED_RISK
DRUGS FOR TREATMENT OF TUBERCULOSIS;RIPOR2;rs10946737;AA + AG;TOXICITY;INCREASED_RISK
NICOTINE;DDC;rs12718541;A;OTHER;INCREASED_RISK
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY
IMIPRAMINE;CYP2C19;rs12248560;CT + TT;LADME_PK;DECREASED_PK
IMIPRAMINE;CYP2C19;rs11188072;CT + TT;LADME_PK;DECREASED_PK
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs12980275;AA;EFFICACY;INCREASED_EFFICACY
;CXCL5;rs352046;GG;OTHER;INCREASED_RISK
NEVIRAPINE;CYP2B6;rs28399499;C;TOXICITY;INCREASED_LIKELIHOOD
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_EFFICACY
WARFARIN;VKORC1;rs9934438;AA + AG;TOXICITY;INCREASED_RISK
CAPECITABINE;CDA;rs602950;G;TOXICITY;INCREASED_RISK
CAPECITABINE;CDA;rs532545;T;TOXICITY;INCREASED_RISK
TENOFOVIR DISOPROXIL FUMARATE;ABCC2;rs717620;TT;TOXICITY;INCREASED_SEVERITY
CAPECITABINE;CDA;rs6690069;A;TOXICITY;INCREASED_RISK
TENOFOVIR;ABCC2;rs717620;CC;TOXICITY;INCREASED_RISK
METHYLPHENIDATE;DRD1;rs4532;CC;TOXICITY;INCREASED_SEVERITY
CAPECITABINE, FLUOROURACIL;DPYD;rs67376798;AA + AT;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_RISKEFFICACY
CAPECITABINE;CES1;rs3217164;G;TOXICITY;INCREASED_RISK
CAPECITABINE;CDA;rs10916825;A;TOXICITY;INCREASED_RISK
CAPECITABINE, FLUOROURACIL;DPYD;rs1801160;CT + TT;TOXICITY;INCREASED_RISK
TENOFOVIR DISOPROXIL FUMARATE;SLC28A2;rs11854484;CT + TT;TOXICITY;INCREASED_SEVERITY
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR2A;rs6311;CC;TOXICITY;DECREASED_LIKELIHOOD
CAPECITABINE;NSUN3;rs144470777;C;TOXICITY;INCREASED_LIKELIHOOD
CAPECITABINE;PHC1;rs187805828;C;TOXICITY;INCREASED_LIKELIHOOD
ALENDRONATE;VDR;rs1544410;CC;EFFICACY;DECREASED_EFFICACY
ASPIRIN;ITGB3;rs5918;TT;EFFICACY;INCREASED_RISKEFFICACY
CAPECITABINE;FAT1;rs116134453;T;TOXICITY;INCREASED_LIKELIHOOD
CISPLATIN;XPC;rs2228001;GG + GT;TOXICITY;INCREASED_RISK
CAPECITABINE;TENM4;rs141531882;C;TOXICITY;INCREASED_LIKELIHOOD
TICAGRELOR;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;EFFICACY
AMOXICILLIN, CLAVULANATE;HLA-DQB1;rs9274407;A;TOXICITY;INCREASED_LIKELIHOOD
CAPECITABINE;CD96;rs77475703;C;TOXICITY;INCREASED_LIKELIHOOD
METHOTREXATE;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK
CYCLOPHOSPHAMIDE, DOCETAXEL, DOXORUBICIN, EPIRUBICIN, FLUOROURACIL, GOSERELIN;SLCO1B1;rs4149056;TT;TOXICITY;INCREASED_RISK
WARFARIN;NQO1;rs1800566;A;DOSAGE;EFFICACY
CAPECITABINE;ZMIZ1;rs117484357;C;TOXICITY;INCREASED_LIKELIHOOD
CAPECITABINE;VPS13D;rs138385713;G;TOXICITY;INCREASED_LIKELIHOOD
CETUXIMAB;RASSF1;rs2236947;CC;EFFICACY;INCREASED_EFFICACY
PAROXETINE;CYP1A2;rs4646425;CC;EFFICACY;INCREASED_EFFICACY
CAPECITABINE;CCDC77;rs141213385;G;TOXICITY;INCREASED_LIKELIHOOD
ANTIPSYCHOTICS;RGS2;rs4606;C;TOXICITY;INCREASED_SEVERITY
PRAVASTATIN;SLCO1B1;rs4149056;C;LADME_PK;INCREASED_PK
DEXMEDETOMIDINE;WBP2NL;rs5758550;AA;EFFICACY;INCREASED_SEVERITYEFFICACY
CAPECITABINE;ADGRG7;rs117308378;T;TOXICITY;INCREASED_LIKELIHOOD
CARBOPLATIN, CISPLATIN;AKT1;rs1130214;AA + AC;EFFICACY;DECREASED_RISKEFFICACY
CYCLOSPORINE, MYCOPHENOLIC ACID, PREDNISONE;NFATC1;rs2280055;CC;EFFICACY;EFFICACY
ASPIRIN, CLOPIDOGREL;PEAR1;rs41273215;T;EFFICACY;INCREASED_RISKEFFICACY
CARBOPLATIN, CISPLATIN;;rs2498804;AA + AC;EFFICACY;DECREASED_RISKEFFICACY
CLOZAPINE, OLANZAPINE, RISPERIDONE;DRD2;rs4436578;CC;TOXICITY;INCREASED_RISK
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED_EFFICACY
VINCRISTINE;ABCC2;rs12826;T;TOXICITY;DECREASED_LIKELIHOOD
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_PK
NICOTINE;GRIN3A;rs10121600;C;OTHER;INCREASED_RISK
ASPIRIN, CLOPIDOGREL;CYP1A2;rs762551;C;EFFICACY;INCREASED_RISKEFFICACY
WARFARIN;VKORC1;rs9923231;TT;EFFICACY;INCREASED_EFFICACY
ASPIRIN, CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_RISKEFFICACY
CITALOPRAM;HTR1B;rs6296;CC;TOXICITY;INCREASED_RISK
PRAVASTATIN;ABCA1;rs2230806;TT;EFFICACY;INCREASED_EFFICACY
ASPIRIN, CLOPIDOGREL;PON1;rs662;T;EFFICACY;INCREASED_RISKEFFICACY
DEXMEDETOMIDINE;ABCG2;rs2231142;GG;EFFICACY;INCREASED_SEVERITYEFFICACY
PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED_EFFICACY
"""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""CELECOXIB"", ""DICLOFENAC"", ""IBUPROFEN"", ""NAPROXEN"", ""PIROXICAM""";CYP2C9;rs1057910;C;TOXICITY;INCREASED_RISK
CAPECITABINE;DPYD;rs75267292;A;TOXICITY;INCREASED_LIKELIHOOD
NICOTINE;GRIN3A;rs11788456;G;OTHER;RISK_
EFAVIRENZ;CYP2B6;rs3745274;TT;TOXICITY;INCREASED_LIKELIHOOD
"""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""CELECOXIB"", ""DICLOFENAC""";CYP2C9;rs1057910;C;TOXICITY;INCREASED_RISK
EFAVIRENZ;CYP2B6;rs3745274;TT;TOXICITY;INCREASED_LIKELIHOOD
PRAVASTATIN;KIF6;rs20455;AG + GG;EFFICACY;DECREASED_RISK
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK
"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS""";F5;rs368967198;AG;TOXICITY;INCREASED_RISK
CAPECITABINE;SSU72;rs146898897;C;TOXICITY;INCREASED_LIKELIHOOD
ASPIRIN, CLOPIDOGREL;F2R;rs168753;T;EFFICACY;DECREASED_RISKEFFICACY
BETA BLOCKING AGENTS;GNB3;rs5443;CT + TT;OTHER;DECREASED_
CARBOPLATIN, CISPLATIN;PIK3CA;rs2699887;CC;TOXICITY;INCREASED_LIKELIHOOD
BETA BLOCKING AGENTS;GNB3;rs5443;CT + TT;OTHER;DECREASED_
CARBOPLATIN, CISPLATIN;PTEN;rs2299939;AC + CC;TOXICITY;DECREASED_LIKELIHOOD
CAPECITABINE;MAN1A1;rs185346775;A;TOXICITY;INCREASED_LIKELIHOOD
CARBOPLATIN, CISPLATIN;AKT1;rs3803304;C;EFFICACY;RISK_EFFICACY
COCAINE;BCHE;rs1803274;TT;OTHER;
PRAVASTATIN;SLCO1B1;rs4149056;CC;LADME_PK;INCREASED_PK
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;EGFR;rs11506105;AA;EFFICACY;INCREASED_EFFICACY
CISPLATIN, FLUOROURACIL;ABCB1;rs1045642;GG;EFFICACY;DECREASED_EFFICACY
ASPIRIN, CLOPIDOGREL;P2RY12;rs2046934;AG + GG;EFFICACY;INCREASED_EFFICACY
HMG COA REDUCTASE INHIBITORS;STAT4;rs7574865;T;TOXICITY;INCREASED_LIKELIHOOD
CISPLATIN, FLUOROURACIL;ABCB1;rs1045642;AA + AG;EFFICACY;DECREASED_RISKEFFICACY
MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
HEROIN;ALDH2;rs671;AA + AG;OTHER;INCREASED_
FENTANYL;CALCA;rs145837941;GG;DOSAGE;DECREASED_SEVERITY
"""METFORMIN"", ""SULFONAMIDES, UREA DERIVATIVES""";KCNJ11;rs5219;T;EFFICACY;INCREASED_LIKELIHOODEFFICACY
ANTIHYPERTENSIVES, BETA BLOCKING AGENTS, DIURETICS;ADRB1;rs1801253;CC;EFFICACY;INCREASED_LIKELIHOODEFFICACY
NICOTINE;GRIN3A;rs17189632;T;OTHER;RISK_
FLUOROURACIL;DPYD;rs3918290;CT + TT;TOXICITY;INCREASED_RISK
HMG COA REDUCTASE INHIBITORS;SLCO1A2;rs4149000;T;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_RISKEFFICACY
TRAMADOL;SLC22A1;rs35167514;del;LADME_PK;INCREASED_PK
EFAVIRENZ;CYP2B6;rs3745274;TT;TOXICITY;DECREASED_LIKELIHOOD
SEVOFLURANE;FASTKD3, MTRR;rs2307116;AA + AG;EFFICACY;INCREASED_EFFICACY
ASPIRIN, CLOPIDOGREL;P2RY12;rs2046934;AG + GG;TOXICITY;INCREASED_RISK
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY
METHOTREXATE;ABCB1;rs1045642;AA;TOXICITY;INCREASED_LIKELIHOOD
TRAMADOL;SLC22A1;rs34130495;A;LADME_PK;INCREASED_PK
TRAMADOL;SLC22A1;rs12208357;T;LADME_PK;PK
METHADONE;KCNJ6;rs2070995;TT;TOXICITY;DECREASED_RISK
IMATINIB;SLCO1A2;rs3764043;CC;LADME_PK;DECREASED_PK
IMATINIB;SLCO1A2;rs4148978;CC;LADME_PK;INCREASED_PK
VINCRISTINE;ABCC2;rs3740066;T;TOXICITY;DECREASED_LIKELIHOOD
IMATINIB;SLCO1A2;rs4148977;CC;LADME_PK;INCREASED_PK
FLUOROURACIL;DPYD;rs55886062;AC;TOXICITY;INCREASED_RISK
FLUCLOXACILLIN;NR1I2;rs3814055;CC;TOXICITY;INCREASED_RISK
CYCLOSPORINE, MYCOPHENOLIC ACID, PREDNISONE;NFATC1;rs3894049;CC;EFFICACY;DECREASED_LIKELIHOODEFFICACY
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_EFFICACY
SEVOFLURANE;FASTKD3, MTRR;rs1801394;AG + GG;EFFICACY;INCREASED_EFFICACY
FLUOROURACIL;DPYD;rs67376798;AT;TOXICITY;INCREASED_RISK
EFAVIRENZ;CYP2B6;rs28399499;CC;TOXICITY;DECREASED_LIKELIHOOD
"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS""";F5;rs143509841;GT;TOXICITY;INCREASED_RISK
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs8099917;G;EFFICACY;DECREASED_LIKELIHOODEFFICACY
"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS""";F5;rs200157005;AG;TOXICITY;INCREASED_RISK
PAROXETINE;CYP1A2;rs4646427;TT;EFFICACY;EFFICACY
CARBAMAZEPINE;SCN1A;rs3812718;CC;OTHER;INCREASED_
METHOTREXATE;MIR1206;rs2114358;GG;TOXICITY;INCREASED_RISK
PAROXETINE;CYP1A2;rs4646425;CC;EFFICACY;INCREASED_EFFICACY
ATORVASTATIN;SLCO1B1;rs2306283;G;LADME_PK;DECREASED_PK
ATORVASTATIN;SLCO1B1;rs4149056;C;LADME_PK;INCREASED_PK
FOLIC ACID, METHOTREXATE;ABCB1;rs1045642;A;TOXICITY;INCREASED_RISK
CYTARABINE, IDARUBICIN;BRD10;rs10758713;AA + AG;EFFICACY;DECREASED_EFFICACY
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;C;TOXICITY;INCREASED_RISK
SORAFENIB;KDR;rs4864950;A;TOXICITY;INCREASED_RISK
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;T;EFFICACY;DECREASED_LIKELIHOODEFFICACY
SORAFENIB;PIK3R5;rs444904;T;TOXICITY;INCREASED_RISK
IRINOTECAN;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs17868323;G;TOXICITY;INCREASED_RISK
CYTARABINE, IDARUBICIN;;rs2897047;AG;EFFICACY;INCREASED_EFFICACY
METHOTREXATE;ABCC2;rs2273697;AA;TOXICITY;INCREASED_LIKELIHOOD
CYTARABINE, IDARUBICIN;;rs6550826;GG;EFFICACY;INCREASED_RISKEFFICACY
METHOTREXATE;ABCB1;rs1128503;AG;TOXICITY;INCREASED_LIKELIHOOD
AZATHIOPRINE, MERCAPTOPURINE;ABCC4;rs3765534;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
METHOTREXATE;ABCC2;rs4148396;CC + CT;TOXICITY;INCREASED_
METHOTREXATE;ABCC2;rs4148396;CC;TOXICITY;INCREASED_LIKELIHOOD
CYTARABINE, IDARUBICIN;;rs9883101;CC;EFFICACY;INCREASED_RISKEFFICACY
FOLIC ACID, METHOTREXATE;TLR4;rs4986790;G;TOXICITY;INCREASED_RISK
ROSUVASTATIN;ABCG2;rs2231142;T;LADME_PK;INCREASED_PK
ROSUVASTATIN;SLCO1B1;rs4149056;C;LADME_PK;INCREASED_PK
FLUOROURACIL, LEUCOVORIN;DPYD;rs67376798;AT;TOXICITY;INCREASED_SEVERITY
PRAVASTATIN;SLCO1B1;rs4149056;C;LADME_PK;INCREASED_PK
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs12980275;AA;EFFICACY;INCREASED_EFFICACY
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_SEVERITY
HYDROCHLOROTHIAZIDE;;rs10792367;G;EFFICACY;DECREASED_EFFICACY
IRINOTECAN;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs17868323;G;DOSAGE;INCREASED_LIKELIHOOD
;HMGCR;rs12654264;AT + TT;OTHER;INCREASED_
DOXORUBICIN;SLC28A3;rs7853758;AA + AG;TOXICITY;DECREASED_LIKELIHOOD
HMG COA REDUCTASE INHIBITORS;ABCB1;rs1045642;AA;TOXICITY;INCREASED_LIKELIHOOD
NICOTINE;CHRNA3;rs3743075;T;TOXICITY;DECREASED_SEVERITY
NICOTINE;CHRNB4;rs7178270;G;TOXICITY;DECREASED_SEVERITY
VINCRISTINE;NDRG1;rs2272653;G;TOXICITY;INCREASED_SEVERITY
NICOTINE;CHRNB4;rs1948;A;TOXICITY;DECREASED_SEVERITY
PLATINUM COMPOUNDS;ERCC2;rs1052555;AA + AG;EFFICACY;DECREASED_EFFICACY
HMG COA REDUCTASE INHIBITORS, SIMVASTATIN;;rs1719247;T;TOXICITY;DECREASED_LIKELIHOOD
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs2306283;AA;TOXICITY;INCREASED_LIKELIHOOD
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED_LIKELIHOOD
HMG COA REDUCTASE INHIBITORS, SIMVASTATIN;;rs1346268;C;TOXICITY;DECREASED_LIKELIHOOD
PRAVASTATIN;SLCO1B1;rs4149056;CT;LADME_PK;INCREASED_PK
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ABCC2;rs3740066;CT + TT;TOXICITY;INCREASED_RISK
IMATINIB;UGT2A1;rs11249454;CC;TOXICITY;INCREASED_RISK
ANTHRACYCLINES AND RELATED SUBSTANCES;ECT2L;rs11155012;A;EFFICACY;INCREASED_RISK
HMG COA REDUCTASE INHIBITORS;ABCB1;rs1128503;AA;TOXICITY;INCREASED_LIKELIHOOD
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ATM;rs1801516;AA;TOXICITY;INCREASED_RISK
GEMCITABINE;SLC28A1;rs3825876;AA;TOXICITY;INCREASED_RISK
ATORVASTATIN;SLCO1B1;rs4149056;CC;LADME_PK;INCREASED_PK
GEMCITABINE;CDA;rs2072671;AC + CC;TOXICITY;DECREASED_RISK
RISPERIDONE;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_
PITAVASTATIN;SLCO1B1;rs2306283;AG + GG;LADME_PK;INCREASED_PK
SORAFENIB;EGFR;rs2330951;C;TOXICITY;INCREASED_RISK
ROSUVASTATIN;SLCO1B1;rs4149056;CC;LADME_PK;INCREASED_PK
HMG COA REDUCTASE INHIBITORS;GATM;rs9806699;A;TOXICITY;DECREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_RISK
EVEROLIMUS;ABCB1;rs2032582;A;TOXICITY, OTHER;INCREASED_LIKELIHOOD
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;CYP1B1;rs1056836;CC;TOXICITY;INCREASED_RISK
AZATHIOPRINE, MERCAPTOPURINE;;rs2647087;C;TOXICITY;INCREASED_RISK
EVEROLIMUS;RPTOR;rs9906827;T;TOXICITY, OTHER;DECREASED_LIKELIHOOD
RADIOTHERAPY;XPC;rs2228001;G;TOXICITY;DECREASED_LIKELIHOOD
EVEROLIMUS;ABCB1;rs1045642;A;TOXICITY, OTHER;INCREASED_LIKELIHOOD
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ATM;rs1801516;AA + AG;TOXICITY;INCREASED_RISK
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;C;TOXICITY;INCREASED_RISK
PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN;PEAR1;rs12041331;AA + AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
SUNITINIB;VEGFA;rs833061;CC + CT;EFFICACY;INCREASED_EFFICACY
AZACITIDINE;MTHFR;rs1801133;AA;EFFICACY;DECREASED_EFFICACY
CLOPIDOGREL;CYP2C19;rs4986893;AA + AG;EFFICACY;INCREASED_RISKEFFICACY
PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN;PEAR1;rs2768759;AA;EFFICACY;INCREASED_LIKELIHOODEFFICACY
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ERCC1;rs3212986;AA;TOXICITY;INCREASED_RISK
IMATINIB;SLC22A1;rs628031;GG;TOXICITY;INCREASED_RISK
ACETAMINOPHEN, IBUPROFEN, LOXOPROFEN, SALICYLAMIDE;;rs6500265;CT + TT;TOXICITY;INCREASED_RISK
IMATINIB;SLC19A1;rs1051266;TT;TOXICITY;INCREASED_RISK
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;GRIA1;rs1994862;CC;OTHER;DECREASED_RISK
EVEROLIMUS;RPTOR;rs9906827;CT + TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY
IMATINIB;CHST1;rs9787901;AA + AG;TOXICITY;INCREASED_RISK
IMATINIB;CYP2F1;rs305968;AA;TOXICITY;INCREASED_RISK
ACETAMINOPHEN, IBUPROFEN, LOXOPROFEN, SALICYLAMIDE;;rs9933632;GT + TT;TOXICITY;INCREASED_RISK
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;CBR1;rs20572;TT;TOXICITY;INCREASED_RISK
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;TP53;rs1042522;GG;TOXICITY;INCREASED_RISK
SORAFENIB;PRKCE;rs11125039;G;TOXICITY;INCREASED_RISK
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;SLC22A16;rs714368;CC + CT;TOXICITY;INCREASED_RISK
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;IL10;rs1800896;C;TOXICITY;INCREASED_RISK
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;XRCC1;rs25487;CT + TT;TOXICITY;INCREASED_RISK
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;CTLA4;rs231775;G;TOXICITY;DECREASED_RISK
;ADH7;rs971074;CT + TT;OTHER;INCREASED_SEVERITY
SORAFENIB;ADAMTS18;rs1346563;A;TOXICITY;INCREASED_RISK
PLATINUM COMPOUNDS;XRCC1;rs25487;CT + TT;EFFICACY;INCREASED_EFFICACY
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;GSTP1;rs1695;AA + AG;TOXICITY;INCREASED_RISK
CISPLATIN;SLC31A1;rs10981694;GG + GT;TOXICITY;INCREASED_SEVERITY
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;CYP2C19;rs12248560;CC;TOXICITY;INCREASED_RISK
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ABCC2;rs3740066;TT;TOXICITY;INCREASED_RISK
DEXMEDETOMIDINE;ABCC9;rs11046209;AA;EFFICACY;INCREASED_SEVERITYEFFICACY
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ABCB1;rs1045642;GG;TOXICITY;INCREASED_RISK
VINCRISTINE;CEP72;rs12522955;A;TOXICITY;INCREASED_LIKELIHOOD
CAPECITABINE;;rs72765700;T;TOXICITY;INCREASED_LIKELIHOOD
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ABCG2;rs2231142;GT;TOXICITY;INCREASED_RISK
ANTINEOPLASTIC AGENTS, MERCAPTOPURINE, METHOTREXATE;ABCC4;rs2274407;AC;TOXICITY;INCREASED_SEVERITY
AZATHIOPRINE, MERCAPTOPURINE;FTO;rs79206939;A;TOXICITY;INCREASED_RISK
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ALDH3A1;rs2228100;CG + GG;TOXICITY;INCREASED_RISK
ANTINEOPLASTIC AGENTS, MERCAPTOPURINE, METHOTREXATE;ABCC4;rs2274407;AC;EFFICACY;DECREASED_EFFICACY
PRAVASTATIN;HMGCR;rs17238540;GT;EFFICACY;DECREASED_EFFICACY
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_RISKEFFICACY
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ABCC2;rs2273697;GG;TOXICITY;INCREASED_RISK
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;SLC22A16;rs6907567;AA;TOXICITY;INCREASED_RISK
EVEROLIMUS;FGFR4;rs351855;A;TOXICITY, OTHER;DECREASED_LIKELIHOOD
VINCRISTINE;CEP72;rs924607;TT;TOXICITY;INCREASED_LIKELIHOOD
AZATHIOPRINE, MERCAPTOPURINE;;rs2834826;T;TOXICITY;INCREASED_RISK
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;CYP2C19;rs4244285;AA + AG;TOXICITY;INCREASED_RISK
IMATINIB;SLC19A1;rs12659;AG + GG;TOXICITY;DECREASED_RISK
AZATHIOPRINE, MERCAPTOPURINE;FTO;rs16952570;C;TOXICITY;INCREASED_RISK
AZACITIDINE;XRCC1;rs25487;CC;EFFICACY;DECREASED_EFFICACY
IMATINIB;NQO1;rs10517;GG;EFFICACY;DECREASED_EFFICACY
EVEROLIMUS;PIK3R1;rs10515074;G;TOXICITY, OTHER;DECREASED_LIKELIHOOD
DESLORATADINE;HRH1;rs901865;CC;TOXICITY;INCREASED_SEVERITY
IMATINIB;ABCC2;rs2273697;GG;EFFICACY;DECREASED_EFFICACY
CYTARABINE, DOXORUBICIN, LEUCOVORIN, METHOTREXATE, PREDNISONE, VINCRISTINE;NOS3;rs1799983;TT;TOXICITY;DECREASED_
IMATINIB;ABCB4;rs1202283;AA + AG;EFFICACY;INCREASED_EFFICACY
EVEROLIMUS;PIK3R1;rs10515074;G;TOXICITY, OTHER;INCREASED_LIKELIHOOD
CAPECITABINE;MIR2054;rs10024471;A;TOXICITY;INCREASED_LIKELIHOOD
AZATHIOPRINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
METHOTREXATE;DHFR;rs1105525;CT + TT;EFFICACY;DECREASED_EFFICACY
ANTIPSYCHOTICS, CLOZAPINE, OLANZAPINE;PRKAB2;rs3766522;TT;TOXICITY;DECREASED_SEVERITY
METHADONE;NECTIN4;rs11265549;AA;TOXICITY;INCREASED_LIKELIHOOD
CAPECITABINE;SPRY2;rs117876855;A;TOXICITY;INCREASED_LIKELIHOOD
AZATHIOPRINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_LIKELIHOOD
CAPECITABINE;SPRY2;rs139544515;A;TOXICITY;INCREASED_LIKELIHOOD
HMG COA REDUCTASE INHIBITORS;HMGCR;rs12654264;AA;EFFICACY;DECREASED_RISK
RIVAROXABAN;CYP3A4;rs2246709;AA;TOXICITY;DECREASED_LIKELIHOOD
METHOTREXATE;GGH;rs11545078;A;TOXICITY;INCREASED_LIKELIHOOD
CAPECITABINE;NCOA7;rs185217050;T;TOXICITY;INCREASED_LIKELIHOOD
CAPECITABINE;CCDC70;rs139368788;A;TOXICITY;INCREASED_LIKELIHOOD
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
;HMGCR;rs12654264;AT + TT;OTHER;INCREASED_
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ERCC1;rs11615;AG + GG;TOXICITY;INCREASED_RISK
CAPECITABINE;TMEM131L;rs117412990;G;TOXICITY;INCREASED_LIKELIHOOD
PRAVASTATIN;HMGCR;rs17244841;AT;EFFICACY;DECREASED_EFFICACY
HMG COA REDUCTASE INHIBITORS;HMGCR;rs12654264;TT;EFFICACY;DECREASED_RISK
CAPECITABINE;SIRPA;rs191934521;G;TOXICITY;INCREASED_LIKELIHOOD
ANTIPSYCHOTICS, CLOZAPINE, OLANZAPINE;PRKAA2;rs10789038;AA;TOXICITY;DECREASED_SEVERITY
RIVAROXABAN;CYP3A4;rs3735451;TT;TOXICITY;DECREASED_LIKELIHOOD
CAPECITABINE;LMNTD1;rs146644707;T;TOXICITY;INCREASED_LIKELIHOOD
METHOTREXATE;MTHFR;rs1801133;GG;TOXICITY;DECREASED_RISK
ANTINEOPLASTIC AGENTS;RBFOX1;rs6500843;G;EFFICACY;INCREASED_RISK
HMG COA REDUCTASE INHIBITORS;HMGCR;rs12654264;AA;EFFICACY;DECREASED_RISK
PLATINUM;XRCC5;rs1051685;G;TOXICITY;DECREASED_SEVERITY
CLOZAPINE, OLANZAPINE, RISPERIDONE;LEP;rs7799039;AG + GG;TOXICITY;INCREASED_LIKELIHOOD
IRINOTECAN;ABCC1;rs17287570;A;TOXICITY;DECREASED_LIKELIHOOD
SORAFENIB;EPAS1;rs1868089;C;TOXICITY;INCREASED_RISK
PLATINUM;XRCC5;rs6941;A;TOXICITY;INCREASED_SEVERITY
CYCLOPHOSPHAMIDE;CYP2A6;rs143731390;A;TOXICITY;INCREASED_LIKELIHOOD
IRINOTECAN;ABCG2;rs2622604;T;TOXICITY;INCREASED_LIKELIHOOD
FOLIC ACID;MTHFD1;rs2236225;AA;OTHER;DECREASED_LIKELIHOOD
METHOTREXATE;DHFR;rs442767;GG;EFFICACY;DECREASED_EFFICACY
IRINOTECAN;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs11692021;CT + TT;TOXICITY;DECREASED_LIKELIHOOD
PLATINUM;AQP2;rs10875989;T;TOXICITY;INCREASED_SEVERITY
APIXABAN, RIVAROXABAN;ABCG2;rs3114018;AA + AC;TOXICITY;INCREASED_RISK
IRINOTECAN;SLCO1B3;rs7977213;G;TOXICITY;INCREASED_LIKELIHOOD
METHOTREXATE;DHFR;rs408626;TT;EFFICACY;DECREASED_EFFICACY
CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;T;TOXICITY;DECREASED_LIKELIHOOD
PLATINUM;AQP2;rs3759125;AA + AC;TOXICITY;INCREASED_SEVERITY
IRINOTECAN;SLCO1B3;rs10841661;T;TOXICITY;INCREASED_LIKELIHOOD
METHOTREXATE;DHFR;rs1650697;AA;EFFICACY;DECREASED_EFFICACY
APIXABAN, RIVAROXABAN;ABCG2;rs2622604;CT + TT;TOXICITY;INCREASED_RISK
PLATINUM;AQP2;rs461872;A;TOXICITY;DECREASED_SEVERITY
PLATINUM;AQP2;rs7305534;CC + CT;TOXICITY;INCREASED_SEVERITY
MEPHENYTOIN, TOLBUTAMIDE;CYP2C19;rs41291556;C;LADME_PK;PK
PLATINUM;CD74;rs2748249;A;TOXICITY;INCREASED_SEVERITY
ASPIRIN;TBXAS1;rs6962291;AA;OTHER;DECREASED_RISK
PLATINUM;CD74;rs1560661;C;TOXICITY;DECREASED_SEVERITY
CYTARABINE;CDA;rs2072671;AA;TOXICITY, LADME_PK;DECREASED_RISK
WARFARIN;;rs12777823;A;DOSAGE;EFFICACY
WARFARIN;;rs12777823;A;DOSAGE;EFFICACY
;ALDH1A2;rs12915901;A;OTHER;INCREASED_LIKELIHOOD
RALOXIFENE, TAMOXIFEN;;rs10030044;G;EFFICACY;INCREASED_RISKEFFICACY
CAPECITABINE, FLUOROURACIL;DPYD;rs2297595;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
;SLC2A1;rs841844;CG + GG;TOXICITY;INCREASED_SEVERITY
CAPECITABINE, FLUOROURACIL;DPYD;rs2297595;TT;TOXICITY;INCREASED_SEVERITY
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_RISKEFFICACY
DASATINIB;ABL1;rs121913459;CT;OTHER, LADME_PK;DECREASED_PK
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;DECREASED_SEVERITY
HYDROCHLOROTHIAZIDE;AGT;rs5051;T;EFFICACY;INCREASED_EFFICACY
HYDROCHLOROTHIAZIDE;AGTR1;rs5186;A;EFFICACY;INCREASED_EFFICACY
TAMOXIFEN;ESR2;rs4986938;CC;OTHER;INCREASED_
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_SEVERITY
ONDANSETRON;ABCB1;rs1045642;AA;EFFICACY;DECREASED_LIKELIHOOD
TAMOXIFEN;ESR1;rs9340799;GG;OTHER;DECREASED_
TALINOLOL;ABCC2;rs2273697;A;OTHER;INCREASED_PK
CLOZAPINE, OLANZAPINE, RISPERIDONE;HTR2C;rs1414334;C;TOXICITY;INCREASED_LIKELIHOOD
DOXORUBICIN;CBR3;rs8133052;G;TOXICITY, LADME_PK;INCREASED_PK
ONDANSETRON;ABCB1;rs2032582;AA;EFFICACY;DECREASED_LIKELIHOOD
CLOZAPINE, OLANZAPINE, RISPERIDONE;HTR2C;rs518147;C;TOXICITY;INCREASED_LIKELIHOOD
BEVACIZUMAB, CYANOCOBALAMIN, FOLIC ACID, PEMETREXED;MTHFR;rs1801131;GG + GT;EFFICACY;INCREASED_EFFICACY
ARTESUNATE, PRIMAQUINE, PYRIMETHAMINE, SULFADOXINE;G6PD, IKBKG;rs1050828;CT;TOXICITY;INCREASED_RISK
RALOXIFENE, TAMOXIFEN;ZNF423;rs8060157;A;EFFICACY;DECREASED_RISKEFFICACY
TACROLIMUS;ABCB1;rs1045642;AA + AG;EFFICACY;EFFICACY
CARBAMAZEPINE;ABCC2;rs2273697;AA + AG;TOXICITY, LADME_PK;INCREASED_RISK
ARTESUNATE, PRIMAQUINE, PYRIMETHAMINE, SULFADOXINE;G6PD, IKBKG;rs1050828;TT;OTHER;INCREASED_RISK
SORAFENIB;VEGFB;rs12366035;T;TOXICITY;INCREASED_RISK
CYTARABINE;CDA;rs532545;TT;EFFICACY;DECREASED_EFFICACY
CYTARABINE;CDA;rs532545;TT;EFFICACY;INCREASED_RISK
VINCRISTINE;CEP72;rs71585289;C;TOXICITY;INCREASED_SEVERITY
CYCLOSPORINE, TACROLIMUS;ABCB1;rs1128503;AA + AG;EFFICACY;INCREASED_RISK
CLOPIDOGREL;P2RY12;rs2046934;GG;TOXICITY;INCREASED_LIKELIHOOD
VINCRISTINE;MIR6076;rs35650931;CC + CG;TOXICITY;DECREASED_RISK
SORAFENIB;WWOX;rs9927200;A;TOXICITY;INCREASED_RISK
DOXEPIN;CYP2C19;rs4244285;AA;LADME_PK;DECREASED_PK
ANTHRACYCLINES AND RELATED SUBSTANCES;RARG;rs2229774;A;TOXICITY;INCREASED_RISK
VINCRISTINE;MIR4481;rs7896283;G;TOXICITY;INCREASED_RISK
CLOMIPRAMINE;CYP2C19;rs4244285;AG;LADME_PK;INCREASED_PK
CAPECITABINE, FLUOROURACIL;DPYD;rs2297595;CC;EFFICACY;DECREASED_EFFICACY
METHOTREXATE;SLC19A1;rs1051266;CT;EFFICACY;INCREASED_RISK
CORTICOSTEROIDS;ACP1;rs11553746;TT;TOXICITY;INCREASED_LIKELIHOOD
SORAFENIB;MAP2K6;rs11651488;C;TOXICITY;INCREASED_RISK
METHOTREXATE;MTHFR;rs1801131;GT;EFFICACY;DECREASED_RISK
SORAFENIB;CDH13;rs17682789;C;TOXICITY;DECREASED_RISK
TACROLIMUS;CYP3A5;rs776746;CC;EFFICACY;DECREASED_LIKELIHOODEFFICACY
CLOMIPRAMINE;CYP2C19;rs4244285;AA;LADME_PK;INCREASED_PK
PAROXETINE;FKBP5;rs1360780;T;OTHER;INCREASED_RISK
CLOMIPRAMINE, LIOTHYRONINE, LITHIUM, NEFAZODONE, PAROXETINE, VENLAFAXINE;FKBP5;rs1360780;T;OTHER;INCREASED_RISK
ILOPERIDONE;CYP2D6;rs1065852;GG;OTHER;INCREASED_
GEMCITABINE;SLC28A1;rs12148896;A;TOXICITY;DECREASED_RISK
METHOTREXATE;MTHFR;rs1801133;AA;EFFICACY;INCREASED_RISK
CLOMIPRAMINE, LIOTHYRONINE, LITHIUM, NEFAZODONE, VENLAFAXINE;HTR1B;rs130058;A;EFFICACY;DECREASED_RISK
PAROXETINE;HTR1B;rs130058;A;OTHER;INCREASED_RISK
GEMCITABINE;CDA;rs471760;A;TOXICITY;DECREASED_RISK
CANNABIDIOL;ABCC5;rs3749442;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
CISPLATIN;ACYP2;rs1872328;AG;TOXICITY;INCREASED_RISK
CLOMIPRAMINE, LIOTHYRONINE, LITHIUM, NEFAZODONE, PAROXETINE, VENLAFAXINE;ABCB1;rs2032582;A;OTHER;INCREASED_RISK
MELPHALAN;SLC7A5;rs4240803;AA + AG;TOXICITY;DECREASED_RISK
ANTIPSYCHOTICS;MC4R;rs17782313;CC + CT;OTHER;INCREASED_RISK
PLATINUM;SLC2A1;rs3738514;T;TOXICITY;DECREASED_SEVERITY
DOXORUBICIN;RARG;rs2229774;AA;TOXICITY;INCREASED_LIKELIHOOD
VINCRISTINE;GARS1;rs1049402;G;TOXICITY;INCREASED_SEVERITY
SORAFENIB;EGFR;rs917881;A;TOXICITY;INCREASED_RISK
VINCRISTINE;FGD4;rs12823621;A;TOXICITY;INCREASED_SEVERITY
CARBOPLATIN, CISPLATIN;SLC31A1;rs7851395;AA;EFFICACY;INCREASED_EFFICACY
VINCRISTINE;MIR3117;rs12402181;AA + AG;TOXICITY;DECREASED_RISK
FLUOROURACIL, OXALIPLATIN;ERCC2, KLC3;rs13181;GT;EFFICACY;INCREASED_EFFICACY
PLATINUM;SLC2A1;rs4658;CC;TOXICITY;DECREASED_SEVERITY
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;ITPA;rs1127354;CC;TOXICITY;INCREASED_SEVERITY
FLUOROURACIL, OXALIPLATIN;GSTP1;rs1695;AG + GG;EFFICACY;INCREASED_EFFICACY
;ADD1;rs4961;GT + TT;OTHER;INCREASED_
BLEOMYCIN, CISPLATIN, ETOPOSIDE;ERCC2;rs238406;GT + TT;TOXICITY;INCREASED_RISK
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP3A5;rs776746;CC + CT;TOXICITY;INCREASED_LIKELIHOOD
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK
;RAD52, WNK1;rs2277869;CC;OTHER;INCREASED_
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;;rs13422094;C;EFFICACY;EFFICACY
SUNITINIB;IL13;rs1800925;TT;OTHER;INCREASED_SEVERITY
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;;rs12211463;G;EFFICACY;EFFICACY
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;;rs7757130;A;EFFICACY;EFFICACY
FENTANYL;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_LIKELIHOOD
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;;rs2473967;G;EFFICACY;EFFICACY
THIAZIDES, PLAIN;ADD1;rs4961;GG;EFFICACY;DECREASED_RISK
BLEOMYCIN, CISPLATIN, ETOPOSIDE;ERCC2;rs1799793;TT;TOXICITY;INCREASED_RISK
SUNITINIB;IL13;rs1800925;TT;OTHER;INCREASED_RISK
FENTANYL;COMT;rs4680;AG;TOXICITY;INCREASED_LIKELIHOOD
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;RHBDF2;rs12948783;AA + AG;EFFICACY;DECREASED_EFFICACY
ACE INHIBITORS, PLAIN;SH2B1;rs192613545;T;TOXICITY;INCREASED_LIKELIHOOD
RADIOTHERAPY;OSMR;rs1239344;T;TOXICITY;INCREASED_RISK
BLEOMYCIN, CISPLATIN, ETOPOSIDE;BLMH;rs1050565;CC;TOXICITY;INCREASED_RISK
RADIOTHERAPY;CDK1;rs10711;G;TOXICITY;INCREASED_RISK
BLEOMYCIN, CISPLATIN, ETOPOSIDE;BLMH;rs1050565;CC;TOXICITY;INCREASED_RISK
CELECOXIB;CYP2C9;rs1799853;CT;LADME_PK;PK
HYDROCHLOROTHIAZIDE;REN;rs11240688;GG;EFFICACY;INCREASED_EFFICACY
HYDROCHLOROTHIAZIDE;YEATS4;rs7297610;C;EFFICACY;INCREASED_EFFICACY
ACE INHIBITORS, PLAIN;RBFOX3;rs62063838;C;TOXICITY;INCREASED_LIKELIHOOD
HYDROCHLOROTHIAZIDE;ADD1;rs4961;GT + TT;EFFICACY;INCREASED_EFFICACY
RADIOTHERAPY;PRKCE;rs940052;G;TOXICITY;DECREASED_RISK
ACE INHIBITORS, PLAIN;MBOAT1;rs10946364;T;TOXICITY;INCREASED_LIKELIHOOD
RADIOTHERAPY;PRKCE;rs11125035;T;TOXICITY;DECREASED_RISK
ROFECOXIB;PTGS1;rs3842787;T;EFFICACY;EFFICACY
BLEOMYCIN, CISPLATIN, ETOPOSIDE;ERCC1;rs11615;AA;TOXICITY;INCREASED_RISK
RADIOTHERAPY;RIGI;rs11795343;C;TOXICITY;INCREASED_RISK
CISPLATIN;TPMT;rs12201199;T;TOXICITY;INCREASED_RISK
DRUGS FOR TREATMENT OF TUBERCULOSIS;;rs1495741;AA;TOXICITY;INCREASED_LIKELIHOOD
ACE INHIBITORS, PLAIN;RBFOX3;rs56044629;G;TOXICITY;INCREASED_LIKELIHOOD
HYDROCHLOROTHIAZIDE;WNK1;rs880054;TT;EFFICACY;DECREASED_EFFICACY
RADIOTHERAPY;;rs7259857;C;TOXICITY;DECREASED_RISK
CELECOXIB;PTGS1;rs3842787;T;EFFICACY;EFFICACY
;COL1A1;rs1800012;AA + AC;;INCREASED_RISK
HYDROCHLOROTHIAZIDE;ADD1;rs4961;T;EFFICACY;DECREASED_EFFICACY
ACE INHIBITORS, PLAIN;GABRG2;rs77370934;G;TOXICITY;INCREASED_LIKELIHOOD
;COL1A1;rs1800012;AA + AC;;DECREASED_
VINCRISTINE;BAHD1;rs3803357;AA + AC;TOXICITY;DECREASED_LIKELIHOOD
ACE INHIBITORS, PLAIN;RBFOX3;rs56209714;G;TOXICITY;INCREASED_LIKELIHOOD
CAPECITABINE, FLUOROURACIL;DPYD;rs1801160;CT + TT;TOXICITY;INCREASED_RISK
METHYLPREDNISOLONE, PREDNISOLONE;ABCB1;rs1045642;AA;TOXICITY;DECREASED_RISK
BLEOMYCIN, CISPLATIN, ETOPOSIDE;GSTP1;rs1695;GG;TOXICITY;INCREASED_RISK
ANASTROZOLE, LETROZOLE, TAMOXIFEN;ZNF613;rs8113308;C;EFFICACY;DECREASED_EFFICACY
PIRFENIDONE;CYP1A2;rs762551;AA;TOXICITY;DECREASED_LIKELIHOOD
BLEOMYCIN, CISPLATIN, ETOPOSIDE;ERCC2;rs13181;GG + GT;TOXICITY;INCREASED_RISK
CISPLATIN;OTOS;rs2291767;CC + CT;TOXICITY;DECREASED_RISK
ACE INHIBITORS, PLAIN;RBFOX3;rs2061538;G;TOXICITY;INCREASED_LIKELIHOOD
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR2A;rs6311;CC;TOXICITY;INCREASED_LIKELIHOOD
CITALOPRAM;HTR2A;rs6311;CC;TOXICITY;INCREASED_LIKELIHOOD
TACROLIMUS;CYP3A5;rs776746;CT + TT;TOXICITY;INCREASED_RISK
MERCAPTOPURINE, METHOTREXATE;MTHFR;rs1801131;GG;TOXICITY;DECREASED_RISK
SUNITINIB;CXCL8;rs1126647;TT;OTHER;INCREASED_LIKELIHOOD
BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;PDGFRB;rs2302273;AA + AG;EFFICACY;INCREASED_EFFICACY
ETHANOL;PNPLA3;rs738409;GG;TOXICITY;INCREASED_RISK
BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;RGS5;rs2661280;CC + CG;EFFICACY;INCREASED_EFFICACY
SORAFENIB;EPAS1;rs9973653;T;TOXICITY;DECREASED_RISK
;WT1;rs16754;CC + CT;OTHER;INCREASED_LIKELIHOOD
TACROLIMUS;CYP3A5;rs776746;CT + TT;EFFICACY;INCREASED_RISKEFFICACY
MERCAPTOPURINE;ITPA;rs1127354;A;TOXICITY;INCREASED_RISK
CANNABINOIDS;FAAH;rs324420;AA;TOXICITY;DECREASED_RISK
SORAFENIB;;rs315498;C;TOXICITY;DECREASED_RISK
CYCLOPHOSPHAMIDE;GSTA1;rs3957357;A;TOXICITY;INCREASED_LIKELIHOOD
VINCRISTINE;MRPL47;rs10513762;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
FLUOROURACIL;DPYD;rs67376798;AT;TOXICITY;INCREASED_RISK
VINCRISTINE;SYNE2;rs2781377;A;TOXICITY;INCREASED_LIKELIHOOD
SORAFENIB;EPAS1;rs4035887;A;TOXICITY;INCREASED_RISK
ANTIPSYCHOTICS;COMT;rs4680;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_EFFICACY
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_LIKELIHOOD
METHOTREXATE;DHFR;rs408626;CC;EFFICACY;DECREASED_
METHOTREXATE;MTHFR;rs1801131;G;TOXICITY;INCREASED_LIKELIHOOD
CYCLOPHOSPHAMIDE;GSTA1;rs1051775;C;TOXICITY;INCREASED_LIKELIHOOD
EFAVIRENZ;ABCB1;rs1045642;A;TOXICITY;INCREASED_LIKELIHOOD
DOXORUBICIN;GALNT14;rs9679162;TT;EFFICACY;INCREASED_EFFICACY
ASPIRIN;CYP2D6;rs28360521;CC;TOXICITY, OTHER;INCREASED_RISK
DESFLURANE, PROPOFOL;ATP8B3;rs45574836;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
LOSARTAN;CAMK1D;rs10752271;AG + GG;EFFICACY;DECREASED_SEVERITYEFFICACY
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK
METHOTREXATE;DHFR;rs408626;TT;TOXICITY;INCREASED_RISK
LOSARTAN;CAMK1D;rs10737062;AG + GG;EFFICACY;DECREASED_SEVERITYEFFICACY
CYCLOPHOSPHAMIDE;GSTA1;rs1051775;C;TOXICITY;DECREASED_LIKELIHOOD
METHOTREXATE;MTHFR;rs1801131;T;TOXICITY;INCREASED_LIKELIHOOD
METHOTREXATE;DHFR;rs442767;GT;TOXICITY;INCREASED_RISK
CELECOXIB;CYP2C9;rs1057910;C;EFFICACY;DECREASED_RISK
MERCAPTOPURINE;SLC19A1;rs1051266;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
BLEOMYCIN, CISPLATIN, ETOPOSIDE;CYP3A4;rs2740574;CT;TOXICITY;INCREASED_RISK
MERCAPTOPURINE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
EFAVIRENZ;ABCB1;rs1045642;A;EFFICACY;DECREASED_LIKELIHOODEFFICACY
BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;CSPG4;rs1127648;AG;EFFICACY;DECREASED_EFFICACY
SORAFENIB;;rs10958704;G;TOXICITY;INCREASED_RISK
METHOTREXATE;SHMT1;rs1979277;AG;TOXICITY;DECREASED_LIKELIHOOD
METHOTREXATE;FASTKD3, MTRR;rs1801394;AG;TOXICITY;INCREASED_
SORAFENIB;EPAS1;rs7557402;G;TOXICITY;INCREASED_RISK
METHOTREXATE;MTHFR;rs1801131;TT;TOXICITY;INCREASED_LIKELIHOOD
CYCLOPHOSPHAMIDE;CYP2B6;rs3211371;T;TOXICITY;INCREASED_LIKELIHOOD
APIXABAN, RIVAROXABAN;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK
EFAVIRENZ;ABCB1;rs2032582;A;EFFICACY;DECREASED_LIKELIHOODEFFICACY
CYCLOPHOSPHAMIDE, DOCETAXEL;VEGFA;rs1570360;AA;EFFICACY;DECREASED_EFFICACY
CARBOPLATIN, GEMCITABINE;OR4D6;rs1453542;CC;TOXICITY;INCREASED_SEVERITY
SORAFENIB;MAP2K6;rs12948059;G;TOXICITY;INCREASED_RISK
CARBOPLATIN, GEMCITABINE;DDX53;rs5925720;T;TOXICITY;DECREASED_SEVERITY
METHOTREXATE;MTHFD1;rs2236225;AA;OTHER;INCREASED_PK
METHOTREXATE;FASTKD3, MTRR;rs1801394;AA;OTHER;INCREASED_PK
IRINOTECAN;SEMA3C;rs11979430;T;TOXICITY;INCREASED_SEVERITY
ANTIPSYCHOTICS;DRD2;rs1800497;A;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;TOXICITY;INCREASED_RISK
ANTIPSYCHOTICS;COMT;rs4680;AA + AG;TOXICITY;DECREASED_RISK
IRINOTECAN;SEMA3C;rs7779029;C;TOXICITY;INCREASED_SEVERITY
ANTIEPILEPTICS;ABCB1;rs2032582;C;EFFICACY;EFFICACY
ANTIPSYCHOTICS;DRD2;rs1800497;G;TOXICITY;INCREASED_RISK
ANTIEPILEPTICS;ABCB1;rs2032582;C;EFFICACY;EFFICACY
ANTIPSYCHOTICS;DRD2;rs1800497;G;TOXICITY;INCREASED_RISK
IRINOTECAN;;rs1661167;G;TOXICITY;INCREASED_SEVERITY
ANTIEPILEPTICS;ABCB1;rs2032582;C;EFFICACY;EFFICACY
AMISULPRIDE, CLOZAPINE, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR2C;rs498207;AA;TOXICITY;INCREASED_LIKELIHOOD
CISPLATIN, CYCLOPHOSPHAMIDE;CYP2E1;rs6413432;TT;EFFICACY;INCREASED_EFFICACY
BUDESONIDE;FCER2;rs28364072;G;OTHER;
CYCLOPHOSPHAMIDE;NOS3;rs1799983;TT;EFFICACY;INCREASED_EFFICACY
AMISULPRIDE, CLOZAPINE, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR2C;rs3813928;GG;TOXICITY;INCREASED_LIKELIHOOD
MYCOPHENOLATE MOFETIL;IL12A;rs568408;A;TOXICITY;INCREASED_RISK
IRINOTECAN;PLCB1;rs2745761;C;TOXICITY;INCREASED_SEVERITY
CYCLOPHOSPHAMIDE;NOS3;rs2070744;CC;EFFICACY;INCREASED_EFFICACY
AMISULPRIDE, CLOZAPINE, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR2C;rs3813929;CC;TOXICITY;INCREASED_LIKELIHOOD
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL, METHOTREXATE;NOS3;rs1799983;GG + GT;EFFICACY;INCREASED_EFFICACY
IRINOTECAN;PDZRN3;rs11128347;C;TOXICITY;INCREASED_SEVERITY
METHADONE;UGT2B7;rs4554144;TT;EFFICACY, LADME_PK;INCREASED_SEVERITY
DAPSONE;HLA-DRB1;rs201929247;A;TOXICITY;INCREASED_RISK
OLANZAPINE;PPARG;rs1801282;CG;OTHER;INCREASED_
METHADONE;UGT2B7;rs11940316;CC;EFFICACY, LADME_PK;INCREASED_SEVERITY
CORTICOSTEROIDS;BCL2L11;rs2241843;AA;TOXICITY;INCREASED_RISK
METHADONE;UGT2B7;rs7438135;AA;EFFICACY, LADME_PK;INCREASED_SEVERITY
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY
METHADONE;UGT2B7;rs7662029;GG;EFFICACY, LADME_PK;INCREASED_SEVERITY
CISPLATIN, CYCLOPHOSPHAMIDE;GSTA1;rs3957357;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
OXALIPLATIN;PIN1;rs2233678;CC + CG;EFFICACY;DECREASED_EFFICACY
METHADONE;UGT2B7;rs7668258;CC;EFFICACY, LADME_PK;INCREASED_SEVERITY
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2C9;rs9332096;CT + TT;TOXICITY;DECREASED_RISK
METHOTREXATE;ABCG2;rs2231142;TT;TOXICITY;DECREASED_LIKELIHOOD
METHOTREXATE;AMPD1;rs17602729;AG;TOXICITY;INCREASED_LIKELIHOOD
ANTIEPILEPTICS;ABCB1;rs1045642;A;EFFICACY;INCREASED_RISKEFFICACY
METHADONE;UGT2B7;rs7439366;CC;EFFICACY, LADME_PK;INCREASED_SEVERITY
ANTIEPILEPTICS;ABCB1;rs1128503;A;EFFICACY;INCREASED_RISKEFFICACY
ANTIEPILEPTICS;ABCB1;rs3789243;G;EFFICACY;INCREASED_RISKEFFICACY
METHADONE;UGT2B7;rs4292394;GG;EFFICACY, LADME_PK;INCREASED_SEVERITY
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2C19;rs4986893;AA + AG;TOXICITY;DECREASED_RISK
CISPLATIN, CYCLOPHOSPHAMIDE;CYP2E1;rs2070676;CG;TOXICITY;INCREASED_RISK
ANTIEPILEPTICS;ABCB1;rs3789243;G;EFFICACY;INCREASED_RISKEFFICACY
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_RISK
THIAZIDES, PLAIN;GNB3;rs5443;CC;TOXICITY;INCREASED_RISK
AMLODIPINE;RYR3;rs877087;TT;EFFICACY;INCREASED_RISK
FLUOROURACIL;GSTP1;rs1695;GG;TOXICITY;DECREASED_RISK
;COL1A1;rs1800012;AA;;DECREASED_
METHADONE;UGT2B7;rs6600879;GG;EFFICACY, LADME_PK;INCREASED_SEVERITY
;COL1A1;rs1800012;AA + AC;;DECREASED_
METHADONE;UGT2B7;rs6600880;AA;EFFICACY, LADME_PK;INCREASED_SEVERITY
PLATINUM COMPOUNDS;EIF3A;rs10510050;A;TOXICITY;INCREASED_RISK
CAPECITABINE;DPYD;rs67376798;AT;TOXICITY;INCREASED_RISK
THIAZIDES, PLAIN;AGTR1;rs5186;AA + AC;TOXICITY;INCREASED_RISK
THIAZIDES, PLAIN;ACE;rs4341;GG;TOXICITY;INCREASED_RISK
ATORVASTATIN, RIFAMPIN;SLCO1B1;rs4149056;TT;LADME_PK;PK
CAPECITABINE, FLUOROURACIL;MIR27A;rs895819;C;TOXICITY;RISK_
ATORVASTATIN;FDPS;rs2297480;TT;TOXICITY;INCREASED_
ETHANOL;OPRM1;rs1799971;G;;INCREASED_
;ABCC2;rs3740066;C;LADME_PK;
CISPLATIN;GSTM4;rs560018;CC;EFFICACY, TOXICITY;INCREASED_EFFICACY
ATORVASTATIN;FDPS;rs11264359;AA;TOXICITY;INCREASED_
IRINOTECAN;C8orf34;rs1517114;C;TOXICITY;INCREASED_SEVERITY
DICLOXACILLIN, PROBENECID;ABCB1;rs1045642;GG;OTHER, LADME_PK;INCREASED_PK
ANTIPSYCHOTICS, CLOZAPINE, OLANZAPINE, RISPERIDONE;HTR2C;rs1414334;C;TOXICITY;INCREASED_LIKELIHOOD
ETHANOL;OPRM1;rs1799971;G;OTHER;RISK_
CYCLOSPORINE, DICLOXACILLIN;ABCB1;rs2032582;CC;OTHER, LADME_PK;INCREASED_PK
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2E1;rs2031920;CT + TT;TOXICITY;DECREASED_RISK
ATORVASTATIN, FLUVASTATIN, PRAVASTATIN, ROSUVASTATIN, SIMVASTATIN;SLCO1B1;rs4149056;CC;;INCREASED_
PLATINUM COMPOUNDS;MDM2;rs1690924;CC;EFFICACY;DECREASED_EFFICACY
METHOTREXATE;SLC19A1;rs1051266;TT;LADME_PK;INCREASED_PK
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED_EFFICACY
SEVOFLURANE;GRIN2B;rs1806201;AA + AG;OTHER;INCREASED_
CLOPIDOGREL;CYP2C19;rs28399504;G;EFFICACY;DECREASED_EFFICACY
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;ADRB2;rs1042714;GG;EFFICACY;INCREASED_
METHOTREXATE;CCND1;rs9344;AA;TOXICITY;DECREASED_SEVERITY
RISPERIDONE;ABCB1;rs1045642;A;TOXICITY;INCREASED_
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;DECREASED_SEVERITY
PACLITAXEL;SOD2;rs4880;AA;TOXICITY;INCREASED_RISK
MERCAPTOPURINE, METHOTREXATE;SLC19A1;rs1051266;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
METHYLPHENIDATE;ABCB1;rs2032582;AA;TOXICITY;INCREASED_
DOCETAXEL;ERCC2;rs13181;TT;TOXICITY;INCREASED_RISK
CYCLOSPORINE, TACROLIMUS;CRTC2;rs8450;AA;TOXICITY;INCREASED_RISK
DOCETAXEL;ERCC1;rs11615;AA;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;rs12248560;T;EFFICACY;DECREASED_EFFICACY
METFORMIN;SP1;rs2683511;C;LADME_PK;DECREASED_PK
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
NICOTINE;CHRNA3, CHRNA5;rs16969968;A;TOXICITY;INCREASED_RISK
METFORMIN;;rs10747673;G;EFFICACY;DECREASED_EFFICACY
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
METFORMIN;;rs10747673;G;LADME_PK;DECREASED_PK
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
METHOTREXATE;SLC19A1;rs1051266;TT;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;ATP10A;rs12913988;AA + AG;EFFICACY;INCREASED_LIKELIHOOD
PLATINUM COMPOUNDS;EIF3A;rs4752220;A;TOXICITY;INCREASED_RISK
CHOP, RITUXIMAB;NCF4;rs1883112;AG + GG;TOXICITY;DECREASED_RISK
CLOPIDOGREL;CYP2C9;rs1057910;AC + CC;EFFICACY;INCREASED_RISKEFFICACY
PLATINUM COMPOUNDS;EIF3A;rs1409314;A;TOXICITY;INCREASED_RISK
PLATINUM COMPOUNDS;EIF3A;rs4752219;C;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C9;rs1057910;AC + CC;EFFICACY;INCREASED_RISKEFFICACY
MERCAPTOPURINE, METHOTREXATE;GSTP1;rs1695;GG;TOXICITY;INCREASED_LIKELIHOOD
CLOZAPINE;HTR2C;rs3813929;T;TOXICITY;DECREASED_RISK
ACENOCOUMAROL;ABCB1;rs1045642;GG + GT;TOXICITY;INCREASED_LIKELIHOOD
RISPERIDONE;ABCB1;rs2032582;A;TOXICITY;INCREASED_
METHOTREXATE;SLC19A1;rs1051266;TT;LADME_PK;INCREASED_PK
SEVOFLURANE;KCNK3;rs1275988;CT + TT;OTHER;INCREASED_
LEUCOVORIN, MERCAPTOPURINE, METHOTREXATE;SLC19A1;rs1051266;CC;TOXICITY;INCREASED_LIKELIHOOD
LEUCOVORIN, MERCAPTOPURINE, METHOTREXATE;SLC19A1;rs1051266;TT;TOXICITY;INCREASED_LIKELIHOOD
DOCETAXEL;CYP3A4;rs2740574;CC + CT;TOXICITY;INCREASED_RISK
METFORMIN;SP1;rs784888;G;EFFICACY;DECREASED_SEVERITY
PLATINUM COMPOUNDS;MTR;rs1805087;AA + AG;EFFICACY;DECREASED_EFFICACY
SEVOFLURANE;GABRA2;rs279858;CC + CT;OTHER;DECREASED_
LEUCOVORIN, MERCAPTOPURINE, METHOTREXATE;SLC19A1;rs1051266;TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
PLATINUM COMPOUNDS;EIF3A;rs7091672;T;TOXICITY;INCREASED_RISK
PACLITAXEL;CYP2C8;rs1113129;CG + GG;TOXICITY;INCREASED_RISK
METFORMIN;PPARA;rs149711321;T;EFFICACY;DECREASED_EFFICACY
;COL1A1;rs1800012;AA;;INCREASED_RISK
ACENOCOUMAROL;CYP4F2;rs2108622;CT + TT;TOXICITY;DECREASED_LIKELIHOOD
PLATINUM COMPOUNDS;SLC19A1;rs1051266;TT;EFFICACY;DECREASED_EFFICACY
PACLITAXEL;CYP2C8;rs1934951;CT + TT;TOXICITY;INCREASED_RISK
LENALIDOMIDE;VEGFA;rs699947;AA;EFFICACY;DECREASED_EFFICACY
METFORMIN;SP1;rs2683511;C;EFFICACY;DECREASED_EFFICACY
SEVOFLURANE;FASTKD3, MTRR;rs1801394;AG + GG;OTHER;DECREASED_
CLOPIDOGREL;CYP2C19;rs28399504;G;TOXICITY;INCREASED_RISK
BUPROPION, NICOTINE;DRD1;rs2168631;A;EFFICACY;INCREASED_LIKELIHOODEFFICACY
SIMVASTATIN;HMGCR;rs17238540;TT;EFFICACY;INCREASED_EFFICACY
;NR3C1;rs9324918;C;OTHER;INCREASED_
CLOPIDOGREL;CYP2C19;rs4986893;A;TOXICITY;INCREASED_RISK
SEVOFLURANE;FASTKD3, MTRR;rs2307116;AA + AG;OTHER;DECREASED_
PACLITAXEL;ERCC1;rs3212986;AA + AC;TOXICITY;INCREASED_RISK
MORPHINE;ABCC3;rs1978153;C;TOXICITY;INCREASED_SEVERITY
;P2RY12;rs2046934;G;;INCREASED_RISK
CLOPIDOGREL;CYP2C19;rs12248560;T;TOXICITY;INCREASED_RISK
BUPROPION, NICOTINE;DRD1;rs11749035;T;EFFICACY;INCREASED_LIKELIHOODEFFICACY
CLOPIDOGREL;CYP2C19;rs12248560;T;EFFICACY;DECREASED_EFFICACY
PAZOPANIB, SUNITINIB;CXCL8;rs1126647;T;EFFICACY;DECREASED_EFFICACY
;NR3C1;rs2963155;G;OTHER;INCREASED_
MORPHINE;ABCC3;rs733392;G;TOXICITY;INCREASED_SEVERITY
METHADONE;UGT2B7;rs6600893;CC;EFFICACY, LADME_PK;INCREASED_SEVERITY
FENTANYL;MYD88;rs6853;G;TOXICITY;DECREASED_RISK
METHOTREXATE, PREDNISONE;SLC19A1;rs1051266;TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY
BUPROPION, NICOTINE;DRD1;rs11746641;G;EFFICACY;INCREASED_LIKELIHOODEFFICACY
;NR3C1;rs33389;T;OTHER;INCREASED_
SPIRONOLACTONE;ACE;rs4343;AA + AG;EFFICACY;EFFICACY
SIMVASTATIN;HMGCR;rs17244841;AA;EFFICACY;INCREASED_EFFICACY
DOCETAXEL;ERCC1;rs3212986;CC;TOXICITY;INCREASED_RISK
SEVOFLURANE;CYP2E1;rs3813867;CC + CG;OTHER;DECREASED_
CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE, RITUXIMAB, VINCRISTINE;GSTA1;rs3957357;AA + AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
SEVOFLURANE;CYP2E1, DUX1;rs2031920;CT + TT;OTHER;DECREASED_
ANTIHYPERTENSIVES, DIURETICS;NOS3;rs2070744;CC;EFFICACY;INCREASED_RISKEFFICACY
CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE, RITUXIMAB, VINCRISTINE;CYBA;rs4673;AA;EFFICACY;DECREASED_LIKELIHOODEFFICACY
IBUPROFEN;PTGS2;rs20417;CG + GG;EFFICACY;INCREASED_EFFICACY
DIFLOMOTECAN;ABCG2;rs2231142;T;LADME_PK;INCREASED_PK
CYCLOSPORINE;ABCB1;rs2032582;AA;EFFICACY;INCREASED_RISKEFFICACY
CYCLOSPORINE, TACROLIMUS;CRTC2;rs8450;AA;TOXICITY;INCREASED_RISK
ROFECOXIB;PTGS2;rs20417;CC;EFFICACY;INCREASED_EFFICACY
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;;rs2884129;G;EFFICACY;EFFICACY
HMG COA REDUCTASE INHIBITORS;;rs13210472;C;TOXICITY;INCREASED_RISK
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;;rs7104613;T;EFFICACY;EFFICACY
PAZOPANIB, SUNITINIB;CXCL8;rs4073;A;EFFICACY;DECREASED_EFFICACY
BLEOMYCIN, CISPLATIN, ETOPOSIDE;GSTP1;rs1695;GG;TOXICITY;INCREASED_RISK
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;;rs10413396;T;EFFICACY;EFFICACY
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED_EFFICACY
METHOTREXATE;CCND1;rs9344;AA;EFFICACY;DECREASED_EFFICACY
BLEOMYCIN, CISPLATIN, ETOPOSIDE;ERCC1;rs3212986;AC + CC;TOXICITY;DECREASED_RISK
ASPIRIN;PTGS1;rs10306114;AA + AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
FLUOROURACIL;DPYD;rs67376798;A;TOXICITY;INCREASED_SEVERITY
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCB1;rs2032582;CC;EFFICACY;INCREASED_RISKEFFICACY
CYCLOSPORINE, TACROLIMUS;CRTC2;rs8450;AA + AG;TOXICITY;INCREASED_
CLOPIDOGREL;CYP2C19;rs4244285;A;LADME_PK;DECREASED_PK
ACENOCOUMAROL;VKORC1;rs9923231;TT;DOSAGE;DECREASED_EFFICACY
FLUOROURACIL;DPYD;rs1801160;T;TOXICITY;INCREASED_LIKELIHOOD
CLOPIDOGREL;CYP2C19;rs4244285;A;TOXICITY;INCREASED_RISK
MORPHINE;ABCC3;rs886493;G;TOXICITY;INCREASED_SEVERITY
BLEOMYCIN, CISPLATIN, ETOPOSIDE;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK
MORPHINE;ABCC3;rs7216383;T;TOXICITY;INCREASED_SEVERITY
METHOTREXATE;ABCB1;rs1045642;A;TOXICITY;DECREASED_LIKELIHOOD
ETHANOL;;rs10516440;A;TOXICITY;DECREASED_RISK
TRAMADOL;ABCB1;rs1045642;A;EFFICACY;INCREASED_LIKELIHOODEFFICACY
CITALOPRAM;CYP2C19;rs12248560;TT;LADME_PK;DECREASED_PK
TRAMADOL;ABCB1;rs2032582;A;EFFICACY;INCREASED_LIKELIHOODEFFICACY
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOODEFFICACY
PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs1127354;A;TOXICITY;DECREASED_SEVERITY
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY, TOXICITY;INCREASED_RISK
METHOTREXATE;ABCC2;rs17222723;A;TOXICITY;INCREASED_LIKELIHOOD
RISPERIDONE;UGT1A1;rs887829;CT;TOXICITY;INCREASED_RISK
FLUOXETINE;CRHR1;rs242941;CC;EFFICACY;INCREASED_EFFICACY
RISPERIDONE;UGT1A1;rs10929302;AG;TOXICITY;INCREASED_RISK
SARILUMAB;IL6R;rs11265618;CC;EFFICACY;INCREASED_LIKELIHOOD
CISPLATIN;ERCC2;rs1799793;CT + TT;EFFICACY;INCREASED_EFFICACY
CISPLATIN;GSTP1;rs1138272;CT + TT;EFFICACY;DECREASED_EFFICACY
SARILUMAB;IL6R;rs4845625;TT;EFFICACY;INCREASED_LIKELIHOOD
VITAMIN K ANTAGONISTS;CYP4F2;rs2108622;TT;EFFICACY;INCREASED_RISKEFFICACY
RISPERIDONE;HTR2C;rs6318;GG;TOXICITY;INCREASED_SEVERITY
WARFARIN;CRP;rs1205;CT + TT;TOXICITY;INCREASED_RISK
HYDROCHLOROTHIAZIDE;TCF7L2;rs4132670;A;TOXICITY;INCREASED_RISK
HYDROCHLOROTHIAZIDE;TCF7L2;rs7917983;T;TOXICITY;INCREASED_RISK
ATORVASTATIN, CERIVASTATIN, FLUVASTATIN, PRAVASTATIN, ROSUVASTATIN, SIMVASTATIN;HMGCR;rs17238540;GT;EFFICACY;DECREASED_LIKELIHOODEFFICACY
HYDROCHLOROTHIAZIDE;TCF7L2;rs4506565;T;TOXICITY;INCREASED_RISK
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
CITALOPRAM;CYP2C19;rs4244285;AA;LADME_PK;INCREASED_PK
LENALIDOMIDE;ABCB1;rs2032582;CC;EFFICACY;DECREASED_EFFICACY
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;XRCC1;rs25487;CC;OTHER;
DOCETAXEL, THALIDOMIDE;CHST3;rs4148950;A;TOXICITY;INCREASED_RISK
IRINOTECAN;UGT1A9;rs3832043;T/del + del/del;TOXICITY;INCREASED_LIKELIHOOD
BUPRENORPHINE, FENTANYL, TRAMADOL;COMT;rs4680;AA;TOXICITY;INCREASED_LIKELIHOOD
SARILUMAB;IL6R;rs4537545;CC;EFFICACY;INCREASED_LIKELIHOOD
CALCIUM, ETIDRONIC ACID;VDR;rs1544410;TT;EFFICACY;INCREASED_EFFICACY
SARILUMAB;IL6R;rs2228145;AA;EFFICACY;INCREASED_LIKELIHOOD
BUPRENORPHINE, FENTANYL, TRAMADOL;OPRD1;rs2234918;CT;TOXICITY;DECREASED_LIKELIHOOD
VALPROIC ACID;SOD2;rs4880;AA + AG;TOXICITY;DECREASED_LIKELIHOOD
SARILUMAB;IL6R;rs4329505;TT;EFFICACY;INCREASED_LIKELIHOOD
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY
BUPRENORPHINE, FENTANYL, TRAMADOL;ARRB2;rs1045280;TT;TOXICITY;INCREASED_LIKELIHOOD
PEGINTERFERON ALFA-2A, RIBAVIRIN;;rs4273729;GG;EFFICACY;INCREASED_EFFICACY
BISPHOSPHONATES;CYP2C8;rs1934951;TT;TOXICITY;INCREASED_RISK
BUPRENORPHINE, FENTANYL, TRAMADOL;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_LIKELIHOOD
BUPRENORPHINE, FENTANYL, TRAMADOL;COMT;rs4680;AG;TOXICITY;INCREASED_LIKELIHOOD
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs12980275;AA;EFFICACY;INCREASED_EFFICACY
BUPRENORPHINE, FENTANYL, TRAMADOL;OPRM1;rs1799971;AA;TOXICITY;INCREASED_LIKELIHOOD
BUPRENORPHINE, FENTANYL, TRAMADOL;COMT;rs4680;AA + GG;TOXICITY;INCREASED_LIKELIHOOD
;IFNL3, IFNL4;rs12979860;CC;OTHER;INCREASED_LIKELIHOOD
BUPRENORPHINE, FENTANYL, TRAMADOL;OPRM1;rs1799971;AA;TOXICITY;INCREASED_LIKELIHOOD
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ABCC2;rs717620;CC;TOXICITY;INCREASED_RISK
BUPRENORPHINE, FENTANYL, TRAMADOL;OPRM1;rs1799971;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
LENALIDOMIDE;CRBN;rs1705814;CC;DOSAGE, TOXICITY;INCREASED_LIKELIHOOD
BUPRENORPHINE, FENTANYL, TRAMADOL;COMT;rs4680;AG;TOXICITY;DECREASED_LIKELIHOOD
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ERCC1;rs11615;AA;TOXICITY;INCREASED_RISK
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;XRCC1;rs25487;CC;TOXICITY;DECREASED_RISK
RIFAMPIN;NR1I2;rs2472677;T;OTHER, LADME_PK;DECREASED_PK
CARBAMAZEPINE, LAMOTRIGINE, OXCARBAZEPINE, PHENYTOIN, TOPIRAMATE;SCN2A;rs2304016;A;EFFICACY;EFFICACY
CAPECITABINE, OXALIPLATIN;PTGS2;rs5275;AA;EFFICACY;INCREASED_
;CETP;rs708272;A;;
HMG COA REDUCTASE INHIBITORS;CETP;rs708272;A;EFFICACY;DECREASED_RISKEFFICACY
DIURETICS;ADD1;rs4961;GT + TT;EFFICACY;DECREASED_LIKELIHOOD
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;EFFICACY
ETHANOL;DRD2;rs1076560;A;OTHER;INCREASED_RISK
CLOPIDOGREL;P2RY12;rs2046934;AG + GG;EFFICACY;INCREASED_EFFICACY
METHOTREXATE;ABCC2;rs717620;CT + TT;TOXICITY;INCREASED_LIKELIHOOD
HYDROCHLOROTHIAZIDE;ADD1;rs4961;GT + TT;EFFICACY;INCREASED_EFFICACY
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK
BROMPERIDOL, NEMONAPRIDE;DRD2;rs1799732;GG;EFFICACY;INCREASED_EFFICACY
THIAZIDES, PLAIN;SLC12A3;rs13306673;CC;EFFICACY;INCREASED_EFFICACY
VALPROIC ACID;ABCB1;rs3789243;GG;EFFICACY;DECREASED_LIKELIHOOD
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY
AZATHIOPRINE;ITPA;rs1127354;AC;TOXICITY;INCREASED_RISK
VALPROIC ACID;ABCB1;rs3789243;GG;EFFICACY;INCREASED_LIKELIHOOD
ATORVASTATIN, ROSUVASTATIN;CYP3A5;rs776746;CC;TOXICITY;INCREASED_LIKELIHOOD
METHOTREXATE;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_LIKELIHOODEFFICACY
THIAZIDES, PLAIN;ADRB3;rs4994;AA;EFFICACY;INCREASED_EFFICACY
TRASTUZUMAB;FCGR2A;rs1801274;AA;EFFICACY;INCREASED_EFFICACY
IRINOTECAN;UGT1A9;rs3832043;T/del + del/del;TOXICITY;INCREASED_LIKELIHOOD
ASPARAGINASE;CPA2;rs199695765;T;TOXICITY;INCREASED_RISK
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs12980275;AA;EFFICACY;INCREASED_EFFICACY
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs12980275;AA;EFFICACY;INCREASED_EFFICACY
DAPSONE;HLA-DRB1;rs701829;T;TOXICITY;INCREASED_RISK
TACROLIMUS;POR;rs1057868;CT + TT;TOXICITY;INCREASED_RISK
WARFARIN;THBD;rs1042580;CC + CT;TOXICITY;DECREASED_RISK
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED_EFFICACY
METHYLPHENIDATE;CES1;rs3815583;AC + CC;TOXICITY;INCREASED_RISK
ACE INHIBITORS, PLAIN;BDKRB2;rs8012552;C;TOXICITY;INCREASED_RISK
CORTICOSTEROIDS;BCL2L11;rs724710;CC;TOXICITY;INCREASED_RISK
ACE INHIBITORS, PLAIN;MME;rs2016848;A;TOXICITY;INCREASED_RISK
IRINOTECAN;PIN1;rs2233678;CC + CG;EFFICACY;INCREASED_EFFICACY
PEGINTERFERON ALFA-2A, RIBAVIRIN;;rs4273729;GG;EFFICACY;INCREASED_EFFICACY
HYDROCHLOROTHIAZIDE;ADD1;rs4961;GT;EFFICACY;INCREASED_EFFICACY
ACENOCOUMAROL;VKORC1;rs9934438;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
ASPIRIN;ACE;rs4291;AT + TT;TOXICITY;INCREASED_RISK
MYCOPHENOLATE MOFETIL;CYP2C8;rs11572103;A;TOXICITY;INCREASED_RISK
HYDROCHLOROTHIAZIDE;ADD1;rs4961;GT + TT;EFFICACY;INCREASED_EFFICACY
MYCOPHENOLATE MOFETIL;CYP2C8;rs11572076;T;TOXICITY;INCREASED_RISK
ACE INHIBITORS, PLAIN;PTGER3;rs11209716;C;TOXICITY;DECREASED_RISK
MYCOPHENOLATE MOFETIL;HUS1;rs1056663;T;TOXICITY;DECREASED_RISK
DAPSONE;HLA-DRB1;rs17211071;A;TOXICITY;INCREASED_RISK
TACROLIMUS;PPARA;rs4253728;AA + AG;TOXICITY;INCREASED_RISK
MYCOPHENOLATE MOFETIL;HUS1;rs2037483;A;TOXICITY;DECREASED_RISK
;ADD1;rs4961;GT + TT;OTHER;INCREASED_LIKELIHOOD
FLUOROURACIL;ABCB1;rs2032582;C;TOXICITY;DECREASED_LIKELIHOOD
FLUOROURACIL;SLCO1B1;rs2306283;A;TOXICITY;INCREASED_LIKELIHOOD
;ARG1;rs2781666;TT;OTHER;INCREASED_SEVERITY
TACROLIMUS;CYP3A4;rs2740574;TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY
EPIRUBICIN;ABCC1;rs246221;CT;TOXICITY;INCREASED_LIKELIHOOD
LEVODOPA;COMT;rs4680;AA;TOXICITY;INCREASED_LIKELIHOOD
METHOTREXATE;SLC19A1;rs1051266;TT;TOXICITY;INCREASED_RISK
DAUNORUBICIN, DOXORUBICIN;ABCC2;rs8187710;A;TOXICITY;INCREASED_LIKELIHOOD
FOLFOX;DPYD;DPYD c.1129-5923C>G, c.1236G>A (HapB3);c.1129-5923C>G, c.1236G>A (HapB3);EFFICACY;DECREASED_LIKELIHOODEFFICACY
DAUNORUBICIN, DOXORUBICIN;HFE;rs1799945;G;TOXICITY;DECREASED_LIKELIHOOD
DAUNORUBICIN, DOXORUBICIN;GPR35;rs12468485;T;TOXICITY;INCREASED_LIKELIHOOD
DAUNORUBICIN, DOXORUBICIN;UGT1A6;rs17863783;T;TOXICITY;INCREASED_LIKELIHOOD
DAUNORUBICIN, DOXORUBICIN;GSTA2;rs2180314;G;TOXICITY;DECREASED_LIKELIHOOD
DAUNORUBICIN, DOXORUBICIN;ETFB;rs79338777;A;TOXICITY;INCREASED_LIKELIHOOD
DAUNORUBICIN, DOXORUBICIN;HNMT;rs17583889;A;TOXICITY;INCREASED_LIKELIHOOD
DAUNORUBICIN, DOXORUBICIN;ABCC5;rs7627754;AA + AT;TOXICITY;DECREASED_LIKELIHOOD
CEFAZOLIN, CEFDINIR, CEFTRIAXONE, CEFUROXIME, CEPHALEXIN;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED_LIKELIHOOD
TACROLIMUS;CYP2B6;rs3745274;GT;EFFICACY;DECREASED_LIKELIHOODEFFICACY
CORTICOSTEROIDS;WNT7B;rs73175102;A;TOXICITY;INCREASED_LIKELIHOOD
CORTICOSTEROIDS;POGK;rs115587273;A;TOXICITY;INCREASED_LIKELIHOOD
CORTICOSTEROIDS;FAM240C;rs78233573;A;TOXICITY;INCREASED_LIKELIHOOD
CORTICOSTEROIDS;ZNF37A;rs376867011;A;TOXICITY;INCREASED_LIKELIHOOD
CODEINE, HYDROCODONE, TRAMADOL;CYP2D6;CYP2D6;intermediate_metabolizer;EFFICACY;INCREASED_LIKELIHOODEFFICACY
GANCICLOVIR, VALGANCICLOVIR;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4;*2 + *3 + *4;;INCREASED_LIKELIHOOD
VALPROIC ACID;ACOT1;rs758109;T;TOXICITY;INCREASED_LIKELIHOOD
TACROLIMUS;SLCO1B1;rs2306283;AA + AG;TOXICITY;DECREASED_LIKELIHOOD
AZATHIOPRINE;MOCOS;rs73430958;GT;TOXICITY;INCREASED_LIKELIHOOD
VALPROIC ACID;GABPA;rs59288687;CC;TOXICITY;DECREASED_LIKELIHOOD
VALPROIC ACID;NQO1;rs10517;GG;TOXICITY;DECREASED_LIKELIHOOD
VALPROIC ACID;PPARA;rs881740;G;TOXICITY;INCREASED_LIKELIHOOD
METHOTREXATE;SLCO1B3;rs7311358;AA;TOXICITY;INCREASED_LIKELIHOOD
METHOTREXATE;SLCO1B3;rs4149117;GG;TOXICITY;INCREASED_LIKELIHOOD
METHOTREXATE;SLCO1B1;rs2306283;AA + AG;TOXICITY;INCREASED_LIKELIHOOD
APIXABAN;APOE;rs7412;C;TOXICITY;INCREASED_LIKELIHOOD
APIXABAN;APOE;rs429358;C;TOXICITY;INCREASED_LIKELIHOOD
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;IFNL3;rs8099917;GG;TOXICITY;INCREASED_LIKELIHOOD
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;IFNL3;rs12980275;GG;TOXICITY;INCREASED_LIKELIHOOD
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;IFNL3;rs12979860;TT;TOXICITY;INCREASED_LIKELIHOOD
TACROLIMUS;ABCB1;rs9282564;TT;EFFICACY;DECREASED_RISKEFFICACY
TACROLIMUS;ABCC2;rs2273697;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY
TACROLIMUS;SLCO1B1;rs4149056;TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY
TACROLIMUS;CYP2C19;rs4244285;AA;TOXICITY;INCREASED_LIKELIHOOD
AZATHIOPRINE;NUDT15;rs116855232;CT;TOXICITY;INCREASED_LIKELIHOOD
AZATHIOPRINE;RRM1;rs1735053;AG + GG;TOXICITY;INCREASED_LIKELIHOOD
AZATHIOPRINE;TPMT;rs9465102;GT + TT;TOXICITY;INCREASED_LIKELIHOOD
CISPLATIN;TRPA1;rs920829;TT;TOXICITY;DECREASED_LIKELIHOOD
FOLFOX, XELOX;DPYD;rs1801265;AG + GG;TOXICITY;INCREASED_LIKELIHOOD
FLUOXETINE;CYP2D6;CYP2D6;ultrarapid_metabolizer;EFFICACY, TOXICITY;INCREASED_LIKELIHOOD
CYCLOSPORINE;SLC29A1;rs693955;AA;EFFICACY;DECREASED_LIKELIHOODEFFICACY
AFATINIB, ERLOTINIB, GEFITINIB;AKT1;rs2494750;CC;EFFICACY;INCREASED_LIKELIHOODEFFICACY
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*44:03;*44:03;TOXICITY;INCREASED_LIKELIHOOD
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*38:01;*38:01;TOXICITY;INCREASED_LIKELIHOOD
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;HLA-C*04:01;*04:01;TOXICITY;INCREASED_LIKELIHOOD
FOLFOX, XELOX;GSTP1;rs1695;GG;TOXICITY;DECREASED_LIKELIHOOD
FOLFOX, XELOX;TYMS;rs11280056;TTA/TTA + TTA/TTAAAGTTA;TOXICITY;DECREASED_LIKELIHOOD
FOLFOX, XELOX;TYMS;rs45445694;(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;TOXICITY;INCREASED_LIKELIHOOD
FOLFOX, XELOX;GSTP1;rs1695;GG;TOXICITY;INCREASED_LIKELIHOOD
AZATHIOPRINE;HLA-DQA1;HLA-DQA1*02:01;*02:01;TOXICITY;INCREASED_LIKELIHOOD
AZATHIOPRINE;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_LIKELIHOOD
HMG COA REDUCTASE INHIBITORS;ABCG2;rs2231142;T;TOXICITY;INCREASED_LIKELIHOOD
AMITRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;TOXICITY;INCREASED_RISK
AZATHIOPRINE, MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;*3A + *3B + *3C;TOXICITY;INCREASED_LIKELIHOOD
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;TOXICITY;INCREASED_LIKELIHOOD
CODEINE, MORPHINE, OXYCODONE;OPRM1;rs1799971;AA;TOXICITY;INCREASED_LIKELIHOOD
